0001213900-24-09711810-Q Unicycive Therapeutics, Inc. 20241113202411130705400705410705410 0 0001213900-24-097118 10-Q 77 20240930 20241113 20241113 Unicycive Therapeutics, Inc. 0001766140 2834 813638692 DE 1231 10-Q 34 001-40582 241451142 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 10-Q 1 ea0220114-10q_unicycive.htm QUARTERLY REPORT Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from ____ to ____ Â Commission file number: 001-40582 Â UNICYCIVE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Â Delaware Â 2834 Â 81-3638692 (State or other jurisdiction of incorporation or organization) Â (Primary Standard Industrial Classification Code Number) Â (I.R.S. Employer Identification Number) Â 4300 El Camino Real, Suite 210 Los Altos, CA 94022 (650) 351-4495 (Address and telephone number of principal executive offices) Â Not applicable (Former name, former address, and former fiscal year, if changed since last report) Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. â˜’ Yes â˜ No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜’ Yes â˜ No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Emerging growth company â˜’ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). â˜ Yes â˜’ No Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock, par value $0.001 per share Â UNCY Â The NASDAQ Stock Market, LLC Â As of November 13, 2024, there were 103,796,406 shares of the Companyâ€™s common stock, par value $0.001 per share, issued and outstanding. Â Â Â Â Â Â TABLE OF CONTENTS Â Â Â Page No. PART I â€“ FINANCIAL INFORMATION Â Â Â ITEM 1. FINANCIAL STATEMENTS 1 Â Â Â Â Balance Sheets â€“ As of December 31, 2023 and September 30, 2024 (unaudited) 1 Â Â Â Â Statements of Operations (Unaudited) â€“ Three and Nine months Ended September 30, 2023 and 2024 2 Â Â Â Â Statements of Stockholdersâ€™ (Deficit) Equity (Unaudited) â€“ Three and Nine months Ended September 30, 2023 and 2024 3 Â Â Â Â Statements of Cash Flows (Unaudited) â€“ Nine months Ended September 30, 2023 and 2024 4 Â Â Â Â Notes to Financial Statements (Unaudited) 5 Â Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29 Â Â Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 38 Â Â Â ITEM 4. CONTROLS AND PROCEDURES 38 Â Â Â PART II â€“ OTHER INFORMATION 39 Â Â Â ITEM 1. LEGAL PROCEEDINGS 39 Â Â Â ITEM 1A. RISK FACTORS 39 Â Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 40 Â Â Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES 40 Â Â Â ITEM 4. MINE SAFETY DISCLOSURES 40 Â Â Â ITEM 5. OTHER INFORMATION 40 Â Â Â ITEM 6. EXHIBITS 40 Â Â Â SIGNATURES 41 Â i Â Â PART I â€“ FINANCIAL INFORMATION Â ITEM 1. FINANCIAL STATEMENTS Â Â Unicycive Therapeutics, Inc. Balance Sheets (In thousands, except for share and per share amounts) Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â SeptemberÂ 30,Â Â Â 2023Â Â 2024Â AssetsÂ Â Â Â (Unaudited)Â Current assets:Â Â Â Â Â Â Cash and cash equivalentsÂ $9,701Â Â $32,347Â Prepaid expenses and other current assetsÂ Â 3,698Â Â Â 5,394Â Total current assetsÂ Â 13,399Â Â Â 37,741Â Right of use asset, netÂ Â 766Â Â Â 772Â Property, plant and equipment, netÂ Â 26Â Â Â 61Â Total assetsÂ $14,191Â Â $38,574Â Â Â Â Â Â Â Â Â Â Â Â Liabilities and stockholdersâ€™ (deficit) equityÂ Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Accounts payableÂ $839Â Â $548Â Accrued liabilitiesÂ Â 3,234Â Â Â 2,992Â Warrant liabilityÂ Â 13,134Â Â Â 6,377Â Operating lease liability - currentÂ Â 327Â Â Â 542Â Total current liabilitiesÂ Â 17,534Â Â Â 10,459Â Operating lease liability â€“ long termÂ Â 466Â Â Â 265Â Total liabilitiesÂ Â 18,000Â Â Â 10,724Â Commitments and contingencies (Note 8)Â Â Â Â Â Â Â Stockholdersâ€™ (deficit) equity:Â Â Â Â Â Â Â Series A-2 Prime preferred stock, $0.001 par value per share â€“ 43,649 Series A-2 shares authorized at December 31, 2023 and 21,388.01 Series A-2 Prime shares authorized at September 30, 2024; 43,649 Series A-2 shares outstanding at December 31, 2023 and 11,111.24 Series A-2 Prime shares outstanding at September 30, 2024Â Â -Â Â Â -Â Series B-2 preferred stock, $0.001 par value per share â€“ zero Series B-2 shares authorized at December 31, 2023 and 7,882 Series B-2 Prime shares authorized at September 30, 2024; zero Series B-2 shares outstanding at December 31, 2023 and 7,882 Series B-2 shares outstanding at September 30, 2024Â Â -Â Â Â -Â Preferred stock: $0.001 par value per shareâ€”10,000,000 shares authorized at December 31, 2023 and September 30, 2024; zero shares issued and outstanding at December 31, 2023 and September 30, 2024Â Â -Â Â Â -Â Common stock, $0.001 par value per share â€“ 200,000,000 shares authorized at December 31, 2023 and 400,000,000 shares authorized at September 30, 2024; 34,756,049 and 97,858,406 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectivelyÂ Â 35Â Â Â 98Â Additional paid-in capitalÂ Â 60,697Â Â Â 107,497Â Accumulated deficitÂ Â (64,541)Â Â (79,745) Total stockholdersâ€™ (deficit) equityÂ Â (3,809)Â Â 27,850Â Total liabilities and stockholdersâ€™ (deficit) equityÂ $14,191Â Â $38,574Â Â See accompanying notes to the financial statements Â 1 Â Â Unicycive Therapeutics, Inc. Statements of Operations (In thousands, except for share and per share amounts) (Unaudited) Â Â Â Three Months Ended September 30,Â Â Â Nine Months Ended SeptemberÂ 30,Â Â Â 2023Â Â 2024Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Â Â Â Â Licensing revenuesÂ $-Â Â $-Â Â $675Â Â $-Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â 3,372Â Â Â 3,045Â Â Â 8,669Â Â Â 14,726Â General and administrativeÂ Â 2,566Â Â Â 3,206Â Â Â 6,467Â Â Â 8,130Â Total operating expensesÂ Â 5,938Â Â Â 6,251Â Â Â 15,136Â Â Â 22,856Â Loss from operationsÂ Â (5,938)Â Â (6,251)Â Â (14,461)Â Â (22,856) Other income (expenses):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ Â 227Â Â Â 416Â Â Â 475Â Â Â 947Â Interest expenseÂ Â (18)Â Â (15)Â Â (63)Â Â (51) Change in fair value of warrant liabilityÂ Â 1,396Â Â Â 1,754Â Â Â (8,697)Â Â 6,756Â Total other income (expenses)Â Â 1,605Â Â Â 2,155Â Â Â (8,285)Â Â 7,652Â Net lossÂ Â (4,333)Â Â (4,096)Â Â (22,746)Â Â (15,204) Deemed dividends to Series A-1 preferred stockholdersÂ Â (72)Â Â -Â Â Â (867)Â Â -Â Cash dividends to Series B-1 preferred stockholdersÂ Â -Â Â Â -Â Â Â -Â Â Â (1095) Net loss attributable to common stockholdersÂ $(4,405)Â $(4,096)Â $(23,613)Â $(16,299) Net loss per share attributable to common stockholders, basic and dilutedÂ $(0.13)Â $(0.05)Â $(1.12)Â $(0.30) Weighted-average shares outstanding used in computing net loss per share, basic and dilutedÂ Â 32,633,074Â Â Â 88,943,212Â Â Â 21,100,206Â Â Â 54,073,701Â Â See accompanying notes to the financial statements Â 2 Â Â Unicycive Therapeutics, Inc. Statements of Mezzanine Equity and Stockholdersâ€™ Deficit (In thousands, except share amounts) (Unaudited)Â Â Â Â Series A-1Â Â Â Â Â Â Â Series A-2Â Â AdditionalÂ Â Â Â Â Â Â Â Preferred StockÂ Â Common StockÂ Â Preferred StockÂ Â Paid-InÂ Â AccumulatedÂ Â StockholdersÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis or at all. If the Company is unable to secure additional capital, it may be required to curtail any clinical trials and development of new or existing products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. Based on the Companyâ€™s current level of expenditures, the Company believes that it has sufficient resources such that there is not substantial doubt about the ability to continue operations for at least one year after the date that these financial statements are available to be issued. Â 5 Â Â 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€). Â The accompanying unaudited financial statements of the Company as of September 30, 2024 have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and, accordingly, they do not include all information and footnote disclosures required by accounting principles generally accepted in the U.S. (â€œGAAPâ€). The Company believes the footnotes and other disclosures made in the financial statements are adequate for a fair presentation of the results of the interim periods presented. The financial statements include all adjustments (solely of a normal recurring nature) which are, in the opinion of management, necessary to make the information presented not misleading. You should read these financial statements and the accompanying notes in conjunction with the financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. Â Use of Estimates Â The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates. Â Â Revenue Recognition Â The Company recognizes revenue in accordance with Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers (â€œASC 606â€). The Company applies the five-step model in ASC 606 and recognizes revenue from product sales or services rendered when control of the promised goods or services are transferred to a counterparty in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. Â Warrant Liability Â In conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), the Company established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued (and have since been issued â€” see Note 12), subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. The Company accounts for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liability was initially measured at fair value and is remeasured at fair value each reporting period. Changes in the fair value of the warrant liability are recognized in earnings during each period. The warrant liability is measured using Level 3 fair value inputs. See Note 12 for a description of warrant liability and the related valuations.Â 6 Â Â Segment Information Â The Company operates and manages its business as one reportable operating segment. The Companyâ€™s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Â Risks and Uncertainties Â The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companyâ€™s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Companyâ€™s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Companyâ€™s ability to attract and retain employees necessary to support its growth. Â The Companyâ€™s general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. Â Any product candidates developed by the Company will require approvals from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Companyâ€™s current product candidates or any future product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company. Â The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs, which would materially and adversely affect its business, financial condition and operations. Â The Company is dependent upon the services of its employees, consultants and other third parties. Â Property, Plant and Equipment Â Property, plant, and equipment are recorded at cost less accumulated depreciation. Additions, improvements, and major renewals or replacements that substantially extend the useful life of an asset are capitalized. Repairs and maintenance expenditures are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Â Â Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value at that time. At September 30, 2024, management determined there were no impairments of the Companyâ€™s property and equipment.Â 7 Â Â Leases Â The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Companyâ€™s right to use an underlying asset during the lease term, and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Â Fair Value of Financial Instruments Â The Companyâ€™s financial instruments include the warrant liability, cash and cash equivalents, accounts payable and accrued liabilities. Â Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The fair value hierarchy contains the following levels: Â Â â— Level 1 â€” defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets; Â Â â— Level 2 â€” defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and Â Â â— Level 3 â€” defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable. Â Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands): Â Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â -Â Â $Â Â Â Â -Â Â $6,377Â Â $6,377Â Total liabilities at fair valueÂ $-Â Â $-Â Â $6,377Â Â $6,377Â Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands): Â Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â Â -Â Â $Â Â Â Â Â -Â Â $13,134Â Â $13,134Â Total liabilities at fair valueÂ $-Â Â $-Â Â $13,134Â Â $13,134Â Â 8 Â Â The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands): Â Â Â Nine months Ended September 30, 2024Â Fair value at January 1, 2023Â $-Â Issuance of Warrants (March 3, 2023)Â Â 2,831Â Change in fair value of WarrantsÂ Â 10,375Â Fair value at March 31, 2023Â Â 13,206Â Change in fair value of warrantsÂ Â (282) Fair value at June 30, 2023Â Â 12,924Â Change in fair value of warrantsÂ Â (1,396) Fair value at September 30, 2023Â $11,528Â Â Â Â Â Â Â Fair value at January 1, 2024Â $13,134Â Change in fair value of warrantsÂ Â 11,807Â Fair value at March 31, 2024Â Â 24,941Â Change in fair value of warrantsÂ Â (16,810) Fair value at June 30, 2024Â Â 8,131Â Change in fair value of warrantsÂ Â (1,754) Fair value at September 30, 2024Â $6,377Â Â The expense relating to the change in fair value of the warrant liability of $8.7 million and $6.8 million for the nine months ended September 30, 2023 and September 30, 2024, respectively, is included in other income (expense) in the statements of operations. Â ASC 820, Fair Value Measurement and Disclosures requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of December 31, 2023 and September 30, 2024, the recorded values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to the short-term nature of the instruments. Cash and cash equivalents, accounts payable, and accrued liabilities are Level 1 financial instruments. Â Concentration of Credit Risk Â Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024. Â Prepaid Expenses and Other Current Assets Â Prepaid expenses and other current assets represent costs incurred that benefit future periods. These costs are amortized over specific time periods based on the agreements. Â Research and Development Expenses Â Substantially all the Companyâ€™s research and development expenses consist of expenses incurred in connection with the development of the Companyâ€™s product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on the Companyâ€™s behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for the Companyâ€™s research and product development employees. The Company expenses both internal and external research and development expenses as they are incurred.Â 9 Â Â General and Administrative Expenses Â General and administrative expenses represent personnel costs for employees involved in general corporate functions, including finance, accounting, legal and human resources, among others. Additional costs included in general and administrative expenses consist of professional fees for legal (including patent costs), audit and other consulting services, stock-based compensation and other general corporate overhead expenses as well as costs from a service agreement with a related party (See Note 7). Â Patent Costs Â The Company expenses all costs as incurred in connection with patent licenses and applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are reflected in general and administrative expenses in the statements of operations. Â Stock-Based Compensation Â The Company accounts for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. The Company recognizes forfeitures related to stock-based compensation as they occur. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, risk-free interest rate, and the estimated fair value (prior to the Companyâ€™s initial public offering) or the public market closing price of the Companyâ€™s underlying common stock on the date of grant. Â Income Taxes Â The Company accounts for corporate income taxes in accordance with GAAP as stipulated in ASC, Topic 740, Income Taxes, (â€œASC 740â€). This standard entails the use of the asset and liability method of computing the provision for income tax expense. Current tax expense results from corporate tax payable at the Federal and California jurisdictions for the Company, which relates to the current accounting period. Deferred tax expense results primarily from temporary differences between financial statement and tax return reporting, which result in additional tax payable in future periods. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates and law. Net future tax benefits are subject to a valuation allowance when management expects that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. Â Current and non-current tax assets and liabilities are based upon an estimate of taxes refundable or payable for each of the jurisdictions in which the Company is subject to tax. In the ordinary course of business there is inherent uncertainty in quantifying income tax positions. The Company assess income tax positions and record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Companyâ€™s policy is to recognize interest or penalties related to income tax matters in income tax expense. Â The Tax Cuts and Jobs Act of 2017 eliminated the option to immediately deduct research and development expenditures in the year incurred under Section 174, which became effective January 1, 2022. We are monitoring legislation for any further changes to Section 174 and the impact, if any, to the financial statements in 2024. Â Comprehensive Loss Â Comprehensive loss includes all changes in equity (net assets) during a period from non-owner sources. There were no elements of other comprehensive income (loss) in the periods presented, as a result comprehensive loss is the same as net loss for each period presented.Â 10 Â Â Net Income (Loss) per Share Â Basic and diluted net income (loss) per share is presented in conformity with theÂ two-classÂ method required for participating securities. Basic and diluted net income (loss) for common stock and for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. Diluted net income (loss) per share includes potentially dilutive securities outstanding for the period. See Note 14 for reconciliations of basic and diluted net income (loss) per share. Â Recent Accounting Pronouncements Â From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption. Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements. Â The Company adopted Accounting Standards Update (â€œASUâ€) No. 2016-13, Financial Instruments â€” Credit Losses (â€œASC 326â€), as of October 1, 2023. This new standard adds to U.S. GAAP an impairment model, known as the current expected credit loss (â€œCECLâ€) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the timelier recognition of losses. Under the CECL model, entities estimate credit losses over the entire contractual term from the date of initial recognition of the financial instrument. As the Company does not currently have any trade receivables, there was no cumulative effect adjustment, and the adoption of this standard did not have a material impact on the Companyâ€™s financial statements. Â Income Taxes Disclosures â€” In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ ASU 2023-09 requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. Â 3. Significant Agreements Â With regards to manufacturing, testing and potential commercial supply of oxylanthanum carbonate, on October 31, 2020, the Company entered into an agreement with Shilpa Medicare Ltd (â€œShilpaâ€) based in India. Pursuant to the Agreement, Shilpa provides certain development, manufacturing, supply and other CMC-related services related to the development and commercialization of oxylanthanum carbonate (â€œOLCâ€). Â In June 2024, the Company entered into the First Amendment to

Manufacturing and Supply Agreement with Shilpa (the â€œAmendmentâ€). The Company has entered into the Amendment in anticipation of an increased manufacturing demand for OLC. Pursuant to the Amendment, the Company has agreed to make a binding purchase order for tablets of OLC and Shilpa has agreed to deliver such order by September 30, 2025. In addition, the Company has agreed to order additional tablets for delivery between December 31, 2025, and September 30, 2026. Further, the Company has agreed to make certain milestone payments and to provide certain funding to Shilpa for a new manufacturing line. The initial term of the Agreement shall continue until the eighth (8th) anniversary of the date of receipt by the Company of FDA approval of its NDA of OLC (the â€œInitial Termâ€). Following the Initial Term, the Agreement shall continue in effect for consecutive periods of four (4) years each unless earlier terminated pursuant to the terms of the Agreement. Â In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No payments were made upon execution of the agreement but payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. If the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.Â 11 Â Â In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. (â€œSpectrum Agreementâ€) pursuant to which the Company purchased certain assets from Spectrum, including Spectrumâ€™s right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALANâ„¢ (â€œRenalanâ€) and RZB 014, also known as SPI 014 (â€œSPIâ€ and together with Renalan, the â€œCompoundsâ€), to further develop and commercialize oxylanthanum carbonate and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Companyâ€™s shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the oxylanthanum carbonate Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Companyâ€™s common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrumâ€™s ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Companyâ€™s stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Companyâ€™s initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. In the event an NDA filing for oxylanthanum carbonate is accepted by the FDA, the Company will be required to pay $0.2 million to Altair Nanomaterials, Inc., (â€œAltairâ€) in accordance with the Spectrum Agreement. In addition, in the event FDA approval for oxylanthanum carbonate is received, the Company will be required to pay $4.5 million to Altair. The Company is also required to pay Spectrum 40% of all the Companyâ€™s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Spectrum Agreement) and 20% of all other sublicense income. The Companyâ€™s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Spectrum Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million resulting from a sublicense development agreement with Leeâ€™s Pharmaceutical (HK) Limited. In February 2023, the Company received an upfront payment of approximately $0.7 million resulting from a sublicense development agreement with Lotus International Pte Ltd. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the nine months ended September 30, 2023.Â Â On July 19, 2021, the Company entered into an agreement with Syneos Health LLC (â€œSyneosâ€) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The initial budget for the study, which includes clinical pharmacology, translational sciences, and bioanalytical services, was approximately $2.3 million. Approximately $2.0 million has been paid to Syneos and the research was completed during 2023. Â On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited (â€œQuotientâ€), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494.Â The initial budget for the study is approximately $3.7 million, and subsequent revisions reduced the overall budget to $2.9 million. Related payments totaling approximately $2.8 million have been paid to Quotient as of September 30, 2024, approximately 2.8 million of related expense has been recorded, and approximately $0.6 million and $0.6 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively. Â On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. (â€œCBCCâ€), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of oxylanthanum carbonate. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.4 million have been paid to CBCC as of March 31, 2023, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million, and the research was completed as of March 31, 2023. Â On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. Â On April 10, 2023, the Company entered into an agreement with Inotiv that provides preclinical trial and related services, for the purpose of performing research in support of UNI-494. The budget for these services is approximately $2.9 million. Approximately $2.9 million has been paid to Inotiv as of September 30, 2024 and approximately $0.3 million and $0.1 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively.Â 12 Â Â On July 14, 2022, the Company entered into a license agreement with Leeâ€™s Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Leeâ€™s Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Leeâ€™s Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.Â Â On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. The budget for the services is approximately $2.7 million, and approximately $2.7 million has been paid to Celerion as of December 31, 2023, and the research was completed during 2023. Â On February 1, 2023, the Company entered into a license agreement with Lotus International Pte Ltd. (â€œLotusâ€) (see Note 4). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements. Â On June 29, 2023 and October 26, 2023, the Company entered into services agreements with Shilpa Medicare Ltd related to NDA filing support for oxylanthanum carbonate. The agreements provide for total payments of up to $3.7 million, and the Company has made $3.0 million in payments pursuant to the agreements as of September 30, 2024. Â 4. Licensing Revenues Â On July 14, 2022, the Company entered into a license agreement (the â€œLeeâ€™s Agreementâ€) with Leeâ€™s Pharmaceutical (HK) Limited (â€œLeeâ€™sâ€). Under the terms of the agreement, Leeâ€™s Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Leeâ€™s will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Leeâ€™s with oxylanthanum carbonate product. The Company has received an upfront payment of approximately $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements. Â The Company has evaluated the Leeâ€™s Agreement in accordance with ASC 808, Collaborative Arrangements (â€œASC 808â€) and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entityâ€™s â€œordinary activitiesâ€. The Leeâ€™s Agreement is consistent with the Companyâ€™s current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship. Â The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Leeâ€™s, and therefore the promise does not represent a current performance obligation. The Company has concluded the agreement contains one performance obligation â€“ the IP license. Â ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved.Â 13 Â Â For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date. Â The Company has concluded that at contract inception the total transaction price is the $1.0 million upfront fee. Â The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP as it contains all the necessary information for Leeâ€™s to develop for commercialization in the Territory. Unicyciveâ€™s ongoing activities do not significantly affect the standalone functionality of the IP. In addition, the functionality of the IP is not expected to substantially change during the license period based on Unicyciveâ€™s activities. The revenue should therefore be recognized at a point in time. This intellectual property was transferred to Leeâ€™s in July 2022. Â On February 1, 2023, the Company entered into a license agreement (the â€œLotus Agreementâ€) with Lotus International Pte Ltd. (â€œLotusâ€). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has agreed to complete development of the drug product, at its own expense, as required for obtaining regulatory approval in the U.S. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Lotus with oxylanthanum carbonate product. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements. Â The Company has evaluated the Lotus Agreement in accordance with ASC 808 and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entityâ€™s â€œordinary activitiesâ€. The Lotus Agreement is consistent with the Companyâ€™s current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship. Â The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Lotus, and therefore the promise does not represent a current performance obligation. The Company evaluated the development services and concluded that although not material in cost, they are highly interrelated with the license grant. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. The combination of the license grant and development services is distinct as Lotus plans to use the product of this bundled unit for developing its regulatory applications. The Company concluded that the Lotus agreement contains one performance obligation, the bundle of the license grant and development services. Â ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved.Â 14 Â Â For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date. Â The Company has concluded that at contract inception the total transaction price is $675,000 amount of the upfront payment. ASC 606 generally requires an entity to allocate the transaction price to the performance obligations in proportion to their standalone selling prices (i.e., on a relative standalone selling price basis). The Company identified the bundle of the license grant and development services as the single performance obligation in the agreement. The $675,000 initial transaction price will therefore be entirely allocated to this obligation. Â The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP. However, since it is not distinct, revenue must be recognized based on the combination of the functional IP and the related development services. Lotus will not simultaneously receive and consume the benefits of the oxylanthanum carbonate IP or development services. Since the performance of the development services creates an asset that will also be used by the Company and can be licensed to other customers outside of the Territory, the Company is considered to control the asset as it is created, and it does create an asset with an alternative use. Therefore, the Company concluded that control is not deemed to be transferred over time and is instead transferred at a point in time. The intellectual property was transferred to Lotus in February 2023, and the development services were determined to be immaterial to the contract. The Company has recognized a total of $675,000 in the accompanying statements of operations as licensing revenue for the nine months ended September 30, 2023. Â 5. Balance Sheet Components Â Prepaid expenses and other current assets as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Prepaid directorsâ€™ and officersâ€™ liability insurance premiumsÂ $270Â Â $397Â Prepaid preclinical servicesÂ Â 3,103Â Â Â 4,310Â OtherÂ Â 325Â Â Â 687Â TotalÂ $3,698Â Â $5,394Â Â Property, plant and equipment as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Leasehold improvementsÂ $21Â Â $37Â Furniture and fixturesÂ Â 21Â Â Â 29Â Lab EquipmentÂ Â -Â Â Â 26Â SubtotalÂ Â 42Â Â Â 92Â Less accumulated depreciationÂ Â (16)Â Â (31) NetÂ $26Â Â $61Â Â 15 Â Â Accounts payable as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Trade accounts payableÂ $821Â Â $519Â Credit card liabilityÂ Â 18Â Â Â 29Â TotalÂ $839Â Â $548Â Â Accrued liabilities as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Accrued labor costsÂ $1,917Â Â $1,402Â Accrued drug development costsÂ Â 1,034Â Â Â 1,068Â OtherÂ Â 283Â Â Â 522Â TotalÂ $3,234Â Â $2,992Â Â 6. Operating Lease Â The Company leases office space under an operating lease. In December 2021, the Company entered into a lease agreement for 2,367 square feet of office space commencing December 1, 2021. The initial lease term was for two years, and there was an

option to extend the lease for an additional year. On March 3, 2023, the Company expanded its leased space through a lease amendment by an additional 2,456 square feet commencing March 15, 2023. The term of the amended lease is for three years with an option to extend the lease for three additional years. Â The lease amendment represents a modification of the original lease, and the Company evaluated the new agreement under ASC 842, Leases. The Company classified the lease as an operating lease and, on March 15, 2023, determined that the present value of the lease was approximately $1.0 million using an estimated incremental borrowing rate of 10%. During the nine months ended September 30, 2024, the Company reflected amortization of right-of-use asset of approximately $ 265,000, resulting in a right of use asset balance of approximately $0.8 million. Â During the nine months ended September 30, 2024, the Company made cash payments on the lease of $ 329,000 towards the lease liabilities. As of September 30, 2024, the total lease liability was approximately $ 0.8 million. Â As of September 30, 2024, maturities of the Companyâ€™s lease liabilities are as follows (in thousands, unaudited): Â Â Â Operating LeaseÂ Year ending December 31, 2024Â $144Â Year ending December 31, 2025Â Â 608Â Year ending December 31, 2026Â Â 118Â Total lease paymentsÂ Â 871Â Less imputed interest rate / present value discountÂ Â (64) Present value of lease liabilityÂ Â 807Â Less current portionÂ Â (542) Long term portionÂ $265Â Â 7. Related Party Transactions Â Loan from Chief Executive Officer and Stockholder Â The Company received advances from the stockholder of $210,000 during February 2023. The Company repaid amounts owed to the stockholder of $210,000 plus accrued interest during March 2023. Â 16 Â Â 8. Commitments and Contingencies Â Contingencies Â The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Companyâ€™s financial statements. The Company currently has no pending claims or legal proceedings. Â In December 2022, the Company signed an advisory services agreement with Maxim Group LLC (â€œMaximâ€) pursuant to which the Company will pay Maxim $100,000 upon the closing of a private placement of the Companyâ€™s equity or equity-linked securities. Maxim provided advisory services with respect to a private placement securities purchase agreement with certain healthcare-focused institutional investors, which closed in March of 2023. The Company paid the $100,000 advisory fee in March 2023. Â Indemnification Â In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. Â The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. However, the Company may record charges in the future as a result of these indemnification obligations. Â Additionally, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Companyâ€™s request in such capacity. The indemnification period covers all pertinent events and occurrences during the directorâ€™s or officerâ€™s service. Â Employee Benefit Plan Â In December 2021, the Company implemented a 401(k) Plan which covers all eligible employees of the Company (the â€œ401(k) Planâ€). Employer matching contributions are immediately 100% vested. The Companyâ€™s 401(k) Plan provides that the Company match each participantâ€™s contribution at 100% up to 4% of the employeeâ€™s eligible compensation. Company contributions to the 401(k) Plan totaled approximately $107,000 and $104,000 for the year ended December 31, 2023 and for the nine months ended September 30, 2024, respectively. Â 9. Stockholdersâ€™ Deficit Â Authorized Common Stock Â The Company is authorized to issue up to 400,000,000 shares of common stock at par value of $0.001 per share. Â Issuance of Common Stock and Warrants from Initial Public Offering Â During July 2021, as a result of its initial public offering, the Company issued 5,000,000 shares of common stock and 4,000,000 warrants to investors in exchange for cash at $5.00 per unit, consisting of $4.99 per share of common stock and $.0125 per four fifths of a warrant. The warrants have a 5-year term and an exercise price of $6.00 per warrant. The underwriters exercised their option to purchase an additional 600,000 warrants, and the Company received $7,500 in proceeds.Â 17 Â Â As a result of the initial public offering, the Companyâ€™s outstanding convertible notes and unpaid accrued interest were converted into 736,773 shares of common stock. Additionally, in accordance with the original terms of the warrant agreements convertible noteholders were granted a total of 184,193 common stock warrants with a 5-year term and with an exercise price of $6.00 per warrant. Â The warrants from the initial public offering are equity classified. The following table summarizes activity for the Companyâ€™s IPO warrants for the nine months ended September 30, 2024: Â Â Â

investors that provided $50 million in gross proceeds to us through a private placement. Pursuant to the securities purchase agreement, we issued to institutional investors $50.0 million in shares of our Series B-1 Convertible Preferred Stock. 50,000 Shares of Series B-1 Convertible Preferred Stock were issued at a price of $1,000.00 per share and each share is convertible into shares of common stock at a rate equal to the initial $1,000 purchase price divided by the initial conversion price of $1.00 per share. Â Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the â€œSeries B Certificate of Designationâ€), as of March 14, 2024, each share of Series B-1 Preferred Stock is, subject to approval of the Companyâ€™s stockholders, convertible into shares of common stock of the Company and, if applicable, shares of Series B-2 Convertible Preferred Stock (the â€œSeries B-2 Preferred Stockâ€), in lieu of common stock Â The Company has designatedÂ 50,000Â shares of Series A-1 Preferred Stock and 50,000Â shares of Series B-2 Preferred Stock. The Series B Certificate of Designation states that, to the extent that the conversion of the Series B-1 preferred stock results in a beneficial ownership interest in excess of the maximum percentage of common stock upon conversion, the holders will receive the as converted equivalent for the remaining shares in preferred stock. Â Â On June 20, 2024, we held our annual stockholder meeting, and as a result, stockholder approval for the conversion of the Series B-1 Convertible Preferred Stock was obtained. On July 5, 2024, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, the Company issued 42,118,000 shares of common stock and 7,882 shares of Series B-2 preferred stock in settlement of the automatic conversion of the Series B-1 Convertible Preferred Stock.Â 21 Â Â The Series B-1 Preferred Stock have the following rights: Â Dividends: Prior to the receiving Stockholder Approval, dividends will accrue, on all issued and outstanding shares of Series A-1 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts); provided that such annual dividend rate shall increase to fourteen percent (14%) if Stockholder Approval is not obtained at the first meeting of stockholders following the date of the Preferred Stock offering. If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding of the Series B-1 Preferred Stock. At all times following the Issuance Date, while shares of Series B-1 Preferred Stock are issued and outstanding, holders of Series B Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of SeriesÂ B-1 Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) are paid on shares of the Common Stock. Stockholder approval was received on June 20, 2024. Â Voting: : Subject to certain limitations described in the Series B Certificate of Designation holders of the Series B-1 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis as determined by dividing the liquidation preference with respect to such shares of Series B-1 Preferred Stock by the conversion price. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Unless and until the Company has obtained the Stockholder Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series B Preferred Stock (for purposes of calculating the number of aggregate votes that the holders of Series B Preferred Stock are entitled to on an as-converted basis) will be equal to that number of shares equal to 19.9% of the Companyâ€™s outstanding Common Stock as of the Signing Date (excluding for purposes of the calculation, any securities issued on the Signing Date) (the â€œCapâ€), which each such holder being able to vote the number of shares of Series B Preferred Stock held by it relative to the total number of shares of Series B Preferred Stock then outstanding multiplied by the Cap. Notwithstanding the foregoing, the holders of the Series B Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis with regard to the approval of the issuance of Common Stock upon conversion of the Series B Preferred Stock. Â On the tenth trading day following the announcement of the Stockholder Approval, each share of Series B-1 Preferred Stock shall automatically convert into a unit consisting of: (1) the number of shares of common stock equal to the quotient ofÂ (A) the liquidation preference with respect to such share of Series B-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holderâ€™s beneficial ownership to exceed 9.99%, such holder shall receive shares of Series B-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership divided by 1,000. Â Â Liquidation Preference: The Series B-1 Preferred Stock had a liquidation preference of one-times the original per share priceÂ of $1,000Â per share, plus any accrued but unpaid dividends thereon, whether or not declared, subject to certain customary anti-dilution adjustments. Â The Series B-2 Preferred Stock has the following rights: Â Dividends: Dividends will accrue, on all issued and outstanding shares of Series B-2 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts). If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding. Â Voting: Subject to certain limitations described in the Series B Certificate of Designation, the Series B-2 Preferred Stock is voting stock. Holders of the Series B-2 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series B-2 Preferred Stock will be entitled to one vote for each whole share of common stock into which their Series B-2 Preferred Stock is then-convertible on all matters submitted to a vote of stockholders.Â 22 Â Â Liquidation. Upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series B Preferred Stock and common stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series B Preferred Stock as if they had been converted to common stock pursuant to the terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Series B Certificate of Designation or otherwise. Â Conversion: Subject to the limitations set forth in the Series B Certificate of Designation, at the option of the holder thereof, each share of Series B-2 Preferred Stock, is convertible into the number of shares of common stock equal to the quotient of (A) the stated value ($1,000), divided by (B) the conversion price on the applicable conversion date, which is $1.00 as of the date of this report. Â 12. Warrant Liability Â In connection with the Series A Preferred Stock Offering (see Note 10), the Company issued the Warrants. Â After the Warrants were legally issued as a result of the automatic conversion of the Series A-1 Preferred Stock upon shareholder approval, they became immediately exercisable at the option of the holder. The Company determined that the Warrants, while initially contingently issuable, qualified as derivative instruments pursuant to ASC 815-40, Contracts in an Entityâ€™s Own Equity and that the Warrants were considered issued for accounting purposes concurrently with the Series A-1 Preferred Stock. Â On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the conversion of the Series A-1 Preferred Stock was obtained. On July 11, 2023, pursuant to the Series A Certificate of Designation, the Company issued, in addition to common stock and Series A-2 Preferred Stock, (i) a Tranche A Warrant to acquire 47,852,430 shares of Series A-3 Preferred Stock, (ii) a Tranche B Warrant to acquire 43,502,206 shares of Series A-4 Preferred Stock, and (iii) a Tranche C Warrant to acquire 69,603,531 shares of Series A-5 Preferred Stock. See Note 10 for discussion of exchange agreement related to Series A-2 Preferred Stock and warrants. Â The Warrants are recognized as liabilities in the balance sheets and were initially recognized at fair value at the time of issuance. The Warrants are also subject to remeasurement at each balance sheet date after issuance. Any change in fair value is recognized as a component of other income (expense) in the statements of operations in the period of change. Â The valuation of the Warrants contains unobservable inputs that reflect the Companyâ€™s own assumptions for which there is little market data. Accordingly, the Warrants are measured at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs. The significant unobservable inputs used in the fair value measurement of the Companyâ€™s Warrants include, but are not limited to, probability of obtaining certain shareholder approvals, probability of reaching certain technical milestones related to the development of oxylanthanum carbonate, and the estimated term of the Warrants. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, a change in the assumption used for the probability of obtaining certain shareholder approvals is not correlated to a change in the probability of reaching certain technical milestones. However, a change to the assumption used for the probability of obtaining certain shareholder approvals or a change in the probability of reaching certain technical milestones would have been accompanied by a directionally opposite change and a directionally similar change, respectively, in the assumption used for the estimated term.Â 23 Â Â The fair value of the Warrants associated with the Companyâ€™s March 2023 private placement transaction was determined as of March 3, 2023, and March 31, 2023, by using a Monte Carlo simulation technique (â€œMCSâ€) to value the embedded derivatives associated with the Warrants. The MCS methodology calculates the theoretical value of a warrant based on certain parameters, including: (i) the threshold of exercising the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, (vi) the number of paths, (vii) estimated probability assumptions surrounding shareholder approval as well as the achievement by the Company of technical milestones associated with regulatory and commercial progress, and (viii) an estimated discount for lack of marketability. Â The MCS valuation model was used for the valuation performed as of the transaction inception on March 3, 2023, and on March 31, 2023, due to uncertainty in the timing of shareholder approval and the potential variability in the Warrant exercise price. On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the issuance of common shares upon the conversion of the Series A-1 Preferred Stock was obtained and the exercise price for the Warrants became fixed. Therefore, as of December 31, 2023 and September 30, 2024, the fair value of the Warrants was determined using a Black Scholes model using parameters including (i) the exercise price of the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, and (vi) estimated probability assumptions surrounding the achievement by the Company of technical milestones associated with regulatory and commercial progress. Â These valuation techniques involve managementâ€™s estimates and judgment based on unobservable inputs and are classified in Level 3. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Generally, a significant increase (decrease) in the probabilities of shareholder approval and the achievement of technical milestones would have resulted in a significantly higher (lower) fair value measurement; however, changes in other inputs such as expected term and price of the underlying common stock will have a directionally opposite impact on fair value measurement. Â The Company uses a third-party valuation expert to assist in the determination of the fair value of the Warrants. The tables below summarize the valuation inputs into the Black Scholes model for the liability associated with the three tranches of Warrants at December 31, 2023 and September 30, 2024. Â Tranche A WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.54Â Â $0.54Â VolatilityÂ Â 96.5%Â â€“Â 139.2%Â Â 107.7%Â -Â 129.2% Risk free rateÂ Â 4.6% â€“ 5.3%Â Â 3.8% â€“ 4.1% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 0.5 â€“ 1.5Â Â Â 0.7 â€“ 1.7Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 29.3%Â Â 36.55 â€“ 38.50% Â Tranche B WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.59Â Â $0.59Â VolatilityÂ Â 114.6% - 139.2%Â Â 109.8%Â â€“Â 129.2% Risk free rateÂ Â 4.4% â€“ 4.8%Â Â 3.7% â€“ 3.8% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 1.0 â€“ 2.0Â Â Â 1.3 â€“ 2.3Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 12.0%Â Â 11.0% Â 24 Â Â Tranche C WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.74Â Â $0.74Â VolatilityÂ Â 107.8%Â -Â 114.6%Â Â 116.1%Â -Â 129.2% Risk free rateÂ Â 4.0%- 4.4%Â Â 3.6% â€“ 3.8% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 2.0 - 3.0Â Â Â 1.7 â€“ 2.7Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 4.3 % - 12.5%Â Â 0.01%-27.46% Â As of the issuance date (March 3, 2023), the Company estimated the fair value of the Warrants to be $2.8 million. As of December 31, 2023 and September 30, 2024, the Company estimated the fair value of the Warrants to be $13.1 million and $6.4 million, respectively. Â The following table summarizes activity for the Companyâ€™s preferred stock warrants for the nine months ended September 30, 2024: Â Â Â

expected term of the options. Â Risk-free Interest Rate - The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options. Â Expected Dividend â€“ Through September 30, 2024, the Company has never declared nor paid any cash dividends to common stockholders. SERIES B-1 DIVIDENDS PAID IN CASHThe Company shall modify its dividend policy to state that the Company intends to pay dividends to all stockholders, including holders of Series A Preferred Stock on an as-if-converted-to-common-stock basis, on a quarterly basis in an amount of which the aggregate of all quarterly dividends shall equal at least seventy-five percent (75%) of its annual net cash flow from operations following the approval of oxylanthanum carbonate by the FDA if obtained, and the commencement of commercial sales. Â The following averaged assumptions were used to calculate the fair value of awards granted to employees, directors and non-employees for the nine months ended September 30, 2023 and September 30, 2024: Â Â Â Nine months Ended Â Â September 30, Â Â 2023Â 2024 Â Â Â Â Â Expected volatilityÂ 104% â€“ 108%Â 104% - 106% Risk-free interest rateÂ 4.35%Â â€“Â 4.36%Â 3.77%Â - 4.65% Dividend yieldÂ -Â - Expected termÂ 5.92 yearsÂ 6.25 years Â 14. Net Loss Per Share Â The Company computes net loss per share using the two-class method. The two-class method uses an earnings allocation formula that determines net loss per share for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. Â Â Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units; (ii) common stock to be issued upon the assumed exercise of the Companyâ€™s common stock warrants; (iii) convertible preferred stock; and (iv) prior to issuance, the issuable warrants related to the Companyâ€™s March private placement financing.Â 27 Â Â The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended SeptemberÂ 30, Â Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Basic net loss per share Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (4,333) Â $ (4,096) Â $ (22,746) Â $ (15,204) Deemed dividends on preferred stock Â Â (72) Â Â - Â Â Â (867) Â Â Â Â Â Cash Dividends to Series B holders Â Â - Â Â Â - Â Â Â - Â Â Â (1,095) Net loss attributable to common shares, basic and diluted Â Â (4,405) Â Â (4,096) Â Â (23,613) Â Â (16,299) Â Denominator: Â Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 32,633,074 Â Â Â 88,943,212 Â Â Â 21,100,206 Â Â Â 54,073,701 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (0.13) Â $ (0.05) Â $ (1.12) Â $ (0.30) Â The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Â Â Â Three Months EndedÂ September 30,Â Â Â Nine Months EndedÂ September 30,Â Â Â Â 2023Â Â 2024Â Â 2023Â Â 2024Â Options to purchase common stockÂ 10,321,616Â Â Â 13,671,140Â Â Â 10,321,616Â Â Â 13,671,140Â Warrants to purchase common stockÂ 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Restricted stock unitsÂ Â -Â Â Â 21,765Â Â Â Â -Â Â Â 21,765Â Common stock issuable upon conversion of Series B-2 convertible preferred stockÂ Â -Â Â Â 7,882,000Â Â Â Â -Â Â Â 7,882,000Â Common stock issuable upon conversion of Series A-2 Prime convertible preferred stockÂ 43,649,000Â Â Â 22,676,000Â Â Â 43,649,000Â Â Â 22,676,000Â Warrants to purchase convertible preferred stockÂ 160,958,167Â Â Â 160,958,167Â Â Â 160,958,167Â Â Â 160,958,167Â TotalÂ 176,063,976Â Â Â 209,993,175Â Â Â 176,063,976Â Â Â 209,993,175Â Â Â Â 15. Subsequent Events Â On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. Â 28 Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â Forward Looking Statements Â This Quarterly Report on Form 10-Q for the nine-month period ended September 30, 2024 contains â€œforward-looking statementsâ€ within the meaning of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). These forward-looking statements contain information about our expectations, beliefs or intentions regarding our product development and commercialization efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. These forward-looking statements are based on managementâ€™s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. These statements may be identified by words such as â€œexpects,â€ â€œplans,â€ â€œprojects,â€ â€œwill,â€ â€œmay,â€ â€œanticipates,â€ â€œbelieves,â€ â€œshould,â€ â€œintends,â€ â€œestimates,â€ and other words of similar meaning. Â Actual results could differ materially from those contained in forward-looking statements. Many factors could cause actual results to differ materially from those in forward-looking statements, including those matters discussed below. Readers are urged to read the risk factors set forth in the Companyâ€™s recent filings with the U. S. Securities and Exchange Commission (the â€œSECâ€). These filings are available at the SECâ€™s website (www.sec.gov). Â Other unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise from time to time. Given these risks and uncertainties, the forward-looking statements discussed in this report may not prove to be accurate. Accordingly, you should not place undue reliance on these forward-looking statements, which only reflect the views of the Companyâ€™s management as of the date of this report. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required by law. Â The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this quarterly report and in our previously filed Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under â€œRisk Factorsâ€ and elsewhere in this quarterly report. See â€œInformation Regarding Forward-Looking Statements.â€ All amounts in this report are in U.S. dollars, unless otherwise noted. Â Overview Â We are a biotechnology company dedicated to developing treatments for kidney disease that have the potential to offer clinical benefit. Our development programs are focused on the development of two novel therapies: oxylanthanum carbonate , for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Â Chronic kidney disease (CKD) is the gradual loss of kidney function that can get worse over time leading to lasting damage. Our initial focus is developing drugs and getting them approved in the U.S., and then to partner with the other global biopharmaceutical companies in the rest of the world. According to United States Renal Data System (USRDS) 2022 Annual Data Report, 30 million (14%) of adults in the United States are estimated to have CKD and, of these, approximately 13 million patients have advanced CKD (stage 3-5). Approximately 550,000 patients (ESRD) are on dialysis and of those, approximately 450,000 patients (~80%) take phosphate binders to control hyperphosphatemia (too much phosphorus in their blood). The number of patients with ESRD in the U.S. is increasing steadily and is projected to reach between 971,000 and 1,259,000 patients in 2030. Â AKI is a sudden episode of kidney failure or kidney damage (within the first 90 days of injury). After 90 days, the patient is considered to have progressed into CKD. AKI affects more than 2 million US patients and costs the healthcare system in excess of $9 billion per year. More than 300,000 patients per year in the U.S. die due to AKI that has many causes. Â 29 Â Â Our business model is to license technologies and drugs and pursue development, regulatory approval, and commercialization of those products in global markets. Many biotechnology companies utilize similar strategies of in-licensing and then developing and commercializing drugs. We believe, however, that our management teamâ€™s broad network, expertise in the biopharmaceutical industry, and successful track record gives us an advantage in identifying and bringing these assets into the Company at an attractive price with limited upfront cost. Â Since our formation we have devoted substantially all of our resources to developing our product candidates. We have incurred significant operating losses to date. Our net losses were $22.7 million and $15.2Â million for the nine months ended September 30, 2023, and September 30, 2024, respectively. As of September 30, 2024, we had an accumulated deficit of $79.7 million. We expect that our operating expenses will increase significantly as we advance our product candidates through pre-clinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. Â We have funded our operations primarily from the sale and issuance of common and preferred stock, convertible promissory notes and from a loan, including cash and deferred salary from our Chief Executive Officer and principal stockholder. Â Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of our current product candidates and future product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into agreements to raise capital as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our current product candidates and future product candidates. Â We plan to continue to use third-party service providers, including contract manufacturing organizations, to carry out our pre-clinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. Â Recent Developments Â New Drug Application Â On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. Â Series B Preferred Financing Â On March 13, 2024, we signed a securities purchase agreement with certain healthcare-focused institutional investors that provided $50 million in gross proceeds to us through a private placement. Pursuant to the securities purchase agreement, we issued to institutional investors $50.0 million in shares of our Series B-1 Convertible Preferred Stock. 50,000 Shares of Series B-1 Convertible Preferred Stock were issued at a price of $1,000.00 per share and each share is convertible into shares of common stock at a rate equal to the initial $1,000 purchase price divided by the initial conversion price of $1.00 per share. Â On June 20, 2024, we held our annual stockholder meeting, and as a result, stockholder approval for the conversion of the Series B-1 Convertible Preferred Stock was obtained. On July 5, 2024, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, the Company issued 42,118,000 shares of common stock and 7,882 shares of Series B-2 preferred stock in settlement of the automatic conversion of the Series B-1 Convertible Preferred Stock Â Components of Results of Operations Â Revenues Â We recognize revenue from product sales or services rendered when control of the promised goods is transferred to a counterparty in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as we satisfy a performance obligation. We may earn licensing revenue in the future if we negotiate business development arrangements with third parties. Â 30 Â Â Research and Development Expenses Â Substantially all of our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for our research and product development employees and allocated overheads, including information technology costs and utilities and expenses for the issuance of shares pursuant to the anti-dilution clause in the purchase of in process research and development technology. We expense both internal and external research and development expenses as they are incurred. Â We do not allocate our costs by product candidate, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, laboratory supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, are not tracked by product candidate. Â We expect our research and development expenses to increase substantially for at least the next few years, as we seek to initiate additional clinical trials for our product candidates, complete our clinical programs, pursue regulatory approval of our product candidates and prepare for the possible commercialization of such product candidates. Predicting the timing or cost to complete our clinical programs or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty. Â General and Administrative Expenses Â General and administrative expenses consist principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for legal, consulting, accounting and tax services, including information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses. Â We anticipate that our general and administrative expenses will increase as a result of increased personnel costs, expanded infrastructure and higher consulting, legal and accounting services costs associated with complying with the applicable stock exchange and the SEC requirements, investor relations costs and director and officer insurance premiums associated with being a public company. Â Other Expenses Â Other expenses consist of the change in fair value of our warrant liability, interest income and interest expense. Â Results of Operations Â Comparison of the Three Months Ended September 30, 2023 and 2024 Â The following table summarizes our results of operations for the periods indicated (in thousands): Â Â Â Three Months Ended September 30,Â Â Â Â Â Â Â Â Â 2023Â Â 2024Â Â ChangeÂ Â % ChangeÂ Â Â (unaudited)Â Â (unaudited)Â Â Â Â Â Â Â Â Licensing revenues:Â $-Â Â $-Â Â $-Â Â Â -Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ 3,372Â Â Â 3,045Â Â Â (327)Â Â (10)% General and administrativeÂ 2,566Â Â Â 3,206Â Â Â 640Â Â Â 25% Total operating expensesÂ 5,938Â Â Â 6,251Â Â Â 313Â Â Â 5% Loss from operationsÂ Â (5,938)Â Â Â (6,251)Â Â (313)Â Â 5% Other income (expenses):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ 227Â Â Â 416Â Â Â 188Â Â Â 83% Interest expenseÂ Â (18)Â Â (15)Â Â 3Â Â Â (17)% Change in fair value of warrant liabilityÂ 1,396Â Â Â 1,754Â Â Â 358Â Â Â 26% Total other income (expenses)Â Â 1,605Â Â Â 2,155Â Â Â 549Â Â Â 34% Â Net lossÂ $(4,333)Â $(4,096)Â $236Â Â Â (5)% Â 31 Â Â Licensing Revenues Â There was no Licensing revenue recorded in the three months ended September 30, 2023 or in the three months ended September 30, 2024. We may earn additional licensing revenue in the future if we negotiate business development arrangements with third parties. Â Research and Development Expenses Â Research and development expenses decreased by approximately $0.4 million, or 10%, from approximately $3.4 million for the three months ended September 30, 2023, to approximately $3.0 million for the three months ended September 30, 2024. The decrease in research and development expenses was primarily due to a $0.4 million decrease in drug development costs. Labor costs increased $151,000 from the prior period. Consulting and other costs increased $89,000. Non-cash stock compensation costs decreased $176,000. Â General and Administrative Expenses Â General and administrative expenses increased by 640,000, or 25%, from approximately $2.6 million for the three months ended September 30, 2023, to approximately $3.2 million for the three months ended September 30, 2024 primarily due to an decrease of $149,000 in non-cash stock compensation costs. Insurance expense decreased $2,000. Labor costs increased $76,000 from the prior period. Travel, rent, and other costs increased $715,000. Â Other Income (Expenses) Â Other income (expenses) increased $ 0.5 million, or 34%, from $1.6 million in the three months ended September 30, 2023 to $2.2 million for the three months ended September 30, 2024 due primarily to a change in fair value of our warrant liability. Â Comparison of the Nine Months Ended September 30, 2023 and 2024 Â Â Â Nine months Ended September 30,Â 2023Â Â 2024Â Â ChangeÂ Â % ChangeÂ Â Â (unaudited)Â Â (unaudited)Â Â Â Â Â Â Â Â Licensing revenues:Â $675Â Â $-Â Â $(675)Â Â (100)% Operating expenses:Â Research and developmentÂ 8,669Â Â Â 14,726Â Â Â 6,057Â Â Â 70% General and administrativeÂ 6,467Â Â Â 8,130Â Â Â 1,663Â Â Â 26% Total operating expensesÂ 15,136Â Â Â 22,856Â Â Â 7,720Â Â Â 51% Loss from operationsÂ (14,461)Â Â (22,856)Â Â (8,395)Â Â 58% Other income (expenses):Â Interest incomeÂ 475Â Â Â 947Â Â Â 472Â Â Â 99% Interest expenseÂ Â (63)Â Â (51)Â Â 12Â Â Â (19)% Change in fair value of warrant liabilityÂ (8,697)Â Â 6,756Â Â Â 15,453Â Â Â (178)% Total other income (expenses)Â Â (8,285)Â Â 7,652Â Â Â 15,937Â Â Â (192)% Â Net lossÂ $(22,746)Â $(15,204)Â 7,542Â Â Â (33)% Â 32 Â Â Licensing Revenues Â Licensing revenues decreased approximately $0.7 million, or 100%, from the nine months ended September 30, 2023 due to an upfront payment of approximately $0.7 million associated with a licensing agreement entered into with Lotus International Pte Ltd. in February 2023. There was no comparable revenue earned in the current period. We may earn additional licensing revenue in the future if we negotiate business development arrangements with third parties. Â Research and Development Expenses Â Research and development expenses increased by approximately

$6.0 million, or 70%, from approximately $8.7 million for the nine months ended September 30, 2023 to approximately $14.7 million for the nine months ended September 30, 2024. The increase in research and development expenses was primarily due to a $5.4 million increase in drug development costs. Labor costs increased $272,000 from the prior period. Consulting and other costs increased $206,000. Non-cash stock compensation increased $170,000. Â General and Administrative Expenses Â General and administrative expenses increased by $1.7 million, or 26%, from approximately 6.5 million for the nine months ended September 30, 2023 to approximately $8.1 million for the nine months ended September 30, 2024 due to an increase of $380,000 in noncash stock compensation expense. Labor costs increased $355,000. Insurance, travel and other costs increased $928,000 from the prior period. Â Other Income (Expenses) Â Other income (expenses) increased by $15.5 million (income), or 178%, from $8.7 million expense in the nine months ended September 30, 2023 to $6.8 million income for the nine months ended September 30, 2024 due primarily to the change in fair value of our warrant liability.Â Â Liquidity and Capital Resources Â Sources of Liquidity Â Since our formation through DecemberÂ 31, 2020, we have funded our operations with the sale of common and preferred stock, convertible notes and from a loan from our Chief Executive Officer and principal stockholder. Â As a result of our initial public offering (â€œIPOâ€), on July 13, 2021 we began trading on the Nasdaq Capital Market under the symbol â€œUNCYâ€, and on July 15, 2021 we received approximately $22.3 million in net proceeds after deducting the underwriting discounts, commissions and offering expenses. We have used the net proceeds from the IPO to complete pre-clinical and clinical studies, submit regulatory filings to the FDA, and for general and corporate purposes, including hiring additional management and conducting market research and other commercial planning. Â Future revenue streams may consist of collaboration or licensing revenue as well as product sales. Â On March 3, 2023, we entered into a securities purchase agreement with certain healthcare-focused institutional investors that may provide up to $130.0 million in gross proceeds through a private placement and that included initial upfront funding of $30.0 million. Proceeds from the offering will be used to support our NDA submission with the FDA for approval of oxylanthanum carbonate for the treatment of hyperphosphatemia in the U.S. and, if approved, for the commercial launch of oxylanthanum carbonate in the U.S. Â On March 13, 2024, we entered into a securities purchase agreement with certain accredited investors pursuant to which we agreed to issue and sell, in a private placement, 50,000 shares of our Series B Convertible Preferred Stock, par value $0.001 per share at a purchase price of $1,000 per share with an initial conversion price of $1.00 per share, for an aggregate purchase price of $50.0 million. Â 33 Â Â Future Funding Requirements Â We have incurred net losses since our inception. For the nine months ended September 30, 2024, we had a net loss of $15.2 million, and we expect to incur substantial additional losses in future periods. As of September 30, 2024, we had an accumulated deficit of $79.7 million. Â We expect to continue incurring losses in the future and will be required to raise additional capital in the future to complete our clinical trials, pursue product development initiatives and penetrate markets for the sale of our products. We believe that we will continue to have access to capital resources through possible equity offerings, debt financings, corporate collaborations or other means. There can be no assurance that we will be able to obtain additional financing on terms acceptable to us, on a timely basis or at all. If we are unable to secure additional capital, we may be required to curtail any clinical trials and development of new or existing products and take additional measures to reduce expenses in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. Based on our current level of expenditures, we believe that we have sufficient resources such that there is not substantial doubt about our ability to continue operations for at least one year after the date that these financial statements are available to be issued. Â We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors, including: Â Â â— the scope, timing, rate of progress and costs of our drug discovery efforts, pre-clinical development activities, laboratory testing and clinical trials for our current product candidates and future product candidates; Â Â â— the number and scope of clinical programs we decide to pursue; Â Â â— the cost, timing and outcome of preparing for and undergoing regulatory review of our current product candidates and future product candidates; Â Â â— the scope and costs of development and commercial manufacturing activities; Â Â â— the cost and timing associated with commercializing our current product candidates and future product candidates, if they receive marketing approval; Â Â â— the extent to which we acquire orÂ in-licenseÂ other product candidates and technologies; Â Â â— the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; Â Â â— our ability to establish and maintain collaborations on favorable terms, if at all; Â Â â— our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our current product candidates and future product candidates and, ultimately, the sale of our products, following FDA approval; Â Â â— the impact, if any, of the coronavirus pandemic on our business operations; Â Â â— our ability to access capital; Â Â â— our implementation of operational, financial and management systems; and Â Â â— the costs associated with being a public company. Â 34 Â Â A change in the outcome of any of these or other variables with respect to the development of any of our current product candidates or future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Â Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition. Â Related Party Payable Â The Company received advances from the stockholder of $210,000 during February 2023. The Company repaid amounts owed to the stockholder of $210,000 plus accrued interest during March 2023. Â Summary of Cash Flows Â The following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands): Â Â Â Â Nine Months Ended September 30,Â Â Â Â 2023Â Â 2024Â Â Â Â (unaudited)Â Â (unaudited)Â Â Net cash (used in) provided by:Â Â Â Â Â Â Â Operating activitiesÂ $(13,844)Â $(22,027) Investing activitiesÂ Â (12)Â Â (50) Financing activitiesÂ Â 27,746Â Â Â Â 44,723Â Net increase in cash and cash equivalentsÂ $13,890Â Â $22,646Â Â Cash Flows from Operating Activities Â Net cash used in operating activities was $ 22.0 million for the nine months ended September 30, 2024. Cash used in operating activities was primarily due to the use of funds for development costs associated with our drug candidates, labor costs, consulting services, and other corporate expenditures for investor relations, compliance, and legal services. Â Net cash used in operating activities was $13.8 million for the nine months ended September 30, 2023. Cash used in operating activities was primarily due to the use of funds for development costs associated with our drug candidates, labor costs, consulting services, and other corporate expenditures for investor relations, compliance, and legal services. Â Cash Flows from Investing Activities Â Net cash used in investing activities was $50,000 for the nine months ended September 30, 2024 and was due to the purchase of lab equipment. Â Net cash used in investing activities was $12,000 for the nine months ended September 30, 2023 and was due to the purchase of furniture and fixtures for our corporate office. Â 35 Â Â Cash Flows from Financing Activities Â Net cash provided by financing activities was $44.7 million during the nine months ended September 30, 2024 due primarily to the private placement financing agreement we signed on March 13, 2024 , partially offset by dividends paid to preferred stockholders. Â Net cash provided by financing activities was $27.7 million during the nine months ended September 30, 2023 due primarily to the private placement financing agreement we signed on March 3, 2023. Â Critical Accounting Policies, Significant Judgments and Use of Estimates Â Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We consider our critical accounting policies and estimates to be related to revenue, research and development, stock-based compensation, debt and equity classification and warrant liabilities. There have been no other material changes to our critical accounting policies and estimates during the nine months ended September 30, 2024 from those used for the year ended December 31, 2023. The below policies represent our critical accounting policies. Â Revenue Recognition Â We implemented ASC 606, Revenue from Contracts with Customers. This included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures. We recognize revenue from product sales or services rendered when control of the promised goods are transferred to a counterparty in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as we satisfy a performance obligation. Â Debt and Equity Classification Â In conjunction with the issuance of Series A-1 Preferred Stock in March 2023, and in conjunction with the issuance of Series B-1 Preferred Stock in March 2024, we initially account for the preferred stock as temporary, or mezzanine, equity. The Series A-1 and Series B-1 Preferred Stock do not fall within the scope of ASC 480, Distinguishing Liabilities from Equity, do not contain any embedded derivatives that require bifurcation, and are not classified as liabilities. However, as the Series A-1 and Series B-1 Preferred Stock, at issuance, are contingently redeemable upon the occurrence of an event that is not solely within our control, they are required to be initially classified as mezzanine equity and measured at the amount of net proceeds received. As the Series A-1 and Series B-1 Preferred Stock are not currently redeemable or probable of becoming redeemable, no subsequent remeasurement is required. Â Warrant Liabilities Â In conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), we established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued, subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. We account for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liabilities are initially measured at fair value, resulting in an implied discount on the related preferred stock financing arrangement (recognized as a partial offset to the carrying value of the Series A-1 Preferred Stock), and are remeasured at fair value each reporting period. Changes in the fair value of the warrant liabilities are recognized in earnings during each period. The warrant liabilities are measured using Level 3 fair value inputs. See Note 12 for a description of warrant liabilities and the related valuations. Â 36 Â Â Research and Development Â We expense costs when incurred related to the research and development associated with the design, development and testing of product candidates, as well as acquisition of product candidates or compounds. Research and development expenses include fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for our research and product development employees and allocated overheads, including information technology costs and utilities and expenses for issuance of shares pursuant to anti-dilution clause in the purchase of IPR&D technology. We expense both internal and external research and development expenses as they are incurred. Â Stock-Based Compensation Â We account for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. We recognize forfeitures related to stock-based compensation as they occur. We estimate the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, and the risk-free interest rate. Â JOBS Act Accounting Election Â On AprilÂ 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an â€œemerging growth companyâ€ can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an â€œemerging growth companyâ€ can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Â We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards. Â Subject to certain conditions set forth in the JOBS Act, as an â€œemerging growth company,â€ we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditorâ€™s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with the requirement adopted by the Public Company Accounting Oversight Board (â€œPCAOBâ€) regarding the communication of critical audit matters in the auditorâ€™s report on financial statements. We will remain an â€œemerging growth companyâ€ until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Â Recent Accounting Pronouncements Â See the section titled â€œSummary of Significant Accounting Policiesâ€”Recent Accounting Pronouncementsâ€ in Note 2 to our financial statements included elsewhere in this quarterly report for additional information. Â Off-Balance Sheet Arrangements Â We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules. Â Â 37 Â Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â As a smaller reporting company, we are not required to provide the information required by this item. Â ITEM 4. CONTROLS AND PROCEDURES Â As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of the Companyâ€™s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer each concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SECâ€™s rules and forms, and that such information has been accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, in a manner that allows timely decisions regarding required disclosure. Â In evaluating the effectiveness of our internal control over financial reporting, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework 2013. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer determined, based upon the existence of the material weakness described below, that we did not maintain effective internal control over financial reporting as of September 30, 2024. Specifically, we lack a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately while maintaining appropriate segregation of duties. Without such professionals, we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries. Â The lack of adequate staffing levels and expertise of unusual or infrequent transactions with complex or infrequently applied accounting topics resulted in the insufficient level of supervision, review and approval of certain information used to prepare our financial statements and the maintenance of effective controls to adequately monitor and review significant transactions for financial statement completeness and accuracy. These control deficiencies, although varying in severity, contributed to the material weakness in the control environment. If one or more material weaknesses persist or if we fail to establish and maintain effective internal control over financial reporting, our ability to accurately report our financial results could be adversely affected. Â The above material weakness did not result in a material misstatement of our previously issued financial statements, however, it could result in a misstatement of our account balances or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected. Â Management is taking steps to remediate the material weakness in our internal control over financial reporting. To address the issues, we plan to hire additional personnel. Specifically, management has: Â Â Â â— Increased the number of accounting personnel; Â Â Â â— Engaged third party experts to assist management in analyses and conclusions

involving complex or infrequently applied accounting treatment; and Â Â â— Engaged third party experts to assist management in completing a comprehensive risk assessment to identify, design and implement control activities. Â In addition, management is taking steps to review and enhance business policies, procedures and related internal controls to standardize business processes. Â We expect to complete the remediation by the end of 2024. We expect to incur additional costs to remediate this weakness. Â Changes in Internal Control Over Financial Reporting Â There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting. Â 38 Â Â PART II â€“ OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS Â We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. We may periodically be the subject of various pending or threatened legal actions and claims arising out of our operations in the normal course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. In the opinion of management, adequate provision has been made in our financial statements at September 30, 2024 with respect to such matters. Â ITEM 1A. RISK FACTORS Â There have been no material changes from the risk factors disclosed in our FormÂ 10-K for the year ended December 31, 2023, except for the following: Â If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. Â Our Common Stock is currently listed on the Nasdaq Capital Market and the continued listing of our Common Stock on the Nasdaq Capital Market is contingent on our continued compliance with a number of listing requirements. If we are unable to comply with the continued listing requirements of the Nasdaq Capital Market, our Common Stock would be delisted from the Nasdaq Capital Market, which would limit investorsâ€™ ability to effect transactions in our Common Stock and subject us to additional trading restrictions. In order to maintain our listing, we must maintain certain share prices, financial and share distribution targets, including maintaining a minimum amount of stockholdersâ€™ equity and a minimum number of public stockholders, as well as satisfy other listing requirements of the Nasdaq Capital Market. In addition to these objective standards, Nasdaq Capital Market may delist the securities of any issuer for other reasons involving the judgment of Nasdaq Capital Market. Â On July 9, 2024, we received written notice from theÂ Nasdaq Stock Market, LLCÂ (â€œNasdaqâ€) that we were not in compliance withÂ Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of our common stock had been below $1.00 per share for 30 consecutive business days.Â In accordance with Nasdaq Listing RuleÂ 5810, we have a period of 180 calendar days, or until January 6, 2025, to regain compliance with the minimum bid price requirement and market value of common stock requirement. To regain compliance with the Nasdaq bid price requirement, the closing bid price of our common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during this 180 calendar day period. In the event we do not regain compliance by January 6, 2025, we may be eligible for an additional 180 calendar day grace period; however, there can be no assurance that we will regain compliance with the Nasdaq continued listing requirements. Â There is no assurance that we will be able to maintain compliance with the Nasdaq Capital Market continued listing standards and/or continue our listing on the Nasdaq Capital Market in the future. Â If the Nasdaq Capital Market delists our Common Stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect the Common Stock would qualify to be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including: Â â—a limited availability of market quotations for our securities; â—reduced liquidity for our securities; â—substantially impair our ability to raise additional funds; â—the loss of institutional investor interest and a decreased ability to issue additional securities or obtain additional financing in the future; â—a determination that our Common Stock is a â€œpenny stock,â€ which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; â—a limited amount of news and analyst coverage; and â—potential breaches of representations or covenants of our agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements, which, regardless of merit, could result in costly litigation, significant liabilities and diversion of our managementâ€™s time and attention and could have a material adverse effect on our financial condition, business and results of operations. Â 39 Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â Not applicable Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES Â Not applicable. Â ITEM 4. MINE SAFETY DISCLOSURES Â Not applicable. Â ITEM 5. OTHER INFORMATION Â Rule 10b5-1 Trading Plans Â During the three months ended SeptemberÂ 30, 2024, no Section 16 officers and directorsÂ adopted, modified orÂ terminatedÂ a â€œRule 10b5-1 trading arrangementâ€ (as defined in Item 408 of Regulation S-K of the Exchange Act), except that on September 20, 2024, Shalabh Gupta, M.D., our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 900,000 shares of our common stock beginning on January 20, 2025 and terminating on January 19, 2026. Â Certificate of Correction Â On November 8, 2024, we filed a Certificate of Correction with the Secretary of State of Delaware (â€œCertificate of Correctionâ€) for our Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (â€œSeries B Certificate of Designationâ€) filed with the Secretary of State of Delaware on March 14, 2024. The Certificate of Correction was filed to correct certain scrivenerâ€™s errors in the Series B Certificate of Designation with respect to voting rights for the Series B Convertible Preferred Stock under Section 4(a) and conversion at the option of holder under Section 6(c) thereof. Specifically, Section 4(a) of the Series B Certificate of Designation inadvertently stated that the â€œVoting Conversion Priceâ€ be used for determining the as-converted amount of the Series B Convertible Preferred Stock instead of using the â€œConversion Priceâ€ for such determination and also failed to reference the limitations imposed by Section 6(f). In addition, Section 6(c) of the Series B Certificate of Designation inadvertently used a fixed number of shares of common stock into which shares of Series B-2 Convertible Preferred Stock convert into (one thousand shares), instead of based on the conversion rate equal to the Stated Value ($1,000) divided by the Conversion Price ($1.00). Pursuant to Section 103(f) of the Delaware General Corporation Law, the correction was effective as of March 14, 2024, except as to those persons who are substantially and adversely affected by the correction, and as to those persons the correction was effective as of November 8, 2024. Â The foregoing description of the Certificate of Correction is qualified in its entirety by reference to the full text of the Certificate of Correction, which is filed herewith as Exhibit 3.1 and incorporated herein by reference. Â ITEM 6. EXHIBITS Â Exhibit No. Â Description 3.1 Â Certificate of Correction to Series B Preferred Certificate of Designation filed with the Delaware Secretary of State on November 8, 2024 31.1 Â Certification of Principal Executive Officer required under RuleÂ 13a-14(a)/15d-14(a)Â under the Exchange Act. 31.2 Â Certification of Principal Financial Officer required under RuleÂ 13a-14(a)/15d-14(a)Â under the Exchange Act. 32.1 Â Certification of Principal Executive Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002. 32.2 Â Certification of Principal Financial Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002. 101.INS Â Inline XBRL Instance Document. 101.SCH Â Inline XBRL Taxonomy Extension Schema Document. 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â @ Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because such information is both not material and is the type that the Company treats as private or confidential. Â 40 Â Â SIGNATURES Â Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 13th day of November, 2024. Â Signature Â Title Â Date Â Â Â Â Â /s/ Shalabh Gupta Â Chief Executive Officer, President and Chairman Â November 13, 2024 Shalabh Gupta Â (Principal Executive Officer) Â Â Â Â Â Â /s/ John Townsend Â Chief Financial Officer Â November 13, 2024 John Townsend Â (Principal Financial and Accounting Officer) Â Â Â Â 41 Â Â false --12-31 Q3 0001766140 0001766140 2024-01-01 2024-09-30 0001766140 2024-11-13 0001766140 2023-12-31 0001766140 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-12-31 0001766140 uncy:SeriesA2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2023-12-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-09-30 0001766140 us-gaap:PreferredStockMember 2023-12-31 0001766140 us-gaap:PreferredStockMember 2024-09-30 0001766140 2023-07-01 2023-09-30 0001766140 2024-07-01 2024-09-30 0001766140 2023-01-01 2023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2023-07-01 2023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2023-01-01 2023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2024-01-01 2024-09-30 0001766140 uncy:SeriesBHoldersMember 2023-07-01 2023-09-30 0001766140 uncy:SeriesBHoldersMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesBHoldersMember 2023-01-01 2023-09-30 0001766140 uncy:SeriesBHoldersMember 2024-01-01 2024-09-30 0001766140 uncy:SeriesA1PreferredStockMember 2022-12-31 0001766140 us-gaap:CommonStockMember 2022-12-31 0001766140 uncy:SeriesA2PreferredStockMember 2022-12-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001766140 us-gaap:RetainedEarningsMember 2022-12-31 0001766140 2022-12-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-01-01 2023-03-31 0001766140 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2023-01-01 2023-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001766140 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001766140 2023-01-01 2023-03-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-03-31 0001766140 us-gaap:CommonStockMember 2023-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2023-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001766140 us-gaap:RetainedEarningsMember 2023-03-31 0001766140 2023-03-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-04-01 2023-06-30 0001766140 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-04-01 2023-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001766140 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001766140 2023-04-01 2023-06-30 0001766140 uncy:SeriesA1PreferredStockMember 2023-06-30 0001766140 us-gaap:CommonStockMember 2023-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001766140 us-gaap:RetainedEarningsMember 2023-06-30 0001766140 2023-06-30 0001766140 uncy:SeriesA1PreferredStockMember 2023-07-01 2023-09-30 0001766140 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-07-01 2023-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001766140 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001766140 uncy:SeriesA1PreferredStockMember 2023-09-30 0001766140 us-gaap:CommonStockMember 2023-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001766140 us-gaap:RetainedEarningsMember 2023-09-30 0001766140 2023-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2023-12-31 0001766140 us-gaap:CommonStockMember 2023-12-31 0001766140 uncy:SeriesA2PreferredStockMember 2023-12-31 0001766140 uncy:SeriesA2PrimePreferredStockMember 2023-12-31 0001766140 uncy:SeriesB2PreferredStockMember 2023-12-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001766140 us-gaap:RetainedEarningsMember 2023-12-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-01-01 2024-03-31 0001766140 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2024-01-01 2024-03-31 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-01-01 2024-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001766140 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001766140 2024-01-01 2024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-01-01 2024-03-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-03-31 0001766140 us-gaap:CommonStockMember 2024-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2024-03-31 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001766140 us-gaap:RetainedEarningsMember 2024-03-31 0001766140 2024-03-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-04-01 2024-06-30 0001766140 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-04-01 2024-06-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-04-01 2024-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001766140 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001766140 2024-04-01 2024-06-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-04-01 2024-06-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-06-30 0001766140 us-gaap:CommonStockMember 2024-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-06-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-06-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001766140 us-gaap:RetainedEarningsMember 2024-06-30 0001766140 2024-06-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-07-01 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-07-01 2024-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001766140 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001766140 us-gaap:RetainedEarningsMember 2024-09-30 0001766140 2024-09-30 0001766140 stpr:DE 2024-01-01 2024-09-30 0001766140 us-gaap:IPOMember 2021-07-15 2021-07-15 0001766140 us-gaap:PrivatePlacementMember 2023-03-03 2023-03-03 0001766140 us-gaap:PrivatePlacementMember 2024-03-13 2024-03-13 0001766140 us-gaap:SeriesBPreferredStockMember 2024-03-13 0001766140 2024-03-13 2024-03-13 0001766140 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001766140 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001766140 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2024-04-01 2024-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-07-01 2024-09-30 0001766140 uncy:ExclusiveLicenseAgreementMember 2017-10-01 2017-10-31 0001766140 2017-10-01 2017-10-31 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2018-09-01 2018-09-30 0001766140 uncy:InvestmentMember uncy:SpectrumPharmaceuticalsIncMember 2018-09-30 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2018-09-30 0001766140 2021-07-13 0001766140 us-gaap:CommonStockMember 2021-07-13 2021-07-13 0001766140 2021-01-01 2021-09-30 0001766140 uncy:AltairNanomaterialsIncMember 2021-01-01 2021-09-30 0001766140 uncy:AltairMember 2021-01-01 2021-09-30 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2021-01-01 2021-09-30 0001766140 uncy:SublicenseDevelopmentAgreementMember 2022-08-31 0001766140 uncy:SublicenseDevelopmentAgreementMember 2023-02-28 0001766140 uncy:LotusInternationalPteLtdMember 2023-01-01 2023-09-30 0001766140 uncy:SyneosHealthLLCMember 2021-07-19 2021-07-19 0001766140 uncy:QuotientSciencesLimitedMember 2022-01-06 2022-01-06 0001766140 2022-01-06 0001766140 uncy:QuotientSciencesLimitedMember 2024-09-30 0001766140 uncy:QuotientSciencesLimitedMember 2024-01-01 2024-09-30 0001766140 uncy:QuotientSciencesLimitedMember 2023-12-31 0001766140 uncy:CBCCGlobalResearchIncMember 2022-02-09 2022-02-09 0001766140 uncy:CBCCGlobalResearchIncMember 2023-03-31 2023-03-31 0001766140 2023-03-31 2023-03-31 0001766140 2023-04-10 2023-04-10 0001766140 uncy:InotivMember 2024-01-01 2024-09-30 0001766140 uncy:InotivMember 2023-12-31 0001766140 uncy:InotivMember 2024-09-30 0001766140 uncy:LeesPharmaceuticalHKLimitedMember 2022-07-14 0001766140 uncy:LeesPharmaceuticalHKLimitedMember 2022-07-14 2022-07-14 0001766140 srt:MinimumMember 2022-07-14 2022-07-14 0001766140 srt:MaximumMember 2022-07-14 2022-07-14 0001766140 uncy:OxylanthanumCarbonateMember 2023-01-01 2023-12-31 0001766140 uncy:OxylanthanumCarbonateMember 2023-12-31 0001766140 uncy:LotusInternationalPteLtdMember 2023-02-01 0001766140 2023-02-01 2023-02-01 0001766140 uncy:ShilpaMedicareLtdMember 2024-01-01 2024-09-30 0001766140 uncy:UpfrontPaymentMember 2022-07-14 2022-07-14 0001766140 uncy:MilestonePaymentMember 2022-07-14 2022-07-14 0001766140 us-gaap:OtherContractMember 2024-01-01 2024-09-30 0001766140 uncy:UpfrontPaymentMember 2023-02-01 2023-02-01 0001766140 uncy:MilestonePaymentMember 2023-02-01 2023-02-01 0001766140 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001766140 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001766140 us-

gaap:FurnitureAndFixturesMember 2023-12-31 0001766140 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001766140 us-gaap:EquipmentMember 2023-12-31 0001766140 us-gaap:EquipmentMember 2024-09-30 0001766140 2021-12-31 0001766140 2023-03-15 0001766140 uncy:OperatingLeaseMember 2023-03-15 0001766140 uncy:OperatingLeaseMember 2024-01-01 2024-09-30 0001766140 uncy:OperatingLeaseMember 2024-09-30 0001766140 srt:ChiefExecutiveOfficerMember 2023-02-28 0001766140 2023-03-01 2023-03-31 0001766140 uncy:MaximGroupLLCMember 2022-12-01 2022-12-31 0001766140 uncy:MaximGroupLLCMember 2023-03-01 2023-03-31 0001766140 2021-12-01 2021-12-31 0001766140 srt:MaximumMember 2021-12-01 2021-12-31 0001766140 srt:MinimumMember 2021-12-01 2021-12-31 0001766140 2023-01-01 2023-12-31 0001766140 us-gaap:IPOMember 2021-07-31 0001766140 us-gaap:WarrantMember 2021-07-31 0001766140 2021-07-31 0001766140 us-gaap:CommonStockMember 2021-07-31 0001766140 us-gaap:WarrantMember 2021-07-01 2021-07-31 0001766140 us-gaap:WarrantMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2023-06-26 0001766140 uncy:SeriesA2PreferredStockMember 2023-06-26 0001766140 2023-12-31 2023-12-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-03-03 2023-03-03 0001766140 uncy:SeriesA3PreferredStockMember uncy:TrancheAWarrantMember 2023-03-03 0001766140 uncy:SeriesA4PreferredStockMember uncy:TrancheBWarrantMember 2023-03-03 0001766140 uncy:SeriesA5PreferredStockMember uncy:TrancheCWarrantMember 2023-03-03 0001766140 uncy:TrancheAWarrantMember 2023-03-03 2023-03-03 0001766140 uncy:TrancheBWarrantMember 2023-03-03 2023-03-03 0001766140 uncy:TrancheCWarrantMember 2023-03-03 2023-03-03 0001766140 uncy:SeriesA1PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA4PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA5PreferredStockMember 2024-09-30 0001766140 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMember 2023-03-31 0001766140 uncy:SeriesACertificateOfDesignationMember 2023-07-11 0001766140 2023-07-11 2023-07-11 0001766140 uncy:ShareholderMember uncy:SeriesA1PreferredStockMember 2023-12-31 0001766140 uncy:ShareholderMember uncy:SeriesA2PreferredStockMember 2023-12-31 0001766140 us-gaap:PreferredStockMember 2024-03-13 2024-03-13 0001766140 us-gaap:WarrantMember uncy:SeriesA3PreferredStockMember 2023-07-11 0001766140 us-gaap:WarrantMember uncy:SeriesA4PreferredStockMember 2023-07-11 0001766140 uncy:AmendedTrancheBWarrantsMember 2023-07-11 0001766140 uncy:OriginalTrancheCWarrantsMember 2023-07-11 0001766140 uncy:AmendedTrancheCWarrantsMember uncy:SeriesA5ConvertiblePreferredStockMember 2023-07-11 0001766140 us-gaap:WarrantMember uncy:SeriesA3PreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMember uncy:SeriesA4PreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMember uncy:SeriesA5PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PrimeConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA4ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA5ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMember uncy:SeriesA2PrimePreferredStockMember 2024-03-13 0001766140 uncy:ExchangeAgreementMember uncy:SeriesA3ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMember uncy:SeriesA4ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMember uncy:SeriesA5ConvertiblePreferredStockMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMember uncy:SeriesA2PrimeConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesB1ConvertiblePreferredStockMember 2024-03-13 2024-03-13 0001766140 uncy:SeriesB1ConvertiblePreferredStockMember uncy:SecuritiesPurchaseAgreementMember 2024-03-13 2024-03-13 0001766140 uncy:SeriesB1PreferredStockMember 2024-03-13 0001766140 uncy:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesBCertificateOfDesignationMember 2024-07-05 0001766140 uncy:SeriesB2PreferredStockMember 2024-07-05 0001766140 uncy:SeriesB1PreferredStockMember 2024-01-01 2024-09-30 0001766140 uncy:SeriesB1PreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001766140 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3PreferredStockMember uncy:TrancheAWarrantMember 2023-07-11 0001766140 uncy:SeriesA4PreferredStockMember uncy:TrancheBWarrantMember 2023-07-11 0001766140 uncy:SeriesA5PreferredStockMember uncy:TrancheCWarrantMember 2023-07-11 0001766140 2023-03-03 2023-03-03 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheBWarrantMember 2023-12-31 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMember uncy:MeasurementInputProbabilityForFDAApprovalMember uncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:WarrantMember 2023-12-31 0001766140 2023-06-26 0001766140 2023-06-26 2023-06-26 0001766140 uncy:ShareholdersMember 2024-06-20 2024-06-20 0001766140 2024-06-20 2024-06-20 0001766140 us-gaap:StockOptionMember 2024-09-30 0001766140 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001766140 2021-01-01 2021-12-31 0001766140 2022-05-01 2022-05-31 0001766140 2022-05-31 0001766140 2023-08-01 2023-08-31 0001766140 2023-08-31 0001766140 2024-08-01 2024-08-31 0001766140 2024-08-31 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001766140 srt:MinimumMember 2023-01-01 2023-09-30 0001766140 srt:MaximumMember 2023-01-01 2023-09-30 0001766140 srt:MinimumMember 2024-01-01 2024-09-30 0001766140 srt:MaximumMember 2024-01-01 2024-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001766140 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001766140 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001766140 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001766140 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001766140
uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001766140
uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001766140 uncy:ShalabhGuptaMember 2024-07-01 2024-09-30 0001766140 uncy:ShalabhGuptaMember 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft EX-3.1 2 ea022011401ex3-1_unicycive.htm CERTIFICATE OF CORRECTION TO SERIES B PREFERRED CERTIFICATE OF DESIGNATION FILED WITH THE DELAWARE SECRETARY OF STATE ON NOVEMBER 8, 2024 Exhibit 3.1 Â STATE OF DELAWARE Â CERTIFICATE OF CORRECTION Â Unicycive Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware. Â DOES HEREBY CERTIFY: Â 1. The name of the corporation is Unicycive Therapeutics, Inc. Â 2. That the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (â€œSeries B Certificate of Designationâ€) was filed by the Secretary of State of Delaware on March 14, 2024, and that said Series B Certificate of Designation requires correction as permitted by Section 103 of the General Corporation Law of the State of Delaware. Â 3. The inaccuracy or defect of said Series B Certificate of Designation is as follows: Â a. Section 4(a) of the Series B Certificate of Designation inadvertently stated that the â€œVoting Conversion Priceâ€ be used for determining the as-converted amount of the Series B Preferred Stock instead of using the â€œConversion Priceâ€ for such determination and also failed to reference the limitations imposed by Section 6(f). Â b. Section 6(c) of the Series B Certificate of Designation inadvertently used a fixed number of shares of common stock into which shares of Series B-2 Preferred Stock convert into (one thousand shares), instead of based on the conversion rate equal to the Stated Value ($1,000) divided by the Conversion Price ($1.00) on a conversion date. Â 4. Section 4(a) of the Series B Certificate of Designation is hereby amended by (i) inserting â€œand Section 6(f)â€ after â€œSection 4(a)â€ in the first sentence of such section and (ii) deleting the reference to â€œVoting Conversion Priceâ€ and inserting â€œConversion Priceâ€ lieu thereof in the second sentence of such section. Â 5. Section 6(c) of the Series B Certificate of Designation in correct form should read in its entirety as follow: Â â€œ(c)Â Conversions at Option of Holder. Subject to Section 6(b) and the limitations set forth in Section 6(f), at the option of the Holder thereof, each share of Series B-2 Preferred Stock, shall convert into the number of shares of Common Stock equal to the quotient of (A) the Stated Value, divided by (B) the Conversion Price on the applicable Conversion Date.â€ Â IN WITNESS WHEREOF, Unicycive Therapeutics, Inc. has caused this Certificate of Correction this 8th day of November 2024. Â Â /s/ Shalabh Gupta Â By: Shalabh Gupta, CEO EX-31.1 3 ea022011401ex31-1_unicycive.htm CERTIFICATION Exhibit 31.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Shalabh Gupta, M.D., certify that: Â Â (1) I have reviewed this Form 10-Q of Unicycive Therapeutics, Inc.; Â Â (2) Based on my

knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â (4) The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; and Â Â (5) The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 By: /s/ Shalabh Gupta, M.D. Â Â Shalabh Gupta, M.D. Â Â Chief Executive Officer (Principal Executive Officer) EX-31.2 4 ea022011401ex31-2_unicycive.htm CERTIFICATION Exhibit 31.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, John Townsend, certify that: Â Â (1) I have reviewed this Form 10-Q of Unicycive Therapeutics, Inc.; Â Â (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â (4) The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; and Â Â (5) The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 By: /s/ John Townsend Â Â John Townsend Â Â Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.1 5 ea022011401ex32-1_unicycive.htm CERTIFICATION Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Unicycive Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the three month period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 13, 2024 (the â€œReportâ€), I, Shalabh Gupta, M.D., Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report. Â By: /s/ Shalabh Gupta, M.D. Â Â Shalabh Gupta, M.D. Â Â Chief Executive Officer Â A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-32.2 6 ea022011401ex32-2_unicycive.htm CERTIFICATION Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Unicycive Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the three month period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 13, 2024 (the â€œReportâ€), I, John Townsend, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report. Â By: /s/ John Townsend Â Â John Townsend Â Â Chief Financial Officer Â A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 7 uncy-20240930.xsd XBRL SCHEMA FILE 995301 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Statements of Mezzanine Equity and Stockholdersâ€™ Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Significant Agreements link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Licensing Revenues link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Balance Sheet Components link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Operating Lease link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Stockholdersâ€™ Deficit link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Issuance of Series A-1 Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Issuance of Series B-1 Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Warrant Liability link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Operating Lease (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Stockholdersâ€™ Deficit (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Warrant Liability (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Significant Agreements (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Licensing Revenues (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Balance Sheet Components (Details) - Schedule of Accounts Payable link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Balance Sheet Components (Details) - Schedule of Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Operating Lease (Details) link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Operating Lease (Details) - Schedule of Maturities of Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Stockholdersâ€™ Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Stockholdersâ€™ Deficit (Details) - Schedule of Summarizes Activity for Warrants link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Issuance of Series A-1 Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Issuance of Series B-1 Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Warrant Liability (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 uncy-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 uncy-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 uncy-20240930_lab.xml XBRL LABEL FILE Rule 10b5-1 Arrangement Modified [Flag] Rule 10b5-1 Arrangement Modified. Non-Rule 10b5-1 Arrangement Modified [Flag] Non-Rule 10b5-1 Arrangement Terminated. Total current assets Total assets Total current liabilities Total liabilities Class of Stock [Axis] Total stockholdersâ€™ (deficit) equity Balance Balance Total liabilities and stockholdersâ€™ (deficit) equity Total operating expenses Loss from operations Total other income (expenses) Net loss Net income (loss) Net loss Net loss attributable to common stockholders Net loss attributable to common shares, basic Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash and cash equivalents Organization and Description of Business [Abstract] Summary of Significant Accounting Policies [Abstract] Total liabilities at fair value Fair Value Hierarchy and NAV [Axis] Fair value opening balance Fair value ending balance Warrant liability Significant Agreements [Abstract] Licensing Revenues [Abstract] Balance Sheet Components [Abstract] Schedule of Prepaid Expenses and Other Current Assets [Abstract] Total Prepaid expenses and other current assets Long-Lived Tangible Asset [Axis] Net Property, plant and equipment, net Schedule of Accounts Payable [Abstract] Total Accounts payable Schedule of Accrued Liabilities [Abstract] Total Accrued liabilities Operating Lease [Abstract] Schedule of Maturities of Lease Liabilities [Abstract] Total lease payments Present value of lease liability Lease liability Related Party Transactions [Abstract] Commitments and Contingencies [Abstract] Stockholdersâ€™ Deficit [Abstract] Schedule of Summarizes Activity for Warrants [Abstract] Number of Shares Underlying Outstanding Warrants, Outstanding at Ending Weighted- Average Exercise Price, Outstanding at Ending Aggregate Intrinsic Value, Outstanding at Ending Aggregate Intrinsic Value, Outstanding at Beginning Aggregate Intrinsic Value, Outstanding at Ending Issuance of Series A-1 Preferred Stock [Abstract] Issuance of Series B-1 Preferred Stock [Abstract] Warrant Liability [Abstract] Measurement Input Type [Axis] Vesting [Axis] Statistical Measurement [Axis] Number of Shares Underlying Outstanding Warrants, Outstanding at Beginning Number of Shares Underlying Outstanding Warrants, Outstanding at Ending Weighted- Average Exercise Price, Outstanding at Beginning Weighted-Average Exercise Price, Outstanding at Ending Class of Warrant or Right [Axis] Stock-Based Compensation [Abstract] Schedule of Summarizes Activity for Stock Options under all Plans [Abstract] Number of Shares Underlying Outstanding Options, Outstanding at ending balance Weighted-Average Exercise Price, Outstanding at ending balance Aggregate Intrinsic Value, Outstanding at ending balance Statement of Income Location, Balance [Axis] Net Loss Per Share [Abstract] Schedule of Basic and Diluted Net Loss Per Share [Abstract] Antidilutive Securities [Axis] Subsequent Events [Abstract] Shalabh Gupta [Member] Current assets: Right of use asset, net Liabilities and stockholdersâ€™ (deficit) equity Current liabilities: Operating lease liability - current Less current portion Operating lease liability â€“ long term Long term portion Commitments and contingencies (Note 8) Stockholdersâ€™ (deficit) equity: Preferred stock value Investors of convertible preferred stock Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares Designated shares Preferred stock, shares outstanding Preferred stock, shares issued Preferred stock shares issued Common stock, $0.001 par value per share â€“ 200,000,000 shares authorized at December 31, 2023 and 400,000,000 shares authorized at September 30, 2024; 34,756,049 and 97,858,406 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock share issued Share issued Common stock shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Licensing revenues Operating expenses: Research and development General and administrative Other income (expenses): Interest income Net loss per share attributable to common stockholders, basic (in Dollars per share) Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share) Net loss per share attributable to common stockholders,diluted (in Dollars per share) Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in Shares) Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in Shares) Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in Shares) Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability Common stock valued Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability (in Shares) Issued of common shares (in Shares) Share issued Deemed dividends on Series A-1 preferred stock Issuance of common stock for exercise of options Issuance of common stock for

exercise of options (in Shares) Number of Shares Underlying Outstanding Options, Options exercised Stock-based compensation expense Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock (in Shares) Issuance of Series B-1 preferred stock, net of issuance costs Issuance of Series B-1 preferred stock, net of issuance costs (in Shares) Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock (in Shares) Conversion of Series A-2 Prime preferred stock into common stock Conversion of Series A-2 Prime preferred stock into common stock (in Shares) Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock (in Shares) Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Stock-based compensation expense Change in fair value of warrant liability Change in fair value of warrant liability Change in fair value of Warrants Amortization of operating lease right of use asset Changes in assets and liabilities: Accounts payable and accrued liabilities Operating lease liability Cash flows from investing activities Cash flows from financing activities Issuance costs related to issuance of Series B-1 preferred stock Gross proceed (in Dollars) Proceeds from issuance of Series B-1 preferred stock Proceeds from issuance of Series A-1 preferred stock and warrants Supplemental cash flow information Accrued dividends on preferred stock Fair value of warrants issued in connection with the issuance of preferred stock Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock Deferred insurance charges included in prepaid expenses and other current assets Deferred preclinical and other charges included in prepaid expenses and other current assets Cash paid for interest Cash paid for income taxes Interest expense Deemed dividends to Series A-1 preferred stockholders Cash dividends to Series B-1 preferred stockholders Dividends on Series B-1 preferred stock Prepaid expense and other current assets Purchases of property, plant, and equipment Payments on financed insurance policies Issuance costs related to issuance of Series A-1 preferred stock and warrants Dividends on preferred stock Series A-2 Preferred Stock Series A-2 Preferred Stock [Member] Series B-2 Preferred Stock Series B-1 Preferred Stock Series B-1 Preferred Stock [Member] Series B-1 preferred stock [Member] Preferred Stock Preferred Stock [Member] Series A-1 Preferred Stockholders Series B Holders Series A-1 Preferred Stock Series A-1 Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Accumulated Deficit Series A-2 Prime Preferred Stock Series A-2 Prime Preferred Stock [Member] Series B-2 Preferred Stock Series B-2 Preferred Stock [Member] Organization and Description of Business Summary of Significant Accounting Policies Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 Issuance of Warrants (March 3, 2023) Proceeds of warrants (in Dollars) Significant Agreements Licensing Revenues Balance Sheet Components Schedule of Prepaid Expenses and Other Current Assets Prepaid directorsâ€™ and officersâ€™ liability insurance premiums Prepaid preclinical services Other Schedule of Property, Plant and Equipment Subtotal Schedule of Accounts Payable Trade accounts payable Credit card liability Schedule of Accrued Liabilities Accrued labor costs Accrued drug development costs Other Operating Lease Schedule of Maturities of Lease Liabilities Year ending December 31, 2024 Year ending December 31, 2025 Year ending December 31, 2026 Related Party Transactions Commitments and Contingencies Stockholdersâ€™ Deficit Schedule of Summarizes Activity for Warrants Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending Weighted- Average Remaining Contractual Term (in Years), Outstanding at Beginning Number of Shares Underlying Outstanding Warrants, Warrants granted Weighted- Average Exercise Price, Warrants granted Aggregate Intrinsic Value, Warrants granted Number of Shares Underlying Outstanding Warrants, Warrants exercised Weighted- Average Exercise Price, Warrants exercised Aggregate Intrinsic Value, Warrants exercised Issuance of Series A-1 Preferred Stock Issuance of Series B-1 Preferred Stock Warrant Liability Schedule of Valuation Inputs into the Black Scholes Model for the Liability Warrants measurement inputs Schedule of Issuable Preferred Stock Warrants Number of Shares Underlying Outstanding Warrants, Warrants contingently issuable Weighted- Average Exercise Price, Warrants contingently issuable Weighted- Average Remaining Contractual Term (in Years), Warrants contingently issuable Aggregate Intrinsic Value, Warrants contingently issuable Number of Shares Underlying Outstanding Warrants, Warrants exercised Weighted- Average Exercise Price, Warrants exercised Weighted- Average Remaining Contractual Term (in Years), Warrants exercised Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending Stock-based Compensation Schedule of Summarizes Activity for Stock Options under all Plans Weighted-Average Remaining Contractual Term (in Years), Outstanding at ending balance Number of Shares Underlying Outstanding Options, Options granted Weighted-Average Exercise Price, Options granted Weighted-Average Remaining Contractual Term (in Years), Options granted Number of Shares Underlying Outstanding Options, Options forfeited Weighted-Average Exercise Price, Options forfeited Weighted-Average Remaining Contractual Term (in Years), Options forfeited Aggregate Intrinsic Value, Options forfeited Weighted-Average Exercise Price, Options exercised Weighted-Average Remaining Contractual Term (in Years), Options exercised Aggregate Intrinsic Value, Options exercised Number of Shares Underlying Outstanding Options, Options vested and exercisable Weighted-Average Exercise Price, Options vested and exercisable Weighted-Average Remaining Contractual Term (in Years), Options vested and exercisable Aggregate Intrinsic Value, Outstanding, Options vested and exercisable Schedule of Stock-Based Compensation Expense Total stock-based compensation Schedule of Fair Value of Awards Granted Expected volatility Risk-free interest rate Dividend yield Expected term Net Loss Per Share Schedule of Basic and Diluted Net Loss Per Share Basic net loss per share Numerator: Cash Dividends to Series B holders Net loss attributable to common shares, diluted Denominator: Schedule of Outstanding Shares Potentially Dilutive Securities Antidilutive Securities Anti-dilution shares of common stock (in Shares) Subsequent Events Less accumulated depreciation Less imputed interest rate / present value discount Deemed dividends on preferred stock Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Significant Other Observable Inputs (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Level 3 [Member] Leasehold improvements [Member] Furniture and fixtures [Member] Lab Equipment [Member] Measurement Input, Appraised Value [Member] Tranche A Warrant [Member] Measurement Input, Exercise Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Expected Term [Member] Measurement Input, Discount for Lack of Marketability [Member] Measurement Input Probability for FDA Approval [Member] Tranche B Warrant [Member] Tranche C Warrant [Member] Minimum [Member] Maximum [Member] Warrant liability [Member] Warrants to purchase common stock [Member] Warrant [Member] Warrants [Member] Research and development [Member] General and administrative [Member] Options to purchase common stock [Member] Restricted stock units [Member] Common stock issuable upon conversion of Series B-2 convertible preferred stock [Member] Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock [Member] Warrants to purchase convertible preferred stock [Member] Geographical [Axis] Sale of Stock [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related and Nonrelated Parties [Axis] Investment, Name [Axis] Related Party Transaction [Axis] Derivative Instrument [Axis] Lease Contractual Term [Axis] Title and Position [Axis] Incorporation date Net proceeds Aggregate net proceeds (in Dollars) Proceeds from private placement Net proceeds from private placement Net proceeds Number of reportable operating segment Tax benefit rate Agreement due payments Second clinical trial payment Percentage of royalty payment Interest on ownership Public market capitalization Research and development expenses Required to pay Sublicense income percentage Significant payment received Accounts payable or accrued expense Revision overall budget Related payments Payments to related party Initial agreement amount Research related payments Milestone payments Royalties percentage Payment amount Upfornt payments Milestone payments Upfront fees Transaction price Licensing revenue Square feet of office space (in Square Feet) Initial lease term Option to extend the lease term Present value of the lease Discount rate of lease Amortization of right-of-use asset Right of use asset balance Cash payments on lease Advances Repaid amount Advisory fee Employer matching contributions, percentage Employeeâ€™s eligible compensation Company contributions Shares warrants Warrant acquired shares Acquired warrant shares Exchange for cash price, per unit (in Dollars per share) Warrants term Exercise price per warrant (in Dollars per share) Warrants exercise price (in Dollars per share) Purchase of additional warrants Shares of common stock Auto-conversion preferred shares Convertible debt shares granted Auto-conversion of the series A preferred stock Number of share issued Agent fees and offering expenses (in Dollars) Aggregate exercise price (in Dollars) Aggregate fair value (in Dollars) Aggregate offering costs (in Dollars) Initial carrying value (in Dollars) Aggregate shares Original price per share (in Dollars per share) Preferred stock conversion price (in Dollars per share) Conversion Price (in Dollars per share) Common stock voting rights Voting rights of common stock Proceed amount (in Dollars) Share issued price per share (in Dollars per share) Purchase price (in Dollars per share) Annual rate Annual dividend rate Outstanding common stock percentage Divided shares Liquidation preference (in Dollars) Voting rights of preferred stock Conversion shares Fair value of warrants Common stock, shares reserved for issuance Number of shares reserved Available common shares Unrecognized compensation cost (in Dollars) Recognized period Exercised stock options Stock options, proceeds (in Dollars) Options remained unvested Vested portion options (in Dollars) Share of restricted stock Grant date fair value (in Dollars) Fair value per share (in Dollars per share) Grant date fair value (in Dollars per share) Annual net cash flow from operations percentage Basis of Presentation Use of Estimates Revenue Recognition Warrant Liability Segment Information Risks and Uncertainties Property, Plant and Equipment Leases Fair Value of Financial Instruments Concentration of Credit Risk Prepaid Expenses and Other Current Assets Research and Development Expenses General and Administrative Expenses Patent Costs Stock-Based Compensation Income Taxes Comprehensive Loss Net Income (Loss) per Share Recent Accounting Pronouncements Delaware [Member] IPO [Member] Private Placement [Member] Series B Convertible Preferred Stock [Member] Series B Preferred Stock [Member] Exclusive license agreement [Member] Spectrum Pharmaceuticals, Inc. [Member] Investment [Member] Altair Nanomaterials, Inc [Member] Altair [Member] Sublicense Development Agreement [Member] Lotus International Pte Ltd [Member] Syneos Health LLC [Member] Quotient Sciences Limited [Member] CBCC Global Research Inc [Member] Inotiv [Member] Leeâ€™s Pharmaceutical (HK) Limited [Member] Oxylanthanum Carbonate [Member] Shilpa Medicare Ltd [Member] Upfront Payment [Member] Milestone Payment [Member] Other Contract [Member] Operating Lease [Member] Chief Executive Officer [Member] Maxim Group LLC [Member] Series A-3 Preferred Stock [Member] Series A-4 Preferred Stock [Member] Series A-5 Preferred Stock [Member] Series A Preferred Stock [Member] Series A Certificate of Designation [Member] Shareholder [Member] Amended Tranche B Warrants [Member] Original Tranche C Warrants [Member] Amended Tranche C Warrants [Member] Series A-5 Convertible Preferred Stock [Member] Series A-2 Prime Convertible Preferred Stock [Member] Series A-3 Convertible Preferred Stock [Member] Series A-4 Convertible Preferred Stock [Member] Exchange Agreement [Member] Series B-1 Convertible Preferred Stock [Member] Securities Purchase Agreement [Member] Series B Certificate of Designation [Member] Shareholders [Member] Stock Options [Member] Class of Stock [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Net Loss Per Share (Tables) [Table] Net loss per share [Abstract] Fair Value Hierarchy and NAV [Domain] Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Table] Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 [Line Items] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Line Items] Measurement Input Type [Domain] Vesting [Domain] Statistical Measurement [Domain] Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Table] Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Class of Warrant or Right [Domain] Partners' Capital, Master Limited Partnership, Preferred Unit [Table] Schedule of Issuable Preferred Stock Warrants [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Stock-Based Compensation Expense [Line Items] Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Sale of Stock [Domain] Geographical [Domain] Organization and Description of Business (Details) [Table] Organization and Description of Business [Line Items] Summary of Significant Accounting Policies (Details) [Table] Summary of Significant Accounting Policies [Line Items] Investment, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Related and Nonrelated Parties [Domain] Related Party Transaction [Domain] Significant Agreements (Details) [Table] Significant Agreements [Line Items] Derivative Contract [Domain] Licensing Revenues (Details) [Table] Licensing Revenues [Line Items] Lease Contractual Term [Domain] Operating Lease (Details) [Table] Operating Lease [Line Items] Title and Position [Domain] Related Party Transactions (Details) [Table] Related Party Transactions [Line Items] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Stockholdersâ€™ Deficit (Details) [Table] Stockholdersâ€™ Deficit [Line Items] Issuance of Series A-1 Preferred Stock (Details) [Table] Issuance of Series A-1 Preferred Stock [Line Items] Issuance of Series B-1 Preferred Stock (Details) [Table] Issuance of Series B-1 Preferred Stock [Line Items] Warrant Liability (Details) [Table] Warrant Liability [Line Items] Award Type [Domain] Stock-Based Compensation (Details) [Table] Stock-Based Compensation [Line Items] The amount of accrued drug development costs. Represent the amount of aggregate exercise price. Aggregate shares. Amount of agreement due payments . Annual net cash flow from operations percentage. The percentage of annual rate percent. Amount of preferred stock cash dividend. Deemed dividends on Series A-1 preferred stock . The amount of deferred insurance charges included in prepaid expenses and other current assets. Represent the deferred preclinical charges included in prepaid expenses and other current assets. The represents value as an milestone payment for revenue. The represents value as an upfornt payment of revenue. Number of share options exercised stock option. Fair value of warrants issued in connection with the issuance of preferred stock. Initial carrying value. Amount of issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock. The entire disclosure for issuance of series B-1 preferred stock. The amount of issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock. Amount of milestone payments. Net proceeds from private placement ampount. Original price per share. Outstanding common stock percentage. Disclosure of accounting policy for patent costs. The total payment amount. The cash outflow from financing insurance policies. Preferred stock cash dividends. Disclosure of accounting policy for prepaid expenses. The amount of prepaid preclinical service. The cash inflow from issuance of preferred stock. Number of additional warrants purchased. Revisions reduced the overall budget. Disclosure of accounting policy for risks and uncertainties. Percentage of royalties. Percentage of royalty payment. The amount of second clinical trial payment. Weighted average exercise price warrant exercised. Weighted average exercise price granted. The number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. The number of Warrants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). The number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Weighted- Average Remaining Contractual Term (in Years). Weighted average exercise price warrant outstanding. The weighted average fair value at outstanding date for equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). The weighted average fair value at warrants exercised for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). The number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. The number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. The amount of aggregate intrinsic value, options forfeited. Intrinsic value of outstanding award under Warrants exercised. Excludes share and unit options. Intrinsic value of outstanding award under warrants granted. Excludes share and unit options. Intrinsic value of warrant issued award under share-based payment arrangement. Excludes share and unit options. Number of shares weighted-average remaining contractual term, options granted. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of shares weighted-average remaining contractual term, options forfeited. The entire disclosure for significant agreements. Significant payment received. Number of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock. Number of shares of stock issued during the period pursuant to series B-1 preferred stock, net of issuance costs. Number of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock. Represent the amount of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock. Value of stock issued as a result of the series B-1 preferred stock, net of issuance costs. Represent the amount of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock. Sublicense income percentage. Transaction price. Upfront fees amount. Preferred Stock Dividends and Other Adjustments Capitalization, Long-Term Debt and Equity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Annual Rate Percentage Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Equity

Instruments Other Than Options Weighted Average Exercise Price Warrants Issued Earnings Per Share, Diluted Derivatives, Policy [Policy Text Block] Stock Issued During Period Shares Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr Investment Member Retained Earnings [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Exercised Series BCertificate Of Designation Member Series B Preferred Stock [Member] Weighted Average Number of Shares Outstanding, Basic Preferred Stock, Convertible, Shares Issuable Measurement Input, Exercise Price [Member] Lees Pharmaceutical HKLimited Member Stock Issued During Period Value Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Exercised Stock Option Payments of Ordinary Dividends, Preferred Stock and Preference Stock Stock Issued During Period, Shares, New Issues Agreement Due Payments Investment Income, Interest Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Additional Paid in Capital Operating Expenses [Abstract] Original Price Per Share Supplemental Cash Flow Information [Abstract] Stock Issued During Period, Shares, Conversion of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Initial Carrying Value Warrants and Rights Outstanding Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule Of Outstanding Shares Potentially Dilutive Securities Abstract Equity, Attributable to Parent [Abstract] Accounts Payable, Trade, Current Preferred Stock, Shares Issued Earnings Per Share, Basic [Abstract] Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Termin Years Options Granted Exclusive License Agreement Member Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Prepaid Insurance Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Liabilities, Fair Value Disclosure Selling, General and Administrative Expenses, Policy [Policy Text Block] Retained Earnings (Accumulated Deficit) Depreciation Net Cash Provided by (Used in) Investing Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease) Payments to Acquire Property, Plant, and Equipment Business Description and Basis of Presentation [Text Block] Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Granted Finance Lease, Right-of-Use Asset, Amortization Series B1 Convertible Preferred Stock Member Share-Based Payment Arrangement [Policy Text Block] Preferred Stock, Shares Authorized Interest Paid, Excluding Capitalized Interest, Operating Activities Series ACertificate Of Designation Member Repayments of Debt Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Common Stock Issuable Upon Conversion Of Series B2 Convertible Preferred Stock Member Purchase Of Additional Warrants Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Maximum [Member] Income Tax, Policy [Policy Text Block] Series A2 Prime Convertible Preferred Stock Member Warrants To Purchase Convertible Preferred Stock Member Proceeds from License Fees Received Common Stock, Shares Authorized Preferred Stock, Dividend Rate, Percentage Shalabh Gupta Member Proceed From Issuance Of Preferred Stock Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating Lease, Liability, Noncurrent Other Accrued Liabilities, Current CBCCGlobal Research Inc Member Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Preferred Stock [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Accrued Liabilities [Table Text Block] Share-Based Payment Arrangement, Expense Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Accrued Salaries, Current Stock Issued During Period Value Issuance Of Series B1 Preferred Stock Net Of Issuance Costs Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Options Forfeited Deferred Revenue Upfornt Payments Class of Warrant or Right, Number of Securities Called by Warrants or Rights Prepaid Expense Other, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Net Cash Provided by (Used in) Investing Activities [Abstract] Annual Net Cash Flow From Operations Percentage Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule Of Stock Based Compensation Expense Abstract Significant Payment Received Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Significant Accounting Policies [Text Block] Upfront Fees Segment Reporting, Policy [Policy Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Two Common Stock, Capital Shares Reserved for Future Issuance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms2 Fair Value, Inputs, Level 3 [Member] DELAWARE Chief Executive Officer [Member] Related Party Transactions Disclosure [Text Block] Net Cash Provided by (Used in) Operating Activities Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding Equity Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule Of Changes In Fair Value Of The Warrant Liability Classified In Level3 Abstract Payments of Stock Issuance Costs Operating Lease, Right-of-Use Asset, Periodic Reduction Fair Value, Inputs, Level 1 [Member] Preferred Stock, Convertible, Conversion Price Preferred Stock, Voting Rights Cash Dividends Preferred Stock Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Exercised Measurement Input, Appraised Value [Member] Equity, Attributable to Parent Revenue from Contract with Customer [Text Block] Measurement Input, Expected Dividend Rate [Member] Other Expenses Property, Plant and Equipment, Policy [Policy Text Block] Rule10b51 Arrangement Modified Flag Furniture and Fixtures [Member] Preferred Stock [Text Block] Fair Value Adjustment of Warrants Lessee, Operating Lease, Discount Rate Altair Nanomaterials Inc Member Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Patent Costs Policy Text Block Proceeds from Sale of Other Receivables Net Income (Loss) Available to Common Stockholders, Basic Lotus International Pte Ltd Member Revisions Reduced The Overall Budget Measurement Input, Discount for Lack of Marketability [Member] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Shareholder Member Lessee, Operating Lease, Liability, to be Paid Net Proceeds From Private Placement Share-Based Payment Arrangement, Option, Activity [Table Text Block] Equity [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Tranche AWarrant Member Sale of Stock, Number of Shares Issued in Transaction Restricted Investments, at Fair Value Property, Plant and Equipment [Table Text Block] Operating Expenses Statement of Financial Position [Abstract] Risks And Uncertainties Policy Text Block Securities Purchase Agreement Member Stock Issued During Period Shares Issuance Of Series B1 Preferred Stock Net Of Issuance Costs Research and Development Expense, Policy [Policy Text Block] Shares Issued, Price Per Share Lessee, Operating Lease, Liability, to be Paid, Year One Amended Tranche BWarrants Member Stock Issued During Period Shares Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr Adjustments to Additional Paid in Capital, Other Series A2 Prime Preferred Stock Member Stock Issued During Period, Shares, Conversion of Convertible Securities Aggregate Shares Issuance Of Series B1 Preferred Stock Text Block Second Clinical Trial Payment Series A3 Preferred Stock Member Amended Tranche CWarrants Member Quotient Sciences Limited Member Milestone Payment Member Conversion of Stock, Shares Issued Schedule of Other Current Assets [Table Text Block] Deemed Dividends On Series A1 Preferred Stock Preferred Stock, Liquidation Preference, Value Lessee, Operating Lease, Liability, Undiscounted Excess Amount Costs and Expenses, Related Party Share-Based Payment Arrangement, Noncash Expense Number of Reportable Segments Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Series A5 Preferred Stock Member Preferred Stock Cash Dividends To Series BHolders Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Termin Years Options Forfeited Dividends, Preferred Stock, Cash Operating Lease Member Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Sublicense Development Agreement Member Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Comprehensive Income, Policy [Policy Text Block] Series A Preferred Stock [Member] Nonoperating Income (Expense) [Abstract] Income Taxes Paid, Net Series A1 Preferred Stock Member Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Noninterest Expense Investment Advisory Fees Common Stock, Value, Issued Proceeds from Issuance of Warrants Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Tranche CWarrant Member Lessee, Leases [Policy Text Block] Operating Lease, Payments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Syneos Health LLCMember Increase (Decrease) in Prepaid Expense and Other Assets IPO [Member] Transaction Price Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Derivatives and Fair Value [Text Block] Spectrum Pharmaceuticals Inc Member Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Preferred Units, Offering Costs Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from Issuance of Convertible Preferred Stock Deferred Revenue Milestone Payments Adjustment of Warrants Granted for Services Equipment [Member] Research and Development Expense [Member] Income Statement [Abstract] Lessee, Operating Leases [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Supplemental Balance Sheet Disclosures [Text Block] Tranche BWarrant Member Schedule Of Property Plant And Equipment Abstract Earnings Per Share, Basic Assets Liabilities Common Stock, Voting Rights Research and Development Expense Subsequent Events [Text Block] Other Research and Development Expense Aggregate Exercise Price Stock Issued Prepaid Expenses Policy Text Block Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr Series A1 Preferred Stockholders Member Significant Agreement Text Block Schedule Of Valuation Inputs Into The Black Scholes Model For The Liability Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Milestone Payments Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions Warrants and Rights Outstanding, Measurement Input Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Issued Proceeds from Stock Plans Lessee, Operating Lease, Option to Extend Accrued Drug Development Costs Current Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Conversion of Stock, Shares Converted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Exercise Price Warrants and Rights Outstanding, Term Repayments of Related Party Debt Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Measurement Input Probability For FDAApproval Member Option Contract Indexed to Equity, Settlement, Share, Fair Value Per Share Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Series BHolders Member Shilpa Medicare Ltd Member Property, Plant and Equipment, Gross Interest Expense, Nonoperating Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price Defined Contribution Plan, Employer Discretionary Contribution Amount Royalty Pecentage Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Payments On Financed Insurance Policies Series A3 Convertible Preferred Stock Member Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr Leasehold Improvements [Member] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Operating Income (Loss) Series A4 Convertible Preferred Stock Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Operating Lease, Liability Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Original Tranche CWarrants Member Sale of Stock, Price Per Share Revenue from Contract with Customer [Policy Text Block] Series A5 Convertible Preferred Stock Member Common Stock [Member] Net Income (Loss) Available to Common Stockholders, Diluted Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock Measurement Input, Price Volatility [Member] Proceeds from Issuance Initial Public Offering Series B2 Preferred Stock Member Statement of Cash Flows [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Other Prepaid Expense, Current Measurement Input, Risk Free Interest Rate [Member] Operating Lease, Liability, Current Area of Land Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity Method Investment, Ownership Percentage Common Stock Dividends, Shares Advances to Affiliate Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Royalties Percentage Inotiv Member Liabilities, Current [Abstract] Stock Issued During Period, Value, Conversion of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets Series A2 Preferred Stock Member Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Upfront Payment Member General and Administrative Expense [Member] Share-Based Payment Arrangement [Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Outstanding Lessee, Operating Lease, Term of Contract Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Schedule Of Fair Value Hierarchy Of Financial Liabilities Measured At Fair Value Abstract Increase (Decrease) in Accounts Payable and Accrued Liabilities Earnings Per Share [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Other Contract [Member] Revenues Share Price Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Conversion of Convertible Securities Restricted Stock Units (RSUs) [Member] Treasury Stock, Common, Shares Common Stock Issuable Upon Conversion Of Series A2 Prime Convertible Preferred Stock Member General and Administrative Expense Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Issued Outstanding Common Stock Percentage Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Stock Issued During Period Value Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Exercised Noninterest Expense Transfer Agent and Custodian Fees Common Stock, Par or Stated Value Per Share Sublicense Income Percentage Earnings Per Share, Policy [Policy Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from Issuance of Private Placement Increase (Decrease) in Other Operating Liabilities [Abstract] Other Liabilities, Current Exchange Agreement Member Altair Member Weighted Average Number of Shares Outstanding, Diluted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Private Placement [Member] Prepaid Preclinical Services Current Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Issued Assets, Current [Abstract] Shareholders Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Convertible Preferred Stock, Shares Issued upon Conversion Liabilities, Current Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Oxylanthanum Carbonate Member Initial Franchise Fees Accrued Liabilities, Current Non Rule10b51 Arrangement Modified Schedule of Preferred Units [Table Text Block] Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Measurement Input, Expected Term [Member] Series A4 Preferred Stock Member Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Payment Amount Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Schedule Of Fair Value Of Awards Granted Abstract Accounts Payable and Accrued Liabilities Class of Warrant or Right, Exercise Price of Warrants or Rights Preferred Stock, Value, Issued Liabilities and Equity Maxim Group LLCMember Nonoperating Income (Expense) Preferred Stock, Par or Stated Value Per Share Operating Lease, Right-of-Use Asset Assets, Current Schedule Of Issuable Preferred Stock Warrants Abstract EX-101.PRE 11 uncy-20240930_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 13, 2024 Document Information [Line

Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current Yes Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Information [Line Items] Â Â Entity Registrant Name UNICYCIVE THERAPEUTICS, INC. Â Entity Central Index Key 0001766140 Â Entity File Number 001-40582 Â Entity Tax Identification Number 81-3638692 Â Entity Incorporation, State or Country Code DE Â Current Fiscal Year End Date --12-31 Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Contact Personnel [Line Items] Â Â Entity Address, Address Line One 4300 El Camino Real Â Entity Address, Address Line Two Suite 210 Â Entity Address, City or Town Los Altos Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94022 Â Entity Phone Fax Numbers [Line Items] Â Â City Area Code (650) Â Local Phone Number 351-4495 Â Entity Listings [Line Items] Â Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol UNCY Â Security Exchange Name NASDAQ Â Entity Common Stock, Shares Outstanding Â 103,796,406 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 32,347 $ 9,701 Prepaid expenses and other current assets 5,394 3,698 Total current assets 37,741 13,399 Right of use asset, net 772 766 Property, plant and equipment, net 61 26 Total assets 38,574 14,191 Current liabilities: Â Â Accounts payable 548 839 Accrued liabilities 2,992 3,234 Warrant liability 6,377 13,134 Operating lease liability - current 542 327 Total current liabilities 10,459 17,534 Operating lease liability â€“ long term 265 466 Total liabilities 10,724 18,000 Commitments and contingencies (Note 8) Stockholdersâ€™ (deficit) equity: Â Â Common stock, $0.001 par value per share â€“ 200,000,000 shares authorized at December 31, 2023 and 400,000,000 shares authorized at September 30, 2024; 34,756,049 and 97,858,406 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively 98 35 Additional paid-in capital 107,497 60,697 Accumulated deficit (79,745) (64,541) Total stockholdersâ€™ (deficit) equity 27,850 (3,809) Total liabilities and stockholdersâ€™ (deficit) equity 38,574 14,191 Series A-2 Preferred Stock Â Â Stockholdersâ€™ (deficit) equity: Â Â Preferred stock value Series B-2 Preferred Stock Â Â Stockholdersâ€™ (deficit) equity: Â Â Preferred stock value Preferred Stock Â Â Stockholdersâ€™ (deficit) equity: Â Â Preferred stock value X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesB1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheets (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 400,000,000 200,000,000 Common stock, shares issued 97,858,406 34,756,049 Common stock, shares outstanding 97,858,406 34,756,049 Series A-2 Preferred Stock Â Â Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 21,388.01 43,649 Preferred stock, shares outstanding 11,111.24 43,649 Series B-2 Preferred Stock Â Â Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 7,882 Preferred stock, shares outstanding 7,882 Preferred Stock Â Â Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares outstanding Preferred stock, shares issued X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesB1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Licensing revenues $ 675 Operating expenses: Â Â Â Â Research and development 3,045 3,372 14,726 8,669 General and administrative 3,206 2,566 8,130 6,467 Total operating expenses 6,251 5,938 22,856 15,136 Loss from operations (6,251) (5,938) (22,856) (14,461) Other income (expenses): Â Â Â Â Interest income 416 227 947 475 Interest expense (15) (18) (51) (63) Change in fair value of warrant liability 1,754 1,396 6,756 (8,697) Total other income (expenses) 2,155 1,605 7,652 (8,285) Net loss (4,096) (4,333) (15,204) (22,746) Net loss attributable to common stockholders $ (4,096) $ (4,405) $ (16,299) $ (23,613) Net loss per share attributable to common stockholders, basic (in Dollars per share) $ (0.05) $ (0.13) $ (0.3) $ (1.12) Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share) $ (0.05) $ (0.13) $ (0.3) $ (1.12) Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) 88,943,212 32,633,074 54,073,701 21,100,206 Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in Shares) 88,943,212 32,633,074 54,073,701 21,100,206 Series A-1 Preferred Stockholders Â Â Â Â Other income (expenses): Â Â Â Â Deemed dividends to Series A-1 preferred stockholders $ (72) $ (867) Series B Holders Â Â Â Â Other income (expenses): Â Â Â Â Cash dividends to Series B-1 preferred stockholders $ (1,095) X - DefinitionPreferred stock cash dividends. + ReferencesNo definition available. + Details Name: uncy_PreferredStockCashDividendsToSeriesBHolders Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic

942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_PreferredStockDividendsAndOtherAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of

intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA1PreferredStockholdersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesBHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Mezzanine Equity and Stockholdersâ€™ Deficit (Unaudited) - USD ($) $ in Thousands Series A-1 Preferred Stock Common Stock Series A-2 Preferred Stock Additional Paid-In Capital Accumulated Deficit Series B-1 Preferred Stock Series A-2 Prime Preferred Stock Series B-2 Preferred Stock Total Balance at Dec. 31, 2022 $ 15 $ 33,516 $ (33,997) Â Â Â $ (466) Balance (in Shares) at Dec. 31, 2022 15,231,655 Â Â Â Â Â Â Net income (loss) (14,575) Â Â Â (14,575) Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability $ 25,407 Â Â Â Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability (in Shares) 30,190 Â Â Â Â Â Â Deemed dividends on Series A-1 preferred stock $ 192 (192) Â Â Â (192) Issuance of common stock for exercise of options 7 Â Â Â 7 Issuance of common stock for exercise of options (in Shares) 2,181 Â Â Â Â Â Â Stock-based compensation expense 144 Â Â Â 144 Balance at Mar. 31, 2023 $ 25,599 $ 15 33,475 (48,572) Â Â Â (15,082) Balance (in Shares) at Mar. 31, 2023 30,190 15,233,836 Â Â Â Â Â Â Balance at Dec. 31, 2022 $ 15 33,516 (33,997) Â Â Â (466) Balance (in Shares) at Dec. 31, 2022 15,231,655 Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â (22,746) Balance at Sep. 30, 2023 $ 35 $ 44 60,098 (56,743) Â Â Â 3,434 Balance (in Shares) at Sep. 30, 2023 34,754,401 43,649 Â Â Â Â Â Â Balance at Mar. 31, 2023 $ 25,599 $ 15 33,475 (48,572) Â Â Â (15,082) Balance (in Shares) at Mar. 31, 2023 30,190 15,233,836 Â Â Â Â Â Â Net income (loss) (3,838) Â Â Â (3,838) Deemed dividends on Series A-1 preferred stock 603 (603) Â Â Â (603) Issuance of common stock for exercise of options 7 Â Â Â 7 Issuance of common stock for exercise of options (in Shares) 2,180 Â Â Â Â Â Â Stock-based compensation expense 144 Â Â Â 144 Balance at Jun. 30, 2023 $ 26,202 $ 15 33,023 (52,410) Â Â Â (19,372) Balance (in Shares) at Jun. 30, 2023 30,190 15,236,016 Â Â Â Â Â Â Net income (loss) (4,333) Â Â Â (4,333) Deemed dividends on Series A-1 preferred stock 72 (72) Â Â Â (72) Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock $ (26,274) $ 20 $ 44 26,211 Â Â Â 26,275 Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock (in Shares) (30,190) 19,516,205 43,649 Â Â Â Â Â Â Issuance of common stock for exercise of options 7 Â Â Â 7 Issuance of common stock for exercise of options (in Shares) 2,180 Â Â Â Â Â Â Stock-based compensation expense 929 Â Â Â 929 Balance at Sep. 30, 2023 $ 35 $ 44 60,098 (56,743) Â Â Â 3,434 Balance (in Shares) at Sep. 30, 2023 34,754,401 43,649 Â Â Â Â Â Â Balance at Dec. 31, 2023 Â $ 35 60,697 (64,541) (3,809) Balance (in Shares) at Dec. 31, 2023 Â 34,756,049 43,649 Â Â Â Net income (loss) Â (20,963) Â (20,963) Issuance of Series B-1 preferred stock, net of issuance costs Â $ 46,187 Issuance of Series B-1 preferred stock, net of issuance costs (in Shares) Â Â Â 50,000 Â Dividends on Series B-1 preferred stock Â (208) (208) Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock Â Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock (in Shares) Â (43,649) Â Â 21,388.01 Â Conversion of Series A-2 Prime preferred stock into common stock Â $ 2 (2) Conversion of Series A-2 Prime preferred stock into common stock (in Shares) Â 2,850,000 Â Â (1,396.5) Â Issuance of common stock for exercise of options Â 2 2 Issuance of common stock for exercise of options (in Shares) Â 581 Â Â Â Stock-based compensation expense Â 522 522 Balance at Mar. 31, 2024 Â $ 37 61,011 (85,504) $ 46,187 (24,456) Balance (in Shares) at Mar. 31, 2024 Â 37,606,630 Â Â 50,000 19,991.51 Â Balance at Dec. 31, 2023 Â $ 35 60,697 (64,541) (3,809) Balance (in Shares) at Dec. 31, 2023 Â 34,756,049 43,649 Â Â Â Net income (loss) Â Â Â Â Â Â Â Â $ (15,204) Issuance of common stock for exercise of options (in Shares) Â Â Â Â Â Â Â Â 1,357 Balance at Sep. 30, 2024 Â $ 98 104,497 (79,745) $ 27,850 Balance (in Shares) at Sep. 30, 2024 Â 97,858,406 Â Â 11,111.24 7,882 Â Balance at Mar. 31, 2024 Â $ 37 61,011 (85,504) $ 46,187 (24,456) Balance (in Shares) at Mar. 31, 2024 Â 37,606,630 Â Â 50,000 19,991.51 Â Net income (loss) Â 9,855 Â 9,855 Dividends on Series B-1 preferred stock Â (887) (887) Conversion of Series A-2 Prime preferred stock into common stock Â $ 6 (6) Conversion of Series A-2 Prime preferred stock into common stock (in Shares) Â 5,956,000 Â Â (2,918.44) Â Issuance of common stock for exercise of options Â 1 1 Issuance of common stock for exercise of options (in Shares) Â 10,582 Â Â Â Stock-based compensation expense Â 641 641 Balance at Jun. 30, 2024 Â $ 43 60,760 (75,649) $ 46,187 (14,846) Balance (in Shares) at Jun. 30, 2024 Â 43,573,212 Â Â 50,000 17,073.07 Â Net income (loss) Â (4,096) (4,096) Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock Â $ 55 46,132 $ (46,187) 46,187 Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock (in Shares) Â 54,285,000 Â Â (50,000) (5,961.83) 7,882 Â Issuance of common stock for exercise of options Â Issuance of common stock for exercise of options (in Shares) Â 194 Â Â Â Stock-based compensation expense Â 605 605 Balance at Sep. 30, 2024 Â $ 98 $ 104,497 $ (79,745) $ 27,850 Balance (in Shares) at Sep. 30, 2024 Â 97,858,406 Â Â 11,111.24 7,882 Â X - DefinitionDeemed dividends on Series A-1 preferred stock . + ReferencesNo definition available. + Details Name: uncy_DeemedDividendsOnSeriesA1PreferredStock Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to series B-1 preferred stock, net of issuance costs. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent the amount of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the series B-1 preferred stock, net of issuance costs. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent the amount of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of other increase (decrease) in additional paid in capital (APIC). + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -

Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net loss $ (15,204) $ (22,746) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation expense 15 6 Stock-based compensation expense 1,768 1,217 Change in fair value of warrant liability (6,756) 8,697 Amortization of operating lease right of use asset 279 196 Changes in assets and liabilities: Â Â Prepaid expense and other current assets (1,677) (1,884) Accounts payable and accrued liabilities (181) 849 Operating lease liability (271) (179) Net cash used in operating activities (22,027) (13,844) Cash flows from investing activities Â Â Purchases of property, plant, and equipment (50) (12) Net cash used in investing activities (50) (12) Cash flows from financing activities Â Â Payments on financed insurance policies (368) (291) Issuance costs related to issuance of Series B-1 preferred stock (3,813) Proceeds from issuance of Series B-1 preferred stock 50,000 Issuance costs related to issuance of Series A-1 preferred stock and warrants (2,153) Proceeds from issuance of Series A-1 preferred stock and warrants 30,190 Dividends on preferred stock (1,095) Net cash provided by financing activities 44,723 27,746 Net increase in cash and cash equivalents 22,646 13,890 Cash and cash equivalents at the beginning of the period 9,701 455 Cash and cash equivalents at the end of the period 32,347 14,345 Supplemental cash flow information Â Â Accrued dividends on preferred stock 867 Fair value of warrants issued in connection with the issuance of preferred stock 2,831 Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock 26,274 Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock 46,187 Deferred insurance charges included in prepaid expenses and other current assets 397 Deferred preclinical and other charges included in prepaid expenses and other current assets 19 293 Cash paid for interest 51 Cash paid for income taxes X - DefinitionThe amount of deferred insurance charges included in prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: uncy_DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent the deferred preclinical charges included in prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: uncy_DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of warrants issued in connection with the issuance of preferred stock. + ReferencesNo definition available. + Details Name: uncy_FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_IssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow from financing insurance policies. + ReferencesNo definition available. + Details Name: uncy_PaymentsOnFinancedInsurancePolicies Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from issuance of preferred stock. + ReferencesNo definition available. + Details Name: uncy_ProceedFromIssuanceOfPreferredStock Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235

-SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Description of Business 9 Months Ended Sep. 30, 2024 Organization and Description of Business [Abstract] Â Organization and Description of Business 1. Organization and Description of Business Â Overview Â Unicycive Therapeutics, Inc. (â€œthe Companyâ€) was incorporated in the State of Delaware on August 18, 2016. The Company was dormant until July 2017 when it began evaluating a number of drug candidates for in-licensing. Â In September 2018, the Company purchased a second drug candidate, Renazorb RZB 012 and its trademark, RENALAN, and various patents from Spectrum Pharmaceuticals, Inc. (â€œSpectrumâ€) (Note 3). Renazorb (â€œoxylanthanum carbonateâ€) is being developed for the treatment of hyperphosphatemia in patients with Chronic Kidney Disease (â€œCKDâ€). Â In 2017, the Company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte. Ltd, a Singapore-based corporation, (â€œSphaeraâ€) (Note 3). UNI 494 is a pro-drug of nicorandil that is being developed as a treatment for acute kidney injury. Â The Company continues to evaluate the licensing of additional technologies and drugs, targeting orphan diseases and other renal, liver and other metabolic diseases affecting fibrosis and inflammation. Â Liquidity Â The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with governmental regulations and the need to obtain additional financing to fund operations. The Companyâ€™s product candidates currently under development will require significant additional research and development efforts prior to commercialization. Future revenue streams may consist of collaboration or licensing revenue as well as product sales. The Company has not generated any licensing revenue during the nine months ended September 30, 2024. Â The Company has incurred operating losses and negative cash flows from operations since inception and expects to continue to incur negative cash flows from operations in the future. As the Company increases its research and development activities, the operating losses are expected to increase. The Company has historically relied on private equity offerings, debt financing and loans from a stockholder to fund its operations. As of December 31, 2023 and September 30, 2024, the Company had an accumulated deficit of $64.5 million and $79.7 million, respectively. Â In connection with its initial public offering (â€œIPOâ€), on July 13, 2021, the Company began trading on the Nasdaq Capital Market under the symbol â€œUNCYâ€, and on July 15, 2021, received approximately $22.3 million in net proceeds after deducting the underwriting discounts, commissions and other offering expenses. The Company has used the net proceeds from the IPO to complete pre-clinical and clinical studies, prepare regulatory filings for the FDA, and for general and corporate purposes, including hiring additional management and conducting market research and other commercial planning. Â On March 3, 2023, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investors that may provide up to $130.0 million in gross proceeds through a private placement and that included initial upfront funding of $28.0 million in net proceeds. Â On March 13, 2024, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investors to provide $50.0 million in gross proceeds through a private placement. Pursuant to the securities purchase agreement, the Company issued institutional investors $50.0 million in shares of Series B Convertible Preferred Stock. The Company received $46.2 million in net proceeds (net of issuance costs). Â The Company expects to continue incurring losses in the future and will be required to raise additional capital in the future to complete its planned clinical trials, pursue product development initiatives and penetrate markets for the sale of its products. Management believes that the Company will continue to have access to capital resources through possible equity offerings, debt financings, corporate collaborations or other means. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis or at all. If the Company is unable to secure additional capital, it may be required to curtail any clinical trials and development of new or existing products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. Based on the Companyâ€™s current level of expenditures, the Company believes that it has sufficient resources such that there is not substantial doubt about the ability to continue operations for at least one year after the date that these financial statements are available to be issued. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€). Â The accompanying unaudited financial statements of the Company as of September 30, 2024 have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and, accordingly, they do not include all information and footnote disclosures required by accounting principles generally accepted in the U.S. (â€œGAAPâ€). The Company believes the footnotes and other disclosures made in the financial statements are adequate for a fair presentation of the results of the interim periods presented. The financial statements include all adjustments (solely of a normal recurring nature) which are, in the opinion of management, necessary to make the information presented not misleading. You should read these financial statements and the accompanying notes in conjunction with the financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. Â Use of Estimates Â The preparation of financial statements in conformity with GAAP requires management to make certain estimates and

assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates. Â Â Revenue Recognition Â The Company recognizes revenue in accordance with Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers (â€œASC 606â€). The Company applies the five-step model in ASC 606 and recognizes revenue from product sales or services rendered when control of the promised goods or services are transferred to a counterparty in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. Â Warrant Liability Â In conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), the Company established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued (and have since been issued â€" see Note 12), subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. The Company accounts for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liability was initially measured at fair value and is remeasured at fair value each reporting period. Changes in the fair value of the warrant liability are recognized in earnings during each period. The warrant liability is measured using Level 3 fair value inputs. See Note 12 for a description of warrant liability and the related valuations.Â Segment Information Â The Company operates and manages its business as one reportable operating segment. The Companyâ€™s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Â Risks and Uncertainties Â The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companyâ€™s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Companyâ€™s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Companyâ€™s ability to attract and retain employees necessary to support its growth. Â The Companyâ€™s general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. Â Any product candidates developed by the Company will require approvals from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Companyâ€™s current product candidates or any future product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company. Â The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs, which would materially and adversely affect its business, financial condition and operations. Â The Company is dependent upon the services of its employees, consultants and other third parties. Â Property, Plant and Equipment Â Property, plant, and equipment are recorded at cost less accumulated depreciation. Additions, improvements, and major renewals or replacements that substantially extend the useful life of an asset are capitalized. Repairs and maintenance expenditures are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Â Â Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value at that time. At September 30, 2024, management determined there were no impairments of the Companyâ€™s property and equipment.Â Leases Â The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Companyâ€™s right to use an underlying asset during the lease term, and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Â Fair Value of Financial Instruments Â The Companyâ€™s financial instruments include the warrant liability, cash and cash equivalents, accounts payable and accrued liabilities. Â Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The fair value hierarchy contains the following levels: Â Â â— Level 1 â€" defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets; Â Â â— Level 2 â€" defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and Â Â â— Level 3 â€" defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable. Â Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands): Â Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â -Â Â $Â Â Â Â -Â Â $6,377Â Â $6,377Â Total liabilities at fair valueÂ $-Â Â $-Â Â $6,377Â Â $6,377Â Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands): Â Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â -Â Â $Â Â Â Â -Â Â $13,134Â Â $13,134Â Total liabilities at fair valueÂ $-Â Â $-Â Â $13,134Â Â $13,134Â Â The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands): Â Â Â Nine months Ended September 30, 2024Â Fair value at January 1, 2023Â $-Â Issuance of Warrants (March 3, 2023)Â Â 2,831Â Change in fair value of WarrantsÂ Â 10,375Â Fair value at March 31, 2023Â Â 13,206Â Change in fair value of warrantsÂ Â (282) Fair value at June 30, 2023Â Â 12,924Â Change in fair value of warrantsÂ Â (1,396) Fair value at September 30, 2023Â $11,528Â Â Â Â Â Â Fair value at January 1, 2024Â $13,134Â Change in fair value of warrantsÂ Â 11,807Â Fair value at March 31, 2024Â Â 24,941Â Change in fair value of warrantsÂ Â (16,810) Fair value at June 30, 2024Â Â 8,131Â Change in fair value of warrantsÂ Â (1,754) Fair value at September 30, 2024Â $6,377Â Â The expense relating to the change in fair value of the warrant liability of $8.7 million and $6.8 million for the nine months ended September 30, 2023 and September 30, 2024, respectively, is included in other income (expense) in the statements of operations. Â ASC 820, Fair Value Measurement and Disclosures requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of December 31, 2023 and September 30, 2024, the recorded values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to the short-term nature of the instruments. Cash and cash equivalents, accounts payable, and accrued liabilities are Level 1 financial instruments. Â Concentration of Credit Risk Â Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024. Â Prepaid Expenses and Other Current Assets Â Prepaid expenses and other current assets represent costs incurred that benefit future periods. These costs are amortized over specific time periods based on the agreements. Â Research and Development Expenses Â Substantially all the Companyâ€™s research and development expenses consist of expenses incurred in connection with the development of the Companyâ€™s product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on the Companyâ€™s behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for the Companyâ€™s research and product development employees. The Company expenses both internal and external research and development expenses as they are incurred.Â General and Administrative Expenses Â General and administrative expenses represent personnel costs for employees involved in general corporate functions, including finance, accounting, legal and human resources, among others. Additional costs included in general and administrative expenses consist of professional fees for legal (including patent costs), audit and other consulting services, stock-based compensation and other general corporate overhead expenses as well as costs from a service agreement with a related party (See Note 7). Â Patent Costs Â The Company expenses all costs as incurred in connection with patent licenses and applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are reflected in general and administrative expenses in the statements of operations. Â Stock-Based Compensation Â The Company accounts for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. The Company recognizes forfeitures related to stock-based compensation as they occur. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, risk-free interest rate, and the estimated fair value (prior to the Companyâ€™s initial public offering) or the public market closing price of the Companyâ€™s underlying common stock on the date of grant. Â Income Taxes Â The Company accounts for corporate income taxes in accordance with GAAP as stipulated in ASC, Topic 740, Income Taxes, (â€œASC 740â€). This standard entails the use of the asset and liability method of computing the provision for income tax expense. Current tax expense results from corporate tax payable at the Federal and California jurisdictions for the Company, which relates to the current accounting period. Deferred tax expense results primarily from temporary differences between financial statement and tax return reporting, which result in additional tax payable in future periods. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates and law. Net future tax benefits are subject to a valuation allowance when management expects that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. Â Current and non-current tax assets and liabilities are based upon an estimate of taxes refundable or payable for each of the jurisdictions in which the Company is subject to tax. In the ordinary course of business there is inherent uncertainty in quantifying income tax positions. The Company assess income tax positions and record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Companyâ€™s policy is to recognize interest or penalties related to income tax matters in income tax expense. Â The Tax Cuts and Jobs Act of 2017 eliminated the option to immediately deduct research and development expenditures in the year incurred under Section 174, which became effective January 1, 2022. We are monitoring legislation for any further changes to Section 174 and the impact, if any, to the financial statements in 2024. Â Comprehensive Loss Â Comprehensive loss includes all changes in equity (net assets) during a period from non-owner sources. There were no elements of other comprehensive income (loss) in the periods presented, as a result comprehensive loss is the same as net loss for each period presented.Â Net Income (Loss) per Share Â Basic and diluted net income (loss) per share is presented in conformity with theÂ two-classÂ method required for participating securities. Basic and diluted net income (loss) for common stock and for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. Diluted net income (loss) per share includes potentially dilutive securities outstanding for the period. See Note 14 for reconciliations of basic and diluted net income (loss) per share. Â Recent Accounting Pronouncements Â From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption. Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements. Â The Company adopted Accounting Standards Update (â€œASUâ€) No. 2016-13, Financial Instruments â€" Credit Losses (â€œASC 326â€), as of October 1, 2023. This new standard adds to U.S. GAAP an impairment model, known as the current expected credit loss (â€œCECLâ€) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the timelier recognition of losses. Under the CECL model, entities estimate credit losses over the entire contractual term from the date of initial recognition of the financial instrument. As the Company does not currently have any trade receivables, there was no cumulative effect adjustment, and the adoption of this standard did not have a material impact on the Companyâ€™s financial statements. Â Income Taxes Disclosures â€" In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ ASU 2023-09 requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements 9 Months Ended Sep. 30, 2024 Significant Agreements [Abstract] Â Significant Agreements 3. Significant Agreements Â With regards to manufacturing, testing and potential commercial supply of oxylanthanum carbonate, on October 31, 2020, the Company entered into an agreement with Shilpa Medicare Ltd (â€œShilpaâ€) based in India. Pursuant to the Agreement, Shilpa provides certain development, manufacturing, supply and other CMC-related services related to the development and commercialization of oxylanthanum carbonate (â€œOLCâ€). Â In June 2024, the Company entered into the First Amendment to Manufacturing and Supply Agreement with Shilpa (the â€œAmendmentâ€). The Company has entered into the Amendment in anticipation of an increased manufacturing demand for OLC. Pursuant to the Amendment, the Company has agreed to make a binding purchase order for tablets of OLC and Shilpa has agreed to deliver such order by September 30, 2025. In addition, the Company has agreed to order additional tablets for delivery between December 31, 2025, and September 30, 2026. Further, the Company has agreed to make certain milestone payments and to provide certain funding to Shilpa for a new manufacturing line. The initial term of the Agreement shall continue until the eighth (8th) anniversary of the date of receipt by the Company of FDA approval of its NDA of OLC (the â€œInitial Termâ€). Following the Initial Term, the Agreement shall continue in effect for consecutive periods of four (4) years each unless earlier terminated pursuant to the terms of the Agreement. Â In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No

payments were made upon execution of the agreement but payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. If the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.Â In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. (â€œSpectrum Agreementâ€) pursuant to which the Company purchased certain assets from Spectrum, including Spectrumâ€™s right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALANâ„¢ (â€œRenalanâ€) and RZB 014, also known as SPI 014 (â€œSPIâ€ and together with Renalan, the â€œCompoundsâ€), to further develop and commercialize oxylanthanum carbonate and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Companyâ€™s shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the oxylanthanum carbonate Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Companyâ€™s common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrumâ€™s ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Companyâ€™s stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Companyâ€™s initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. In the event an NDA filing for oxylanthanum carbonate is accepted by the FDA, the Company will be required to pay $0.2 million to Altair Nanomaterials, Inc., (â€œAltairâ€) in accordance with the Spectrum Agreement. In addition, in the event FDA approval for oxylanthanum carbonate is received, the Company will be required to pay $4.5 million to Altair. The Company is also required to pay Spectrum 40% of all the Companyâ€™s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Spectrum Agreement) and 20% of all other sublicense income. The Companyâ€™s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Spectrum Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million resulting from a sublicense development agreement with Leeâ€™s Pharmaceutical (HK) Limited. In February 2023, the Company received an upfront payment of approximately $0.7 million resulting from a sublicense development agreement with Lotus International Pte Ltd. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the nine months ended September 30, 2023.Â Â On July 19, 2021, the Company entered into an agreement with Syneos Health LLC (â€œSyneosâ€) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The initial budget for the study, which includes clinical pharmacology, translational sciences, and bioanalytical services, was approximately $2.3 million. Approximately $2.0 million has been paid to Syneos and the research was completed during 2023. Â On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited (â€œQuotientâ€), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494.Â The initial budget for the study is approximately $3.7 million, and subsequent revisions reduced the overall budget to $2.9 million. Related payments totaling approximately $2.8 million have been paid to Quotient as of September 30, 2024, approximately 2.8 million of related expense has been recorded, and approximately $0.6 million and $0.6 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively. Â On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. (â€œCBCCâ€), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of oxylanthanum carbonate. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.4 million have been paid to CBCC as of March 31, 2023, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million, and the research was completed as of March 31, 2023. Â On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. Â On April 10, 2023, the Company entered into an agreement with Inotiv that provides preclinical trial and related services, for the purpose of performing research in support of UNI-494. The budget for these services is approximately $2.9 million. Approximately $2.9 million has been paid to Inotiv as of September 30, 2024 and approximately $0.3 million and $0.1 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively.Â On July 14, 2022, the Company entered into a license agreement with Leeâ€™s Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Leeâ€™s Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Leeâ€™s Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.Â Â On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. The budget for the services is approximately $2.7 million, and approximately $2.7 million has been paid to Celerion as of December 31, 2023, and the research was completed during 2023. Â On February 1, 2023, the Company entered into a license agreement with Lotus International Pte Ltd. (â€œLotusâ€) (see Note 4). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements. Â On June 29, 2023 and October 26, 2023, the Company entered into services agreements with Shilpa Medicare Ltd related to NDA filing support for oxylanthanum carbonate. The agreements provide for total payments of up to $3.7 million, and the Company has made $3.0 million in payments pursuant to the agreements as of September 30, 2024. X - DefinitionThe entire disclosure for significant agreements. + ReferencesNo definition available. + Details Name: uncy_SignificantAgreementTextBlock Namespace Prefix: uncy_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CollateralizedAgreementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Licensing Revenues 9 Months Ended Sep. 30, 2024 Licensing Revenues [Abstract] Â Licensing Revenues 4. Licensing Revenues Â On July 14, 2022, the Company entered into a license agreement (the â€œLeeâ€™s Agreementâ€) with Leeâ€™s Pharmaceutical (HK) Limited (â€œLeeâ€™sâ€). Under the terms of the agreement, Leeâ€™s Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Leeâ€™s will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Leeâ€™s with oxylanthanum carbonate product. The Company has received an upfront payment of approximately $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements. Â The Company has evaluated the Leeâ€™s Agreement in accordance with ASC 808, Collaborative Arrangements (â€œASC 808â€) and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entityâ€™s â€œordinary activitiesâ€. The Leeâ€™s Agreement is consistent with the Companyâ€™s current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship. Â The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Leeâ€™s, and therefore the promise does not represent a current performance obligation. The Company has concluded the agreement contains one performance obligation â€“ the IP license. Â ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved.Â For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date. Â The Company has concluded that at contract inception the total transaction price is the $1.0 million upfront fee. Â The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP as it contains all the necessary information for Leeâ€™s to develop for commercialization in the Territory. Unicyciveâ€™s ongoing activities do not significantly affect the standalone functionality of the IP. In addition, the functionality of the IP is not expected to substantially change during the license period based on Unicyciveâ€™s activities. The revenue should therefore be recognized at a point in time. This intellectual property was transferred to Leeâ€™s in July 2022. Â On February 1, 2023, the Company entered into a license agreement (the â€œLotus Agreementâ€) with Lotus International Pte Ltd. (â€œLotusâ€). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has agreed to complete development of the drug product, at its own expense, as required for obtaining regulatory approval in the U.S. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Lotus with oxylanthanum carbonate product. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements. Â The Company has evaluated the Lotus Agreement in accordance with ASC 808 and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entityâ€™s â€œordinary activitiesâ€. The Lotus Agreement is consistent with the Companyâ€™s current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship. Â The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Lotus, and therefore the promise does not represent a current performance obligation. The Company evaluated the development services and concluded that although not material in cost, they are highly interrelated with the license grant. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. The combination of the license grant and development services is distinct as Lotus plans to use the product of this bundled unit for developing its regulatory applications. The Company concluded that the Lotus agreement contains one performance obligation, the bundle of the license grant and development services. Â ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved.Â For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date. Â The Company has concluded that at contract inception the total transaction price is $675,000 amount of the upfront payment. ASC 606 generally requires an entity to allocate the transaction price to the performance obligations in proportion to their standalone selling prices (i.e., on a relative standalone selling price basis). The Company identified the bundle of the license grant and development services as the single performance obligation in the agreement. The $675,000 initial transaction price will therefore be entirely allocated to this obligation. Â The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP. However, since it is not distinct, revenue must be recognized based on the combination of the functional IP and the related development services. Lotus will not simultaneously receive and consume the benefits of the oxylanthanum carbonate IP or development services. Since the performance of the development services creates an asset that will also be used by the Company and can be licensed to other customers outside of the Territory, the Company is considered to control the asset as it is created, and it does create an asset with an alternative use. Therefore, the Company concluded that control is not deemed to be transferred over time and is instead transferred at a point in time. The intellectual property was transferred to Lotus in February 2023, and the development services were determined to be immaterial to the contract. The Company has recognized a total of $675,000 in the accompanying statements of operations as licensing revenue for the nine months ended September 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8:

http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components 9 Months Ended Sep. 30, 2024 Balance Sheet Components [Abstract] Â Balance Sheet Components 5. Balance Sheet Components Â Prepaid expenses and other current assets as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Prepaid directorsâ€™ and officersâ€™ liability insurance premiumsÂ $270Â Â $397Â Prepaid preclinical servicesÂ Â 3,103Â Â Â 4,310Â OtherÂ Â 325Â Â Â 687Â TotalÂ $3,698Â Â $5,394Â Â Property, plant and equipment as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Leasehold improvementsÂ $21Â Â $37Â Furniture and fixturesÂ Â 21Â Â Â 29Â Lab EquipmentÂ Â -Â Â Â Â 26Â SubtotalÂ Â 42Â Â Â 92Â Less accumulated depreciationÂ Â (16)Â Â (31) NetÂ $26Â Â $61Â Â Accounts payable as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Trade accounts payableÂ $821Â Â $519Â Credit card liabilityÂ Â 18Â Â Â 29Â TotalÂ $839Â Â $548Â Â Accrued liabilities as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Accrued labor costsÂ $1,917Â Â $1,402Â Accrued drug development costsÂ Â 1,034Â Â Â 1,068Â OtherÂ Â 283Â Â Â 522Â TotalÂ $3,234Â Â $2,992Â X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Lease 9 Months Ended Sep. 30, 2024 Operating Lease [Abstract] Â Operating Lease 6. Operating Lease Â The Company leases office space under an operating lease. In December 2021, the Company entered into a lease agreement for 2,367 square feet of office space commencing December 1, 2021. The initial lease term was for two years, and there was an option to extend the lease for an additional year. On March 3, 2023, the Company expanded its leased space through a lease amendment by an additional 2,456 square feet commencing March 15, 2023. The term of the amended lease is for three years with an option to extend the lease for three additional years. Â The lease amendment represents a modification of the original lease, and the Company evaluated the new agreement under ASC 842, Leases. The Company classified the lease as an operating lease and, on March 15, 2023, determined that the present value of the lease was approximately $1.0 million using an estimated incremental borrowing rate of 10%. During the nine months ended September 30, 2024, the Company reflected amortization of right-of-use asset of approximately $ 265,000, resulting in a right of use asset balance of approximately $0.8 million. Â During the nine months ended September 30, 2024, the Company made cash payments on the lease of $ 329,000 towards the lease liabilities. As of September 30, 2024, the total lease liability was approximately $ 0.8 million. Â As of September 30, 2024, maturities of the Companyâ€™s lease liabilities are as follows (in thousands, unaudited): Â Â Â Operating LeaseÂ Year ending December 31, 2024Â $144Â Year ending December 31, 2025Â Â 608Â Year ending December 31, 2026Â Â 118Â Total lease paymentsÂ Â 871Â Less imputed interest rate / present value discountÂ Â (64) Present value of lease liabilityÂ Â 807Â Less current portionÂ Â (542) Long term portionÂ $265Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesOperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions 7. Related Party Transactions Â Loan from Chief Executive Officer and Stockholder Â The Company received advances from the stockholder of $210,000 during February 2023. The Company repaid amounts owed to the stockholder of $210,000 plus accrued interest during March 2023. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] Â Commitments and Contingencies 8. Commitments and Contingencies Â Contingencies Â The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Companyâ€™s financial statements. The Company currently has no pending claims or legal proceedings. Â In December 2022, the Company signed an advisory services agreement with Maxim Group LLC (â€œMaximâ€) pursuant to which the Company will pay Maxim $100,000 upon the closing of a private placement of the Companyâ€™s equity or equity-linked securities. Maxim provided advisory services with respect to a private placement securities purchase agreement with certain healthcare-focused institutional investors, which closed in March of 2023. The Company paid the $100,000 advisory fee in March 2023. Â Indemnification Â In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. Â The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. However, the Company may record charges in the future as a result of these indemnification obligations. Â Additionally, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Companyâ€™s request in such capacity. The indemnification period covers all pertinent events and occurrences during the directorâ€™s or officerâ€™s service. Â Employee Benefit Plan Â In December 2021, the Company implemented a 401(k) Plan which covers all eligible employees of the Company (the â€œ401(k) Planâ€). Employer matching contributions are immediately 100% vested. The Companyâ€™s 401(k) Plan provides that the Company match each participantâ€™s contribution at 100% up to 4% of the employeeâ€™s eligible compensation. Company contributions to the 401(k) Plan totaled approximately $107,000 and $104,000 for the year ended December 31, 2023 and for the nine months ended September 30, 2024, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Deficit 9 Months Ended Sep. 30, 2024 Stockholdersâ€™ Deficit [Abstract] Â Stockholdersâ€™ Deficit 9. Stockholdersâ€™ Deficit Â Authorized Common Stock Â The Company is authorized to issue up to 400,000,000 shares of common stock at par value of $0.001 per share. Â Issuance of Common Stock and Warrants from Initial Public Offering Â During July 2021, as a result of its initial public offering, the Company issued 5,000,000 shares of common stock and 4,000,000 warrants to investors in exchange for cash at $5.00 per unit, consisting of $4.99 per share of common stock and $.0125 per four fifths of a warrant. The warrants have a 5-year term and an exercise price of $6.00 per warrant. The underwriters exercised their option to purchase an additional 600,000 warrants, and the Company received $7,500 in proceeds.Â As a result of the initial public offering, the Companyâ€™s outstanding convertible notes and unpaid accrued interest were converted into 736,773 shares of common stock. Additionally, in accordance with the original terms of the warrant agreements convertible noteholders were granted a total of 184,193 common stock warrants with a 5-year term and with an exercise price of $6.00 per warrant. Â The warrants from the initial public offering are equity classified. The following table summarizes activity for the Companyâ€™s IPO warrants for the nine months ended September 30, 2024: Â Â Â Â Â Â Â Â Weighted-Â Â Â Â Â Â Number ofÂ Â Â Â Â AverageÂ Â Â Â Â Â SharesÂ Â Weighted-Â Â RemainingÂ Â AggregateÂ Â Â Â UnderlyingÂ Â AverageÂ Â ContractualÂ Â IntrinsicÂ Â Â OutstandingÂ Â ExerciseÂ Â TermÂ Â ValueÂ Â Â WarrantsÂ Â PriceÂ Â (in Years)Â Â (inÂ thousands)Â Outstanding, December 31, 2023Â Â 4,784,193Â Â Â 6.00Â Â Â 2.54Â Â Â Â Â Â Â Â -Â Warrants grantedÂ Â -Â Â Â -Â Â Â -Â Warrants exercisedÂ Â -Â Â Â -Â Â Â -Â Outstanding, September 30, 2024Â Â 4,784,193Â Â Â 6.00Â Â Â 1.79Â Â Â -Â Â See Note 12 for information on preferred stock warrants associated with our sale in March of Series A-1 Preferred Stock. Â Issuance of Common Stock Upon Conversion of Series A-1 Preferred Stock Â On June 26, 2023, the Company held its annual shareholder meeting and, as a result, shareholder approval for the issuance of common shares upon the conversion of the Series A-1 Preferred Stock was obtained (see Notes 10 and 11). On July 11, 2023, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (the â€œSeries A Certificate of Designationâ€), the Company issued a total of 19,516,205 shares of common stock and 43,649 Series A-2 Preferred Stock in settlement of the auto-conversion of the Series A-1 Preferred Stock. Â Voting Rights of Common Stock Â Each holder of shares of common stock shall be entitled to one vote for each share thereof held. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Issuance of Series A-1 Preferred Stock 9 Months Ended Sep. 30, 2024 Issuance of Series A-1 Preferred Stock [Abstract] Â Issuance of Series A-1 Preferred Stock Note 10. Issuance of Series A-1 Preferred Stock Â On March 3, 2023, the Company issued and sold, in a private placement, 30,190 shares of Series A-1 Preferred Stock for an aggregate net proceeds of $28.0 million (the â€œPreferred Stock Offeringâ€), net of placement agent fees and offering expenses of $2.2 million. The Company intends to use the net proceeds from the Preferred Stock Offering to support the Companyâ€™s New Drug Application (NDA) submission for approval of oxylanthanum carbonate for the treatment of hyperphosphatemia and, if approved, for the commercial launch of oxylanthanum carbonate in the U.S. Â Pursuant to the Series A Certificate of Designation, as of March 3, 2023, each share of Series A-1 Preferred Stock was, subject to approval of the Companyâ€™s stockholders, convertible into a unit (â€œUnitâ€) consisting of: (i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of common stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares (excluding deemed dividends) of Series A-3 Preferred Stock (the â€œTranche A Warrantâ€), (iii) a tranche B warrant to acquire approximately 42,432,672 shares (excluding deemed dividends) of Series A-4 Preferred Stock (the â€œTranche B Warrantâ€), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares (excluding deemed dividends) of Series A-5 Preferred Stock (the â€œTranche C Warrantâ€, together with the Tranche A Warrant and the Tranche B Warrant, the â€œWarrantsâ€). The Tranche A Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Companyâ€™s announcement of receipt of FDA approval for oxylanthanum carbonate, the Tranche B Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Companyâ€™s announcement of receipt of Transitional Drug Add-On Payment Adjustment (â€œTDAPAâ€) approval for oxylanthanum carbonate, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million is exercisable until 21 days following four quarters of commercial sales of oxylanthanum carbonate following receipt of TDAPA approval.Â The Company has designated 30,190 shares of Series A-1 Preferred Stock, 1,800,000 shares of Series A-2 Preferred Stock, 1,800,000 shares of Series A-3 Preferred Stock, 1,800,000 shares of Series A-4 Preferred Stock, and 3,600,000 shares of Series A-5 Preferred Stock, together the â€œSeries A Preferred Stockâ€. The Series A Preferred Stock has a par value of $0.001 per share. The Series A Certificate of Designation states that, to the extent that the conversion of the Series A-1 preferred stock as well as the exercise of the Warrants into Series A-2, Series A-3, Series A-4, and Series A-5 preferred stock results in a beneficial ownership interest in excess of the maximum percentage of common stock upon conversion, the holders will receive the as converted equivalent for the remaining shares in preferred stock.Â Â The Company determined that the Warrants are freestanding from the Series A-1 Preferred Stock, because the stock will automatically convert into shares of common stock, and the holders will be able to sell those shares while retaining the Warrants. The Company noted that at contract inception, the Warrants were contingently issuable upon the occurrence of a specified event (shareholder approval). Â In connection with the Series A-1 Preferred Stock issuance, the Company recognized liabilities for the associated Warrants, which had an aggregate fair value of $2.8 million at the time of issuance. Offering costs of $0.2 million were allocated to the Warrants and expensed during March 2023. The fair value of the Warrants was accounted for as a reduction to the net proceeds of the Preferred Stock Offering, which resulted in an initial carrying value of $25.4 million for the Series A-1 Preferred Stock (net of $2.0 million of placement agent fees and offering costs allocated to the Series A-1 Preferred Stock). Refer to Note 12 for disclosures related to the Warrants. Â On June 26, 2023, the Company held its annual shareholder meeting and, as a result, shareholder approval for the conversion of the Series A-1 Preferred Stock was obtained. On July 11, 2023, pursuant to the Series A Certificate of Designation, the Company issued 19,516,205 shares of common stock (see Note 9) and 43,649 shares of Series A-2 Preferred Stock in partial settlement of the auto-conversion of the Series A-1 preferred shares. As of December 31, 2023, there were zero shares of Series A-1 preferred stock issued and outstanding and there were 43,649 shares of Series A-2 Preferred Stock issued and outstanding. Â The Series A-2, A-3, A-4, and A-5 Preferred Stock have the following rights: Â Dividends: While shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends(other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.Â Â Voting: Holders of the Series A-2, A-3, A-4, and A-5 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis as determined by dividing the liquidation preference with respect to such shares of Preferred Stock by the conversion price. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders. Â At the option of the holder thereof, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, or Series A-5 Preferred Stock shall be convertible into one share of common stock.Â Exchange Agreement Â On March 13, 2024,Â the Company entered into an exchange agreement (the â€œExchange Agreementâ€) with certain accredited investors (the â€œInvestorsâ€), pursuant to which the Investors surrendered all shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as â€œSeries A-2 Prime Preferredâ€ (the â€œExchanged Preferredâ€) having rights set forth the Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (the â€œAmended Series A Certificate of Designationâ€). Â Concurrent with execution of the Exchange Agreement, but prior to filing of the Amended Series A Certificate of Designation with the Delaware Secretary of State, the Company filed Certificates of Elimination for each of its Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the â€œCertificates of Eliminationâ€) with the Delaware Secretary of State. Â Concurrent with the execution of the Exchange Agreement, the Company and each Investor have amended and restated the following warrants: (i) tranche A warrants to acquire an aggregate of 47,852,430 shares of Series A-3 Convertible Preferred Stock of the Company that were issued on July 11 2023 (the â€œOriginal Tranche A Warrantsâ€) have been amended and restated to acquire an aggregate of 25,840.3122 shares of Series A-3 Convertible Preferred Stock (as amended, the â€œAmended Tranche A Warrantsâ€); (ii) tranche B warrants to acquire an aggregate of 43,502,206 shares of Series A-4 Convertible Preferred Stock of the Company that were issued on July 11, 2023 (the â€œOriginal Tranche B Warrantsâ€) have been amended and restated to acquire an aggregate of 25,666.30154 shares of Series A-4 Convertible Preferred Stock (as amended, the â€œAmended Tranche B Warrantsâ€) and (iii) tranche C warrants to acquire an aggregate of 69,603,531 shares of Series A-5 Convertible Preferred Stock of the Company that were issued on July 11, 2023(the â€œOriginal Tranche C Warrantsâ€, and together with the Original Tranche A Warrants and Tranche B Warrants, the â€œOriginal Warrantsâ€) have been amended and restated to acquire 51,506.61294 shares of Series A-5 Convertible Preferred Stock (as amended, the â€œAmended Tranche C Warrants,â€ together with the Amended Tranche A Warrants and the Amended Tranche B Warrants, the â€œAmended Warrantsâ€). The Amended Warrants have the same terms and conditions as the original warrants except that such Amended Warrants: (i) reduced the amount of shares of Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock into which such Amended Warrants are convertible as described above; (ii) allow for the issuance of fractional shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, as applicable upon exercise of such Amended Warrants and (ii) revised the exercise price to be $1,000 per share of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, as applicable in such Amended Warrants. The aggregate exercise price, the amount of shares of Common Stock upon conversion of the Series A-3 Preferred Stock, the Series A-4 Preferred Stock and the Series A-5 Preferred Stock and exercise period in the Amended Warrants did not change from the Original Warrants. Â Subject to the terms and limitations contained in the Amended Series A Certificate of Designation, each share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock are convertible into a number shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock by the applicable conversion price of $0.49, $0.54, $0.59 and $0.74 of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock, respectively. Â Pursuant to the terms of the Exchange Agreement, effective March 13, 2024, the Company filed theÂ Amended Certificate of Designation with the Delaware Secretary of State designating, 21,400 shares as Series A-2Â Prime Preferred Stock, 25,900 shares as Series A-3Â Convertible Preferred Stock, 25,700 shares as Series A-4Â Convertible Preferred Stock, and 51,600 shares as Series A-5Â Convertible Preferred Stock (all such series of preferred stock referred to herein collectively as â€œSeries A Preferred Stockâ€), each with a stated value of $1,000 per share (the â€œOriginal Per Share Priceâ€). The Amended Certificate of Designation sets forth the rights, preferences and limitations of the shares of Series AÂ Preferred Stock. Terms not otherwise defined in this item shall have the meanings given in the Amended Certificate of Designation. The Amended Certificate of Designation was filed with an effective date of March 14, 2024.Â Dividends.Â At all times following the Issuance Date, while shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of SeriesÂ A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Amended Certificate of Designation) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Amended Certificate of Designation) are paid on shares of the Common Stock. Â Voting Rights.Â Subject to certain limitations described in the Amended Certificate of Designation, the Series A Preferred Stock is voting stock. Holders of the Series A Preferred Stock are entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock basis. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders. Â Liquidation. Upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series A Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of the Amended Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Amended Certificate of Designation or otherwise. Â Conversion.Â Subject to the limitations set forth in the Amended Certificate of Designation, at the option of the holder, each share of Series A-2 Prime Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock shall be convertible into a number shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock by the applicable conversion price of $0.49, $0.54, $0.59 and $0.74 for the Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_DividendsPreferredStockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details Name: us-gaap_PreferredStockTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Issuance of Series B-1 Preferred Stock 9 Months Ended Sep. 30, 2024 Issuance of Series B-1 Preferred Stock [Abstract] Â Issuance of Series B-1 Preferred Stock Note 11. Issuance of Series B-1 Preferred Stock Â On March 13, 2024, we signed a securities purchase agreement with certain healthcare-focused institutional investors that provided $50 million in gross proceeds to us through a private placement. Pursuant to the securities purchase agreement, we issued to institutional investors $50.0 million in shares of our Series B-1 Convertible Preferred Stock. 50,000 Shares of Series B-1 Convertible Preferred Stock were issued at a price of $1,000.00 per share and each share is convertible into shares of common stock at a rate equal to the initial $1,000 purchase price divided by the initial conversion price of $1.00 per share. Â Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the â€œSeries B Certificate of Designationâ€), as of March 14, 2024, each share of Series B-1 Preferred Stock is, subject to approval of the Companyâ€™s stockholders, convertible into shares of common stock of the Company and, if applicable, shares of Series B-2 Convertible Preferred Stock (the â€œSeries B-2 Preferred Stockâ€), in lieu of common stock Â The Company has designatedÂ 50,000Â shares of Series A-1 Preferred Stock and 50,000Â shares of Series B-2 Preferred Stock. The Series B Certificate of Designation states that, to the extent that the conversion of the Series B-1 preferred stock results in a beneficial ownership interest in excess of the maximum percentage of common stock upon conversion, the holders will receive the as converted equivalent for the remaining shares in preferred stock. Â Â On June 20, 2024, we held our annual stockholder meeting, and as a result, stockholder approval for the conversion of the Series B-1 Convertible Preferred Stock was obtained. On July 5, 2024, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, the Company issued 42,118,000 shares of common stock and 7,882 shares of Series B-2 preferred stock in settlement of the automatic conversion of the Series B-1 Convertible Preferred Stock.Â The Series B-1 Preferred Stock have the following rights: Â Dividends: Prior to the receiving Stockholder Approval, dividends will accrue, on all issued and outstanding shares of Series A-1 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts); provided that such annual dividend rate shall increase to fourteen percent (14%) if Stockholder Approval is not obtained at the first meeting of stockholders following the date of the Preferred Stock offering. If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding of the Series B-1 Preferred Stock. At all times following the Issuance Date, while shares of Series B-1 Preferred Stock are issued and outstanding, holders of Series B Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of SeriesÂ B-1 Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) are paid on shares of the Common Stock. Stockholder approval was received on June 20, 2024. Â Voting: : Subject to certain limitations described in the Series B Certificate of Designation holders of the Series B-1 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis as determined by dividing the liquidation preference with respect to such shares of Series B-1 Preferred Stock by the conversion price. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Unless and until the Company has obtained the Stockholder Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series B Preferred Stock (for purposes of calculating the number of aggregate votes that the holders of Series B Preferred Stock are entitled to on an as-converted basis) will be equal to that number of shares equal to 19.9% of the Companyâ€™s outstanding Common Stock as of the Signing Date (excluding for purposes of the calculation, any securities issued on the Signing Date) (the â€œCapâ€), which each such holder being able to vote the number of shares of Series B Preferred Stock held by it relative to the total number of shares of Series B Preferred Stock then outstanding multiplied by the Cap. Notwithstanding the foregoing, the holders of the Series B Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis with regard to the approval of the issuance of Common Stock upon conversion of the Series B Preferred Stock. Â On the tenth trading day following the announcement of the Stockholder Approval, each share of Series B-1 Preferred Stock shall automatically convert into a unit consisting of: (1) the number of shares of common stock equal to the quotient ofÂ (A) the liquidation preference with respect to such share of Series B-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holderâ€™s beneficial ownership to exceed 9.99%, such holder shall

receive shares of Series B-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership divided by 1,000. Â Â Liquidation Preference: The Series B-1 Preferred Stock had a liquidation preference of one-times the original per share priceÂ of $1,000Â per share, plus any accrued but unpaid dividends thereon, whether or not declared, subject to certain customary anti-dilution adjustments. Â The Series B-2 Preferred Stock has the following rights: Â Dividends: Dividends will accrue, on all issued and outstanding shares of Series B-2 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts). If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding. Â Voting: Subject to certain limitations described in the Series B Certificate of Designation, the Series B-2 Preferred Stock is voting stock. Holders of the Series B-2 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series B-2 Preferred Stock will be entitled to one vote for each whole share of common stock into which their Series B-2 Preferred Stock is then-convertible on all matters submitted to a vote of stockholders.Â Liquidation. Upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series B Preferred Stock and common stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series B Preferred Stock as if they had been converted to common stock pursuant to the terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Series B Certificate of Designation or otherwise. Â Conversion: Subject to the limitations set forth in the Series B Certificate of Designation, at the option of the holder thereof, each share of Series B-2 Preferred Stock, is convertible into the number of shares of common stock equal to the quotient of (A) the stated value ($1,000), divided by (B) the conversion price on the applicable conversion date, which is $1.00 as of the date of this report. X - DefinitionThe entire disclosure for issuance of series B-1 preferred stock. + ReferencesNo definition available. + Details Name: uncy_IssuanceOfSeriesB1PreferredStockTextBlock Namespace Prefix: uncy_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Warrant Liability 9 Months Ended Sep. 30, 2024 Warrant Liability [Abstract] Â Warrant Liability 12. Warrant Liability Â In connection with the Series A Preferred Stock Offering (see Note 10), the Company issued the Warrants. Â After the Warrants were legally issued as a result of the automatic conversion of the Series A-1 Preferred Stock upon shareholder approval, they became immediately exercisable at the option of the holder. The Company determined that the Warrants, while initially contingently issuable, qualified as derivative instruments pursuant to ASC 815-40, Contracts in an Entityâ€™s Own Equity and that the Warrants were considered issued for accounting purposes concurrently with the Series A-1 Preferred Stock. Â On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the conversion of the Series A-1 Preferred Stock was obtained. On July 11, 2023, pursuant to the Series A Certificate of Designation, the Company issued, in addition to common stock and Series A-2 Preferred Stock, (i) a Tranche A Warrant to acquire 47,852,430 shares of Series A-3 Preferred Stock, (ii) a Tranche B Warrant to acquire 43,502,206 shares of Series A-4 Preferred Stock, and (iii) a Tranche C Warrant to acquire 69,603,531 shares of Series A-5 Preferred Stock. See Note 10 for discussion of exchange agreement related to Series A-2 Preferred Stock and warrants. Â The Warrants are recognized as liabilities in the balance sheets and were initially recognized at fair value at the time of issuance. The Warrants are also subject to remeasurement at each balance sheet date after issuance. Any change in fair value is recognized as a component of other income (expense) in the statements of operations in the period of change. Â The valuation of the Warrants contains unobservable inputs that reflect the Companyâ€™s own assumptions for which there is little market data. Accordingly, the Warrants are measured at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs. The significant unobservable inputs used in the fair value measurement of the Companyâ€™s Warrants include, but are not limited to, probability of obtaining certain shareholder approvals, probability of reaching certain technical milestones related to the development of oxylanthanum carbonate, and the estimated term of the Warrants. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, a change in the assumption used for the probability of obtaining certain shareholder approvals is not correlated to a change in the probability of reaching certain technical milestones. However, a change to the assumption used for the probability of obtaining certain shareholder approvals or a change in the probability of reaching certain technical milestones would have been accompanied by a directionally opposite change and a directionally similar change, respectively, in the assumption used for the estimated term.Â The fair value of the Warrants associated with the Companyâ€™s March 2023 private placement transaction was determined as of March 3, 2023, and March 31, 2023, by using a Monte Carlo simulation technique (â€œMCSâ€) to value the embedded derivatives associated with the Warrants. The MCS methodology calculates the theoretical value of a warrant based on certain parameters, including: (i) the threshold of exercising the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, (vi) the number of paths, (vii) estimated probability assumptions surrounding shareholder approval as well as the achievement by the Company of technical milestones associated with regulatory and commercial progress, and (viii) an estimated discount for lack of marketability. Â The MCS valuation model was used for the valuation performed as of the transaction inception on March 3, 2023, and on March 31, 2023, due to uncertainty in the timing of shareholder approval and the potential variability in the Warrant exercise price. On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the issuance of common shares upon the conversion of the Series A-1 Preferred Stock was obtained and the exercise price for the Warrants became fixed. Therefore, as of December 31, 2023 and September 30, 2024, the fair value of the Warrants was determined using a Black Scholes model using parameters including (i) the exercise price of the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, and (vi) estimated probability assumptions surrounding the achievement by the Company of technical milestones associated with regulatory and commercial progress. Â These valuation techniques involve managementâ€™s estimates and judgment based on unobservable inputs and are classified in Level 3. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Generally, a significant increase (decrease) in the probabilities of shareholder approval and the achievement of technical milestones would have resulted in a significantly higher (lower) fair value measurement; however, changes in other inputs such as expected term and price of the underlying common stock will have a directionally opposite impact on fair value measurement. Â The Company uses a third-party valuation expert to assist in the determination of the fair value of the Warrants. The tables below summarize the valuation inputs into the Black Scholes model for the liability associated with the three tranches of Warrants at December 31, 2023 and September 30, 2024. Â Tranche A WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.54Â Â $0.54Â VolatilityÂ Â 96.5%Â â€“Â 139.2%Â Â 107.7%Â -Â 129.2% Risk free rateÂ Â 4.6% â€“ 5.3%Â Â 3.8% â€“ 4.1% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 0.5 â€“ 1.5Â Â Â 0.7 â€“ 1.7Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 29.3%Â Â 36.55 â€“ 38.50% Â Tranche B WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.59Â Â $0.59Â VolatilityÂ Â 114.6% - 139.2%Â Â 109.8%Â â€“Â 129.2% Risk free rateÂ Â 4.4% â€“ 4.8%Â Â 3.7% â€“ 3.8% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 1.0 â€“ 2.0Â Â Â 1.3 â€“ 2.3Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 12.0%Â Â 11.0% Â Tranche C WarrantÂ At DecemberÂ 31, 2023Â Â At September 30, 2024Â Fair value of underlying stockÂ $0.87Â Â $0.41Â Exercise priceÂ $0.74Â Â $0.74Â VolatilityÂ Â 107.8%Â -Â 114.6%Â Â 116.1%Â -Â 129.2% Risk free rateÂ Â 4.0%- 4.4%Â Â 3.6% â€“ 3.8% Dividend yieldÂ Â 0%Â Â 0% Term (in years)Â Â 2.0 - 3.0Â Â Â 1.7 â€“ 2.7Â Discount for lack of marketabilityÂ Â 12.5%Â Â 7.5% Probability for FDA approvalÂ Â 4.3 % - 12.5%Â Â 0.01%-27.46% Â As of the issuance date (March 3, 2023), the Company estimated the fair value of the Warrants to be $2.8 million. As of December 31, 2023 and September 30, 2024, the Company estimated the fair value of the Warrants to be $13.1 million and $6.4 million, respectively. Â The following table summarizes activity for the Companyâ€™s preferred stock warrants for the nine months ended September 30, 2024: Â Â Â

dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units; (ii) common stock to be issued upon the assumed exercise of the Companyâ€™s common stock warrants; (iii) convertible preferred stock; and (iv) prior to issuance, the issuable warrants related to the Companyâ€™s March private placement financing.Â The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended SeptemberÂ 30, Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Basic net loss per share Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (4,333) Â $ (4,096) Â $ (22,746) Â $ (15,204) Deemed dividends on preferred stock Â Â (72) Â Â - Â Â Â (867) Â Â Â Â Cash Dividends to Series B holders Â Â - Â Â Â - Â Â Â - Â Â Â (1,095) Net loss attributable to common shares, basic and diluted Â Â (4,405) Â Â (4,096) Â Â (23,613) Â Â (16,299) Â Denominator: Â Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 32,633,074 Â Â 88,943,212 Â Â Â 21,100,206 Â Â Â 54,073,701 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (0.13) Â $ (0.05) Â $ (1.12) Â $ (0.30) Â The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Â Â Â Three Months EndedÂ September 30,Â Â Nine Months EndedÂ September 30,Â Â Â 2023Â Â 2024Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Â Â Â Â Options to purchase common stockÂ Â 10,321,616Â Â Â 13,671,140Â Â Â 10,321,616Â Â Â 13,671,140Â Warrants to purchase common stockÂ Â 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Restricted stock unitsÂ Â -Â Â Â 21,765Â Â Â -Â Â Â 21,765Â Common stock issuable upon conversion of Series B-2 convertible preferred stockÂ Â -Â Â Â 7,882,000Â Â Â -Â Â Â 7,882,000Â Common stock issuable upon conversion of Series A-2 Prime convertible preferred stockÂ Â 43,649,000Â Â Â 22,676,000Â Â Â 43,649,000Â Â Â 22,676,000Â Warrants to purchase convertible preferred stockÂ Â 160,958,167Â Â Â 160,958,167Â Â Â 160,958,167Â Â Â 160,958,167Â TotalÂ Â 176,063,976Â Â Â 209,993,175Â Â Â 176,063,976Â Â Â 209,993,175Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events 15. Subsequent Events Â On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ (4,096) $ 9,855 $ (20,963) $ (4,333) $ (3,838) $ (14,575) $ (15,204) $ (22,746) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements - Shalabh Gupta [Member] 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement During the three months ended SeptemberÂ 30, 2024, no Section 16 officers and directorsÂ adopted, modified orÂ terminatedÂ a â€œRule 10b5-1 trading arrangementâ€ (as defined in Item 408 of Regulation S-K of the Exchange Act), except that on September 20, 2024, Shalabh Gupta, M.D., our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 900,000 shares of our common stock beginning on January 20, 2025 and terminating on January 19, 2026. Name Shalabh Gupta Title M.D., our Chief Executive Officer Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date September 20, 2024 Rule 10b5-1 Arrangement Terminated true Non-Rule 10b5-1 Arrangement Terminated false Termination Date January 19, 2026 Aggregate Available 900,000 Rule 10b5-1 Arrangement Modified [Flag] false Non-Rule 10b5-1 Arrangement Modified [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrTerminationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNon-Rule 10b5-1 Arrangement Terminated. + ReferencesNo definition available. + Details Name: uncy_NonRule10b51ArrangementModified Namespace Prefix: uncy_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRule 10b5-1 Arrangement Modified. + ReferencesNo definition available. + Details Name: uncy_Rule10b51ArrangementModifiedFlag Namespace Prefix: uncy_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Details Name: ecd_IndividualAxis=uncy_ShalabhGuptaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€).The accompanying unaudited financial statements of the Company as of September 30, 2024 have been prepared in accordance with the

instructions to Form 10-Q and Article 10 of Regulation S-X and, accordingly, they do not include all information and footnote disclosures required by accounting principles generally accepted in the U.S. (â€œGAAPâ€). The Company believes the footnotes and other disclosures made in the financial statements are adequate for a fair presentation of the results of the interim periods presented. The financial statements include all adjustments (solely of a normal recurring nature) which are, in the opinion of management, necessary to make the information presented not misleading. You should read these financial statements and the accompanying notes in conjunction with the financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates. Revenue Recognition Â Revenue RecognitionThe Company recognizes revenue in accordance with Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers (â€œASC 606â€). The Company applies the five-step model in ASC 606 and recognizes revenue from product sales or services rendered when control of the promised goods or services are transferred to a counterparty in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. Warrant Liability Warrant LiabilityIn conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), the Company established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued (and have since been issued â€“ see Note 12), subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. The Company accounts for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liability was initially measured at fair value and is remeasured at fair value each reporting period. Changes in the fair value of the warrant liability are recognized in earnings during each period. The warrant liability is measured using Level 3 fair value inputs. See Note 12 for a description of warrant liability and the related valuations.Â Segment Information Segment InformationThe Company operates and manages its business as one reportable operating segment. The Companyâ€™s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Risks and Uncertainties Risks and UncertaintiesThe Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companyâ€™s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Companyâ€™s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Companyâ€™s ability to attract and retain employees necessary to support its growth.The Companyâ€™s general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions.Any product candidates developed by the Company will require approvals from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Companyâ€™s current product candidates or any future product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company.The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs, which would materially and adversely affect its business, financial condition and operations.The Company is dependent upon the services of its employees, consultants and other third parties. Property, Plant and Equipment Property, Plant and EquipmentProperty, plant, and equipment are recorded at cost less accumulated depreciation. Additions, improvements, and major renewals or replacements that substantially extend the useful life of an asset are capitalized. Repairs and maintenance expenditures are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value at that time. At September 30, 2024, management determined there were no impairments of the Companyâ€™s property and equipment.Â Leases LeasesThe Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Companyâ€™s right to use an underlying asset during the lease term, and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Companyâ€™s financial instruments include the warrant liability, cash and cash equivalents, accounts payable and accrued liabilities.Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The fair value hierarchy contains the following levels: Â â— Level 1 â€“ defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets; Â â— Level 2 â€“ defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and Â â— Level 3 â€“ defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable. Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands): Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â -Â Â $Â Â Â Â -Â Â $6,377Â Â $6,377Â Total liabilities at fair valueÂ $-Â Â $-Â Â $6,377Â Â $6,377Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands): Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â Â -Â Â $Â Â Â Â Â -Â Â $13,134Â Â $13,134Â Total liabilities at fair valueÂ $-Â Â $-Â Â $13,134Â Â $13,134Â Â The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands): Â Â Nine months Ended September 30, 2024Â Fair value at January 1, 2023Â $-Â Issuance of Warrants (March 3, 2023)Â Â 2,831Â Change in fair value of WarrantsÂ Â 10,375Â Fair value at March 31, 2023Â Â 13,206Â Change in fair value of warrantsÂ Â (282) Fair value at June 30, 2023Â Â 12,924Â Change in fair value of warrantsÂ Â (1,396) Fair value at September 30, 2023Â $11,528Â Â Â Â Â Â Fair value at January 1, 2024Â $13,134Â Change in fair value of warrantsÂ Â 11,807Â Fair value at March 31, 2024Â Â 24,941Â Change in fair value of warrantsÂ Â (16,810) Fair value at June 30, 2024Â Â 8,131Â Change in fair value of warrantsÂ Â (1,754) Fair value at September 30, 2024Â $6,377Â The expense relating to the change in fair value of the warrant liability of $8.7 million and $6.8 million for the nine months ended September 30, 2023 and September 30, 2024, respectively, is included in other income (expense) in the statements of operations.ASC 820, Fair Value Measurement and Disclosures requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of December 31, 2023 and September 30, 2024, the recorded values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to the short-term nature of the instruments. Cash and cash equivalents, accounts payable, and accrued liabilities are Level 1 financial instruments. Concentration of Credit Risk Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024. Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets represent costs incurred that benefit future periods. These costs are amortized over specific time periods based on the agreements. Research and Development Expenses Research and Development ExpensesSubstantially all the Companyâ€™s research and development expenses consist of expenses incurred in connection with the development of the Companyâ€™s product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on the Companyâ€™s behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for the Companyâ€™s research and product development employees. The Company expenses both internal and external research and development expenses as they are incurred.Â General and Administrative Expenses General and Administrative ExpensesGeneral and administrative expenses represent personnel costs for employees involved in general corporate functions, including finance, accounting, legal and human resources, among others. Additional costs included in general and administrative expenses consist of professional fees for legal (including patent costs), audit and other consulting services, stock-based compensation and other general corporate overhead expenses as well as costs from a service agreement with a related party (See Note 7). Patent Costs Patent CostsThe Company expenses all costs as incurred in connection with patent licenses and applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are reflected in general and administrative expenses in the statements of operations. Stock-Based Compensation Stock-Based CompensationThe Company accounts for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. The Company recognizes forfeitures related to stock-based compensation as they occur. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, risk-free interest rate, and the estimated fair value (prior to the Companyâ€™s initial public offering) or the public market closing price of the Companyâ€™s underlying common stock on the date of grant. Income Taxes Income TaxesThe Company accounts for corporate income taxes in accordance with GAAP as stipulated in ASC, Topic 740, Income Taxes, (â€œASC 740â€). This standard entails the use of the asset and liability method of computing the provision for income tax expense. Current tax expense results from corporate tax payable at the Federal and California jurisdictions for the Company, which relates to the current accounting period. Deferred tax expense results primarily from temporary differences between financial statement and tax return reporting, which result in additional tax payable in future periods. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates and law. Net future tax benefits are subject to a valuation allowance when management expects that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.Current and non-current tax assets and liabilities are based upon an estimate of taxes refundable or payable for each of the jurisdictions in which the Company is subject to tax. In the ordinary course of business there is inherent uncertainty in quantifying income tax positions. The Company assess income tax positions and record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Companyâ€™s policy is to recognize interest or penalties related to income tax matters in income tax expense.The Tax Cuts and Jobs Act of 2017 eliminated the option to immediately deduct research and development expenditures in the year incurred under Section 174, which became effective January 1, 2022. We are monitoring legislation for any further changes to Section 174 and the impact, if any, to the financial statements in 2024. Comprehensive Loss Comprehensive LossComprehensive loss includes all changes in equity (net assets) during a period from non-owner sources. There were no elements of other comprehensive income (loss) in the periods presented, as a result comprehensive loss is the same as net loss for each period presented.Â Net Income (Loss) per Share Net Income (Loss) per ShareBasic and diluted net income (loss) per share is presented in conformity with theÂ two-classÂ method required for participating securities. Basic and diluted net income (loss) for common stock and for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. Diluted net income (loss) per share includes potentially dilutive securities outstanding for the period. See Note 14 for reconciliations of basic and diluted net income (loss) per share. Recent Accounting Pronouncements Recent Accounting PronouncementsFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Companyâ€™s financial position or results of operations upon adoption.In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements.The Company adopted Accounting Standards Update (â€œASUâ€) No. 2016-13, Financial Instruments â€“ Credit Losses (â€œASC 326â€), as of October 1, 2023. This new standard adds to U.S. GAAP an impairment model, known as the current expected credit loss (â€œCECLâ€) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the timelier recognition of losses. Under the CECL model, entities estimate credit losses over the entire contractual term from the date of initial recognition of the financial instrument. As the Company does not currently have any trade receivables, there was no cumulative effect adjustment, and the adoption of this standard did not have a material impact on the Companyâ€™s financial statements.Income Taxes Disclosures â€“ In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ ASU 2023-09 requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. X - DefinitionDisclosure of accounting policy for patent costs. + ReferencesNo definition available. + Details Name: uncy_PatentCostsPolicyTextBlock Namespace Prefix: uncy_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for prepaid expenses. + ReferencesNo definition available. + Details Name: uncy_PrepaidExpensesPolicyTextBlock Namespace Prefix: uncy_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for risks and uncertainties. + ReferencesNo definition available. + Details Name: uncy_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix: uncy_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-

types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary

of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies [Abstract] Â Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands): Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â -Â Â $Â Â Â Â -Â Â $6,377Â Â $6,377Â Total liabilities at fair valueÂ $-Â Â $-Â Â $6,377Â Â $6,377Â The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands): Â Â Quoted Prices in Active Markets for Identical AssetsÂ Â Significant Other Observable InputsÂ Â Significant Unobservable InputsÂ Â Â Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â TotalÂ Warrant liabilityÂ $Â Â Â Â Â -Â Â $Â Â Â Â Â -Â Â $13,134Â Â $13,134Â Total liabilities at fair valueÂ $-Â Â $-Â Â $13,134Â Â $13,134Â Â Â Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands): Â Â Nine months Ended September 30, 2024Â Fair value at January 1, 2023Â $-Â Issuance of Warrants (March 3, 2023)Â Â 2,831Â Change in fair value of WarrantsÂ Â 10,375Â Fair value at March 31, 2023Â Â 13,206Â Change in fair value of warrantsÂ Â (282) Fair value at June 30, 2023Â Â 12,924Â Change in fair value of warrantsÂ Â (1,396) Fair value at September 30, 2023Â $11,528Â Â Â Â Â Â Fair value at January 1, 2024Â $13,134Â Change in fair value of warrantsÂ Â 11,807Â Fair value at March 31, 2024Â Â 24,941Â Change in fair value of warrantsÂ Â (16,810) Fair value at June 30, 2024Â Â 8,131Â Change in fair value of warrantsÂ Â (1,754) Fair value at September 30, 2024Â $6,377Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Balance Sheet Components [Abstract] Â Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Prepaid directorsâ€™ and officersâ€™ liability insurance premiumsÂ $270Â Â $397Â Prepaid preclinical servicesÂ Â 3,103Â Â Â 4,310Â OtherÂ Â 325Â Â Â 687Â TotalÂ $3,698Â Â $5,394Â Schedule of Property, Plant and Equipment Property, plant and equipment as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Leasehold improvementsÂ $21Â Â $37Â Furniture and fixturesÂ Â 21Â Â Â 29Â Lab EquipmentÂ Â -Â Â Â 26Â SubtotalÂ Â 42Â Â Â 92Â Less accumulated depreciationÂ Â (16)Â Â (31) NetÂ $26Â Â $61Â Â Schedule of Accounts Payable Accounts payable as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Trade accounts payableÂ $821Â Â $519Â Credit card liabilityÂ Â 18Â Â Â 29Â TotalÂ $839Â Â $548Â Schedule of Accrued Liabilities Accrued liabilities as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands): Â Â As ofÂ Â As ofÂ Â Â DecemberÂ 31,Â Â September 30,Â Â Â 2023Â Â 2024Â Â Â Â Â Â Â Accrued labor costsÂ $1,917Â Â $1,402Â Accrued drug development costsÂ Â 1,034Â Â Â 1,068Â OtherÂ Â 283Â Â Â 522Â TotalÂ $3,234Â Â $2,992Â X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Lease (Tables) 9 Months Ended Sep. 30, 2024 Operating Lease [Abstract] Â Schedule of Maturities of Lease Liabilities As of September 30, 2024, maturities of the Companyâ€™s lease liabilities are as follows (in thousands, unaudited): Â Â Operating LeaseÂ Year ending December 31, 2024Â $144Â Year ending December 31, 2025Â Â 608Â Year ending December 31, 2026Â Â 118Â Total lease paymentsÂ Â 871Â Less imputed interest rate / present value discountÂ Â (64) Present value of lease liabilityÂ Â 807Â Less current portionÂ Â (542) Long term portionÂ $265Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesOperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Deficit (Tables) 9 Months Ended Sep. 30, 2024 Stockholdersâ€™ Deficit [Abstract] Â Schedule of Summarizes Activity for Warrants The warrants from the initial public offering are equity classified. The following table summarizes activity for the Companyâ€™s IPO warrants for the nine months ended September 30, 2024: Â Â Â Â Â Â Â

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Net loss per share [Abstract] Â Schedule of Basic and Diluted Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data): Â Â Three Months Ended September 30, Â Â Nine Months Ended SeptemberÂ 30, Â Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Basic net loss per share Â Â Â Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (4,333) Â $ (4,096) Â $ (22,746) Â $ (15,204) Deemed dividends on preferred stock Â Â (72) Â Â - Â Â Â (867) Â Â Â Â Cash Dividends to Series B holders Â Â - Â Â Â - Â Â Â - Â Â Â (1,095) Net loss attributable to common shares, basic and diluted Â Â (4,405) Â Â (4,096) Â Â (23,613) Â Â (16,299) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 32,633,074 Â Â Â 88,943,212 Â Â Â 21,100,206 Â Â Â 54,073,701 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (0.13) Â $ (0.05) Â $ (1.12) Â $ (0.30) Schedule of Outstanding Shares Potentially Dilutive Securities The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Â Â Three Months EndedÂ September 30,Â Â Nine Months EndedÂ September 30,Â Â Â 2023Â Â 2024Â Â 2023Â Â 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â Options to purchase common stockÂ Â 10,321,616Â Â Â 13,671,140Â Â Â 10,321,616Â Â Â 13,671,140Â Warrants to purchase common stockÂ Â 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Â Â 4,784,193Â Restricted stock unitsÂ Â -Â Â Â 21,765Â Â Â -Â Â Â 21,765Â Common stock issuable upon conversion of Series B-2 convertible preferred stockÂ Â -Â Â Â 7,882,000Â Â Â -Â Â Â 7,882,000Â Common stock issuable upon conversion of Series A-2 Prime convertible preferred stockÂ Â 43,649,000Â Â Â 22,676,000Â Â Â 43,649,000Â Â Â 22,676,000Â Warrants to purchase convertible preferred stockÂ Â 160,958,167Â Â Â 160,958,167Â Â Â 160,958,167Â Â 160,958,167Â TotalÂ Â 176,063,976Â Â Â 209,993,175Â Â Â 176,063,976Â Â Â 209,993,175Â X - ReferencesNo definition available. + Details Name: uncy_NetLossPerShareTablesLineItems Namespace Prefix: uncy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Description of Business (Details) - USD ($) $ in Thousands 9 Months Ended Mar. 13, 2024 Mar. 03, 2023 Jul. 15, 2021 Sep. 30, 2024 Dec. 31, 2023 Organization and Description of Business [Line Items] Â Â Â Â Â Accumulated deficit Â Â Â $ (79,745) $ (64,541) Net proceeds $ 46,200 Â Â Â Â Delaware [Member] Â Â Â Â Â Organization and Description of Business [Line Items] Â Â Â Â Â Incorporation date Â Â Â Aug. 18, 2016 Â Series B Convertible Preferred Stock [Member] Â Â Â Â Â Organization and Description of Business [Line Items] Â Â Â Â Â Investors of convertible preferred stock 50,000 Â Â Â Â IPO [Member] Â Â Â Â Â Organization and Description of Business [Line Items] Â Â Â Â Â Net proceeds Â Â $ 22,300 Â Â Private Placement [Member] Â Â Â Â Â Organization and Description of Business [Line Items] Â Â Â Â Â Proceeds from private placement $ 50,000 $ 130,000 Â Â Â Net proceeds from private placement Â $ 28,000 Â Â Â X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNet proceeds from private placement ampount. + ReferencesNo definition available. + Details Name: uncy_NetProceedsFromPrivatePlacement Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the sale of receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_StatementGeographicalAxis=stpr_DE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Summary of Significant Accounting Policies [Line Items] Â Â Â Â Number of reportable operating segment Â Â 1 Â Change in fair value of warrant liability $ (1,754) $ (1,396) $ (6,756) $ 8,697 Tax benefit rate Â Â 50.00% Â Warrant [Member] Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Change in fair value of warrant liability Â Â $ (6,800) $ (8,700) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 + Details Name: us-gaap_ChangeInAccountingEstimateLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items] Â Â Â Â Â Â Â Â Warrant liability $ 6,377 Â Â $ 13,134 Â Â Â Â Total liabilities at fair value 6,377 Â Â 13,134 Â Â Â Â Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Â Â Â Â Â Â Â Â Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items] Â Â Â Â Â Â Â Â Warrant liability Â Â Â Â Â Â Total liabilities at fair value Â Â Â Â Â Â Significant Other Observable Inputs (Level 2) [Member] Â Â Â Â Â Â Â Â Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items] Â Â Â Â Â Â Â Â Warrant liability Â Â Â Â Â Â Total liabilities at fair value Â Â Â Â Â Â Significant Unobservable Inputs (Level 3) [Member] Â Â Â Â Â Â Â Â Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items] Â Â Â Â Â Â Â Â Warrant liability 6,377 $ 8,131 $ 24,941 13,134 $ 11,528 $ 12,924 $ 13,206 Total liabilities at fair value $ 6,377 Â Â $ 13,134 Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 - Level 3 [Member] - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 [Line Items] Â Â Â Â Â Â Â Â Fair value opening balance $ 8,131 $ 24,941 $ 13,134 $ 12,924 $ 13,206 $ 13,134 Fair value ending balance 6,377 8,131 24,941 11,528 12,924 13,206 $ 6,377 $ 11,528 Issuance of Warrants (March 3, 2023) Â Â Â Â Â 2,831 Â Â Change in fair value of Warrants $ (1,754) $ (16,810) $ 11,807 $ (1,396) $ (282) $ 10,375 Â Â X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Apr. 10, 2023 Mar. 31, 2023 Feb. 01, 2023 Jul. 14, 2022 Feb. 09, 2022 Jan. 06, 2022 Jul. 19, 2021 Jul. 13, 2021 Sep. 30, 2018 Oct. 31, 2017 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2021 Dec. 31, 2023 Feb. 28, 2023 Aug. 31, 2022 Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Agreement due payments Â Â Â Â Â Â Â Â $ 1,650,000 Â Â Â Â Â Â Â Â Â Second clinical trial payment Â Â Â Â Â Â Â Â Â $ 50,000 Â Â Â Â Â Â Â Â Â Percentage of royalty payment Â Â Â Â Â Â Â Â 2.00% Â Â Â Â Â Â Â Â Â Common stock valued Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Public market capitalization Â Â Â Â Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Anti-dilution shares of common stock (in Shares) Â Â Â Â Â Â Â Â 209,993,175 176,063,976 Â 209,993,175 176,063,976 Â Â Â Â Research and development expenses Â Â Â Â Â Â Â Â Â Â Â Â $ 2,200,000 Â Â Â Â Sublicense income percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â 40.00% Â Â Â Accounts payable or accrued expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 2,000,000 Â Â Revision overall budget Â Â Â Â Â $ 2,900,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Prepaid expenses and other current assets Â Â Â Â Â Â Â Â $ 5,394,000 Â Â $ 5,394,000 Â Â 3,698,000 Â Â Research related payments $ 2,900,000 $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Milestone payments Â Â $ 3,700,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Payment amount Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,700,000 Â Â Â Â Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalties percentage Â Â Â 7.00% Â Â Â Â Â Â Â Â Â Â Â Â Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalties percentage Â Â Â 10.00% Â Â Â Â Â Â Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Anti-dilution shares of common stock (in Shares) Â Â Â Â Â Â Â 438,374 Â Â Â Â Â Â Â Â Â Â Â Â Â Lotus International Pte Ltd [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sublicense income percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20.00% Â Â Â Â Syneos Health LLC [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â Â Â Â $ 2,300,000 Â Â Â Â Â Â Â Â Â Â Â Quotient Sciences Limited [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â Â Â Â $ 3,700,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Spectrum Pharmaceuticals, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued of common shares (in Shares) Â Â Â Â Â Â Â 313,663 Â Â Â Â Â Â Â Â Â Common stock valued Â Â Â Â Â Â Â $ 4,000 Â Â Â Â Â Â Â Â Â Public market capitalization Â Â Â Â Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Sublicense income percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20.00% Â Â Â Altair Nanomaterials, Inc [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Required to pay Â Â Â Â Â Â Â Â Â Â Â Â Â $ 200,000 Â Â Â Altair [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Required to pay Â Â Â Â Â Â Â Â Â Â Â Â Â $ 4,500,000 Â Â Â Quotient Sciences Limited [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Related payments Â Â Â Â Â Â Â Â Â Â Â Â Â 2,800,000 Â Â 2,800,000 Â Â Â Â Â Payments to related party Â Â Â Â Â Â Â Â Â Â Â Â Â 2,800,000 Â Â Â Â Â Prepaid expenses and other current assets Â Â Â Â Â Â Â Â 600,000 Â Â 600,000 Â Â 600,000 Â Â CBCC Global Research Inc [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expenses Â Â Â Â $ 1,400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Initial agreement amount Â 400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research related payments Â $ 400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Inotiv [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Payments to related party Â Â Â Â Â Â Â Â Â Â Â 2,900,000 Â Â Â Â Prepaid expenses and other current assets Â Â Â Â Â Â Â Â $ 100,000 Â Â 100,000 Â Â 300,000 Â Â Leeâ€™s Pharmaceutical (HK) Limited [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant payment received Â Â Â $ 1,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Milestone payments Â Â Â $ 1,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Oxylanthanum Carbonate [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Related payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,700,000 Â Â Research related payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 2,700,000 Â Â Lotus International Pte Ltd [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant payment received Â Â $ 700,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Shilpa Medicare Ltd [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Payment amount Â Â Â Â Â Â Â Â Â Â Â Â Â $ 3,000,000 Â Â Â Â Â Exclusive license agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Agreement due payments Â Â Â Â Â Â Â Â $ 50,000 Â Â Â Â Â Â Â Â Â Sublicense Development Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant payment received Â Â Â Â Â Â Â Â Â Â Â Â Â $ 700,000 $ 1,000,000 Investment [Member] | Spectrum Pharmaceuticals, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Significant Agreements [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest on ownership Â Â Â Â Â Â Â Â 4.00% Â Â Â Â Â Â Â Â Â Â Â X - DefinitionAmount of agreement due payments . + ReferencesNo definition available. + Details Name: uncy_AgreementDuePayments Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of milestone payments. + ReferencesNo definition available. + Details Name: uncy_MilestonePayments Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe total payment amount. + ReferencesNo definition available. + Details Name: uncy_PaymentAmount Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRevisions reduced the overall budget. + ReferencesNo definition available. + Details Name: uncy_RevisionsReducedTheOverallBudget Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of royalties. + ReferencesNo definition available. + Details Name: uncy_RoyaltiesPercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalty payment. + ReferencesNo definition available. + Details Name: uncy_RoyaltyPecentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of second clinical trial payment. + ReferencesNo definition available. + Details Name: uncy_SecondClinicalTrialPayment Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: uncy_SignificantAgreementsLineItems Namespace Prefix: uncy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSignificant payment received. + ReferencesNo definition available. + Details Name: uncy_SignificantPaymentReceived Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSublicense income percentage. + ReferencesNo definition available. + Details Name: uncy_SublicenseIncomePercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of consolidated capitalization which comprises long-term debt and equity instruments. + ReferencesNo definition available. + Details Name: us-gaap_CapitalizationLongtermDebtAndEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCosts of sales and operating expenses for the period incurred from transactions with related parties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpensesRelatedParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe amount of initial franchise fees. + ReferencesNo definition available. + Details Name: us-gaap_InitialFranchiseFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of other research and development expense. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_OtherResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the

normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseOtherNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=uncy_LotusInternationalPteLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=uncy_SyneosHealthLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=uncy_QuotientSciencesLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_SpectrumPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_AltairNanomaterialsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_AltairMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_QuotientSciencesLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_CBCCGlobalResearchIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_InotivMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_LeesPharmaceuticalHKLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_OxylanthanumCarbonateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_LotusInternationalPteLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_ShilpaMedicareLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uncy_ExclusiveLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uncy_SublicenseDevelopmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uncy_InvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Licensing Revenues (Details) - USD ($) 9 Months Ended Feb. 01, 2023 Jul. 14, 2022 Sep. 30, 2024 Sep. 30, 2023 Licensing Revenues [Line Items] Â Â Â Â Upfront fees Â Â $ 675,000 Â Transaction price Â Â 675,000 Â Licensing revenue Â Â Â $ 675,000 Upfront Payment [Member] Â Â Â Â Licensing Revenues [Line Items] Â Â Â Â Upfront payments $ 700,000 $ 1,000,000 Â Â Milestone Payment [Member] Â Â Â Â Licensing Revenues [Line Items] Â Â Â Â Milestone payments $ 3,700,000 $ 1,000,000 Â Â Other Contract [Member] Â Â Â Â Licensing Revenues [Line Items] Â Â Â Â Upfront fees Â Â $ 1,000,000 Â Minimum [Member] Â Â Â Â Licensing Revenues [Line Items] Â Â Â Â Royalties percentage Â 7.00% Â Â Maximum [Member] Â Â Â Â Licensing Revenues [Line Items] Â Â Â Â Royalties percentage Â 10.00% Â Â X - DefinitionThe represents value as an milestone payment for revenue. + ReferencesNo definition available. + Details Name: uncy_DeferredRevenueMilestonePayments Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe represents value as an upfront payment of revenue. + ReferencesNo definition available. + Details Name: uncy_DeferredRevenueUpfrontPayments Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: uncy_LicensingRevenuesLineItems Namespace Prefix: uncy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of royalties. + ReferencesNo definition available. + Details Name: uncy_RoyaltiesPercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionTransaction price. + ReferencesNo definition available. + Details Name: uncy_TransactionPrice Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront fees amount. + ReferencesNo definition available. + Details Name: uncy_UpfrontFees Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received from licensees for license fees during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromLicenseFeesReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_UpfrontPaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_MilestonePaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Prepaid Expenses and Other Current Assets [Abstract] Â Â Prepaid directorsâ€™ and officersâ€™ liability insurance premiums $ 397 $ 270 Prepaid preclinical services 4,310 3,103 Other 687 325 Total $ 5,394 $ 3,698 X - DefinitionThe amount of prepaid preclinical service. + ReferencesNo definition available. + Details Name: uncy_PrepaidPreclinicalServicesCurrent Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Property, Plant and Equipment [Line Items] Â Â Subtotal $ 92 $ 42 Less accumulated depreciation (31) (16) Net 61 26 Leasehold improvements [Member] Â Â Schedule of Property, Plant and Equipment [Line Items] Â Â Subtotal 37 21 Furniture and fixtures [Member] Â Â Schedule of Property, Plant and Equipment [Line Items] Â Â Subtotal 29 21 Lab Equipment [Member] Â Â Schedule of Property, Plant and Equipment [Line Items] Â Â Subtotal $ 26 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Details) - Schedule of Accounts Payable - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Accounts Payable [Abstract] Â Â Trade accounts payable $ 519 $ 821 Credit card liability 29 18 Total $ 548 $ 839 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Details) - Schedule of Accrued Liabilities - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Accrued Liabilities [Abstract] Â Â Accrued labor costs $ 1,402 $ 1,917 Accrued drug development costs 1,068 1,034 Other 522 283 Total $ 2,992 $ 3,234 X - DefinitionThe amount of accrued drug development costs. + ReferencesNo definition available. + Details Name: uncy_AccruedDrugDevelopmentCostsCurrent Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Lease (Details) 9 Months Ended Sep. 30, 2024 USD ($) Mar. 15, 2023 USD ($) ftÂ² Dec. 31, 2021 ftÂ² Dec. 31, 2024 USD ($) ftÂ² Operating Lease [Line Items] Â Â Â Square feet of office space (in Square Feet) | ftÂ² Â 2,456 2,367 Initial lease term 2 years Â Â Option to extend the lease term three additional years Â Â Discount rate of lease Â 10.00% Â Lease liability $ 807,000 Â Â Operating Lease [Member] Â Â Â Operating Lease [Line Items] Â Â Â Present value of the lease Â $ 1,000,000 Â Amortization of right-of-use asset 265,000 Â Â Right of use asset balance 800,000 Â Â Cash payments on lease 329,000 Â Â Lease liability $ 800,000 Â Â X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OperatingLeasedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481161/840-30-50-1 + Details Name: us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=uncy_OperatingLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Lease (Details) - Schedule of Maturities of Lease Liabilities - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Maturities of Lease Liabilities [Abstract] Â Â Year ending December 31, 2024 $ 144 Â Year ending December 31, 2025 608 Â Year ending December 31, 2026 118 Â Total lease payments 871 Â Less imputed interest rate / present value discount (64) Â Present value of lease liability 807 Â Less current portion (542) $ (327) Long term portion $ 265 $ 466 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions (Details) - USD ($) 1 Months Ended Mar. 31, 2023 Feb. 28, 2023 Related Party Transactions [Line Items] Â Â Repaid amount $ 210,000 Â Chief Executive Officer [Member] Â Â Related Party Transactions [Line Items] Â Â Advances Â $ 210,000 X - DefinitionLong-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-2 + Details Name: us-gaap_AdvancesToAffiliate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember

Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - USD ($) 1 Months Ended 9 Months Ended 12 Months Ended Mar. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Sep. 30, 2024 Dec. 31, 2023 Commitments and Contingencies [Line Items] Â Â Â Â Â Employer matching contributions, percentage Â Â 100.00% Â Â Company contributions Â Â Â $ 104,000 $ 107,000 Maxim Group LLC [Member] Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Advisory fee $ 100,000 $ 100,000 Â Â Â Maximum [Member] Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Employeeâ€™s eligible compensation Â Â 100.00% Â Â Minimum [Member] Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Employeeâ€™s eligible compensation Â Â 4.00% Â Â X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum percentage of employee gross pay the employee may contribute to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThis represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NoninterestExpenseInvestmentAdvisoryFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_MaximGroupLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Deficit (Details) - USD ($) 1 Months Ended 9 Months Ended Jul. 11, 2023 Jul. 31, 2021 Sep. 30, 2024 Dec. 31, 2023 Jun. 26, 2023 Stockholdersâ€™ Deficit [Line Items] Â Â Â Â Â Common stock, shares authorized Â Â 400,000,000 200,000,000 Â Common stock, par value (in Dollars per share) Â Â $ 0.001 $ 0.001 Â Common stock share issued Â Â 97,858,406 34,756,049 Â Exchange for cash price, per unit (in Dollars per share) Â $ 5 Â Â Â Shares of common stock 43,649 Â 736,773 Â Â Convertible debt shares granted Â Â 184,193 Â Â Warrant [Member] Â Â Â Â Â Stockholdersâ€™ Deficit [Line Items] Â Â Â Â Â Shares warrants Â 4,000,000 47,852,430 Â Â Exchange for cash price, per unit (in Dollars per share) Â $ 0.0125 Â Â Â Warrants term Â 5 years 5 years Â Â Exercise price per warrant (in Dollars per share) Â $ 6 $ 6 Â Â Purchase of additional warrants Â 600,000 Â Â Â Proceeds of warrants (in Dollars) Â $ 7,500 Â Â Â Common Stock [Member] Â Â Â Â Â Stockholdersâ€™ Deficit [Line Items] Â Â Â Â Â Exchange for cash price, per unit (in Dollars per share) Â $ 4.99 Â Â Â Auto-conversion of the series A preferred stock Â Â Â Â 19,516,205 Series A-2 Preferred Stock [Member] Â Â Â Â Â Stockholdersâ€™ Deficit [Line Items] Â Â Â Â Â Auto-conversion of the series A preferred stock Â Â Â Â 43,649 IPO [Member] Â Â Â Â Â Stockholdersâ€™ Deficit [Line Items] Â Â Â Â Â Common stock share issued Â 5,000,000 Â Â Â X - DefinitionNumber of additional warrants purchased. + ReferencesNo definition available. + Details Name: uncy_PurchaseOfAdditionalWarrants Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued for each share of convertible preferred stock that is converted. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16 + Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Deficit (Details) - Schedule of Summarizes Activity for Warrants - USD ($) 9 Months Ended Dec. 31, 2023 Sep. 30, 2024 Schedule of Summarizes Activity for Warrants [Abstract] Â Â Number of Shares Underlying Outstanding Warrants, Outstanding at Ending 4,784,193 4,784,193 Weighted- Average Exercise Price, Outstanding at Ending $ 6 $ 6 Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending 2 years 6 months 14 days 1 year 9 months 14 days Aggregate Intrinsic Value, Outstanding at Ending Number of Shares Underlying Outstanding Warrants, Warrants granted Â Weighted- Average Exercise Price, Warrants granted Â Aggregate Intrinsic Value, Warrants granted Â Number of Shares Underlying Outstanding Warrants, Warrants exercised Â Weighted- Average Exercise Price, Warrants exercised Â Aggregate Intrinsic Value, Warrants exercised Â X - ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price warrant exercised. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price granted. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price warrant outstanding. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: instant X - DefinitionIntrinsic value of outstanding award under Warrants exercised. Excludes share and unit options. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntrinsic value of outstanding award under warrants granted. Excludes share and unit options. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 - SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Issuance of Series A-1 Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions 9 Months Ended Mar. 13, 2024 Jul. 11, 2023 Mar. 03, 2023 Sep. 30, 2024 Dec. 31, 2023 Mar. 31, 2023 Jul. 31, 2021 Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Â Aggregate fair value (in Dollars) Â Â Â $ 2.8 Â Â Â Share issued Â Â Â 97,858,406 34,756,049 Â Â Auto-conversion preferred shares Â 43,649 Â 736,773 Â Â Â Original price per share (in Dollars per share) Â Â Â $ 1,000 Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 1 Â Â Â Common stock voting rights Â Â Â one Â Â Â Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â Â Â 47,852,430 Â Â 4,000,000 Aggregate offering costs (in Dollars) Â Â Â Â Â Â $ 0.2 Â Warrants exercise price (in Dollars per share) Â Â Â $ 6 Â Â $ 6 Amended Tranche B Warrants [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 25,666.30154 Â Â Â Â Â Original Tranche C Warrants [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 69,603,531 Â Â Â Â Â Tranche A Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Aggregate exercise price (in Dollars) Â Â $ 25.0 Â Â Â Â Tranche B Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Aggregate exercise price (in Dollars) Â Â 25.0 Â Â Â Â Tranche C Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Aggregate exercise price (in Dollars) Â Â $ 50.0 Â Â Â Â Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Number of share issued Â Â 30,190 Â Â Â Â Aggregate net proceeds (in Dollars) Â Â $ 28.0 Â Â Â Agent fees and offering expenses (in Dollars) Â Â $ 2.2 Â Â Â Preferred stock, shares Â Â Â 30,190 Â Â Â Aggregate offering costs (in Dollars) Â Â Â $ 2.0 Â Â Â Initial carrying value (in Dollars) Â Â Â $ 25.4 Â Â Â Series A-1 Preferred Stock [Member] | Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 50,000 Â Â Â Series A-1 Preferred Stock [Member] | Shareholder [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued Â Â Â 0 Â Â Preferred stock, shares outstanding Â Â Â Â 0 Â Â Series A-3 Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 1,800,000 Â Â Â Series A-3 Preferred Stock [Member] | Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 25,840.3122 Â Â Â Â Â Warrants exercise price (in Dollars per share) Â Â Â $ 1,000 Â Â Â Series A-3 Preferred Stock [Member] | Tranche A Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 47,852,430 46,675,940 Â Â Â Â Series A-4 Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 1,800,000 Â Â Â Series A-4 Preferred Stock [Member] | Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 43,502,206 Â Â Â Â Â Warrants exercise price (in Dollars per share) Â Â Â $ 1,000 Â Â Â Series A-4 Preferred Stock [Member] | Tranche B Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 43,502,206 42,432,672 Â Â Â Â Series A-5 Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 3,600,000 Â Â Â Series A-5 Preferred Stock [Member] | Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrants exercise price (in Dollars per share) Â Â Â $ 1,000 Â Â Â Series A-5 Preferred Stock [Member] | Tranche C Warrant [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 69,603,531 67,892,276 Â Â Â Â Series A-2 Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 21,388.01 43,649 Â Â Preferred stock, par value (in Dollars per share) Â Â Â $ 0.001 $ 0.001 Â Â Preferred stock, shares outstanding Â Â Â 11,111.24 43,649 Â Â Series A-2 Preferred Stock [Member] | Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 1,800,000 Â Â Â Series A-2 Preferred Stock [Member] | Shareholder [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued Â Â Â 43,649 Â Â Preferred stock, shares outstanding Â Â Â 43,649 Â Â Series A Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, par value (in Dollars per share) Â Â Â $ 0.001 Â Â Â Series A Certificate of Designation [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Share issued Â 19,516,205 Â Â Â Â Â Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares Â Â Â 10,000,000 10,000,000 Â Â Preferred stock, par value (in Dollars per share) Â Â Â $ 0.001 $ 0.001 Â Â Preferred stock, shares issued Â Â Â Â Â Preferred stock, shares outstanding Â Â Â Â Â Aggregate shares 21,388.01 Â Â Â Â Â Â Original price per share (in Dollars per share) Â Â Â $ 1,000 Â Â Â Series A-5 Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.74 Â Â Â Series A-5 Convertible Preferred Stock [Member] | Amended Tranche C Warrants [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Warrant acquired shares Â 51,506.61294 Â Â Â Â Â Series A-5 Convertible Preferred Stock [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued Â Â Â 51,600 Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.74 Â Â Â Series A-2 Prime Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â 0.49 Â Â Â Series A-2 Prime Convertible Preferred Stock [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â 0.49 Â Â Â Series A-3 Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.54 Â Â Â Series A-3 Convertible Preferred Stock [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued Â Â Â 25,900 Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.54 Â Â Â Series A-4 Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.59 Â Â Â Series A-4 Convertible Preferred Stock [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued Â Â Â 25,700 Â Â Â Preferred stock conversion price (in Dollars per share) Â Â Â $ 0.59 Â Â Â Series A-2 Prime Preferred Stock [Member] | Exchange Agreement [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Preferred stock, shares issued 21,400 Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Issuance of Series A-1 Preferred Stock [Line Items] Â Â Â Â Â Â Â Original price per share (in Dollars per share) Â Â Â $ 1,000 Â Â Â Common stock voting rights Â Â Â one Â Â Â X - DefinitionRepresent the amount of aggregate exercise price. + ReferencesNo definition available. + Details Name: uncy_AggregateExercisePrice Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate shares. + ReferencesNo definition available. + Details Name: uncy_AggregateShares Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionInitial carrying value. + ReferencesNo definition available. + Details Name: uncy_InitialCarryingValue Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: uncy_IssuanceOfSeriesA1PreferredStockLineItems Namespace Prefix: uncy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOriginal price per share. + ReferencesNo definition available. + Details Name: uncy_OriginalPricePerShare Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFees paid to an agent employed by a corporation or mutual fund to maintain shareholder records, including purchases, sales, and account balances. Also includes custodian fees incurred during an accounting period from an agent, bank, trust company, or other organization that holds and safeguards an individual's, mutual fund's, or investment company's assets for them. These fees will be billed back to the client and are a component of noninterest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NoninterestExpenseTransferAgentAndCustodianFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cumulative amount of offering costs allocated to the preferred partners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5 + Details Name: us-gaap_PreferredUnitsOfferingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of preferred stock and warrants for common stock issued. + ReferencesNo definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=uncy_AmendedTrancheBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=uncy_OriginalTrancheCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheAWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheCWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_ShareholderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA3PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA4PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA5PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesACertificateOfDesignationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA5ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=uncy_AmendedTrancheCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=uncy_ExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PrimeConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA3ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA4ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA2PrimePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Issuance of Series B-1 Preferred Stock (Details) - USD ($) 9 Months Ended Mar. 13, 2024 Sep. 30, 2024 Sep. 30, 2023 Jul. 05, 2024 Dec. 31, 2023 Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Gross proceed (in Dollars) Â $ (3,813,000) Â Â Conversion Price (in Dollars per share) Â $ 1 Â Â Â Common stock shares issued Â 97,858,406 Â Â 34,756,049 Annual dividend rate Â 8.00% Â Â Â Voting rights of common stock Â one Â Â Â Divided shares Â 1,000 Â Â Â Liquidation preference (in Dollars) Â $ 1,000 Â Â Â Voting rights of preferred stock Â one Â Â Â Conversion shares Â 1,000,000 Â Â Â Series B-1 Convertible Preferred Stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Proceed amount (in Dollars) $ 50,000,000 Â Â Â Â Series B-1 Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Share issued 50,000 Â Â Â Â Series B-1 preferred stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Share issued price per share (in Dollars per share) $ 1,000 Â Â Â Â Purchase price (in Dollars per share) 1,000 Â Â Â Â Conversion Price (in Dollars per share) $ 1 Â Â Â Â Designated shares Â 7,882 Â Â Annual rate Â 8.00% Â Â Â Annual dividend rate Â 14.00% Â Â Â Outstanding common stock percentage Â 9.99% Â Â Â Series A-1 Preferred Stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Designated shares Â 30,190 Â Â Â Series B-2 Preferred Stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Designated shares Â 50,000 Â Â Â Preferred stock shares issued Â Â Â 7,882 Â Outstanding common stock percentage Â 9.99% Â Â Â Series B Certificate of Designation [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Common stock shares issued Â Â Â 42,118,000 Â Series B Preferred Stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Outstanding common stock percentage Â 19.90% Â Â Â Preferred Stock [Member] | Series B-1 preferred stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Voting rights of common stock Â one Â Â Â Preferred Stock [Member] | Series A-1 Preferred Stock [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Designated shares Â 50,000 Â Â Â Private Placement [Member] Â Â Â Â Â Issuance of Series B-1 Preferred Stock [Line Items] Â Â Â Â Â Gross proceed (in Dollars) $ 50,000,000 Â Â Â Â X - DefinitionThe percentage of annual rate percent. + ReferencesNo definition available. + Details Name: uncy_AnnualRatePercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionOutstanding common stock percentage. + ReferencesNo definition available. + Details Name: uncy_OutstandingCommonStockPercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from issuance of preferred stock. + ReferencesNo definition available. + Details Name: uncy_ProceedFromIssuanceOfPreferredStock Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_CommonStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionValue of the difference between preference in liquidation and the par or stated values of the preferred shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_PreferredStockLiquidationPreferenceValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_PreferredStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesB1ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uncy_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesB1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesB2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesBCertificateOfDesignationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Warrant

Liability (Details) - USD ($) $ in Millions 9 Months Ended 12 Months Ended Mar. 03, 2023 Sep. 30, 2024 Dec. 31, 2023 Jul. 11, 2023 Warrant Liability [Line Items] Â Â Â Â Fair value of warrants $ 2.8 $ 6.4 $ 13.1 Â Tranche A Warrant [Member] | Series A-3 Preferred Stock [Member] Â Â Â Â Warrant Liability [Line Items] Â Â Â Â Acquired warrant shares 46,675,940 Â Â 47,852,430 Tranche B Warrant [Member] | Series A-4 Preferred Stock [Member] Â Â Â Â Warrant Liability [Line Items] Â Â Â Â Acquired warrant shares 42,432,672 Â Â 43,502,206 Tranche C Warrant [Member] | Series A-5 Preferred Stock [Member] Â Â Â Â Warrant Liability [Line Items] Â Â Â Â Acquired warrant shares 67,892,276 Â Â 69,603,531 X - DefinitionAdjustment for noncash service expenses paid for by granting of warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentOfWarrantsGrantedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_VestingAxis=uncy_TrancheAWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA3PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA4PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheCWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uncy_SeriesA5PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability Sep. 30, 2024 Dec. 31, 2023 Measurement Input, Appraised Value [Member] | Tranche A Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.41 0.87 Measurement Input, Appraised Value [Member] | Tranche B Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.41 0.87 Measurement Input, Appraised Value [Member] | Tranche C Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.41 0.87 Measurement Input, Exercise Price [Member] | Tranche A Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.54 0.54 Measurement Input, Exercise Price [Member] | Tranche B Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.59 0.59 Measurement Input, Exercise Price [Member] | Tranche C Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.74 0.74 Measurement Input, Price Volatility [Member] | Tranche A Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 107.7 96.5 Measurement Input, Price Volatility [Member] | Tranche A Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 129.2 139.2 Measurement Input, Price Volatility [Member] | Tranche B Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 109.8 114.6 Measurement Input, Price Volatility [Member] | Tranche B Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 129.2 139.2 Measurement Input, Price Volatility [Member] | Tranche C Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 116.1 107.8 Measurement Input, Price Volatility [Member] | Tranche C Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 129.2 114.6 Measurement Input, Risk Free Interest Rate [Member] | Tranche A Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 3.8 4.6 Measurement Input, Risk Free Interest Rate [Member] | Tranche A Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 4.1 5.3 Measurement Input, Risk Free Interest Rate [Member] | Tranche B Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 3.7 4.4 Measurement Input, Risk Free Interest Rate [Member] | Tranche B Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 3.8 4.8 Measurement Input, Risk Free Interest Rate [Member] | Tranche C Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 3.6 4 Measurement Input, Risk Free Interest Rate [Member] | Tranche C Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 3.8 4.4 Measurement Input, Expected Dividend Rate [Member] | Tranche A Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0 0 Measurement Input, Expected Dividend Rate [Member] | Tranche B Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0 0 Measurement Input, Expected Dividend Rate [Member] | Tranche C Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0 0 Measurement Input, Expected Term [Member] | Tranche A Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.7 0.5 Measurement Input, Expected Term [Member] | Tranche A Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 1.7 1.5 Measurement Input, Expected Term [Member] | Tranche B Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 1.3 1 Measurement Input, Expected Term [Member] | Tranche B Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 2.3 2 Measurement Input, Expected Term [Member] | Tranche C Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 1.7 2 Measurement Input, Expected Term [Member] | Tranche C Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 2.7 3 Measurement Input, Discount for Lack of Marketability [Member] | Tranche A Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 7.5 12.5 Measurement Input, Discount for Lack of Marketability [Member] | Tranche B Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 7.5 12.5 Measurement Input, Discount for Lack of Marketability [Member] | Tranche C Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 7.5 12.5 Measurement Input Probability for FDA Approval [Member] | Tranche A Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs Â 29.3 Measurement Input Probability for FDA Approval [Member] | Tranche A Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 36.55 Â Measurement Input Probability for FDA Approval [Member] | Tranche A Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 38.5 Â Measurement Input Probability for FDA Approval [Member] | Tranche B Warrant [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 11 12 Measurement Input Probability for FDA Approval [Member] | Tranche C Warrant [Member] | Minimum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 0.01 4.3 Measurement Input Probability for FDA Approval [Member] | Tranche C Warrant [Member] | Maximum [Member] Â Â Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items] Â Â Warrants measurement inputs 27.46 12.5 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4 + Details Name: us-gaap_AssumptionForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputAppraisedValueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheAWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=uncy_TrancheCWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=uncy_MeasurementInputProbabilityForFDAApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants - Warrant liability [Member] $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Schedule of Issuable Preferred Stock Warrants [Line Items] Â Number of Shares Underlying Outstanding Warrants, Outstanding at Beginning | shares 160,958,167 Weighted- Average Exercise Price, Outstanding at Beginning | $ / shares $ 0.64 Weighted- Average Remaining Contractual Term (in Years), Outstanding at Beginning 2 years 4 months 2 days Aggregate Intrinsic Value, Outstanding at Beginning | $ $ 36,864 Number of Shares Underlying Outstanding Warrants, Warrants contingently issuable | shares Weighted- Average Exercise Price, Warrants contingently issuable | $ / shares Weighted- Average Remaining Contractual Term (in Years), Warrants contingently issuable Aggregate Intrinsic Value, Warrants contingently issuable | $ Number of Shares Underlying Outstanding Warrants, Warrants exercised | shares Weighted- Average Exercise Price, Warrants exercised | $ / shares Weighted- Average Remaining Contractual Term (in Years), Warrants exercised Aggregate Intrinsic Value, Warrants exercised | $ Number of Shares Underlying Outstanding Warrants, Outstanding at Ending | shares 160,958,167 Weighted- Average Exercise Price, Outstanding at Ending | $ / shares $ 0.64 Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending 2 years 4 months 13 days Aggregate Intrinsic Value, Outstanding at Ending | $ X - DefinitionThe number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsExercised Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of Warrants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsIssued Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted- Average Remaining Contractual Term (in Years). + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2 Namespace Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at outstanding date for equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceOutstanding Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average fair value at warrants exercised for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercised Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsIssued Namespace Prefix: uncy_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsExercised Namespace Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsIssued Namespace

Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under Warrants exercised. Excludes share and unit options. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntrinsic value of warrant issued award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsIssued Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductWarrantyLiabilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - USD ($) 1 Months Ended 9 Months Ended 12 Months Ended Jun. 20, 2024 Jun. 26, 2023 Aug. 31, 2024 Aug. 31, 2023 May 31, 2022 Sep. 30, 2024 Dec. 31, 2021 Dec. 31, 2023 Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Common stock, shares reserved for issuance Â 1,302,326 Â Â Â Â Â Â Number of shares reserved 20,775,996 12,775,996 Â Â Â Â Â Â Available common shares Â Â Â Â Â 7,433,327 Â 2,815,503 Exercised stock options Â Â Â Â Â Â Â 383,721 Â Stock options, proceeds (in Dollars) Â Â Â Â Â Â Â $ 119,000 Â Options remained unvested Â Â Â Â Â Â 0 Â Â Vested portion options (in Dollars) Â Â Â Â Â Â $ 2,500 Â Â Share of restricted stock Â Â 11,765 10,000 10,000 Â Â Â Grant date fair value (in Dollars) Â Â $ 4,000 $ 7,500 $ 7,200 Â Â Â Fair value per share (in Dollars per share) Â Â $ 0.34 Â $ 0.72 Â Â Â Grant date fair value (in Dollars per share) Â Â Â $ 0.75 Â Â Â Â Annual net cash flow from operations percentage Â Â Â Â Â 75.00% Â Â Stock Options [Member] Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Unrecognized compensation cost (in Dollars) Â Â Â Â Â Â $ 6,000,000 Â Â Recognized period Â Â Â Â Â Â 4 years Â Â Shareholders [Member] Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Number of shares reserved 8,000,000 Â Â Â Â Â Â Â X - DefinitionAnnual net cash flow from operations percentage. + ReferencesNo definition available. + Details Name: uncy_AnnualNetCashFlowFromOperationsPercentage Namespace Prefix: uncy_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options exercised stock option. + ReferencesNo definition available. + Details Name: uncy_ExercisedStockOption Namespace Prefix: uncy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value per share that would be issued upon settlement of option contract indexed to equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_OptionContractIndexedToEquitySettlementShareFairValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate value of all restricted investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2 + Details Name: us-gaap_RestrictedInvestmentsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of increase (decrease) of non-vested options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uncy_ShareholdersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans $ / shares in Units, $ in Thousands 9 Months Ended Dec. 31, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Schedule of Summarizes

Activity for Stock Options under all Plans [Abstract] Â Â Number of Shares Underlying Outstanding Options, Outstanding at ending balance | shares 10,302,086 13,671,140 Weighted-Average Exercise Price, Outstanding at ending balance | $ / shares $ 1 $ 1 Weighted-Average Remaining Contractual Term (in Years), Outstanding at ending balance 9 years 4 months 2 days 8 years 10 months 2 days Aggregate Intrinsic Value, Outstanding at ending balance | $ $ 1,196 $ 81 Number of Shares Underlying Outstanding Options, Options vested and exercisable | shares Â 4,675,005 Weighted-Average Exercise Price, Options vested and exercisable | $ / shares Â $ 1.28 Weighted-Average Remaining Contractual Term (in Years), Options vested and exercisable Â 8 years 3 months 21 days Aggregate Intrinsic Value, Outstanding, Options vested and exercisable | $ Â $ 39 Number of Shares Underlying Outstanding Options, Options granted | shares Â 3,370,411 Weighted-Average Exercise Price, Options granted | $ / shares Â $ 1 Weighted-Average Remaining Contractual Term (in Years), Options granted Â 9 years 7 months 6 days Number of Shares Underlying Outstanding Options, Options forfeited | shares Â Weighted-Average Exercise Price, Options forfeited | $ / shares Â Weighted-Average Remaining Contractual Term (in Years), Options forfeited Â Aggregate Intrinsic Value, Options forfeited | $ Â Number of Shares Underlying Outstanding Options, Options exercised | shares Â (1,357) Weighted-Average Exercise Price, Options exercised | $ / shares Â $ 3.27 Weighted-Average Remaining Contractual Term (in Years), Options exercised Â Aggregate Intrinsic Value, Options exercised | $ Â X - DefinitionThe amount of aggregate intrinsic value, options forfeited. + ReferencesNo definition available. + Details Name: uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueOptionsForfeited Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares weighted-average remaining contractual term, options granted. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerminYearsOptionsGranted Namespace Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Namespace Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares weighted-average remaining contractual term, options forfeited. + ReferencesNo definition available. + Details Name: uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminYearsOptionsForfeited Namespace Prefix: uncy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Stock-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation $ 605 $ 929 $ 1,768 $ 1,217 Research and development [Member] Â Â Â Â Schedule of Stock-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation 275 450 785 614 General and administrative [Member] Â Â Â Â Schedule of Stock-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation $ 330 $ 479 $ 983 $ 603 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Dividend yield Expected term 6 years 3 months 5 years 11 months 1 day Minimum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Expected volatility 104.00% 104.00% Risk-free interest rate 3.77% 4.35% Maximum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Expected volatility 106.00% 108.00% Risk-free interest rate 4.65% 4.36% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Â Â Â Â Net loss $ (4,096) $ 9,855 $ (20,963) $ (4,333) $ (3,838) $ (14,575) $ (15,204) $ (22,746) Deemed dividends on preferred stock Â Â (72) Â Â (867) Cash Dividends to Series B holders Â Â Â Â (1,095) Net loss attributable to common shares, basic (4,096) Â Â (4,405) Â Â (16,299) (23,613) Net loss attributable to common shares, diluted $ (4,096) Â Â $ (4,405) Â Â $ (16,299) $ (23,613) Denominator: Â Â Â Â Â Â Â Â Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in Shares) 88,943,212 Â Â 32,633,074 Â Â 54,073,701 21,100,206 Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in Shares) 88,943,212 Â Â 32,633,074 Â Â 54,073,701 21,100,206 Net loss per share attributable to common stockholders, basic (in Dollars per share) $ (0.05) Â Â $ (0.13) Â Â $ (0.3) $ (1.12) Net loss per share attributable to common stockholders,diluted (in Dollars per share) $ (0.05) Â Â $ (0.13) Â Â $ (0.3) $ (1.12) X - DefinitionAmount of preferred stock cash dividend. + ReferencesNo definition available. + Details Name: uncy_CashDividendsPreferredStock Namespace Prefix: uncy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of paid and unpaid preferred stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsPreferredStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, or income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 209,993,175 176,063,976 209,993,175 176,063,976 Options to purchase common stock [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 13,671,140 10,321,616 13,671,140 10,321,616 Warrants to purchase common stock [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 4,784,193 4,784,193 4,784,193 4,784,193 Restricted stock units [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 21,765 21,765 Common stock issuable upon conversion of Series B-2 convertible preferred stock [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 7,882,000 7,882,000 Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 22,676,000 43,649,000 22,676,000 43,649,000 Warrants to purchase convertible preferred stock [Member] Â Â Â Â Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items] Â Â Â Â Antidilutive Securities 160,958,167 160,958,167 160,958,167 160,958,167 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=uncy_CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMemb Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=uncy_CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStock! Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=uncy_WarrantsToPurchaseConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (+$X;5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M "Q.&U9/"X#!>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NDF!0]3E N($$A*30-PBQ]LBFC9*C-J]/6W9.B%X (ZQ_WS^ M++G!J+%/])SZ2(D]Y:LQM%W6&#?BP!PU0,8#!9O+*=%-S5V?@N7IF?80+7[8 M/8&]JEL(Q-99MC #B[@2A6D<:DQDN4\GO,,5'S]3N\ < K44J.,,LI0@S#PQ M'L>V@0M@AC&ED+\+Y%;B4OT3NW1 G))C]FMJ&(9RJ)?9 M;8\S'21IPGO]9W]L'852EK@LI"UEOI=+5C5;U^^SZP^\B"KG=_X? M&Y\%30._[L\ 5!+ P04 " "Q.&U9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4? N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!? F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P' T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>? 8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY= <7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8]*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_VJ0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M +$X;5DF]/F??08 +\D 8 >&PO=V]R:W-H965T&UL MM9IO;^(V',??BL6FZ2:5$CM Z:U%HBG=H?4XKK0W==,>N(F!Z)*8V0ZT[WZ_ M_&E*3X[HN9)2R"_+_G$=OQQR,6>B^]RPYA"SV$0R_ M>6BG^,ZD\/#U: I-"@\P3U0RAP=_^I[:7'9&'>2Q%8T#=6_K>W LQ0&1UP.Z(L;)=N> (MLZ0<0B M?W_?PEYHIE@H M_]&=LBRRKX],!N9'N:4NN^S R)-,[%AG_,M/>&C]IN-]I[W]/V"OF]*+^GO M7[9,1VHNQU;WJP[)6-40:5 @#>HA?8VI4P+^B.;;E0.CQSE!*Q[J0XQJJ& M>,,";UBSQ02%:VW:7:OYS%DK&D@MH+&L(>!9 7AF/*AII'SU L,1VBZ; U!R MX4-.+ 1PZRC-@8_:RYYC+&K(."H81\9#FD +>FDKW@1TK4,RUUKV^ MT]3_7FEO^4OUP4:W>.6_8VM? *IA.%)K34#M>CP0]S&?.HS/[-D7WGZ9WD\7T MX7[F+$_0;.Z<:KG;=":_LIWLW%LP#5'CG#7'MJCX;F>MPTSPJ4:X9INY'(!RI>BGJ"E@ED6 M<8$<'D./AH[-/?TH-J=? 3[7(;8@2+DT)FU4GU[XW4ZW)+([$=;N8=&VL!6U# MGG!I3]@L/:\7I9PW!L0XA(*41D4$?X'1XIZJ8+ M52I0"R5>"+[S(U??!\V9 MSD0+VH8]V:4]V;7LJ0!=<*E B__RMY76?R3QO&\1[5K'7- >4M!0I&]>Y5B\V M' ;G#:SPLB6=//[CS#L)47X6VM KN]0KVZQ%Z9B="$:KF]<<\&$XL'[5@K4A M5O;!SVYF#[KEZ5W%M'6K%^M'0NP![O;[YP,M7QM"99="9??K=-];7R:+N!J] M]IW,*(=OP[/LTK-L\SVC>U\%YLZCEJL-B[)+B[*/*$ >FK!8<#MOWEND#%A+K&#&C9*6U2*_DP?EYR%+&Z1IR0,[NS&V[+/S8=\:7OVY MAY"]@T=$DL5J^N2,1&YR2S![6J1XMW@Z9Y(^D](K=\\>[?E,D[6N1 %;0:EU M>@;?+[*G9;(-Q;?I R=/7"D>IB\WC'I,)#O YRO.U>M&\@7%,TOC_P!02P,$ M% @ L3AM65*7UF_N!0]AP !@ !X;"]W;W)KT06)Y51VD\V%:0Y);N MKU_)=NW8DI4$P@/43NX]/E;$F. M^27=D4)^LZ$LQT+>LH<9WS&"UU52GLV0XP2S'*?%9#&O/KMCBSDM1986Y(X! M7N8Y9L^W)*-/-Q,X>?G@4_JP%>J#V6*^PP]D1<27W1V3=[,699WFI. I+0 C MFYO)>WBU=)%*J"+^3<+&GV-5V+[R$Y_HTT?2%.0K MO(1FO/H?/#6QS@0D)1PG0&TE 30(Z-L%M$MRJT)I9 M5=8'+/!BSN@38"I:HJF+:FRJ;%E-6JAI7 DFOTUEGECOGX'7H.T)^WM.2X6//Y3,B'J919T@#?UL!H!'A%=I? =:8 .<@SI"_M MZ1](M-AE>[VTV>RQ+9.U-:)*CQW!&]9,D8* 3#GLLXK4STU@&<&4-OIBN]P M0FXFJVM;HV],42\RV0LP82=4&^E^DCSF3Q MQEFLH8(*2NWYQX6+7"^.HA:(1JU%*-CICO\7F.]'F_M_'"X$O4HZ,%X9 /%+;7XJ)Z6I?@^S5*1$G-CB_9V,X$UBL8.IU:.=;9>)\D MM)2=#.SP,[[/B%&7'+TW>-%@0@Q!D3NR[^>F,)#]%A)UOLS8F0(]64:Q\-] M9XA2K7F$8R>$T*H]BZ^8,;RW:IZ-#)&^UV3_&C+4HZ +1REV^@7M O:/ Y8 MI,4#R(BT:!U5Z4^:SFLD[1HF7AM5/ TR*K\4A.5&]KIFH< ? #O#'1@)VN0;NP MU:-\:'1UO8).B(8=V106.8XSPK%3-FB7MB7-\U0H':L-34(+-=:D2"1?\9O M*@B(WAF)6X'-K148G?6O _6+[[021E9%6@F:?-O2;$T8KQ93> W>RD-5FJ3B M7:7PXMDH4= JPJ=JU+GQ^J/0R3*TBF"U!.0)E:O!F(+7SJ7C0"E8#$@;7A(@ MMQ_@6\Q(N]_DF7OJU/_J;^32*<66LO0_*298 'D:(OF]S'LY$55+RSN4)L]@ MHLEK#F+7P/6FH1],'2^N,.)P&OG1U'."%XB4XOGEWHLX_H /^8;U.U<\'LHVHL\>%/.,F>)?* MMF(\$>HF0;82+Q[JH"$N<()X1%509R?003M1YF6&A9R/9A<9:>I&X2*,0V_8 ME$UQ@>= [(S84[9VM[9:B[LO\B,UOI*^["!1&OC-DKX==N)$SXME09S:0W6QH MHE*MZI\NQF O#.V!OF_1WN0U2Z=/ IG0NN/0F>1D-TB=;->K>!-/ MPIGO^J/0.2O7[JR.7N%VG!-6^!F ZEIG>R^EU!O!OS![2L.,K*1R,YE*(62 MU2_9ZAM!=]5[JGL]!,VKRRW!YRD#XF=)<:2;AC'58Q(FVFJ1G=NPU8(>1!0FL&&('^*8L%\/ M$-'34L/:RXFOX3X0ZH2^6J1D#UL0W](-DR.]1/'#&!(>T@0QV"VU>WRWQJY* MR"*^AW#BM6.DI#Q1^JP&?_M+S5",( )/* @B?XZPABA22)+'CP)4*^=4B?7C M%_0OF7@IYHEP6-/HW] 7P5)S->3#CAPB\96>_H)"D*/P!KQ[!N=\EC'T)!W MX(+&1;)D$(=)_DM^%C>BEH#M,PEFD6 .3;"*!"L3FC/+9#T2058+1D^(J6B) MI@ZR>Y-E2S5AHA[C5C!Y-91Y8O5 (I)X@+8*@:.;#6&0B !$Z)&(?T*?T1)(M1SR0I_E"%W)&E:=[!? I#CFZ>0=]". D&6<8M,P[0[TM?]Z8_@R726L$^?R)('(0 67A;_"[V.: 3HV';122? M5XS;D68KLL':+EG;XUF'G!^Z&=LM'O.9ZBV,7U%N!UHV3-G:MCS;KY.R=<9 MSU>^_K@@B1\F^R[2SE#2[? S;11KX%@3'PT59)Z*+; MBZ7*QAU/B0=+3=8%#NP(VNKC!SPU_NPR\#N!-63/2MFS7MF5UCC;(T9>B M&OS=DK\[CO\@4^>8;MVJV'+=28NSVW:_-3VWU.8EY_E5G"]89-XBC=5GHJI" M@_1\#&EL5%7.&.*0AV$.Z0<;:Y'W0FM*KQ5X_/^[)CCDDTNAC4U5'4;]Q?N MZYQ2@-87T\QUS=><>Z?N?CRH[\E4!1WW5_0KO83;Q;I+5N_<5\BJ*C[N+_E# M#-:+,-I@[X36U%MU#+B_97@? @SG##'8IK*FA:B!P?P=QI<&FK96(N_O+(9%- MZE43@$=V 0-=U(LZR!^%M+<#-957[0.^KG\XWU[W XX1_7:@7+1>V[JJ_PW^ M(6P?)AQ%L)/(QF0FEPS+M^+Y0- TV\T^42'WQMEA ,0'I@+D]1VEXF6@-LCE M'R*K_P!02P,$% @ L3AM65JS1\)1!@ =R$!@ !X;"]W;W)KZIQ[=7DI^>Z%BR]RS9A"7 _LD/>C MM5*;V_%8+MV 9?[D?X=^AQ,?T>:W*$^/9W88^LP53GS>/0A^- M&Y8DS5DA4UX@P5;WH[?X-B9^..!"_).R%WGT&952GCC_4AZ\3^Y'3GE%+&-+ M55)0_6_'YBS+2B9]'?_5I*-FSG+@\><#^^^5>"WFB4HVY]F_::+6]Z/)"""5L M1;>9^LA? WK%:4'6!2Y[)ZB]ZJ;'.""VW4O&\'JRO($^+_7_ZM3;B:(#F@0>0 M>@#I#O!Z!KCU /?<&;QZ@'?N#'X]H)(^WFNOC(NHHK,[P5^0*-&:K?Q0N5^- MUGZE19DH"R7TMZD>IV8+1173@5<2\17Z>\,$+0,HT=7G@FZ35+'D-;I&GQ<1 MNGKU&KU":8$^K?E6TB*1=V.E+Z$D&B_KZ1[VTY&>Z5ST@1=]J+5%<)"P!QD?V M\5/+^+&6WN@G!_T/Q$JX8)L;Y#IO$'&(!US/_/SA+B3GYV:/?WCV$S/<)AG< MBL_KX?LS798EH'C6)6#'BBT#(VSE* O;K=S0);L?Z0^O[21O*ONK2+IF\A1SU+E?PZR\X M<'Z#;!V2+!J2+!Z([" "02? A,)WYK:'S4C%5LFEB5XA M4JG*5-PQ@BB%.YS+G)HCX00<4F:)=IV.8!,4>$$("PX;P:%5\">NM%QN MW'"0W-" !4\:P1-[L>92HI7@^4&T M7K4AL1-C\FM +8 "Y (H2"\ PYX78%CPM!$\M1=3M69"]Q]+GC-T=8CO:["B M3H>LJ$.214.2Q0.1G80#.VWKZ%@S\'VAF.95=4S ;M Q4L'#W<("@ @).ZD' M@*9>!Q1#T_6MX?

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}$ MQ7(#RM4;4-^.LM5G8S0EIXLYOI:3)$JRKDBJCU3ZIVAPN4F((U2H8GRZHH M9.YDN7HG"[UF2QJNBJA5\5U8FEHO4"%2TU _0- F*"V'T@HHK832&(HF=@9N MLKEZD\UD\98>.47P(- "!4I=PO)3%F^AHN4F((W*H8X:E,8&\BJ*EQMEKMXH M.YL68T]_.0RO2VQT"[O"\CA9+:9NC$?M8G-53\7SCO47]498+X'K.[;\ 8U MHZ"T$DIC5$:Y[LXYK$ MTP@;:HQ!:6PP(:)BN>/EZATOP+08L=E'^;9'[?A"@5*BUC.YVADJ6FX"TN@4 M:J1!:6P@KZ)*N8OFCM_^~=R!+LPT/#UV/RZ;[:=Z=SP24+NOG11W MH@Q39]UP-O)E@:OE7&5"02VCK'-QB0UEH>LXLC!!9EYN M(($VJ806F,SFS? MH2(>=\(\O1/VCTC&

)R,VF\P6)^3-DZ%S)V]^+T/9 M_UTNC=7 QO\/V>Q%+H9%4K[\9&J>BQ=G2 @C]&=Q]O*'WTPO)L].*+Q("B]. M2;]'9${[+F8_9$=O_+.T&B;7FNC#,*L"]:E9P1:-EM1XQ*XS%'XQ7!:N5Q1+)
MRRQ7VZW0.?Y$(M=UN6-JQ=2770GA&PC8LISKI:JX%2.&M/LUMVHI-)M/72@1 M4+L1[$IM:U[M&(0*+0HF*^S/D:11.Z0IE+O=R++F[+THH+P6(}TMV(,??O-D M-IL_?
*%L&='H%O9^D[^G3M2 M.NJ[9.:O[ZZBC6/8QG[?5,+EQ E'THTW4AN;76+OPNV/R^^{)CF%;KU5EX-> M?T!B@A9)3JO+'SN[;[@YU""MR>!;6"AS62>K$6M9Y2@C%+6>K^&U+>F&@L-@ M_$
DH]R^!T@'!Y "8+P38)PM)= F76C%]2(4K4#:IC^8;YY$S&QX62(A (NJ M$:S!OV5&C[@RNF$/GMC-0ZA3D3<,VH4HHJ#DP-\:?I&UI5ATS<6=-Z\O&:) M!.R.WQ)V5>
:-''07UF^#CG^$C@G9V1M5HE=Q]N+1[C.CTU; 4V*U0K_AW(/+ M1N0-=1VL%E]JPH%MI1K-'BP>LIW@&FG# :NF0B3H;UU*A)1<)HD%BJS> S_= M.@?N=-B+3#N;3!^?9-
E,?,G+QI!>)6@+6A[P;KWA0G- C0$@^:>-*@L"ELL; M"-84)%I\B'2S!I,!,H6K A^OW[+%T\4H>&6/ \?9-0 7 7@'10$I M8*^IP13BB_.@YPR2W2JZ;&R[C"1_]V@RFDPFL
Q64(-1,3M5N442V>83#8HX:W',(A-?3@3#/D:5(M*@<_0!+>)ON:9KF5EBK%'GQAA\L"H+=H\CV&]MUT?/&(TK@D/[*/ MM==LK\:0ZH:7(F40A2=MH-6.EW;7B0#MPDNC,O@05XFBX '
30C+!K/F[[AOA86AXSGW63[6XC7+"H7:TB1 M:)&3/@"25MNT^XCJ6MDXL^,UVF#Z^)GQ>0.3I2T%/4C6&LND#Q+)+FE<(:EE^S#7UZQR70V8WM%D]F MSY+%M
PM1C*3]O(2%OL2;F_>TN7663=OP[)0&M:"TCUS#@]R?0C# G*60K4P M<;?1$$OL-T/B6!=$#\:F*H^B'8QJ(,KWHQ@004X>ZY&@#H/^MGR1F @%\N&[!7%"YN&BA1L$*E+7
M\3Q"F!- 0^JE*@5GPREEN?NQD&7CB(;:4A\M\BY@KA/@8>V^8(;W=M7KCB M[YLOOQ&)<<7=N";%:YT:8;C?MN)I' HK4B.Z(\M&|(-?\ M+2N)\AP'84,42PA?"\>#[C>AUKB?L:
E#:DKJDC.=DD%7'HFU$*MNKQ M::W M+$R/ONDE;/(JIZ:(FDT>1=<^>B[C* !:YLY7[JZ_C-5^.@$UDSW8DL8V:D!* MPH'KBMJJ\TIA]*.J]UJ"JJW29A^H$CF*< MN
J.O@@IJ[(#F02I(;G',A0CR0'?MJCUG5JE+'4&*+]_I2Z-NON8%9T.-'1A MS@8)"O[1R"]LZX\W'-?34RN:KWRB#ED:U-.\B+"OFR7J/[)*?Q+6A2IENFMU
M#@L.MY1^9G\M4%Y+VYLAD7LE1BE++4K;#_Q*TR("!Y*C"6$Z&M0T]NEA#X4& MECIYS+*F*:V?J?\Y#?RD0A3$O+!^-X,;FG"J_6CB*)DMYD]&\\>+/F5EP]$G MV@-
G)M1TV=>'J'*=6Y?\T!#D3>G53KO[1#M6-\B(*M6PK"\O:!9[3E]7^L-Q MW#)JQ:7VU21F29#A:UVNUA4*(KK-V7@6/4G^(=,X2(V>R[HG"^)+33V\(4_G
MRMC6F78#IHSB"S^@N2$"L"YB4T9:$#I<577X_^S[+=>UKF1)JXB7AIDVHZKE M&MV65]#\#G2N2]&+-S6RWTWZ-EZ6EKQSS2M%Y94ZZM"^C5)+XI])S0RA,\\Q
M4Q,$LM3D#Q7)WGPNN\;V1L;CML*M?NX$AYXV,(L&+L:/#@WLXX,<2$W8OG.2 M"8N)JZM$8(-4XU+3C7'@>[7U98EJ3.?.6O,JG$S%[K6]VT>'9[;I+%(>7]F0 M'5>E,O34:W=
Q4/#X 9\&%$()SG"SO8COC.<]9:XVO5@?X]]R0SPX#"%)Y> MNP0VO0;-A0"Y !?& <3>4?43=)PPF]C-PVS@/*%GTXD."^"Y;-8-/(-DF?6C M'S%!2=/4*!&5;=5=[3>,T_$DBY#PO.@RC
H+[SJC=WK8'W7>"9'\TI]VV(.? M?WG(WDF,E\1#T/J-6.J&#(;>\Y[>V?WTGHP?LW]5;V4; Z4 &=\=H8&_L>Y< MUP<[IZH? C>G+!F^6?[P M]_6SUY'6HT;$,DXKY'1QL(G?
ERF$]PZC!S1\5,B'FCZ W(H<'=O-.@?XZ M4* /AN'],YI=)91A/PN,[_ LG6S%HX_&"<"X#>KO'VS\ MH5%@,?RZ#;;'_$X1CT^T0S=G'W]A_IU(P*TGZS3KN5.@3NBRP5BW1WYA[J((M
^[T-IC,/82,*RQUK?3]P("DNT%;-[RC<]E,(%!C?3\X$=8JL=%DX?6"K.- MIKH2-D#L$-FG;=0_!."FLRZKJ(NEB:R[=8953SIXP/C4 T2*!W?I?Y#9=*K2 M,Z4KSAU=>S4BPR3$4?
>G"^HMJ,<[H-^+),2=1G8O'(@@W9#23N6V04QOKS#O MZC 3TPG6$,SHG_JFW6/G_Y=*3'<6OH,V(+4XCOO,>=WCX+TS+((@#'K' M97T+Z \.APDBO"VU)
(2^\,A<[HM(QG1*Y4IRA$J;_ <*3?M\ MOWX5PN[PNH_9MQ58XS/M[%]15Z>1V*W'[2N(^X(QFI=]&P9AX&6M9# 0;CS%_-I@(\WWBGOXO M$;=O41=?AWQVY&WB-TXK[$F47:M,
\L'H[9QW0HTWOGR=O^_KC\3#RW6DC[^\6\._$%'BM_73@(J=K61%1^QGQ66_;+H(Q'W6B-,URY< MV:5!HH=3,[-W G'"+4Y]1\!&E1TKH*/=M>5A2WG N^\&NN_VTEEE>Z 8/JN@
M)^FD*)VH?>M'*0%N(5-YGG#Q<39'-(A2K@D*F7."=-#U[S^E/UV,'UT\ M_MZMFV)X=,)YOI% 3E2]]CDB5Y($B#6=[BF]VWNMU5UEVDR:/?XGBL>5*.D+ M BI<[!J-%#>?
[M/(_#=]QT#_M/I MU\H>>M-C+'=XML'2V49L2]U#:3*_-^&Y+0C-V7^8VP:SW)V9W:H&QOZBM.#C MK,]G2;M,'W6Q^U%7=G_JVGT3<76/Q;H'8?2=X&Z?
L3"X9AW&6C6VH8]:#HEK MB)O8(#<-L5!+0:[U=%ENC\=!' MO>>3Z\1@[7[P)RHIJFL_PH[74W?L%_Z3[?;Q_T'\)@VUO2ZKQ0K+ 7('IWY M#T;B#ZMJ]R'W4EFKMN[/C8"5FA[
_94"E80?M$'ZLO_E/P!02P,$% @ ML3AM68U=,_WL"P <"D !D !X;"]W;W)K&UL M[5I;CQNW%7Z?7T$H3F #BE9[B>W&]@)KIX;=..C"&ZZW+,TMI(>CW9UY!JK9,&'JO+H9#Y_?
%1)74_.G_/:I3U_;EI? MZEI=6N':JI)V^U*59O-BC\>2-7ZDKY#\VEQ=-11Z70E:J= M-K6P:OEBGA;O)C,B2%5JMP3!8G_KM4K
M599$"&Q\C#0GW95TT_E$Y*WSIHJ'P4&EZ_"_O(EZ&!QX>NC 23QPPGR'BYC+ M'Z27Y\^MV0A+NT&-?K"H?!K,Z9J,GER)\$KUS9QVS9W=1OZ=%[J9Q-A-[9/Y[+?
[6EEMQ?,::/9D*OU;B ME:D:66^%JKVRJA"Z]D;(K.3S2LB550I1Z,5*VOW-5T]/3N;/WBE%OXZ?/'/B M(NW@=\?/'L&%_5H,MURN)2(H5ZW7N2S%PS<_/@*#E?:X[^$NR41HEGV 1UEF
M$\Q53I@E/W1,3>^Z9J/+4BP4L,,U!KI8E$H QA"TUP"C)IRW:J7)$Q@CEKHD MC5R*5=F%IZ!56)5VM=RZEX8W#L1_PSY<.Y MLAZ * R8M>+":5DC:.VO"@
JW@*+BD+3A6/VF=^UO%;"F7+ -ICR6^:#9-=5 M8T"=^8WJ*&R[$F"W:',OEM94(\,20R0VK>7&>=9B;JI*V5S+4O_6T3HL)IV- M'E%D,(75WEBM(,U+R"@::3V>@ET*
0=B;XJ^))S"!J)4@?(20=?:I&;7-@U< MLO>R#32F%EOQH=;Y-@=B![7$?0-U9>QE!UB.RIB)GP>*6$L'I>8*1&'?6K0- M=(4K&[GEJZ$!MOJ-!MHKW/;@>#8'Z)8EFTK=-$@ECJ2+5$
AP]-P&RD+/Q6 MNU:)LL-&O$H6*F5;Y^O.>U@/R5=5J5>=HT*G%)'6;&7)^@6'"^4W2M7BR==\ M[GC^-1//9+[6\.LD" $3V-5+3034JBTE+!:]&)QRN\I2\/I64I"2_??& M?
*8IL^;&%K+.58C\BZM7XNG\Z12TRE(N# 47E'5AK:Q7X:[1586!:+7QD*TD M;G';]$)C%S16::=(R12-NE!B94P!?3(N2+%LX4OW\BNK&*OI;BG(OI;DMY2T MR:
(#X4((4^0J&$&Q[(F1CM6.'*CEK;7TJU&6JR12A%G D!Q8NVK-39V7;1'5 MVK.(=4(-F)E<9R\QQM_CXV>,!&\O4TS.6.>/YX_A5 6PSX-+5B)($K@A/13B M6D)DJMN/#$=;24T
M6VO!%_ :PEZO:CA@+EG]U\HZ:#S2EI5I@Z?F;47."0_);,A4%%X&1W]3,2Y(MX2:'F@D=PGE$4,!8(*-TSL";/6^`_]'[_<(2EZY=./6Q!>^0!38T)>!@)GZ) M![+1
1?..T]^!6;WA#9[F\3RMU0=#J.UDMN0?B+DA/>FCDA<-:5*R)L21H[\ M0[EKFO4Q.]T-6FA+>X;?NWQ+>KXIQ<@NZ[WIU4T\U66/@?&S8/P"EHFV'VJ? M4'. /9)1Z@?
(7"T0HJ?'7&N,R27.1D"TI .&-R#KINR8&\XXR#PUP38-.V7_X4=]T;4MD)/3;"U?_: M%W]7OH#(W'<0VH(%(L;,&P\/V!5!.Y9M5&*DNF6I?O_&0>$&7?!5!THF9!-<
MMD00T?
5@!@N@IP=Y*;E)#8TZAQX>0H2Y !?/,/JP1H"7Q4J;7^U4G%E,!3_' M49V3*@2O;PO M01:CG,C)M8%:/&=37;$;@-/]:+*!%=FQEE!T$&%H)AV[0NH(9]0COE8+VY)Q
M8[@<;A.S'LL.M(G&MX<;1'[YENC5,OK<)1SQG0=0/!Q2Z/I!L;\?S(;](%/] MPUJ_>_9$(O5$VPPL79D6\OT(R\G;[5[/W5V-GOC<1B_[(QJ]7JA=F.D[O5C(MJ*%NDUV&_$Y%+.K-
IN9XPA53P2T9Y]K NUD0U) EADU+,DAD\,/LZM,:S^SS M&\]HN,]H.;/]+>>#^>Q)WV12S=AWER30@]/^/2G@<#EW[SXRXW;T5L?8MXQ_ M;7\X#O8[.D/F-'8L8ZI+;1W5D)1TJ9Q?
*YZ@A((Y)$["-MFWDH301#NZALN! M>B1.O"H+A4ZAENB!J/7+1SWID) ,K_??$MJ<^IK*2=KW;X9?0ECI!_EIFR J M2C>-K+?DE>2LVTR[KB_U.. MCMK
R6FL+S47T+V6*E,HZ+4P#3D-@JWBE")MN?T6.76ELH4V7N%DSG=U+4Z7 M4ZG:ZO&P*Z9@NPU2'_T_J"$;0P+H<6'5#P\.@4*?3L2"0&;8ZR-!%\9^VQG- MJC*(O-;-
[,\WU2##WC'/8":SSYEGC"%@F (Z;PW=Z[@.+CU*G-6:]9/8)L" M MM,4QLV7_7D,0"@J*'M;TL,5//K&";0&[;Y=4%:6NBQ0ZB)E4QQ70M@16#T-IF0 !B31E>-XS.TI!3'!=VQY
PE%C!OR=AT(*+!2.(O MQ&5@950!C(1FU>[5^8 4Q40(\ 9IB\ORUG5>P)4$T\:1P&$!_L$[S9LC;7(_ M:A7W6I$'LGS1D M7Z9>7Z9>_]=3KP>/GWPWG<_G W1D;Q\W4#W8KU0-
G"H9Q_9Y<3+<@8".P;S? M=7A(0GX:J\^P6=OAJ,G!HTDC3,Z)AWJF9E,".!EKQ&MU<#NAH7:/0M)/BNQJ MAV*0"C^Q#(CE,'T&4!Z,BY2%4GH.;'3Z!PC?
+JCU^PLHR5<6SI+Z=]F+"N M8,_[_D'L6,_'&;"C!3DEL\B6_6_PE(*M0QM\:KMU.3*D 2T7(K0%IJ*Q% M*D[W%R2#J4^87"++PQ64:5W9M_NQ3G9M%9QT
8]>:M]]]##403;2P7BP-;CX MBC6PX]C+P\5ZCN#W(78(!&)-PZS+TAE25NM"[T8#GN'H";4-O>ZG1R96RJE9 M%U&XUA6!\]CT4'+8K1I_!6 M?
<+LEIU)#^:T84B;7'%@UJPSZP9RX@T-3;G^#KFSQ&W M:7C5HT2P3AX:]RUA&^#.A]$1!4_'2#KE=WG2<.B@O^X0,U7%3XH4_1!V6[2 M.IWM^\[J:/
5'+QMQ=_ZN3!\"1_$=:O=YX07X2NZ?GOX%Q&G:5?4GY1JB:/S MV9/O]&I3@_>-/Q-W<)XN#;_7,/2RM(&O%\:X],#?=!]9'G^'U!+ P04 M" "Q.&U9.3@,I;L# !J"0 &0
'AL+W=OM7#-2B2 !O)%&R+:6V 3MMT07:W:#N[AX6>Z"ED4U4$E62 MBI-_OT/*5AP@\:*78B_\G'E\\SC\F.VE^J9WB ;NZZK1-OYBYL5NUF,G.5*+!6P6ZJVNN M'E98R?
WQW1D[$"QF+=_B<?[:VB7C"@%*+&1@O9@,)R[B^CZU5B M[9W!GP+W^J0--I*-E-]LY]=B[H>6$%:8&XO J;K#&ZPJ"T0TOA\P_6%)ZWC: M/J)_<+%3+!NN\496?XG"
[.9^ZD.!)>\]\T7N/^(AGK"RV6E70G[WC:>^)W MVLCZX$P,:M'T-;_Z'#BD(

[SY- X2;=-V*4V7($]K0#DLYGOU<(#6R2#_%OD:KB/TXV#3G-(ME445$BH?79UG&#ZH[-US8CNUP,!-$;L*U4-)D+?A-CXZV2-V>/5+=EV59B_9 M'Q0<^J3U",.X-TR<7\>BP?U6DG %!2H& I0@2+(H&\;;J':E\DSE-DNB'1E_ M\)M:TC.?[R767@99 &C,L2+?Q/6)7)_4*<()*,T5*>B)6;SB6FJCFK:AHWF" ML.4)6F=]][&R*25/O?K#:@NM!I+,R=:]8,N^I-">
<0F8N;1;6ZH7@U\5J7$' M2,B:Z1+<;',/XM\[Q>N>,F&_*_0M+]E/C4R*,=WQADIRO,R5TQ;-MU>!=QH_ M^\ VJTYT S;!VB19JP?#)V93>&PL(8F+C!(8BZ/\@:X%OC/;[B* &D"[/,"I M':])Q=S$1:;%@,NT!^BW1]*G$))42 MZ8G;)OPL)DUJI"B!K+31ACCRD6KMMCR]T7C@CU:68U6DRL=:4+5SZC5%S=$Y!
ML4_8#_1C'K+GD.>OVUB(V89.$.P#NXR00Q,Q/L@J&R/Q@&[V@VAPX)* MXH,Y%+?_+,%6:%7/)X-^U%IG_7?/]%UN*JH.R-F:'B?<82JQPBB/N!=AZ=ID M7]M\;U5B92 59\8,S]S84M?
*COKS2=J MBE^9B5AOT+17 D@5U"2+:0!UVW*H+3S_2A+P'Q=!,YQHB\#[7!$LE\O)V72V MF _)8)RQ1V3@C9!LYFBN'*X.DL/RPE].019GL^`6]B"YWN?)850,5UV>;%'6 M2_I';
(AV]$%J85EO_P+#6\Q >39Y2RXF]-$?; =IB4!Q#QJYRBCPT9G4Q>, M@27[@*F6#8\GN]^RNKRG8A5K*7,C9+ 1S=*T9Z1A@ZV187S#VE"Y;:K^^@$0\N
M!^6TE=K*J3.Y-,GSLQG-SNI)%78.OIB3XJ M93M3HEZG8X"QUO<]YKS*8D<2.].2KZB%=:KN&O4$%,D(1RJL*H*J05'!4[8 M;?,4#PT2:G..G;(1RW4T/4Z-Q[4O-WS6%%5/XU9\!Y+
[[;3_4/C;+L8'_4) M'3NV#RJE)75O&]??4HRJ[^TVEMK W\#F6X+BALSDV%@(/:EB<"J?#I8W"M:H ME7T=L$SE[3GVUVU^V0'4_,+'/XNY^7-!F@:O7LR_"(V8]XW!\"ONH-4=?4? MR3-
6-5+NBO7:[!['MXIC:U+6_+RQ]ZT#&]Y M1 *P\86[\\A"AHY6U4PK2;?Z6WW M?;W5TGYMUN43B""UQD!# XH=1J9(K,D#4J"0FLE")+;+62>.B>#X/(!F=X!I MVHUB^]DQ3\H[
MO6OJ'.T>'6(YX>2_-L3RFB&6<11# ZSV$.@K#K!HEH,X U,,TZKOI M^>S'=:XS!^ZE>/8$%X]#K-++[BZ>2> MN+]K/2RW0)ZH./>X
'J%MVED.KIX7G'Y#1V*G9Z=,)=)4J=4,K,FBS>6^^4F* M>10X-U$Y*_,']0;&K#U(STZ*DD,/-##:=0J:YY\!%A: N\^X?-$?\-DDHA(
MF@?;ZQD0,=02X>>'G(/]32LJ36QNJ4FM.G6S>VTSR7N"8^/[I]6/5M C5;/W M;0O!H7&V'3JW2^>>E_BFI?-(_^ ;5XZ>?5CDBTKGWK.-_].ME4ZQ//1[SE/G M5[F)R._HM\?8ABK3POQ
M_ZT_GGSI?E5;[/<_#8:TGQ0'\UBL8:M -?BR)1! MU9M"9?0;WY4J"I70RXV ["G'!?#]6D&,L6_P@OI'WV_ U!+ P04 " "Q M.&U9 8(>R:T* #9(P & 0 'AL+W=OO(*9-
X0$TXYF)W3B.8\!V=M$NFFY0;[L/BWW@2)P1&TE42,J. M__U^AZ1N<\LD318(XI%$'I[[^3W*K*TN3T]-DHF" MFZFJ1(DG*Z4+;G&IUZ>FTH*G;E.1GRYFLOJ/"R[+T?
65N_=.7U^IVN:R%.\T M,W51CF_GE[1FM=PO^D.+1]'XSDF2IU'NZ^#E]/9H10R(7B24*'"\>Q)W(G0Q8JE8\3JWOZG'GT20YYSH M)2HW[G_VZ-
>>ST8LJ8U51=@,#@I9^K_\8]!#;\/%O@V+L&'A^/8'.2[?<,NO MK[1Z9)I6@QK]<**ZW6!.EF24>ZOQ5&*?O?[9F)J7B6!JQ>Z%EL*PV\F^O3BW.HAVG2:!
[Z^DN]M!]R=ZJTF:&_:U,13K6T87#:.W MBX,$[T4U9<]G,5O,%F<'Z#UO!7_NZ#W_2X*S_]PLC=7PG?_NTH$_XFSW$11/ MEZ;BB7@]0L
8H1_$Z/J'[^8_SEX=$."L%>#L$/6_8+G#='}55K#Y?,J.U- _ M2_:6ZR2+YL^]<6+V*)B1ZQ)+.#,BJ;6TM+NJL0P1Q/A:"X'(MG!VF[%$:(OT MP3+!)$"G6*E;3#JWJ=0:.*BT?.&2LU.V?
DLGLUF[+[= M?-Q&*@;+B/HRHGM;?G]G"A.0;02VG/%>)DRP9,L7$K#DAYM64+.COU$%05$ M,NX<1UN3/L6'&@H(&I0EU(=+?UBKQ&D M.^)R)1-B >O?"'(][E(^+KU:!-
S8Q,R5'..$_446TKI53B0BU"CVH%I/:.4/ MWUTL%K-7?D-T>X %MW+^:APS[LYQD<+F9TVD]'1^.,HDV#?U\D\4,U(QK\CY MH;+
^YTJ*EX^T7'S%ZJ,Y&R3J3R%.N.C;3DD1GJ*F5S183F$P^ZXM[-E=G%(M8=&VPMR6C66=GA HN13U%F__ZAB+X$FHO%[)H!!"9(NUFQUZ)-OO6[^#KZD[M]PA#@TO<](DI;H) ?
+24Y%RRHNN>?V_X'#BMVI.]P. -R,*00CA;8E#@7 1) MI!Y+T,AD1::$;QM+2\1'>'CKR@ (LJ@+"IL$' !=;>FSKO"S8RAV^X+'("WG M.1A(!!"3>\#;A #^$.C(H#D(1T"%[KD6!
!EN6ZT*LM-@:94*?Y1ER):S']% M(A-YZA(B+TO*'SW/9050#6C&SFI@@0>EQ(-5;2PTS!Q4<\]7HZV<24&ZI%HD
MTL!N_L3.&VZKC2KQM3)/=$SFB0>A&SR\VO'F8GG'BB_CB8K';W3=L M1-73"&MS7YV#]G@-% J.DZ,U>SB,=H1EQH.CK52./H$<23N57;(WKE:4J;F$ MO2296 67(_>DE?
<]9[@)SA"'&H-]WIMYDN@:"8PZ 5P&!9)ZT*H@>,NTY[T' M3$Z;R#5T-FI2'*N M@P]47#I+)MQD/M):@8-VO!S!V=^S&0N=D7V%M6(MW!PT^GC-
NWW*&Q%]#'Y!+OTTFT9]3(8$AV5##0@$4!XR.F7=P^2B/& MO?!V'0$O*#GI@NI0)!#W2$2]F[&_:XY1#5\]ND<=@,S5*KSH*GPM7X)%$Z
M=;9U31$10'DO=L#3O65G3$,.EQ:\0ZM^TQ',TW("1D091]PK3V[%R9>*QKY4 MM(/X:NSB]M-230?YIH4&5-F#LSH"A$-8@T.F[ ]%">L71UBE'UZ'0]_)V,07]3YA<%*SD=P-^B
M8:\TV.=!I*_L0"J6:*-;@MVL)\0]F8V*,F6_ESG!9HH)'F9#Y)8UH.#WG+= MWJ@#&O2DK(LE+$3T6\4,@LT7U"8R4IHDI$T^WH#B6P&_U8,2T 48K91!U#AT
MD2=USFUCR(Z;KCZ1_*9K18Y)^=O6"](6M0+.K<:N-D;+P0@ YVPII7T\?SE] M^6Q/[SJHE@,=\BZ$$%OTF*H@.T'OD]=N.;E)HYAF;L<:G)<;>]&.\$ 4/U MJ8X'G?X=K[H.U6L5?
CSH\1-9*J&/\(\[JD M817AQ\^B1M@CZFNS0.\DTES2*KN5-0 MRI\VRJ7U8-J(C?$X4A9:K#!9V'$_.SF#A>A;#A::HOCIP4+TR<'"_Z\-C_:X[68;WD'^;P#X
MXR',WY$L#!5%YQ:^R@0\'&UV"-M;-S'95^X0!JP<#X$&-4N\\+6JM2&XUZ;]=^1)!>VDZS%"IK U: M45^.6Z^,NM'%YWAE@/ZJLCWH$TJ>3[FKO?AD1[*2)MIZL?1UD(=[EY(RX*4:
M><97D?$G\$-XLQBR5O?*J@\QTF9H!A%A/?]JL>LJNHFBI&E!!05/=[VH/^U] M;E$(O78?E= +$B0H_^5%>[?];N7&?Z[1+?&ULQ5IK M;]M&%OW.7S%PF\(&9%F49-G.PX-
&<&T7;1/$:8O%8C^,R)$T#L5"[= MT*Q5@2<+#W-9XM8N3]S:*IGRH3P[&8]&LY-7+TU59KI0[2UP M59Y+NWVM,K-Y=1 ?U L?]')5TL+)Y.+ Y%4KC1Y. P)>Q+C!TAG6 -'#*WJJ#R^^^
MB6>C%X_(.FUDG3Y&_6G^>)3$?@'C\5#AR)'0TX$/7)E_+8BNTH.*169!>^7%5) ECHA26^5Y6H0GM5R M'L?W)*W6V.96TJJ5R5+PENNU-
;L<3A5JS@0FY4&,5WH4K.:4*&$^511!IV) MV4!\KF2F%]H; "STK:1:A8.(T@HE$.9:5Q;;BS(JC;BZN1;G\>GQ%#ER#9(4
MR0Z[A2R0A"4\^]TWY^/X[(43[S98^ER1L]\5XA]5H<1XQIDUZ;MMI;)4:)"1 M10%QHJ[M2C+ET,N:;:,XKF6M]1?0 MOQ>CU\J6,%X")Q*;-\KI92');_OB17,$[SJC0$GHV.#\=#Z:3D3>.
(Z$:FI-=O8EFC^CK MO40G@]/1># >S:(]1*?WB9(B(-RC?+V/\NQB,!N!^B3>)^[I+N4AGC6)SXY. MM4.;JIVL[I*51(+N;1*4>0B5#*X)B6F^TP;W$\";YIR\%;*' 5B"1F6>C_
M^!3)0@$C8KJ(R,MSF4%+);@3.D^."DR;>UT2I5A(;06"M6IRO036(!4X+4%J MCQ0RQ6),^^KL[31F5A&V2Q-@4Y2;;#OKBD N"P=.H[7(" M=V2YRG)[DX#]RA%
MEFS9EYW;/(K5TE2 M+4'IPV6W"D=U%7;WSEF^SNZQ4B6K JIE):90@4LE.NF*TF=DDW,NE;$W&T1 MW'!]4>4BD79N4&J5KS>T'51T3NP()V)O-
QNC$5FI7O07R@ZR:D^@I0'&ERB(E#V:-HOU^&X@=5($,RBC/9 M24=&'4W<"O9PW=*^Q!5-0W04ZG!JA,#NF'>7Y]JQUU#\"!W193LJ!,\]087H M"U3 Z:\AS)6BL2SAQ$
.1O,M>*1H2XQ'N6J;]=HX9$+-FC-W9X]# MKF32ABT#"HRUXFF/7/L7'FTB5E#$^J3O%I:=D@@R)M&\G^!RM"^S?Y$618Y@ M"TQ$6 ZFRH#'.8D U@HG ^!FN-< 2,G-UY^>U+B'%
Y+#1:"G7QMDSQZJ>A: MVLR0':J0(=[TGZ' (8DU'KWXY?J&K^(71Q0A7CLV0#Y7*0:W#O"\I^9.%I.- M0 _9A!Q-36:6:&!^F4JG8=*VMI@<=A"C<(M!1'Z/6? YUCM/ATO@(F$Y8)Y
M>!OXHY#.D6B@L988HOD)'K5AV>14<-PHD0MXPH M\9 -GXBK;_Q!NS:N6D22FQ0MF?*DE[3-A@B0AMY,-=G#+NVD&&))^.S'WSVI
MU:XVV956'!!5$6(3=@\U!+J0M<%FG\&CN@FN 8\+0IV0TS:S=J!18_ 0Q"%8 MAU\VG8E'IK/HB=-9C489#H8AR$\ /#O_3P,A^>8C^/W5([*E##44C7+RTXW%&_9D&)'B@H'!2N
M.Z0TK8T\ ^UO:7XWY)(%J7MP5*OCL?Z?5;KT>.)$\1B]AOFG'IXQ X47%!Z<^G&) MN# 'NN-II*Y/E)&FAC_-L-<)@XX7>6 9A#DL87'ZV%DN%O5 1],4WXXK%E4) MV+Q7_1T<[?
8@_!;@UZ-JU :9]N\<]K>P4%&[H?90;'6 I:]_M77_QFSP0JQJ M6-VQ:CU\<["X"@9$5>DE* O\0-;WWS1M-#HS"[N#9J,&\6KD$CQAB@<&R_Z+
MR(H&*0F>VJ;'J%Y(WC9G2$C+KPXILEU9QTA=$GOC_\-EU',L*6>H=,.$XI4V\I6V[@:9[I2;>["3H)_OZ]M*;Z8#4^?":Y&\0L13RZ& M8_%,Q*.SX=DS<2SB,2]$'U"-15.-
Q70X:P^=#BMTO388Q#;_2M3A6T MW&I"!2/LPK_H(\7?(1R[5=)BD(9(K0"X'@W/.O=G(.,!F7@0D$%,G'LFSNC_
MZ'VG+=*1MV^NVD2%/BPMU&ZY3LZ'IRS9O5>;7\GR%^&C;_DX9BL>=XQ^T;7A M@Z:?=NU\SJ8_:YV]=DT M?/1LC7@^9UN3T5F(V3!^-,!'SX[)UFS>V=\T+RE\C"-
DV+..8;]R3$\YI(_K M$Z/A*'YV/#X;3DG3JV;::' TO^D][,T8_:_&HLZ[AL??,J!HHM5_.X95T.$R M%-1AX/AEB+AN#CW&T5\SCB>H-($S,_AV!I^%A?X+EH"+3(9NP,B0$573%IS_
MWKTV,+'??5VR;@:)T!IK8>K^4 "S YSS=\R*OF/>H^]S\0=_ :_28_%K,U)? MH84#&8H;/]BT6SZH/+SUNEH"9R[)=;^U25&?][]TXSP;ST:#B]/SO3SSF3F; M4O6@1)S,!N>XZ[VHO_>]
(D+7_VFVU7-+VCSJ27#?J@^(0-?'8M^WW2>=7R(MRB_YJQ8D'Y+2_RBA66U^TG'E?\G0;O>_!T$B+>F[ATPM+PSF\'!##)H?NES^%U!+ P04 " "Q.&U9 MSRS1#)L)L(%%@ &0
'AL+W=O=7-#3Q(%HB1==?0/L9#*3!28VG$P&B\4^M,B6U C)YK";5K1?OZ>Z M28JR94^RP#[8(IO5=>DZ=:K(BZVJONJ-$(9]R[-"7PXVQI1GHY%.-B+G>JA* M4>#)2E4Y-[BMUB-
=5H*G=E.>C:(@F(YR+HO!U85=NZNN+E1M,EF(NXKI.L]Y MM;L1F=I>#L)!NW OUQM#"Z.KBY*OQ2=A_BCO*MR-.BVIS$6AI2I8)5:7@^OP M[&9,\E;@BQ1;W;MF%,E2J:]T\R&]'
3DD,A$8D@#Q\^#>"NRC!3!C;\:G8/. M)&WL7[?:W)O8$TF>E'A)U$.61SX+ JB\0OZXB[4 MV.J+?S!4]J_KI385\'O8U$[I>/C2JEFSG3)$W$Y0%%H43V(P=7//X73X/P%
ME\>=R^.7M#TX;NRW8/^ILQ*)/>S09[)@B2J*IG2VTFR8 MV0BLY64F:,U3*[M">GBQ^_FG>13.SC7[<'?KJQ\PGJK2P"!G!4J4%%1B0T7] M(CXJY9F!V.)**@X69GQPFTG-
]AM7LAE#40YN0^=W!WDV&O(>60X"LZM.*W: M^_#\S9"]5QD81Q9KJT^L5L(2 NY:SQOMOFLT+U2VL0)\RZM4H\IV;"F8
MU+J&_S50736;PKGS0'4+"\^YA'+,G)ULYP)I'+RK)*1)2.]=_$UMQ8.H?,:S MK+6ZMJ/;@GMN&*_@>&VTX45*<7'=QM%%YQV-#@F$ 234R*(6S"B*:ZU@ND!D MRYV5-
J+*M4]2J:0,:P8SK*Q4(M(:T&8:+0)= % .AX[2+(VW669R80O,^'9 M@!A?5T* Q=$ZV#5,&YZ1?Z$?!Y$?1U.F-YRT8PW@R($V33!E6X%HFXI*R:Y- M! <$6%E7=&4HD,,X2^L1EE6--
!9%S3,O!S72:2D">0'IJ04YU0-9WJ@,!Z[) M\4J1*:@!(-'@M&@-%'6^1%+@8N-LY]=CI;[UE/?BC/S9;.(O%E//[1VZ:J,] M#;7Y3NM31SI =OY X=P/@H#^&E_\OW7RP">J6QAN?
&*M3Y\?'-ZD"E4K!$ M=T>/W?MJ=8E">1-:J(**4V#3U$95N\KJ&'B$1PPE4R()*S4 MTQ44A21) IFR)Z)[5.8*!BR('HGF/(@[;E-@3_2;1PE&5+/+GX+E)$*?! M>T>1QQ^XS
C&!X7?'%!K"QW*-,:Z7))[PI;JH=F9/XYC '[V#."]O[%(&5KM M*+U&W:^)C/X@\]G.+C;[WL(H]5N4)T@= MJ48[2-AMC]I^^2:J1 +QG\%*[O/0%NW33R@'2#Q-4CHGX)7^HV]-
!M5:VS& M;4^/_Q0.+ PL]03S*7O%PB$*:3&,QW3MAZB(ULJZ L/@3)"S6>"/PW O/0UP M?=I)XCQ70I+LJ5T_/7@JFDA2]AJ<-YFQ-W@<#XJ[O[=,$L##VIS.X-@Y:
M!^;#.;D[#SL;#Z@7RUQI:\["@S\#4C:&R@DX9&)51G.HC"F^>/$RL $EE*]: M%X!<:GMY.T)XB=(&=9MQ$ M:UWH>AIS/%+>SUB/Q^-Y[,)0C(>QT-;^L ./A23N?
A6&"R)I3Q:NA0K+4*Q$ M_Z2)RG5HBJ8]%6*-O66XCKA>=_V,,HRXWC@.?"ZQEH.[]M^JKFQ1BM2K"P>4 M(4K(N;1WN)N"QWN%&UFYV^E&OA67%7NP3$(QS'R\M]I6 WUD
M&IGB?:&2VLS&SEP0#X:SR)'P8X.>,]B<&+0T,>R#NJ[7>)%KFM'_/Z[)#\8U M>3$N.SI2<"ZT"I6*0"9'@AM_3W"A/YM._N?@QG;X^8'@'XO'W![>/9.HVM9%L MN"T45:7M]F;R.&#
AI\Z.BN2K*89JN6M7H4].]^O2=6"#/YJB[LVQ>GR1U^ M<=WT_WT'-QO,UI81>D7F/=/+8RMH^?^P89YYGZV>_NL[^T@*^RN/JO;@SK/J MK>KNRKL'O5FXD-D4[SF9^ND]
'UF/*%F%LVH_TQ#:F:S^<3[5108#S+'<&F. M.8+>RNVD.9XM6!P';(JI;3&/O<^6EI]+!?0MH@7I=AW.QZNI_9U-Y^P]@>5+ MBRC[2MSU44HZR*S.6W9CHIQZY=YX](@,84N
)CN@:L@7PI *AVH\ A/LSS#!- M-[,SS%LWZSF#/2>^*,!"9D2:]U)_/5U1*C 4"0()NZ5UI_"P/[$P&)_8-^PP/,?-_,2MG.)G>N+MSU.V MYUG1&8R'\62_#7?3$TQDLQEM'
^GDQ.O.^B=%!G-=:=[_2>S";#1>1&#C8= M1A-W>>R#SZCW:2X7U=I^@-2 :UT8]YG6N^V^<5Z[3WM[!%.2[QJ3,,K'" M5B+N
:O<1T=W8U1I/_0ME3$]MY<;P3%]DP">KY0R[0T9Z+[\7OT74$L#!!0 M (+$X;5E0%3-7KP4 ',. 9 >&PO=V]R:W-H965T)MVNI/NF2,4.^U)70=X/2F.9Z--)YR6JJ MA[)A
B<+J6IJ*B6(]TH1@NG5%>C* C244VY&,QNW=ZSFMW*UE11EN4@M=,:"X%46QQ-[@/ MKQ\2*^\$_N9LK??6Q'HRE_*3??B]N!L$EA"K6&XL L7/BCVRJK) H/&YQQQL M35K%_?
4&_5?G.WR94\T>9?61%Z:\&TP&I& +VE;FO5S_QGI_QA8OEY5V_VZ MDXV# BH(5A_HC\-F2BC:D'J*S@"^L&9(X\$D41,D9O'CK9.SPXA]VDOQS M/]=&H2;^/>9O!Y<,X;
((HET2QO%3?\;GOQYH!/9=BQ90UC3BP+TSE7..A M@)!UT)IDBLO")^N2";?1&^1PN>[97Y,+?DDPM;5!>%Q G:AL;("T MBQDJ"9')+9?NL!72(6LN JPM35_D*BM-
M,T06A6M*A]JUE2LU#S[C+<)SQ[4X756[N@IG+0AE:W&H?91%SEK3*_I MY+AU(Q=C"GR1,Z[F#'P[B-WT^; MTU_(1>+'<4PNNV4P3;ME%/E9TJ_#L1\%";GTWC
$L]CK4#C[G:-9!*TK0T&(9]TH.ABYG-\S",-GMQ@-5AIQS,FCY,B]W\K+[N)NBW M,Q'E;F=6019*UM]VF$4YTU?V=;*;F[JX]Z.PPG.64R2GGXC]=*V]M6RK@I3(M*"28;4?#-\Q^HJ_^[
3Q ^G\?F5]_[HC$=#P6B6CK>+PQ?*=JZZ6=^-:-WG8M.@5]&YV0W@ MS)],(C\(@OWU_[9S#SO/"O>&L];0&6DR=<8PFM(L="]>QH<'X+^=#SQ
M0XRL'UA['Z2A%0FMN33VIUF*"IGZTVGLA]GXY/ZQ3\W1WD4 TWGIKCOVA=H* MT]T)MKO;&]5]=Y'8B7?7,;SYEASU6;$%5(-A-AYTGTF;!R,;=ZV82X-+BEN6 MN!4R905POI!HY?
[!&MC>,V?_ 5!+ P04 " "Q.&U9_)UO? " Z!@ M&0 'AL+W=OJ#XL]X%7L76=W#.'O.[L&2M4$Y<7>RYFSYXQWQIVU M-D\V121XR3-
ENT%*5%R'H8U3S(6MZ0(5[RRTR07QU"Q#6Q@4B0_*LS"JUR_" M7$@5]#I^;6)Z'5U2)A5.#-@RSX79###3ZV[0"+B+CW*9DEL(>YU"+'&*-"LF MAF?
AGB61.2HKM0*#BV[0;UP/6@[O 3\DKNW!&)R3N=9/;O(UZ09U)P@SC,DQ M"'ZM<(A9YHA8QO.6,]@?Z0(/QSOVL??.7N;"XE!G/V5":3>X#"#!A2@S>M3K M+
[CUTW9\LK[F>SW"K_[2R),0,]5]'(ME$OH%T4F8^$+Y_1^U#\#TD IPJPVK<%8:T:K9(M-^%Y*E*/G9P;A?P\++) M!-\,H0+HIT!2IMD7*R%P*D H*YO46 MUI)2B%.CE8SA228*-Y!
(BUR4<#K\/CH#/CZ1(MM8:6O.\;U>588;C0/'0BE= MJAB3$]9&7@5KAE18;A*Q2U+B%]EWY>-VZ-TZ@.4^%8"'SXVLO^&?1)F?!%@ MC C]F.!T,IJ-
7K^X;8[_J!W_A55>]8PE26DU7,Y8(9]'.X0@O$G_(Y%3.S M5HF2#&&6$ PH6@Z,6[LW\Z2],OB5H W;&0.9R3,A+W(RBP:&)0-"*0JY5(#B M;XWN4)I*(1'>K3J%U*
<'>\51^KW$4NSY"A.Y+^3B(>#XR. 2*TA$7*'\EF MBJI\?*D7DI2I7[I;7W? &'!.,DJ6$20);C\AZ_5/NP]C' J0#G$/". &X% MN$T!KP*\IH!? 7Y3H%4!K:9
NP+:37>I4P&=IAZZ%=!5Y5">GSK\$>0PZ%.R M 51:"$4Y4]6D:"F"9:UON!4/$T$QX,Y? -K!N:(JO<&APB,$A:FA!44@6OP MM!B!RXLK< $2#'[&I& 01ZQO1RC2\-/3 M?/<$;XJ)#YZ3@
N4WP+6^ ,=R/$T\=Z?Q;P4^B8].XP^0"MP^BM\W M#][5X./FP>OP2?/@=?CT_W9^]N'<]PK!K=\ 5^FY'WD#=(5>RGEZ.7DW]5@. M0S0PQ.7#$%TC(_C\R6Y97W55=DZQT3G%
[L\I-CZGV.2<8M-SBLW.)+97QUY= MQ]XI]>"':(QF."09 I??"6-7NMHM)5I*0K9!Z^#:L[JMOKG>+@[ESN6:(KE1GQD!("LS+KTR]6C=_MZKG.5@?VKV)K5F?
BF:Q[.W>Y&ULG9?;;N,V$(;O\Q0#+;!H <V2"'^^3C#PWBVX^*K+! 5O%4E MDW.O4&ISZ_LR*; B$,B^>V;YG M$<]XK4K*\%F K*N*B._W6/+=W N0!
<<+S0ME.OQXMB$YKE#]M7D6NN5W*BFM MD$G*&0C,YMXBO+T/Q\; COB;XDX>/8.9RIKSKZ;QE,Z]P!!AB8DR$D3_;$! MR]H:8YOK:C7^32&Q\][]<]V\GHR:R+Q@9?
_T%05_8CLA M"YCP4MIOV#5CQR,/DEHJ7K7&FJ"BK/DE;VT@C@RFP0F#J#6(+'?CR%(^$D7B MF> [$&:T5C,/=JK66L-19K*R4D*_I=I.Q4\ZOBD*>!4DI2R'A1"$Y:CCKB1<
MPJH@)5D7\$N]402^++%:H_AWYBOMV@CX2>OFOG$3G7!S!4O.5"'A$TLQ_=': MU\@==[3GOH^<@BO<#.$J&$ 41".0!1$H';)773BNK.S5"=F^, Q@_1V>6$JW M-*U)V3?
Y1G34+VHVUJW+XE"04D) MKR@J"3SKRV4?M%OVL19&0Q5XH0J!"%630#0)!!U^9==^EX,!,*Z[F[T63C1' M1A,4$@A+(:5"O^&Z-;BH>$HSJC6X (?/TRC*+A[J4N$,%B/+T-0+3XYX-
M1 MX1W\1*39^F1Z/#I[>D,"*P2-3/ \"W M1(/K-T0!9X[@C[O@CYU1^H-4V!=;MJ4/N\I!,>DH)DZ]5ZK*7@RWV7+X.!P MKP4\%!0S'2Q,:G-(7OS9), ^!=MVA73M|'"?V:#W"
(N5Z!:5]T&Y!)6IT<$T[MKJD[<9Q=OH/-+9J14KK@;CJX&Z>.!3 K61_IO7EUFQ\V9]1N3@=3&!QNBN!= MJ33G#F7D1,3.B)Y)9WATCX7O3N@90K?PN:2&T0$Q-;P+SF?G;/O^'
M"RQT7S6GTK;?T?3K?Z24[_J+*K4.2V M?160\)JILCK>KL:>=%4AH?A38&])"$G3$*)F38-AM<:230U:]-0?&/KQ#57 MNNJTCX6N\U&8 ?I]QKG:-XR#[I]#_!]02P,$% @
L3AM6;$K3;2M'0 M %T !D !X;"]W;W)K&ULO5QM]9Z3]5KQYZNJ(A.Y (3#P?,O$CA_?KKIQO 8,CA MV,E>7=5N3)$S0*/1+T^_-\^VNISO3:F4;]MBK+"[LFZ:;8OGCZMT[79Z'IJ
MMZ:D7Y:VVNB&_JQ63^MM973&+VV*I_/S\ZNG&YV73UY]R]]]J%Y]:]NFR$OS MH5)UN]GH:O?:%/;QNR>S)_Z+C_EJW>"+IZ^^W>J5N3?-I^V'BOYZ&D;)\HTI MZ]R6JC++
[Y[X$9\50F8BJ_UXU^]6UE'U6%IVDT?."E\MM$7%YB5^Z;BG[-Z;WFU6V:VK9L M\G*E/M@B3W-33]1B\W_LU(G_\O3;IPU-AY>>IF[HUS+T_C0S]4/MFS6M7I3 M9B;KO_^4R
RTSCVMK^>C]Z;[51=G$_4_'Q^.3+>15C[!8]W<6P\D41EE^H^ M7Y7Y,D]UV:@!EJC_NEW4344B]-]#?)I!+H>G@2$ZJ]+SJ_.7(XNX#(NX'O]U6M=YS66\ %CEXV&L
\1^0>&43^MC5KFI2[37!>] MIF\-:613*UUFI%"IW6QUN0.G2MN8.EGK!Z,6QI2*5KK5EW'_CC[.7IE(GNT=:6NLUXB*&U)#0@9KF3%Y3F*>Y!P69AJB!P MZNL6AZ'RDH2E9;-3J\8JV
\U.S_[!_/MMFKRM#*T!2;Z:%9MP=Q.[L_^ P], MW)A$>K&;8,"=RBPX3 .G19O1\HJ"/HM-9MM&PRZM;; +*LOKM+!U2QM)=O/7 M-@>EB]U7LSWQ;)_>3T=8[/FU,$5N'F@DO..)$
FQ]%75HV>C,^.W=5BP*EI= M1E33-PDM4&FUU^6%8NAVCK\CVUO[O&Q(+#9J2_^U6>U?,=GTN!S*7M+V1QY?N3VA:F@&E(-'&>^%S0=&E;52SLNJ'5G*K'=9ZN0?
+$K\EN\])1N-$E MN34,-U&E24U=P]:0-&ST9^,([G8P$,O[O,GK@EPLS355_VE;5:]M6V0)W"[> MK$>TLMF7?MD.HB^UY2]M*0U;* AFAV?(/%)I"R0B-GURUK=EF5+
M8WPT6ULUBB;P(O_O"ILH,]4I/;(SNE(&'D%]3UP1%9NQBEU,Z*&"?@C4L0C> M@^]YDSNA>O-;NM;ERB1$ _&)X8&7TOLW=UY(0<0/NJ+]F=^(D]'K.VS8&V?
MC9K)3\1ZVMLW=9-O8(V&#.WO&X%E4PQ*$.XCHHN=A,3DS2YA%D$IO8K7D< % M*4M-U1 R4R;,QH:[)@RV==9XIMH##8\'*1<\)Q5%KA=Y M$3:#9:'3;SQ,
,+$@(IC[\E,&=`C57=4FH=(,K\1+*UIL*R%1C(= WK_0\>2 MR$P) ;0/Q]D",T3:5MM2+PKS4JWM([U[ML83ABPT7P6O9=:.@8L;5UCN^G/6Q"7FQ3$X1>_,(;9NDC M27AO'4F\#F_?
J^;('M"%&FG\ 9#,%*T%LY/DGH,JPPF +@76(DW9%W];= M!).P*VR5'W31\B8^ZJH"?=$^3Y;/0UYYGA2!;4V]&M6S MC()B,DFI)?X=0T6C@pP-S4P=,\C5O+]_[#_E4=[0$&4-
X*9A&S*3%]]9M:OSJTD@@'EWYW:K%K-YQS&#J>KX=;PYZ+T3O=T6N7?>%!^= MU8W9JHW-#!"&?\I0?(SL/]/&X-J6(%04X M3N7O0/EI369. X'62"9#*)S
1/(W&1B$K7 ML"GT$&%GVEW3 :M)'U/&7+8%A<+8=O!;@=_U"T74$@G+'1Y)@@(&1YC2ZP 2 M\6,P> P@@#WMHLA7VBN]9P*/,J$HE1A'P:/ #N:L3AWLH,5, 'lL"GN\]WO" MOX-
'7SE77U""V1$!)JK>WR!Z:F7[!2.S#!F"JZ#*;@>-04_.^/TWAFGW9A M&!UBV! '4%9!%-:61@BBPH+OCV;)11K.0F_AU4FU&F,^A$8?G9^VI<@ MLHWDB7(*],E1'9A;'[4(X+GP:
(H\I_A"2=M1HUTGK$ PSPLAE>8XP4:R(ZMS M$,YQC^N4=_LI>JHG1.UL5-:DP:O;9'!+6Y)T6G*B6JWEME#?K2.4/QQ?O3C M#!>^U!Y0DEKZ!6#U,<(X&8C+8,BN0hC$ZOP8^6>
FVO(_>@SE+WA"<(H:. MR-U-D+N;4;F[-RN&'N\ZG#\D>;][D!Y;!$ X"",0D+22>+)H:>?(>2<0C=+# M*, 9#SIH];6,WN-T /5W9-T(J?Y&^!NI,_7W);DF@*#'-44$SM+R,]V F4ES

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w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

WY,XS2;&6HC-5:>316N2X.R2;4@JWUDQGF A3_EC M)]MP@I>%*(D[5K?K=!),4V,Z+J[=\^F8Y2*F*;GG*,N3!/,?[TG,=A/#-)XO M?*2/:Z$N=*;C#7XD-O=FT%_5+0;RMP2H'35C H!8.V M@F$I&+85C$K!J+##_OLKOOP9%G@ZYFR'N!HM:>J@<%"AEM\Y3979YX++=ZG4 MB>E\;W+$5FA.'U.ZHA%.!;J.(I:G@J:/Z)[%-*
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
MK@E>$JX&R/=7C(GG$[6;N-IC/_T?4$L#!!0 (+$X;5G2B#SR#@0 &42 M 9 >&PO=V]R:W-H965T?XVN=> M;#P^4_:51P@)\"V)"9\8D1#'D6GR($()Y/?TB(A\LJLH/)CPS!,",E ML>E8EF&.!IDD#V_1'%]#PQ;./2\!X?(J$:S.GX M"]HB\2'XPN3=V:I$N($$8XI 0SM)\:#/=KX"I\!/F)TYE?70(UD1^E7=;,) M)X:E D(Q"H12@/+OA&8HCI60#..?
0M,HNU3$Z^N+^C(;NQS+#G(TH_$G'(IH M8@P,$*(]3&/QGI[7J!A/7^D%-.;9+S@76_L 0 6!+FT) 8+0;TOP"H+7EN 7!+_M+ T*PJ!M#\." M,,S2(?>8J%S?"B:?8LD3TVV>XX#NP18? M"-[C !(!'H* ID1@<@ O-,8!1AR\G2,!<>R'Q0JQA,2H1BX4O)R]?D9)3O$ MOLBF#]LY>/OF#KQ1R+\CFG)(0CXVA1RX"M\,BD$^YH-T7AFD"YXI$1$'"Q*B M4,-?-
_.'#7Q33G@YZ\YEUA^=1L$M.MX#U_H#.);3T\0S:Z;_E9)&^KR9_@R9 MI-NOTA?M@W]:+F-4^O.#L:0!$B7Q+F6EVFI MS=QI.K!=>VR>KI.S#G)ZPUX%-:^CI)+;NT4M-
"AGZ%102YV68WFWJ%7C1.BG M&>B\;Q7YYM=[N_&S7_K9;^LG(N%_V)E+]:]&XKF^7[&$#JI(/J^#-)XOZBC; M[CN#BIL:5-WSE095]WS=KWE5'^&F#KH-
Z\8(KS3":S1BPWFJYEVM(\4:(G=R MQ^UD=E?K00_4E:7HGZM7M[9?K]2H#,=RAO85N7-48?9]L"JE.A" M)^8.*]6^U*"<@5-
Y<6@ZM%R_7S&X<=9^UN".Q'*#S:MOS@2Q0W9@P4'VV9CO M?\O6\DSD(3L*J+0_VJ.5K6E?VZ--?N3Q0SX_@)%OKP,F',1H+[NR[GU9)2P_ MU,AO!#UF7[P[*N3WA^&O0K@'C7.
T[&IU4XG 9)PW[>>N6C,!2-78B+:FJ*;]V4U5K=^>GV]F M-V*1;]ZLUF*Y^Y^OJW*15[LORV_GFW4I\NM#H\7\?'!Q,3E?Y,7R[,.DW-E!-EO-
BZ6(2F6S72SR\M'^FGMT_D13?;JK]$^/E?U;^;):?=]_ M85^_/[O8;Y&8BUFU]_+=/[?BLYC/]])N._Y5HVX;'C^^UXW#F]^]F2_Y M1GQ>S?^GN*YNWI]=GBG7XFN^G5?)ZH!,F6TW
MU6I1-]YMP:)8WOV;_ZR_$4<-U-$S#09U@\&I#89U@^&I#49U@]&I#<9U@_&I M#29U@\FI#:9U@^FI#2[K!I>G-KBJ&UP];C!^;L==W.^YBU/[4!]V]I.]_6PO M]
[M;/7E_J_<[7#UYCZOWNUQ]LL^?W;#[G:Z>O-?5^]VNGKS?U?L=KS[9\Y/G MFMSO>O7D?:_>[WSUR=Y_]K?P?N\/#GO__X7_C!::'F5?WA7KGXHY?[U.V__ MX##D'-
KO!HEBN1\=TZK<_6^Q:U=]2(MOR^)K,[.O:MSF>U[=S9@V=L5?%7R^IFH^C+:W'=T=Z3 MMQ^^U#Z4M[]ZJ7WRPO8/),#Y[AO]\-T>W'^W/PVDXL=U^491+_Y0!A>#8<<& M?
98W]_-=\Z'Z;'--WMP07]XH%\\WU^7-G>U\M_&C0_-!1W/CE-ZOGFUNOM![MOMPUGSS;W#IEX^]Z5SN:VZO&N_)_+FFIA)WWMZPJ_, MX/+9YMD+H\WVVT/O \GH-7RH%<.#-
^Q7*_[I[5ZGV)58;/ZW8R,_W:&C;G3_ MZ?_M9IW/Q/NSW\KM&?"G7=\0G,8W$=!(S2,PD,8O$;!)S2,P=/QGQN\9[LDN?Q (2"TDL M(K&8Q!(22TDL@[#6>#]Y&.\GTO$^$N5L-
[+GWX2R^JJ4JU_YO/HE&^^E7-_Q MGL0T$M-)S" QD\0L$K-)S"$Q]PY3!T<#_L6;B\&C\9[LTB>Q@,1"$HM(+":Q MA,12$LL@K#7>3Q_&^ZETO/^\6BQ62V53K6;?E=M\ONT\>?
I)BO0=Y4E,(S&= MQ P2,TG,(C&;Q!P2K Y4,= MN)1_[M]^F17SXM_Y_K+&KH(@U?H6!!+32$PG,8/$3!*S M2,R^[)Y,>3*?
XI"]NB3FD9A/8@&)A206D5A,8@F)I22605AKQ+]Z&/&OY"=Q MEU7QM^MBOCU1_ND(S/R<[,R]F-DB^OE6MQ*^:K M]>&:&_%S+98;T7F]C=SL.R*CFH9J.JH9J&:BFH5J-
JHYJ.:BFH=]/JH%]!:B M6H1]<:T='PX.!AU'@PG:;8IJ&:6U2\%1;DN57X1SF)S9# I*L=Q)/A?*^N$T M;6<5D'*]JP"I::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6UJC,^ZC MQR6 [#-
%M8S2VB5@T)2 @7RV9C9;;?<)K'7^*_\R%\]J5/+9K-R*Z_L#@LY* M(%5[5P)2TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6DUEI"%UWG
MFE*TVXS2VL6@R>:JTG37AT3<%H=;UJQN19G/Y\J7[?4WT7EYIESJ70#02"ZJ MZ:AFH)I9:ZT?TZN.'U,+[=9&-0?57%3S4,U'M0#50E2+4"U&M0354E3+**U= M)K\[?
Z>0+*K=4JQSHN'3_Z;PSF"574C2F6V+%V4>[#5 M//5-1&MBB:.HEM79\ M^GDXN;KL^"1/=IM16GL@;]*UJCQ>^W"2MQ3SO!+7TILJ$]CBIV?(C]WO%#M
M>)TFW[C>HRV:B44U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R2FL/ M[DV45I5G:?UB+C;5:BF_18X2'S)6?ZE@A4TU!-K[7'=V^<7K3^J.WC:0/=!A/5+%2S4+8VYI
M@$:$44U#-1W5#%0S4^IL$\>ZA;.BOUWU)#W=YEDXH29W>8S^I::BFHYJ! M:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ"-BFJ9936KA%-.'DP?I4))70)
M8%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+**U=,9K$ M\T">;6E)%WT;M\H'EH5--1S4 U$]4L5+-K[3A#-1I+#]>/;B?LH+VZJ.:A MFH]J
:J%]!:A6HQJ"-JEJ)916KLP-"H@3P.[:VJ[4:QEY4HEXP3&I)&-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U% MM8S2VB6C25(/+E]E]@D-
5Z.:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^]@6H%]): MA&HQJB6HEJ):1FGMBM&$JP?R%8W[+I,FYWJ7"C15C6HZJAFH9J*:A6HVJCFH MYJ*:AVH^]@6H%J):5&N/+A@TS0;44U3)*:Y6
89.6'LK3TNFOI5AM M%$OD\'I&\;S/TMDE.=:W *":AFHZJAFH9J*:A6HVJCFHYJ*:AVH^]@6H%]): MA&HQJB6HEJ):1FGM0M%DJ8?]:\PN#=%X-:IJ*:CFH%])JI9J&:CFH-J+JIY
MJ.:C6H!J(:I%J!:C6H)J*:IEE-:N&(.F8LA78YO53/?JVU:W$KYJOUX1;? M]XNP==8+-%R-:AJJZ:AFH])):M:P8\W98<FXZWJZK8#_WI;/?/3&P4KU@4^^7;I+--:(H:
MU314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)*:Q>,)FV] M>_@:LTTCM&*0FH9J.JH9J&:BFH5J-JHYJ.:BFH=]/JH%]!:B6H1],:HEJ):B
M6D9I[8K19*^)RX,W6NV"4U>HYJ&:CJJ&:AF#I^NOMVYQ)>%=FNCFH-J+JIY MJ.:C6H!J(:I%J!:C6H)J*:IEE-8N!4VH>B@/5:=K,:O*[4*);O)RL>MG6^V.
M).:;/Q1[.7LCGW)"L]2HIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%]%: MC&H)JJ6HEE%:NVHTB>OA]%6FG-# -:IIJ*:CFH%])JI9J&:CFH-J+JIYJ.:C M6H!J(:I%J!:C6H)J*:IEE-
:N&$W@>BA?NMK>;+;B^OAV37?W;WKA?DURM7?% M0 /7J*:CFH%])JI9J&:CFE-KQW=_&JK#R638GEUST5X]5/-1+4"U$-4B5(M1 M+4&U%-4R2FO7@B9*/91'J3\?W[#O-
I_O"D/GV(\FJ%%-0S4=U0Q4,U'-0C4; MU9Q:.SZU,GIR7L5%^_10S4>U -5"5(M0+4:U!-525,LHK37RCYH$]4B>H(X. M-]%0%GGY753*+%\753XO_GVX:5]7"9!S?4L
JFFHIJ.:@6HFJEFH9J.:4VO' M)6!<+_G]J R@_7JHYJ-:@&HAJD6H%J-:@FHIJF64UBX#33YZ)%)KNN^]E.1< M[S* !J-134U_-5"5(M0+:XU^9V9$K3/%-4R M2FN7@$%3
N2!YX_S*Bl*)B;*XO^9(>LF1'.U="-#$,ZKJ&:@FHEJ M%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:6U"T83BQX-7^.2HQ&:BT8U M#=5T5#-0S40U"!5L5'-0S44U#!5\5
M0+42U"-5B5$M0+46UC-+:%:/)1>\> MR@XQ$O&O:5&*:Z5:*>O\5V=UD J]JP.I::BFHYJ!:B:J6:AFHYJ#:BZJ>:CF MHUJ :B&J1:@6UUKK_E\=YY\2M-<4U3)*:X_[3;IY)$\WUU-
+TGDD-,N,:AJJ MZ:AFH])A:JV:CFH)J+:AZJ^:@6H%](:A&JQ:B6H%]*:AFEM:M#$W@>35YE M'@D-.Z.:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^]@6H%]):A&HQJB6HEJ):1FGM
MBM&$G4?RY:5/F4="@\VHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%]%: M7&NM,,NXRP/1 MB9CG^P.*=?[K4"NZRH.4$U#-1W5#%0S4/[,PTN M.Z8U?+3;
-7"4]]$A'8;HUJ":BFJ9936'M2;>/-8'F^.ZL%\?*@?!C@RZKS MU('?G?32_C&KAB>\A0GN-42TY\3VD M:*\9I;5'\29S/)8OQ?SYT^?/BCE??ND>%W.P]>J.)8U3347Q*ZS$+#=
[UPLTO8QJ.JH9XZC=K)ZNCCH-8$^W60C4;U1Q42%Y9;I!-'D5M\Z@6H:JNFH9J":B6H6JMFH4Z:]U=EL@((E]U MA1/0:F-42U
M1;6,TMHEH,DB3U[((O^9()K<[ET2T&PRJNFH9J":B6H6JMFH MYJ":BVI>K;4N'NL*HJ&!]J63IZFCKO>0X3V&J-:TO$>AEU!-+37C-+:H_B@ M&
<7E<6)/B+_^Y7*@3O^^4:*;O%SLNMI6Q2R?*[]9[N\GW9=4WD7OP1Q-%:.: MCFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%]%:C&H))J6HEE%:NWPT.>;)]ZR=
M/$&3S*BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:6H5J,.@FJI:B645][M8C1)YMU#V0'"<<6H+T-52C$3Q:VX[BP54JYWJ2 U#=7T6GLZ#_#H -1 NS51 MS4(U&]4<5'-1S4,U']4"5
M1+4*U&-425$M1+:.T=A5HTLD3>3K9+^9B4ZUV M!PFR*((?_F_RY7:A?,[++ZME7@GY&08TE8QJ M&JKJ&:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:6UJT6379Y,
M7^4, YIB1C4-U714,U#-1#4+U6Q4SHCEF2FN/_$V.>2)-O?6[SY'JOFH%J!:B&H1JL6HEM3:Y.42@ :3*:U5 J9-,'DJ#R9[MJVJ[4>QE),)L@\55_C#,,4C3"CFH9J.JH9J&:B MFH5J-
JHYJ.:BFH=]/JH%J!:B6H1],:HEJ):B6D9I[8HQ:"J&/#3=-\,@YWJ7 M"C0@76O'AXE=1XDZVJN!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ M9936+@)-]'DJ7\(YO2GFZUSQO?
6N$)0GS#"AF6=4TU!-1S4#U4Q4LU#-1C4' MU5Q4\U#-1[4 U4)4BU M1K4$U5)4RRBM72]:S//NX6O,,(W0BD%]&JKIJ&:@
MFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:6U*T:3CYI*\]'U_;4E M"W7*@=[% D'ZH$LKU5GX#/CG4NTB@,6E4TU'-0#43U2Q4LU'-036WUHXG2\9/ MITH\M%,?
U0)4"U$M0K48U1)42U$MHI3VZ-^$I*?RD'2Z_7(_MZ2)6S%?K0^E MX.-I\TQH:!K5-%334?$:\TR7:+ :U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40
MU2)4BU$M0;44U3)*:U>,)EA]*5\ANF],3L[U+A5HHAK5=%0S4,U$-0O5;%1S M4,U%-0_5?%0+4"U$M0C58E1+4"V]?+IL>%=P-^MXW>.E9=KC^Z 9W^4Q:'MY
M*S95:\Y(^3\E78M956X7CY:3WORAV,O9&^GLDKR_W@4 S4FCFHYJ!J]9J&:A MFHUJ#JJYJ.:AFH[] :J%]!:A6HQJ":JEJ)916KN6-&GJRU=92/H2#56CFH9J M.JH9J&:BFH5J-
JHYJ.:BFH=]/JH%]!:B6H1],:HEJ):B6D9I[8K1A*IW#^5' M'Y78N96R6BJK'TM1;FZ*=6>-D#]]:P2I::BFHYJ!:B:J6:AFHYI3:^K@Z(C[MXLW%]'U<[J*=>]CFHUJ
:B&J1:@6HUJ":BFJ991V-_B?;VZ$]+2\RC^\6XCR MF_@LYO.-,MN'G_>=*#VKE.+KKCBH;S\.SLZ?/.^H;UVUXWE/?1MT/1^J;^/# M\^=-MQ_>K?-OPL_+:\5RH\S%U]TF7+S9!P/+XMO-
PQ?5:KW])3]3OJRJ:K4X M/+P1^;4HlR_8_?_7U;JZ_V+?P8]5^?WP-C_\/U!+ P04 " "Q.&U9T>"U MX'0$ P(0 &0 'AL+W=OS&MN5]!PF3 YY!JLlLN$B8 MTKMB:\M,
%L704EL>XXSMA,6I58P+8[=B6#*]RJ.4K@31.Z3A(GG6XCY<6:Y MULN!^VB]4_D!.YAF; L/H!ZS.Z'W])JRCA)(9<13(F SLSZY-Z%7!!0M_H[@ M*$^V27XI2\Y_Y#M?
US/+R4<$,:Q4CF#ZXP!SB..SKBRRA@W;Q^]>'[] =4&CG+?BL2S^DV/9UK^VR&HO M%4^J8*W]*$K+3_94"7$2X [?"?"] . 2 +*\%\'C-X)&%8!PTM[&%4!Q:7; MY47PE&F6#
5_AWEK3\HU"_2):ZQ6E^8WRH(0^&^DX%7R+5KGKZ9;;AO$,.O7?,+GG^Y:]^_Z3;DJX)$_MLQP-L2..P&YNGH1F9L!3-+
MYQL)X@!6\,M/[MCYO4MK3!C%A(5(L)8KP]]5H8D>/&8;H6]ZL@&07188H_M: M@ FC)6Q

TBXT]'5CXDG6_2ZS>/Y\1QWF33^=MFKM/1CAH'U%<[M)%A+.]=IIO..4;U%%(,N&O1-?$F2,>(TWWH6/C"GE5)#39.)W)IV.AMU9QSRLWB(BT=HB-@6I:ZRL M@C_5#@29Z]F-T)-
T<])!+451:125%F+1VIXTY:@[1$\ZJ#4J*HVBTD(L6MN; MIIIUS>7LN>*S.&]C4"M92O:V0P78G7;UKBI9UUS0;N(TBC9)^9DA%K0HM(H M*BW$HK7-:$I?
=X*>C%!K8%0:1:6%6+2V-TT=[!H+NN">/[-81=]2#(2V2;%M MYY<_9DQO0T]:ZYWD$6?@E).J^L]|/6M"+72Q:&WAFU+7-=>Z"_9T/D-A5]=S
M5!I%I858M/;Z4E,Z>PYVAO)0ZV=4&D6EA5BTMC=-_>P9:\"+,Y09T]L0MRM# MO-[@ MRM\2+)C81]DD,6PTTAE,]*1/E,OSY8[B6;'^O.1*\;38W %;@\@;Z/,;SM7+
M3MY!_2.)X']02P,$% @ L3AM67#BIA_& @ 7 < !D !X;"]W;W)K M&ULK55=;YLP%/TK%JVJ5EH+@82D;8+4IINVAVE1 MTVX/TQX\T,TI*YQH;-=F,AJ+ M2G-
6P$P25>4YE2^WP,5ZXO2(]_LMI1RX(JF K^@R4ZFS@CAR20THKK>[^#(V>@XRQ.GHEG):Q$#FMF6F(B% 856Y/0.-&5< MG9%S,L?>22H.1*1D]&D+"$?
G[&1%"A"BX1\TQE(,JVD1"RY40HPPSEYG-^1 MT^,SHO-/=OR\62@ML6U_=1E05^QW5S1'^4J5-(:) M@V=5@5R!$YT<]4+ONLN,_Y3LE3E!:TYP*'NT,21A$D^]D.KD:.3WAM?6&)&F
M+(:_;YS1!>-.OV"#J$K:3D1..:ORSC:I2X>VM+F?5E%P.1R[JVWQ^S'^T&MC M7FGJMYKZ[]*$U&+<8S'EQ/B&6CIIUMD&6Q3Z0<_;X;D?A#%!-]%!2W1PD*AM
MO"Y&@[UBX6C7N/V8P!]T\PE;/N%!/@!"4[[%)SI2(@LKI#:#\H"']'.XS< MK;O/_`>^4KG$9B(<4H1Y%T,4).N[O)YH4=KK<"$T7JYVF.'O#Z0)P/U4"+V9 MF!NV_:%&?P!02P,$% @
L3AM62HZ] Q6 P ?0X !D !X;"]W;W)K M&ULO5==3]LP%/TK5H8FD(!\]8.R-M(H0T."]:)C M>T![<)/;UL*)@^VT\.]GNR%-,@HZGAI[>2>XW.OCQV[OV3\7LP!)'],:2(&
MUES*]-2V13B'&(MCED*BWDP9C[%473ZS1 9CD+?IB*N>7;!$)(9$ M$)8@#M.!]=4]';HM#3 1OP@L1:F-="H3QNYUYS(:6(Y6!!1"]2FP^EO $"C5 M3$K'0TYJ%6-J8+G]S'YADE?)3+"
(:._223G ^O$0A%,<4;E#5M^ASRAMN8+ M&17F%RWS6,="828DBW.P4A"39/6/'_-"E JT7J EP.\MP+\'.";1%?*3%KG M6.*@S]D2<1VMV'3#U,;@538DT=,XEERI)0HG@S-.
<1("&AO/#%FCL_1_MX! MVD,D03_G+!,J0O1MJ<3J(>TP%W:V$N:](FP,Z3'RG4/D.5ZK!CYLAI]#]."N M@?M5N*U*5-
3)*^KD&3[_-3EO+L'=E8*B2PFQ^%.7]F]<5OTX>M6>BA2',+#4 MLA3 %V %GS^Y'>=+71%V1%8IB5^4Q&]B#\;91#*):5V2*V3'(/5.L@AZ7M]>
ME*5OAK36(15!K4)0]U'0%0BA]H4PBS.*)41J.:NT0X+UAE&G,1HC$*6<+ MB,WJO[N&> *\UL"-A-L:>$=DE=R[1>[=#UK3W5V69$=DE9*<%"4Y>?>:/MDP MG]]]X<_-
$,^MlV>O$-1K%'21\83(C(.9D2EYU.UF?S82;CL9.R*KY.XZZX^S M\T$.S0?:455VQ58M2^G,XK[;I3FTXL'>"YO6Q;SB4W=]0' ;/[;!%9Z4YZ/!
MH,U$6_%_S@#N.M#@.M_E$4;CQM;EV5';-6RK(\B;O-9I-&BK8VC3^DSGLMO MI*^7C^J4VZ6[@;Z876,^(XE %*:*V3GNJE7 5W>=54>RU%P7)DRJRX=ISM7]
M$+@.4.^GC,GGCKZ!%#?.X"]02P,$% @ L3AM68WH;&ULK57+;MLP$/P50@V*!&BBE^4Z MKBS #Q3IH8 1)^VAZ(&6UA81BE1)RH[_OB0E"W[(1@^]2%QR9SBS(E?QEHLW
MF0,H]%Y0)D=.KE0Y=%V9YE!@^UEB"5-.?Y),Y2-GX* ,5KBBZIEOGZ#Q M8P6FG$K[1-LFUW-06DG%BP:L%12$U6_\WM3A .#W+@""!A#*R!L *$U6BNS MMF98X206?
(N$R=9L9F!K8]':#6'F*RZ4T*M$XU0RP12S%-#"'IDI+TK.@"F) M;F>@,*'R#MVCA3X[644!\14:IRFO3,(<[_!2S]VCU\4,W=[24Q MRV3L*JW/[.*FC99)K26XHX4!Y0,*O4\H\
()>!WQZ'3Z#5,-|"P^/X:ZN2EN: MH"U-8/G"2W*NN?XU7DHE]"'\W>6S)NYU$YN+.90E3F'DZ)LG06S 23Y^\/O> MER[7_XGLJ 9A6X/P&GOR(G &^JXU[LO:?9?
EFJ=O>4SKV"21_QB[FT,GYSF# MP&|SC@3V6H&|]P*G C*B4(I%ABC!2T*)VQ]IJVFB@[V#4WGG*?Z@6UW4JHNN MEX\K3+O41.?
5Z@U.Y)SG#,+'$SWNP0D74N:B!FYFED!71IBM7OJHE MD,*!*N;C($C\BE#N9:D;F\DL%8UFE,-,(M54%9%_;H&)S=@+O>W '5V5V@[X M65J3%%D0!1/!?M!"EV/O
MTD,%+$G#])W8?(+.S\CRY8(I]T6;+C;P4-XH+:H.;!14E+=_\M3E80<0Q@< MN /@UP*B#A YHZTR9VM*-,E2*39(VFC#9ALN-PYMW%!N=W&NI9FE!]>S6\((MSP'-
W9&9B*H6'+A6Z'0*FE"FSM![-#=GIV@8(+%$-WDN&RCO%TH6E%%-09F(MA_D4G9Z@$^. MPZ>0&WCHX-%SN&\2TV<']]G!CB\Z).+)26YBC^&K+:<7QI!LJVW;T:)V!6LA
MM"E_KEF:!PJD#3#S2R'TMF-K8/_D97\!4$L#!!0 (+$X;5E=D!&2%00 M (D3 9 >&PO=V]R:W-H965T3R=.-U1]HVO 01ZR;."SZRU$.6=;?<X#3GF UI"(9^DE.58R"9; MV;QD@!-
ME&>VYSB!G6-26.%4WWMFX91N1$8*>&:(;_(P0+$U_*9R9;=4!*20\$)+1"#=&;=NW>1.U(&NL,-%S2OC64[)T7U M'[_40AP9>/X% Z\V\$X-@@L&?FW@GQBXDPL&P]I@)6I7-
$Z1%C@<,KH#C'5 M6]+4A1936TOW2:'6?2&8?$JDG0@_E"P(,4*?0(I'[]0&"2\7=36TB\ZF3' M->]A0GD74+?HB19BS=O10))VJ26TVKFYNWG]N 9@0LH!\AW?D6>XPW1UT6$
M;G[NFM?PQ*Q2_N>/);QV\R,R+();3LW:^%K ML/^#;_'7)]D!/0K(^=]=RU'1AMTTE3#N>)ECF%DR(W!@6[!"_=? Z?)YWB-MZ U'P=3>'@O7T$,T,U"L&0#" M24(46*[10V-G&LU[
G6TG#<:#@VNAP1'M--(9!,9*"VG]:O2SHCY]]]5<%< MIVC?. /W9&_U-&)+ETFCR\2H2Y70,X*7)"/BM4N0"A Y M-E1Z@K4DN6TDN7UCNYV\9X@7P+K?-,92=
<&2Y^PJ"=82T7.11O3J\50XWK M2:5%?M+:41W6P:PS'9P65B6N+LXW.7$WV[Q32"+M:J/=L[[N._CE)87T- MV]:(.VCD&36ZSRD3Y'1^LWY-
2(]8^JM[3]/U&QA[F'$2G5MYY41.,SC.;>?"K MPZDG6ENJ0RGO&FO<4'] *XT::>3G:8:+N#N<_#.))AWK/SK5$_T>9[A[J M=-=/@OVJ"]:6YY#U>Z:2^X?*!EJ
M0O!FV/1:H_=%JW2QC\XN3SE%*Q;Z@!FM.W\#]0 M2P,$% @ L3AM67)GB?@F P V H !D !X;"]W;W)K&ULK99M;]HP$,>_BI554R>-Y@$(T$&D%C1M4]NATFZ:IKTPR0%6
MG3BS'6B_8IZHD;72.KVT;16N M(*;J0J20X)>%D#'5V)5+6Z42:)2+8FY[CN/;.66)0$SL:D,AB+3G"4PE41E M<4SE\S5PL1E9KK4=N&/+E38#=C!,Z1)FH!_2J<2>75F)6
R)8B(A$8AC$]] M'+N.$>0SOC+8]D)TV,2AS(1Y-VW,TLAP3$7 (M3%!\;6&,7!N+&$WPK:I;"=@Q:1Y5@3]FDPE&)#]D!- MUDPCSTVN1AJ6F&6<:8E?&>IT\"4%235+EN0&,!OD?
*:_J[>D1:9X9Z),@Y$ M+,@MU9EDFH$RO6+N#:-SQHO!%GF83U]N8VY1+D50GROG%]YT-=$OZ3L;V4 MM*N4M)NL!]^!2@))9'8-IAOB.0W M+T+33GA^8E+Z3/^1W3MU>(?
,#L4GN+]%D37D&)&(J%%FBZS![1Y@M__! -09R(F:_PNPW8D[W2/"N M+%:.EW?E@Z+_]RISE$@><=]U3<%%]I8]>WYWH(T$_#[0@B][9CB MIBIF@]]02P,$% @ L3AM6;SCA'J8 @
;P@ !D !X;"]W;W)K&ULM59=;]HP%/TK5C9-K;21D%"H6(A$::M56C74KMM# MM0>3W!"K_LAL ^V_G^V$#*8T$Q/C@=C./286VZB'!?PCLE\[[4;+ BN8"?]=9+J8>.
<>RB#'*ZKOQ.83U'K.+%\JJ'+_:%/% M#D8>2E=*"U:#30:,\J)GVL?=@"&IQT0UH#P3\@%4!4 R(GM,K,R;K&&B>O M%!LD:;1ALPWGC4,;-83;5;S7TKPE!J>3.Z!80X;F6.H7]%5BKK
S6*&32]"8 M4'6*/]"'^TMT\O8T]K69TR+]M.:_J/C#5_C[Z%9P72ATQ3/(]O&^R;5).-PF M?!%V$MYBV4-1_ST*@S!JR6?6#;^&10^%YVWPO72BQK_(\46'^_?XV<2B&PU.
M_6@SKB(>M!/;TSM6)4YAXIGCJ"NP4O>O>D/@X]MJH]$M?NTQ(^/@Q&^R;5).-PF M?!%V$MYBV4-1_ST*@S!JR6?6#;^&10^%YVWPO72BQK_(\46'^_?XV<2B&PU.
MF&9KS%-0;2([D8>*'/WM%,3I^SMW.@.Y=*5.H=2>L>IZ;T;;:CIU1<3_'5Z5 M8G-E+HE92PJY@0:]D=EKLBIO54>+TE6(A="FWKAF8;X(0-H \SX70F\[=H+F M&R/Y!5!+ P04 "
"Q.&U9JY/KGQ$$ ",&P &0 'AL+W=O"R&V:4O%X PG?3RS7>JKXQM8;5538TW%.UW /ZGM^)W3);BA+ MED(F&<^(@-7$NG:O(M/[
MOZ"^H'!BWDBRU^RK|KV'8O$6ZEX6HOU"%*65?_TH0[$D4!SN@5>+?">"_P7 M!+U:T#M5X-<"_]0A]6M!_[E@\)0@4 L&9>RK8)61#]BBT['@>R**UII6')1V
ME6H=8)85,^M>"7V6:9V:SGB:,J6GBI*$9DLRXYEBV1JRF($D'P-0E"7R$_F# M?+\/R,?WG\:VTMT68CNNN[BINO!>Z,(EN\]0RQ[S03LE;S>;TW '[>Z.?
F](7_=LV\BNUWLXNL?"5S&L/$ MTFE7@MB!-?WPSATX7[IVQ;UV67$7.N79BP !,65K#!L?6.[SA.V_^HJ]GP MN%G+C$%CQL!HQIP^L)3*?@V)[>W,_)C#ND"1&>V-

)+.]0,3%F#"0DQ8A 1K M>3MLO!V^X;-QB.DV)BS A(68L @)UG)[U+@],M[)U\L=DUP\DA5T/OQ&'?G# M^27-S$YK%AC'<,\6L.1#$>E!:BT$)468=':IA\M;+BG?&K AWQ54&T,'3+5/-:=BS3))$EAII',Q[%M$5%L_54'QO-RJ6'"E>%H> M;H N010-]/D5Y^JI4'30;,!-_P=02P,$% @ L3AM64,>[JPJ!@ ,C(M !D !X;"]W;W)K&ULM9OO;]HX&,?_%8N=IDW: M2F)(
AM%:IM8M]--AU;M]F*Z%VXP$"V).=N4[O]Z"@R*@+/%WPO;R MX#TJFG+'^8_BX-/R^L;I!7\&*>RO(_VE=EO6" XIU4 M/*N#=0VR)*]>Z4/=$0,SZV25P=XYP;X
M=8!?]GW5665/AU31^4SP/1)%:4TKWI1RE=&Z@Y.\.+-NE=#?)CI.S6\5CW]L M>+ID0KY^-<%N\!&%;)7$B4)O0J9HDLJWZ#WZ>ANB-[^]G0V53EJ$#N,ZP4V5 M #^1P$6?
>:XV$D7YDBT[XD-[_-02/]2-;5J,'UM\C:W /W;I!7+==P@[>-35 MGC/"1U6XV]4<>_@MV^IPIPP?=X1']O"0Q4WVKLJ3YRJ7?R#L=X4;?3EJSIY1
MR1O]PMGS_4]=&'U2+)/_=-3TNB*/N\G%A/I!;FG,+@=ZQI1,W+/!_/4KUW<^ M=FD&"0LA81$DC #!#*W'C=9C&WU^P[-,+P6RD/P=DANJ4R"Z4QLNDO\Z1_:U
M%=A78DA86&,\$E8LOO?SL5/_S8:WA_J=EL3=)0E0!0UQO$87%5=#90\B:J!F%AHY$#F)$ P0XQI(\:TF2DOOV="}7*[3[@T=JWS?"B$0M_L^R.B<[+>#NBKV"@ MM!"4%H'2"!3-
E/9@V^^^V,ZM1D-)#DD+06D1*(U T4S)<2LY/F=EW%>#6G8J M:R7T5A8_M>][3]5:NHKDC M>:8V'OK)]%G4.67^ M:F0$V@("13/U:AT4UVZA1],Q(EDU2 LAUL]5?89AJ_V2DTI[W
3ZQP/PV2(1 M:)T(%,U4]?507+N)LM@)/6EJE?0&CRZ72'S%$WMBQJHE^*>VAI^YYH&F34" MI1$HFJEA:[FX=L]E(7C,V++]{:C% DHC4#13 MP]9E<>TV2VUFEML(^_X0TLRX
:6%H+0(E$:@:*:^K7'C3E]N?PCJX8#20E!: M!$HC4#3S9_'6[<%VMP=R.V)/U?<4J&G3P_WAQ?3(J0U!E&5O>$]077K5A2"=*F$176FBV8D*PY=-NN3U#;T5!31]06@1* M(S7-
L(VGGNMCI]U+FZJVA@Y^QM"IY7N/T:(1\/D5V4[MK20D#02=0 T D4S MU6I=(OQR]!@4'<(E!:"TB]O&H&BF9*W%A*V6R\0TS:HR01*"T%I$2B-X(X[MA(Q?
ATU)6Y<)VUVF3XN_[),SJ($$2@M!:1$HC4#13%E;6PK[+S' +?,;$ MNGQ80:*8[W)5W0W??-H\$'%5/@8P;(M73U-\IF*=Y!*E;*5#G8M][.H'E"H M#A3?EC?
4WW&E>%:^W3"JAWY10'^_XEP]'A0)FL=$YO\#4$L#!!0 (+$X M;5E%%V$ZFP, $\/ 9 >&PO=V]R:W-H965T)-@T6Q%[0TEHE(HI>D[+A/7Y*2 M%3M0N)&;WE@DQ?EGYA-
)O.IVCD>#HB3#"46H*HQP:GF"1;2<7Q7RGJ5#ZUX6%[K_ZG M25XELR "IRRYHY%2A!'!@$G6<,@M(@>&K0P:L=51H8SE9IN M&#;&6F5#, T9YY*KMU39R?
%D/%##17X'*':@%!7>$^6T6LI]I>$X_?)0DBN5OJ_-8%?%8[:]8[T]K\4:Q+B MR%'[6R#?H#-^^\;O>A_J*+R2V!&3=L6D;5,??\G3!7)#9$64/-
RJ;\^3'R[NC42+U6E&M.D:%XXYQK$^TS;C=Z[?]@5H)F\/T_W_>46:= M*K..-;,[!OY"F8.D[/X#V&E!Z$):G E^&R*R M$W7KUZ]D&R486(6.&/4J1CVK\B2..
<9$(GQ20*CZ>POA&TGR]!_6ZJ%^[T$= M@U_7.4+0KQ#T7WG[5=@[QG>]1OE)1#LZDTIG*)?2!PW?),UV:!,R7U'.ZAJZ/%/4$L#!!0 (+$X;5DGM^I.W10 +=4 M 0 9
>&PO=V]R:W-H965T >+ M!$ALD10I*=MMP'%]9;&]TYB>S%P,]D*Q:5N((CP4W=T#Y,X3%55')-]696_KQ^*HHJ^+N;+]?NSAZIZ_.GB8GWS4"RFZ_/5 M8[&L_^1N52ZF5?
UM>7^Q?BR+Z>UVH\7\(AD,\HO%=+8\NWRW_=G\O+=ZJF: MSY;%QS):/RT6T_)?/Q?SU9?W9_'9[@=_F=T_5)L?7%R^>YS>%Y^*ZM?'CV7] MW<6+H=^6>CGKT,NMFP_?
5.5]MG7S^;WZ;K MXGHU__OLMGIX?S8^BVZ+N^G3O/K+ZHLIFF>4;;R:U7R[_7?TI7GLX"RZ>5I7 MJT6S<;T'BIGR^;_3K\UOHK5!/'QE@Z39(.FI0=ILD/:=8-AL..QND+VR0=9L
MD/4=(6\VR/MN,&HV&/7=8-QL,-[^[3[_=6S_+L6TFEZ^*U=?HG+SZ%K;?+$- MQ';K^]]PMMR$]U-5UG\ZJ[>K+G]9KY^FRYLB6MU%GXIR5JRCJQ_CZ&.=H*(L
MB]OH4[6Z^3WZ3A35=#9??Q_]&/WZ243?_>G[Z$_11;1^F);U)K-E].MR5JU_MJ'I8?_UA-I_7P5R_NZCJ7=P,="'3[(Y\WIWDE=V91!I6R^IA';S=/#VPN>@Q^B!] M=7/IW_Q3\7@>I8-
7=UJY-Q?%3;WYZSNO>^R\9W/3XU??;!Y[_B;3EZ2F6R_]MMJ3^XW_I(:)?]F*Q_K\#._WS\R##PX-LIHJ?
UH_3F^+]63T7K(OR>#_SH4'A(3)"9)3)&8)C$#84X@AR^!'/KTRZO[^[*XGU9%=#>=E='GZ?RI MB+ZK7_[$:CZ?ENOO#\7/2X;&C\0$B8I5Y8_5I,Z5&L_K5KCL!/B?
(NW5H@DA,D)A\QK)6@";C<38>#O). MBO8?F Y'63X83MP':G+W#(0Y"]M6/-ZOEYZ+8?5Y5L^5]5&[6] [.?%XK-$PD)DA,^G]EJV5Q MZ(T=N0>;Q R$.?F*!W91;.#]=?
U]6I;3917]XT.Q^*TH#RXD^(G08*&:0#6) M:@K5-*H92G-CUUJ+C4^QO-6,0B63U 2J2513J*91S5":F\S$)C/I]8(XO?GG MT\S_3M,O!:>/U 2JR49SW@>/QEDR3+OO&-!Q-
;]90\]BL/WGY4FXH;$+]K%W M^;6U0+JZ]U_-H=I-ZMUM3ZZ2.IW@R.$KM*CFD0UA6H:U0RENZ&S1J"523D_U.(AX,#GWZH/T#H#U62C M'5L[Z?Z;H30W2;.GF+SIO ??D3]:4J":0#7Y%BTZ./]!D$:?GZ$T-WJV
MFIB\Z5)0QUI8OQ[*#X#ZMH_6'"0T.X U12]:50SE.9&RE8,$W_%\.=R=C];3N?-171> MCK]"CLK0E@'5![*K)1CMR.1UT3(UJAM*X;;[N4VGlF$77J^7G3:_U MV[P(^LS)D2%"
\=R@N4DRRF6TRQG,*X3S[@5S_@4RVZ[8;"(HN==L)QD.<5R MFN4,QG4BFK0BVK>8V+X)B6ZV+Z/KS6M$]/,\VC!0?+"9:3+*=83K.F[W7^WVR Z$AQ.M7UA.LIQB.PG&
YN>..+@]AG0[+&8QSXQ>W6IVX9ZNSN6[.;%&\ MO=OQ#Q0FZ'?]0$YO3%ENQV4DSMN[$SCW>MU*'94S7@<$XSKQ:W4[<<]N)V0:?\.2 MD'\WPJ/)-CLH)UE.L9QF.8-QG0BWFIWX-
,U.S#8[*"=83K*<8CG-<@;C.A%M M-3MQT*DPWS;)L\T/R@F6DSONZ"3/-CXH9S"N$[)6XQ/W;'S2;WB7SG8Z*"=8 M3K*<8CG-
<@;C.O%L=3KQ:3J=F.UT4$ZPG&0YQ7*;Y0S&=2+:ZG3BH$[GVR9P MMNQ!.<%RYB^W9WF([.JIF.8-QG?BUNIZXY\U3^DW@;WE_SC9 *"=83K*< M8CG-<@;CW/
FK:8H.='<5WTG8]P|+9ZG&2 MT_0X"=OCH)Q@.,.DI^MQ_$.%QY3M<5!.[KC.!+[7XZ"C M:I8S&-->)7ZO'27KV./TF\#!N7DCCMZ%,GV,2AG,,Z-7]KJ8]+ ,W? XT?_ MT,%Q1#G!)6:O'2?
T]SO5JL:B/ M%7NT-7XH_+6.;6M03K*<8CG-<@;C.B%LM37I:=]:E&UK4$ZPG&0YQ7*:Y0S& M=2+::FM2?UL#7.C\R!#A\61;6I23.^[(Q<[9437+&8SKQ*[5T]3^EJ:9GI_7
M=CZOJMGR/JJ3^% =OI*?7PM/&%NYH)P\|JM;+8O#+W1LM8)R!N.>$W>Q?BB* M2DRKZ>6[15'>%]?%?+Z.;E9/RYK?O%|^^6F43[:;0/YTE9Q=U%O:AU^^>YS> M%Q^F9?
T"N([FQ5VZ>!\5/^OL4WB[IMJ];@AH]]65;5:;+]**:W1;EY0/WG M=ZM5M?MF,\"75?G[=O&ULO9Q;,^NX%87_"N$6Q1F@)5 ML4\3 XE%3D\Q!S4FF.E#T0?
%9FSAZ.*1Y&0*],=7DA71M.5M,[/@E\2W_6U* M2]HBERC>O67Y]V(M9K<)5_))EK]LYGGU;MA1EE$BTR+*4I;+E_O!@_U%^%8=
MT/SBUTB^%7NO6;TISUGVO7[S=7D_L.H6R5@NRAH15O]>Y4S&<4VJVO%;"QUT M.>O _=?O=-%L?+4QSV$A9UG\KVA9KN\'XP%;RI=P&Y<_9V]_E^T&^35OD<5%
M\Y>]M;^U!FRQ+V-Y_>N*5K]HY&BJQT;S2M]99[+)7LJL\5W]BF091C% MQ0_L_OE*6"?_OS#W;"L\M>4X:+--=OE[/>&<#O_'-KYAEG\R MNZ##
[FHLMM]V;5]Z78'@MOPW#]V(/S[IRJ.?2UE4ORGI]&/NR1>?Y*Z3'XI M-N%"W@^]:EC(_%4.IG_YDSVR_M8G'Q(6(&$<"1,@F"]:[U\GN243ICWE6%&R3 M9PM9:?
PI2EF0Q7&8%WWG]R/),E5W!QLUL/H"^#K][QYMU[*LN^'KOG(?R,KZ M1$,V7H!@FFA^)YI/BC;+TE>9-Q?W>1Y5Y^R>;FPCJXI#.LQEKX(DV%1!_TA! M^T Z9#J.A D03--OU.DW.J-?
DE3:%4U%;;0J6%35W\.+XDXRDF4JV0[F[TDV MN1W[8\\:'2B'S,J1,'&\";YWZX\L;I)M@J;*::?*+:G*0YINPY@MH]=H*=,E MR\-2]NE!4DSUV,%L9VJKK!MK?"
&,B5'P@0(I@DV[@0;DX+]FI51NF)Y/7@H MZG[+8N^\ZE..Q)DJ1[@^DM]]! M4TT5;&DC6D)H3@ZE"11-5W%OU&^;EI<.B@X74=IAK&&3F\E]3D3D6DYE"90-
%TV9;O8Y/!^NN>U[!0LH^=8 M'OLNWV3R+/->SX7.8"PJU'6!TCB4)E T77GEO-C>-1PW&VK*0&D!E,:A-(&B MZ>HK"\>F/9QY:[F%2;9-R_/]IV.OQ;?Z:NV,SFNL(-3!@=
($BJ8KJ$P5364?-MOEB'A60/JUS*1%:' %GBH280E!9 :1Q*$RB:?H@H M1\F^O4J)AUI.4%H I7$H3:!HNOK*GK)I#^BI[H83QFX;[A_6],."CO1Y BB- M0VD"1=/U4BZ43=M0>V?
HP7"8KLU0Z1FUVH,86 ME!9 :1Q*$RB:KKXRP!S:7]JOS=797M1$[6Z<&MQ.:;/01N2,;HNQJE /#$H3 M*)JNJO+ '-H#ZWK5&\/;XDZ_DW6H()X"J T#J4)%$W749EB#FV*_8$)#BV9
MF)0PHY,;RPAUN* T@:+I,B]'RZ$G%P6RB%9I6)*WlFB&\074.SJ1;\=CY\"/ MAN;D4)KX"(U14..9.K^ 50MPA*"Z T#J4)%$U_.$*Y12X||>FBKBS- M,'[ZP3KJRKJ6/3F<6P%-
RJ$T@:+IHBF3QSUC\KR?IHY1@::IQC)"S1\HC4-I M D73U5;FC^M)I[R?V[ )]4 M0VD"1=-%4P:12QM$\X/;;&>?A:%YQ@\")SM!:=R]Q,@2])RZ?LHQ=)$ G-!8<^DP@E,:A-
(&BZ0>"\M&\T57*,M1.@|("*(U#:0)%T]57=II' MS^RZZ!X4S3#6]O:B>U#0!Q*$RB:+IIRP3S:!9OGT6OM=L_C*L?!9W%IF+%Z M4!<,2N-0FD#1=)&54^9=9?*6! 7.H+0 2N-
0FD#1]-4RE7?FTY.WS!8Y]8\7 MESJQU *=UE1 *(U#:0)%VPDXW%NO.I'YJEE9O*@&0=NTW*W^W'W:K5[^T*S9 M??#YS/X2[-8@5YC=DNC?
PGP5I06+Y4N%M&YNJRMDOEME?/>FS#;-JMC/65EF M2?-R+<.ES.L?5-^_9%GY_J9.T*WU/OT_4$L#!!0 (+$X;5GX76!-V0, M (<5 9 >&PO=V]R:W-H965TFHM-N']@\F&< Z24QM
ZVT'[.A4#8$!U6?H%< MYO\;SXP]D3TY,OXLM@ 2_)U/#*B8$*<2R0!#U=X!'2-.'L;QO88:C<|'>'E|HK\K@U?]K(B M1Y9^H8G<3HV1@1)8DWTJ/[+C7U
'Y!6\F*6B_$'7RM;W#!3OA619+58CR&A> M_9,?=2(N!+9[0X!K ;X6W/+@U +G6N#?$+BUP'WID+Q:4(9N5K&7B0N)),&$ MLR/BA;6B%1=E]DNURA?-BXFRE%R|I4HG@R^$AR
)3<4; M]!9]7H;H]:LWZ!6B.5K0-%6U%1-3*L>%W(QK)X^5$WS#R1@M6"ZW D5Y DF' M/NS7V[@'8*](F[#Q*>PY[B4N"!\@R_D#80L[70'URY>P&R#'*N5N5SS]\A!B
M);=O~H_ZY7_OTP&R.^6M9#C-'"!*GO/B.?#U@S)![R5DXEO'^.85S^WF%;WM M0>Q(#%-#-2\!_ !&\/MOMF_lV95JG:!0)RS2!&L5Q6V*XO;1@W>$O.+95@HH/PR'
@]'$/%PFNT6")U/AM M79KS;MGNW??=U:.<_ZQN?S@:8SSTKWN4UEVP5EK4%<78MQS/L:]ZE'EQ$)4! MWY0G@ +%);_+ZDRJ>=]<,L[*LS7$;%X=42X(W]!&ULS5U=;]LV M%/TKA
<,&]#9U+?4)0':I,4*-$"0=NU#L0?%9AHADN5)7QHTJ'K43;Y$[#EO_4ZJ<[E+T\?JQ8?5^8Q6);&8+8L*(RQ_M/+%+%L<55%G(OPWJ['#0JF/[]SWZ^_KLR[.Y"W-VF<9?HU7Q<#
[S9V3%$[L-M M7-RFSW^QYHR<"F^9QGG]+WENVM(966[S(DV:SF4%2;3>_0Q?&B9:'0R[IX/9
M=#"'=K":#E9]HKO*ZM.Z"HOPXBQ+GTE6M2[1JE]];NK>Y=E$ZVH;$HJ^(24U;T/U2WOV*+0T7.P9>D3>;319&.5O5Y#*R[9HE=RS[A_Q'/I>LEN21-V3/\/Y-$1'2 M(U=2?
IUOPB4[GY5:S5GVQ&87O_YBN/1/$2U(8!Q)UH$DJT:W^L8,[X(AWSZ6 MX.1#P9)<2)]%21H2&$>:?2#-EEY9S162DZ1UB44U9Z+SWH'Y-5CUW_33!9W;
MQMGBJ7T^HD:^=VC$U>D9@*\(8H0-2H3P'^H4Y_ @5<#E*],BJ@XDQI4'$@*M%% @$D:$AA' MFD'!B%%,#31H)T0@;-6G J-E&@U5';Q[8=FRU &YR:+E3U@A^9%5AQ0+C><)
M+*-A:B,%]5$8]'QO(&--*2&2UD,EN R=^QC,9QHQ=<*[LV0V[=18ACFBN1' M5AY3)#2>)W"/AJ./&%#])!8:3QPX2D/JO93%X(HN\^!8#"=:\;6"D3/D3FZ4 M&
(89)/F1E<<4*8WG"8RDX>LC!E1KB87&$P?FTI#:,&4Q!(++W.O,#"=:\0M& M8.E,N:43B&&G@2]I7 [X;O"&&*7RS>MH'27;1+Z,)"U'>1T)"8TG#SRF:6BC M$!/5=&*A\
<2UUBGE"Y6*"FG0#*-U\1O4FWM'&A&U"]RYTR,2L'JFW.JABB1\ M.2T2U'5#+#2>//">IJV/2%#-*!8:3QR845.^EJDJ$D<@$C.8F\L$#FG(./%(EW=N,H5,)ZMHB%AI/'IA2T]-
'):@%N0N-)PY9^Q M\Y%4IC_<4JYLV>%=;GZC= M1O6M6&@\<>!;:=2HO4$FE&.DQ-1*WO>DRI:8!5MY:C]IX4R9$9!7>#$0N,Y M!/MJZQ/#VZB>%0N-
)PX\JXT:PS=HIZR7H)7==R?O@$UTE&-X!:&,7O:25Z7\ MF?8IUC@=L*^./FF\@^I9L=!XXL"S.JAIO^(V:W6W4=S3KM63ELG/2H!C^@H MY__K9(!TXF\N7!GF*-
TP'OZN@3QSNHAA4+C2>N]601:ASO"&+V[G0B:M7K MNQSPB(YR%/_N9<.6!5N1]^@I6K'U2N%&7GA^]$N:6&@\7^!3'7W2=P?5G&*A M\<2!.750T_<&K3TIT&-
%R)KP58(3=)0S]^%R&/AP(JB)18:_W@@N%%7GYC= M1;6@6&@\<6!!7=28O4&3R4:A*\2_)ZK'*X/E\.P#\++*U >U2F6)EVPG:X^
M>;J+ZC6QT'CBP&NZ]'EZ0R:5@ZP)7R48.U0RXU9;7 MHCS*4RQ NF [77U"->,[\ MA#Q&)X#R6E1'&0N-9PYLJ*=/5.ZA^E$L>)XX*,>:E3N"4)PHQ6"-^=D=9R5 MT:,-\'^>>U-,G'?
=0+2D6&D\<6%(/-1WW!+FW MV=6&V]%&SR?0C^AC=$YG[P6Y2&>8LW1 T/JZ1.(>ZA^% N-)P[\ MJ(<;B'N"]%M@JX*AVO#!__G*:?A(;0R8-^2U*.]J-<4"I)NU-
SY[Z(/Y\Y4S*LH7Z;;\G4UAA^KH2U'_SK, M'EEQ&,NQ,9^\&N5!GF(]T@<_ZNN3??NH=A0+C2<.[*B/FGW[@E3;;]UJ-^!%SW3[G>L
MW(G#CCZQUH[Q5#'*5];6P"VSY74H[W:+!7=$G-DB3I\D?U\+&GF3[")/6]O(M4]Q]Y*D@J.]^IX*@44\L8]#6-O)4,=!75LCH"/-$:>KC/L6*JD%;6\U3?2+^ M?
2UHY$VRVSQM;3=/;IZ*MY&E7-L+'X'MNA0S:VG*>*J;]2,(98-M.E*8^ M]I/L2D]:V])3??+_?2UHY$VR.SUM;4U/FI]UMYTUO;A_[;MO=VHA;M'Z M&LCJ2SBOP^Q[M,Y)S.[+;G1>?
7HHVWVMY>Y%D6[J;X:\2XLB3>I?'UBX8EG5 MH'S_/DV+_8QJRR8/WRYZ\3]02P,$% @ L3AM60PO!D4#! 8Q$!D M !X;"]W;W)K&ULM5C;MLX$/V5@;98)$:77S/ MV@9R6VR
IAO$38-%T0=:&MM$)-%+4G8,[,=W*-F2@Y69VDE?;)+BS)PSY!&' MZB^%?%(S1 W/29RJ@3/3>G[FNBJ<8<+4J9AC2D\F0B9,4U=.7367R*+<*(G=
MP//:;L)XZ@S[^=B='/9%IF,>XIT$E24)DZL+C,5RX/C.9N">3V?:#+C#_IQ- M<83Z87XGJ>>67B*>8*JX2$'B9,"<^V<7?L\8Y#.^#9RN M Q%.6!;K>['\"]>$6L9?
*&*5_\)R/==S(,R4%LG:F! D/"W^V?,Z$5L&S5T& MP=H@R'$'@7*45TRS85^*)4@SF[R91DXUMR9P/#6K,M*2GG*RT\-')B5+-7SB M;,QCKE=P=(6:\5@=PT<8T2:(LAA!3.!&J8R-
]7U'>4,I,8*1%N$3K%THFK_Q M>OMUB,D:Y'3Z "VK&)"K@*3RD7*L3&J3VEYG(%$LCU7J9@NLTPNBEO4N9*-,1;-)Q>$5@=CG!^"@WO! (O:,+#Z J./AQO M8R_^+)$:9>
(;>:3&KDA[I?;;)S*'&XV)^EZ7IB)6LSZ64?:9FK,0!PY)5Z%< MH#/_3>_[?UA8=(LF31MWH>?,[/"AL>HR-$#+8:.5SR=PM^95IK6UK0W9$Y> MC#(-
%SCE:6HZ_]7FMZ!8@&CE(,R[9C$D_+U6UV]W^NZB!G^KQ-^RXG_,E8O1 M1SA?H*17$5P_HPRY,NO!0[3BK;9&'>8B<&\+LW?:;M;#;9=PVWO*O4?S^C5X M+DD-
DEYT&8QA'H$CDA?_R'3ZG@WBSK@=@@!K(Q/:$)2R"^ B*ULJNB4Y#I6 MS^?3J<01ICE? -XJW]7@KE'1I@V4->B7'WAOU\"HGNRJLX??
GY7O56>?[&NG8"=>> M6U8D!Y#<.M#]0R7T^KK54K'&.X!*4%$)?I7:<+UE(ZO"[/$/H%:=_K[U2-Y' M9-M4L/*RQSR 3E4"^/8:X.W**EG6&K-&/X!851OX]N+@9]3T8H%]X5MC' "_
MJA5\^TG]YMKLNFA91=3>MS+SJW+ M]<#>]=F)=Y7E-+9HS+SJ^K MY<'[U6; M%2QJ@=L! ,*\R\QNOE69^51?X]L+@YXNS:A5J.;Q7 >!NW7L3E-/\=F].MRS5
MQ16X'"V_(0P7]^9J>O'YX99]B<5Q#@A4^^T0]M9%C?ZHJ[%/+]%CX6F.WG> MG"$C,9D)!'PBA-YT3(#RN\KP!U!+ P04 " "Q.&U9)@[&$*$&]/ M&0 'AL+W=OCW8"K&[' Y3?
\LBFE[P'8OE-VN>1%3(C\EFF.X2 M1E=Y4!0.]=%H.HQH$ ^65_FZ#\GXBN[%,3L0T+2?131Y, MT\8RR7;ED?.OV0=O=3T895O$0:#'$'EGR=VQ\(P(\GM^%9"!U7.++"Y_$*W
M\YV7. ,-(4W;'PW^"E=A>#^8#LF)KN@_%1_[LLG*')AG/YV&:_T^>B[9CV=C? MIX)'9;#<@BB(B[_T>WD@&@':^)4 O0S0SPTPR@#C,&#R2L"X#!B?FV%2!DP. M XQ7 J9EP/3<39]5
;/#@.DK ?,R8'IN/BS*@$6N0W'^\I-O4D&75PE_)DG6 M6M*RA=R@/%J>\R#.9'\0B?PVD'%B^2"X_7]K=1E1>YX)*^AE.86OC&9H$&8 MOB7OR:<'D[SX]>W54,B,6=S0+^EF0==?
H6ODGL=BFQ(K7K%51[RCCE^%=V6QU^3W^\1.M=YU(=_F_'9MY6V#'W=CLUG:9[JC\@?RWI6RY(D-EK_] MHDU'OW?)AH292)B%A-
E(F(.$N4B8!X*U?!Y7/H]5!*5T.)+VIIG6[TBZI3(% M*=.LB!Q4D2!-]S3V69?42G9?J0O8)(=E8[6GI6;(BU:?7@V?FKXBDUI(F(V$
M.4B8BX1Y(%=CUTGE2T3IZU_[Z)$EA*\/7>W2FE7M3I7LW3W)@3!]#1ORRU\P5[#)"/">K; M,2)A)A)F(6VN9,CZ[HV=@P#'W6OJ!=9%+O.*D^UR:3D5$E7;7HWDJ[R;*;VS MOK%$#
[(19WZ);GR7C3@[O5."^G]'A)E(F(6$V4B8@X2YLR.?C+DQROZ#F@Y[MH)PM-^>5FW.EFP]-(]^17<)]QE8I>1/$Q.1A2).T:_[@5DGM*RH29B)A%A)F
M(V$.$N86L&ES_*0M1]/1@:B@G"U1%Y6H"Z6H?Q>*RO%B-A4L^])]_12T3UP M5*+ZVHF$F4B8A8392)BS..KY#EQRD>D\$*PEIC:JIV)'2C4_YQZ2'4_RF;2R M,SW9A;]I?
2V%TDPHS8+2;"C-*6G-OD^?'9\+C2GAZ*U?6V4#C3U/3\[[,D> MP25<)($O7D:FG98J6;TM1=+,DM9ZM:K=FTTG[Y%E=S49'=S?[O&8.=!=<*,U#
MT=IBZ;58NE(L)Z&Q("LJ&%G3('"%/--RST_V@$MK;,"3-+&G-WF%\I(35T6IV MU(?87:WT8[V0V^]":1Z*UM:K+MUHRIGTI5T[M6-),7O3M*M>V^T9M(0#I9DE M;=$<,%T8XT//H-
69SIPS_=!':-T%2O-0M+:/=>E%4]=>3G9WIX2$EE^@-!-* MLTK:@6J3PPX26G^!TEPHS4/1VN+6-1A-782YB>,|#4G,!%INB7K4!+6"8_D MLPM+:/'X(I=\%@NZZ:P"TDPHS8+2;"C-
@=)<*,U#T=IFUU4E35U6^A0GS.>;./A/JNTW MU?9Y*DY/"4#+2U":";594)H-I3G:<5EH.AH=3XFYT+0>BM96MZXS:>I"T\=: M7#D$#GAG@4G-
Z"THM,0$I5E0F@VE.2?,Y)C\8+*'Z>QLH>4G%*W1R ;Z_J2K MZT_Y?/Z6ARN6J ?$:DY?:Z$T$TJSH#0;2G.@-!=*\U"TMLEU94K7?LZ_6(=6 MJ: T$TJSH#0;2G.@-
!=*\U"TMMEU:4Q7E\9Z_>ZY9#4KD?.N@=>=.FEO49$T M"TJSH30'2G.A-]%*T0=-EXQC%BRR=]/3>53V#X6Q=MSU=KJ'=B;_W/@_6F M=FD7;[+6F.+%VGN:;

((X)2%;2V0V_3@@2?&N:O%!\%W^(N,C%X)'^>*643E: MR1K([]>'E_U!+ P04 " "Q.&U9W^X5]^<$!4&0 &0 M 'AL+W=O?P\NA$ M&FP8?Q)+2B4\1V$LAM92RM6-
;0MO22,BKMF*QNK.G/&(2'7*%[98<4K\=%(4 MVMAQ.G9$@M@:#=)K]WPT8(D,@YC>> @62ZDOV*/! MBBSHE,K'U3U79W81Q0\B&HN Q<#I?&B-T^ M7 ZMG@4^G9,DE]L\SO-
;5U/(^%(OT+FWRL8X&7",FB?+*](KB()<\)YT14 M)K3V3<#Y!'SL!#>?X*9 L\I26'=$DM& LPUP/5I%TP4]7MXH('R8L4MTA2,KOQ1V5) C%>[B"J6H>/PDIL#E,T_4,_J4" MQGH)
OD"JIL@#01?5GJR@"3V*0<2AG ?$G7^#FP02\+5K""&QSB0XE)=5,=? MERP1)/;%P)8*CZ[*lO+:)UGM>$_M??C,8KD4\$%E\W?GVXJ'<@@R\)>,6&P/>
M4>\;7'0)V,$N/$[OX.+=^VKMV4]=I>; 4[I2@9TT<.O8P#L0W&(]W323NR_3 MFY?JK_%,2*ZVU]\U.&^SI*WZ[%IS;L2*>'1H*5$1E*^I-?KU%]1Q?JLC[4S! M=HAJ%42U3-%'?R313.'6-
&5+*AY"%^"> %?$BFDZLGT.*/IVT$"VKZQ%R7 <[O<[7E?YJ!GH=KH(M9QBX [6=H&U;<3Z M/14SZE^-UY0K<88/SY1[@:!PSP./'L96=FH=OBQYIUKV#\!,(W80=0I$G6:(
M'JA^9NFJ)TH3=/LF)(2OE$=PH53F3TJX>'\ :!TV-&!H051ID08?/)2 M*Q#F0+T\$'),D7:HZA94=8VAQXL%IPLB*7Q2Q 3J >S!-Q(FQRQI'2/=UVN) M^C]V\NM!O3TKWBM@],Z\7W-
]6U.A&@74;:!9VY-9:-ZPQDJ:BESOU:9N=;IM MQVG7\]$O^.B_<4\?PF_>U,;L33G(@O6K/7.-> 4$(*>T+L[/$0$C,W5DF MI MRL8!6%LM< LI0(>T
%7L'CJ#&AS3/;4\&9,WY@F]4A&WOZ=I<$D _CDZLN D MUE28A,.*46E241&:W6\>)2@S6IASM<8N'NL7T"EW4-F MO_=6LZJT'-@_QHR-J3DAFI&:TFLBL]E\ZRXK&*LER9B[,4DG
M1#.25#I99+:RIF=P7>?4K&GCW&N_#79I1;#:C;U6+@HY: M!L[J14^)9MHAN#2LV&Q8CU"+G;:HY>*LOO24:+5X6P,)$0 M 9 >&PO=V]R:W-H965T0D]/2L(W'@[MLGW)Y8 :+
M"N]A _QK=4O%SFQ9DJR DF6D1!1V2^.3?1W9E@0HB;\R,+&S-9*N; FYEYO/ MR=*PI$600\PE!19?1UA#GDLF8\]<"'F.%A0H$K4DAZH]AE<&W(7"P=^H VHCR3 M0PZ(I-
"3@.A!KD&(?]V$Z.WK=^@URDKT)24'ALN$+4PNI)5:S;BQ;57;YCQA MFXMN2,E3AJ(R@60 'X[CYR-X4\2I#9;S&*R5,TJX@>H*N=9[Y%B.-V#/^OEP
M=\B=_Z<]^L_:.\%PV\IQ%9_[%-]+BN+;GP*-/G,HV#]#A5"K\H95R69YS2H< MP](0W9 !/8(1O'EE^];'H2SH) MUDD6:R#KY\MI\>6/LP1?"<8Z8RM1692H^
MR]104FH^7_')%\XQ*W)PCR>Q_I29N[,NS+AI8P]]6==H6A R+&GK5#'Y4GK M\F34Y3L11$SC%(G^(]X>1_%;K,1+CJ-O-U!L@0Z6XBCE2TM1)UFHDRS21-;)
MB]_FO?]UK!.KUSHN M9::S'D]T*>/;WG#CF+4.ST8=_AU*H,)EV3=P(]Y=&>,4RROM:.L8)7UI*>HD M"W6219K(.IF9MYF9_[K6,=>9+YUDH4ZR2!-9)U^V]7/ L#0WCX;P_"[@NKW.
ML!X0\J;]F\> T'SF]OK'@)!ON;T&8IZ-6 70O9IMF7#E4/+ZSMR>MO/S)S4U M]LY7]O7:'C@/Y;RM1KJ?]/6P?H/I/BL9RF$G5%E74]']J:#W_UAM.*C7@;0D7 MXZ):IH 3H%) /-
\1PA\W4D'[+T3P U!+ P04 " "Q.&U9[/A670# "] M#0 &0 'AL+W=O MF>=A)AF/-D(^]6 1D^,+(1D6)NE7/]JD(!S MY\2H'P5!XC-,N>).W-ZM3$>BU)1PN)5(E8QAN9T
%9NQ%WK/&W=DN=)VPT]' M!5["'/27XE::E=^@Y(0!5T1P)&$Q]]["RVD86P=G\97 1NW<(TOE7H@N[C) MQUY@,P(*F;80V%S6, 5*+9+)X[$&]9J8UG'W_AG]DR-OR-QC!5-!OY%
MN8=R6."2ZCNQ^0=J0@.+EPFJW" ;5+9#8YR52@M6.YL,&.'5%3_50NPXA,,C M#E'M$!TX1/TC#G'MX)3S]\PP4OPS9"M.'DM0Z/N_!@?=:&#]OS91JZ#]]]"V\R]5@3,8>Z:U%
<@U>.F[M\(D^*M-D1.![>G3;_3I=Z&GUV1-X*V@*5",6*N3]J8=2,,:H0PK"%0B'*\[:"6--22 M3N09X825#'V? ;L'V5]HG0BO+=03@>V1'39DAV_1R,-3ZG,BL#U]SAM=SG^M
MSM>"&A4HT=LVOA5(6+U^[8BQ3L->8%[4ZUTB/[/:R_"BR?"B,\,[HA[.%A(M$?.M,@IH)+&&MBPKH##9B1_T@G@X/,BSW:X?#]HS#8.7CW+0W5KXZ:>MU0WQ
MVMHY%=H^X9TI)'R+]]JCGDJC$Z'M:Q2I:!2=HL5JE,/N20YJ]XC9^9'2?1EX MPLYYX35M5B/]T#_)X##7(X9QPV9Y K-WD? M[$_LV<0-V"\PU<%FAN62<(4H+
ODT!N:SZ^LS@K50HO"C=OW0IOAW=VNS/D* MI#4PSO="Z.>%#=^(0 &0 M 'AL+W=O3S"3Q%1NG MP,P"!M-I.IFEZ3XK6(GMD4E&:,_OO(%QQCAF*P>^@*V?+Y/YTB?CVX>'#!Y
MHUN$&/@11PD=*EO&=H^J2E=;%$/Z@'F.(!CDH#A2#4VS MU1B&B3(:Y&7/9#3 *8O"!#T30-,XAN3?,8KP8:CHRK'@6[C9LJQ '0UV<(.6 MB+WLG@F_4RN6((Q10D.<
(+60^6K_KC0S0R06_P=H@.M78,LE%>,W[*;13!4 MM,PC%*$5RR@@_]NC"8JBC(G[\4])JE1U9L#Z]9%]E@?/@WF%%$UP]#T,V':H M]!40H#5.(_8-
'WQ4!M3+^%8XHODO.)2VF@)6*64X+L'<@SA,BG_XHVR(&H#S MB %&"3": .L"P"P!9E> 50*LKH!>">AU!=@EP.X*<$J T[65^B6@W[4&MP2X MN1R*_LL[?PH9'
T(/@"267.V[*)74([F?1XFF=B7C/"G(<>QT9_\??H4@R+&GK5+I],X<!:C"$-5P F 9B&4_"RG(*; M+[?@"U !S4\|"!RG@(F2/JJG1W7+4K7'#7!$\X M85L*O"1
@0#OM^/=%KS*FZYJ/^/8?F.CE7")=@_ U.Z H1F6P)]). SW-&F% M3]OA3Y!PN'X1[G5WWA3 9]V=%\'GW9T7P?V?:_G%IV, $8)9O4AFSF=>>I'2 M&!'(,'D4J;K 6F)L-]]TAUJ$;3;%C-
!%9FW^R?6LT%5KK5^2*SGJ%9IV8+ M40"&8[TWQDGK]ZK6[[6V_A2AF(^B0;@/ \2'0\ G?[R3UX@07LR'_M6;J&-: M2<6" :(T\@F>RVE$)IE7D/7JS>T8#1G(K'
ND\R7U#\+02OT;4"XK3B:9)8%F4RGYC+) M?/M<3;KF-O+AXN?;X4263B5+I[,X<!"C)'Q-&7SE:PZNSA6.8YX5BW7$7;;L M#59))-99)Y,LEF,LGF,LE\F60+260GLM6U]IT[MK37Q?
<^W(P TZ[K?AE%$&DR!,-B"E?"T1)EDNW*4L*TF.Z7*'2(&X MF#BS)4@Y+RP'7W##N?*M/GHKW+[3SE)\O^[:IJ$W)O"3]MBN?1.DLGF"*$S# M-DW-::P,9U+KG4ME\P51]"S-,1U-
;^15@:6AZYIF:!>6N'IM?UG_'VFT'.(_M5*G>6:6MT5VM4IELGB"*2RJ56>]<*ILOB.*22L\M/U"I\:Y2H]L4\M,Y<8JC M")(:@5AXA1MN?0:C/30G:I-
V;Z]6G4PV3QR"WMRFDUKI7"J;7]D6:\>@]G4 MFR!2 ,:&6(D[%]GY2H+?NZ7Y6;/7U23U0D,KFB4,X5YO4PP*I;'[) M]J':!)$*U*;6SGIC1#;YAP*4"R9-6'%:5956'R-\S8_@&^5C_7&N"\K]
[..% M_&SYG;[X\N$)DDV84!"A-:]*>W!X)B;%QP3%#<.[_*3Y%3.&X_QRBR 7;V; MGZ\Q9L>;K(+JDX[1?U!+ P04 " "Q.&U9'3XVX>X$ "A(P &0 'AL M+W=O=.E%L=I[<>H+
FL;':#N[A+???LN#P%C$P2YD?PF,3#SF]V9Y8\'[^+ M^%>QHU2B;VF2B:6VDW)_H^LBW-T-=L3S-U9<-X&DAUR+>ZV',:1*53FNBF M83AZ&L29MEJ4YQ[Y:L%RF<09?
>1(Y&D:\.]W-&&'I8:UUO-/\78GBQ/Z:K$/ MMG1-Y=_[1ZZ.](82Q2G-1,PRQ.EFJ=WB&V'*:A4-I\4],#^+H,RJF\LS8U^+@ M0[34C&)$-*&A+!"!^O="[VF2%"0UCO]]J-
;$+!R//[_2_R@GKR;$' AZSY+/ M<21W2VVNH8AN@CR13^SP)ZTG-"MX(4M$^1<=:EM#0V$N)$MK9S6'-,ZJ_\&W M.A%'#HK3[V#6#N:I@_V&@U4[6&,CV+6#/3;"K'8HIZY7
M6"M:\:',?NFM\A5GQ4)92ZZNQLI/KOY2:_CP(]4H[6NX!3](M/91 GXE=T MA=9J849Y0A';H$^Y%#+(HCC;5I;*B4F:R3A(DN_(CY.*#I:TS#GL8S5]2LD
M2L%+M58BXAZ6(_KKAJ7^<:X+/3 ,KD3B&01C7K_6%_;\!?5SE]$F6^)NK. M' 2NZ?X:6<9OR#1,NV<\]^/=K;I[%AT\N[HG618S;JQ2I[U%N_'EL67CXJ'
M/DB:BG_[ED85W.X/7DCGC=@'(5U]2AL%Y2]46_W\$W:,W_OJ @GS(6$$"-:I MH-U4T!ZBKVY5?:+STO15HP+-2E#QW'E9F8;G>19V9PO]Y3C5YY;8=0S'\ERG
M:^F/9I(QS$X&9DT&9H,9^+0OGE0"28;V.0]WZFF#0I:FZNFE5#?\BKX\T/29 M\MX5.HB>ND(A83XDC #!.O5QFOHXE]08|[*"D# ?$D: 8)T*NDT%72B-<<_O M-W=MEXF'V\S[X^\
[L1!Y*QNB'ROSH4L>Z&\?.&H;I UY<6BO[LR MZPLR+BS5>#:4\T;>!H5M<"B3;PA(F@]*(U"T;E';QAG/+BILH,TU*,T'I1$H M6K>.;8.-![N_2<+FG
F-_Y^;AG':GPV'G"]M(R,2@(C=_+7M+1[N;Z>*VZT2 MMT<>I_3]$CVQ<>+ M_>I\"#<>: MNG)!:3XHC4#1NE5K.WL37U*!3-"W * T'Y1&H&C=.K9O >0CX-
LX$2NA&A3*N735>7NT']0XDVY<;'IZ9 ME"PM/^YH$%%>&*CK&Z9NGOJ@"-#LREG]#U!+ P04 " "Q.&U9=>/6 &8# M "9%P #0 'AL+W-T>6QEP>(7G4ZN#" F'AXF/@^;4RZ?
Y#T'F5,>+ M MW C]C1A9B.8V&=))I)F,JFZN"NPF-AYPF8$>R^0*.*LL])7* M4MV(&9EG@I0>-HRJH65GE/,[N'S]3+:T5TEKW\S4EZ4>CBC[4.0T5M*K@V/&>12?:DLT&IS'2
2M=YI%*Q63OR6Y+\GJ[4IIQ6">ZY>X*>_^T\SZF@ MDO"V:5W[QSS+KW8<]-_*# M4S!Y"C79?[,K^TM,^J=@LGL*)H.C-.E5#[ZMI^NM9^LZZL [S,C| 6]0GJ
M3)>,*R:JWH+%,17/'K&UO")33K?U]?DQ3'|8O4#H7$S%=T7A2=>5\6C8=W=!9JP\0=I&;\F-',(I[| A@6![, M <8Q+"S/_S2> 3H>@V'>!E9D@'(&*,>P;,BD_&)Y[)Q(?^PCC:(@"$-L1B<3
MJX,)-F|A"'|V-!W?N1][F/N4U_XP?_P%02P,$% M @ L3AM69>*NQS $P(L !?3T\$MP>:4#M.*2VBZD8 M_1!2:5K5N %(MB6/:(M7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?
S+W\PPU1>5*(Y5;&GC3Y?YVX$G1 MH2)8%II"R=.B':5 `D]/Y9Z:>E4D_LGZJ49CS86+N]'@Y-OH&*F]_4 M%J3;LU*ZXM9MZO70;#7PPFP ;%4.X]'H:EAQ(0-/^7,&"5D*(2>RC&@]&
F8UZ_D-IL5?2\G*1 M:U66XT'4[O@"VHK\]'GA(1_YTC0MEB\?N ,9#ZY&[H0KH8UM>C3GYXYQ!ZYS MNU5;]4F4%O246_A=JWHKY-]?QEW%,+B,)@Z'OVT0K_7_":-:K40.4Y77%4C;
MQE%#Z0&EV8BM&3#)*Q@/)FH'VE^/^X&[HKTVZZ""2.EKX7;HNZ+!HT.YY267 M.; F:B9@BA&F^)Q,[&+.M3M@ \UX,+\$D D"F=!"+OSO^CZ&J[16[WX)N^["+ MOR2OBP
R12#3(9!7 MM)#W>NU"MV|V,"X+-@63:[%MMM4]@'R#0+XACF1=55R_^# NQ%H*=QB7EMWD MN:JE%0'D6P3R+3%D2+;6T-[Z@.T=PO:.EFWFNDGCM, >8 >RAI K&F%I>G3&
MG,@FJMHJ^2IN$:H18H]\3X N?",4S"G$Y;M'S:7A3>72 M"1RFD8C8(^Y65L*VZ<_GE8DKAEP80>:B, HPC43D'E'YTT:5!6CSU:4^=YBP M(1RFCXC8'W?
&U,VSX=,>:!\./PF>>>6QI@[8F)W+.JE@6^UZ\0^[EY)(\:D$1-+8\Y?V*X)6'.X?SBFPN2E M,G4W>NADA%@A=ZX@<'G/RZ/P?KOQS\?ZJ&J),8G$Q!(Y5'@.;ZY*X=7Q*UN^
MM!N=.C_&-!)3:P2K3[_&(28FE)A8**=]+7;QR!N2'YB84&+]*4FWY/LUYD? MQYA)8NK92%_1T$N):24FULJ1[WH),;'$Q&(Y);[CX9A@EDF(+7/LO[Y()IAO M$NI)"C:)
[^2?!#-.0FP@F)T;GF$&RJBG/R?GNZ_+MPPS4$;^ 0""V8TF9J#L*]N3F*&Y5N&?@-P M#@.=Q S+MPPS4$9LH+Y%CN!1#S$Q V7$!D(QNV,3,U#6&&AX^""]<,*54'QV M/V%<>\[+?
*Z9_],^YTTS_P)F59?EQ+7=RYGBQ>'[JL.W81_^!5[+ P04 M" "Q.&U9$R?LNN\! "E(@ &@ 'AL+U]R96QS+W=OZ)0A&51G ;- MJJRQY>V_^F2-??>4]VW9=<=QN^O'V<=A?
QR7S::4_E]*XU/?7Y>+JR M[H9#6T[+89/Z=O7:;G+2^7R1A]\SFON[GS-GSY][_]^)W7]16^6';O5VR,?R MR^#TW@VOXS;GTLR>VV43R[D])'_O+Z3&=#W)UFMS,'E^6S?
#X(DV]':00I/6# M#(*L?I!#D-BOJK01Z*^]M!'HKZJT$>BOJK01Z*^]M M!'H;ZFT$>AOJ;01Z&^IM!'K;9+.&$0 M]R#+#O8U ;T.]C4!O0[V-0&]#O8U ;T.] MC4!O0[V-0&]'O9U
;T>]G4!O1[V=0&]'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VH MMQ/H[:BW$^CMJ+<3Z!VH=Q#H':AW$.@=]'<0Z!VH=Q#H':AW$.@=DX^5!'H' MZAT$>@?]'01Z!^H=?ZGW6#[W>;ST?
_Q^7])=3G=FR^//R^_3Z$BS/."?Y* MN?\"4$L#!!0 (+$X;5EB(^<8V $ $@B 3 6T-O;G1E;G1?5'EP M97-=+GAM;,W:74^#,!0&X+^R<&M&UZ_Y$>>-<>]M>^
.+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F M1[]BSA1KLR(F9K,Y*VP7J8O3V-?(KBYO:&DV39S<[M+K4-MND7EJ0[.VWD_L MLQ:9<;ZI"Q/3.-MVY9>4Z5M"GE8.
MW7W6_*^+FGR M8'R\,VV:Q78-"_&EH9"/E_BF1[MG"=3AHHHMDV^+WHRGAS3 M#M/^RH_,\],!::9#]ZZD$[,T^%QIT?2KYZZ5(A\K,<_\2,QE3[Z^Z@_]9+* M7V:GI7VV?
CV<1V##[?@]_GS&'_4/[$.]"%!^E @?6B0/N8@?9R"]'$&TLSX;?B"Y>@502P$"% ,4 " "Q.&U9 M!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM M;%!+ 0(4 Q0 (+$X;5D\+@,%[@ "L" 1
" :\ M !D;V-0&UL4$L! A0# M% @ L3AM62;T^9]]!@ OR0 !@ ("!#0@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM65]SI\)1 M!@ =R$!@ ("!H1@ 'AL+W=OIP/*1D' #\(0
& @('D, >&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM62)F4MH'"@ (A@ !@ M ("!,S@ 'AL+W=OJ$QRP/ #E+P & M @('X7@ >&PO=V]R:W-H965T&UL4$L! A0# M% @
L3AM68U=,_WL"P <"D !D ("!6FX 'AL+W=O M@ >&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM61"8 MVN9\ @ LP4 !D ("!7H, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
L3AM6?/M_MCM#P #X !D M ("!TI, 'AL+W=OR:T* #9(P &0 @('VHP >&PO M=V]R:W-H965T&UL4$L! A0#% @ L3AM6<\LT0R;" !18 !D ("! M^KH 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% M @ L3AM61AN.8/H @ 3@L !D ("!V

&PO=V]R:W-H965TC3 !X M;"]W;W)K&UL4$L! A0#% @ L3AM61H2@MO@ M P '0L !D ("!S/$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM66$%$!@K P ZP8 !D M ("!/OT
'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ L3AM69A3V$^]!]0L !D ("!" L! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ML3AM641]ZV@[!0 ;R\ !D ("!=1@!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM6='@M>!T! M,"$!D ("!*CP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM68WH;&PO=V]R:W-H M965T&UL4$L!
M A0#% @ L3AM67)GB?@F P V H !D ("!)5$! 'AL M+W=OI@" M !O" &0 @(&"5 $ >&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM M64,>]PJ!@ ,C(!D ("!F5L!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM60ZZ[FJ:"]UT M !D ("!X'H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM60PO!D4#! 8Q$!D M ("!09(!
'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ L3AM67281PY[P D1 !D ("!<:(! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ L3AM61T^ M-N'N! H2, !D ("!:Z\!
'AL+W=O/6 &8# "9%P #0 M @ &0M $ >&PO'+>M@0)\F / " 0JY 0!X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " "Q.&U9$R?LNN\! "E(@ &@ M@ 'MO0$
>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "Q M.&U98B/G&-@! !((@ $P @ $4P $ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 0@!" 42 =P@$! end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0;
} /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .reu table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 383 333 1 false 93 0 false 5 false false R1.htm 995100 - Document
- Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Balance Sheets Sheet
http://www.uncy.com/role/ConsolidatedBalanceSheet Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Balance Sheets (Parentheticals) Sheet
http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Statements of
Operations (Unaudited) Sheet http://www.uncy.com/role/ConsolidatedIncomeStatement Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 -
Statement - Statements of Mezzanine Equity and Stockholders??? Deficit (Unaudited) Sheet http://www.uncy.com/role/ShareholdersEquityType2or3 Statements of Mezzanine
Equity and Stockholders??? Deficit (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Statements of Cash Flows (Unaudited) Sheet
http://www.uncy.com/role/ConsolidatedCashFlow Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Organization and Description of
Business Sheet http://www.uncy.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 995307 - Disclosure -
Summary of Significant Accounting Policies Sheet http://www.uncy.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8
false false R9.htm 995308 - Disclosure - Significant Agreements Sheet http://www.uncy.com/role/SignificantAgreements Significant Agreements Notes 9 false false R10.htm
995309 - Disclosure - Licensing Revenues Sheet http://www.uncy.com/role/LicensingRevenues Licensing Revenues Notes 10 false false R11.htm 995310 - Disclosure - Balance
Sheet Components Sheet http://www.uncy.com/role/BalanceSheetComponents Balance Sheet Components Notes 11 false false R12.htm 995311 - Disclosure - Operating Lease
Sheet http://www.uncy.com/role/OperatingLease Operating Lease Notes 12 false false R13.htm 995312 - Disclosure - Related Party Transactions Sheet
http://www.uncy.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 995313 - Disclosure - Commitments and Contingencies Sheet

http://www.uncy.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 995314 - Disclosure - Stockholders??? Deficit Sheet http://www.uncy.com/role/StockholdersDeficit Stockholders??? Deficit Notes 15 false false R16.htm 995315 - Disclosure - Issuance of Series A-1 Preferred Stock Sheet http://www.uncy.com/role/IssuanceofSeriesA1PreferredStock Issuance of Series A-1 Preferred Stock Notes 16 false false R17.htm 995316 - Disclosure - Issuance of Series B-1 Preferred Stock Sheet http://www.uncy.com/role/IssuanceofSeriesB1PreferredStock Issuance of Series B-1 Preferred Stock Notes 17 false false R18.htm 995317 - Disclosure - Warrant Liability Sheet http://www.uncy.com/role/WarrantLiability Warrant Liability Notes 18 false false R19.htm 995318 - Disclosure - Stock-Based Compensation Sheet http://www.uncy.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 995319 - Disclosure - Net Loss Per Share Sheet http://www.uncy.com/role/NetLossPerShare Net Loss Per Share Notes 20 false false R21.htm 995320 - Disclosure - Subsequent Events Sheet http://www.uncy.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.uncy.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.uncy.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 996001 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.uncy.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 996002 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.uncy.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.uncy.com/role/BalanceSheetComponents 26 false false R27.htm 996003 - Disclosure - Operating Lease (Tables) Sheet http://www.uncy.com/role/OperatingLeaseTables Operating Lease (Tables) Tables http://www.uncy.com/role/OperatingLease 27 false false R28.htm 996004 - Disclosure - Stockholders??? Deficit (Tables) Sheet http://www.uncy.com/role/StockholdersDeficitTables Stockholders??? Deficit (Tables) Tables http://www.uncy.com/role/StockholdersDeficit 28 false false R29.htm 996005 - Disclosure - Warrant Liability (Tables) Sheet http://www.uncy.com/role/WarrantLiabilityTables Warrant Liability (Tables) Tables http://www.uncy.com/role/WarrantLiability 29 false false R30.htm 996006 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.uncy.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.uncy.com/role/StockBasedCompensation 30 false false R31.htm 996007 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.uncy.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.uncy.com/role/NetLossPerShare 31 false false R32.htm 996008 - Disclosure - Organization and Description of Business (Details) Sheet http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.uncy.com/role/OrganizationandDescriptionofBusiness 32 false false R33.htm 996009 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables 33 false false R34.htm 996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value Sheet http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value Details http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables 34 false false R35.htm 996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 Sheet http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 Details http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables 35 false false R36.htm 996012 - Disclosure - Significant Agreements (Details) Sheet http://www.uncy.com/role/SignificantAgreementsDetails Significant Agreements (Details) Details http://www.uncy.com/role/SignificantAgreements 36 false false R37.htm 996013 - Disclosure - Licensing Revenues (Details) Sheet http://www.uncy.com/role/LicensingRevenuesDetails Licensing Revenues (Details) Details http://www.uncy.com/role/LicensingRevenues 37 false false R38.htm 996014 - Disclosure - Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets Sheet http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets Details http://www.uncy.com/role/BalanceSheetComponentsTables 38 false false R39.htm 996015 - Disclosure - Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment Sheet http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment Details http://www.uncy.com/role/BalanceSheetComponentsTables 39 false false R40.htm 996016 - Disclosure - Balance Sheet Components (Details) - Schedule of Accounts Payable Sheet http://www.uncy.com/role/ScheduleofAccountsPayableTable Balance Sheet Components (Details) - Schedule of Accounts Payable Details http://www.uncy.com/role/BalanceSheetComponentsTables 40 false false R41.htm 996017 - Disclosure - Balance Sheet Components (Details) - Schedule of Accrued Liabilities Sheet http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable Balance Sheet Components (Details) - Schedule of Accrued Liabilities Details http://www.uncy.com/role/BalanceSheetComponentsTables 41 false false R42.htm 996018 - Disclosure - Operating Lease (Details) Sheet http://www.uncy.com/role/OperatingLeaseDetails Operating Lease (Details) Details http://www.uncy.com/role/OperatingLeaseTables 42 false false R43.htm 996019 - Disclosure - Operating Lease (Details) - Schedule of Maturities of Lease Liabilities Sheet http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable Operating Lease (Details) - Schedule of Maturities of Lease Liabilities Details http://www.uncy.com/role/OperatingLeaseTables 43 false false R44.htm 996020 - Disclosure - Related Party Transactions (Details) Sheet http://www.uncy.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.uncy.com/role/RelatedPartyTransactions 44 false false R45.htm 996021 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.uncy.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.uncy.com/role/CommitmentsandContingencies 45 false false R46.htm 996022 - Disclosure - Stockholders??? Deficit (Details) Sheet http://www.uncy.com/role/StockholdersDeficitDetails Stockholders??? Deficit (Details) Details http://www.uncy.com/role/StockholdersDeficitTables 46 false false R47.htm 996023 - Disclosure - Stockholders??? Deficit (Details) - Schedule of Summarizes Activity for Warrants Sheet http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable Stockholders??? Deficit (Details) - Schedule of Summarizes Activity for Warrants Details http://www.uncy.com/role/StockholdersDeficitTables 47 false false R48.htm 996024 - Disclosure - Issuance of Series A-1 Preferred Stock (Details) Sheet http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails Issuance of Series A-1 Preferred Stock (Details) Details http://www.uncy.com/role/IssuanceofSeriesA1PreferredStock 48 false false R49.htm 996025 - Disclosure - Issuance of Series B-1 Preferred Stock (Details) Sheet http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails Issuance of Series B-1 Preferred Stock (Details) Details http://www.uncy.com/role/IssuanceofSeriesB1PreferredStock 49 false false R50.htm 996026 - Disclosure - Warrant Liability (Details) Sheet http://www.uncy.com/role/WarrantLiabilityDetails Warrant Liability (Details) Details http://www.uncy.com/role/WarrantLiabilityTables 50 false false R51.htm 996027 - Disclosure - Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability Sheet http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability Details http://www.uncy.com/role/WarrantLiabilityTables 51 false false R52.htm 996028 - Disclosure - Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants Sheet http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants Details http://www.uncy.com/role/WarrantLiabilityTables 52 false false R53.htm 996029 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.uncy.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.uncy.com/role/StockBasedCompensationTables 53 false false R54.htm 996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans Sheet http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans Details http://www.uncy.com/role/StockBasedCompensationTables 54 false false R55.htm 996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense Sheet http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense Details http://www.uncy.com/role/StockBasedCompensationTables 55 false false R56.htm 996032 - Disclosure - Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted Sheet http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted Details http://www.uncy.com/role/StockBasedCompensationTables 56 false false R57.htm 996033 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Sheet http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Details http://www.uncy.com/role/NetLossPerShareTables 57 false false R58.htm 996034 - Disclosure - Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities Sheet http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities Details http://www.uncy.com/role/NetLossPerShareTables 58 false false All Reports Book All Reports ea0220114-10q_unicycive.htm uncy-20240930.xsd uncy-20240930_cal.xml uncy-20240930_def.xml uncy-20240930_lab.xml uncy-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0220114-10q_unicycive.htm": { "nsprefix": "uncy", "nsuri": "http://www.uncy.com/20240930", "dts": { "inline": { "local": ["ea0220114-10q_unicycive.htm"] }, "schema": { "local": ["uncy-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["uncy-20240930_cal.xml"] }, "definitionLink": { "local": ["uncy-20240930_def.xml"] }, "labelLink": { "local": ["uncy-20240930_lab.xml"] }, "presentationLink": { "local": ["uncy-20240930_pre.xml"] } }, "keyStandard": 265, "keyCustom": 68, "axisStandard": 21, "axisCustom": 0, "memberStandard": 32, "memberCustom": 50, "hidden": { "total": 298, "http://fasb.org/us-gaap/2024": 241, "http://www.uncy.com/20240930": 53, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 383, "entityCount": 1, "segmentCount": 93, "elementCount": 766, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 936, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 10 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.uncy.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R3": { "role": "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Balance Sheets (Parentheticals)", "shortName": "Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockSharesIssued", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R4": { "role": "http://www.uncy.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Statements of Operations (Unaudited)", "shortName": "Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c12", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c12", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef":

"ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.uncy.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Statements of Mezzanine Equity and Stockholders\u2019 Deficit (Unaudited)", "shortName": "Statements of Mezzanine Equity and Stockholders\u2019 Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c22", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c31", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R6": { "role": "http://www.uncy.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Statements of Cash Flows (Unaudited)", "shortName": "Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R7": { "role": "http://www.uncy.com/role/OrganizationandDescriptionofBusiness", "longName": "995306 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.uncy.com/role/SummaryofSignificantAccountingPolicies", "longName": "995307 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.uncy.com/role/SignificantAgreements", "longName": "995308 - Disclosure - Significant Agreements", "shortName": "Significant Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "uncy:SignificantAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "uncy:SignificantAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.uncy.com/role/LicensingRevenues", "longName": "995309 - Disclosure - Licensing Revenues", "shortName": "Licensing Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.uncy.com/role/BalanceSheetComponents", "longName": "995310 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.uncy.com/role/OperatingLease", "longName": "995311 - Disclosure - Operating Lease", "shortName": "Operating Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.uncy.com/role/RelatedPartyTransactions", "longName": "995312 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.uncy.com/role/CommitmentsandContingencies", "longName": "995313 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.uncy.com/role/StockholdersDeficit", "longName": "995314 - Disclosure - Stockholders\u2019 Deficit", "shortName": "Stockholders\u2019 Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStock", "longName": "995315 - Disclosure - Issuance of Series A-1 Preferred Stock", "shortName": "Issuance of Series A-1 Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStock", "longName": "995316 - Disclosure - Issuance of Series B-1 Preferred Stock", "shortName": "Issuance of Series B-1 Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "uncy:IssuanceOfSeriesB1PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "uncy:IssuanceOfSeriesB1PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.uncy.com/role/WarrantLiability", "longName": "995317 - Disclosure - Warrant Liability", "shortName": "Warrant Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.uncy.com/role/StockBasedCompensation", "longName": "995318 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.uncy.com/role/NetLossPerShare", "longName": "995319 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.uncy.com/role/SubsequentEvents", "longName": "995320 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c11", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c381", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c381", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.uncy.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.uncy.com/role/BalanceSheetComponentsTables", "longName": "996002 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.uncy.com/role/OperatingLeaseTables", "longName": "996003 - Disclosure - Operating Lease (Tables)", "shortName": "Operating Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.uncy.com/role/StockholdersDeficitTables", "longName": "996004 - Disclosure - Stockholders\u2019 Deficit (Tables)", "shortName": "Stockholders\u2019 Deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.uncy.com/role/WarrantLiabilityTables", "longName": "996005 - Disclosure - Warrant Liability (Tables)", "shortName": "Warrant Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.uncy.com/role/StockBasedCompensationTables", "longName": "996006 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.uncy.com/role/NetLossPerShareTables", "longName": "996007 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "longName": "996008 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c120", "name": "us-gaap:ProceedsFromSaleOfOtherReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R33": { "role": "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996009 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable", "longName": "996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R35": { "role": "http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c139", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c130", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R36": { "role": "http://www.uncy.com/role/SignificantAgreementsDetails", "longName": "996012 - Disclosure - Significant Agreements (Details)", "shortName": "Significant Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c142", "name": "uncy:AgreementDuePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["p", "uncy:SignificantAgreementTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c142", "name": "uncy:AgreementDuePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["p", "uncy:SignificantAgreementTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.uncy.com/role/LicensingRevenuesDetails", "longName": "996013 - Disclosure - Licensing Revenues (Details)", "shortName": "Licensing Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "uncy:UpfrontFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "uncy:UpfrontFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable", "longName": "996014 - Disclosure - Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets", "shortName": "Balance Sheet Components (Details) - Schedule of Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable", "longName": "996015 - Disclosure - Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment", "shortName": "Balance Sheet Components (Details) - Schedule of Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.uncy.com/role/ScheduleofAccountsPayableTable", "longName": "996016 - Disclosure - Balance Sheet Components (Details) - Schedule of Accounts Payable", "shortName": "Balance Sheet Components (Details) - Schedule of Accounts Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable", "longName": "996017 - Disclosure - Balance Sheet Components (Details) - Schedule of Accrued Liabilities", "shortName": "Balance Sheet Components (Details) - Schedule of Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.uncy.com/role/OperatingLeaseDetails", "longName": "996018 - Disclosure - Operating Lease (Details)", "shortName": "Operating Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c189", "name": "us-gaap:AreaOfLand", "unitRef": "sqft", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c189", "name": "us-gaap:AreaOfLand", "unitRef": "sqft", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable", "longName": "996019 - Disclosure - Operating Lease (Details) - Schedule of Maturities of Lease Liabilities", "shortName": "Operating Lease (Details) - Schedule of Maturities of Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.uncy.com/role/RelatedPartyTransactionsDetails", "longName": "996020 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c194", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c194", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang":

null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.uncy.com/role/CommitmentsandContingenciesDetails", "longName": "996021 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c197", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c197", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.uncy.com/role/StockholdersDeficitDetails", "longName": "996022 - Disclosure - Stockholders\u2019 Deficit (Details)", "shortName": "Stockholders\u2019 Deficit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c203", "name": "us-gaap:SharePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R47": { "role": "http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable", "longName": "996023 - Disclosure - Stockholders\u2019 Deficit (Details) - Schedule of Summarizes Activity for Warrants", "shortName": "Stockholders\u2019 Deficit (Details) - Schedule of Summarizes Activity for Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "longName": "996024 - Disclosure - Issuance of Series A-1 Preferred Stock (Details)", "shortName": "Issuance of Series A-1 Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "longName": "996025 - Disclosure - Issuance of Series B-1 Preferred Stock (Details)", "shortName": "Issuance of Series B-1 Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c0", "name": "uncy:ProceedFromIssuanceOfPreferredStock", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PreferredStockDividendRatePercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R50": { "role": "http://www.uncy.com/role/WarrantLiabilityDetails", "longName": "996026 - Disclosure - Warrant Liability (Details)", "shortName": "Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c261", "name": "us-gaap:AdjustmentOfWarrantsGrantedForServices", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c261", "name": "us-gaap:AdjustmentOfWarrantsGrantedForServices", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "longName": "996027 - Disclosure - Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability", "shortName": "Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c263", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c263", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "longName": "996028 - Disclosure - Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants", "shortName": "Warrant Liability (Details) - Schedule of Issuable Preferred Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c331", "name": "uncy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c331", "name": "uncy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.uncy.com/role/StockBasedCompensationDetails", "longName": "996029 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c332", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c332", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable", "longName": "996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans", "shortName": "Stock-Based Compensation (Details) - Schedule of Summarizes Activity for Stock Options under all Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable", "longName": "996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense", "shortName": "Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c11", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c11", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable", "longName": "996032 - Disclosure - Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted", "shortName": "Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable", "longName": "996033 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share", "shortName": "Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c11", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c10", "name": "us-gaap:DividendsPreferredStockCash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } }, "R58": { "role": "http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "longName": "996034 - Disclosure - Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities", "shortName": "Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c11", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "first": true }, "uniqueAnchor": { "contextRef": "c358", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220114-10q_unicycive.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable or accrued expense", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": ["r88", "r89"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.uncy.com/role/ScheduleofAccountsPayableTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofAccountsPayableTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45", "r627"] }, "us-gaap_AccountsPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofAccountsPayableTable": { "parentTag": "us-

gaap_AccountsPayableCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r14", "r45"] }, "uncy_AccruedDrugDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AccruedDrugDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued drug development costs", "documentation": "The amount of accrued drug development costs.", "label": "Accrued Drug Development Costs Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r47"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued labor costs", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r47", "r595"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r29", "r113", "r447"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r706"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r55", "r627", "r909"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r472", "r791", "r792", "r793", "r794", "r851", "r910"] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": ["r762"] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b). File Number" } } }, "auth_ref": ["r762"] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": ["r760"] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r719"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r719"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r719"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r719"] }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "presentation": ["http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "label": "Adjustment of Warrants Granted for Services", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } }, "auth_ref": ["r5"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on Series B-1 preferred stock", "label": "Adjustments to Additional Paid in Capital, Other", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvancesToAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvancesToAffiliate", "crdr": "debit", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Advances", "label": "Advances to Affiliate", "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients." } } }, "auth_ref": ["r868"] }, "uncy_AggregateExercisePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AggregateExercisePrice", "crdr": "credit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate exercise price (in Dollars)", "documentation": "Represent the amount of aggregate exercise price.", "label": "Aggregate Exercise Price" } } }, "auth_ref": [] }, "uncy_AggregateShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AggregateShares", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shares", "documentation": "Aggregate shares.", "label": "Aggregate Shares" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r753"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r669", "r680", "r696", "r731"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r672", "r683", "r699", "r734"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r754"] }, "uncy_AgreementDuePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AgreementDuePayments", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agreement due payments", "documentation": "Amount of agreement due payments .", "label": "Agreement Due Payments" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r719"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r726"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r673", "r684", "r700", "r726", "r735", "r739", "r747"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r745"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r305", "r314"] }, "uncy_AltairMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AltairMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Altair [Member]", "label": "Altair Member" } } }, "auth_ref": [] }, "uncy_AltairNanomaterialsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AltairNanomaterialsIncMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Altair Nanomaterials, Inc [Member]", "label": "Altair Nanomaterials Inc Member" } } }, "auth_ref": [] }, "uncy_AmendedTrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AmendedTrancheBWarrantsMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amended Tranche B Warrants [Member]",

"label": "Amended Tranche BWarrants Member" } } }, "auth_ref": [] }, "uncy_AmendedTrancheCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AmendedTrancheCWarrantsMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amended Tranche C Warrants [Member]", "label": "Amended Tranche CWarrants Member" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r676"] }, "uncy_AnnualNetCashFlowFromOperationsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AnnualNetCashFlowFromOperationsPercentage", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual net cash flow from operations percentage", "documentation": "Annual net cash flow from operations percentage.", "label": "Annual Net Cash Flow From Operations Percentage" } } }, "auth_ref": [] }, "uncy_AnnualRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "AnnualRatePercentage", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual rate", "documentation": "The percentage of annual rate percent.", "label": "Annual Rate Percentage" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "verboseLabel": "Anti-dilution shares of common stock (in Shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r168"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r23"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r23"] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Square feet of office space (in Square Feet)", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r336"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r87", "r97", "r114", "r137", "r173", "r177", "r190", "r191", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r337", "r339", "r366", "r438", "r510", "r603", "r604", "r627", "r648", "r812", "r813", "r870"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r110", "r118", "r137", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r337", "r339", "r366", "r627", "r812", "r813", "r870"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssumptionForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssumptionForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable"], "lang": { "en-us": { "role": { "label": "Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r401"] }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Issuance of Series B-1 Preferred Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r676"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r661", "r664", "r676"] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r661", "r664", "r676"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r661", "r664", "r676"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r758"] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r742"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r743"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r738"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r738"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r738"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r738"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r738"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r738"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r300", "r301", "r302", "r303", "r304"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r741"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r740"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r739"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r739"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Components [Abstract]" } } },

"auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r664", "r676"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusiness"], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r44", "r72", "r73"] }, "uncy_CBCCGlobalResearchIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "CBCCGlobalResearchIncMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "CBCC Global Research Inc [Member]", "label": "CBCCGlobal Research Inc Member" } } }, "auth_ref": [] }, "us-gaap_CapitalizationLongtermDebtAndEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizationLongtermDebtAndEquity", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Public market capitalization", "label": "Capitalization, Long-Term Debt and Equity", "documentation": "Amount of consolidated capitalization which comprises long-term debt and equity instruments." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "periodEndLabel": "Cash and cash equivalents at the end of the period", "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r17", "r68", "r133"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r68"] }, "uncy_CashDividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "CashDividendsPreferredStock", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash Dividends to Series B holders", "documentation": "Amount of preferred stock cash dividend.", "label": "Cash Dividends Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateLineItems", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r147"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r717"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r804"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r714"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r712"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r107", "r115", "r116", "r117", "r137", "r157", "r158", "r165", "r167", "r175", "r176", "r201", "r216", "r218", "r219", "r220", "r223", "r224", "r228", "r229", "r232", "r235", "r242", "r366", "r464", "r465", "r466", "r467", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r498", "r519", "r541", "r569", "r570", "r571", "r572", "r573", "r771", "r789", "r795"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r32"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per warrant (in Dollars per share)", "verboseLabel": "Warrants exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r243"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Warrant Liability [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares warrants", "verboseLabel": "Warrant acquired shares", "netLabel": "Acquired warrant shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r243"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r718"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r718"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r336"] }, "us-gaap_CollateralizedAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollateralizedAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Significant Agreements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r51", "r90", "r440", "r497"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.uncy.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": {

"terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r76", "r208", "r209", "r578", "r807", "r809"] }, "uncy_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares reserved for issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r54"] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsShares", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Divided shares", "label": "Common Stock Dividends, Shares", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": ["r8"] }, "uncy_CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock [Member]", "label": "Common Stock Issuable Upon Conversion Of Series A2 Prime Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuable upon conversion of Series B-2 convertible preferred stock [Member]", "label": "Common Stock Issuable Upon Conversion Of Series B2 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3", "http://www.uncy.com/role/SignificantAgreementsDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r638", "r639", "r640", "r642", "r643", "r644", "r645", "r791", "r792", "r794", "r851", "r908", "r910"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r54"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r54", "r498"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock share issued", "netLabel": "Share issued", "label": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r54"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r54", "r498", "r516", "r910", "r911"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value per share \u2013 200,000,000 shares authorized at December 31, 2023 and 400,000,000 shares authorized at September 30, 2024; 34,756,049 and 97,858,406 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r54", "r442", "r627"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock voting rights", "verboseLabel": "Voting rights of common stock", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r30"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r723"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r722"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r724"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r721"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r43", "r101"] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r664"] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock", "verboseLabel": "Auto-conversion preferred shares", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt shares granted", "label": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Auto-conversion of the series A preferred stock", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": ["r13", "r30", "r53", "r78", "r238"] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research related payments", "label": "Costs and Expenses, Related Party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": ["r60"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "stpr_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "DE", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Delaware [Member]", "label": "DELAWARE" } } }, "auth_ref": [] }, "uncy_DeemedDividendsOnSeriesA1PreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "DeemedDividendsOnSeriesA1PreferredStock", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Deemed dividends on Series A-1 preferred stock", "documentation": "Deemed dividends on Series A-1 preferred stock\r \n.", "label": "Deemed Dividends On Series A1 Preferred Stock" } } }, "auth_ref": [] }, "uncy_DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets": { "xbrltype": "monetaryItemType",

"nsuri": "http://www.uncy.com/20240930", "localname": "DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Deferred insurance charges included in prepaid expenses and other current assets", "documentation": "The amount of deferred insurance charges included in prepaid expenses and other current assets.", "label": "Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets" } } }, "auth_ref": [] }, "uncy_DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Deferred preclinical and other charges included in prepaid expenses and other current assets", "documentation": "Represent the deferred preclinical charges included in prepaid expenses and other current assets.", "label": "Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets" } } }, "auth_ref": [] }, "uncy_DeferredRevenueMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "DeferredRevenueMilestonePayments", "crdr": "credit", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "documentation": "The represents value as an milestone payment for revenue.", "label": "Deferred Revenue Milestone Payments" } } }, "auth_ref": [] }, "uncy_DeferredRevenueUpforntPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "DeferredRevenueUpforntPayments", "crdr": "credit", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Upfornt payments", "documentation": "The represents value as an upfornt payment of revenue.", "label": "Deferred Revenue Upfornt Payments" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Company contributions", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contributions, percentage", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee\u2019s eligible compensation", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r688", "r689", "r703"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r28"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r487", "r489", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r529", "r530", "r531", "r532", "r535", "r536", "r537", "r538", "r561", "r562", "r563", "r564", "r638", "r640", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r39", "r40", "r41", "r85", "r487", "r489", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r529", "r530", "r531", "r532", "r535", "r536", "r537", "r538", "r561", "r562", "r563", "r564", "r596", "r638", "r640", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864"] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesAndFairValueTextBlock", "presentation": ["http://www.uncy.com/role/WarrantLiability"], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liability", "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": ["r84", "r86"] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liability", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r9", "r36", "r37", "r38", "r42", "r138", "r152"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.uncy.com/role/StockBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r272", "r275", "r306", "r307", "r309", "r618"] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r688", "r689", "r703"] }, "us-gaap_DividendsPreferredStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStockAbstract", "lang": { "en-us": { "role": { "label": "Issuance of Series A-1 Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStockCash", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividends on preferred stock", "label": "Dividends, Preferred Stock, Cash", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r3", "r79"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r664"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r661", "r664", "r676"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r661", "r664", "r676", "r727"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": ["r661", "r664", "r676", "r727"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in

the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r662"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r650"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r664"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r664"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r704"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r653"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r716"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r154", "r157", "r165", "r166", "r167", "r172", "r332", "r335", "r349", "r350", "r435", "r451", "r597"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Basic and Diluted Net Loss Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders,diluted (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r157", "r165", "r166", "r167", "r172", "r332", "r335", "r349", "r350", "r435", "r451", "r597"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r23", "r24", "r169"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.uncy.com/role/NetLossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r153", "r168", "r170", "r171"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": ["r766"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit rate", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law." } } }, "auth_ref": ["r845"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": ["r766"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": ["r767"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": ["r766"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": ["r767"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } } }, "auth_ref": ["r765"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": ["r767"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": ["r769"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-Based Compensation Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r308"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Recognized period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r308"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Options to purchase common stock [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r652"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r656"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r652"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r652"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r768"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r652"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Incorporation date", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r757"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": ["r756"] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [

"r676"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r652"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r652"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r652"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r652"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r759"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r710"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r752"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r752"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r752"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r108", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r174", "r202", "r203", "r204", "r245", "r326", "r327", "r329", "r330", "r331", "r333", "r334", "r335", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r388", "r450", "r456", "r457", "r458", "r472", "r541"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r198", "r199", "r200", "r328", "r772", "r773", "r774", "r846", "r847", "r848", "r849"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest on ownership", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r198"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r720"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r669", "r680", "r696", "r731"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r666", "r677", "r693", "r728"] }, "uncy_ExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ExchangeAgreementMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exchange Agreement [Member]", "label": "Exchange Agreement Member" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "uncy_ExclusiveLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ExclusiveLicenseAgreementMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exclusive license agreement [Member]", "label": "Exclusive License Agreement Member" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r726"] }, "uncy_ExercisedStockOption": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ExercisedStockOption", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercised stock options", "documentation": "Number of share options exercised stock option.", "label": "Exercised Stock Option" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": ["r764"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": ["r764"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liability", "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair value of Warrants", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r353", "r354", "r355", "r621"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r225", "r264", "r265", "r266", "r267", "r268", "r269", "r351", "r352", "r353", "r354", "r355", "r362", "r363", "r365", "r397", "r398", "r399", "r610", "r611", "r614", "r615", "r616", "r619", "r621"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r225", "r264", "r269", "r352", "r363", "r397", "r614", "r615", "r616", "r619"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r225", "r264", "r269", "r352", "r353", "r363", "r398", "r610", "r611", "r614", "r615", "r616", "r619"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]", "verboseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r225", "r264", "r265", "r266", "r267", "r268", "r269", "r352", "r353", "r354", "r355", "r363", "r399", "r610", "r611", "r614", "r615", "r616", "r619", "r621"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The

disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": ["r852", "r853"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table"], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r356", "r357", "r358", "r359", "r360", "r361"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r356", "r357", "r358", "r359", "r360", "r361", "r364"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r356", "r361", "r364"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r225", "r264", "r265", "r266", "r267", "r268", "r269", "r351", "r352", "r353", "r354", "r355", "r362", "r363", "r365", "r397", "r398", "r399", "r610", "r611", "r614", "r615", "r616", "r619", "r621"] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r356", "r357", "r359", "r360", "r361", "r364"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r7"] }, "uncy_FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants issued in connection with the issuance of preferred stock", "documentation": "Fair value of warrants issued in connection with the issuance of preferred stock." , "label": "Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r378", "r382", "r626"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r673", "r684", "r700", "r735"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r673", "r684", "r700", "r735"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r673", "r684", "r700", "r735"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r673", "r684", "r700", "r735"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r673", "r684", "r700", "r735"] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r663", "r687"] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r715"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r62", "r521"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r62"] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r661", "r664", "r676"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r205", "r206", "r207", "r357", "r361", "r364", "r453", "r455", "r526", "r590", "r620", "r880"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r206", "r207", "r357", "r361", "r364", "r453", "r455", "r526", "r590", "r620", "r880"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r121", "r318", "r319", "r320", "r321", "r322", "r325", "r463"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r18", "r132", "r323", "r324"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r776", "r787"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilitiesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Other Operating Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-

gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expense and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r673", "r684", "r700", "r726", "r735", "r739", "r747"] }, "uncy_InitialCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "InitialCarryingValue", "crdr": "debit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial carrying value (in Dollars)", "documentation": "Initial carrying value.", "label": "Initial Carrying Value" } } }, "auth_ref": [] }, "us-gaap_InitialFranchiseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InitialFranchiseFees", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial agreement amount", "label": "Initial Franchise Fees", "documentation": "The amount of initial franchise fees." } } }, "auth_ref": [] }, "uncy_InotivMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "InotivMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inotiv [Member]", "label": "Inotiv Member" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r745"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r665", "r751"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r665", "r751"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r665", "r751"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r181", "r784"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r128", "r130", "r131"] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r689", "r690", "r691", "r692"] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r705"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r705"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r705"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r173", "r180", "r191", "r603", "r783"] }, "uncy_InvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "InvestmentMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment [Member]", "label": "Investment Member" } } }, "auth_ref": [] }, "uncy_IssuanceOfSeriesA1PreferredStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceOfSeriesA1PreferredStockLineItems", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Issuance of Series A-1 Preferred Stock [Line Items]" } } }, "auth_ref": [] }, "uncy_IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock", "documentation": "Amount of issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock.", "label": "Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr" } } }, "auth_ref": [] }, "uncy_IssuanceOfSeriesB1PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceOfSeriesB1PreferredStockTextBlock", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStock"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-1 Preferred Stock", "documentation": "The entire disclosure for issuance of series B-1 preferred stock.", "label": "Issuance Of Series B1 Preferred Stock Text Block" } } }, "auth_ref": [] }, "uncy_IssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock", "documentation": "The amount of issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock.", "label": "Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr" } } }, "auth_ref": [] }, "uncy_IssuanceofSeriesA1PreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceofSeriesA1PreferredStockDetailsTable", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Issuance of Series A-1 Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "uncy_IssuanceofSeriesB1PreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "IssuanceofSeriesB1PreferredStockDetailsTable", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "label": "Issuance of Series B-1 Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r387", "r775"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r387", "r775"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r75", "r386"] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesOperatingAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease [Abstract]" } } }, "auth_ref": [] }, "uncy_LeesPharmaceuticalHKLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "LeesPharmaceuticalHKLimitedMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lee\u2019s Pharmaceutical (HK) Limited [Member]", "label": "Lees Pharmaceutical HKLimited Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": ["r649"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r380"] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discount rate of lease", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": ["r625"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.uncy.com/role/OperatingLeaseTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r867"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r385"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Year ending December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r385"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Year ending December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r385"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {

```
"http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year ending December 31, 2024",
"label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r867" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ],
"lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest rate / present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref":
[ "r385" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.uncy.com/role/OperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to extend
the lease term", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease.
Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r381" ] }, "us-
gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract",
"presentation": [ "http://www.uncy.com/role/OperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial lease term", "label": "Lessee, Operating Lease, Term of
Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and
thirteen days." } } }, "auth_ref": [ "r866" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.uncy.com/role/OperatingLease" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease",
"label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of
operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r374" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.uncy.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": {
"totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing
economic benefit to others." } } }, "auth_ref": [ "r12", "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r137", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222",
"r223", "r224", "r338", "r339", "r340", "r366", "r496", "r598", "r648", "r812", "r870", "r871" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.uncy.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity", "label":
"Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } },
"auth_ref": [ "r59", "r91", "r444", "r627", "r790", "r805", "r865" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.uncy.com/role/ConsolidatedBalanceSheet" ], "lang": {
"en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 (deficit) equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.uncy.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation":
"Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } },
"auth_ref": [ "r48", "r111", "r137", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r338", "r339", "r340", "r366", "r627", "r812", "r870", "r871" ]
}, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.uncy.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } },
"auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair
value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r352", "r852" ] },
"uncy_LicensingRevenuesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "LicensingRevenuesDetailsTable",
"presentation": [ "http://www.uncy.com/role/LicensingRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Licensing Revenues (Details) [Table]" } } } }, "auth_ref": [] },
"uncy_LicensingRevenuesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "LicensingRevenuesLineItems", "presentation": [
"http://www.uncy.com/role/LicensingRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Licensing Revenues [Line Items]" } } }, "auth_ref": [] },
"dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } },
"auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems",
"presentation": [ "http://www.uncy.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r211", "r212", "r215", "r315", "r609", "r810", "r811" ] }, "uncy_LotusInternationalPteLtdMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "LotusInternationalPteLtdMember", "presentation": [
"http://www.uncy.com/role/SignificantAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lotus International Pte Ltd [Member]", "label": "Lotus International
Pte Ltd Member" } } }, "auth_ref": [] }, "uncy_MaximGroupLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname":
"MaximGroupLLCMember", "presentation": [ "http://www.uncy.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maxim Group
LLC [Member]", "label": "Maxim Group LLCMember" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "MaximumMember", "presentation": [ "http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/LicensingRevenuesDetails",
"http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable",
"http://www.uncy.com/role/SignificantAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [
"r211", "r212", "r213", "r214", "r271", "r315", "r355", "r403", "r452", "r454", "r461", "r488", "r489", "r549", "r553", "r557", "r558", "r565", "r588", "r589", "r607", "r612",
"r617", "r621", "r622", "r623", "r624", "r636", "r814", "r872", "r873", "r874", "r875", "r876", "r877" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure
[Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r718" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } }
}, "auth_ref": [ "r718" ] }, "us-gaap_MeasurementInputAppraisedValueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputAppraisedValueMember", "presentation": [ "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang":
{ "en-us": { "role": { "terseLabel": "Measurement Input, Appraised Value [Member]", "label": "Measurement Input, Appraised Value [Member]", "documentation":
"Measurement input using assessed value of property." } } }, "auth_ref": [ "r854", "r855", "r856" ] }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input,
Discount for Lack of Marketability [Member]", "label": "Measurement Input, Discount for Lack of Marketability [Member]", "documentation": "Measurement input using
amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly." } } }, "auth_ref": [ "r621", "r854",
"r855", "r856" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputExercisePriceMember", "presentation": [ "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": {
"en-us": { "role": { "terseLabel": "Measurement Input, Exercise Price [Member]", "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement
input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r854", "r855", "r856" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input,
Expected Dividend Rate [Member]", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to
be paid to holder of share per year." } } }, "auth_ref": [ "r854", "r855", "r856" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input,
Expected Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to
be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r854", "r855", "r856" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Price
Volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase
(decrease) for given set of returns." } } }, "auth_ref": [ "r621", "r854", "r855", "r856" ] }, "uncy_MeasurementInputProbabilityForFDAApprovalMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "MeasurementInputProbabilityForFDAApprovalMember", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input
Probability for FDA Approval [Member]", "label": "Measurement Input Probability For FDAApproval Member" } } }, "auth_ref": [] }, "us-
gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ],
"lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]",
"documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r854", "r855", "r856" ] }, "us-
gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]",
"documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r353", "r354", "r355", "r621" ] },
"uncy_MilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "MilestonePaymentMember", "presentation": [
"http://www.uncy.com/role/LicensingRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payment [Member]", "label": "Milestone Payment Member" } } },
"auth_ref": [] }, "uncy_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "MilestonePayments", "crdr": "debit",
"presentation": [ "http://www.uncy.com/role/SignificantAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "documentation": "Amount of
milestone payments.", "label": "Milestone Payments" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "MinimumMember", "presentation": [ "http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/LicensingRevenuesDetails",
"http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable",
"http://www.uncy.com/role/SignificantAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [
"r211", "r212", "r213", "r214", "r271", "r315", "r355", "r403", "r452", "r454", "r461", "r488", "r489", "r549", "r553", "r557", "r558", "r565", "r588", "r589", "r607", "r612",
"r617", "r621", "r622", "r623", "r636", "r814", "r872", "r873", "r874", "r875", "r876", "r877" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r738" ] },
"ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel":
```

"Material Terms of Trading Arrangement" } } }, "auth_ref": ["r746"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r719"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r129"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r129"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r68", "r69", "r71"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable", "http://www.uncy.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net income (loss)", "netLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r61", "r71", "r93", "r109", "r119", "r120", "r124", "r137", "r142", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r163", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r332", "r335", "r350", "r366", "r449", "r518", "r539", "r540", "r646", "r812"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "terseLabel": "Net loss attributable to common shares, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r127", "r144", "r145", "r146", "r147", "r154", "r155", "r164", "r167", "r335"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to common shares, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r127", "r156", "r159", "r160", "r161", "r162", "r164", "r167"] }, "uncy_NetLossPerShareTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "NetLossPerShareTablesLineItems", "presentation": ["http://www.uncy.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Net loss per share [Abstract]" } } }, "auth_ref": [] }, "uncy_NetLossPerShareTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "NetLossPerShareTablesTable", "presentation": ["http://www.uncy.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Tables) [Table]" } } }, "auth_ref": [] }, "uncy_NetProceedsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "NetProceedsFromPrivatePlacement", "crdr": "credit", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from private placement", "documentation": "Net proceeds from private placement ampount.", "label": "Net Proceeds From Private Placement" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": ["r689", "r690", "r691", "r692"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": ["r763"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": ["r763"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r718"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r673", "r684", "r700", "r726", "r735"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r709"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r708"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r726"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r746"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r746"] }, "uncy_NonRule10b51ArrangementModified": { "xbrltype": "booleanItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "NonRule10b51ArrangementModified", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Modified [Flag]", "documentation": "Non-Rule 10b5-1 Arrangement Terminated.", "label": "Non Rule10b51 Arrangement Modified" } } }, "auth_ref": [] }, "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoninterestExpenseInvestmentAdvisoryFees", "crdr": "debit", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Advisory fee", "label": "Noninterest Expense Investment Advisory Fees", "documentation": "This represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses." } } }, "auth_ref": ["r92"] }, "us-gaap_NoninterestExpenseTransferAgentAndCustodianFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoninterestExpenseTransferAgentAndCustodianFees", "crdr": "debit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agent fees and offering expenses (in Dollars)", "label": "Noninterest Expense Transfer Agent and Custodian Fees", "documentation": "Fees paid to an agent employed by a corporation or mutual fund to maintain shareholder records, including purchases, sales, and account balances. Also includes custodian fees incurred during an accounting period from an agent, bank, trust company, or other organization that holds and safeguards an individual's, mutual fund's, or investment company's assets for them. These fees will be billed back to the client and are a component of noninterest expense." } } }, "auth_ref": ["r92"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "label": "Nonoperating Income

(Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r64"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable operating segment", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r600", "r606", "r799"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r96", "r599", "r798", "r800", "r801", "r802", "r803"] }, "uncy_OperatingLeaseDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OperatingLeaseDetailsTable", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Lease Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails", "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liability", "terseLabel": "Lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r377"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability - current", "negatedLabel": "Less current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r377"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability \u2013 long term", "verboseLabel": "Long term portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r377"] }, "uncy_OperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OperatingLeaseMember", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease [Member]", "label": "Operating Lease Member" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash payments on lease", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r379", "r383"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r376"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating lease right of use asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r788"] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OptionContractIndexedToEquitySettlementShareFairValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionContractIndexedToEquitySettlementShareFairValuePerShare", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value per share (in Dollars per share)", "label": "Option Contract Indexed to Equity, Settlement, Share, Fair Value Per Share", "documentation": "Fair value per share that would be issued upon settlement of option contract indexed to equity." } } }, "auth_ref": ["r850"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "auth_ref": [] }, "uncy_OrganizationandDescriptionofBusinessDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OrganizationandDescriptionofBusinessDetailsTable", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "auth_ref": [] }, "uncy_OriginalPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OriginalPricePerShare", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Original price per share (in Dollars per share)", "documentation": "Original price per share.", "label": "Original Price Per Share" } } }, "auth_ref": [] }, "uncy_OriginalTrancheCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OriginalTrancheCWarrantsMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Original Tranche C Warrants [Member]", "label": "Original Tranche CWarrants Member" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofAccruedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r47"] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherContractMember", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Contract [Member]", "label": "Other Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is classified as other." } } }, "auth_ref": ["r592", "r596", "r614"] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Required to pay", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": ["r62", "r63"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Credit card liability", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r47", "r627"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r718"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r781", "r806"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r664"] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": ["r844"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r671", "r682", "r698", "r733"] }, "uncy_OutstandingCommonStockPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OutstandingCommonStockPercentage", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding common stock percentage", "documentation": "Outstanding common stock percentage.", "label": "Outstanding Common Stock Percentage" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r674", "r685", "r701", "r736"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r674", "r685", "r701", "r736"] }, "uncy_OxylanthanumCarbonateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "OxylanthanumCarbonateMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Oxylanthanum Carbonate [Member]", "label": "Oxylanthanum Carbonate Member" } } }, "auth_ref": [] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":

"Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "uncy_PatentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PatentCostsPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Patent Costs", "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patent Costs Policy Text Block" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r707"] }, "uncy_PaymentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PaymentAmount", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payment amount", "documentation": "The total payment amount.", "label": "Payment Amount" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on preferred stock", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth_ref": ["r66"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs related to issuance of Series A-1 preferred stock and warrants", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r16"] }, "uncy_PaymentsOnFinancedInsurancePolicies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PaymentsOnFinancedInsurancePolicies", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Payments on financed insurance policies", "documentation": "The cash outflow from financing insurance policies.", "label": "Payments On Financed Insurance Policies" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r65"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r717"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r717"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r709"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r726"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r719"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r708"] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r710"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r755"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r709"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r650"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r650"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r657"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r659"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r650"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r650"] }, "uncy_PreferredStockCashDividendsToSeriesBHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PreferredStockCashDividendsToSeriesBHolders", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends to Series B-1 preferred stockholders", "documentation": "Preferred stock cash dividends.", "label": "Preferred Stock Cash Dividends To Series BHolders" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock conversion price (in Dollars per share)", "verboseLabel": "Conversion Price (in Dollars per share)", "label": "Preferred Stock, Convertible, Conversion Price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": ["r230"] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion shares", "label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": ["r230"] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual dividend rate", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": ["r229", "r550", "r554", "r556", "r566"] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividends to Series A-1 preferred stockholders", "label": "Preferred Stock Dividends and Other Adjustments", "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders." } } }, "auth_ref": ["r22", "r770", "r797"] }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference (in Dollars)", "label": "Preferred Stock, Liquidation Preference, Value", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": ["r135", "r232", "r244"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "verboseLabel": "Preferred Stock [Member]", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r638", "r639", "r642", "r643", "r644", "r645", "r908", "r910"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r53", "r228"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, shares", "netLabel": "Designated shares", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r53", "r498"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r53", "r228"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r53", "r498", "r516", "r910", "r911"] }, "us-

gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockTextBlock", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStock"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-1 Preferred Stock", "label": "Preferred Stock [Text Block]", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": ["r77"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock value", "verboseLabel": "Investors of convertible preferred stock", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r53", "r441", "r627"] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockVotingRights", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Voting rights of preferred stock", "label": "Preferred Stock, Voting Rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r30", "r53"] }, "us-gaap_PreferredUnitsOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsOfferingCosts", "crdr": "debit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering costs (in Dollars)", "label": "Preferred Units, Offering Costs", "documentation": "The cumulative amount of offering costs allocated to the preferred partners." } } }, "auth_ref": ["r80"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r782"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseOtherNoncurrent", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related payments", "label": "Prepaid Expense Other, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r778"] }, "uncy_PrepaidExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PrepaidExpensesPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "documentation": "Disclosure of accounting policy for prepaid expenses.", "label": "Prepaid Expenses Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid directors\u2019 and officers\u2019 liability insurance premiums", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r594", "r608", "r806"] }, "uncy_PrepaidPreclinicalServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PrepaidPreclinicalServicesCurrent", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid preclinical services", "documentation": "The amount of prepaid preclinical service.", "label": "Prepaid Preclinical Services Current" } } }, "auth_ref": [] }, "us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions", "crdr": "credit", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Present value of the lease", "label": "Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions", "documentation": "Present value of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing." } } }, "auth_ref": ["r98"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "uncy_ProceedFromIssuanceOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ProceedFromIssuanceOfPreferredStock", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs related to issuance of Series B-1 preferred stock", "verboseLabel": "Gross proceed (in Dollars)", "documentation": "The cash inflow from issuance of preferred stock.", "label": "Proceed From Issuance Of Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "verboseLabel": "Aggregate net proceeds (in Dollars)", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceed amount (in Dollars)", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Series B-1 preferred stock", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Series A-1 preferred stock and warrants", "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price." } } }, "auth_ref": ["r785"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Issuance of Series B-1 Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Warrants (March 3, 2023)", "verboseLabel": "Proceeds of warrants (in Dollars)", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromLicenseFeesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLicenseFeesReceived", "crdr": "debit", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Licensing revenue", "label": "Proceeds from License Fees Received", "documentation": "Cash received from licensees for license fees during the current period." } } }, "auth_ref": ["r70"] }, "us-gaap_ProceedsFromSaleOfOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherReceivables", "crdr": "debit", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Sale of Other Receivables", "documentation": "Amount of cash inflow from the sale of receivables classified as other." } } }, "auth_ref": ["r15"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options, proceeds (in Dollars)", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r2"] }, "us-gaap_ProductWarrantyLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyLiabilityLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Issuable Preferred Stock Warrants [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r6", "r386"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Subtotal", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r75", "r112", "r448"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r386"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "totalLabel":

"Net", "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r386", "r437", "r448", "r627"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r6", "r102", "r105", "r446"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.uncy.com/role/BalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r75", "r386"] }, "uncy_PurchaseOfAdditionalWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "PurchaseOfAdditionalWarrants", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of additional warrants", "documentation": "Number of additional warrants purchased.", "label": "Purchase Of Additional Warrants" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r707"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r707"] }, "uncy_QuotientSciencesLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "QuotientSciencesLimitedMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Quotient Sciences Limited [Member]", "label": "Quotient Sciences Limited Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/LicensingRevenuesDetails", "http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r211", "r212", "r213", "r214", "r263", "r271", "r301", "r302", "r303", "r315", "r355", "r400", "r402", "r403", "r452", "r454", "r461", "r488", "r489", "r549", "r553", "r557", "r558", "r565", "r588", "r589", "r607", "r612", "r617", "r621", "r622", "r623", "r624", "r636", "r640", "r808", "r814", "r855", "r873", "r874", "r875", "r876", "r877"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/LicensingRevenuesDetails", "http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r211", "r212", "r213", "r214", "r263", "r271", "r301", "r302", "r303", "r315", "r355", "r400", "r402", "r403", "r452", "r454", "r461", "r488", "r489", "r549", "r553", "r557", "r558", "r565", "r588", "r589", "r607", "r612", "r617", "r621", "r622", "r623", "r624", "r636", "r640", "r808", "r814", "r855", "r873", "r874", "r875", "r876", "r877"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r666", "r677", "r693", "r728"] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r650"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/LicensingRevenuesDetails", "http://www.uncy.com/role/SignificantAgreementsDetails", "http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r197", "r270", "r392", "r393", "r439", "r445", "r491", "r492", "r493", "r494", "r495", "r515", "r517", "r548"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r392", "r393", "r869"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r197", "r522", "r523", "r526"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.uncy.com/role/CommitmentsandContingenciesDetails", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/LicensingRevenuesDetails", "http://www.uncy.com/role/SignificantAgreementsDetails", "http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r197", "r270", "r392", "r393", "r439", "r445", "r491", "r492", "r493", "r494", "r495", "r515", "r517", "r548", "r869"] }, "uncy_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r389", "r390", "r391", "r393", "r394", "r469", "r470", "r471", "r524", "r525", "r526", "r545", "r547"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repaid amount", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r786"] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments to related party", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": ["r67"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r317", "r590", "r603", "r878"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r316"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r667", "r678", "r694", "r729"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r668", "r679", "r695", "r730"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r675", "r686", "r702", "r737"] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in Dollars)", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": ["r552", "r559", "r567", "r576", "r577"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {

"http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r56", "r79", "r443", "r459", "r460", "r468", "r499", "r627"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r108", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r202", "r203", "r204", "r326", "r327", "r329", "r330", "r331", "r333", "r334", "r335", "r341", "r343", "r344", "r346", "r348", "r373", "r375", "r456", "r458", "r472", "r910"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Licensing Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r106", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r591"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.uncy.com/role/LicensingRevenues"], "lang": { "en-us": { "role": { "terseLabel": "Licensing Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r106", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r262"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Licensing revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r94", "r95", "r125", "r137", "r173", "r178", "r179", "r189", "r191", "r193", "r194", "r196", "r201", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r366", "r436", "r603", "r812"] }, "uncy_RevisionsReducedTheOverallBudget": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "RevisionsReducedTheOverallBudget", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revision overall budget", "documentation": "Revisions reduced the overall budget.", "label": "Revisions Reduced The Overall Budget" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.uncy.com/role/OperatingLeaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset balance", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r384", "r626"] }, "uncy_RisksAndUncertainties PolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "RisksAndUncertainties PolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "documentation": "Disclosure of accounting policy for risks and uncertainties.", "label": "Risks And Uncertainties Policy Text Block" } } }, "auth_ref": [] }, "uncy_RoyaltiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "RoyaltiesPercentage", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties percentage", "documentation": "Percentage of royalties.", "label": "Royalties Percentage" } } }, "auth_ref": [] }, "uncy_RoyaltyPecentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "RoyaltyPecentage", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalty payment", "documentation": "Percentage of royalty payment.", "label": "Royalty Pecentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r746"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r746"] }, "uncy_Rule10b51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "Rule10b51ArrangementModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Modified [Flag]", "documentation": "Rule 10b5-1 Arrangement Modified.", "label": "Rule10b51 Arrangement Modified Flag" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of share issued", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.uncy.com/role/BalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.uncy.com/role/BalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.uncy.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Shares Potentially Dilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "uncy_ScheduleOfChangesInFairValueOfTheWarrantLiabilityClassifiedInLevel3Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfChangesInFairValueOfTheWarrantLiabilityClassifiedInLevel3Abstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Fair Value Of The Warrant Liability Classified In Level3 Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.uncy.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r796"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.uncy.com/role/ScheduleofStockBasedCompensationExpenseTable"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.uncy.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r35"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r198", "r199", "r200", "r328", "r772", "r773", "r774", "r846", "r847", "r848", "r849"] }, "uncy_ScheduleOfFairValueHierarchyOfFinancialLiabilitiesMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfFairValueHierarchyOfFinancialLiabilitiesMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Hierarchy Of Financial Liabilities Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "uncy_ScheduleOfFairValueOfAwardsGrantedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfFairValueOfAwardsGrantedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Awards Granted Abstract" } } }, "auth_ref": [] }, "uncy_ScheduleOfIssuablePreferredStockWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfIssuablePreferredStockWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Issuable Preferred Stock Warrants Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": ["http://www.uncy.com/role/BalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "uncy_ScheduleOfOutstandingSharesPotentiallyDilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfOutstandingSharesPotentiallyDilutiveSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Shares Potentially Dilutive Securities Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPreferredUnitsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPreferredUnitsTable", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "label": "Partners' Capital, Master Limited Partnership, Preferred Unit [Table]", "documentation": "Disclosure of information about preferred unit of master limited partnership (MLP) that has priority over limited partner unit in liquidation, redemption, conversion, tax status of distribution, and sharing of

distribution. Includes, but is not limited to, description of preferred unit, preferred unit authorized, issued, and outstanding, cumulative cash distribution made to preferred partner, cumulative net income shared by preferred partner, and aggregate account balance of preferred partner." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfPreferredUnitsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPreferredUnitsTextBlock", "presentation": ["http://www.uncy.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Issuable Preferred Stock Warrants", "label": "Schedule of Preferred Units [Table Text Block]", "documentation": "Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners." } } } }, "auth_ref": ["r80"] }, "uncy_ScheduleOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property Plant And Equipment Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.uncy.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6", "r386"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.uncy.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Activity for Stock Options under all Plans", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r10", "r11", "r81"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": ["http://www.uncy.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Awards Granted", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r83"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.uncy.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation Inputs into the Black Scholes Model for the Liability", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r83"] }, "uncy_ScheduleOfStockBasedCompensationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfStockBasedCompensationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Based Compensation Expense Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.uncy.com/role/StockholdersDeficitTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Activity for Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r32"] }, "uncy_ScheduleOfValuationInputsIntoTheBlackScholesModelForTheLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ScheduleOfValuationInputsIntoTheBlackScholesModelForTheLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Valuation Inputs Into The Black Scholes Model For The Liability Abstract" } } }, "auth_ref": [] }, "uncy_SecondClinicalTrialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SecondClinicalTrialPayment", "crdr": "credit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Second clinical trial payment", "documentation": "The amount of second clinical trial payment.", "label": "Second Clinical Trial Payment" } } }, "auth_ref": [] }, "uncy_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement Member" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r651"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r655"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r654"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r660"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r194", "r195", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r484", "r485", "r486", "r551", "r555", "r560", "r568", "r575", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r593", "r613", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r640", "r816", "r879", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r182", "r183", "r184", "r185", "r186", "r187", "r188", "r192", "r194", "r601", "r602", "r605"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expenses", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": ["r843"] }, "uncy_SeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA1PreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Series A-1 Preferred Stock", "verboseLabel": "Series A-1 Preferred Stock [Member]", "label": "Series A1 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA1PreferredStockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA1PreferredStockholdersMember", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Series A-1 Preferred Stockholders", "label": "Series A1 Preferred Stockholders Member" } } }, "auth_ref": [] }, "uncy_SeriesA2PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA2PreferredStockMember", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-2 Preferred Stock", "verboseLabel": "Series A-2 Preferred Stock [Member]", "label": "Series A2 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA2PrimeConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA2PrimeConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-2 Prime Convertible Preferred Stock [Member]", "label": "Series A2 Prime Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA2PrimePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA2PrimePreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Series A-2 Prime Preferred Stock", "verboseLabel": "Series A-2 Prime Preferred Stock [Member]", "label": "Series A2 Prime Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA3ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA3ConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-3 Convertible Preferred Stock [Member]", "label": "Series A3 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA3PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA3PreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-3 Preferred Stock [Member]", "label": "Series A3 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA4ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA4ConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-4 Convertible Preferred Stock [Member]", "label": "Series A4 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA4PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA4PreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-4 Preferred Stock [Member]", "label": "Series A4 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA5ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA5ConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-5 Convertible Preferred Stock [Member]", "label": "Series A5 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesA5PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesA5PreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A-5 Preferred Stock [Member]", "label": "Series A5 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesACertificateOfDesignationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesACertificateOfDesignationMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A Certificate of Designation [Member]", "label": "Series ACertificate Of Designation Member" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock [Member]", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r779", "r780", "r815"] }, "uncy_SeriesB1ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesB1ConvertiblePreferredStockMember", "presentation": [

"http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B-1 Convertible Preferred Stock [Member]", "label": "Series B1 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesB1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesB1PreferredStockMember", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Series B-2 Preferred Stock", "verboseLabel": "Series B-1 Preferred Stock", "netLabel": "Series B-1 Preferred Stock [Member]", "label": "Series B-1 preferred stock [Member]" } } }, "auth_ref": [] }, "uncy_SeriesB2PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesB2PreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Series B-2 Preferred Stock", "verboseLabel": "Series B-2 Preferred Stock [Member]", "label": "Series B2 Preferred Stock Member" } } }, "auth_ref": [] }, "uncy_SeriesBCertificateOfDesignationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesBCertificateOfDesignationMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B Certificate of Designation [Member]", "label": "Series BCertificate Of Designation Member" } } }, "auth_ref": [] }, "uncy_SeriesBHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SeriesBHoldersMember", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Series B Holders", "label": "Series BHolders Member" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B Convertible Preferred Stock [Member]", "verboseLabel": "Series B Preferred Stock [Member]", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r779", "r780", "r815"] }, "uncy_ShalabhGuptaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShalabhGuptaMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Shalabh Gupta [Member]", "label": "Shalabh Gupta Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.uncy.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Warrants, Warrants exercised", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Warrants exercised", "documentation": "Weighted average exercise price warrant exercised.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Exercise Price" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Warrants granted", "documentation": "Weighted average exercise price granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Warrants, Warrants granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares Underlying Outstanding Warrants, Outstanding at Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r288", "r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Activity for Warrants [Abstract]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r288", "r289"] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsExercised", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Warrants, Warrants exercised", "documentation": "The number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Exercised" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsIssued", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Warrants, Warrants contingently issuable", "documentation": "The number of Warrants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Issued" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares Underlying Outstanding Warrants, Outstanding at Beginning", "periodEndLabel": "Number of Shares Underlying Outstanding Warrants, Outstanding at Ending", "documentation": "The number of outstanding equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending", "verboseLabel": "Weighted- Average Remaining Contractual Term (in Years), Outstanding at Beginning", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r82"] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2": { "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms2", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending", "documentation": "Weighted- Average Remaining Contractual Term (in Years).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms2" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted- Average Exercise Price, Outstanding at Ending", "documentation": "Weighted average exercise price warrant outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price" } } }, "auth_ref": [] }, "uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceOutstanding", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted- Average Exercise Price, Outstanding at Beginning", "periodEndLabel": "Weighted- Average Exercise Price, Outstanding at Ending", "documentation": "The weighted average fair value at outstanding

date for equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding" } } }, "auth_ref": [] },
"uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercised", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Warrants exercised", "documentation": "The weighted average fair value at warrants exercised for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Exercised" } } }, "auth_ref": [] },
"uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsIssued": { "xbrltype": "perShareItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsIssued", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Warrants contingently issuable", "documentation": "The number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Issued" } } }, "auth_ref": [] },
"uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsEx
{ "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsExercise
"presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Warrants exercised", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Exercised" } } },
"auth_ref": [] },
"uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsIs
{ "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsIssued"
"presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Warrants contingently issuable", "documentation": "The number of warrants issued equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r273", "r274", "r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r300", "r301", "r302", "r303", "r304"] },
"uncy_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueOptionsForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueOptionsForfeited", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options forfeited", "documentation": "The amount of aggregate intrinsic value, options forfeited.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Options Forfeited" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r295"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Activity for Stock Options under all Plans [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, Options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r33"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares Underlying Outstanding Options, Outstanding at ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted-Average Exercise Price, Outstanding at ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } },
"auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r300", "r301", "r302", "r303", "r304"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Options granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r272", "r279", "r298", "r299", "r300", "r301", "r304", "r310", "r311", "r312", "r313"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options remained unvested", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r34"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exchange for cash price, per unit (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at Ending", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at Beginning", "negatedPeriodEndLabel": "Aggregate Intrinsic Value, Outstanding at Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Warrants exercised", "documentation": "Intrinsic value of outstanding award under Warrants exercised. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Exercised" } } }, "auth_ref": [] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Warrants granted", "documentation": "Intrinsic value of outstanding award under warrants granted. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Granted" } } }, "auth_ref": [] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsIssued", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Warrants contingently issuable", "documentation": "Intrinsic value of warrant issued award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Issued" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r300"] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerminYearsOptionsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerminYearsOptionsGranted", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in Years), Options granted", "documentation": "Number of shares weighted-average remaining contractual term, options granted.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Termin Years Options Granted" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding, Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r33"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in Years), Options vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r33"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares reserved", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "documentation": "Number of increase (decrease) of non-vested options." } } }, "auth_ref": [] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in Years), Options exercised", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in Years), Outstanding at ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r82"] }, "uncy_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminYearsOptionsForfeited": { "xbrltype": "durationItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminYearsOptionsForfeited", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in Years), Options forfeited", "documentation": "Number of shares weighted-average remaining contractual term, options forfeited.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Termin Years Options Forfeited" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested portion options (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r295"] }, "uncy_ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareholderMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shareholder [Member]", "label": "Shareholder Member" } } }, "auth_ref": [] }, "uncy_ShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShareholdersMember",

"presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders [Member]", "label": "Shareholders Member" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share issued price per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "uncy_ShilpaMedicareLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "ShilpaMedicareLtdMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shilpa Medicare Ltd [Member]", "label": "Shilpa Medicare Ltd Member" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r72", "r134"] }, "uncy_SignificantAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SignificantAgreementTextBlock", "presentation": ["http://www.uncy.com/role/SignificantAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Significant Agreements", "documentation": "The entire disclosure for significant agreements.", "label": "Significant Agreement Text Block" } } }, "auth_ref": [] }, "uncy_SignificantAgreementsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SignificantAgreementsDetailsTable", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Significant Agreements (Details) [Table]" } } }, "auth_ref": [] }, "uncy_SignificantAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SignificantAgreementsLineItems", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Significant Agreements [Line Items]" } } }, "auth_ref": [] }, "uncy_SignificantPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SignificantPaymentReceived", "crdr": "debit", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Significant payment received", "documentation": "Significant payment received.", "label": "Significant Payment Received" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r658"] }, "uncy_SpectrumPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SpectrumPharmaceuticalsIncMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Spectrum Pharmaceuticals, Inc. [Member]", "label": "Spectrum Pharmaceuticals Inc Member" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r107", "r115", "r116", "r117", "r137", "r157", "r158", "r165", "r167", "r175", "r176", "r201", "r216", "r218", "r219", "r220", "r223", "r224", "r228", "r229", "r232", "r235", "r242", "r366", "r464", "r465", "r466", "r467", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r498", "r519", "r541", "r569", "r570", "r571", "r572", "r573", "r771", "r789", "r795"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r108", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r174", "r202", "r203", "r204", "r245", "r326", "r327", "r329", "r330", "r331", "r333", "r334", "r335", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r388", "r450", "r456", "r457", "r458", "r472", "r541"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r194", "r195", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r484", "r485", "r486", "r551", "r555", "r560", "r568", "r575", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r593", "r613", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r640", "r816", "r879", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r139", "r140", "r141", "r174", "r375", "r404", "r462", "r483", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r521", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r541", "r641"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r139", "r140", "r141", "r174", "r197", "r375", "r404", "r462", "r483", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r521", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r541", "r641"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r670", "r681", "r697", "r732"] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value (in Dollars)", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "uncy_StockBasedCompensationDetailsScheduleofFairValueofAwardsGrantedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockBasedCompensationDetailsScheduleofFairValueofAwardsGrantedTable", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueofAwardsGrantedTable"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of Fair Value of Awards Granted [Table]" } } }, "auth_ref": [] }, "uncy_StockBasedCompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockBasedCompensationDetailsTable", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accrued dividends on preferred stock", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r8", "r30", "r54", "r57", "r79", "r226"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Series A-2 Prime preferred stock into common stock (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": ["r8", "r30", "r53", "r54", "r79"] }, "uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock (in Shares)", "documentation": "Number of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock.", "label": "Stock Issued During Period Shares Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr" } } }, "auth_ref": [] }, "uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-1 preferred stock, net of issuance costs (in Shares)", "documentation": "Number of shares of stock issued during the period pursuant to series B-1 preferred stock, net of issuance costs.", "label": "Stock Issued During Period Shares Issuance Of Series B1 Preferred Stock Net Of Issuance Costs" } } }, "auth_ref": [] }, "uncy_StockIssuedDuringPeriodSharesIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr": { "xbrltype": "sharesItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock (in Shares)", "documentation": "Number of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock.", "label": "Stock Issued During Period Shares Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/ShareholdersEquityType2or3", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability (in Shares)", "verboseLabel": "Issued of common shares (in Shares)", "netLabel": "Share issued", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r8", "r53",

"r54", "r79", "r464", "r541", "r570"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share of restricted stock", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r8", "r79"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.uncy.com/role/ScheduleofSummarizesActivityforStockOptionsunderallPlansTable", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for exercise of options (in Shares)", "negatedLabel": "Number of Shares Underlying Outstanding Options, Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r8", "r53", "r54", "r79", "r285"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r79"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Series A-2 Prime preferred stock into common stock", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r79"] }, "uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock", "documentation": "Represent the amount of issuance of series A-2 preferred stock and common stock upon conversion of series A-1 preferred stock.", "label": "Stock Issued During Period Value Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr" } } }, "auth_ref": [] }, "uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesB1PreferredStockNetOfIssuanceCosts", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-1 preferred stock, net of issuance costs", "documentation": "Value of stock issued as a result of the series B-1 preferred stock, net of issuance costs.", "label": "Stock Issued During Period Value Issuance Of Series B1 Preferred Stock Net Of Issuance Costs" } } }, "auth_ref": [] }, "uncy_StockIssuedDuringPeriodValueIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesB2PreferredStockAndCommonStockUponConversionOfSeriesB1Preferr", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock", "documentation": "Represent the amount of issuance of series B-2 preferred stock and common stock upon conversion of series B-1 preferred stock.", "label": "Stock Issued During Period Value Issuance Of Series B2 Preferred Stock And Common Stock Upon Conversion Of Series B1 Preferr" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A-1 preferred stock, net of issuance costs and allocated fair value of warrant liability", "verboseLabel": "Common stock valued", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r8", "r53", "r54", "r79", "r472", "r541", "r570", "r647"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r79"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r640"] }, "uncy_StockholdersDeficitDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "StockholdersDeficitDetailsTable", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 (deficit) equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r54", "r57", "r58", "r74", "r500", "r516", "r542", "r543", "r627", "r648", "r790", "r805", "r865", "r910"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 (deficit) equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.uncy.com/role/StockholdersDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Deficit", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r77", "r136", "r227", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r245", "r347", "r544", "r546", "r574"] }, "uncy_SublicenseDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SublicenseDevelopmentAgreementMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sublicense Development Agreement [Member]", "label": "Sublicense Development Agreement Member" } } }, "auth_ref": [] }, "uncy_SublicenseIncomePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SublicenseIncomePercentage", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sublicense income percentage", "documentation": "Sublicense income percentage.", "label": "Sublicense Income Percentage" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.uncy.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r395", "r396"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "uncy_SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable", "presentation": ["http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy of Financial Liabilities Measured at Fair Value [Table]" } } }, "auth_ref": [] }, "uncy_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": ["http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.uncy.com/role/BalanceSheetComponents"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r777"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.uncy.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "uncy_SyneosHealthLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "SyneosHealthLLCMember", "presentation": ["http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Syneos Health LLC [Member]", "label": "Syneos Health LLCMember" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r725"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r804", "r868"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.uncy.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r717"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r724"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r745"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r747"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "uncy_TrancheAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "TrancheAWarrantMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us":

{ "role": { "terseLabel": "Tranche A Warrant [Member]", "label": "Tranche AWarrant Member" } } }, "auth_ref": [] }, "uncy_TrancheBWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "TrancheBWarrantMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tranche B Warrant [Member]", "label": "Tranche BWarrant Member" } } }, "auth_ref": [] }, "uncy_TrancheCWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "TrancheCWarrantMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tranche C Warrant [Member]", "label": "Tranche CWarrant Member" } } }, "auth_ref": [] }, "uncy_TransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "TransactionPrice", "crdr": "debit", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction price", "documentation": "Transaction price.", "label": "Transaction Price" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r748"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r749"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r749"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r747"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r747"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r750"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r748"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.uncy.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Available common shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r31"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesB1PreferredStockDetails", "http://www.uncy.com/role/SignificantAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r336"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r744"] }, "uncy_UpfrontFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "UpfrontFees", "crdr": "debit", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Upfront fees", "documentation": "Upfront fees amount.", "label": "Upfront Fees" } } }, "auth_ref": [] }, "uncy_UpfrontPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "UpfrontPaymentMember", "presentation": ["http://www.uncy.com/role/LicensingRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Upfront Payment [Member]", "label": "Upfront Payment Member" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.uncy.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r25", "r26", "r27", "r99", "r100", "r103", "r104"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r713"] }, "uncy_WarrantLiabilityDetailsScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "WarrantLiabilityDetailsScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable", "presentation": ["http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable"], "lang": { "en-us": { "role": { "label": "Warrant Liability (Details) - Schedule of Valuation Inputs into the Black Scholes Model for the Liability [Table]" } } }, "auth_ref": [] }, "uncy_WarrantLiabilityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "WarrantLiabilityDetailsTable", "presentation": ["http://www.uncy.com/role/WarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Warrant Liability (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.uncy.com/role/IssuanceofSeriesA1PreferredStockDetails", "http://www.uncy.com/role/ScheduleofIssuablePreferredStockWarrantsTable", "http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable", "http://www.uncy.com/role/StockholdersDeficitDetails", "http://www.uncy.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability [Member]", "verboseLabel": "Warrants to purchase common stock [Member]", "netLabel": "Warrant [Member]", "label": "Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r638", "r639", "r642", "r643", "r644", "r645"] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.uncy.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.uncy.com/role/ConsolidatedBalanceSheet", "http://www.uncy.com/role/ScheduleofChangesinFairValueoftheWarrantLiabilityClassifiedinLevel3Table", "http://www.uncy.com/role/ScheduleofFairValueHierarchyofFinancialLiabilitiesMeasuredatFairValueTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value opening balance", "periodEndLabel": "Fair value ending balance", "terseLabel": "Warrant liability", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r854", "r855", "r856"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.uncy.com/role/ScheduleofValuationInputsintotheBlackScholesModelfortheLiabilityTable"], "lang": { "en-us": { "role": { "terseLabel": "Warrants measurement inputs", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r854", "r855", "r856"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.uncy.com/role/StockholdersDeficitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r854", "r855", "r856"] }, "uncy_WarrantsToPurchaseConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.uncy.com/20240930", "localname": "WarrantsToPurchaseConvertiblePreferredStockMember", "presentation": ["http://www.uncy.com/role/ScheduleofOutstandingSharesPotentiallyDilutiveSecuritiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase convertible preferred stock [Member]", "label": "Warrants To Purchase Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in Shares)", "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r156", "r167"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.uncy.com/role/ConsolidatedIncomeStatement", "http://www.uncy.com/role/ScheduleofBasicandDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic (in Shares)", "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r154", "r167"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r761"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r711"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":

"https://asc.fasb.org/235/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481161/840-30-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r332": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r396": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954",

"SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",

"Subparagraph": "ii", "Sentence": "F" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r770": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r771": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-

10-50-5" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r875": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "980", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 78 0001213900-24-097118-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-097118-xbrl.zip M4$L#!!0 (+$X;5D]1ELN-ED! ! O#P ; 96$P,C(P,3$T+3$P<5]U M;FEC>6-I=F4N:'1M[+UK=^) (DC#\G5^AE]G>K3I'N) 0MW/(SZ% MV_7,SO-ECI 2HVDAT9*PB_GU;T1FZ@8"=$$@V>PYVU,&D=/GUY?7R\T>,;5#(>X]M+1 MB(L?"*T67^[*(;C89^%I281;^T609$%N?^[V/W=[PH^G*_A#5MCC,P\V"1NU MW,]\S;\V^7N2WM'DS^HD?.[GQ#$O7*)=/-LOG^"+3[AZ*#G! _BQNG#MO(\ M";[XY*T6!)^66^U.JR/YOR&:GKPX?!%;W'1M19;ZR2^0V^W.) _Y$\(.?VYZ5 MX%G+-"SROU\>OH>/>\G/AX]^\GPLJ1[@&;?7;K7EEB1'%FG! 6(+^0?:M8[4 M;;4'$:C DW_L."E^/5%=XC_N.N'>IZH[H4_"AS$ NM["208U?A-[=&EIJ]CK M\0,D"?I4>]AI!T^ZK6=576R^G7\17]9M(16XB4_3;^*/;R,G@,'P$WSK/XA? MZ<RI_K?6)?1A\U=M&0Y7JJI060_6GN>/A_OP,>PB?7-1->@Z6E#[][^_?'[49F:NMC9VX1O9?;=\/\H(F\@2BZJ.&@/_WJV=X)AD) MOWYB_V@T?IT33Q4TV_*(!13FD9_>)_I#RIY:Y,^E\?+7YA7[OO4$&&Q^@C4_ ML45_G=CZ:O2K;KP(KK_%9@,># M#R:VY]ES^AF\^=-B[>W(9;\9Q 0>^[T2>M>?2;(4*,G2['TI?!JZ-X,M]K^ MI;D!EY9K_(O E_C@Q'9TXK#5OIBJ]H<@P^E M^Y+O?>,$GS:.D #F]"!-0D@J,/N[7=VCCVPY>FZ0CMI2P#LR>C'[_?C]=6/AYNGF^M'87S[5;C^WZO_'-_^=BUW/!V='@JPV-NXNCX_W;W\+OPJ_'SLV5; MM\LY_%1CG.VG]T"F?VUJ(-,L=0YO!K7F\U=;@V2\+WPUKIOX@7+W/4^,GT5N>LR1) M./B?I>K_5LS5_UG8CA=#1Q_!,>PKO(^O_Y,7YXNG[X_G?AX?K^ M[N%)N/_Q\/AC?/LD/-T)<#>?X(*4D>X>Q"D[@?]HW#W37CZSVLAL*OI6%'.?*=[=%^U)=^LQW!FQ'A3Q\'P@)^;NM@W>A@P63 L0Y62FL.#\P0 MPRU=7;561'5:Q$K"^3U]R[6E?X6?Q3 ^:(X>R<(C\PEQA$Y;;&2^T]\,5U/- MO\/+O\$G;FSU87.$*NCF]7XWUWTRNGMXP\<[&C>;JJ:;R,ZHJ6^@X;?)SY0V MYV?*+G[V]#"^?;RA7*NV#.WX\I]S,B\ O_*IHX]%_X!_R=X-OW?-PV'*WL^ M-UST4PE3PR2"M41.^CF]:G1M@7FX^@:_O:4_C=&OU!R!0=I2VMV! (Z89C;8 M/9!GPT4Z]&[AFQ!^O:YOJ5S]_>KF_U[CG7T8WU__>+JY>A2%F]NK"P;#=;@> MZY2C#]<_51%!=P5T0S9@:H!88EF!X;D.:4:7A(VSXY(CWU D0 MNT9,V'B'2?B])BG+G!?.@3$9?B:F^J@YAY,KDU@;5>GH21! @ MNQ";_*LB<-QW&'G@BT9^D*IL/!O7>5)_WNCP4[BB&L7Q!OONI@#&0&IU>IU! M;RCOPRW\AY*\XR_W0AP/7FWZY_#L13,&DNS8^4#I5 #1;H-L=X1_+AW#U0V- MBG=[^NO$^30";A0A;/JL\ZQ:QK_HWQ^W834#*G/L^]XQ@)FM!-B_I:N.+MQ8 M^A)8J:&:;--7I@I"VD>5@'=08 @[T8YO+AXN'B^$Z_G"M%?$8;N,$U32!CD5 M?*+\E_/DMR3Y)UFOX5C7'>*Z_'^^&Q:18AJ4W!PIG79;N#:%*S!-+!ND+!#% MV@T3L^IKFZ^58Z_M@%F]-. NR5+[E(I;;H!>P3_OG"?[U8J=2VF.OMNN,#8] MVST4$"G3N7/N09@:--82>1_PT*OQ^HMRON?>!J%M_C]C$9? \!:0P4.E+9]4 MQX)#W3EO$%G_!,W$F*Z;(U!24-03S%S19@245/C5'\+KC%#M"]TK M3F 2?FY\D#X*,S,T<^@"ZII3/56SN$*K&=TM])O3'_"P?&9E\D-E9)V!; MP?>3?\+>\7GZ*/P(=\'702>@2S=!-XFD,VP+NKIR+X3<_LD@"D)5KZP"YVKI M.+ KYI"$K:*$BWO&E6%S!>R(4(+;EBY]-V:M_;1J+C*EZ:!- 3D,S<\S! # M.:%YCFVAV62N! (FU L,!:!95:,2XJOJJ0+ZXM:O5+C&8NFX2R1E^ *# X+2 M[G+GS=)D>OMCZTGX@&#I7PIR1[Z)QKTNADN,KH%.G$2+Y9PN(O%-AS<%Y!Z MQ6]#X#//=ALB $;X\LL1O0W==CFWP;^^Y]O ;@/0GPK"U0$>KVH:W :6.(GT MX2#?3?Q4 (RT$K]PYW"-X"V.S^<$S'M4K96(X@:6]Z,1W@6GAW]U9OY7U\T M'@FA>]/)U+!H],#%._3O?QG(G)S$*N"33>V;\IU\W5_V>4J^)O/#/N]A]Y;6>5Y(-'2>Y< M\0="@2-U._N@?YO$\]*ZWH^!A=Y6NLM!:X_;&&6V=Q3-4&)(HYOYL@1+$(S& M"-)ZI3*]6.SC#EP0U_EK4][P$>\!_76RV#D%X/VM_$9WRD1>\&"[E?)9J:89JH@S&"";:WBZ/L[@"AD -?P)=P8:ID^T MP@<@1:K5L[R%39T9L%_8% TM.[:]V4LIJ:E1SS0ML;Y)<[^[C<&S9,(WY% M1C#$V<8DY ^3CXV0.CZ?'"05-J183L.:+34S/-+"K<$REOWJJ(O@964F:Z)](+4PPKXSKV/'-KZSE:6=8L=2#.RKUUCVNYA/;_(!I?=P[%N> MID;137QI#C<8-D0=^/XU7P='&D4:=@V[! UH:>EX*VSGL_"7JZOKZV_?4F2U MI'5(SM3]$8:$ZPHMJ+HGP;^V+=EM"K0ID M(%;H MH-^5P+X?/WX=;Y0=,=P*OX/*0SQ1^/[]ZB2Y-Z>2V;FUG+&+\OO6?F%E)%)' MI&7R(HITAPBO^)X[. ;#0C ;8JA6J"[]@9<]#/_M]\N?T65]ZLY;REVUZ+ M/Y(0=]7,E.+P$2^B>[?TJ*4"U _R&A@.H9)[:1GLA?2ZQN)R71D+TCIB?]@3 ME7;/)O!_NP5"$NQ=7 MN7(7>9:F_Z:+ZC+S%W<=;P"ATW26&?RU=L,/C702$ M6G-ULJH5P])B=\5P4%%\)Y(KA->"=""UXG$OXX9]+8J%6(H5GHZ7P[=;T"7) M"?CJ1="P5IL=*C+-R,$BVXV!(7CUMJU,'*+^T9H08#6P\P4]271[O83=X9;S MOSQ*#74CA*T*Z]/XR_=K+'VZNKM]NKY].FI1>$4MN89 "Q48[D/])U']#=;\ M):8W9?GM_+?##]HRR11.,T3B36#@_$/#PHSCST)K&"7<%*]E%R&ZZ]+,#KPA M=#NW]D6B9<&@'%SG#3"/>9\)D-N**'<&HMSM?FR&IXOX[7;V_'MU*Y <<;4T/G*]%X7P&)M&H0=:K7$V@VP=FH?EI:ZU V/Z!_/M'JFU3)H56F.:)T)RQ8&XKQ;$%;"Y@H? M?@3D%U#P$_R64']]-2SB9V5>TU#]!@4SPF:=+HY%OO*9?*M,OODIM;M.J=2A M-;--4*Y=[C2/GPE4T,SO(_"]9]+PUO5DX8[9QJN,@T?F 7WU@G[2G5GPC?3 M?DUFP14E6N5,M.^(:/N8"^H1%S,6O@6I4!$ZCE#N\6BP>Z;!$QG_\N&,__Q$ M.6B.?A_?CG^CYCU7'1Z%KS>/5]$H^TO:%A,>^/[WQYM'],F&7H&KN]NOK-<5 M/O-P_?CC^Q-l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

(Y6%6I"YT"M;Y0PT)KN.+CEBS<.\:< M" N'3 D(=1Y(%H5_V\E=E2AWS9SWSMY$*>Q>=>X<.FI$_[\X#?R>.'2N>>(L M<^"[\/WF1//^<(\PZ%9JNP-@973F>8*X6)_%'HY)#SH%!
(9'>@REG3.??&@V M:'Z\]&:V8_R+Z"GGS ^ YRD=L:=L&H="A/[XT'@U6%Y0O2UC%=/C^#0'ED'5 ME<3.8"'1@%MAX\XEGGQS=.2Q$9WD$-]S\$X63-OA^E5!=8XCH^=#$B5)NDA0
M^[;B>NWLF\BNB+H"E-RJI9[5R;GQ(ZM8:W+X"!)1@G)BY^ @SB%V!FE@7#-AH]15V'1+%S:YS<(TPN<^+G$^]Y$X@VJQ\'TVW!!2 MVQT6L_FHP)$OT^/G)!)@*&7!R6FV*%-
?:;O=WN+97D=&!OE<2'[A7+7T#TM9 M'I:S/-R)R='$__%A8K@N9HW2IAUIA&ME!="@K@)H>"IK)XUXP>B";;6S9N3\ MS)]IYH"H0&U.T0_MY);^WN(N^
1WKIH"]AL#U4W0U(7AJ69="3\\ MT3TYX?2+M@#\53#(OJUZE@ $C<"O:\,>%&]<6%3\(H=Y ,:?$\1NRF: MLJ7. MWHS?S&T%?DIA\:?6"8](=B7SE@$N_'"]?]QQ-_L_35>*.T6(251-,(
MKRFPLM$>K<@>M/?7E[PCSE$;X]B-K*TXPO)OM./V)XI7*,D_=>,QLT"CG6WG MKF5/K /5'HPM/2>=#<\-S(Y=_I ;61C.*K^U66R<9.-$P[+*>=LC(8*]:?9\
MH5HK]&]9M@=+>K;@S8@P-2S5T@RJGX!>-V?C+4X[-*P"@S4[B8,U+P7J](S$M_MO9$1FV,'+JBV.5Y3.H_7/.P 2>7=#4W$+-@)]B;G%:[PGVZC$Q,V&9T4=1I: MF&WR5;+N=: 1:
[W#CUA[FCD@D7^'Y6:N<&WI1/]UXGP:Q:-+*>V=8T^<*P$< MMX:U$QIL/P<#28[1:J5"]#RQL#(3"VMRVC-N3W'M]YU]Q^.E_WJ[B7":A8\R MQK$K[QSCF.08W%NJ_MV
T[EH(SODA5A+LGW28Z8[LOGC//([?79,)\[E_T[8< MV%Y7L0\>.48WOBO(;B_\,$,VNZ]2*A:K9E<^E5-2:HYZ_?UAS#,2BUV/7FG7 MH]3$]>%B X\5ZB5RWDPM-
E.YEB]K70S]6;OGWCWGS91.X@?ME?! 7*(Z&IOM MKH/8-VTZ&^V4"9E2NY#JP@XTMO2OX7'X0.!4^HR,V3&=PL,?3P0[Z:2PZR#L MVBF2VBH)NV(J@XD/NV5[=
(DEGZ*J9K5TC/R>FA\[OT;L4 %_M,2GS5O6Y81FNAHW"UD_]]O*QRLD(3C0@-K&,9!E(3CLORMVSWV3CB@^1!8&Z(^(W5JF<"
<5A#+?200EM-L M:[@#WC9I%1+"@>^$4U0J5[/<;HZZXK"SOX#TS @.)7;S(0IC]%ES0U_=2=;OMNI*4\>>^]*5
M9LV6ZN;87;9W&*%W8VGVG.#A,A7NR4I:^;=Y_K(G3NP!VT%$4%ZP==-*H\]! M[2 "(2_8>M2KIO3J![>37M)^:DZ]%6RGF$URY\V((QCTT,('WX3Y> YIGC?S
M5J]+VOMO\!M,VB>MQ:]MK//&>H%38+"$\2K_7*D42BPP3S$1MXK!1!"&@ M#9LC12H:9:IA=+,(T#IM %]*!,$] NU4M[,C-4=#I5J-H;*S5ZY$U-=@\T_" M+?
5;VP]*/@&D*,=+\;Z/Y=,K-]- M_\8 F,U!T$&_BM@9GEWNQU/Z#X@]G. L]KO96_"\=>R5*"%3HV\KU@8TN3)% MJ]5SR[OBXOF MVV(KOO^Z:->1TLB2?;"OFU:*R28H\H?,
[0S)"DI;>3FO?8! MN["^$6Y>GBPNAC),V^E[AEA1Q2_J3"VEY7#XCLO@ M1,Q>=W\-U-M(-J$!T%L"EK#MUCB_!$Z0,VBM*,V1(G8Z]7,C%1-%^0'618"U M4QCQE0-8(4F0'V
]FA;15^H'L1-=R3Y-S01>5Z\\DJ^S'@B/%BP),Z[:[+ MQRB/6]+Z1';> _FT-Z)(7^?X -6O_JG'EDX3:D(+.)6?0L%1U'DJC\N^(;G; ME/2K-
O9S#^ZU<$]%LRD*'*J,/+SSGRM2T"%,K@KU9TELK]E;?I/'TX(,BYK.(,L&,ND,LG1#AC945R[+&VU)KV0JP42[,EF+.W+?S+^ ME49\==&5VAZ>[(Cl)^-^)
[QV%E&:D"4KPGRL/LPP'WH?#41EX>21^,0TDC\T78 M.,";M=(SS*5']+=)O'$U0,Y$O/[\U'OBT!GW7QF@HN/M$XD4GM^<=M_M9LHL M*+;3^&7*ML]>
<]2^2&2+9SZ905TY):GU,^5$G(I4!DAJB8KPF=0RJ%6G)+5A MIE*NDY%:#RW^"RDI7'$EM?3:WPDIK2=ER4 Y':)R-,Z.XF=3$EIU<-(,#L\)BWGC MVM[-[;=,!.N#?,P@?
KO$D6MW4W[!* V[=R'XHZ0<4' "[79.L>F-W6[*_4 M*%>0&O?:5&5LNa@U8ML,293:[2U]A,_4F#FSN2+$N,_JJIR<[F,[5 5D=$?L MMY(*F0]/B[Y^_(GZ0?U9R2>:S5S.VQX)$50-
=6K56E&EVO8(3?/Q9D28&I9J M:89]PKO]H=Z'WUEY9VXF3-2.S(N_I^/I_2'W0!*7 BWD@S>%4^0IE]F8&VM-!]_L'G89'W,1.L"9]2SOA)6UDB=$3^6>Y%)Y6"SC'V%$GAG8I
MW,+U9.>]M?%HS;\#\O05IKQ0H2G M&;#!0&K5X-%;BSMXLACZA^#VX^-%'XG_]7:N'T[NL_EX:WHN9V-!#W[W\9 MR%+_LO&53 W-\(Z]V0\0U?DJC\N^(;G; ME/2K-
<7L(I/AY[2S\L=:D; M('!FX_+XK>]C07W-&*:7#12"8Q_NPM5_^.ZT2:;9KJPH4[[__K4O ',K;; MO[!IS&EVWLPXE'D[E]RFQ>V>"UUXPCV*3C_-/]NK-S5-Y@E+D X[-UR]\<^G M
+Z<&_A9]YAQS'ES-(9;A;JH:F;>8]TPGWW*^@$N=+YI]1E)+8T2%^26,BF8 M,@7T0%PB8:'* (;EZ)0#E>]>NF1R.-#![P[N>=D/)7.Y>-?36C?7&3SG6M.5\ M::HI(DHG/^GK##3-
%BIQH*=9]BO8#EN+@-**VTWM_C!@])'@R"C_TW *YA"K M/$$=[+QC:G[55#Z>\5]1_%?WO&?\ONWS7JD+P]LT[][N@0./WOG)2H[^6H" M?#_<\)?
M:MW>3*POJJEB)$#UA*]$(QBW$SJ2*,AM>"I[%8 M_I/>+\FAUK1UL +6NMG\>RIRV(U4RP.=LW/(<^Y3IDZ%))V%OX42),*&T/L2 M:UD#UZ.7HD-?/6@N/9@SEG%%+4@6-
DI39MV74S7(/PUL2V5>2L685ZF'[5;L ML >]-3K_S[5W*3K3SW:*FMWTV +B;;W;?:5NV=D[3Y+;?+PZQRC7'
M#L;ZN>Z2>L+LZ8Z&KB(M0H1'#/]QS78]EV9$JJ9I:Q@P3CN'JBP^L5.OZQ=R MG2 ,$%)$_[IT (CW "F;%R7]WR[9[WJ.]_N M*Z_ZSK<[!*N^\^W>O:KO/*]Y>B(OPT8S>LR]W*]O!
<#[_!"&_O),E@'/63O M+;HL11O-M&9@^PL\PP3Q_*@GLRN [I>4>NT2*0K!R+I$]9G*N-I0Y+_M> MZWD@Y;WU51F T*F;8RF7FZ0T_L\%5\+UTFT<2B"6R _B:,9+OW27N\)RPZ*
MI"5GI;:6D)+?ZDOD;]3-QN4YIJB7]XQZKOF!*FG=%,-.G0FYR"I!46[]*:V M5KQ26RM>]9X5?WB-*85/<_<%W&4K 0"+NS9/3075\XB4%EXJAPJZQ:F&M/0 M?
9V)@J(U4;')7;C(9:K4DSPH>CK9ZO=Z)X-X_:]S2Y*S1RV.QT+@FQ?:G?M M0'JFJ;0TM=W7]=Y =J:9M#2SW;OW[D!6FHX<&9KZ9(?]8K"GPHW%JPO]?N)$
MOXHH!E'=Z8'\N31BV<\673&53D7SG_:/7WYWR$][7\[# M0,NW)IT7_HEWI=R?;N'[ ]]776TF5\:VCFI>=HY1??X%39:AME'<7@=92" MI '+2NNFF+-68X=U1SD%(0[;O
RU(PXZ^XMDJD:.QZ^.&TJI:DHK[D/LUC9: MU3U6WF-QXBROZ&TK<(M48H8>_E+ X<)K1'!A5,;]P#L"(&20& l0H#K++Y@.>RA,R&QI "90G#?G/4 M:R=-
\3XK%R4*F/PM,S=@>RB)[11#9JI&C$=/ZQZV!V^AYJ!WK&!5*A2GW'3_ M6(42Q>FRO'3PK70YI.4&5)I6[A+O"9OGRI$Z2/+\4
*:ZLJB(N41Q"GJL1DMEN77L2U@[0E8M+UPZ"U8N/I]UYY6*Z M>R10$3,P=W+]4((KHHB=3A6S&G<#3"HBL@L K%,88$=. Z2B^%QHD-7DZ.::
MM7;80H.A!%PLEUYX5AL*B([*%;+5#H*5]J38(WRKE&<^E+HY+WU5R@SZ-2LS MR:=*E(;^7C'T5],7D#@T4EY7/.ATR%B-PG+!L 5G5:W:!=MV;(77J=B4,LU8WNI4>
M'96_/]NNC8SU0=4M#MJ)@7SM&RMY(62I.5(Z8D\IWN?P]*BH[V5 =U\>^5$! M#.2VT:]%@0Z3XE+MAR3U*U=,7I*15RWZ4;@66%2I.(47>GLENF//*UR*WJ]M M*?
K@39:BYI04RBY%E[MOI'1]4-M2]$'E0OZI=UZ]4/OAU;$RBY#EWALH11]4 M+FVAO"!\.530?S*EZ%2G.M>AO_GBK<&#3\UR'?
J:I0]/4N0[!3#-9:>9'_+3WY5R'7KZQ4:7[.BSQOARX#GU]#TIZPR12G/Y(M%AZ93XBS4:&^[:Q*'CJ%'PFZO9R8I""9;ELHZ\5./_=2+G:Q2P#71E%=F9 :
M;G=3%X145M.EVH2W4YWHGZ+>O0.8ZRABOZN(2GM_3/.]T'UZ1!VEF+DC 9;V M1PRKCYUCW:7!2>Z2G#I'IOJ8.L(].GY3@$XG5?[,&3N G?*;$&S%CH(-^L7V
M"H=T9TKT3=CWH=)NC;D_I*_L+*5/C:B/)N2YHVHVE7'GLQ2X2';FE M=$KB=+Z-^LE3 2+42!@U&@VN_R^BYBA8O6V W9,Q)ZYP2UZ%!WNN6B+[0*2E M(--
+8:XZSP:\"A]MQ]^N@9%*G/#]B^.\+O@_AYZ5OC>#G,J#: ?[L+5?/_MCA.19INFNG)K,O_=2F\&KHWPWVV?[D4TNZYF+G0EY;TZ\3Y-[*!"#VVD<=HX= >U\O&GO):
MG=6%%LM6%$]!2G5/'5:DK='(^P4$P 8R!DLTT6)O,- T)";63>4+,E" M7SD'@6KHK1OKK9]:TY;SI:EZ1*_\25]GAD=:J$6 HF#9KXZZV)I3E/+X$;7Q
MW_\RD*5^NM#27BBDC4Y40!.12^ FU.-3>7HZV'G'375K<[XKRC^JWO> M,W[?]GG/^'W;YSWC]VV?EZ?YO)\#?R530S/>$88/>N!RRT!\/V[WHOO+=KLL M2Y;55Z+Q)"LI.B/
>I2SVQG2+EHD[TEQ[8QXDG#E*EYT2 MPH>G:>4D-#U,G4)4)WI.RT^WUU#7CK;2'GE[P?!;1/#V$L]U,>]16KB/;;F6F7Z0K0_ZY4@KVA6V+
MPU[!)G'U3S.Z3%&*0ZQRLS)\A3!A7,:7S7D7HF"!X@B/&/[CFNUZI7=-W6EV M#8_3L_S+VH@5H*.[!?_0%4(AI<=4P4*DMMAN5[=K9WIXE]76. .T=[DA>LV1 MTA.E0?
$VC:=5[],+O^HU]4R!]>V.Y^JM2Y6SF--OO7*6:QJM5\X>2[_UO-+T1%[=KPG3=A.T^+,;: W- M^36/L]>3.2:IZ2 MTD\N'(MZFEJ.I?K:R[*^^.>-IAI]%9Q.R?WO&Q"2/1(-'
M/8/$8BIQHJYPG<22'G3\3(1R ZZZ.)09DGL# 87*9H&5YZ# M5.Z,3K_QIILOFZ;=>.;,Q_=8K9ZZEWWKEC(W46^_D52!/Y#X.F>V:%!^HI@N&
MY=FQJ:J5@7M]@R6=_&KMB17WG0I"^R@*P@^0_ZD5 @E'YPYJG(C3+VL4YG:0 M[O!L=(%PY4&!O)+4CVIEMWE7P2I3JWK]Y&5R>OT579^$0TOSUJ ML]"
(!.$#O_%+FPW>]PHFE/H&(93:!B%.9,OLGD&_QY[!JH)!_5V;2GWC.DI] MC0>EKI_<67#U*]>(*I>4P ME4,& _>)D<-A QZ[YU6EL! J*U@3G<:,-$ SD!OL _TW6SU:[:><;::;O;MQ[
M6N[033\'.B/,LLZ'KCQ,ST25FJBV&\3O#69GHDE---L-XO<&LS/1T"::I:Z(M]P:S,]&D)IKM3]!W![.3UA)1;_ 7-$.N(E9(U%|[('\N#=?PR"-Q7@R-,'ON M@6CVLT573&7 #9JCKKS?
A'MWR$]]8;:[!M\=S$Y:?W6L"S,L\<*4&SD]Q+B7 MWU5'F_FS7I23.L/ZIQAUT&N?J"'71N_D8O Z2@?PGO166F_M!.S@)(2(/:C[
M8J_=$WN=^A%C>7W2MQ)C!P%6^Y!%]UCQPE0X3KWKZH4*=Y'GH%A^1]XK#;;7 M-!2'0^!HQT[B."RVJQ==3;WU8T4$#PKPWK$2Q HS_D%Y8QNV,GZPT'J2V):]
M>*=V9^4.RIN:MC?UM@>"9M 5NVWE>/FW!X!8D4;;12&&P7!%5+]!8_3V./@H M$(-VQ"Z9$=>NR5&OK@FL!8-TY;(^ZP?"RF6?U@^$VP,@)!KZ_@??ZV;2([5Z M^<&
[E)AAD;K>K;,MMJHM8*T-Q4%W_ZC<2L)*.BJLAH>!565+I,+NP1A<.;<0 MSL1E\KOFSJIB-DA7SIU8Q0!6SD=7Q!6KGJ@=B#L5ZZR=8][*=?@HS*ZR"+D
M!KD"JY6IC>]7KD73;N074C4/BWRI(/+/S<6*46[E7%7IMY[?171:)74W7^Y5 MKKD8TDA7"'9[M6TN%@?JJ9N+(>'F":Q4[/I5SKV8?NN5+4$FJAO]X)^Y7P(Z;=>.=N]1*NIO.9BR-
*A.HK0 >5II9B=1T',WED+KK/Z-+(>5"V^5%^ H MAPP&Q M%56V/05MA428.L'PMHFXLKMRB7B M[E-UB@P,V-I9:[?^6]:=(K:'5:S,V@.Q4EJ1[048)ID6!%CEBJJHWABMJ JZ
MD,D;72)42X\77"T7##.;K2:.W\1LWQV3(A MAW4S5\ZOOT]BY O-5EQZ=VG?HIYT,<@3SBQ1?J95=2NULS.MI%/F"A M]\5! ;O$9:EZC1%V4U&N=EW5$\%]IK9VW@ %':M-
8"]K5ZVSU;:&1PH(^P4 M8;*:-I"1I>F'KKE;/)4V]=KIX5F'KKU3,]4F^]MJVQ9;F^BHR<5Y$Y=N0O; L4 MJB&?>Z>\^1* U 1?6AWQN7?*^R6JQ.-*F)9KM%^-Y@ M=B::U$2SW19_=S
K(1)6M5X0PS96" _:^]-1WAWVT]Z8SG87T+N#66F9RU6Z M,%*)%Z9(3#"A-[/'GY/B-I7]%Y>K\4])-Z ,FPB-13[2G:7SU:, M;52^U@I9.W%U@CLU:(YDM%WW5[3FNE*^3^Z3IP)$*
\>-1]+#GJB6R#T3:(&!Z"* HW>5_30BKIFK6YZ]@(=E M)#O^B4^,/?QLG]^3GVYNZ#->E;\@DO:2-CB9[(/\NE\+1:P#G&CCHQM$OA M%FXF.^^MC4?K1_TR?\5/30"+#CNMN-
/"*+^T9H08 >P[H+",;K97L)F$4S1 M T>P%Z.*Y)=']XOG"!%T&G*E_U$IXU+_036!7S^IHW)I>3+Z81G:2C->B/ T M(XZZ($O/T&'1&TN[^/73)('<2]O*8\ _L,+H2G5GPC?3?G6/O(T/-
Q8P-GOI M@D'B?CSVRW]8ZE(W/*(?]4$L9-]S85+[X;&@*1\>FG);[AP& M6#4Y[=XP:UFDL?4PS1'EVE/DVL+4L>>"O0"AXJ'2B"KWB^$99'?1: +,$DR,
M[]94/I:U;;I4"9Y#]WB^;YD:JAK9K"TF_[+0/@Z>2C)N-2F[^]"/7+9YKJ8\ M!1O2@=$WA"LB@U6^/UBY$Q8;EGC5X%ND%W1^\&)W$ZDK DT?!+SEC$>.W)9(M?
A#:K0X]&&HJ[#86OT;X*?Y;0_ZUQ.(>PTID7I]W\I0;K7_P2/6?N79 MS*FJN1BV_1'77\D"D&PDEF:552A7&AN,'B:-QPN[QN3IQ'F<>L*RN%EF*,G(MPRK5I*/8N/;:T75R1F8JW'4
=Z(L'7N&S.FIO #,,"% [/?VIP;5@<%?S53K MF:"4GJJ&([R@EQ7=1J^JXZ@6"'5#G1BFX:UJ>SN^P;FH\SA47NZF?
V/'BE#BB2Y)>9IM:MCMUW1QM([8[U9FWDGR=1C/;5CR7TPNT/Y,ONIJ M$F 6#.+X!>BV@NJZQ*OMO;CSC_8=3_: K[N;_G#)&$\5A<,U$X^IKDH?VP*]
M/YVI%%C2>&N>D4K5D3)R'ZU&)F-<%#+TRKBTS[LO6<[&X&G58X:C>XV--0V6!6ZW4%3 M4BBGJ:MS]Z9JUAR'AV4*!T&A@O;%?CZ0%845:4.W;M]3_XV36CJC5-BT4@R MIB;
<._:+H1/]RPJ,7#U"C^, BMEH$>>9=\2!DKW"ZLQ1*H3&'LT6:,O9JRX. MQU52=6S8?,]ZQHUAO1 W2\;-V4U13=9/$Q?NEXXV U%)4V(7#K)];R4*"U.U M/)$:9MBS9($.[C?.-@JQ?
S!"_.8P&L#+(?<[YR=+(, M.]XD:.JOX@FZ=51_0]!DHHDNJ"TB%+WB*.M2V .>8>RG9[E MGI@R2R3,%%QLC84!4\N24HYJPSIM41H6YG6:G)V E[VB^Z@8+OAKH +%T:C-N
M42IJZS]*C]CT:;G?>L/]\MWR=1. Z ZB+6%D16P/#]@^_]3)7X&'?L'ID\)D MM=/C5EMJ.[J3_IL/Q60/[U8B8PWATO0&>&\,X]@^^KP8!.534<2^O%^%+GG,
MQA%%?,A.#)Y7A_$^REI0>Z7_P&2 %X!>1(M]F[18B)T@)>+_7X?0>B"NYQ@: MF+/X!0BO^ >1)]E0F/74QNN?FKE$^,(_:-70 YC&U],IT5+%I5$9Q3RR%'KU MF24=B"55D
HDFH;6*TLP'4$'XL'%)(:$HX*P8>B$|'N6A;H/F.3XP8+"\FT3 MJEQD'%PA2DU%>#+(T^YYR%LVE%8:HS@$1NRW#Y@F7R4%24G%:0C6@F;A,26T MU=YH]G7PCMJ]
(H/SRB=$!30;1>SD:(^N%.$MM41ED>;HY6.RVQQU9,!D]B3Y M%)@L/4_^<;E8F+2]L&HRCH$94&!",1C#,2]8952IS93#]*M[WDIMIOP6B;S
M6T\11,@&EPV^>51C/XC1$EU*Q>9ZS=&@=^R>2:E@E#H"LGW09C75N@@9?DOJ MYN72,"Y+< ?*L @CDE?#FU'M+AKDK3/)8I94T+HJ;%C%J/?&N@J,_CL'P/,J &?P&XG_)M5-
MP7A13Y3[246^B_HE/BCUE0X)M^I+L5M5X?Q+9?OXR5/16(D,(7=:\3H_^)*# M'WS)O \P^M@3I4&2DIB5'Y0NB/RN5I':$6T&V*-][3!>0%=PCUB M*R ; D+'-N"F8>'+HU1<4:
(O1TGR@7$?PJ(\"J)%6'FRF>M]-X\"6VQZ=KQ> MJCFO'HW$T]L$,(2+Y1&'N#D[#!]64ARKMNHTU!CTV6(OP<,W))4J09=,)R[
M14W_"C#]=1AG*MX"A1";DECXH=CMVF,YPNYS#K[0- M+8: \K' *^H2LFK.DGTN7'QJM* M/0&VL[=6L1L6/2NT1N&^/]*3/55=0A&P7=1O"1UX[JZ#@NTYCC4%VF_I:NK
MUHJH3HM8_FW0B?'YVO(,;W43["H[BO\\&X:^RBFL2O-T7CY#"<7I($HR&TI MR!+F&QM=(!3\HPIX1!TW9GE@!GB&*?S7TESA#_O"ZXQ8@N%A+JYJ"03CK;R; MK
"VQH0XZ"'7G>6SH,'=,/!,+M>P6Z8!C HNQ_>GGQHH,6P;(& CU"(L M>/=%'>#BXLQ(O1$'BB@\$$OIE^U,A(?_IT5H2S+E)0:.F714G< > H!GKF_'
MW\>WK%_CB^H8]A*;ZWN4D=,JY<<%T8!ASH7[F0H8TR@=@RFX1LG^8P$9?T!! M(70^7H3[\)^U?ZZP0]Y,!83"AIV);<$; 5*A@O(1XSKY(68]H(P"PI/[X'^ M04A6V0E?#5<6ISB
M;^3JO[_Z;WT;%(,W*$XGP:W ;@CP>9Q(A!^W-X(R5'Q4SU1@50V&:>'>(Q?" M=T\'XA > 1\JW'T2#/L+.($8H0'Z^P"1(0GXKP'4JEAMV*+; !P" MJ392,X+*ZR\D_
65TFG',16&P$5:T]L:P R+#2ZW#&YT5CXD 28C"9.FA.P,(:6ZPYBZBSR8H M9YBLV Q24%]LAW8EMN"D(>6"U&H8EF6_4$*"8P,C\GB^%F]A!A F/#6<"?X MB@6Q=&HGPX-_,-
BOA,0-:[0-&CHD@J<9QN(W.*IO YY7IKL910N>$R+ M $L#6-@3!%#TBH6%U_#U=(GWA/4.AY_'U"?DKU+_TL4=ZTO-BRI"/#8$RA0L M)H7TA^0 M"Y(X_F<1F*48FM38U')?H-
"&2_@R(^PRFT[C5"A1*NS0Q0+B M;/C&&5?N9BK2/#!\E_,EZWBE$[C4!KUH_Y:A1JR;*:KS0)!Y$?U:=;!:TAV' M&_C*WA\$>GHINN5UN\U13[G8+,,1YL"R?'+;?9Q.A8[3:X[ZPXO-O
7_.")2 M,Q(DW_S+6BN-YNYSTCF!@ (?8.+Y035//_B-'Q!X>;^SK<51+QHU D@=2BE M2W%*9]X -%RIKLD8QZWJZNJ?PI6Z,%#<_@X6+?&XX,/OW=4<%$R!O^W'!=?
M^>NHN=L(WMCUW^C +02];0A[*P75PO MT#)!!M##1%0BN!.@L#)90W]N^<":,X*+BJ8&3]$)E",Z#\-Z&RZI.POO&!R4 M7=%._(K2$ %U5P(RU89+0 V@-AU M/0?82]-]L=E)
(WH_G\'P=1O!-?%FCKU\GE&_"=-#%OXIN5&A>M',,<9REPNX M7N@M@)2SSE%-?)#BI2/O(8 M5.(*]>CD@S0W2%B_08V$&W0AW"\=W(_G1S1WPGG-M>H7?B7#=A] AX4 &DTC
MI\D+J: GI8">.P/*<:-U" ++2O<,G+@;O%]@[XY+^T"!VG-XN7T@:GJ$(]I- M:+0<C WTWYO>XJ6"!C45Z%YN#4+;]2A_P+P"+$>LU_!8B!U$4)EGUS\0VM2- MF.7..M2B5
M^"'ZA1M0+P.0>&E1,-P55E'A4R6-*6]@7HB.)8M$+G$N@LOX>*GD3-/QQ'2I9 MHQ>>GC'JZIBI+Z0!UC=Q&;SX\>#ZV, [2"B\0W9YT.@:K:OG\8\92ZZ MRGS/N$!G8!U-,$<"-
Z=Z#=4T+X2;Z1];A#OHKT+9:O)-B!CS1<5NC8;@<=BJ M25U[:P2QX0IB'M\&;(7\--BD*1_#3%52_XB]&N ($&-1$ =-(!*FV^,@4X?[M;=!Y29P71IW4GX6PF[-
)Y.YRBBX"PD2("U=*#8>@P]I!&-.L#<>>G[I'OV M73]?:"B-&[/KSET_R]_$ ^+1Z-9@[[CC=>,X2K$ 1S2Z(OL*Z+'A+K590!T.
M5B=3#ZJ[G,"V+:HY8H,0T"PGI!*1$)^#&^,'$1\>#"..+++WNI4Q$:8@DA==,H+H-DGDPGATO6"I8;%DPG*S'1*X+M'>5VFA,7^ MNTE8]X3%HL2[.Z<./],ZV-
0OO[Q&$;%QAKU^P 3l:?W!)EO+:W]#_S=/Z3= M.77I5HOFT0V&A\]CDR^$Q^5\CL$\U&3#G0CA5H3[8%+5*3+ILB"&)R*N@7'% M_IL9,>E6BR)FJ!P ,=MA\X7I$%,AFFD9)(^NL?
\CZ=KP4HX#-;!@73W$9* &.*8S7(*?IM/+Z/Y6A1:H@BYE3TD >?U=-5EC0O6H^%".KS35C>6"\Q&8WHA*"'?P*2'X[7^AY+4&,NO M0+N3VOBBAR UHO'8^E]\0.1KPM;-
%=5O5Z"+4O64>S<%H*!H4S3NW;<|)% : MJ #KE.KS@0$Q6:6F2-^_F_7'Q>)%,?3%/1T3G)L$FHEE/T?W,59T$1F_BG:,V M$>P:/FE0E5J88K>A180=^OTBX:.EZ;G^G[2DT9CS-
I*N_Q-0G86M5SP*4%5' M$N*9^Z#LH4EG3QLJ0![@C,:L;_M:*MH>'X77F8'!#H>(_IGL!1AF;(=AM0 M8PPM8YI/8\,7?Q"^X1"#P68IGN>&"W8$4L"%\'=[*;@S>VGJ#5#A]'7K89UA
M>>>O4S]#!FC+]V M[U66!Y%TEE,RS=0ZS@^7W$VO814,N[II=9GXKR(ZR[!=KLX"+T:"#UY=,76% MBJ>M("U5##%!$3"M+2P(L8^

27>3 SH6K&,P[P:_9/2.AWR;):M1T1&V6]C\ MG1?Z.3A+WLFEDK84>)U8JEHC; L[G)1 C-O!PD+E]FM3/]RE,+-?X<<. MBEQOR1R65*2@_TTWT#=)P:$A^V4*@"K@RNAVPTQ
!"_._O7S_0*!%'$,4>$< M &)ANP9+$HR:8J"=S&,YI-0_%3M'(WH.7V[QS#Z@3)IA%>2DSQ&,/"D]B,HC M"M&WC[[9P==M<$+Q KTZ3>?E$\7S3&F[#R86(&8.-)#784'?7AP \,KAA8
MN>)0PW9^5["P#;_/:6UF6S7*P:42&14'TF3$MP=27+.?+:.."EB=EY;EQ4RJK MCP3^$'C_HLHW@V?,2F H??&LBJGFU@[8WH[Y!%PYDLEP=7
M,>@O4&@1!X2IMZ+P],..C.T[9&JR6-V,L QKG;-?_#E3TV,I!6%H;X(MZ#W# M,YGA0[AVER=569%]TBQ0[_AX!BK I;8:"!QXR7 Q5D="JB@G>K&X,(,LCT;!?#?8*7-O6_+*7R/<-^CW-
C$CWKCBA!+*)$0":<'1Y4=0Y^970O H,ON84$=M7B(F#0WB'M\.][05OG.IOZJB&$@%
MZ]*@=+/%GDX>9=M8RQ41/KB$"+0H4&I_7$MWN)]IQ;B/(&@SBBL('O+54M66E#=3#Q;^C]KUT*82[E6&W43454V1X M7C]-%7[! /9:)T^?
Z6^'1]RCQ!U50:8"\."@QS2\E@!,A\SWR4Q1?C6N:A0!D/?KHAY\GJDG7_@00]D*5J[K4#.*6%VR= M,&4G!P)U'V&(H^?DIV9'ZN1HA>5O1.:!>1V-JPA*
M:2T@BM@MWQ,03MR^HNX^:D%="%=4M(7E)C$:0=F30&W4K.$LG3H\":\-*N) MZ+O\-T3.%%D$MAIL=$DKDK[36'XGN@7#6BPQ >61D :G-193!PD6Z_J0L,G MHF2E'[Q4'E,+*-
^=H^/9FL/L".AE#'W[M ;W,$?,, 7GRC/Z>!Y^I%0K[IEHLJG)<:K0.'B^O%NHH-NJJ=R9<7!40ON MYFGCOC[F*V6%DA/>'0C[)1OZ]B.9>]!B$S[,PGT%QN>&W6&"B;FT#\O=E$$$
M78H<1&'B;3N2>+L "1C+O.TT1[9%-A-OG6"]2!6GRY9.KH"^ F-T*ES_)-J2 M%IO>8I39L8DJSKVDSI]C6S8OR;B# W-OKK9>ECP\8\'K/0?6_J/ M:)U_5IZ$E2-
I%HKR(VP(72)@'H(.!K$-58PG%<0'%UQYS'E_\W-^]3XMY]=?1E-P\;,$N87 M1118!-_DVX\NS01-FTCN]'M5PMN(M[9%OL)%5228%%BO1B.;85A MW0"ZH/.X7']QX-\+L/P-
C7W@+]V(7# L)38B!OL;H18E+[44&C5BO'\)Y1FK6QWT=ASR%IF!9:M!")^2]0) :+27<(}H3Z6@3 M5)$(&U4\B6E'?FE(PH'032V #5@HD<,-W(KZEV]+- M>UM*S&Y;;^#
2H]H@R5]HPJNP;Z-%1%AV;D;*^SCF8LT)2/>MBO6X<$CK&XK M7J 7(> UG[GIVG1#C;6R,;ZG:(&;OZ4@TA"YC'UMJ(=O<1.\\S%2QVNS]'T MG;!:VD_O8YR<-_]IZ
8.,9XL(RW%6/49#]>R6Y>@=]VU1XTQGX0C1'MOD;5* MQJ?PGL0O((9)'1]M T13QGB7;V"EBT^:PF5VL">I5S!3U+E>T$_;PA*-V* MU 4VN*6\UO,)&51X(M]4#K/$L-%;E(>@X*;L

4Y V8SHE^K18DX-EJ9:MB,0 M[MGT30LBPK@N>V0!B>D(!O(CO=$HSE!ZMP5>;C\E?*C*'.B5!37&F)^%C$" MJT"@LSS@L,M3I1A6/G;3/0Z[H=*$-=SS6$2-5>7S-
E[VD#@!VJX2/,>P,)1 M_4O*1+(W,QQ=P,0)H\P$K *Y5O?<8+G'5KB !(S)49K,Z=Q-NU[4G](K-Z!^ M'lAD=%,LC]G?5I6]*MF1XX<#*>H\E,Q)_0T&,TZ&"W6M@-P/! M1
,GWD\.9Y89+#%%&'/6C2V3YBBZF'04N=Q@GS;M]DI>45>F_PXZ;7 9&%$2 M3$Q(\@@WPY"%\C9Q'H"E,\\72"R*TE-F T8B#:5J@E)#&G'@S&]C*"R]H M]M,Z=;YEVM?6#8LS&-
A8LK O51R66\6,!X?P2O@78M&Z)"LW[$A(284Q,#* MD+F&'6 HS>H<(UMS]^1]_?FSC"UV.&:,9RMFW7X9A& M*7*-8N-&5,G$E7[MHS YKF1I-RN2B(V(=E>YZ:!RDBK3X+T
M\MU8C?/61[BDQPA[Q\2/S_,?H"Y#[1(Y$>Y2P/)$@@0/3(1T#]\3L5RNR-?0B M>F%"N-Z(9IOP+$M49X'S>0G%<3'H!1F'.@?[*Z%9,9&MN3L3\M$_IWP2#?4<@0JB;D
MS;'=L434)BBYTI^]OV+*/\5@,A ?Q0@.1 G-(J<&K1KFFQNNB*4#^#?&QW \ M!]/?6"-(U]$;%&6])MK3%@ID7KP6),PF2B$ZCA%E(OV%Q1K!FDSL4G$9Z:1. MW]C
;3+EG^T@FJ2Z^UUANGM0WL>66*@K7_DUJ$H>*!8FZ]J=<*Y&\@[6LCAY MFR+*W6&>6[Z'):L=,Y'M,U"^0XC$O7E+OX4Y;3S.1P. M?'%8'-
KA625A)ZA8B7O@6DO>/6B+/K'XF.'[;NS>]\E=4JE9WS=0GJAPOYL& MX^9N:*L!>A!V5=,RP52+A>Q0:;=+O/+ #G$_3'5!3(7C|")[JABO+
((MY&*+3+CA48R\!^HP..O7P>^9'*OM8W>$)DZ^]?O1RW4_NN?[<:#[T4FZ'TMKD_4# MK3+!]G0NCZ5=6C;=!E>N0'E263=HZDH!4@ZK)"EEZUA/C8H>]3)@1K7QYY)$
M5HXDDT2'YOD[8!DPX8ZCWLW[^'PR38!S>^ M-L6?I>[H;+L_YC$C42JV83HYA?\SD&'\:%3 U>@L/R)BN- 1TFYT/_W&_O25 M@:->E$N!,XOPFHM1[,,B(TV_.W9CZN;SEQ?
XSYV".TJAU9?GJ'[KRC(S_9 M'K#_@QPW+8> ;<$\VGAUI:>DHQFWGL^\3S[:(464.P-1IG8 ;C4"N_(O\:: M9.IMA>;?UF,=ZR?U-89?,B%D\\?[+VYX^;HW[9L9IAY/1KZ;L8R9;)0LOX
MV9H9.@CYSP+[WQ:6A[3D;F"0;/ZWQ?-.,@(JZ8#)=^&=@EPZ@_Q (-\]FZ\; MF\W7R32;CL+K"JA>1KN'2A@6(T>G6#!BYW^YO#L,V2+X[9S2LSV MCH79[%)T4T;NT0J21:6"-
$+5@/7.X*$'9I^"H.RALT1B@!_1>6W8TSL%;65: M(S-[EINC+6QX_:QRMOOY]D#5>?>@*D\"11QY@1OM:]#3/Q6GZJ?E5&=L%9,I M!\#5H%1<[8W?'*FJ]&
>YF$N#_.@!S(,KW\&XEN.6,%V<(TC>0PC9 Z3,Q M(2@Q2K-&AQ7*N3H S#L'CJQ(I5R$/SR'5LZAE7-HY1Q;J;0'^AQ:>4='/H=6 MSJ&56CHF4WM'E.U^_K.WOTS =\^
/V*897!"9WR_W1Q)'5'I*.B]^^A!:E#UWSVHRI-!Q9WW?3DUSJCJYA4.0"R.N4B:SW4 M4HVV5W5KA"6UWTTGK,&Y$U:E.F$I^3IA'3S2(^5K,E+F:*&R:M:B;GG]D,<9
MYG!0D_4W+;6D+>V[8S(D7<5;V HSVH^1MT[2TLXNT0:8*USA$@L4/8Z6H[".L1ZV# MLW\/:)*Z#JF>\%\JW %G)?"4CIT!T03\;S$R"EG'@ZW6<7E^'WZ!!H-?MD#M
M)C)*W/>%"1]B@!W(F"!(RNM"S&CRW+X2P[CNM,N8*_=.I9&B,Y^<^RY#Y&[MJ0^/5/9:MSF2Q4%'RN(&/!3>\URK!&K8RL382,\U41TAF%1L)+L'8(^3.9F6
M2H@=%"*M0'J.:;,D%)D9*:O7'$EML=/O9O8$G-JMO(4W<^Y2B#4G(S\[:J53 MQ@]ZU,]R9HN2#22IG2G5SN ;IH^=5(>6=Z;!O7OSNX9:I4]KT@PYEEX-V]D+*X]OT
M.\WWG,S@4#IY_Y0<00$C2Q&'RGZ?WYDC5($C[%/(BXB7 RKD7> -/7$@M:NM MD>^RU$,%8:GY J]YF@ :L*9*;P)I]_GRF@UCL=[-G Q[92L]CD.\- M0]?
3(#]I9Z_]6^S4<>S!!%*-T4I2B;.5,)^+CIIFTZJI6I<=2>2*\^K&UCPN M^,+?]A!P/#C6+8'W]+=POB%(U(M-0A:FAFG2J7V6OO%6)
(V'8!I/@AN3GCMI2K)#7)P7:;P0RI08NKX"KK[$&R/HX@UMTF,D)&1 D]\V>. MT@S,,+U0I"3%9FL8.,Q46%"BTY!O-^!MP>3QZ"BR\9;&.-LHCHVWUU"$ZFP-
MND"&,7UB8\N^!?]*F\&\ M8XG(5,^.4NY4S]@N$/5L%P)NHV+C/"GK2@?X\L8S)D[(B#2Q+Q06XD()/?;W(PE0^>E-GQ-39P#G.;50<,.P8]G)]*CA M+9F@8VQBHIJ8
^@"0%=T2B0%. F)68*-*0%+@<((?DG;BIG&W-C)8@ R2]C* M! P@'>PKE^"/X8P:,#61R^=@UK/MNFR0L+^\3A:V:W#FS@1X\&4C/ >3 +#< M-#9&$-?"Y/.&DY>B<)^!+
<>F*-.#X/CK]0,!)S9=.@[-#4G%YKOCAT1Z -KP MWQ/?!2[*2(?//[L0;@'32QPOQ2H(9NH+ 9 1"P&T=! 2WLRQE\^S!"%T=+X+ MC,>_ZHS%9&._2TM; >/>(3C:I)H1;N91\
[#$Y]U+Q+CPL%0NS#N,\=)+Z?)):BKP!X\.:Z=CU=%JP%(RRNW\7\6'I:O/#B$U MTW,>X- 8LAI;^E?4W.P%'H"C.=L\\Q1+16]<]Q"CV+;?.'\WS+P(]Q- MM(S8* U\C\L)NM.XKH,FF)?
S&8//I2\T#L@@#%D=3^[6U$WT(+Z::$N&O -K6&#$=G,ZZ9 MYH02F'Y$')PA'9Q(6#\1G3?*;!Q^U]?W-*$SU9R*],A+$S4NQGQ$SE'0T#35 MB0W:F.V@_KA8F-0"]0^C:J _N%0?
X&:]1O4U?Q6^1;#!'-MDRATP(1H@H6IK6Y@.9?%%5@@3_;'5MRS\H"JORO* MO'T]8XRX&O7[%;_6E]Y-M?[P7*V?6X\OL6B_FZ]H7\E8U/Y(3!,6_ WX'MBI M(&G^-PMRP3
Q"\IH;7 G*MWI4+^]7:XGPG5$V&M];I36CPE@K#:91@*IQ M@ :B*;1(ID=T0L"]0ABZ\4V7YAR],S7U6QG@6H#*#-@B5%_0=0IPGP&)'#3 MPF>B8))GOJ/9$V%PM->.AJ>#,P:4
JHW012>*PS%X3J[R<:#7E.<;*(B@<" M?TI]U%LJ$OT:;3.BZC$-X96@\N3ZT,=)VZK_HD9@P#%U5!5\O0IUQI7PX1'TI5L;ENY_
MK*=\'A8+^"H^>RYNRI>=1_H79&&5Z4ACYT\U4D%&EAW.I4? -5I1;*[BQVRP MQKH-QJ\G-S^81;"BL:*0Q8RP?T*NN&0]1T";^F]YX%B*BW-N!#D6L=X8KL=GEV
M8ZY2US5U<$;?]I%9)/AQZ)EQR-0DFI>>2>6,WU;U+O_C<09@^(+<\"K"#.\6 M^%)0C3_D"L\T$0?7P) Y& +_HB&MZ'|\2!9URI+@.G.=$%^0<_-[W*P-6"H:SX-GCJP/I$'#TG7 M
P;$&.K2|<%"3>36HS:S3?0TT>];"R!D?&!NZ\1D[X@|UZ!?"$'&! OM+Y94 M)^/!)^2&]NLNYXL-_1&A27DI' Q40[XW4$/AA)@*)89/@,EGZ 10LT)3-/(% M)A>(#0QRMJ:@03$/#@!
0#TLE 8^2&*9"A_@?.A.LA,]2L#.T0LI+)83N"!P MHBG!)E ?!>Z]XI^S()F F2'H\D*0D6W>PZ6E$\=<<;(*CYQ$B/7QX]_0G*4G M]6=.NW7;I[/,76F7F+H'$)UM08]5,X$S0AKOSE8"]0
M".#HM.$1505_&X_O45V$%1=+Q@SAJ?'C%>S'7@=])I6V*$31)@H?\)D][4O, M^X*OZ5_2Y4?D6Q@+QR1=U=$QI8N&R/'&+5W_KC9H "^6I;42YL2;(2^?4M:[
M#&0(F)LOANOG!89G\=6^BR"R&OD0+6%00[GE%X("^'I30W,:(#UO[%$!KJ; M*X NO,4R5 P\#G=8(;XNB=ZI'Y\,3'0NH2Z$KP0X&HU-;FX2
M^1CV(C17;+N@O.)VG15P8F2$A"9A3(CWBFD 8?) H.FV*!/]>^7L"%"L*^=#T6^F#;Y9(24:92T<0= M#-.@=DEV)&;' 3K'49Q+$'30_-XAE#V)&*:@9?QI!SU8*/K99E>^QI%XF3 A_S
M@I@^Q>63G@#/5P.^QQJ/D!B ^/[EAS)./N-Q+T_KI&5^)4H3_^;[NJ@6X03) MQ$/[:C(Z72ZH8RE, D1$(7=#PQ.T!WHQ (?^':$N/!5N$T=HGS,DIA"%:4&4 M1:@_+X"-4@X(#!CN
5QQX!0.8XP3I&OB4F:)H2U<$_\%YUE:("[H8;]5\.<2 M@[93JMM$&"+-CV+Y6S&I@'E$;N*##5\!=[@=#S!'?4Z=(__B E"A]Q9]@R4 MZE&5'("W,^,\5C8D9THWOP;F0?
79@+P>X*7QI#TKR;XR']^ 6[BWA,'#:X@ M(ITE1S+1%[3Q>"05'01S=[/$\!>!7FYC9C.!-"$(:?^_L))P>E&J RSXQY M$P%F]VJ2Q!H#HHVRAIF(&&G2[OC?UZTGT9XIT9!
@1<@+FD,&Q2 $>[@0 MOE&1@RG029A#-H5$0OD1^+BE$ND+KDM]06"B9D6@IFFL3)SDT)\ M/B9UQ;8D?+?= MJMF*/(L],R+*4X9B$*),)U#S*Q\,"8;-Q|"%YJ\8'B_C)E!\%?
4EOGNH[U:@I M@DJ5_6IA7B0++%*>#W?U%?\#@H.8$4\[#^Q%M^'76.%V@@(K/ZN2!TM!!J&' M3?7-%"WA(,R$=)&1P*.X;_IYH)/Q30\F(4AJGS."2LH(RI/1
MT\V8T7.M.A8LB"H^#;KD%'9[EHG*N$ZY.3KHI^!NM0_?*8- M[$_NBN2A%IU*&9I.K!D+E:>L@-9+'0H70HH]-9A#-A*%P,?ILH[O%F*?&RYW M?Z([;<5",;XGU%W.4HLB]=\YV636
M=:\4RDW-^B!.+22*G2SQ_=7,>9Y(`5YT:8"""^Q>);&+;[B"LUM^%\1[MAK M+! 2VRAUPQJNNV1LCL9A @,]@M=''DARA2\VQI[\L-.W\>,7/^:$'B5F>@1A M)_3)X<\GMNY71*BZO?
#"MW&O%=H=W)W+"[^0<_J>"AHDOA!^6"8Z4.D[7@V7 MT.8$2S";:=#'B<"ICB$@=H?P:]N[0OZJE:[C[M_IAZ^ M!S]H*"Q@45]YT/[X6;B98P"6WUJ@3/88#8CXOXPT!0@#CGY?
#TL@U@P#:[K? MTX.WIG!#8P'NZW.\QH=%9E0+2(-%9JG[V)CSO)X&C3(_+PT6Q89_A]<)E8"I M@=Y_ZJ#$X".@Q:*^C2G&+8*.'E)7Y$B(OL%W3J"&B%V$=BS56%]*N1! 2<9:
M.GI[:*\1#(]ZZ), G$0N'\-[< AW%E3'TYHQU#\]QPZ[V-"0I0EWG";2;/A0 M&CL]|7\#KF4+(9MAA:S^+BD+C$)T)PNRET[R6]XB-U&*Y!R(@5B1#$%F>D2[^CR'?6F"":
=*1>_Z"HL!$ZIWFV?1F ML#O&$T- *6@$4EK5=>K%_W'Q>,&34"O*9H9#N0%->'!-IO,SB57!]BD68SL8V M1;V!_I:NKJ^^!P?D][#P?5C)W0A6\$ M7QM^,L?
T2TEJ$H\)L>6_I#D*VVIK?@/0J?C&[A M@K,)^@*^>*"\-$!A49^?'?+,<^*"Z+R@3NRE1R,6OM+V! +J$^XN')L<,M9&@+3G8(&%GN4((S6XL](7'V)Z"X@
M;!]1O);PXA*>1<6)O)#Q+$!/!DB"T@]Z.G6%NA ?MDP&?.V=U'W*$/_X].M/IP-#5VD8V.W M4$?[Y$8%CP1PHJ!BIA;/T@$(C;!VR+B-#?D0C?Z(WO^
N_X_LX+4J18I!-"EKCPP94.&HN_MJ:7H"EG'1M<1]!BX[BYN87("1H5;($ 4GUE2WM"R7T MS#NK9#W!Z.(Z/7#X)]P] B&0$F%GN0W>?'0;\PT>$K(H)<7;#D\-C;C5TMZGA,'I?
Y#FEG$3, M17C@"W$X49Q-?"GX<)%MFT#4O@PE"A\-B6H1/"",_H MIR >*WQ)PR3 M3_CVY18_CHCUY5;$E9DC=F>A;.H1P?ES&0M%P@[(A;/+_"B+IC!ID[$3*RMH MPJKZ6
QF(1Y-?BVA&"E\Y?CVDH-"0FLZS>2XH/%@?,&5.]C!LA-=;=#&OZ6W MO"<_] OY6X0V]>$(T3^];5Z&58Q=QN.+ZT%O8(S'@[3A([*-JS@LDRP,3@3J M6[\$QO?2] VP0HK,L^;W3_=?
_O;3%MODXGJH-',U =*(D+'DR6Y8W62BFP9K MK8)EB\[7 CS)B[6#F!M/+G_21TK+$PILB,^U2!?=\Z0I:&OV(LH^B-)_D1L- M8Y64S0T?_X"5L:A:,$1 Y2K^O(V):0IY3_#3
A8.:Q2N4FG-[X0@OG4>+3XJ M22R*EZ>6MRBGP$BU1:G(4FI"K#.XAK$E^<.,4\"22M[&]:TP1I&A:A37"C6@ ML7S4,1CS"0.%SP+2BT7/#@W88ZT*):&!,75A((MG\TQP&
(SF[JSW)5\DZ";&OL9BKSWR!'=J,TH,\4J%U8NQY]0SH:Q0>,Y"#$ M9[./0\0A*Z3"5[(F3_3O/&H5N8$$X$*'^3TU4G,]/WG,Y%+,52QL%:X2:1C% M&B/.J9+5L4U?
4H"'"=]_14L\D[(CBN5EZ\4TG?4-'9XY%TGA+ ZGV/3S34H20 M1\E8IA N[2O?,B'F?86(@Q7&OY4:>V4+P\A USL8ZV"#-% B!Y D9RTB6(& MJ#$\)Y&_%@!4I20&;8VV9L)ZB.R ^]7!
<28.\B[WV-]>YPV#A>VL>W#A+IEY* M.>TS96UI'Y+)_QB0$R!L"?_K=?L]0$CBC,Y/&<"DLU]0@X<8O3KA>MYM+.#X6 M2ZI7C 5S3#^]&\$;;
[RRBZZ;R>X6PPT<)U$R\2VLF/CP@W5W15CV.RHG80T3 M5LD2GAM]]%#.H.IUP<49#];&8)*^D>(WMZ96(QP$%]H?V0@1T*%UP@:.A2VV MO!
(\).PVA#FI3%;6#428SUK>7QE(N\)3-IX%DR\4]PJUM.-H.+L&7+W.JLX MXCFM,7V1M]K(F1H12K+[%]?]3CI *4Y>9'BSL . EM5_'WMT1M+-NE1PHO R
M8LIQT!P&'MUB[0GZ/=$!18=']DX-*4=05-2"@:UEM;& M%PN\2A4#[V4D=2Y M%3N &%@MXLRL+F=$6^I23!A<7'<+F"'S#E#H/IF.*^!W"&7.F_1=R(DN-S7 M2POC]RH3/;?
M&5NQ%)NV M0!%$OS\I7B&-JRB "K'H,W2YXO9XAX%J/D2O.X+]JKK<\/XS2KLJ?*> H_$V M')KT+]0[D=%!!'>B?XWK F,&]?K"OF,H-'HS.^:HOR>XA\E].\HV \&7UHI:
MBW$Q37N.+#!3(%Z]EZ+\&!N1#N5YV5*2UAF-=5B61'?AVW>\FD>.5]#9 RV- M"%Z>8PB>T"VQ, _?IP;W;S1%(CY&_QS':3&S?9N"US$IBWQ8R^4 :KS[09L M=R>
(EKNJ%C\9[32E. &-X]FMKWQ=I;0"3I?O*(F0BLP:X^N*=Y,/N);#.(4 M#[#^9EDA"^,Q5OWR'_U1Q\-QR:B"0($_FC-/6J-$Z%@1;JU41(/7HC$4[SZ MU+0#@Y=I0$H4*#4Z7@3-
0V_L*SYVE]DS0O"^B[M2_RH$7TSR]8W!%I@?=U"6<*H&\V6Y%_^-1:%^_]_S8?-+^_#/I6<&&A?D#!2 M!7Q&D_5*T[L{C2)2#@-P"=WFF<)M3N5BDGB69\=R??I?
EKE&N448D\@9T+_D^3 M)%7X3GC@.,Z(QUETF'(%G#-.6P60"__[X='LUG WCB*_Y=GEG!2%# M_6"[##N?AK7[X?LW3+>Y:_<.NVZ!:<;>&%4:6%3(U VX'INNI0^]@2CZ1_H M.U?
38Z,7=ZEZ772I% F&,,QR4V%'.UU](A+ F_]^8,)')W##O5O4?=+WB\3 M_NV3ZW $?ZE=]G"7V3&12)&(&7Q<6D4U3BB<3Z8O4#:@;KB!2*K@^*%OJ!EX M:[NQH,"29-V@F?
KOIA]0QSPF_\G$[/_9NL R^-LW?GB$!1"]#/$-J?1._^,_ M]*A_/553T4AKD3Q@*_L_<"5S^SM;^GEI78]0#4PRU%V7\-!2L^B\@HCLIB+
MD3FL%6VS3JPL/L*8^%U1VPUQF],\2=F<@MU%QY65OR:GLQM)&ZV@OW7B4A] MM03U/ZX/[[@7"L,A)?:_]A@^X3:C@TBC?0_:R:,82&,'U8ZUN,Z0: XT^%<
M$]_9K.UW%5@_1@]EG+WW$M#6!H5W]WU,"O:18AA*[J;TZ&V51S!'6,O"TOQ[MRV+SIS#CF2A[&*BK'H:4:@U;'9R&,1!Z\[/ZUL"[M^_>Z7]?NT!D/1QY'4-H
MX3=D2T":99!G$<2AVYH,'6K*'% 'D9FOD3 (N)V@,<.@LD,PIK\93#%,)(B M01;>D0)YS>C,RW&DS4O1#?7M64B%.FX$+Y.!1SN+>]NW/EKE@NJ]&6J<['VG M+TV-9)JB=]);
(2.,,0TN@/MF2;X88Z8ZSWYUBRS]WZW8.]E;DP* ,HP3U08 MIC0D Q[RY'I_:F1*6L*O0NR3/$13LB6K$7"GF&!3!.PA 7L%YG2V(ZF4HM.X M1%B=:.$-0KC?^)5QZX!-
^D@]2]@8V_F"_184E3&4_4N$/S12ET!)\&AFXUG MK^&!1CIJ?VM$H*S:*R,R7',M??GZ5J1$[*H7[_EM4>_R^V#S%H/KC>M$%>]Z
M7_T"%SL=;>,RE.5X:M6OTCKAE8;\E_X0+X3LL&H9/VR\4ZRDX7V,\B^V8_## M7]2+?LN+TH:OIRBM?RY*:[HHK6)EV1[[D8;)S&&Q@:EEU.B7!#CHE[YHU3U\
M(W>JB[5",*,\>_9SM0AFYF^PDDG4",1:UW@X0R@0)4X,8!A>AD4 -T=_=V\[MIJ'_PX6?_9>+S6^H_HKCG$@;;S<-F-4<]>PG@'4Y9"EDS\,9UO:!1N$&<9"
M'JC3JEQ0(Y=/AQ#Y",?.NZW@-]D4=8Z_+=MLA\FG,\T!>CB4R6G^X3HP"D M:!(@I>ARWBE(6A^"TA^K43Z1QG.>W3%%F%)5(SXYUB]KBCWT7_E@HU^;U^
M!#EPIM"SDQC!1/H9*((0$K4UX_WTH["1 XFA9H"GP7-'H@L F/<#]J6T&!!-~M;?*I,MEE!F!4@ _OJHJ!Z4\OKM.)N9]*P'8FN\($=U_K[.*'TJ07RHT+.Y*M MZS$,_FR89<9ZE(-
R0XBZZSTGRD+E7_G-XFM>.A "]U1_LD,@Y)VUQC)*C"+! M*N:>Z?]9)29^@#B(*A2^LR\^>A<',DT/%A(FP7E&,3#.S.D$I,)YZB/$4.3#Z4HBAJVQPTBOP M3V
M;%LJK2Q"9]SM[#9_P)?R>QH<7LR7%USIJ->S734JIN.SZ4,1[V\X3C9*=}8 MWW <|/.QR]@]\F:Q3C9*="XL\4X&*@Q2YID,?*IZ0K#464;ZDK;4&6[1(+
MEJ5R?!C@*"_#@FEAVNQ0LML1LEO-M#[>-G=WJ5D+M2J9PP*K(5#3MYTANX M?<,L>LPL1]P%%I41V9T0.BBP7$X3Y:9YPCHL [+$JJ%^O45G,J=PMN[:6*$
MF\CWT4(6)#M$2HQ+Q/8U$:S-.I7=.:*PK-ZQ5>DK95RPPW%JL(OE-%\"^R^_@ M1+GP^\K3RZ_O!X\O4UV0V!:>[7CF%"N56K'!9+ M]Y*J%E!,/S)J_EHGOJ@W%E_4:L47];+QQ4*K4-
NC55@^H*C% HIO88^L(94E MMS8F:>*R!!2U:D4=N C: F3^#H6\OGA=HA1%9^/7N@@*C: MZ&UQ0'1P1 '105Y 5&L@('K\=W%2+_ 'O*QP0]+O>M5AS*:)XMBN:7=]@ A<
MOW/7:W/N>FRHTHWG81\N/LS#0HY-^H*?Q#HBXF?C]CBN+EFQ/T(4<$@F*F;* MEK%K6)!HM948OPB G'[A'L<^%NZ&(*G\E+SIDS0"P\\XBMF+Y02;[9_5;,,P+
MQ'ATUX_TF/]Q;10E5KR*]PKB'N#*%-$BOCN#WX!;O)KPQF(3<'@/1;P2] 4W M/"77P?&?V*V> K<+;!6!C[YSJ6^\%U5DAB-!31RI%VRV8?,]*SY+B),?V 6;K1*.%V<%H[Z2]>%"_2
,I2GZ/6@"5P*&B(O+C0IZ!EDN-"05C1;3!ZK M^D"V(,X/NO+QQ&.=9V#AJ&AZ5YA$%/8A34Z*3!!,TT;C$2=(UA((AR|PD!+ MF6+PP|YM)>R#N1M(?0_A-
W#7+%WO*F0=PV/#4^_MS8DIBG#>VAS'Q^%4*AJ' MQX("#[9O:=*T"":J@K(B)%1,8*FZ7AJK1MU;T9:0Y#/(TWCV"A?!^V&PAX5)E M5@GQY!D6UKPN{.1-
M9PTA9UP$KTZD1N[#IF@QUH'JSN,JH<'.-,5T?[XME1_\G_T&\ M?6ZH8$EOKK"'I]3_8JE'2.[$8/&(VWT MB#LB_W#P-J[9<=^(]19O*A?YB1+S-<9\"'!>2]3'_TCR7;K!DF,;X"8C?.&
MT+C0:<0ED8E7D=7I6Q-YS^WT5TG'T>I".@S/2 M<;_M]ZL'@7D7_EVBQWO;^D>!STCI\VB0B1&.O=3BD]!I5#"+J[#;2Q?W&1O$ MI7PH,XSHRA5-DOG7A2E-$WE5;?
#I,L8+D.P9S"-1(\;>&!|#\&I+BZ5L? MQ8@N4I^,Y_;9S5-LI; [C8\=E'!-O)^PK:CZT!M[1U1Q^Y,/C M?:+KL14U:UH/.PD_KG*I*2]>2]QHV:0]!8)V!M%C"(&9YTE*E]-G7=)BEE
MJ&8?!(@KIE"UZ'W8)XHP@2KZQ7P$XIS \GA?B8$6 'EPHX MN0*2+IL+R)K7X$#Q-5K+T6[L(&RL>/LEGK'1F$Y2 M?A-)@B\++1,C2 "T!D1\^ MC_E5Y*!M*$2&)+198TH^GSY!UR"
(C4XMB^4G7'Y\!(-P=OO]$S@/]6%ML:PH M@;NR\J&5H6]9:#=-B7;;=R6%&ABF)=!N^HN@W;1&"R44:+>[B* M^%P\'IK#Z4*\!-#0Y;[R1.YYP"O_YZ".6C1H/;3 Z],]T0.]A M(WB]^?
@+\'-XQF*S!V@NLQE*&N)"@TJ$77M62DC-D685!.#LVIT=CD\0XNY*/ M8=8,*=78J^(*AB494!$M\1TK,K?I-,"7S3_4$DXY("OCRD6>.)9/[*Q31-I ME32?'H6'FFDHG&A&3O+6#Z6
S&(V=\OG*UR2+4!80?YL%#^,VI3)]J48=IW(M*RG" >SUE7*O3/.S!6F5]GX":N2CP9 M*<>42]8E60OQ<'!'A(KT.\NA(0/NEH_B",181!Q8TAI*"EGA1]QT_8EVU/
MSOSYH"M0UNAQOGYI=ZR.P081LRC'HY7Y=3:3^PWS^L(A@\)Y7$J^4$4_D =T ML!!QG:EQA!4?3GBC9>Q',+Y'A/^",R\E'<,GI8E!6I M1^(D' ,IOG'R>]J6AKZC_\-
!0O_/0*E"'1*B@ROB!G[(8'Q5'+2;Q(!#N'D M)^ 87\4%OQ1.OQRBI#E<$)A9-FN5M_'25;>!P*1]*S P4*8V4'RKEVG6HP&
M\2RH!.)O1(&4WEAE!\,6<&L%3#51XT[&$5HZ310%8FU]2PRVC35T]<;_SE* M-;IA)U!FL_D8S49W5ZP@Q#G$\!'Q$#KE(^'6<)F5P5;%8!BV6.^2C>N"CRB]
MR3Z,]D"..OYMS1/3C[0+NK/9Z8LO("&/XO5"C% +T;KF5@Q&@#-R- 0?$#D(M?> 'EKF,?4D-5;](!5(F.S4"$ABO+,D)"M3[!/^!?,L%-XABW>?@A#LOQZ M%?>S,N49HBWX?
5VSOH(7#=DCNPK%6/H CK%B=&ORG&J'DZ>51KEYFXJ2> M%*C%)P7"_M=AP;QLOA/V\SXP$/T/ZCN=I5NBO - _M$&G/]EG7M_89->]_; M_F+M^F!S^Y4;
(U1YIMP<839HP-.C/@BCCLY?K-.;2>#!^*%RPE/HAE"-QXM[M:[E=6Y]7U'Q.3."C]LW?,5I9G<.EGQ@[MN.+ZR^E^TJ;=%;+NFEAXG,HJ"5 M'[;6$Y[K2U0<"?#3_TW/Z?*'PXG#?
@T\\7RX(*EM MA=@^"'VA=\/!4L,P.X444"I;7?C=Q)5=/%B84\7'K9>R+X7-A'!!=ATK#LWX9 M¥XQX{0W:7]?>VO;E_2WPC!OXL2SI*Q;R^/8FKH&'CUB\YU111QQE![LW0I
MS}!'39Y[.V#GV2]N'%_4DMB\ENM]?U' MQC-GB6]SUE68^#S8!?MK=ASZ+T- NC&R#7V)]B-F9R;G M\^0Q;09,,WK=]*2AO'V]O\2M-MQ!NCW0C<_:$Q+1K]D:[_5XS&58(>7NE
MS()<;59D?I37GM6>M.^KA<@3[YU>13+ 11[T1X5RD6&&E279:;&KSGU5DUW] MB^OQM/CFVHE==6ZQY N'R-[O&"4O6MIP%T& '^E+=SM?6Z5LDTK/.) M6&I>
M79XH8(]P8SQ+3W\OHGB_WMD]2H8U8&+69MCPXGID#&;IX<.-,$RJ(>S%03KBY\4X^8(#77V"X.0^PSE88E? ME<-/;2<0F*_$@G-_AR0;T>0]QR0/P?DSP'YOKWZ07;>]-
ZOE!M0D_;VUM[/WC MUH-U;ST&85P!11"&]9*1X]YT^+++\FI8Z&&T,NO>FHY.5;BRO[Q]6]O5Q\:\7?VWRML['#51Q9><;SH.22>=]0F M+WK4QCC,=MR>N/CUM^T\D,/?
1Y.P;8XEO8OK8?\H+XZ7M9#&_8OK65W"M>7: MP/I/<\';3E"!$,(:; H?'KU*O-S;\;N)2/9>HAC\F;6Q ,&Z>]7+| K%*\ M'^UD#YU3PP=T_CB>ES]B.Z4&'Z)-CU'-
D%E\GK:]HS.;7OVTK9GQT+1_1V MW2H@P4[!IA[^%_,9M0>:)8N%!]_[C0/X;:MV363U=\14Y^3B6CP!FXT0]B -'M^:2-5.1[9&60P%J
M!BAELX/V7P$,/9Y>7$]?!=ZB9K2P%I%G%]>C7G$"^D6P%IEJ]9UG+7'$F.DM MHW+AHP\I[?^2[+U*\C'!,?B5:\?>=6)[MJU7SNRJE<*2K+G_'8359WGRK"R MZKZ*>
(#)-1U4EX1SO/H@'!K 73S<4[%>B=JOIF-527N\A5W<]A<0+!V?G PI M/HG?#\T8FW7\?84ARG- LLT1OY8OO[0R/ X7ZJ<&Z"GL.BGN9G K\OT'B38EX
MX^)@0)OB=N=N;*5#O&E_MXIT8-'@M+C+X3DJWV14OA;+IMV+ZU&_^!8[=V5K M=>R]A@!@%T70I7MJ[75B;&K V-R137U0K<:L1&W=?J+P1S7_)B\BCE5]EO69

MS0=R[JCAB')6S6S0V*R:<4-/GE1C;&|OI M\.(Z>'+U9\OT_&3&)IQA!AO&=1+3Q3Q+"R? LPEG;#LT#M?145/Q>7SX4#@E MCOZ[Z2WN]8'!)Z-)8J%9/^_-'8^\-F#EIR:P3UX"'?WD:P
;9B(\EHS%O)!@\O4:[MI;LC-%P19IR!L>& M\2RC6JVML6%T)5;Y]7'VEZ],^@-A^V#T2,+WRZ]SXX:V-%<0IP&#*#P0MVQGX?$R*@TL M4(^EO#T<;PGDJ]*
^14(HCJ*6+N%L(^O\/9POU=];<,;(%MLQQCB26_XI%[^ M?NOA1DK.31S&[W3/6N&$3!Q!*16)(T'([KYR5U=;7XP(A4|CT#PE(U-$)2I&L]BVOC/GC7%[5)$EWZ-8U%'Y/N'$?D6
M0MA4=U!(N]]-N*/AO{MAV79X=(PI X[@48K=_Nl;84CN GUY-.;"TEQ3K: MZ.22(:K-CV/:#! .\ZM-:B55!3ID "66H".Z?2GB^O_M!D2>-W'E?K4>P.X" 0!?QL8!]E5)C0\6X+!/BR.
MW^\5B)#+V]'19K\?G;&U= M:4+R?G]R2PD1PI#V50?7+"#INV34"T_GU/5"*19.+]ZGD[I=]MO4,]-^V&Q9 M' S3.'[0E]_2T0.ESPR=?3Z8G\=%W/%[ ]'4-!:?OBQ@*_>/.#?2LG<%.Z>
MZAG_?;17O/Z2C">O+=<_<@ M-N6A(OTN0KI*=*\^9//48FDA. !O+H91,:594E!>'8@H0SP^NFT\IT M>6FG@3]"7?[FFHZ^\MP' =V];:WT#S^LQ3:P'RW],X%L/#:I,@#:XS I1'V?
MPLZ_Q_*[*PLVO-3-Y2/F#'U&#XQ<'&]&^$6I0E#LX3PA/ MOI!VQ^-:^.7N_5!!SW8 9W[&V?YCNR:.\3G6447?W_<%)QXVM&E9=!5%UO(M:GSPL$-$3W5)C|F^[F_G_V;M
KR^%FO3?F#<7%MWYEK?>.[''LM |S5"WYF> MC;A.AX,'X5_P?ERX6X_|!.:(10-ONZ-_V\)M 3<9:"*6IK8=1.8ZP?H9+B>P MCQ#B(T-V%V!/S2W=5^>B"WH+7\
M9]0 60J/QY<+&YZZV ?RD?Z;B!?F^"/6?BQT!>H <8.K = M2[-6*R39=L-A,HE$O;XB/!?^P@_@MW1(SLA(YBK!*N]-'S>]X8\VFI81{!0@O+^;/^P'_>^>N]WH MQ_WV3K]$VO>
[O]#G].?>+V_T#Z6 M&OC&PISZ\,X[5NWSB\!?=SP[?ZT;+*8)[Z7/(H?.Q/5VO;^1,A[N#;>'PWQ8B%DW'IN E.Z2&G MB#^PU0W7*J;6?G_T0.31XCY>74%/X"I"O[?,=7"_
!5RM7(76Y],4Q"G8,NQ MVS.1TO5 $AF/<>_T+6ZSPL;>.7D TCV.I"K@B.WCEK!IE,/VD DKRXKV'S:AT9LIZ"E3400-00;@*3 'QWL0[_O#
M0G,P["Y;W28GAZ:V9/NHLSK2D[A_!=]PUI>51X4 MNH<]8T%Z\QP_"!U9G'.7H;C'*SLWP!]P8-]PXR.6'&:25B9BR[7#09;'&C%2 M$]N-R[NY X_HS@RJGI C%N8_,-:Z?
FXO2W9460=9G!CELDU/3FO' F\1]N3X M]N+U"+3D:;>3)*#;N?J,#K1SI51@+S=&UD+-[&9#M9MWRW%H5[!
M5K$)/O:O|=*FOVRUX6=_QO:>#FM4*YWHZ)A^]C_DW0TLUI+*JC_DW0TLUI+*SR_6=_=?R.VI>[27 MIL^N9G2-)NTQ<,'MIX_5<2EO<:K<.PDY?X.*BA6[OGV.OL*;_-[@E!,6_;IU M_,#;LHY06#WI_=YTV"
T_Y/KL.(YL^7S1!,$),TR<@19+*B,I';R;V2:0!$ M/>R<<)3Y09^+*]0+8DPS4@B'#4;,U)0L|(IJ/UQ3M)C"2:&[KWD&*%!&>x<7 M#O+]C(;I\/M1LDN")B [KNP?5_?
VG6N[C.H$_1ZU]TV?TV+3L5#FPUZ08[MDFY?=EWRK9G6<7A^0M!B*8,U4UN]]+2.TAP;9G)LI^D8N|)K'R^K29G1*Z-, M2M.!3N_>8BYHN3RW:0;)E?,UV\15466,]XX_=LQUT
MJWBV.W6AWXW_S;^)]=/RPL>]$IZP2?+\BQTW;'IRX,^CDF?S(K\Y1-D;.E+ M=E+ZDBT]9R-GRL9Q@U&_69:.<$*]UR>\,VP$T*]Q+!2QUI9U/PP 9$V?=]= MV-3CCN#(6&?
G@WZ*]2/%=<_";ZYZ^I?P001G;&EOLORB[#^P[6R$2<_;H<;^ M?70=(3X[^G!N'4OOCUD.(M&%S5HQ?I:I{X[K/<'P#Q8%E4SDJM^:22;4.7 MOT5];A[-=8C+M25"":R
^]V^(&OS&J(V?Y% CGI2QZYX496E%A!O9TJEF:07L* M]Y(JT< #$YV7LC8KUFO,C%/O;/2]BK++>W8OCIZW<+A;$#XSQ4%%O';7_$SQTYC0VJ?1S>8#MIJ+QNUDG 'XF*8$
M8&]E.UBS7C4O&!8NT='1*ODHF?RC_O',&=;?A(U0)'U_ZT@SW\]J^\%]:!K|&<Y;5^R#6+#7:URY M:!4EC3WQIL@40D+_J/Q"^!3P_^\+"OL#DR_P%;D.*5@[1!*#T8@>8%5W.#*
M<*P1'.5W:9M.;#Y"'LTFF'Y/CQP5)(N/7\&W.TMJHU'D63I(6+:S22PJ9 M("[^TM]N<$:HLMP.C_|[;WNGWVPY:]'C^/+/3^YLW.'#G 8XP?D B*XQ_H+G[MXWD-!O>]"?
33%Z8W=\&JM33A%@2>90;"K+I_QB[T]ZZ_N<<+1,[;)G Q[Q9]H MP5_$#_$NQ(@93C\WMP[S0=4O$ZVU_^A\:ZDKF]$OR2\E1+.,@J&9).H)72N9 M OD:!]PJ0YZ?)+-2)132:$#?
D&O)-:J_-TFXPU$V?\?PDDVI=9((^N7]HLL M4?1]U@2"I1#>)FA4J?!Y$5*HQO6MK5-OL" E\;)3SA))D 85%H3SN84'-M_Q.M6PM429UN8P?IS37 !KAC8SP9&;-A]OUT:?
T0$S.6V#%@J8.]9B]1T[R) MJ*W=7 URW=SO(6'YH%!.9_. FL(K+PQ[UDAV-;-!G.1I3(M;7&1LOT9TI)E]3N% &ID->16\3/EX MDONF2N0R2B"3?QX QU-+>U.K9FZAY*>MZ;_EAI\X'-
O(*Z88W M.YH5R;'H 6?]HAA<(6WW"^K ,\B8Q7T;-C^>(Q*%^-LI M1%CG$$'O0[Q#-B66%O;;)!A1./HME 0,F*\\RQ(HSBB+DAU#-*9MO@]QBKB M!B(V$&U'@TP%,YBPJ0/?
44/P&%?GED8N&OX.Q1F4'[R,/X+-NO2L@#-3WDX\ M883-7OF>^=QE/*PX =DBJ*H1)X5HKXL!>Y";-4O:XD*T$,$5C;)D#?AQH!6;
MG4SS+O5+%43LS7$E96[3XY_SY4$3T=XRAO'0[XY-*1('B8KCJ,$N10L$,/@ M<>IM+!JQ,NW25T:-'"=MX\99B@6QS#@;Y/*%AIVRJR-VL4C?+Q.F&'4QZ3G-
MCE/P(XH3JM2<3M1'G,A>L'9?*]_4&MI#C?)..T?/'N=_CJ4MOLX4V9G=ME MQPT4A;L0LZ7CB@D4 T!M+\746):SPX0?[ZT:$POYYQJB)[%K)):Z.U-XBR$Y
ME]N%&+*0S""+AV3ECX5XLEN/.G"CF(JFL MX-S8;*VW;Q-VVLNS!(!E'*;SC M;R2A+,44"F]VTG,A-<$5<3IS,JB7')JPE]TU)'P#/&,YL7@X%&*?X0.1UBI+5LC'09 MU$'U>5S]81V
;IUY7#@E<@?,<8@QUV=OROBX-4:R-#5=8#3*A!MK96(RY + @ MR&.,[>\ 0);1$'9"T\(# ?4>77@%=QSET7=D_K.7SH0/+1,V MJ"8UXZ(^.PVN3*H;*[N\R<4U/EU1!%@*>9AT725
ICR1@ LC)5G5<-RU&K^F MA?QJ>'D[,&V6>3ZK!E$Y4%+-MA- LLQ(XS(4"A&Q&!4\3F-QKP%L1$#5%SH M_WS\U'@O@"@ Z_\B?S\M'"G1P%"&6CR,,+R@ #V_"T2]@2[7&_
DSRYS-NX M'H_?T2\VYK,1(6>TJ.XK[V767V 9Z91"F?V6OKL+@U15<.\P"N&)?GIN^ ML;.[F2,]?3BL=)S1A@K?7>GR<*WI:.&'XB?T[40YR1N=%>:NGW4:.11;.[=X
MHHK!WO+848;+F2E^UMPAJ+W(/U33]&23SF9$!NST_E9_T6=94."H: M'"*)&Y6VI&!3";!HELRP;UWYDW29O6OU_$AF/PX<8>0EW?),&MU[*74QHY M_Z;([KD1KQ0'-
KPD4DAPE ^EW.Z,^-D9EI* >54P;T8B*,:.JCW>M!!LS,Z M[(7HH$%)=%![_KW65\'38\!LQW?#$2B=[K)YG:(CFV%',C=C+HUZR$=*<%N&D
MQQ@H/4VJ$"I+YLT"=+?)))DO"4VT6S1<3VN4'W8I/HZ("$3_4Y'M>#[\(US6F M")>T7+PM2D6BR+AAIM1#:D1\+!E6V FA/]VQ%U2(O?W&/?E23CYV?^WWC,%T
MVE'A(B),C0,RD@S# GA,OW3<9_0I$VB3(A.(S%1M3@7E+Q>IK[/*_E>A1XXQ MQOBP,(;U3NC-?+0)C+.LWS$@Z KD-,[1.858587&&7LU_OB'-BP* M'|KMC&SG,&H!",>R[0$[L]8/:
[&5CT^183>K9+29B5O6;5=%^EX'F MA*[?>VMM/]%5]\U:(.C >Z;#'!"@7E90*ZX>)#,?UB#9/!GQ/<65:@&]7HF8HE^D M.1\3D/#G-2ZS DD8M/X\CB^N1SW0G>/.N-
>?99Y'K80LE#N/"C8;PO=-LSCQ MHR2'%5_)XK;XFKK@/OFO>IB#IH0D)IK8&X'!2YOUC^2U"*X0HU!S8#G AE4Z
ML!13\NG,HB7(K=ZS0<$=,9[QI6S@%RMD\Y,$>$EY7Y5R/,KU4Z)+RA/HH]\M M+7_AV7,*W/WT>*6"&
(,GY2=1%=/RA&II*+Y98395$Y(%B8[%_3VU.$Y=$3GB(X?'%:]D60B!+4CIA:2^Q M^$87$6Q14I0R)4X@:_TM:B5&51OA%;B60L)XT@B.K"5(5@IZG-';3,3&\VZ] MC-
LQ"5PWRGH1\>1X[CV:N/MXMS2'3#/)7(I)=MCO6D*JQ"4'E(-.V0F=U(I^ MF7^KI-*J"3.AXGWTDIT]1;'%]EIA46\EQM-M=<9]N8S-56G-.),E]#1)V261 M/R6*0P;3'5)42FBJM-
0(55Y|QLB$R14.%6C<"N[9-OVNI4^;D41-"C>RJQM M6QG05A3-Q%'#%NQFV&W;;H:XFXG">ZRC$.('73NX0C $5) 21R=PHR>;DK(K M/2?E:*U6;/M)%(,B/PB?
L#T(^Z!F#C)L$H,PYX+&A<.&NU)4*E>8C @E,,QI M1V%**=$^HU(B^U^NR\BP1F2Q_C[*%+J=E=SG@.TS]WP5[+9&.\KZNYW0;B>Y MNY5"+R5V6UQV-JP1*:B_XRF%
LG^2\Z]*ERN)1P& M=3PSKT>+%5#/ JZ*&9#(D.#R:6^/7Q7IA)K0:?'A43J-12.'F>HWGM##7EHK M36[&];#>YX&UKG_:K#._>X9ZWP0K\IZ/)@?]#EL)]/%W_= M!
(2+#>C)\::Y8@Z']IX =D^%Q7]2N&EOQ7]:5/S';'E5X5^\>(Z]B&^W@>H_ MJB!#+0P[TS%X[++$$*RPF=O7$ L-P=_&KB]L,V!M87#%OV.\+2@IUJ:90*G+,
MJ2D475)"BCZ82PJ(FU2%98859BG?JOA&2M0KQFLMJ]8K*G>65RV9M3.MF9VI MRB=3FSH!_SHVX(QK!"F*+I#YDEA+6=/21DX\YZ&JGNGMDZV_U6EEEG.E42;F*
MS7A8N_PYCRTD]H!DU63>2#'L5YK=4H0Q0 @(B-[VKVX=ATKV3HZJS8SMKJ7-MKM_BVJ4.ZPB;5XXTF?&J*7'+AIFIL8H_-HVFO* M4/ F3 'HD*WH_H4(?)F"D5H/OXG&!+#T+M:A,,.
[4S4D@&LG?G]L/# JS,#$ ML\[P7M2#C.7$HH2OJ 6*8L+LY0:,)L6ZU'O,,=QLO0UV1U05&FD*.\G'FQ#> M^DQ=]@B|%77-!++$I#C9*:GBI:;;#P_6TF:#-L*B#-I0C(6[VS6EKX.8Z7,"
MEVB4ATC?H*RT(R)>5/54X?8TLZNQ"S/2.5EH[;#)2GEV-B\AC*>B4P]\50T M]M=*]?#9M-]D,CH'/7#@W)&>T_42T8/VY:,G@YV34;'4Q]MV,IPUV1T/*_1
MAJV,ZB2CAVW:S3@K&9UJ =I]H)$B_7R\IHY]1WP_$0)#_#I2X&VO*'27-1": M6L66?9HT'WHPWF\?]8;M:><+#_TV70U[&DT.?O7!*0E,'6@12.)G GX*CH;.M8*J)B@6TO1?WIB\W.
(AU+KBWS'5POX!S?;5R%UN?@B/PKF#+\>)1/P."V&-'M51NMOGQ-U80/6]DRNHO/4Y;'*7]>Q:6M3//>Z21WCA?&'N\\U_>COLTT$1AV MZ;G;NWO56.V.G@1UY!*:>,*CR>@IJLE:-
#IP&"=D_=G4GU>2'MR!KIBY[N9U M1:,ER"..09/.9(X*[A3EZVM,M$7I-NPL\0IG$?ZI)E/-,94D"=1OZ6].<+ M-BT7;FDX8:"TN3F]@4N3 0N[NP,S@4WMY"?4PZ)?1E?;3R-
Z,WH)T\&B!(MJ0Y^ZD2K]$H4VGG*?0T"];+A!EQ;:(S=+'$@.K=$O>"K>R%UQ&(O%N(,G<9\ M"0%SBVZU4[F=OTB=?2B2V'SF+?Y)8$2?H4\-Z6Z/Y"*;X4$B,C2*,PK^!<
M5YF(KLE!4Z.T1DC&9LN,.'\+KD=N!X 4P>@GF7S0:9ES1;O[*[MZI M*CJH9PS_TO8T_"N6A"D[_$NK,OSK('J G5'&8*$3#O9:/K=#ZW M'|8 3*] M@[':?$GP]6Q\<3TQIM,R[8-0629..
(8.U&_^ M:&I=;%-*6'I"+\D^'7/\[!W#GT=O!!H:\,?3U\F]\=P^M\-/C.P?G!A=)# M>\U\8@ I+.&],R$GY/='.$# K.:;$F7YH)P MO^OTDVRPVW660$+QMBNEAX6_!& M.08K8TY0S2?$B#
O'&9Q]=" M;@I+6K\LN+Y'.T29J#[RIS=H M>6S<+6\V!UZ;F-67@!HF$/NB$ C_G&YX[G_%^4SZK7)<#+X; MJ+(V/7[$" "-Q6VF?_L[9!3G*TA_M-<+]UPC&+4=TX]TP3'G3BQ
YPV\%*> M=8DR!3VW3$'Q5*U:H<+;G;<4Y18]H(;C,2VMNCYV*U4H!>G3#E&J4 -+0KU4O M58C\Q;*U"F5F*VG]KU4HN]7<6%+I8H68T@FC!.CD)00L22F.2<&'^R>N!@@Z8X&E6IE
L&3>5LH;.J;** M 1R%6;UF8#;+KQG0!C'9Z@]GC5%55!IP.=&KF/*_EX)I3#ZBWVJ1.:N$H"?A ML,R"'A'RB)-8BGLLOQ!9^@]Q# AQZT3:!],F\VS8#M%=5$]SKNWX\BU66N
MRB3/0WF.(L5\LA[:%-H\EJR&]Z2($OYS@3$8PY,.*@*!](V- $KB*5N"@B]G] M62>-4_PI(Z,7LXOB-4>1:@&=@_^,]HY^.:?U8K+=+7H>@"5:*[X;L)!PY6B$1
MV";J=)M\ZIM8_O.=N8GR=NPJ2U9#@"#2Q%8,R()'SC1:ABQGRH@HM; #-IF; M\@F\V.%%!ZS2T]#*U&1J/FS7@;U9VQ%" #;6P2G+J/O"K_%;W+ISR0Y4E)OD
M"CF:T5P:HB"SPZWL)S@7@L\ MD]B|-)\3_@2XI>#=+&)Q:76THG16GRGK,+A-ABAGM,;;\;$*P<^ Q]S1^UF_M[+W)/$6Q.RL&[/EK"[7-FYR;GR1*4]|\^;LR9,#-Y=LW2BO B#O^
MZ6RG*-J+?J@]N5M0! MS"_X_+889$J&*C/*;>I3?A.=B6K,H#12[#DK.9FCP M.NA=7,-MH+@.C)@V9?(BTV6BO ME(/+@@K&Y&28)2=L'[
Y%FD"C2S"MBR\#OI[&\!S*880!30"&O.*%:'WS'8! M1T&.$<9P:L*+7@#_@.4>@LH"^VIHKUF-K[E$SN*-ZI^:51%+^2AF"?*>^Z\H
MX_.^D22.@IB&7BV)H^T_B=,84+A&KF'0'97/Z@AWKSBKHQ5F=0Z72M RE'DR ME7!JRD6$+/<0L(PU95%:E!EM6;2$VZCX:N?(6(^ZXZX,S)L?]@N6_9$X?1>YS1 TE@#I%21S4$;
(+U-H;G9 M@# Y,'20!DA:7HB^L %2[*K(;8#4@L9'99+$)],YB!FI46%C++,>:'VDI*P MW-Y'$2QR@S$*QQ(V1=257*U0NRZB*[VG=7&85S53(K651?&*X4QG5!#?
YT6W7&VHN_XL!2(+V /JH0)17K[F=M"=9=7<1JG8"'!G(XYF M ^(=LR^/MOO)_WMO4>,&^']'R;YSE1]/VR-8KW_"$LZ;H.5*KD^%POZU.>OV. MF'8&JA\LO;4=/!]90Y.+ZULZ-
HZUB,\ER>QI^9GC/O5+W|(PVVUIO>X;90$5 M?M3T.+C#7$0WJX#=!]'@.^H)L8;+'(->(N@85'7!_>X/T>H.YC MY:6._@&#"A%BY?,3? 2&%)XE^YK#7A-
+9=R@]#:\)X(KH>6(*,@MK3L$(N%W M%UL@-VY$2\FX B\1$$V%4UB'>312^G,%0AH,6% MH2IY5Q:#:F(X=KH:.%1'10'(N JBO@#FDLTK3GD L;F?]J
B002.*S7"J$@MY94:@*7LH+9H./T_.D*E*K11^A ME.H!0;&J-W1HUQBE(IV+UJ&*LA1BK'R/6N.KG&=2 AR7V%[CF3'N LD& MO5*"E1LVX%_"TT,$>=8;'VA8RPQL"UJHT9
/^;LJTZV%+QX.ITYM=_EFQ&=_M5L];N'<.]JM_;WFMBEA-!TLE!GYIH0??Z!9?'*>=;S*KSZY4> GPUV-G=% M^4V,> ?D@0 ',C,CM@]035=.ZGO (M/?
>L0[*M%;G9L*AP7YHE;VT'/B1DZ\9RL.)$E}Q@ATW6"EI,[L;R>&"& M_SN?A(R>.]V4"1"0%26?*T8^0:0LVRMB'<^W.?V[#&BN,P G,T)92QD}3:"K[N%B@G-^N79!B;W1U'SIZ'^W'#CB
M:Y0S4](GY+6%RSVP- D&W#8X"2(5]/)37S'.MA[.R-CW^C7E3B8*.(HZ'$4KR_YDR[TF&S W3P*.A75(N;-(B5.V@eNN]9RT:,9J1[%NL!/,?G MGMU3O+Y2;O@X$.$05(\HS!$
MJ363RF_CLZA]H[TUN[]!UY@197R'IA_HB7 M7OW^[HLHO2(<%>V.U"*X?X24B\)Y]6TF!G:D$3P/IEBXN9?NVKUI#LO#+)]H M O\/QX(]5")*FL+UBA+%X@;9F!Z2R"75?VPA*Q4
0:>NMG0!hQ%_?9X(YXZ,U0R%&/_!BX7<%_M?O_Q#:\VX9_DHDB;L3L%SV<(7IXMO_GU0\5<&XN=VLB)G8P;W/OT+-_%-T
M6XLGIQV5&H@^#37!U(I!TPQ.=K3E78;O#E4_3\2L[!\8N/Z.GBU>_.)1 M[WMK8=%!%MSA0>9-P#\.NS,&N5>,EK@5A*9GEM.W!4(@?2YL[-\BW1FISE!S
M)G;%7Y:A,].J3'L9G:DK=*;&54M5Y4@^09/*3\M0?]<1)?+E.%%H1Z!H ?L> M,83C@.F)E Q[1PM^L'#+_VR7=XS0XI(O&9@!K<,#,\S$D,Y(|(8'\YG")G-\ MTA*S09A_9.*DB1(
BE@Q_W...,5'8YK_9"TP1@A(1Y(Y^PY-$+#[(E;X%GH# M_HT"0D+!HDIQA0<:!@PE.9;$D&)& K6RH.7$PQU?8"QO+DLY)U."3?GBEP0=T=PC._Z/BIE'~.743:S3-
0N1LELY%D//OLF9%@MP M36@IP"$ 07X 5H$RBIN&4>R3A_1BE[W&+GMAD*QMZ<9+>6GH*3&S$FA)ASWR M78/21DHG%;G|+IZ0(#2\;&GG@^P1H]0M6L #5!0\W
M!4MY'5=/5,>(7UHORT3T4KB)7_\6+*_SG\1$D7*\(&19,#OPZ7!!A$72=#. M[>]@HG%2[\)]%_GWM^NPY/'"%H#'A7V.AR:Y'>7:?|%3BXIMY[C($5<1(2F&
MS9#B;X%72CYAR;#$.S+M4>)=[V?=NYM?]KM#HS^8&0W1Z$U:AODQ&_A%'R, M:6O9_6 S0^*[$0?H)S7ED]^*4WEMK8!C_Y'US%'BZU3,'=[26>B/&I- Q3UP MXRP9GD/JC_%
[9.GNX>2I.&]'B?JZ5ZW^&8:S=F*76>"]:X;T>N]-]EQ&?6IBWA0,I^$^*SR_6=_="OMO^G'@;>6RR@DVZ;N-F_ MN!YVTOCPGW2NW@]0W9->FS:#_HZ@+]4:Y-
^FR@-7M2@HVBZ5%9L!FW.# XH MZZC\DGWILUT"NG7BIY9^C/"]_8MNOG\K#&^K7E^HCNS@Q6^]l.?3\)1FT@X MJ47"9F_V[Y@WNI0=_=DR/?]-FW5TF_R7_I3\T70M4TD5W2:?
I4_-"-)[*:VB MZ\0I#B,Z;7);!ET4G;334E9TVN2O#-!?4>QE)]$Y_!7/ (AZ)@#Q1>^L.9M< MF4$"5.EDFCW53]MDP\U !]J4H>(S=[]7R2L')Z!C^]O0O#/RS*M3>[8 -RQ M_DSI^;ZXZ-
>X$Z=M2E\-P$L.O8-.=EBFNL7G:6!PFB?'&8/3"B3(MM$V9\'D%6%PIN,V47YZQN!$G)FTB3,SBM:E)S:U'&8,<L5B< M-9N"=T,,WO74">JK G|KU];@%/9V/6'0S:Q-
(;PASHSKSE3IZWOV:1%N)A[!BA-[,;?8\;)^&H>X;>[%*CV^2VC ASH.A/ M74I%#[IM\EQ$X+GT%7LY&>@-CB5O$;G1>5%DO@L<_0FVQ& MM\F5&8V.$WJ#8\-
;1,7Q&7I3BFEMRH^[9]Q4Q)E9FSC3HU*UH^M=A*,, M6T3%?B-4?,6X*1RXV!Y_>CQ@?6@+8IZCJ>(-PH'2[\]0 4BJT.6[2+]1H!=AH* MK4W](8SQ!GMW.8*>P&V9S.3[ADT5=?
XKC&_NWE^]HX0-(6M#5M$POX9-+6# MCNZWR6>9/+1-HZ)"#^QAV*)=#%$YGS) #. MG8KVW2[1C.N9Y@#?A$,)P MO.X29Y5?QD8/OXD-
]]6BT:OYL^]P/.S[87EAS(SEF1FZR[C(D/N4CH*A!,OU_"'CGZSPXA?,6HP M1C*M+LGB!2TO1S),(0T460U!,R)-_EY:LA-P>\;*R'+'8B($33G'LJ/UHK1L; M4GY\#)FTSI7[GKM/M$09X(?
AN,S?1VY]"@,_M1#Q8_+B)H<3Z1KQ&YT-@Q3$32?6S0',X'P+,;'-MBX,VRT VLXPP >++CN%DX0>K/65?#\V$1UZ4>5U)A,,_Z!O6\]K:6_>S9S27 MFN?X0>@(IQM/O;MJ QT/M.
<;X(\Y9[5AQT7:X2#+^VH|F#9< MPZ?M7-[-W9UGW4E DI++.V)A_B.$E+>3)NJK(,[AU\#7V';12C;-<";%| MMN;/B|V!!$]$1!K?9&BK[WO H]HMW?
J@TIO:>#FM4"ZUKRCO&O5_4BY!NIF, M=%YN35U15GI:K+<,K79+A5E@UC@_O;3QW+!6V?Q_'-4F8P1.\OQ61$RZ]D[M2O6\?587+W_X:VI'S[>.'WA;_-#_'-Q;WO=[T^$5S6%
(\'0ER0Y7 M';Y!=L)MAICHL3%M\M25O<6SK7OVS# 7RS(O=T"%]3/+C_7RI*BID D4G\4 M/)E7]H^K>WNYM. K[+]7*R#251\+7:YX%Y$: -B#+WMVE.O&^!!C7'9OQV7O
MRQLOC73IP@/H,6O]V5R R6=D=(.2%E^5'M298[U,SF6X=>477NWC934I M,SA3)H,RPS-E,B@S:I8RNYD7)2(I0R1K+!:0QJ 4[6!85?W!#_2ENP6#IJ;V
MRW10J4[A\::)KR&$,.M5"R$D&=VO=Z]RY*3TJU)NCN(MM87A9,,-LW{)<$;; M65_Z5?:L)3>R7VSO$)?HQSA*$>#_I"DRTD;&[G^G2]_&XJ'U%NL_5N[6/7P>27+^%=KC1#R=ZX?
^"D1KX[&K?F:2/)',[2U]@95 MGB/(7*>VI5<4K]+EU?[ZM_DA ;E[>L=G1__/[?I9[XW(WNL9NDW7HV.QF_+) M#NX)L+R K:\M_$SCI0-)S//ME_QV@-
SZ6ZP\L#4'5@B/L"S[H%\]J.E6Z03 MX6688\,/-FO< /X[4;\/O?8'OZ9>(N<87]IN_T-?Q4_I[M!Y.[" @HL01,RWJ!X81 &D(IE_"ZQ>[-9@U\"6E&C#>GFG6?1
MQ>AW!:MX=6"<7T%T>?+(<.[#MS8\/I"GIU?(M[Y&*,SYN)C1 M+\)*FL[8IV),>CVC4$,?=FELQ_@UA;T)UC_BU0<B[$]$1!K?9&BK[WO MIHMW?
J@TIO:>#FM4"ZUKRCO&O5_4BY!NIF, M=%YN35U15GI:K+<,K79+A5E@UC@_O;3QW+!6V?Q_'-4F8P1.\OQ61$RZ]D[M2O6\?587+W_X:VI'S[>.'WA;_-#_'-Q;WO=[T^$5S6%
(\'0ER0Y7 M';Y!=L)MAICHL3%M\M25O<6SK7OVS# 7RS(O=T"%]3/+C_7RI*BID D4G\4 M/)E7]H^K>WNYM. K[+]7*R#251\+7:YX%Y$: -B#+WMVE.O&^!!C7'9OQV7O
MRQLOC73IP@/H,6O]V5R R6=D=(.2%E^5'M298[U,SF6X=>477NWC934I M,SA3)H,RPS-E,B@S:I8RNYD7)2(I0R1K+!:0QJ 4[6!85?W!#_2ENP6#IJ;V
MRW10J4[A\::)KR&$,.M5"R$D&=VO=Z]RY*3TJU)NCN(MM87A9,,-LW{)<$;; M65_Z5?:L)3>R7VSO$)?HQSA*$>#_I"DRTD;&[G^G2]_&XJ'U%NL_5N[6/7P>27+^%=KC1#R=ZX?
^"D1KX[&K?F:2/)',[2U]@95 MGB/(7*>VI5<4K]+EU?[ZM_DA ;E[>L=G1__/[?I9[XW(WNL9NDW7HV.QF_+) M#NX)L+R K:\M_$SCI0-)S//ME_QV@-
SZ6ZP\L#4'5@B/L"S[H%\]J.E6Z03 MX6688\,/-FO< /X[4;\/O?8'OZ9>(N<87]IN_T-?Q4_I[M!Y.[" @HL01,RWJ!X81 &D(IE_"ZQ>[-9@U\"6E&C#>GFG6?1
MQ>AW!:MX=6"<7T%T>?+(<.[#MS8\/I"GIU?(M[Y&*,SYN)C1 M+\)*FL[8IV),>CVC4$,?=FELQ_@UA;T)UC_BU0<B[$]$1!K?9&BK[WO MIHMW?
J@TIO:>#FM4"ZUKRCO&O5_4BY!NIF, M=%YN35U15GI:K+<,K79+A5E@UC@_O;3QW+!6V?Q_'-4F8P1.\OQ61$RZ]D[M2O6\?587+W_X:VI'S[>.'WA; -

MP)>,*';;998U&NP4_:"R1;!,\GWWW;G^W:,"WV=V7;";@_,C'*NFP"IC"H;3 MJ*NH=&<_T)27@OEHVFNJCI)-"\Y-09B,RD[\.?Y_>1K5T-"U:32[N)X8P\$ M+DY%;Q?

UQ:GEDT=R=.K:Q*DQ(++OO+^1'U6G>TQ>SW2/T7FZ1[Z4Y@[RV(\W MST--#48']N>R[U9=K(LR?-

***;GC!;\:,DM+EQ[N^25*]PVZW6GTR4ZK\9N>*Y6.O6..N8DG8YI%7M9X+ED]YO^>"Y=84+-=(4NV:.4PC"YG3 M7BYQ,^PB6KA+D(?N5-7,-H/B1UGQV-^]@7"#_,F#_%;!^0Z[?**

1REH,B|OSS7-MFBXK]N,(TRIEQ36R_-5!NOT85P87U[.3+QINURT=:N8LQ4N$2\0%#[L$\>HI M,!<[,ZBILF"^/?V.=1C.#"QF/[\B6?IALF'O<6HM{)_ZS!HS=\IUK\0!AV M1Q?7

V,PZ1K#7O'0Y^:J:FN/%:[1U+2OVGXECN*PB,]"\Q>6?:>-6WIXI?) M 7H E-)6I5=\G#TB)H?H$=$HH:>[MH=HQC#)#'2(%HEZZ5Y>?Q1Z%ZOI+??1@[OK]M$B6!".^+5/;@?IIUI

M8;RZC>P[P $]IMAV;P"L+(Y^UFB&4=:7W+^_7_S% P4>S@MI8B%-6Y5A<.+1 M\]DUA;,4<0]J_3 S2B]?*NGR@@;>AX@LU0R\X<7U$.R[D='M[C+4^\52+B]H M@$FT;LX

PY8&G7YZL&P+5$$[+*1LJF=92+T8@;'106?0:U=Z9;\F3#/4CILP MO5(VS,3B>C"K*ZC8D-G,C.J#7"%C\A M84WVCPZV>WG$,EM5EP:EUAL,)J7UWMIHQ.+3'UV/?X3?

BZN\&=5MG51"6<=5 M^B.OP"CV4ICM8>0@Y"#-# M4KJHD)76QSD(TX$QZ2NFJ,>//>Y0;NL&\F[9V.2H2!?LLBTNXE^P|YBU|#]Z M{@-MCEJ-9=D_L8UAW*DW4S8?

TFR'=36SJ/^,OG$]6C=KFH:'5F@Z;+,2<1)$ M 8[O9=B;"P\6R,D;UN$FRV6\]29$G#FVUP[V(#@"55 MIDE"0=2+F9)?\=86C8NDJYE?UF6EJ'IQ#1NTTB+|$^])@GID4%E+:,[V,?5&*G:

M9O%FUG\WGW%'_7C;28Z3!/T;Z66M M0%7-]I3'_QIVQJ*OD:!4P2_VAX3#5W924W?=8AT[348%UO%R!4*H/Z(4%I^< MP;#&V8EV>TO'G--+C-T%X"$J=@1&VC.HK-

DQ|QH"=R'E0Y*:\KPWV&+NG+1D5 M=UC-T6>'7'B%MW#"0%%_=UF7TF[6$*Q)1Q#SPVV#0- 'E=SW_AB|=4_Z*3*P MYF])VN,7,5QG GGXV3BATWZSO8-/>(^XF@=^V&OK@9

<_,#7*$]JY,!\<"K M+KW&#OQ+%/@43WL0#EHB]D1 WO? QD(]JO7&C/1&.O*;]S>I2S NAZD.#QQ= M.&>C4U0>P_K*HTY4?I_*8X##8BIXQ&:>YOR_E4:-G;1/*8]###9(-*6S:F/(;'

M8"T,.+.;'(#W;H_RICT[(^ 2._8Z= $N%UF[6:W=!?_]\2@;/J OB=VOG!H$- M+R F(P/6-U!HOGN3?&_$I'&QX UZ8^%A'L\,PY_.8KW%5L,BSBDY[9EM@-ER

M6; YU=8AR32Q*SW(F^GS1H91*\+@WK,L"JU(|JR6TW91P0%|$O:Y?4G-Z4?!^ MX&;%O\Y#N0[GOA3T+-R?L%V_= "M#32_3.HK1W4#4]XW+#'PKAR+Q>2P=]9

M).4#BEZU)1QRK9_PE-18*J;%#LZP,GTR\FC36*^,F$8I"87>;WN0PVZ;O;BQ MO1^1,.VA\8JJ'4E+9&@_NRT$UI_4;L^\/8A&R '(Y.V]6($T\& EF+'-"R[9 M4+8,A\KA+)-Z7>

[ME,;GX&PFBC>A&,^T]VUNT&G."E[ZB8G&>_:?Z.3P7!4 M TMU(SPBM\5S:T^!XM-V4'QR<3V9-BCCY6^8?+\@M_' WRW\LPU ^4L'VS']@//Q-%7 MU>MVDXMXX2X$!5(S:X?

43.$NFA2#=/=>=:U4S!MUV\$\;"8PJ%ZN^V<KV;JYR7P>6.*]6D<"98 MRV_/D++9&N_,T&N'5A_V0;;ZU;_DAJNXCX-E+=*E]3EQ;,WF67 LI9H<$3I

M&OU>]4Y,KY%I++&,6!YK3,;%];$[]T7 >S>GV/ X\#6$;$!P$IM!2Z4N!.X(M9V7,]XRL. 1<"'$QIN]O'T3-DV?IS%)Q'<*D1,,V05HURUS#.O6:NX?G#%2[4T5K"'B04]H-ZY#)$SM^[-

M1]OU&$PNO3!X?TP,^.,XT\/2N$54)DZ/)R@3"0D!*PT=_AK*#7_&%?S"69!H M>7PF.D-CPD\0Z<2_1BMC7'ZPEU<;UW8"]M>Y%3Q95GQ=A. 4]WHP?]@/VX?8 MZH!#ML>07?

1=07/3IY]$I:VX"S%^&[[$Z-$4,+#%HLVFG',=)^DI7 <)N18' MR#++V2Q/>M^%4.!EG_+__UQ3L@U_\1&UE6%*(7[6QXA9KM(%[U5[PU<689>Q MIAKY^T#GR

O(LC0)LHL,QR<M1+2,;3%Y-+]7P*)!AFQT*)LV6C<>+A!]>XK.+ MCXL?L-N#PV."EVCAZ>.',S[%'EX&7O=20]E=F/X]"CC_-2E2&TO(%T0@TX&' M+*T-XO?

Pl.'CK_#QST1$=@Y1[KR@HW_;SGT:^AVP4G0OBR@,Q!VQ0BL@>VSY M=HQ4L0/.7P-R\Z<5Z#OFIHX[EDSB5^@ $\UA9\0!ICFDNR.Q$M!*X381;QE>_M$_

.OV0U!.$]YXC%%;SV(\SEH[M^I+(>5(I FRW0U@M,4 6V%17HFAO07@PK MJ,'R?)!M4&8+%),U)E:I<#)Z*XC[\[_0*?Z *7$ICYE.SYVD>?5%H2YZ7GL[L MQP?

<=Q4OH4'V\|;$9G[1OS]O8!\WGCFW%[_HG\#69AO^Y.+6^N/8>'OQ,]HU M<3%BEGK_<\\R_[R:6Z FX,$;HJ2\VK%BM4@G><<2+^,BI'RYO%[<2,2APXF3

MM,C8FY5PX/>VCUIFZUF?5[(K\Y7AJ@GBFZHP4H!^^Q<'.2GSZW^ZL#![C87' MX9T8V0V/X,]]>>X#;2O)E&-.,?PIZC2\.")M24D\O$9@

M'=XSW&MP>6&LF6GO},.^MJD.DOI)@>>=IK!U':+?%^G* 6*/= MYBHLH'@9^RLP?I[;_I]7*\0^WZ)RP?OH*UYWD?GCA=^PQ3<\;DF&-^F#M;3A MWQ^C\PVN1] !(-[/.K8S (YL-

RCZ6 '%#0Y/-%LBDOMHA=MKT\M@B+,/AK2- M"Z%_]=Y^M,%L6I*169"#Y3V/8C^W;VBM#]>VH8%'HZ%@K_$Q@$>/,\!.VUC MVNBY#/#,-!.VUC MVBY^O"(2W CL'M"OV{ZOF

8B,]E@MC/H!/@.]OU@QK/-GO#@;L%R K7 3#,R MN\3D:U):Z[46_33: Z,+TS0FVE,FG!L?F.,$SU"73_6[X4BFHPLU7SP5;&6U7]\?S&NS6>]-! M_]7TYJZ#!)X_TS<_OK_1;?

C2/*"F(H;DAS\\H(5"YBV[&AXP-(!W#&SJ%%H4 M[5C8EE&D+"J0],7.UEN RK"P6>8!61$=3 V6Q$MGPPXUAZH9]=CKA=PXRKJ M!R6*V%*=6#)*UQ1.?%^5:PD!+:A.VZ?

$'$5]FHQ%:ZBT:[!3:==#JK2K#IRN M&,31'"W\"E6T=E4/4I:C"!^U;]7!WMI6IBZA<5E;PS:H//DA5Q62HQ-Y^ M2/OCI:#/R>(<L>$"A-5+]%0..RE(-Y&@1Q2\0*^"VI*V+\[2Z.?

CY3Z%#5D"$ M&ATDVD.$&1(AG2S_J8SF.8BHC4Z R]-NEJA=%0G9^!2V3U/GTR.8?VJ^B.!" MBG3%XEB[7BE5%.'PY=B#N_X(FQ;1O0K.Z6/OWX'"Z6>4XLJ0DZV"1CQ.:@R(

M&IFRVJA5447S'2>NRLJO"2#WQ;6(/.O/ MF$W;62N6'D& M9,#)O!YU9OUD2(NUC-^?KGRIT2+5B#/!F0/]41YQ"H&D15B*O<>Z4TGNTN'I M#Z:'>3]?M+RK'%S.?

$!$Y3%UU=YCAK WJ, S OTWU_=U6(A.*SD=6*Q(SV$N M?1M8/N5TUKC9[TB83MI;$+PY%Y1DW*!&"1X0/)3 #,%C\!P[ZQ,#18\XO-KQ M8&[7)DL0AC@MY7L)?B3CNS"@CHLE^-

K"WIB$BH2#OO48KL!<8,,[2CFY4GHN M3) 2<#3Z,3R8(.V4_X,;%2N*[?DV8$,!:.D'R2D=I%,JO::-*>@<<=OTCB)P; M@+:SS;6VQ%[@[M):K4##B8Q;R WL3_\(I@_.Q3!]3-GYV\6IS

[*QX0)6401 M1E,7I+;V#+9AA,A@\4+!$E? U=+1W6;_FJ_]9OI3?Y(RW0=:K6QC^ K^$G\;V MQF;_$(X!Q'G# <0F4:[*66HA(Y@"27#@BW!N89F*OH?<0/6Q"M(2);/KN+[3*

M2_OQ300=Q34@V)(E_^EO^$OQ5"TO5B$Y%-;M%Y[VB)FPS=KDZ=.5[;Z63;9MP+*OW,8.C-80C@TPG@6K,M4!D47W6!D",25 M;[S!K %7U<+'*$TN_I.^'S\'BE$-WH*V2W-

^5M4>1N*_<6E*55:S0A'.>WXL@ M]$SQ,;$4\LI\L-?//Q?1AK]KV_^V&"G)ZTCWI]5_G7M_N]82>7'T0O"]UX4; M/:+-IQK>)O'1;NVUG%^T4*L9$M#SU@&GS/I-'H2$

MB%+8"CPMN\7'"*<5&X.!]K66@C?-4>/-F??-=%?:G??C+@V&F]4!&F?>'X[W M===HSU>!][^*ZWS;9KHUG^!]8C0N&X&#$9+6!*IQ#--3?24)WVGK9C]6!C$9;, M1]-

>$^3'92#=;!U*K0X)JG8@OOLT-CHSU3CIMI^)';PBPY01HZ5BU=ZWE[Y^TU M\^69S-^M;,?6XY+]&XZ+^H6Z:UO.(BWD@ M-%;%8N]+R]$3]1E"]FQ55CG=-

?)KIZFHF)"D',B5#78C$#9.(3ULL;_N\ MX@X%U6SZGR/Q" WUKF2?,RF*F>C#PR\M=:X9U&PX-'%|:!OC <#HSM10?H: M\"O.:;G]2'^O==)?F)5H?

LGUI']R<3V=&K/AP.CW5'C!L_2W5OK[K9/^POQ# M\TNN)_VSB^M^S^AUNT9?T13V+/WME?[6&3[3HD1#R^R>:>_B>C0$FV=@3+]] M \E^RV,HGUK]I^PP9/U U3\[C6Y_$?

1*M8;ER>XUR31+-R-; =]7'+6B?$N3 M*TWI@ KK'%Q<<SNO+|]X/E[U@3 O>;P*0PX-KK3.\1KA\7H]N*_S\;J/]7G)`MXU48TVAPI?6.U^3BNM?95Q#C?

+Q.ZWBUQC8LBIFTQ#2S%_>$'=XF#@=U'KU'2OT!HM7YMZLRS\LVZR M&VRLQ3?/I*ZBMN7KYZAQ>;(5N<67$HVIE[KXE-R>L>*R:^L6;FO\GU\.6Y MM3"WOB7-

KC;O/6A/[G;IU,]-6,?_8-K2.W8/T5.PJ6ZY7+-,_M96BTIZZRTC=)$]8?HQHU854\4-4GO+C/>+J/+%\!-E35%4-6HTTI=Z"8_WE\ M1$GUE]TS3?;6@+9Y;O>;I[9J?

FU+9&L_NQV^JMV>>7L0C9 @5I7VFH?^=7GE M=9@"\V10\R@YUA:=??Z)#7<,FBI7,Q0-(3'XA9_U&0KR9SZB)G#US=9;W)N^ M%,>ZI M< <9M*Y,Q9:Q9WHD[,$.?P-

C/.D9O:$]Y'&B[)D="7L&K_+TC&L 2 I*GN%^ M3D^3E-3CXR?UX$A(4C^A>-33YDA]V"GG92^:K\]HH/L6CK*=0#$! M4F)T>GOD>GPDD8G(O^X9'UR'}[CI

LZ9&),IWVCVRUV%NO$0=' M)B7'X>*,NOWFI*2=QF!5M7D#:O.+9S]8+ZD\\V7K.'RZ41?.I'!@C(>S5]N@ M?%H?AU,WZ@YIAM)X,CYB6H^.A-:C$Y#KXW#]1MUQ@W+=K-

6>@12H%0LOO'!R M80K5D>V9]<=YPE;M2>7$\3ARS:,NED6,N\9L-#5ZRC$XI= D92El:EP^EC#! M],SE&EP^CLSWJ#L[&;, M9@.C-RG.+9S96[N!U4'9.SB?

WAW8>RRZ>;CWPUM8-*OX!#,=FJ;QE,=>ZPBC M:D+^5O[2_&K5W K2[=RW_MJ",?+A$?I'_VZE"D"4X0V[JW2=G[=&WT:'TZ M6\BO?YOON8X8WBSHN>]7?

7;DXC9#OW(60W^R=\[?[#A+^8](;WWO9.O)EL MUF"1TCF|_/3^Y@V&GK#^`]8_.MX[^T77_/WMOVMRVL2X(?\>OP/CFW++K4#)?

M+4F.ZY6U)$ILRY'DY)P[-34%DDT1,0@P6"0S'^:WO_S=#?0()KB(H($0%;- MG!N+ 'IY]KU//;?XL_V1[=I!Z(O'K_!QK)>]^39Q+#<<6D# YKGE=SW7"IGQ M^N;#^9NXH#;TF16.\-

\[&3F A/CFP+FR*/X;L(#O/)#H=F;^A[M+F#85[OOLHG9MP.&WK#7Y[)>O,&YYWW;0=@%[-H=68%]J'EY2G_X(Y^;G^'!.I\4` A;"/7T&MM#$;2K?.;C_^)U2URS"FR8I

M1Y*'^<&\\Y3^WCSSK;[=^\\!)R/'_B3AT=KGJAOO96OT:D),>1Y9YV_"^3S M]:#+ $_APV.Z276W1YK=XCVD\U;6V(+_>+]?O$@"82V@[#T/Q;)"NO_UM$; M]^-

;ZUV^HA#X]O7]Y4>S>6A^//MT]M/EQ\M/|__]7R?-QO$/=^;%]=WYE[N[MZYM/YMFG"_C_9Q_^W9_C#G10*Z[W=_$B?[N7*\Y\LOV]^\+ROV SA+D1.KHK3ZG"W&!_N

MAW9@_A99/BSN3,Q;-Q*41W,8(5CGX+99WH'NR@6GQN\EX3)L @177E. MLHJ4*,MV Q,QJUG_8<"O|L 15QO$5TL/-'X@"0D2$[<9,B&).$ M@K\V3EN@!EB! 2R)=O :GQ-

+I1\7GW3(S$X]3E0M$'"/S#ENVW\KJG[KOJP M_.JA>3]D 3-F'T_>!&@#W"Y <6IUO0@6C'R3?1NS'E?OL2,HPW3Y[9(XW)O4#CX;U)\)X^6#7^K_;[(M#R[&-P-[9#N6#W@&2I@?B-

LPIV[#4&X# ^Y%T+1P9 =< & M,&\0_ =N*_)1 M/)%Z+[2@%0312%2;\NL;1&&$G5%(WP7E:&CWAO1]VX6]P1\!FT%'_!.^@H@ M:DT^0@(A7S-\._C*O\RA&M

,"]OO12/LT=*#/Y"&A1_LVX.!W8,[HB"FS_IV M+Y1G5+/8U YXS_* M9^`B_U0?EG]_LAUG^F^P@^D_8>^6G@UZ*,M@;#MD66V$0RQ_\OTTX20_KK"7KPLP-;Q7C"""?

MP8\QMP[P4.$,$M"4)]D=[=!!![&-$(? B[_@> M/AXP#L$=^ B5V5P$9+7EPHN@CGN^_##OW6.EUP0,?6[!YY>I&6HG(`Q<4#;: M*KTH"*AGD.,]8*+=H=R G&]J"OZ-/ XX3

M$[W/4/8!GI\.]0X?O,D\N\OC(%"C[@@89QA.8%G6GW,)62 5A;@68_+L6=%#,%-*V6(9UJ +4S@8CHKD. M__?0 ,D&WHY "CA&<0288N3A,"-P5*:**

<("XAGXW81AH.KNQZ(0]V1UJSB[0$ MJ :O'H*,[WDDKH2\@HSX6[M\]G (,$]DH: E0@ M!Q$14>0;R[&:0.$NXWR:9G:Y?P(YT7ODH4)23CZJZFU">09\MZC-G!=RJ'(Q

MICS))0@\PIR /;$F%E/>7[&5(6@0OPH_#)>%3P)@PZ*SL55&O)4?8=XFQC?(<)2#SLI\'SWD4/*B69D#3RNFA>0.G MX4+9D"@VP,=B-LTP#L9U>P),D%,!*5,5DA+B-#GR1<-&

(S#L)XQ4E2'FCDM MX1,&2&KN=X#Q/JAHEHWD?]A0@%%6%N(],)&KOJB=JG/?!$Y=3O MDOIDRH:<^ V/Z+('"B0QG"YSV< ..96K)CBH$0^^->)*YL#K1<+&)6F=/&>@ MT'[R

#OA3_BC;XV!BWQO>FK H2<##F:-.U_6$FC@EON73[=F^[1=,S(?MGH1 MK"C>L4$R^!/S]=FOU]75@,^?"\C8 0$/H-I' PN;JB+TQ+,#*3>Y>FRY)H9+

MP.*%]P&V/E=E'1'TQ&H]4%\"TGKZU@CT.8Y @%2$9X0ON&"'L6;?CQZXY(/ MA[(WJVF-26'M&*60BX8^]9((/Z!';MH?2,FD*9&>OZ#XW41@6T[\ 982OW/?8LULU V"$ZS)UD$'

ML6SU >8(74G\SYX?R1NSP00#3:#/;5[3I5E/U%U8 MK&L0.N^305S$.=(0 N$' = O$5+3M4S+!3,/F>8N,>5NZR\ E[`I\>-^A< M^2CUNR8-D.F392 ML!BC'$]! Y%MB2$Z' 6$Y-

!6*!;D,=)L 'P(%7]PW*8K7]+9B90P],*8(FM3,H?<$_]>O<5Z& M+@S%4P=R="0|>$;?|RQJS _*U-<:^;K\T Z89)!9E0R4 8"$/^%W%$0IY,6# M" P&'XG79ZB-

F0_V(QPIPEOG*@TI,AAJ'&HB3O-UX?_(BN(/ <62 ZZ5!$7 M)3R.Z!#'+X4A9022G(&+XGJD W>)>D T'H#*)+TJ"S#OK()JXF^L#AD^)2X M[-5$\:C?

4M3%.*&8VP#_(WQR]#W#_^EQ[YB"5FKLMH=#(-_=RW&*/(@N3LRP,M$C9C#P /T"]+G:5H?HAODH,:*53.>A!#(HSOILW#XUC@(^2_:W0.F_SVY)_5

M8+XYXKWD9X3Q6QS_LN%]BAFCQQ:PQ)F [A'PO@+B.2-YCJZM3WC5ZT6CB'L/ M^V!#]VPR,KX[/BWV3+?!?<$)625W@+ ^X=%IX7.]M3+TP5%T#RI/C*KZAOW7X

MN.]%#T/T.A!$MCT1OOQ'BGT%C'V=S<1_P$ODNI)>!^39B_R?L+'N<'TROB_[(&F"WI?+_@J=*Q%;R MV:$3CF.T@6%&68'E,&$F!9$EHB"BOZ=_"K6LN395\^QAZ!)1B3O2

M\0WZM 4$C2=(O+0]*Q@*5) ?M$"]\.T0?I\/;38P+[^Q'I\=S9RL+17*]@[%B TH#O3TP%T$8JQ(8^6)NQ#C_Z#/@)GT1N%.%[#S- MA=,4^NXC[C]:C (%IG*HF$_|&X>#A._&JI(^

)BQ>$Y(^1%XBR-^YC$B50A M(4]%""170_P,B!5Q+>4I8;R>")NP;3077-$ I'D4L<)QU 5MR<0P'-RIAS|/ M;BC#+NY#4.,S;L#&L CWX GN;J*R_P<1D.!.2<\?>WSS7$#63!)%G!.+A"(A

M.N$*SX4.C;^K(\O(G4B3-YV.,T"_#$^$YG|C_HBO@J-XQR:UP,\ M"K38R:=AH1[6L\9V"*#$0"3;/%PULL#&5N*A^*0AG[0X%#)0=72!NR.C?V'T

M+^Y&]J:D$FC0%JAS5*A!M9%TE\CS^2BL:3_Q;.48F?A2]*5J&U4E?&#?F#PE MW6?\1A$?%)MOW^ 3M$)R"_$5BC@71L\R'<"]-%OQMHOJC'1Q@NBWS2V_P' M,"O^EK%I7

%P>V+*#+Z%5 AN.'C*!TEX&$$T'@-V4-*C"/T%(A>! @A|OH=E MD&.7P/YC|!TMSQVZ2&YG(\FZVX|YV>|T]2X[$.W\"")$ UYVH#QM* TIEMZF=5I;# M !EQ5IERBC&'>QDL'A]7K'-

SQ!BZNVHBM2S.Y:JEGHJM42F!TDT^>;6++#J&, M#$)A7FF7IZ&3N/DEPN"WW.UXBH3.\3L#RK+!A2X8Y3LP;Y-\TYO8G;!IA5A> MPB958!OL#W*^!%56!/Y@%')Z<#&J-MO;A"X-

86$'AH\O!:0$\I'(G!9!/MS_M"3\^>#B0&D.+ON4#&G;0|X(%!^B*X7:[!5($@=)!N88@TM,#R?DH12+,=>=Y M]D ,2%Q>8%%C4"QT> XMDU4DG'MO0)'OA0)NXA"'YCULI3?

$@!_/0.UYY%6_!)QO& 1GB';!Q\'P?C#+%3[F.(D[-ZCDV:AWQ,3NJFR!/YZ.(L M_C@[2GZE9O89>K@PDL-M$+A$H:63F*VAS\LC3CWUN\'%,*:++;:6R"N?PH* M@O?!;^2C#.#E YAS?

@L!7C02\8LWS7C.*PAD4KFRG 'EDV^,I<]>*!$8)*4 MC$BG?"$91R-Y?"@-SMZD[V-++&BIV)+FSB27M.K[Y)*"BA.2F@$CTY*\+PHU M7XH0;Y7%Z9V:,F"F4P>26U&3QN/--

TDZGIT,.RU:.`%/2Y3ZGFF'<>S7<2B M5%+]*I;QF .&IK)EHU@V4IQ5-OYAX2A/"L$Y#MZY':WQPM^NFQH.0.*BZ+R MR#WP04@1I4"DZ8O $@;?

R%,.!?]QQ(Q"YT%2|"13D^17Q);&U@0Tf=^Z:C^/8 M!|*.29Y7#0!0?%66]G0|-Z+?V6CL>!/&9 D 7X=RG\B(..!E[9B&!%_DJDA\ MFWB8#(1UE?

QR%5%7)*1WGU+*A\SJIS:JU#P9J4RH0!A=E D55RFE=D/6N1*Z M%G;2M+&':'K .Y1AVS.'2HZ%E(Y-?\]JXFZ9 #6_&3B0;#'.\T!X ?,<4KL# MWY6QU6_B'S, _%1_%(@UP(FJ".."%4UI,

E];W*/ 9JW44."9X=R=9LJX9Y#Y0 M@\5"B0:0S;]A/K:9R(G,F M9U] QE3' AQ!R^5DNNX[RISDU7&*6$Q/2>!8G ;Y!>5B549QZ#3DD5#)-K/RIF8@HW6D) 'YHBS#

MJLDT5%W^QDPIF$GGXN5@04#>'5W$U2#LU,G3S[R47H9O9?DG)U>.L<\= >\4 MF6!J3DF\A724FHLA'DP6?)CQ@J*X=0F'J(/%!VB 4?DVD !O(@&?GU4E*ML M>%&

(1G:R$[+H,8B&Y=L6GJ5FV(,X#!5G@J@0B,#4%NYWY>IZLEP/,V)X&@35J\@*6,3)C5Y2Z"SJQ^`3A,+I]$H%]9)*XB2! M4Y3M,EG'\R FX*&+\\-

U1#Z>&BLP:L83+U:,?)F@(OHKQ%:S/1,3*44)&V.@ M*T&'Q*3?4?6$*$:>-5-[4M=_]1/E/7.*H\5]XHUVP'-3C6^GC9TR%.///F1A4 M!Z91@Y=0?X76*QQD\O1>TM(*C(KND;@8USH-

ASU@UFRB\]5U7;5#U("XLFT-LH,1/JL5!LX7-4M,F<[UPQ66IU(>&F2@_TP M$_&,&4G9Z1X$\=]5Y!/Z'7S HJ1; +$/NH,?Q?E1YM!^0#"]^$(HQ#>28$[L M=A;X$ 1>SR;=4J0>

N.FD3G!\PXY16[4"HX'M^#^ZJ?1]JV<^_MJ(L]S8]=92GMQZ]_]EVZ(F[!P4J93;UA?E9\]N:KY;]]_CK%W-2B,Z@*@)+- M],.D\O9U8URA3]O>G=.>DT*X,^?]A[G.$^?)%U["Z$"-

>QVY5M3'OHW7!7+ M?K4.B\S^4GX?SG?B8'-X-X1, M|;]N-8^7VOV;HFR\45]NW_]8O^R8H<[/1.390<323_)NUCI'I[^SKQ5:]9W M_A*.VAG"W//9<5Y+&@'NTSK'_AI9?

F1^NPLA;F6)QAT6QW30B_]$C:J9VV3K:. MIMNF5$":QJY?0JNQ]%.W NQJ@!QJ&5XDF4]KF+C:!VPU0$6.GA)MSM74>ZUE

M",]HOWGM0TN36]B'ABPVOXL,NA9$BLKT$I$.\EJ*Q3=[Q|%^,|D[CE;AK,(MO4XG,N5\#= M19-E*GL)K<[V'2J;_NMCO,E\OOIC9S28VJC=E1?W1-2$?)MUAJ=G;^$3OMT

MZU>P,9[56EU$O4"E*J[%O=],*3:S;4'91OK|),;]S*.@]BK\#EXR^U[4=9B. M]C)Y?$M]0UI.[5JK-3?0T9Q%_W-E?H'/79]OGU3OW,W6W$.W7R)EYIU[W8OI M@3M7?

YFQ[+2+X"V5>56R1F^)YH6MW6E2V-@W*=PVRE))>I+UOPO]?.^'V'L' MVWZ[GIDI>!#C)7E#0>S3'5(5Y)Q1=@3-AK?)6>3Y=KH3K-*(Q\GL1VRC\$UA MI+ MU+'DT/R 7?

E$^Y*D.7BT3E)N3GJL(?'7UM'DFU V33MI$U4@3;KSZ.+0O(X;!XFK,112:1*A MS")A3D>S*/C>MX 7X%Q+]#K_#!$?-SI5IT>>/W4M0@N726BANC0X(V5,!:O9 M/^S$4M0

U&FU)>E]UU';0EMKX4$ 92:(:[%Y"22E)$0&)\/,2.XK6V>5%TD MGM$BZ!..A"A=AZ"E^MPLOJ7%.N*4L,_-_&C30JT:7KW[I,R"W[>Y*<:F2MGF M9FT868HV-

^L\;?';W*SMM"5I<[.V\^[;W)1KD=E?RN_#V^O8\&S+FZD/O*2\ M/A-1+]+ZR_NBX(/T,EMQWIHE,*7;]>MGK+E #ANUW8-AWJ[EOIC2Y1MIB 1VE MS.O8DU=%4.WH*),/N27H-

=]UXVR2]98V8$_9;-M;!I9A-Z6`+:.+HK7HUM\,RM M.UG PU4D:V7S;6^R)NT69'$1EN UBH*SKQL+(.TZPBLOM:!WI^\-*(M'IZM[M ;Z84FIGWOEF$W\WK =-I.

MUH[,.]@$Y!C4P>L" 4AU\"3$WY_3'M4Y[+MN?>?;%9,ZR;7!>OIP>T"]H;3O MA:/OA=/>G5XXS7TOG&WC[[VPLD6/RA-*3+M18Z-=']N1N+\(%MVZ2A7ES$+H MI#M -(8WW1

P=4*-.;R!9KVX8-H^]^'#6_ZG_5I)1&.=:#SQAO$T)>>NS< M VM0WYL/7A@%)GGO74NTV/D<,O-#V#]$%>D5Z_]1Y4]H=]20)&D-U*.Z8BK***

ME;UXL%M/W!G([$4^]A$P9'.!)5OZF/N6/ON6/FK3#TU+GZ/#>]JES_&LECXG M"K'{[@(+462V"TBCG1#Z,M\2#7WD<5[6T*>C-/11O[AD0Y_F4.?(STA'R7=1UY*QR>'#*?53Q})DK CI

MF/*PA4_KI*ZT\)E%!^+\,RFRU>&-=8RXQT_-#*DK5W,D>-H\>8:.]XIF^R8] M^B8]1%"=A%*,U_SI-UPO/3Z). ,:H8E%\26I?BU(5R. 3I>L/[6HF91HSR"G5 MOH=TQZ4:^&P8

IM&\R[8(7]%-FC,$V"Y!;8QA @Z$YP'SV4)1OLS\.["LD[MV'!S(+[X'3\V(D1\,X7!4Y33X#+!I4 ?:>FQYGU)ROH6W_% MC.&CY7]EH8E0YXPXF(RZGF.*-,Y\.O^/6$0T^9/K=))U?, I@-

Z4F\/XKMD\ M;*E=WEQ8"!HJ,=:TPY"6!%P+>]1U8!KTRZ>?)O^T+>#GA>!D5XC;+.#@%"1 M-B&O0HHT\A@0_D8HU4B@*(L9L;(#=X9R _4LAX4H3=A!SX&;[@D=-/Y'$$9]

M&X$81-V1'<(A'R+'"CU_8@Y E+@/@11 5Q=G_&Y0ECTH^FS/\\>>CXZ(<03_ M!?NLH07F1 2/H4U'4-P;@##H6=TR(UUUY.2,.I901*/6[T8CY/(<3QW)!C#Y4 MED:NN)='^~G[

4*"!/$=Q5)8#9TV.@PHSL2YL.YCU&H&E_,0O#RRK!0#CP2#3E6+R,^.BXG)EJ=LTKI"D4I1CP/C2UE MH4/SLUP@9@DQ.WF'9X!G*A>]8 >&//@7Q#Y,7&IXLSS@B("R7R$&B?

R)XXWR/F M6@'O_C8!2H0=UM(A$OJPI6$B::+6!M*1^UP D)V//2",9R'C6Q+ZM1?#N\. M\: U=&KRK[-^S9 ?4L2(7M[8]>6+E<=O(?[.+T1PJP<&$O6&4E 97@HB

MM";0)3ZT8;4G\0%"%T -9"V FP'PEAI>NP9Y:V.'V_[!$,@G.(2LQI(");Q' M/UJL/'V.-:LIKEF-+6G?? =(76^@U3:]4$+/<@[;27I4<^/@B3NT>R0^;"^H4 0A'!3DPVJ4D_9FH$.+0XWI9L'(

M.:.//[<+$EW1""T5AG$B,*=M4C2^.SY-"B5Y<|_J)<,H@V,ITA"'O%>@#T] M"(:@(W0_GQ,&"73?LE%#2 #3$S9S.NBLFI.(2;$%&?H 6-@_Z0TLMC34D!N7 MPNCZ"

SR>8#U&)+%R"V'(-8:I>,%5Q!?XE9OESDV?)KQ^,GOR0.FR.D!^P M N/@N%=Q"%]Z!&/7$%BH >H=!MY!.(D588A"GW5!J;9=B*WQ/R2F;EZM@\;T;\<+DPV ^V'QX

MGG$H7XE@=1^B-,D/ &&=B=BTP!G$KJ!4YSJ%Y38D!J/|$KGR)U$$=?(F:T&1) MXX,!C\/.T+2?3 ,Y$Y4%2+F R+ %|@WL4MR[A!HW7ZROJ;?AMN!>&$'(1Y|(

M*OQEDMP7.!TP_Y$9A&D8.,*K&I&?!/@)NL]LQE74 (@"+U)QX^'*(\9"[M[K M O'P'P[-]Q0-P+[O^%V>C6$Z>" .\"FT%]HH[K"/$B&=(6%(.*8LGR!7$/6& M'-0A88*-"2%ABO5AUB/

]>M%?&/"59\B8>40 PY7!VX,G@<6/6&6;W!W$E)*.0U:#*RRK!0#CP2#3E6+R,^.BXG)EJ=LTKI"D4I1CP/C2UE MH4/SLUP@9@DQ.WF'9X!G*A>]8 >&//@7Q#Y,7&IXLSS@B("R7R$&B?

R)XXWR/F M6@'O_C8!2H0=UM(A$OJPI6$B::+6!M*1^UP D)V//2",9R'C6Q+ZM1?#N\. M\: U=&KRK[-^S9 ?4L2(7M[8]>6+E<=O(?[.+T1PJP<&$O6&4E 97@HB

MM";0)3ZT8;4G\0%"%T -9"V FP'PEAI>NP9Y:V.'V_[!$,@G.(2LQI(");Q' M/UJL/'V.-:LIKEF-+6G?? =(76^@U3:]4$+/<@[;27I4<^/@B3NT>R0^;"^H4 0A'!3DPVJ4D_9FH$.+0XWI9L'(

M.:.//[<+$EW1""T5AG$B,*=M4C2^.SY-"B5Y<|_J)<,H@V,ITA"'O%>@#T] M"(:@(W0_GQ,&"73?LE%#2 #3$S9S.NBLFI.(2;$%&?H 6-@_Z0TLMC34D!N7 MPNCZ"

SR>8#U&)+%R"V'(-8:I>,%5Q!?XE9OESDV?)KQ^,GOR0.FR.D!^P M N/@N%=Q"%]Z!&/7$%BH >H=!MY!.(D588A"GW5!J;9=B*WQ/R2F;EZM@\;T;\<+DPV ^V'QX

MGG$H7XE@=1^B-,D/ &&=B=BTP!G$KJ!4YSJ%Y38D!J/|$KGR)U$$=?(F:T&1) MXX,!C\/.T+2?3 ,Y$Y4%2+F R+ %|@WL4MR[A!HW7ZROJ;?AMN!>&$'(1Y|(

M*OQEDMP7.!TP_Y$9A&D8.,*K&I&?!/@)NL]LQE74 (@"+U)QX^'*(\9"[M[K M O'P'P[-]Q0-P+[O^%V>C6$Z>" .\"FT%]HH[K"/$B&=(6%(.*8LGR!7$/6& M'-0A88*-"2%ABO5AUB/

]>M%?&/"59\B8>40 PY7!VX,G@<6/6&6;W!W$E)*.0U:#*RRK!0#CP2#3E6+R,^.BXG)EJ=LTKI"D4I1CP/C2UE MH4/SLUP@9@DQ.WF'9X!G*A>]8 >&//@7Q#Y,7&IXLSS@B("R7R$&B?

R)XXWR/F M6@'O_C8!2H0=UM(A$OJPI6$B::+6!M*1^UP D)V//2",9R'C6Q+ZM1?#N\. M\: U=&KRK[-^S9 ?4L2(7M[8]>6+E<=O(?[.+T1PJP<&$O6&4E 97@HB

**MM";0)3ZT8;4G\0%"%T -9"V FP'PEAI>NP9Y:V.'V_[!$,@G.(2LQI(");Q' M/UJL/'V.-:LIKEF-+6G?? =(76^@U3:

*P1+,@B$FQ,C MU$*T\:04]/S"A4Q,-@#<0@]PRD^;RN;J@?0DH[YF"CF$+/MJ0!7$NRC2O1G15 MV9P4S""D^C9R#Q&oP$,I7YM?41>DSC?=8766L=B/2OLG5@PA.7F>)9(3;Z)9^ MHHELZ/($SLIUP#WF[#CF(*^3[) '<:*0TB"(*3(N8BC M3SY[M%&U')2$B>VQ:B-2-BU+4R*2?HCC!7!C$>ID$0_QO)SSYQV'(T0>;AQ M*OA3NE) P2'[;S+&7\|^**P%BTYD\H!P>-"Z(I;V1\@=1TAXBTV'VWID=Y[> M2&"RW0,>WF?\W|SW-_;0]8;NH[C/>RYW1ZY8E$9ZUTUD=@CLL^\@++2T'-G M$1X"7P) " ,JRTV",=SAA!>X2F?A@/%8 MC/;1 Y\IQ%W[/L>S1'EMW&5NG?*(LP$NU YX%)M$PXX'!=.A'CQ?=D<^<9Y*0-M0WR/3CN.3L*O1NCD#BD<$WO8T5$^"4(V$KF6:>RSPM 'FZ&&Z8O3Y4EB%QC-0:S,C9YC2XCC> M$^X,4[CV*N>>,$@KL$=CPFYDE2X@D!B#W/-\((Q'VX\"T 8 *"-,R.;1LKC{ M.(E1[=%HA]%HFF'RR+N(GFT.,V:G \GKTZ'\[!%@/0A@8T((RC1>?8/B)Y&O M-24FS76X..]?2-X?\.]|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

M?;.AV]@5KTEAQ*6%*A?N{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|'EK^ MR.JQ*,3:G^#:[6VK<43C!%GBLNAPDB%?>1Q8.O?ZU M^\B","G54__*V"=KQ!3D2!Y>B+?N *(F&MPTQJU7@RNM$VT/UV?ANGE?VDN, M%%YFET_!1KNT[J0S^&S?=@!1'B=ZT6^:=HL(+6TJ7OC?" N@HM!#Q@?M_T/S+\#' ?31O^15=0 Y&3-3,%^F;K,?.I3VIMW5[WX!I*ZA%2+A4GA M6JJ<..%E^Y\LUQO!SfZ[J$3)D9J*A0N=TOJ(5L2%K?7!*Q[H2^L6*JER67!T M*&U&UG->PKNHZW#_X 4ZA;TO_;YY5V$J7[9^DE'Y6,)R[S@I^9 MY83##Q_.MQ6?X\;IZ2H6[6D^,"]M9M5\F/\6>:$-"!SUX'|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

M@\\!)D.^WT5@B&SD+U*,Y5X6.ZWU7(0A*L18EE)!0_% U2:6L45|%>)4LD_G MQZI\$J5^DP\FT,)V6&E&LKC*DA 0] 7Z7=?S^A"SB8T4,]EW14'Q>BZ00$HP M:!$&*<-@A50J2Q0_'7KP9T D/9[G@VW9E\4JJY$+':P*,<)2*I7%92(?@FXO MV*_T,"))5L3.V]W='#N*6>60Y0@2;$+19C*!8]RKFW%
MSQHNKJ@!B1(6#TNY&)'(UZV&I7(^+X/R6RUEHH>1B567\- G%51!G&33 M(R\(>(ZEO\)/!_#&4#6\2WU:R%=;M8C.@MW DPW'f8\#T8A78'&5L]? M[-;EUT6)0\
("11S(.6$(S{5@B(PDA%BJK1M0;-@NZ@7?5+ _/JE#NE%N1E6@ MO"U(,Q7Y"OD%5FO0'R+Xl\$P,/:7*"IE4,1Z9)0?X)=@C,FXYB8M9#@77"O- M3@&IW-3%|E,N(<+-L?3;2<>LZK
]\WW<(!TWA<((MG(_'9>?\]K";4L<[!WZ 62MV1ZSF%+M@<;[BSIB+N0E)S/3!U>?EU *\& M>V?FW==WZ.+'CT_P^Y_OKM'M\5G]^F[\>=O>_[/U:=;O_OSQ;?39OL;N_M5;
M>%S[>SN87'^#)@;[?>?[5VML3^MGM=IQ[?3M|Y^G1_[Q#_RC\>??EW^GVSO+]YV;[>#H\E%O]_N32_/_,EV M[>+'=K<+__QR87X=FP/OSD?
#U\L&7&_/3S7!KV^YH!N[:E_5SO'UV$2S&\6]W MSE'KQ/]YE8?G[G#_L_6S>'A?XS.Y45T[MG:O4RTB8FG"8O2%NO$_![_M\;8GN>?Y@OK*FLQ)-C;QR%-(KA R:.0B?
M+=4$71@XI&WKH6;DQ.G&RAV^5# M-U8-8*^[D(G]H>NBJB>]_=="K$BO*H$*NR.9*SM:XB
MMNRZ1!Z1HC2%KF(C%Y#C+$NLAE;%H97.^K+OGCJSP/>0X[O^!++9M8%Z31"2M M=^Y:T"8#%7F<7D4J&'/O4Z)*KRW><"D<@I?0C!";0<&Q^6X&SXCP&0P@&YSI
M.]E&SJHIK8AGVI.PF%;(*F::2LZB.'TC%P94;Q?Q]W.:7F*;5T"DHJ]]>;^75VA;0K M>EUA_X[&0R=0>"Q.=AJ^VMAP^%VZ&@!@[2=%&=44 ?-_']XTNU"E""4L5" M%5?ONJ/6#
<="6]XD.E-!26IK+S;/".S^^5H;WI%+'$(81X;BZ?0'H)IZD+K M"-D!J2_>2]HYBRR\9BX,Q]M!{^"= 0@W9X00E ^@2]%I M'7TB-=$ETDAA W9>RJ$.NI/JD 1(;.:M8-
(>7T(QF9&4M8IV2%"R&7+"N1!M)0 I3DDPK4$;. MRECI]@__9SY)H!G:IJ.=8QJ3Y_<>K02Z82)_Q(4Q2MB8\.R8B*2/YLT<5S MK#PC4> O,)A_J*4N4](/PT>I*Y?
88_(436V66Z,ZG\/:NKFNRXB19 MZ'\[<;X=^FBGWMAIUE_?>E9*TU)%%3H\%]<^N;&@TD5X*"91EI#E1%]Z#Y>NS.:\244 &134Y_I#Y,%S[PR1OMJI+?=^"]_SW29;P^U%>P?
>C2P@9@,,M,MS;8=@%CY%,Q\< ZG M0XBWC/#*+|)QWEON%"#GU(=3JG.W###T? Q,_W#+QP&|IP%RK&4&8_M*%+8Z@E_=*:!C%RK4&8_M*%+8Z@E_=*:!C%RK4&8_M*%+8,<@VZ;&2YR6(/+(^130MY^P&+M\+LB!2?
L)4XB)++)0W_@E@P]=WA M7KU%XY5C]NK:KILKAUUHK!/G>4AB:M,;@-ZY=X3FR(*.Y0W<:.78YW#] M9EJP]>M '^#%FL9C9("&&\G("SBDUR^L*W$9*61*[8@>!6
M_8T_&!E!+0MMMG]>GFB)?]!>+%HHUTJ2VZCG]*ZH/]=S5SG8[KS$FE M$1"!I +3AZQ$DR"Z3RT^7B5(AU@^BE!M/2 77OB!Q_4*'U'8C;3]!AH0VB^M M[=^O$C;6]C?(A?
YM__YU?O^VGQE-OD_\EN:(HH[K^0]J*SQ]R^6=!4IOD\+ M+EFCSZ"9*M6$43 :N_$;(?O)K=0VNOBU,!;Y,^26Q:T)HG6!W MNJK69V."JJ"71-X2?FH"*E(-]@!P;P WO?M)*5B62PHK.^
MZA-,@13@DPT(98[(W^0A[?JTAZ>J_F%L*E(H"3N C!)S9$(O&NWI <@#_8Q M,F%RF)E%FF.]JKS'6L:GD%L:B\P2-'Z@P=E9"/+2Y]0_D)FAL7(AJ61M<;$ MTQ@3@^?4H0.1ATRFI>-
P501,3/;B7M%S/>P%]>#$^LBX(20>W7M T=A$7K-&-'-B.&3];O[,$[-3HAV%$[\O MVDHK7QM/H0UES8E/UHNTY$I4PY/8VAE\%Y!N-R4MB)[Q3:L] /8 XBER_H M>
]>%K/P4JDK5S5R+?D4QB>/L\HL?V(M64*7"SRK7W=P4_*FGE:SYSC[9<>X M+%G/8YP3]+EJJ.-Q^LB,)C6"&GRO\<)1?*M^A*OMUQV.0S#EL42M*SV7HP]C
M3U\5#$)UM7;326,\O>87[1[%.M.Q-%9[0KG_NKS\S&1N2155AJ_[SV:D"M!\(V[" ZWVEF"6=.\:+.$=T&Z5W08PMD]A4$]B;LUM@
MVH$UAAHO;R|$+NQHY\B&GD]$>0R%>4\l\U@EN!]8=Z4[NC3]?CQ0XMT6D0LU MI0._QJRD<I'F)>D.8*G4!?"TP.5,A8O%$VRG4U&[EXJ8&TMD0*D*OL M@(ZR/JH^V;#8
OTB.'!P-L*NXY_AST#Y9Z=,XE2-,(/,'\P,Z[2"V2UE"<'M%213#V"!E!WJ0N!!W75,Q*4(LNHU\8*L/L+](U(:VJE0)KTA8>M %\EE7 M!/38"^8 0T=GUT5!OP
L.BJ]NB*=EUE+8(]W&$>8'-"&GQOU+(L=OD,L./I M80W6J4CA%9WX4W"!NW8)&!W2$N@:XM8 M$%Y?CY"+5NPN+:LC7$*E02_,(I+9H#V,QHCT4L9A?-C TR^[Y\-2U2#9LU>>
MBP:1XA9K$,<)@'U!X_L.;>O<5+)9]H4<9^*0KLU)=/\F60102)!@YY5VS5&* M<^T)9>W5 KI"Y!"]QX;4&&I\+2SK?PWKG%^C3.>(3V[VALX213T5<#/T4 MB0I4T?
#0L@FU6(^[OE)8Y("_(<_]"&=]:'GQ>DD@_";Q$HBORUH43_6G,!V M[!1H(I,4G+0?I7)V=!8K"TZZX*7=Z7RR76)17T /TI.0M&E_,FBR8$@T7L?W
M!@G.4VT0@W,*PQ<^&F;O%!*D"C8LCK0EJ'ZKW7@IM58LB;S"CF]-=JO;PN MA%Z?V,138$)2L GLS[)WT90N%=9#F&* XC]2=?V 7L@^1,A,,3[/NSZND@F M1R=>V
!NT905W.UV!!"%!TFFA:,3&ND3=II)'Q.+(?1]3UQ\YB5:"\;$54O8L8@4;"P2D"M)>TO48 M;3X/,@MA*O#8U%F^]=A[\SS8*X2IP-X;G>5;C[V]Y\%>(4P%]O9TEF\!]CJT M2NBV$1_V1D?
00^,PY*"5; 4@A=MXHK49SZ*!%L,L;]#992AZR;=6 \U>!:>5 M2.O9G^WGT.>*0!;TN<_ZN4$93/)S!T,?21/X.4#2LU+T\D#SB&1'8"%[!LZA M15H=UB<:+XE$60&3?*-
:7IV0I^(7YXBO?Y)N!5T2U,I0]1=GC PH&^NQP" MVY]H,XW"!R61(HHI4MZ(8L1Y2\$%52!648IV62DZ.DK1498BVE:GU005%/U!1 MX;RA ZHN1FGE
MR&44:&I81^;32:,3RI9:E5HM\!<71?GC\W^R6>4 MX+'2MJ%RA8=*?E_9SQT?%HX/CY1.N\)^V?\X>^2/SP8R7QX!A0K3VZ0GF25) MXT=B?,#D2=W/Y0f4^8V9V9W'8W!:
<__HP+D[7RP65>>OBULI\KN1-9M7[R|K M+:T^R"+3&H!4^,,"*#JFSL4ZUH#E(+E6+T5X!_\M.[\MRR|E_O9@_R',=4S M,]P4Y3//!!FS"KN)H?FQ-!O D0U%_8'"%G&L]
KLG&=O4)EF.8*YXD.--)=? M^4%^5++!)L8%TCGT9&+RWK8ED M4GP$;;+Z$*&A.XTZ[RFD)^[6)&0H)N-3-&;=.4JL()'2M[B/M\;"8&_$KS MJ5K/<*"O0B)Y>I9T'7%-@=$
2*^9%3! %C!DQ]L"*;F;RW L"&$2&=$UH060 M"?530$QFH"F+\>T^QP/J5=A%&I+MS4((W 6[% 8W86RW86C'XOS$_=M:<=N3 M/ B$0Q ;!@6%
<9T(LGA.BZM3P2:/=]"IR0_$@R3M("> !P*WU.KO2RZ H1F#& M=Z5K?G<)#!]_W:V^>=_]1=Z#;[3BF^_"26]%MV@_MIMH0@KY M?BC&7Q4.H8&=1+O;KG17'B0KW:$LI,SKQ
/!$KF(.+S,MK(:3%))[R,348NK M-X3),+-.6JIKD%#4K,5+;L9YH=/,D/#].DG-\24)\8/V(31MZ69HT6SJ/C: M#N_\G>.P)B.PQ7WPF0VK0SN[P<+A"IO8JTHR-DIF7 MN.?
(FQ&JHB'2H:G3Q7[+OV\N;HW_^ MOM,&!OC>/"SJT\+PZ7YB=JKVZ+Q BH5O^\^=]H0:A:$VS1D7EFJUX.6T"%-OW]"S;N["'YTC>*H^[]FIEQNH$5!HF++??]2>CG[!0U5.U
M=G3[6JM:IW?D;O_&[!H%='>QIQ_5,3RX-/Y[URWGZA1NOYX/%L:NS?GNWE M)IW<>,^NIJ-1OFZWIJP>GM]\VZO7H2Z M S M/UR>W5],NZ^=B[>MTLF&97)S?0\;X'>0WYT]X-
! =;I?L0PD! XM#"!=;A;/_:^:; MDSC\U=S*@1#I&>!82J2<>MR(!+BXN]0?R9CGJSH(=G G3K=(;JHOL&43+ 37 MY;0@)WFX*M@]"UYUE]R^9\(3ISB4$K_6C Z'N\O^)TFO@?
W|,'MMF$*"P4]P M|,XQT^AD\=JXI+W-8$#AD6/9V=3P@K=S#1; OR>1&@'@U:S%]1,+1V2WV\ M ZCU$QQ)U,X2G5B#4#]C)-4HM7D)G^NN-_L9,CN\OIVTCTI&9W$!'QP")NF5
M91R9-$@H&_*S"Y#77EIE2T:QASA*;*6C7$?TAKB+$G5)@H?.MFSA;L&M!=!WJ2]\R?T;P' F5QAG2MZ!)+/2^C*-HH M+\E<2*HBJAF8RY=LCM<(^UUT3.8IX
Z(Q<@\S]HG\P4B5"+7S07?LV2Q+'Z MLUC%);AS^93C;,CD.=33WD)(RG'AMV|L+QH|_&_H88*"U(AD@3U*<4;Q]> MTTKJ%BCDB^/#N'9X,1,I/_GDB0:QBVI=[Z1TFT"]/?
1W",IY6D0S%Q R78O7+*+ M\?((_"]2(IJ4?.X4D1 B6.DA.S,?Z?.1-GI7:_]'\LW5O "1IQ=*2=_* M!-/F\T&"%9SDU ?]FJTQ70I783TL5PIPWHU'6X"&;2?E+.)9=@#XN(S TYLW7F M.TWF-
<+27H9$FASK@!,LOQ.S^R$^%BG7]0AI1 *-M?/WXM7I1?\#BUV@\\\ MA!'1A'V &((+DNGN&*"/O'@*21E_]%4D]=(HZ/#R5A#<@0.I:/VPOKMA\:H^@ M,827V+1ZTC\/$E>-
=+\EDO00\ 5>IG<,JP4?>NT13HGUN?2TZU._]T+H(/V M!6QX\#:IXW!Y/0'AJ@L4X,!?T?/HG9C8JGA8(C.8=?=* E"P4 M%0 '5N8WDM,C R-# Y,S!?
9&5F+GAM;.U!6Y/;1+N^_X*K<[+.>'0Z#'V M+,=X-]@7R>UI-7OZ(MNSL>% T42%@A0N+2:^O6G"A<2(%%79** %A]V1^YN M5&9]F965E969]8__?E@&3^Y)G/A1^//3EW]|\?
0)"=W(\\YST]OKY]-KH_/ MS[^]W\]>?(?__C/9\^>O"$_NUD^.H^7]VO6?W,1.F,RB>/GD_Z;+ M__?DV9-%FJY^>O[\RY4+Y#I.? MG]8H/=S%P=^B>/[\U8L7KY]7?
_BT^,N?'M@/&G__Y77^UR_?OGW|//_MYD\3 MO^T/Z;_OG__^X?S;79"E\\P/D]0)748@\7]*\A^>1ZZ3YDA*^7K"_0OV7\^J M/WO&?O3LY;MGKU_^[2'Q-BS2O_'2#9GZ-
_+HYJE.'U]_D_XB@@5V3V))_B M3^EZ17Y^FOC+5< XSW^VB,FL&"]IODJ(^[=Y=/^]S(G2*9AL'[ZA-&XO3IK\E,?@_W!\]W/GN=*H,5D%KKKG(\7;U^_R'EA
M/_DS_O,X"I,H\#VF24=,P 1SO2 DW>>- FRN_OY?, M3]NPDBW=!]$47P"4G< MV%^Q_XIF1UGBAR11TDNE<2#QO,Z62R=>1[-K?QIZ,CXU83IQW2@+4[IW75+(
M7)\HL:XX4L$\#,\U0O.8X,M!C=76#R%A/?==$E)QS;_(/0DS-03W/P);VW4; MQ]R-*%3%BO,E&&?3%7.$Z*3/2>YF**R1YA=0)OJ*!,PXT V FB[FB3DN6W=* M('&_A=L_EDL_S?
64F@5JS-C\]8>IN#9%G\/M'YGD?BIW@!-"EY>OM+>U?08% MVUF29$0[]5$B,9WLY.4E_8#$,?%RLBK\2<< W"7TA$ MWMC@"[FQ-334_/ M?
>?.#^AVK\+=WC>@6QF;WQ$U"1ZS4]22YKNHL@KN?PD&U05)SZ,DN21Q[B6I ML+3["9RK1S1FW!Z,WRAKG[#:3<]IV$HW7+R65$GS=OY]TX]P%D-Y2 M.1Z4.6S?R|69%GX/Z-
@U=WAU_E]_ UPY^SN5AL"Y\,ON&M>U;GC? GK&^Q9 M6$WT>-\#:MZ.V55GL/U#4 OD+HB7!71G?^?X\4"2H34>GR@JR"C&[^3;K|(^5("'(X:E/7:LG2\<*C[2D]*&TK1+%V0724^
M#IPDH;:5>'YX3H]4P6N#Z7>D!;>"-AQ1AV[E^-[I UL'A#GT4\l0?)S%+'0U M21)2VF2]B:H/BZ/5EW%$S7>ZOJ1[3$]HLR#2BAU9C.8B' MP2]B0++#?OY-)9
M,QH&3+>.@,1JG!&OMG;-N&T=!#*^LR'VP4FS,"<2S?*IO1OO\%09E'X?/Y7 M>H9T4_^>6HU9%)>&Q&0:"N/!VUYF O/-]RQ<92FUBVE$S<11X+B?Z!1.LF'
MR",!Y83^N.E/Z,VN"R'X;>?G:CIT\S3=07@]-Y(L_E:ER6E\SASDH74176" M@-E.,*V4$,#94=J=QG*#,YF9?#QXQ:NY'9,O3NPE[YF"$*^+)]+'-*R6644F>"^K_!.N?%OR?7Q"WW M%
(.)F1" 7#,JUTXG)'5\M=M5G>$@=UJEF(K&//0&!-2\MOLI',Y%WP,"OG=A MI<$C]ULH.]0,!NEH;^N'D,N-=UVDP:1L"-@[=^[MD0;"'J. ;4'[L3:=UJ0V%=J^U>,G5@G3<4%.N[<1L-5GF?
0NY@K1ZFKNYR!RA!=&)7 ME5-.=EV5',?2ZK{/)^#Y2V;.H "91V9.%]I1GY1D]A+;V!CT-/>GJ?OGU(+/Z6{](7^^6D:9_50X_.F3FW7]%S7-+)Q@10N2Y[-'6?UYR81
ME;)&SN@_$X*S9SD+H>^_+K4NR!-J]H\%5! H*$#ANR6IW0<5AMW/^!ZFANN MNG;*99'K)P>"4CU?;-63^N94,4Z#_*^HE27S(E9%H[Z=!)'?G$V+X-KDP4=3
MGSTZS_\+RY"T[ME"@36TL558^S#MRVW/K)@(ID[HI/2/0"720@#3J.\Y>T)! M\+2Q+I,VA!2$ 22-/U_T(P]D852G! 1I,(1*>;P$,EKYUEZ8
M%KR!E%*T:B^59:]$G7SMF@D.4T1MPAB\--IQ%X2D3%!OWIQ>^?-%.IW=4N$S MXL!2$--"\!HBJ1-%!*4$(U9+2EV4DN*O0 7CI#4@%9,N!T2P81KL% LU1@<
M@&KZ);ROP96_EN%+95J_XB^:%2 YVLIDK>[I:NZW.H0HYZ(:>=S#D8"0O96D MJ[\&!AN0!5[C\
[ZS*G,*EE!0.+2$C*KG^F)R8Q9GV<%LY%%+I]KIT:O:')26/=U%'#6A<4+$:8]4[_K?!@Y8[111F%:'+8&][F8M"1P3XN*H=(LU.^ MY^4X.,&EXWMGX;&S\E,G)8$CXI=ATI/*%RD<(Z-
5ZP(O)R3>J1.'=*M*)JZ; M+:,\BF_3+1%41@H$1V/$5,#K;=-'W^Q'M8S:\,'9Z&4Q\]O;BP[R88W !SD ML>9W@4I&]KJYU]$\U*N@L'JH5SG4JQSJ57BGCD.]2A=I'.I5#O4JX.I/H5YE MF' ?
ZE4LBT((#4I>5I,4==ZG<6X/O3S2M>UYCR@7+E';YV@5]U85/ZRTDR;] MHOW<)$L7$>OAZ*:,8_8"+(@97#UL,8*HGC903)]0[^"DJ(ECQ1"'"8FUM^IE M96QBB:"B.7;C@RXT'_
D0XSI"#P%0FI,D#KX>1+0LYLY*.;.Y4(2(R4V_B9C>DY"]-M\45I3KPE!8>QQQXQPA&4C)]HJ+B6I*2@]6;IL"V"]EDQ:H%%IY]Y-#$48
MB+UMAB6(&H6QV+/%6='!N\BZB,&I2]fK8X7@ :_WG*A(E=W6VP:7$IV1SWS&4E VI,/E MYIW0B?=:5]Q=$%U6@$6EIC6V-:5!#DTSX'+;%\;E=VC]H&L!)A)MRDC&9$4
MS:|KCCT*9Z&)ACSW!RGZX0]WD1*+]ET(]XL4VB):!_>?]*)##HC5&T0\E- M^JS]]X:'FZ@9>56*,.N,-^C%I V.-"NHLV6;W#M^P.Y(;Z):LD5YWY_X(UI
M^Q2H#W^Y;>.ID%ED(M>]V+Y*]\.07CN-H;>QY)XZD'-RD;$93&=[*648*T:/|@BND#3!K Z]P#<6 M"'Y*5<),K-2E/OQ-3!O/2]ZRVPW8[,NWG(MO>P]]
[+03?:H>Q3F/0\1\R];.6&)"2,#LQTLG)ON'5HH>9CM-+"<9+TT3)%B M-GRT=IQ0.MVWT@+/QN1*91@9F9TSHY:8"9::V3DG0[,LT,#(T$Q)>A@)6_YWV!NH>P>P0?!&&0_\0BP4
MJMJ-%;_K_LP98#S(\Q# *ES_%CLKFSVA@)?ZC1W8'F/HFA^<%KFHAYP@G)P@-MN&3AW-*QM55TY#C)8BK;2VKZHJ*M#?LQ:T,]G;4[I2_Z:SZH^,,HV4T:XNT.
ML"0'+4D,B!$\W78.M^U:^M,"8YI6GVXPU0%SA.7.MUF$8).Y=A-Q#L!YBAMX MM$*5[M S8300E/ONQDXDQ]H<1^$]|:$H1]-9\>_4OPO(-7'I7R*\;M>-EZ&+
MNB/2\E,$H/@+0S,0^:LR,P+/N"/;"@VV,&W +874UIHO:(\@'4L33&F*>JJ M[E&B/.(C-=M<+!7RZY"/73MAJ/QYS\TUW>TJ"NM<[[B0\">R3MP,>;WW+!?5 M_#
[,HYPMS<)@9[!VIV^Q5(H%7U8I6AT7Y$O^<FS[]B2W-T;]*NJA5P@-O^2#4 MP]Z%MTMTT"$\3?PJ 0I+-_7M^@FA+'J;2K9IVXI6245<:=DA-&9%^(I E MF#]PFZ>CXH]GZ Y<-
VX>4P.7$>Y5'H%?/FNXRE8TRP,=AZ/ P>D6,($ W ' M+O_=,5@3TX?2.SZ"7A1I3[X>Y!YH6\N6'_< =/(O"%3$PY-VD ZR5@ 5U MMEBW^28CY7QV(WF!?P6[O8@N:[# M(:
(W"5;Y.=*^97AO=[#.&^^"Z,O3!OS-!\N[U0!.9Q4-K%;$0E)=^E.1E(UW M&4?L].(=K6\3]MC)]J7CQ$WIN29_GAZIPZ(^ \.PU0*9[Z1.:0.,4GKWK62T MF6NT/,.-5B(-&\R,9NCZ
6E0OHGLKDX4%H?@22NN7AP1]:0,&VG4'5G%Q/4= M!.>L,3-(3=F]JF+OHDE5O5GNX\%[3RT$_D6L,C#%RMK_]"AM4?A=FW]VJD5
M_#FA6G7%6NE,9Y3[29*0=+*.XM3_FNL83H]7:?)VG;&^-$%?*BHU#(;MM-V8 M,7%"BO^E?.#S"=-A,.!A#R5G3)C("55PG!B/HR)BO'T[!*F'O5 M[+AJQ\JT$?H7,&3"XO;0886(%4$-
?:0W'_?9F;ANE%'+=^FL66,D]GJ,ZU(;.M7FV"Z,]@Q,1C5 8U]}$:],?,JK%#53Q U]6JTI5G\-$DSH48K[N__=(?2K6%O,C$+4.RFAQ M<0X3[_S0"5V+]EO$P&.PWT*
X;L'5&9E6A)F+'19S/YU&06^N[>4>:.^0*(QC M]UDE8WW>/DZB@A6\]2W>18E<0KQW=$K;?$6#[*&5<48O)A6LT.QF23T1D:>[M=?$#0G_9(CR !YN,F+#Y0ETWN7<$'R?
6N;$7LTT>(J?-"I@KW$IJD,DEN1(5 M8HESKE%0IAU-HKJ%=''9D9D!.L4(2ULD#95'^3JN\DTY4]_6WH #>[%,:'N@ M@3IXTU/M*5D[(UFU !V6B-F)"2G[D%%G_\=":?
=.P*9T18_DL>^6*=-T'LT? MU/ZR2/3>#>^>/KA!YN6OQKL+)YR3*WJ^/W-"/AYNF?FK9XB@!2N;WEC95AU MFL>0U'#TVU9'28!WC*YB5!EJ53S]Y 15\.HLG$7Q,L\
PBK04*0ZHN1G92!5 M7)&NE80OH>55'!HJTPXI=>54!+Y$2%%F\:=.BN4VL;(@>,8JAT-JZ2F/O_GI MXF9!.@7S0 A9KKPSD"0,/&<)/3$0$\(!.=E;F:9DYE429G'&?TL3-LR M8[D|@T!
(V;U>-=0#*)A5XH?&.D!9<,DO?9?.#5T+.A,;HSF 0UKJN9LEOZ8D MIN<^UDR GC2!''?=T4>WD'HDX71A+PIM;IP'DF#)8X_^-QP 5@];RS!]Z^8 MQG,G+&N6G-
[(8D;^WG3C6AVE"5^2+9%_'O]+(SJVFH$M\TS&%YY=#%A<*;Y M.U%&B9Q@$'T_ RIJ"X&_ V%_BB OPHS8,"],015 MH?JR-)&$TIOBL&OV.ELNG7@=$:[|>>C/Z+9,-
]JB"H5U:]K)0&OI0F/41&*/ M_%8K"#XATSYA(IBP%I4B4Y)F(E,N(D&EZ.R7"'"Z:^:8L&#O<9:DU!F-D119E:J]]R09\N*Y.U
MZBEIBKSYZK0JKA;,_9$3L*C4I8*0=/.R+?!RJ=.X(LRT>"=^:N:6Q6C.CR+1 M+E>=M5-KG5J-#)I+1$/;XDZB)WG>3;8<7-6J!^ 3?Z-Z67!*,%*O?-!D6S&+ MLTQX5#JLBW-
Z[B.D"0[:2I 0LIG2"185W<99OVI4.5RO73B=*T3.V'BY)?: MHL.PH=?13@?-B9*0,VX@P1MY.[*P/"AURG9/R:K";KI/&KBJ=8[!;ER\7/I% MQRR'W>KFAWD2BB-'9@?
G#:')#J$M&&BG:!W:'7)%5>A@+21-XO:R08TTH9$(MJ@FS8J8:<"B*I48LHH"23D[H]ZZ?0N\^=1(LU35=7T0IUAJ2$.OX/M?>P/CK
M19VNS69U*A+>R]%40]/*LJA2BZ+=W+&=Y$%B8=7P8"S1&34C&LIZZ-A+0<> M%;L>EZ(f\6.'+@L!*AVM?T{5=%[E?DB+0H@I@R3Q/8R&5\]K2;5S%#N:/:V
M#%@EX*>$\H'L_]A?2?U[@M]*5TS+]&YD.RKSES?I_U@[MB92'_%N5!9T.;]Y,6C=?XOV//#B#-FRY3G MG8%+D-#2T-6(CBEC5A5'I46@+<;7;A'I-ITGJ+ZFO!-V29&=PFZ|:8ED%Q2D
MAQDDZ7.X*TF3N+V8E9[H=#%%>XZA%AK %;2 T%B$)L(*[6VL.S)G!\$KLF(O M(R@$"]HQ;:) MA&I-FC;5JV"Z)\ RRY0+%N*A3'(#0= "OAP3_5<4T"^N/Y>Q*R4EOVVJ6WI' E
M^0J^)"1H "^"L9<3$:(:4IB!78A>&//1MH-2#% M,(Q6V>9.NW|K/U:DISE>R;5!':2P/$)33@8O#B[H%N)&BC24;*RZ02%:S"Y M9$9C$OE 58(!?
Z&"*4=,%JPGPSTIZ/<12%0F.R*G11W*2IK"T =(]@FN%&74 MQF(KI:A5 H_<@UR0+S4^XRBD_W1)[?B.*SUM\F.ZE=;'MI(Q/U1BKDR@LCL9YQ1&06NI*'YV7I$;XT(!I>_AT M%\3+
C*=[3?*SG%$"YJI$[9Y?="A^Y(&LFHM-^ NRWN_)A^$E327I0]0:,]1 M;Q6I-//)I,-F"L0BL:Y+1_=]AKRG16O BM4 <0Z-H$?]B6:-I:LR5]!VN,6 MMHH)<%VS'9Y\M/FH6O>IAK[@Y-F,?
U?U 5BPH&lV%O'YGI2:&W4ANWW.T): M)8^D!='&X+63]#HR3.,K?IY +"LSYI/]4T;ZC9'\:,;3H'6WJ85L-7V;O2]I M8MVM_Y\
<>*B.4EQI9NPT$M1:IXDV;+X64]>&PASEELQZ7;,@!:-ZC+LH$:, MGC:W%-H>3^Z7WF@ES050]#>1Y<4E###E-]DLI6V)UVG4EWCYR#ON,0" (>*:LO9Z7(51&M"KDE\[f.001NCDR
?CF5ES=C]QSQDC[H4L.29 M>/AZ!,VGQ3 L@GZ!2[&'8&Z[-[*92=X@+XO=!?T+%G8>G-?8A=-':MS :"FO M%,FK^_\V9*CY'4G(G"'946QW? M31:Y:-;
[6VX4IE3V\5;,C\ 38I:;$3;N)OFQU(+7S^%W:N MMS1EWQ7I/BXYP]3W&'5Z\+MFN2CYN>_TH7CBNVBWL5QEU:.]?75QO0*02N2R M]\+ B C
MSQ;97K.8Y6AQ=EFX)#1,E@UW=;5LW1.2.GZ0P&N%^,U22[QA'?GV'1(+.KU] M1]66Y#N[39W,QM%Z?P;GK"!W\N"C+7PQ4<3H\8)^&;O9'7E&?\K*>+8]IVO;
MG&4CT)IR*Y$34B+@AF;)XW8&F+$FU$++[K2E&=>8YH5532CMU0H\Z@L"2$Y*RFU'1^X%,"7WI:C5*!=]ZZ9M9;W/ H;-^ MQ<2L%C[8DKE, I+'3'\=[QPPCE)_'##6S1++%V0WV?
$X<)*$GAP)U=3"4DF" M?Y;K9=%#?9 L#]&^>=#]H-R2LMG$[6Y$[!)7$JD2&N[P\!.(W(BQ8GR';(ML1UB;(<8VR'&=CCQ]W3BAX^Q'4[\?3IR'4_XI0)N?V6Z8@98S!)BPSCE(\M9
M!KA23H^Y$9YX?V5)RBP0FI3%M"RFS?=^)FL'6]KU #%]LI,GHI73FL=;H#& MS,C4]4Y*H@6UBC1.(94.Y4Y6-"=S%E)=8@L:9Q;;X>UE_QN(LFG[=H$"/DK6
M?D)*@_^/2W_FN$Y15+16'2DEF\E'L.B:FDE!$"_5.(6>QR7BK2#]O& &AT:X= M$?@X?H,"P_W;:[MN(HS]$R-JUT&H]6ESZGW:9#G;L/WUL.YA% AV+XGE-[M#
MN"U1)FOVA%D1=O+PN!&(@;=U5#<9!G%J?\U_SF726#Q@K$UR U/J =P M$E')G@==Z!<$/H(F(&4[8@VZRG/L%%J(HZ9![W2TQXF2[1#!O3*3$#-?!+M0 MQ8Z'%/T741K
2^H2,>Z8-CYF;*Y\'I2N79(CWM&T4!GLV;,N^BA7*%ULY? M+S9@W&M'XZX,?O=#*L&L8ZLD,%?1M0T*O@T$?]!IV B=<<<[:J

W>0DPWI/1XNTJ343OIE4$;HB3,>HT*>S=W¦B.L$?Q(&_(3)FQ.YQQD1# ME%^MDD@`[7RJQ-0)*¦A_2&^^D.">?(C"= $=43=FP¦XU52_¦T{J\VN/&:*K M-/+F2V1) RKJ-L\2?
8E^@S16,%V5$4NRMNM-]25EE<@[N'!O0X]N+RRH0[S3 M!Y?^Z63)_JM/27-Y>,3[/¦_W4@G^#A^";N>D%R=V/7)9;=L%D4 M5S6J*/WY.4]*,8IS4B2CY[\9[3DX?
2.SZ";F,_=UZ;MZK%'98L[M56E1HF^J %,W"FTZMF\S.S(K@ M+?WY<13F'DWF!#?RRK4['YT.TPUHHU)<*)L>*A^CX_/IZ%Q9.PH¦E =M@^_M*'PORB&/'0_H=)
S3[P!'Q)4./Q6S[\VD4>(O6\FU>?V5(4(RSFKZ[O-)@¦' M9*L]{K=T&>*EK];MU^[&¦&[7]_FQF44R!&?N2^SR.YHAJNV 710U'@_J;4\| M2I?_$5KE;>P_FRD/VTG9LOG-
>^>6M:14_K>V[N097_FTBS;_5(@1GL7L.5*S M1UNS,+*3NR^G[;VJ#:_>0@N(R@#:IL[M/6E9A3>6#5>N !TP3>Q#[263G&ND MKI=<,E@A6GFCR[ZG:CTFRT<;YR&N-GHH/3 %A/
[)@KZ7LK46R8%28[LX3.]F6V98/=-[+; FV.S7'LW+[P=ER*VNZ,V/HQ9^3 M\BEFA"(V)9+V#(D\K"<*FK3CAW8F MW"7?N*CN17IM%*U>T7:37RN ?
2V^G.C'!G,':PZD5^[31M9I=T$R'0Y2> MA+NTK_SDT[N8D.JB[,D>UF$ L+CE:0(397VA0#&=$5<]ER"?^!D)/1Z$Z> M\'C%*4)36N0 *4Y64->K&&L$+1;-
P$BO#IY"LCZ$W$[*KDKOHOC<<3]-9Q^< M^!-)R^AC+Y)48F&\2U,-86F"NG;T87_OCNY*HBP,Y63*O.6HVQA*Z8XY M:D90*;3,.5F<54+@A!PEB);+V;>Y1%X46J1MMD(?0
I54;24@F#8V5UGE'0 MV#W2)=45$L?$NTXC]Y-RJR73]Z:\S$U+(NO-A=8>1"'/3DGH=8@$U-\4+B&\ MI>)(!¦_3WJ>%M?1$[V>KR9'W?'8+7MTS!DV$>!PX";43Y4RF<;YH$5)C^'0&
M]CHV5Y/KHA2@!MU<2401)15&1*F/Y#)!6HQ46:4RTDB9 982>/J,5$Y6\VF@ M1 5_6=YT5% ,_D@6%/'L]{^ MJ/3ON#V!>B^^-&3:XG%#S_L9)'K0KSS9ZWDW'$56Y?
*@N7I"E;>,#*O9U*&E MX5!;&IH=4P<%'F;KM4,/PC'W(#17;MMM P%?Y1B,<\6BJ3H=0;"[VCT=¥C M*5S%#DB11;[6H#18@U&;UXA#TET=V2IT(/NHON
<)#]DC[LE0l9D/=:MIG,.M6+DU%0#Z1MYJ0R!=K;;(XPA-LTV)RIN;#A)FQJSL2V*+:H3E+]5I;>[M7C,/6,WU¦:2?/#;P4.[MU:&W6QV1^]RBL'O->&N4(.;H%>6S:,1RPSBEC MYP
G""X#)Y2DB_=Z/U^R]RZ*9\1/,WIBF83>Z!+VCP1D/PK*J_-#$D37V,C^D.3(<[OIW; M:Z*-L>?P"D/%>Y[!.%^< -/VOO4%N%\DPLIMG@"':\1W^!SCBYT#L]F[DA_8
MT¦/-9XS8*6BO!O$^??>/&>K0*EF-EG5R1!ZQ*M<'CQA?,.0YCC8\8K7[W^_G MY<`\8I,9E&;D' _Y¦-F3__GMP\7 MG[¦.?_DN>//OR?O5Y?GGWS_.?<&;VQ_(Z?._OLL6GSX2-
W;>7(:__O[^_^AC.@C?^[¦^]_SU+_\\\XY6/[Y?'+W, M/B7!]5^O[]Y¦#5[¦]NZ[%^O;%P_?92>+]\O+H^GR^M=T\=WS]¦^_,S\G_¦ZX MO3O#^_^^?/7K[//MT=5W1Z_^^/CE MN^],
[L/UQ<7;Q6=R^^G+_,>?__?)\?75LV??N'WI>X5"\^8+/Y>F)SI@H[++ MZ.$TC2%¦l'9/7?%Z7Z06EN"\CZ-D,-6% @X/WARLP*4H2BJF6BQ.J1#"2#G
MHWPFNA=%AE0/Q.Q3_U"/,A:YF#5]4$5=O9%Q6:_-" MVC@\>'&P H?:.(X7:,%J8'9,SHLO^P2/I35'DB:A]^R0&\+\-W:,;$H!^W!)#; M;T_KAX6_0OIJGSG9DC8$K6RO> R_?
HEO2JZPK386_PF7YTD69[TE&69@7,\ZY M3NK)\)PBE>Z^ACX#WW"TV$!:E>J{GN2PX^163([2Q=5C_AM6V9ZUI%)W80>9 M$;BX _5E#^&TOL1?
*;+H^LY[VM9V1=Y$J1,,.@%6B>6#D<;5B$]CA6UD, L& MF8.T-TOVBEF8$.ES,B8K[72Y"]U(<5C/80# MA=26D.N4'M/9\,A_SEK>0 72)?1V35*OV@-
;YR0U/%.NXF@$!'"$=N:6ZVZ$__>!TCH#5US6_D]:"ZX!DB[K?7:DT/$]Z : M_<@9M7HW8DU9D82NV($-*Z;+\'"=D"Z=(-*,79#T/$]22Q+G$Y)&=LURGYR8
MY35NJ.0\Y&WG3_R$33]/5<-I<;Y'V_QPT4JGSSDUYF#K[L1$T/6%)T$1YT:3 MKH'B^NX:SVV$D6P.(0 M4,+!D6F+1@@9> "%A<_9T!RJ2E=&HN_' ,T4!92C4V,13NX=/V!|]U/9-E
M%,:4%U% "20%MXP3A#D; MR:S0BM=>N0DC.XB231NK\VC=/@!"S25DL,[#BC5G/:P5.4:4TA;U6>I, M+O=;"DMR=7V+52(NH&7QML-$/!+@%%[0-
;@>WEZFL*Z4S$N[747A<13>DSC) M3?8UB2GK1Z^*GZ4>_9/F#E@)0=3?#HE775Q-7#=;9@'KI'Y'879] MZ-M4:8{6-QBT*PH-N!?,.F;.I5.02XB7LSC)/;0A=F,>BGP
M]9/]=.W5W6&+-70-[E<(O,/E/9[N[<0_':R%]-UW3AO3;D)>W,=.^;+X@:9VZ M6-]\9;;"F@I.]$SUEUM;'$ZRKMK M7!&74.VY"PCTA94"P4WC. : =2\D[G ;6:;F3N,KUDX!X5*?3\?
VI;ZY;G?2LER7:U4>;420KHP4Z")=>G/EY/5! H4:%=IWTK99$*AD->$0F] M3JJV/5=D%<4IL[%ET!V\;3&?D,43M*:'H0 :5BK9M@^\]U>6I(S:1I?P7J)L
MHV7S1&4F+PEV2+W!9C/BLJ-=T2GTQGE@;TJPIUU#UP_\HF*F/*\5/PKG^0PN MJ>L$'XKLS,[XQ-Y= O)H-/SAN>8+SV-2! R RY1RYIN-#N>$S#M%BH

67A/"K.Z_U~ M6'(${5&YG%_*6TS^5]7]3V-8);_!]$L82CR187]B$@,WD4 #-KR0K@Q$AB51, M$B235$5V]M))>Q,?VCGYAO[-=%:[* {%K;3L-;]3]MN2K!2.9R9-3;8N]UQ MVB]T4*
(,ZF10[EE:"%@OPM3?9L]E\U2&-F VTZ. M=":S;1FC9W%:>0UK%,LS@8[-]#4,/^[PAR*ZS1M:9PX%G540F/IA'%Q6J#9P M@)TX(6F:@P/G?_'U_G?V!;WTA!6!>1>8VZN^C_E/JU*^'-
QD.^U/%.6O5FIJC7+,_LCV^S6M_D>8<6 MA(!%P>2=[!8)9>O<=^D"))L-04/396/8RR4UO +7]*2\=%Q" M70?7">@Z,>AP\W).32%'>)DU RAN#1#3S>.CXZ/WP?1G1-F?
RO=>*\A1^V#@>#8GIQ+(-#@9$)(T=ZM?_JGO M-LE'&;RE4 !"VO!&&_WIPSIPPG3AA-GRV(GOZ&$D;0TL\YXL$GP_<.463EVA MX^,'*^4 \JKJQYMF>]^W@@>9.ND3X+)*12V?=
MTH>!=TH^!!.8,^@U+5[VL!I_CE?K-#;.Z8_9U["#3MNEO34C"W_MD;/3U2O,Q/O)&-=GN>27) O^:_@GP93(FK}[= 4ER:0"N=?0#GPC4IZ%N,.32OG#U 9[H*(
MTZRVO91X^B4D<;+P5V4;D3V[U7BS+=X9M.?2AAS_)5!H2S\E,G*)_G.H_"M.3T"+D_(73H)O8(Y8"&]4!R%[Z>#H$9TH-?,_/+\@ : /M8O"C$8]0B9:NG M(KP]80_P;3(Y3A]6++
<#6/X*!,[MLU\VF4]%%S6>4R/-"]OI?/B~B6S^%>*P0: .@^7AO.CH3CPUQ/F?CP1QP?PK MQ(67VD;^0]%:,*$4654"-7#T)W1([]QW[OP@W\F.LSAF:7]%]_[B/Z!=!E,V
MAB_;SD!7LH>\K\B]SZK!$BNB)>YQ+M9D.DIB9T@.,,]\.5$+"TH'&<-Y6@V- M2@;PQ8Z7.5DYOE=N>G6AK,*Q+3&XY-),*N$!9AWL+G?6Y5A>M8$N7;71T]| MP+
(2DAJ5NR8&K1*6Z$T>@(5%;6JN)Y,D(6EE:%&75SO%,44VE!"LY,5-6;ZLO'@%K.;?WTY=CN\WJ%$^\>Q_]0Z\/5??B M]_F ;55_:/1Q:/0QV$8?I6-\0O)7E?,7:A)6?,ABW7[R":$?G)
4HD8#6PXU MY*#K\/>('M/](7;NJ^SQ7Z[HHQO6AVG(DU9;U%,K*ST5I#ME&P6(S M*I4S[%Z.Z2Y .)V03LB,Q#'Q2M^6;@A1O-D0U.+EDB'LW6IKQ*IE,& T&=RA
M:79Y*AW$VEVJ.?]";]7#K6H'F$4WJ]#YG:57N9\V(W:=]QR8@:./8F)U*ER#G M_&H'I,N8,]8$XWY"PI=R?YI0S>>WR6212XB7L'%HLM,ODU|¦BC| *IZ8VK E MHPJ9M"
(4/GM@NB(Q=:/"^3EQ6%-@<<>]D6O:H. 5Z89[.$%YJ6)BAM:C%23U M9 //!YTAZNY]HH"6,;8X(?$2(9;.)8/EE*@%SN6: M6#NXWR=,7 NHE.\Y-!#Z+;(3AZT>T"
M"!PQVM9[)=0!SWM(36?OLC2+27G)DW-1Q0*OG8#D/[ASW$_UJV3P0WQ7?D9F M60$$@-2SK4TI3_PD+VF_EW?NB$;J$M5_Y\
MD4YGMPG)>9XLHS@MVU8!RT^5ZJ@.,LS*42F$Y_;2E)LGI'3W+A\0[T\?W 6[M4'X7Q\[U-8+=3]GA(X*FKW'M-8»RD5-JL 8@& M:_&)%M9XQ;._;H1]\&'O-
'B9D1BW&QQ:6/<;4G*&_:W%B*E?=2@-U/>EAZJ, M:OV#5."]+;4S]"[\=. GB7.0L^_]fW,*8!*+]O'M5Y0I:.85)!5[^B&W]JN:G(U0C]U9;)VL\S53L+: M4&()\X0!1'+?
+?;OLKQ0,W#"T^4JB-8D_N"D[H+.I?'[HK086+P=&+&;FJ G M\2YXXR1454&+(YNY1" :H8>_-&$;P3:P#-.8 ML)\Z\;K^1RB/?G9D9O3ZH(RZ-$;_#(@?
RMZ$064;L*$=_T4([7I.KM+?,^G MTV;YZ=-93A;K%D!"S/#BQ$=*_1) -D;?V4QJ8MF@%P(==^LT$*)[?#IX M?]M:.$]1.1NOQ/-!P^D^7"-SX2SI/VN!$!0@G@)!.RE-RGK;D)<"?/!-
R)2) M@P?Y%*5G>]+$#%)^1 %,GS6WP<> D":*)Y-(9HXGD@X9SKU&G@V(26PA8 MO]>0JF;CW;06A+"2R_9I@1LYCCQLFK1NTE S81VD9L34[.93N.\ O!@O'I MC-
"""4##B4BU$L0T9:V4^N@,(!]H4E65BDC#M %+"5DU=Q!B0HME87E M:41AOO11>C'OCV\SW,9W@)J/I^YA@M$4_YK&/DDFKR[CL@$N5P[\<(]H +LW M'Q*@Y=-
'4?:SRRF*DF_'M9BSH![_:+SDO(4$)5VG-&8HL#?"'H3"BQR3.NP[ML&#MPUM#=KUP8KK:LG01Q?Y7*:W(DHV#;Y&!%H%,[2'N&I4+YUX&N?')"_O MQG-)XIP1/(EQ*5I-
E^@D.CZ("KWD09;,69)D^,.NLI&+7]@$LL@HME,QJ5MM\MD;$)46;)F\4^ZXM_[0\8[6Y=\EY1_V$@#0X&9TLNZCUEJMM7[FJE=2W_] M[A\J[<C,YIU2!2:@G7P!I-
)Z!72G69!DCJAYX=SUB,2QT'DDQN7:R)'3[!^ M"S*B<_I 8M=;"IW9_'*$$ HQ&+']%KEY=7RUA[&KL=^*'GAM28B-;"> 302?M\V5Z!@CO M21, -
HI3>:%:9.H+5$1PX>XA#N3B7]"2XBMC(5IL,NDIB MX 4*I5KX=P%!I'K#-RNHG#+(8H@]3BPUU'$5+2:"%?R%H58$)Z'[@Q]-"MO
M%EXV689N/L(<@^WFTDYS#URAPZ0^FHD_IXB/>K:QUH#]]1TQDLO&U=-#":*O MXB'=SB19Q42;]7+OX+-<#^EWA_2[0_I=NS0.+5703=ZAK\JAK\JAK\KX^J](
M>>W()#YB&XB9LLPAB6[_AE:-I[_"I)2]PK!985J#P=8?08I,%7#V.TT?/HY M\]/U<;1<12'K/(=Y(FZEA;7">CX3M^,H?_G/3'P[U% ,8SL-K%"LWL%8I+5U
M\7!P0O$&6VF!&T"N5(9Q1NXD&$Q7\")-)6,<0!/-6'!EJ=^*NMJP!$4H&64D! MQ5PUQ[9^A&W1MQ:LT;L$-.B &Z-]S"W:(!W$$V0O$(6_N'50Y'L
MH4CV4*0+E0?)SK=N@DP$E6R<"_+V+^WE?!1Z+)N;;\X\P:_?:K2.C#$]&A6F MN_-$:,U=TCHVQO1X5)CNSE.AKLNX1/MEUO+M]@$&4;&J4*+-F3YLX*%&[W57 MN-L'&
O0QO8L141> M[MAAJ_:7!% D:@..0BZ*V,@K&XT/98!RD8XU'I'($&H530_M0'*0SK6*.0A M1T2E$K&;\8*Q6&,_<7'!4"@-/#2QQ&YB^5(A@ZOW20F3P)0]1/ BH4/[0AOM
M"YDUF2SSPMR=&Y1$PZ2*1[" J4G!5H !/B@\C?VY'SK!SC6+#O"2(89P#%7"- M7@8%<+W OKA-P!>/,$]MYP$/&"P^?7
7^8OR\YCDN9\B/.^M6O1E531],X8'HEFGV\GY2U5FQU'C+*QI 'OH7H>T M#?-CW@_.""%RT*I>VIE9G#$(GN,SN M^=SNB,_'..'DI6I6LA8Z2S<#50Q2D/
MW'_G.576TY,)BD3':A=5,97>QIL>8O)>1*%7&=S"O3!)F/=%J?M1R4B#S=K?.M0Q]LNK(SSL-.9RHM/N:*MO*99)Y98A&W+3XT"7'321)'LTO1V7;! !4 M< N#' ![42UE=>O-
8#Q+ITQV;/92&|9*M% %#/LGB8\1*U_'N;/A4!FM->2A M5DE)%)3HX1&1(^1'1$H8)EF>/?#!B3^1=$MQ%TY1WMP FF6$0N&L2$U MD,U?(A$.V-|+) #"Y,Y+(L8,X%T2HPA^VP-
#&$U8N72&UBY,1;4;X7<^=KTD MCSE+^D_I+M4*!.vVJ];J,2\|C >?1=F!]Q)3E)[=%JZP D3LL'CH70UD.)5Z M5X-WXCWTKC[TKC[TKC8R>
(>GZ[]:.N[3=?"W78>GZPY/UUENB3W8I^MNZ-], M9Q,6LI_G#*)8LW8:@^K0KVO&.+#!UO95(9@ME602>A=1Z&Q_4G_X"Z706Y>Z MY<[90GVN2U
;52Q!J.D(N+TK!58XHE8P0KNVTM-2"SH=+R9BL* MB& 4\+;:>P,1C+G//#6_Z;&UZ#TVH^VS3>]2U;RQG@)' S9L^5IO>(I#>I+*1 M!MRY20,.E1+$#CU\CWKKX=M,.
8#_I\BUV$T*5 M*;>W$'R5UC?930%8>+++>"J(.,8>*_"$MN1W!\6NR]"N\PS!S@BL6IR.Q2\+4 MF2OVO&O[<-PVCX\'^#LRK;(^\>]!CX2>2!K :X=#\K&M(AZR"DUF#]J6HUC>O
M¦L)488ZM?4aW^MI=&C;*F390.,NH8F1I,2F_<=%U5U7I.VOJ20"ZL74+C-XPB M%!5ZR'3?Y<¦]SYGOY9?IQ2I(Z)*6]G3 ,YV [+B]%FV0Y;ULN@L9<=L3$!K_ MZA2AJ-"!!C0VMCUZ[/]
[MMPHFQV=^\Z=' CI6MYB M ZS1U1YNF!VMSIM=,_1]1 Y0ZFTRA ,@NNWF%G61Y(P M.XE0]5,?V6JMCXKJU6U. Q*TE)Z2"DH]8G-LZZ6(+3K6@C=ZNXD&'? RFGW. M+5;
(Z"#>1W^(;[9<6M?VR,NCP6O:#]71A^KH0W5TB\M:/N Y$3RCS/%5V[^T M=\)N]34VGBEGGBCYLSM/ >MC>C0J3'?G"6[#:[2.C3$]'A6FN_-4:1MB6K;X MNFO98OL (ZFCXTT?
MO%1C=[?n\+=/L!8X.9,'ZTH|_NN<+]\%OY!5 M)#HV";MBJ,*X86\(L5KEX|%Z^R>7SCIO MG+%B3VLRP0 AHPV.!'HZG<.'L/TWI ;3L3,_5 !K>X7%";Z?$4"]H;G1.G MZW}]
[M&Z_AN$B*(&8;2\)+4(H[]JU^VE#K# 37A:,.$).[80L!YVU-=G0M>0 MF]#N$P(/0G*D8S$("2T;S#ZTN4%G;= 03%|S:,0E@VG?=@#"NM^2[<4);S/>
M\A=ZEX$3LM8@.,\58+!H]XN7?*VT%%XM"/'PH.@3_; *6%EFU^%8426E; M,&Y\,%WQ^H[!]#AHC&^UK1*BZ=UK=M!$%:<'$^-U$05TZ-8^OKP3ZOYG=D,W M?
+=^>]QLF2I*&UM+US|%5G[]$76Z!5)2'R?1X;>96D6DZI="72859N^Q8Q= MX+B"N0@P?;4[^?sEN=N=7+/YD$R[.^2];GIR%;DSHWY^0XG\Q=EULE]T6<. H M73^B!K]W+KF_8>-
G\;K,>,_7#T:E%I_.(U0) :@*;8K,7O)9KH)H34AY^= ^ MKPM6T9#0#3.?0G(340M9__UQE*074?H'2:^(&\U#A%8<>"P\NMT,4:0*/9<& M182%5:3;=_DC]G?0;ZOWS/PC-
'M]BQ^\]O4[+U3ORWNULYC2X:CUP\ M?^R*3;GRC\O?L!A\Z3GW$G:$Y]INR 3Q$-2'Q.4-L6PWP>DAQAI'YDA;TYCL(T=MSTC.Z1#\2[MB8H"';Y)FA9);_F4-
MP@-3/NQHN|6AX7G_LUZS;@NVST*JYEFNW--T M0>*;A1-6D>CJ:/X;82G0(A^3V)G3O+4YA,G)5C69A!3>GP6;1"PJK29,^R% M>D'28R=9O NB+^Q8.UU1'G+VC!]DJHSV:
R<)H@*[>8$M0S_>,X(,S^;R?K_ M U!+ P04 " "Q.&U9+DY[']*K #3_P@~%0 '5N8WDM,C R-# Y,S!? M;&%B+GAM;.Q]ZW/DMK'O]_-7X#]W4MZ*Y)5V[:SM).?6Z+%K)=]5HH>=Q)5*
M421FAC&"!,AU?BOOP#X'N)-$*#6_G!.O"_':*!_:'0W&MU__G]/FP@\PC0+ MD_@OGQU_'BlO3BXO/_M___O _?_X_AX?@'8QAZN4P M \[<)HLMK=^".Y2+\Z62;H!G^>;%^_0K/-
\^^W+EQ_?OS"1]]D?IC'+"E2 M'V;X!W\XB#]LNSQ-(>[P6W!70/-A>03'K\"KHV^_>O/M5W\$]W>GZ!^OOBR; M_,^?HS#^Z<'+(9![TQI£?/NN,]/201E\DZ>KEJZ.CUR_K#$\KO_SV"?
_0^_]C M:_+U\3???/.2_+7Y- MI'Z)NCU_^X_WEK;^&&^\PC+/L&P)_3)(W< D(Y=_FNRW\ MRV=9N-E&F"#RVSJ%2SHA49J^Q.U?QC#'WR#!SC^(Q[@=^BG2^\!1[\'_7]
MS05S+M\T?90-7OZO4B"G_ + 1S]]H)W9V;P*8=Q %M$X9X3O_=-A.&?FR*" MQTI_8]P8F0)[D743CEZ'W$$9A'L*)MC5E !=[>TB&U :/VF9N M8<#F4Q<2C%E]|_=.?]!/POK.[XS-!
<$]_)$K;-;U84.=N'$;;TNKO(S6^*C":3A M=L_?K;#*QS)+_/R ?&Q&>U[$P>224#B<>2^W@BY%)4E6P0)>'#P+F2G+Y20V/RIPL0 M^@3'(N{B]I_-Q$RRR3#1&>'E_]H"14L$
Q;X3P!SI89&$G<-J>H&/*(BHN] M.?;U7R5T$CBI-]KA3G#&&&/8UZI$6"%20Q?D.1KF(^0? \"KX7")\?0$3*P M"R#^Q'5-O@\PGTRV]/MV8>CU"&L=
L,$<1.C/+D\6*A=ZS!],Q/C1_0C3AX1Q M; MO1#/!8)WR6FRV21Q5P$_\,+0GU*$28QN7Z%6I% @!(&7YVGX4.2X$Y GP"?= M],RYV0A*>30PT2FY8-;B4_1I9(EB+E?7'B+_
#S@3F8DIJTQ]DC?54Z6[JK(M<;PO#HPV[2D?!._,2;M/"4.$5/Y#\'D8@[+-"[?N6A:'>GY$ZN0,;WMK]/D,0Q@<++*[SV!P$3<.FX6?AX]3!$XH M#.Q$KY0DCJ-
2^[@'4*"&R"+L.'.]HJU\XPRZ_<4#I4ETO0!,T:YB!]AY@*> MM(@%G T*<;+P#.NFLXP_-_S)S\] G+)YZ]Q9/X-TD_.ETOHFXZYM4K)=NS/D
M;+>PZ@4?!F3KX3@&\A^P'="EJ>4&R-T-ZX!7NC;B*%+GM(FG\48(W3ZC:&,% MW+))V%?!RD*\A>("K,(]Q 9/<84\[3W0 MY2^)D6<'¦]TP_=Z+"G@69GZ49$5J.I!3,)@#XY|/D?
R+@QPL47/PB-N[5 _E MV,EX4,!.: 5T3N.GO9-?\YW2@$^BL/)$F1Q4#;[@% M($U TX;$O,%BL4CBI^2X< MSO@6YYWU(FI81DS72@UJV<>2H$D1OD],]>-%Y0%&-
T5TD*JR+MHUSG<*M M%P,5BTQTI%,A!Z>]=!T385%E9,N 5""-=2;[:QC@G)]=E2]@?I=/;' 28^ @ MZ@R475,AZP"Q&ICHPE9U!:,$KGW,NG+2I#*%\TBZU@\5^*B(LWTOI!V+4)(P
MF]%>RPK8E15E#@![6OM=/CF%'8R0"CM7/=|=H47,T +Y^WF*[X61WAYI/X#66 M&=%N/D%)BI@Y2N+5X67X" -PAWX/9M+PIV!K](@YJ19V\>NGD_B"\2S[NH0$R0E^W ?
H=#*CZR=I%N]A36)9](N8L+]W!3<7 M;BHF,7-V3@DY)84:-XXH+CF,HX%L9'K5B6>^_B/\2I?XP5_6YD>8YFQ@C6+Y M1&"0P8KY;Y)CD';ST?
D%/.N%G)FK(YFQ!GC1O>P>22'TAH0QG!9SJ58K*T%8? MGR@0]PW0/?R(BW5#?2O$G]"'<1EIF4%*%!3,,LNVXBXA$N891#21QUQC,N M^2R'=1'K+TD;/^J?H'-;?
>WZ5%7E%K&%#]"& "_HFEVT0%?H0Z,X<:FL9\R5]V9[O]8]SG59S2M9?FN[O4 MBS.<\">)IPIH$PYG-8!71 VKXGK9#)VH-MP/MJT+%_]D902RZ&;RG9,,*\ M# F. QRHB: ,8_S
L8V1FRQJ7&5LNYINDN)%IO-HEWC+^K4Y.PFE2YCP(?T&BO$I3N /+) 7ULZX9"7@W MJ!]D_];+O1F+@ _%Y@&FSV_W5W2[JF1];X*LF#OR1[+U239[K]Z.3@G_ 4K$ 9]?%N6
QT>*HN V-]-2.(/$# _SA<'B<;>"IX_ MP=0/,WB=AOZ>&Q@30G;XT3>OC\I=[H"TR?(FL#:\N]DRMG[=Y!!4C4#=*!!F M$EO=YDYW#V.RYQVS<90"\" F^4&9Y,5JE<*5E\.+,$_#.
M]DF]EXB)"KJ9B M^D)47DEP-&.&\&@:@J9EF4QO)#5<*0>.L3_0%VTUMVA.(-=3I\8U24/YI$[D M[+X$%&]FB?V,8+EIJSIBEQ-/ ?13$L@I"V;'=INO^&YGR))1\<["W'!D3C(
MKI&B!=,4!L2I/-%%@F@TBZE=!:0P5)B++"M(=A#L_$!['2L\#X!TP<@GIFQ;=!6.V]#36US+J&^!EBP",Z41ZIH9I3B6CN6#9C>[F4
ML/Q351[$)OQH+BEPI%C8D\+"V8^(R7T//1R)@!6.BWA;Y!/ELF .8Q-&+"(8 M",I\#LCW #>817)C$=>Z\.`.>@1ROJ\]D)H'[=GBWI@9U@&{JHOAA!P @(* M [I\WY^.NJ*6I?
E_;K#9(LMCU*##7_2OEK?]OBQPM3<@,Q8(B56T2KX7@>YN M=\M?ZK)CS@ZG-+/;O/*>\6I97@:W=\$=$[76AI@.?NOW?)]$3^/*9[M Y[@(
M4T4%##VEG\Y5X;@]8N$2<004;$?!S'4A:/<$QD-E?ML2SV!+[!I:1&S 0.*/8XEE_A@O:[#WV,5LW9^)RD@;>:095?(MO-[S.>[,1SV5PS+2)Y#^X.B5 !W6;S M>FVGBXK!
(SRM5=/.!*0MTRO,_39)ES#,2=&/&*=/#U/20W81E\1/M0NLT?U. MGN2ISFO$:[SROKX;$!38F@5>% &<\ICZ1.\YOOQ'9,^P[=&T[ZP8\UBI,^\ZG9@!F,T8!F,TB/_*.X.6W2
M>;V7LSL_D3].TF7!W,3/?!=+/X]SP#5GJG>'R'Y]WRW^!Z=[EZS33&=T4_5 M/M7=2T?G1/N5PL1#L.+V$\V$(?Y$#@(N\<>8,O,N0!Y(5A/%<0CA1$&5<4!(M^RR;@[K9 :B+H.YY$!U
6H*975"*%D+SF' 5+Y]V09LX#P.\I.$CO(5^E1_]_F/ MB@ &957SS;;(B9Rl6@X(V!$[F. TGD2BQ'I$TZ#I>UV&H"VQ0Q.?PO@ZY7[MF'CI1SB:BH<,_EP@E>;\$4[W$)
(YC$T%A$4$ZQ1H/@?E]W-Y\R7B6<^8XLUY M1#0A^N?Z7;'-O?=PZ.UGA_?M-YLB?STS<3J=!A;WRP\!^1+\6'[KB._\->^& MY-#FIGU -^M=3U5ECC]&];*$-"I843&]ZN;?.CW$>
S]'3 ,^>D?'VT_"2B MXFIYQTS$REF&4\,>R7]V,2PB MXFSI>3X)G$+V1)'!$CM]Y8R=%V%@L)!=BH$V\3'U M?#K/D>-@F(?ZEIFLL.-4,]'!#19VAB8ZU:8P@9L1DE6_GE09BM_0>IL=^"N"
MN"CVHPB!7K$?E;72/1*M55_EEUUU!4*U$!)3F!'L.E63U6FD*K)0E'3E%,5 M#.9 EO$IS#9MLW*L.!0Z!?[9T_6Y>CJT2!8TF*<#.SR(WCC_TJE)95G,";),4
M^R_F6,)P'#!&%&1E=/X!3<3FQN^,9]7DEJ5*>?\3_>7X3R!*T!_1^!N7)XPT MDR5@M[2/;K%7*HD2SO MY??*>WV.:Q*!KU^X5@ D^'E9RFM,((S\>YEO(5M%E+)!3*O6M6\ ?
SN#YT/2 M1J^$F:N;3;..;AG"*0$+:"-8]>10BV&5LJP25Q(M2EK-U+7HX7.IGFJ3/<@)- M4$*!8%!#TR-)-RQS4A8DA1YK<[CX 6R^M*E9_'L;@+(DB#Z$0J88@P]V\F\'B M1*QG@Y"[2-
H6;W^,\OW1HLC7"7X\;+HBHV P!WXN/D6R^,O*9UM>T|!Y&F09 MIK*A1ET'T\>]\N%#HXIV#C'8X]+E, 5#C@Q:A8WCD5N"14P3K:;$&+) M'#Z#[FIUOX7T".%[G)*YW|?
\|^N+HZ+AC#S8V8',%A4@X."K_;ZBWXZ><9] G MT9C@]?$!^QK5:^+-_E+4[!8!IVIW1-I]^2?P^LN#-U_]\>#HRV|(']^\.?CZ MJZ\/OCSZ8Q_1Y(|)_T$IG8KA(_<-],:%,;
<+C'8N!14+D/ON]-3QUW.5-U9 MG%U$D'#HH6GG7294 MRI5[\G,\A^9/+SEG&H<:FC>M%O:>C|GQ[_;SJO+)N65%~@_+8'SRHSZ/;7K MDCO4+,XML>,2>GC1O)9S 93 ;2E<
FVW^"((0AR0Z$777AA-LR]R#"F M6*.X@!.#%M9+_>9K9+&%P2&RU?RR@>,C0<'XWBM'SHRU@7,#6,Y4"(X MY+"R)E1MR%55T+9RK41(,+%_@(BF/D(8O8,Q0FJ^EXFS
,,4KQW=TTH!*- M9OM25T / U=5*P(KK]?.:6"O)"N[T)*9O[X_YD,2)[4<++#.@5OU.=.")QW.A MR J8IV .&TB",LS\(D8\0;\8 M1A=S&.MG(8L2!#J/U=8&X4(?P_8!1Z6"DS(YPIEI MVR

E+_3*'(/?QL*D^_WW$95P\'#_#R7$K>NGB!FU<3@LSUXX__;[K%(_M3PRT>A0?9QV#%@[@ZO,-_^^%*Q*'*J>R$'LS0-X>\WG8ZZZ;B_MW#CW4:O)Z_M<^6=6.R/.Q5BNG??.]<:TUQ<*F-[<"5I$2@J!J25U5#&EY_XER+_J5!#A%KA9NNGA67UL'S_"4B>36\!Z) %4=:1\ECA0C^T@9_MD0:+,58E;*>.]5_=W7[LJR*%QF4B0XGK*V@4X,\'!R(H22"?N!J&[3Y](AB.6#]C09[^]'_MNC;!AS=/SR+C$*>6;99&S/Z@+'Y@<;>[%#OV0G0^X&0"2_M0#=MJ5WXT>3)HZ8O*]_BDMQEI3PJ-;^9N!lL<,W!\Q=YXF,^&L8&?XYU7)PX_MINX,P@WJ/7P.Q@'V55JY'-=B-WTS9SZ~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lO6< M7&B>[5 =!78V,3:RRV31#ZE %LU9_"XE"?O+#KI5F=S%4$W(&/U\U]4 &6\$M9(B4/T#T1XH\&'V$:1)AW>#5HY,A8.K.*EULOD+%"%*ZA]N(91QA^&8)%UXTR*[3:"^(++ MB[#B^18IV!?Q,DDWY)I@(M-%=E3[B83E"&-%IG1:ET%UV%Y!YG;3@=L,)D5FM]V)5%!,&3';@8].8ZW;M]%GV,=L33IS>O7SI\WCXPV$/%<T:2*8CFN;RO;UR M+]\N)P#'\,?0QX'X(_7=&HZR6XT,9*T9DPFJ&0!\2PNOR:I"$&5IM'I\&- M /(U@W>,+EO]v67Z=F$D:-669I\;4<-O;S$1I/.6ASIWPR>06=[J-I4P9.E!?0 MP.:: GGF!.^LW6VN9_O,26I52B!O8BS(B69U-9>NH+91>Q'M18! 1Z-LO3"HXM(R1!H)^3DM4+,X)_%K.BQZ1_K-YMRQ'JAQ1E>%F"!P%^.4H5=^:R5)-)(‘4J.1E;?1V3IQX>#>*C M/X8^,K(GWR"C![-\XIBB6[1'MFW_W0U@9+^XVBZF@#?8,$:8,2JL#8$&9CDN M&_$!F@\OIO?N(‘YBCP1>< 3!(D!%\9YMG'K)&9SIQYL-Y2V9TGUF^T+WSGF V M%,18& [AX'#$D0Q(2N!G(<3OWD;0,3NW%(M+F.>*M0HFU2AH2.+F/EMU5M9A+E2(QWM'$"FO"FE=E?=NIJ?I9'VN=W \&[XRE!W:! M+WR89,O$Y@G'&;9.H@)2<(P&"'004:,,WDYDF=I:&5$K3QI*4E$K:7)>FZUP],GQ7+0K8+I#)YWZ5L5K;M97NT,ADBGME@J=1 M4D0X*$RK1RDS^*OG-9F7T\0(/OAOJJ27;DS,H[>K-Y'_5[,T4XE^-#+KM9!52,54L@%4M\0F_MK-IVKFVV56N7RJ<\YUJE4W(]=$WSNOME$X'&]#5F3,!1AW*35(E'DHE'3O,. MQI9@/4VT,1=+V\/8]MRHZ;;?TVA08-\{T]!2QAR:TXL9?230H:JV4+H%*J@! M6. AYF"?1F>EF^=U8+|H*8<;5OQ^MQ)*C:9;IX\Z99C29DP73=GT>PK1.TX1 M0:0'G&PF@!_+EO]v62W")#^.=$L84RM5*N]41@>.=BJ=&OY./9G=3N4S90\9 MG"FIV:EL@&C@[%3L@64QPMD,-\>%H"Bl%KLT%6NY--A=H\O)YLV."AUN1+B]> M\7FQ;S -›/&L&?%JA)DD/+0,7YCWCC7+,Z>E#S2. !5_P4T!B6B&-L\O 2VT MHTLL*9_AHH]3)Q=[F!VZY5:W_[C]6*\&**9)9 P.SM7A_,\S.T2&9_OFB' M MM"K?]0{'U$V1[V: DCX1 LL#?.<\"H2WQlG^7!J^ES>1]!H$>'81;1A>%*0 M@FI7D8IBQYFR(Q>1CN%)8<*,?$1F=MSE=]0N=IWR1;IK!_^UO!C0P*UZ3 MYZ%.G1,BMG15//J\[%<#H=)!K='266"WMN[H9=;/]<<(6)MD]_''Z@.',','M[@, MDF2NN M;GPU8C-F>..K$@O F;*C&U^=V P*$^9C>!OBQPC#^Z3(T-&>96@,".H1@9=W6LZD9+,.CJ@%@Y67V,H>N(^3APRFC[BZX$6\+7+T9[0ZJ-6D M>L@D)+JK+&]P%A*[JU/LM;/1T!]PTN4J^7"SP7;@-/*R#,G=.C/9)7Q$2_-ZM+G6W)X*H[NY3XI#QJB-6JXKTJX;,H6R(H"Q(-[!K_2GX_#T^6,#K X"F_=I- M%2^P7[K 7*2>BBAXS5Q5MZ>:&=UY@:T+6:#OK.AKP*H6D:@;CB&5YMZ[@lV#L!A;2PSK&N<5,WE@'9X4L;0RP788^C#-L/%<=N0*:)H?[UX(*2Z'MTNG4\CGQ M(BSX;M<0YF=AYD<)<U]JF<^RH#.VT^I.(.@88]V: M .GR6:,Q YEWPB.LZH_M22W,F!)0E0UTM1QF"[[#6OMDV)0?V$'Y*&GB)$S+.@/3>3=O->D75!V#Q5Z> M=T>X5<9"#[5]:Z:?%G1+8GZJ?";&3;N!]@'T'OCM_\]4SOM43:%&Q_BQJW12>S30HW8;%QG9V8QN".:G;W0RT[=-I4M)#.BBB+> M)BG5J4[Y1[HAI]OY,..?JL-+ELU[CC"9=1GG"Z>/\"Y-L@E\X;S!W/C".10Q M0P4>\]0?"C\G1/4X)X6F=K+:?HM&GZ\""]DK;X?U»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|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{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{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}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|"|;%Z-[HUIW D@2QGWP M1&[0]@Y1YP 3,.FN2@M+N[1Y$AC8.]M&VZ*1!TEO9JC/.PJ+.ZG9I=>#!-7M:?>-LR]J 3X#+6]Z!^")I6G9 L3F'5@=MGH9J 8-@B"DLVYBT M[O[!RW">S3:1{@+OF17$.^ADUWY2U;Q8(D1E%4!L_Z#JS)F^R+V4U+.'I;_ M.\5ETM0DN[J78ZGA>XBR+3 *78 MXSC8(4QB6.[Q1R^,O"I+^&:H63N!M)S7!SR9ZP+GCHY>*4)D1Y/IL'^(2'E M)6!<)W=)3G.,M[^'3^4^)#D_X3Y#?2351S^8KSF_71T6M>%)IL*_KW<=I\ MTLN13Y[MS."=ABTH=G?3M$P8H85-1EAY\B"ML?H)?VSG+6GV:>Y;+F*M;&8V4Y3/6WP_63_=+AUBI7XH==|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}B+0V@OXC4C0/V:ODVC+W8#[K?V,W=0%UW^$C&*QQ8/1R$02DE+$?U2/T!?K63ZO<>BL!/+!19$]#"5G[(92,J/P0/YV]&_29(YK?])9N*C MHIG@U0N#2N4BZM=D H_EH-8 XY@N=$M-L*-^$ $NSK1P*()CT"3#>P7A=\ M(=P^5<(^!,-8X@[EPA;C$<3R(%4-L&F6-L!";5QG6A5SL?\H33!S.46M"N\\ M2\!#A!E\"XT.\=0A'/@A;70P7=[D4^ U]Z?>!FL9CN-&>,SJPH4Y4UV_XFF2 MY1EV459N@RX&33NQ>4.YD#H\@D2.Q)1]EKEP6DMPL>>M%LUQM6NC%L)7M F3[!# KQ53?4;AN6Q=F+G5;'8PZ*]W FO{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}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|"|;%Z-[HUIW D@2QGWP M1&[0]@Y1YP 3,.FN2@M+N[1Y$AC8.]M&VZ*1!TEO9JC/.PJ+.ZG9I=>#!-7M:?>-LR]J 3X#+6]Z!^")I6G9 L3F'5@=MGH9J 8-@B"DLVYBT M[O[!RW">S3:1{@+OF17$.^ADUWY2U;Q8(D1E%4!L_Z#JS)F^R+V4U+.'I;_ M.\5ETM0DN[J78ZGA>XBR+3 *78 MXSC8(4QB6.[Q1R^,O"I+^&:H63N!M)S7!SR9ZP+GCHY>*4)D1Y/IL'^(2'E M)6!<)W=)3G.,M[^'3^4^)#D_X3Y#?2351S^8KSF_71T6M>%)IL*_KW<=I\ MTLN13Y[MS."=ABTH=G?3M$P8H85-1EAY\B"ML?H)?VSG+6GV:>Y;+F*M;&8V4Y3/6WP_63_=+AUBI7XH==|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}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|"|;%Z-[HUIW D@2QGWP M1&[0]@Y1YP 3,.FN2@M+N[1Y$AC8.]M&VZ*1!TEO9JC/.PJ+.ZG9I=>#!-7M:?>-LR]J 3X#+6]Z!^")I6G9 L3F'5@=MGH9J 8-@B"DLVYBT M[O[!RW">S3:1{@+OF17$.^ADUWY2U;Q8(D1E%4!L_Z#JS)F^R+V4U+.'I;_ M.\5ETM0DN[J78ZGA>XBR+3 *78 MXSC8(4QB6.[Q1R^,O"I+^&:H63N!M)S7!SR9ZP+GCHY>*4)D1Y/IL'^(2'E M)6!<)W=)3G.,M[^'3^4^)#D_X3Y#?2351S^8KSF_71T6M>%)IL*_KW<=I\

#DFDD*EYBXGJ.Z??>4[AYER;%5NTN@M;.KA.;0@%+:OG B,=6WMV0Q_)U;,,*C4"/,T/3?*L'#[M8*^_5N1, MV>UTWX6'G$5#NZ+ M)XF%T;\S\5*X3J*

;C$S;TOV6]E&S#X!O'K;Y7>SN&YG+G?G2H0V.UWV+C8P M#F!PEWJQOX8G576:3(‘5_!L&KY<6E@!WF4;4#4")Z!NYMY3)L6=-@1<.'M-

MZ_@J#5=A[$55SZ<:*!%T8=U]RB6'Y4BM&C50.>5 Q<$-NQ276@>K> FT2K/V M0*@#%7X/+@6*'$SV!0H/)6X%B@@BXMF/<[=|U7E(/H]>%O5E%SB25(E-.+5< M \Z,.4E.#NQJF?49!{)7UVFX@0:1)M>A@}D2;"W"M >E%%GBOH*?%'W'W_R M"$;R8L$@_H1!.8&>B"KQMI F*8]*K;@;HA/^N ?3!)KWA)-*"Q:!>?:1 9:UAK]%:B.ORZZ6I,^S9..%L6,4 :8

M0$!$'$0,*6!%B^,/\9%1*;+EQTXS:K/9TZL.0I^A?N&M'!TP6%VY\Y *;%Q(M]#HW;0'QD- ?FBD8JH_C^0SI_RGI5^F#/5=&M\@#FN?E17#B*R.<'@PK@M/*"BCVCPUWV! =**

M'Q@?$<8'+@B6$7S\N'C{R/->=T:G'%_XV!B<*3HGRELO3+_WH@*^AUY6I&7E MIN;'[T*8HBFM=Y,<-&IC6P*:#FT,Z.'/ ?D>- U(;? /B^^'!Y6+DT]+ ^]T3

M3'V9]/RMQ6;CI;MD>1NN8N)YB_.V3%<8M2OX)03#*;OTU#(H(O)LA(>BW M,/9B/_2BR!{"""/B'ZZ(#[R\;2%_:+JBS8K%YG""S-S)A!KB'VCIZ179JR@" MGU9B=[HH.:F=W -$OA-ET MA@[7,TCJ786/<)%EZ*RM!M_50U_%-_@R*473.?&R,+N/DX<,IH^8C(MX6^3H MSXA9J VY!YC*:K="LJ=(lL22)<9%]T^X/-@.QX@ X+^B*Y/](D12MVF)ODT

M@RTY^;EKDD2;-RY33$#B5#TED8$9"./N,8G^D*]A_5JIV<s[0.]/D/Z(=C!j M<8G+A(#7C%/U>>],N4/4-+-&%?M-MC#-=]XB#K#GFE1PN4.-)W$.R8QH M]W23H(A9E25>'5XB32@=^AW$J])E"*#%\@)M!78VZ\2++F5U/I7A(M#&A3C1"3(Z$4"` X&QM:GME2(M'84=SQM),3?[(3F#.0Q6@ -A6L7)-M@\K. MPTWF<=\BYET72X*IZ[L^OX<9]LQ.@H^WY:#BGJ#,_!1?3,7U8O*BRX*AG-2 M#@7 R6MOL"EF+!EQMS=+/-X,E#A/M9E!9NN)'#,,08'ZLS"_-/2R8A2V=.- M.3VX;\$V);$*B3#)PCA/D!U^$GG^3^@C-(L?1+ .;)FDZ.>F&_F+T$D),!|:

MSKSNG'(;#- .72&L]\MF(/)HPZZ5/"'N%#(^] @ A * 2"|`;_MUJN;,0FES M,3DY*T>H<05K,(&Y=@(>6U$7/ZF@&A74=-]>;^/@6YS6A2Y44?K=")RK3Y)XE+ .]15,.[RM=(7 M:lQ-4U#X>07K77-83>AB%8QGV8D U T/0*4P47TO M+K FQ=:K=V!VDWH6S48(F EWQJ?$$JZ^=XPCS93 X^WU(LEQ\]-(@>X>U/1@H/;TR M,9 M]=\4P;Q$.[3-(/%*"OVK' =4]%BI>T_?S((H_8MDRD.C Z'+KV%PG?07\>5T%P"3DVLQU&3JN8B?"0]B5S*B*+9^_K;7 M&45*V8(L=&4AZ2E[I1+@LXCP,PH@4"F[S4'[P-

M.$;@F'L^]8%U'#*FC2:0;: M=@<-MYR-$T&6L[T|)9D%&>VOIX]R_N1'10"#MV@6^$@K\DK!,_?2&.V$?E*) MR?P'1HBSG:+/4*]-]A1T'9-**

SB_O@6G7N07$>N5FE,'@4G0T3T#QM9>VQ\\ MDH*I5"]C9,W@<%"G6L+^OT+Z4X[T)QSM21IGX#K)D6X5>E&T V?#LV9&$1&& M,2<^CC19H'ML>7AO$VL+GX-72Q(OX?F37;1(#&CUPEE(#@O7>L'Y-8NX!7E6 M(@2\W)H^)AP0.TM7&$CZAU.5JFW7>-P8'E4"6*2V7U;$;1<$AB@Z7[H]B6$ M%'/JL&C^-+6KC*Z\./R%"#=T.)S!S$]#$O"5+$^*#

FWK,Y5(^]I5.[4IE=1 ME3AF7=*V&^*6Z'2$)5+1=5<>CZ#X!HRZW._5+-19/U_EWFD3HER0MTZ:T%X=9 MZ;[P&7_NB,[)"U&2;/HU#-)]]B-P4I@[*+8<`*D]:(332^[;J$?E=QD$R7]

MLQKUH$>=R61[SM^8Z/-<+Z5=3^YKB7V2)^4B;DX)5XL!*:38 !K]A.? M#@;,R@_+.*[ZE81E.TJ.7;4Q)3'GS?==@Q/>HQ_]DQ0\4AW=KL-3C3C6TY6N MPM2-*20*9_??

5_D;XH=>7@SZC6.1 4$3*#WWI<;":A[,-S!"@C7 3SBF28%. M&<#R)=>0 @8"]P_+!.;X*KW\)VY(CM8YH(O-KRZ &%/6OA_]C>U&YL_EDT/ M-I<2 89((!I1;O>=XP?

***2^\>!&T@R0[AD==ME3#3A7V8C6\440-2\/OJO5- M0ZZ?T8'5*>/7R@#,P]G;.K M3=*-G[#CFCB3I1/C#F59Z>'1PL!3VP34,69Q^RK#P>Z))9RZ7J&IR]"'<1;& MJQOX"."PZ7*[\%:M1,N&:S\KG4;4#>:DSM4BC6-K!'/7],3/^A8[3CB-+=5 MFXY-@CPNYG %),<--B(H%S,Z9\\E]+)&"!5>= ?3S20G#V<@BQ>1;"I8Z,$- M0*<%P$WF86B+>=**

<|MQ%D)FM!$,%EKRY-^OT'Y,(1QR(R6*8+!{-Z=\8F1Q-)\WA/),;(K8"06 M0.<{"[,(Y+F*P@?PP)KA_"2$UX,']O M[ZD$&&

<@FVX$)A5:.)N/UB_F8\^EP%\&W6AA_!QIG40!3!%EZ?YNI7KH(^ M;*E5 CIX:6*J5K__W=>OCM_\"52M9R63)#G5S^LB6 UM3>]V>,C"(/327>=5 MVU1B2#"8Y>1Z7&

(T,#:G"%TYMO8>-8]70^LZG^1S1?0FRUN8(F&W.&X2NY(A ME(644H?6%"H5]EA!NE47)!]<= (6A\>#/+@SL@YU>-N(->45TSP8ZW&N&,,P MA)T ?>+>:!V6TA2-@!U<;0^4V3D G-Q"Z;FY]D%]8EK;<3MT)NUX5,G#[N1Y M23L9WC*EG7#%1CQH*(@'Y+V7_@3S=I0F6P89KZ1B*D5/BP2[3QLT*!R'Y/F8 MJV, TGO-H+N&!FO$C:[Q9C^4F$>(1I6U.000RS!'5-K,0

H"6EF9J42<8##+ M+'VQ*$B#:DX6K!PSA56%1EJPM7%,%OCAXV:3Q.1?]L$(=^ MST!&OOO"X8&^1S)=>;M3,JU,22QL!7;TK(*5%20:@?452L0% C5G3O6/0O MID)9==9\{2]!'=>] 'FIUZV?ALE'W&&Y2IJ/8EQ:F4?-U\Q14[9 8@ADOZH M"[!$?0"\("!]>@';IAO'W)&=[9!E:NODXG G%-Z@O2QF&C[.6YZ0S52R,<5B MJ_K+%RXO FFS83"%-

F7K^PC#X@R'V<,XR/J7/V))MFTN$S)RF4 V4E#UYO+X MX,QJP SA"M@^KL^PC T:DJYB^L4PBSUE\X8-&4"F3><&?8]GO__=4_ GS"&W M DYRS@/F*:V5"SWXK"+C(LZ%-_'G2*%906SBI@L#G 1(TJW7AA4)11Q BZ2 M<*S2X,N75W+F35!S-JP" WXY&QEJGX2QA@!>$"D4I=N-XJE0@W68&G;#F<*36X$©)G58V+* M#%OLGS4E154F@=O=A!-&Q$

NM&2QXTAHPx&7@ĐQ?8\S'RPJ?NH31NP3%+T,1E@ M'B!@S9.)7/fR.&;._18M<)R/8%E1]M P#)TE<^37WD1%WNBW6Q7?M_2D7D**

MBN2P9[*H0X'S:^+E)QX89(F69FCM,*KU[/)WEPHV;58#?K"G;IT+377+YB8^ MPP%26#B?)G$,2<@0?F:,=DD;D2FG<)-RHX]U7=^/5?<@)/WC(|)O1@ ?T1#D M?

T[X5E[*KG;/6=BI09(,+?\QI/QA-"YB$- 403ST]SX,%OCAXV:3Q.1?]L$(=^ 1HADIK;9G_HE= M&*MSOS5P+.!E5]?#%OJ4*"!\<:N1MX+4Y 5CC:ZHD/HF.>7;7UJ?PK[4=!W

M\"D_B3@G %:MT A.K*#,/.C!!=++)FIO%UY9&X7+QH=K<##G+F2\8-4<>)8' M%&I \T0D2OHN&(HX.1DG3OAPF0%@QBRJ&%3C669;FDC;T.TA-#"9,X<206P5 MS\0,_H##^Q,?

PB##EUK7) TKO(X\G]O1,HTLB S=]EUYX;QP,U#I'ZP^ M9Y8NUKRMTMR1E>++U6YUY]AQ+@%M\X+P;R&;)%"-MBZ]K+ZR@M4D9K)U0O

MSU]=L@QBJ\MP;4E[HFAN2:_[@6RV6<2>VX YHF5PL"]F$=R+O/TO3S)L92J MO*6E]N=T;_0HIRSU8%]VW2BUKG 5OT6B$DVGO86K}\GQEIR$%B1%WH;I+$DW

M>!NTUYW;JB>')X;$/%D,$J^-=6],7_ONA4K<)96Z_5V9>(3%O6M>D(CC6T&%_MZ0V9IKHT#O9<_]I1Y'&S=^OK5OIQITECG'!57&PT3%3G%AE!Z!&IDVH1[C5? MNK?V6=F10ZU-

-#<6BT2KX6)'$2,+VUB\>XICWBD6QNTA-MMK((F)4K@FN3CV M=Q?J<>UEB)Q%$) \R5Y47T2)+V.]IDU[N[>M>@S<2C[.O(;L$2Z"_?UT Q]#

M[+O+,;F!0(+T';9*K1YAZ4712!"O(E'I-.Y"6#V&,4V@85"12W#_QAQ?=$1P]\#(S'C\)>ID)>&7E39TG+JQ8UD34/8#Q%E48+# !^1*[HUIW09X9:,]

M)Z6U:M<&VIF,KW,\AD.8S8&GMG6?Z2;]#B-M&ABORJX="B^7JV81N-(\M&[M M3C?GTB:^6I.OKN_C *81#ACLW+35%F6SKWDG<=S8V$GG\A$2,@X?2{J.^I8E

M;*DZ0)C'3ROPMZ5/^7-D211QF+^H0Z8/D#WHY3C\,@RB'?H^S')B99"PZLY8 M7H9'Q\;C@Q<13TRVAC `@9<[]}C-BX,6-Y4^P#Z=PT%A#;^FU" MV8)\>;#WF[?%?

NFP3++>38KF95=\A&E"?&{(!<_QZ]NS@Q:]\"Y,\G>?^ZV+/ MA94]BT7H_,3S^S^7<^Y3,G3TN#C/O3: V:>UX;HS[JO3-Q G!54AWZN_?9?N$UNNAEN@GYPIRQYF-**

+FB>UOMLPL=Z ;K4ID MGI^6&L6;ND;3K_FR"B\WD0Q?HF5X6:?TE[H-1\)83,9-.R_7V_IGVK MXNG;3T$Q1S_#KVU76?:DJ8+]DS6H69D&!/+7_2nI^A<:>-7\#M^A1S[%5@* M:[O/FGT5QN#WWC;)_G0=_S-^'Y_=Q=^A_]DM?P/D<,H/0._@]fX_ N=7[X]? MGU5?=E({Y66FIR3%U"X17<3Q&$.P0Q-&?86/$&P0R6LT/-[#^3I$G\(8;=*= MP\=CLT6$NUVKA]U/V-

J47)!/[;3\M6]%UZ>G!NR>CWY:3;E)J7^!HCP'OIE MQ]RKV^3= G#G+^I:(4;PKJWTGX\:)+:+>L>GR70U1;-')UF.7H/'@03^[! M>6.R)BZMQ5WTX;A_)4OT-"3,

W0V_#!P@NX:$4X\6SJ3+]>F'A-162'!N'3')'--9 M<]ES*/9KME--__AHA0:89-LI'^3N]+U*$KA\S1\I_$%S6.L9()Z+ NM*5;B*PV7HH]_M MJ4(Y(B]WUG;7UN-

TK+OS9CB$@W@]G,BJE]P*@S?0A^@L8PJ/3HO&WDJK-@[= M:,\&P0>87RWKCTBN66D=!O\7 2(S<'%;I+CC'.0)I;# 2DQ MW-

T(@V+SLP:L>$G'H5*694Y.,Z6)3%%=@BM'=2M+2!4BF3LLC9:=L,WH^56%^^IK!]_6E44\=P(4SD9V2 M%5%>AW"-T@'FC4MS2L

HYCBXTE29Q10*@(+4G%0=F#4Z,>@"4[*H3L(2X,/U^%!?,2lLA>+"]@\+B N?]>6?5"9HP7P7^++"<>=*1-(%;/H@O3H!?2Z<89QMY0GW6*6Y7*:/ !XK3[UMF'M1^

O9.)=)O.*W<&?P(4?DE5$W+![VFQX W/B0 MI%'!S0DCRP[<["'Y"=)X)KTNQG50'K?&AHE7EW8%]F+$I1[#/.1)W!OI"'0' M YW1P,,.=+^K1@1DR -P5;]^Z0R+0R?

***@9TH"M.M(PU$D['+DKC'1\TBC@LO MNL'5(WM:$BV71_DMP!^#]FNG"@J-_%QRIZC35%\ZZ]A4$2X'D=9&B%@#D/ > M(H@D#OHE10;(9>@]A%&({$]O?X;\(;**

[SK/K%=5_<*JFZ)A*XZ!IV>P8^D;X [M!Z3W?SN5X&/6A;HK1Z^S'9D_I_?@M-U.!@:"$^^D.B$ Y82HU /0H;)2_3"= M]?$!FKB].H%;32L@Q+;O

***2 %>Q)T;@A6H()KJ[9!XC5B!#J,4$;_)($4-)060#E7BOE-O%=7RW!;75E M]PKLNP@0,:"DIOH!TP-:@KJMC^O6S^;-^^CG' 5D3,7AJ%R2I&#Z1WD,<"\|%^**

MY55_!\H/G>D%^Q0/N$6?DEVQ?0-QE3(8U"<)?W'KKT%S=/Y8-OBWJPW'G09- M2/,F;-7JTU?0WGIA2BZA%F@_;TJ=#)=>=>Y M"_@.(D)S;-).Z.#!)(#R/KQ# MQ ' 9 !,:!Z@)

(3X!MU;DU.MLU &DQEPK>)UC@I7>R_Y9V:CI).-UBO'6;FUF MX?X5UQQYZ\ZFU4.A1>]0&4!P"M. MK[O1>1>'Y$?

HL[@SD/AM:'9EUEYU7PR3OAS%^.M,F\9$C?6S>CO:1U=IM.,A M0P0[=B_ZEV1,P@'H]'#0\U6@'^85D<"^CA}YCX8+Z(MT7> M\RCSS[).4T#:'NQ?$E#L4P=-

***EX/BQR7$OVN[]= MAAO\()C/^MP0|%"INF^OF%=Y1!.,Z!N2"Z%1;709I2_HL.W!|58\)?.O-OI M]3WK# M PB'1[5=ES\Z5_O5EX-J NBNJU-5@L-WCWF!_B1_(E$3,|24D1J<^X H$[* M+YS'F,O-E2I:%5;)9N1HG8?FK(UX)B1H_6WB$^P/FO=L81%_C!RE#E'FT*R MO4 NWS/5-T02=^-E@X/FHL[I'1UK'C30\^=LT6W17-5U@D8K@SVXBF^@7Z1I MY13+ [N/D(8/|(U9?B"6/_HR6!;4B&HY0.6TO7]Z$;OU>+AX6C,B\3DB$=<= MM/2.@/ZPW(!?-\)PBD6EH6@ZYME H/L S_E>P+*"A"F7K9_L3>OSK>=GV<_?X^?**

_%4M7*L5C(G&0,R=L!W8S*LMDIHY8OSY M+$T8:S!8/&0E'83&@:0#]%N#'NHUSU8XY&QH7!%,W=ZMRE8:K$(,!'UGU,PN6 MTE-_7.D>S;,2ASG^]/0-/#.+.U"_K;8;B,B1[WHU;O6;Z/DXT5<>)E;'@T\,-H3D7*FGD,HRV8QVXGFDNC=,]W'(3A(AX[\][!.4N(MVY M#3-6FKFR-X^Q=K;=LB-SCW]/RL+73]H;&_S81BZ"%,V2O/"S\-

'XM,4*4RHIU)/JOO"XO1SW!V2E"] :U"T7=(U* =<5%\%&FIU MU]K@B3]":-_>WF2TL16&PW1@5!YQ%\G.1*V;+|',_*,.WR$M]@/39W!.H7+

MLLO#5T>OOCZSYO71%T]9\#LS@]A[5S224LP*7BS/U;(K=N18WD9[7H]X;M)V# MNG>'GY]#,&E=O"86VK(LDF/7A=1(%2.\MG69Z&#T5.+K?R!*F$ M*=8(YR*WV!-CF@6<9;!L

NRESKE+O0'>%BE>8*9;<"_T $@K9 -5[9SK0UP MID1U$(I6P&J85"]ZIPWD9U_,#5X[=!XXN+H<$TZ&&LLDF+KEC;&?BH4\AA%* M+$H&&M*0)QFD{F-

RD:4R16P>H%^2P*<#+OOQ_DKL65Y)B:VL$%5H21NET@MR5);\^M? M)+X(%C[)DK0GD.W;8D D0D02&0^^20\1_2#F7$RIJ-

;PW65*=*$LPP8)_S8]U>;^I.0[I6C7"GCDO.,KJ4Y;0E MX FZ7O2(O[I1KN%D3V)UC !SUJU%@2'6L>]IDI M*G%NFDEU[5D4S7^9#0FLO6,F?$VVO*Y

M)B]5*X@3=0GUV=8B(\1/>-P_DWM_-,?B4K$M#Z:=X @*5BMRO05!V8F!,]V0$ MMC-_"NDRCPAC>S7V?:192" 8D'!*0(^$(@) =,GTM%+V)&@SY

M20WG34ZO/8:^SP$N2Y]G7'HQF=][5R_7[%+54/:1/=.F>P66"E46ZODI$ '5 M# 1=360?1'6RX-0AW4+7S>(IY8U0ITOL=.,,U!?F5O1^WS+#H6TO:;MN2K[I

MV(!XFN=J^UE46$U+R54[$:,K/H>\,]@DS.[(?\!HR7:\$ES3/%65R$5T,':U-ME^?ES+&_M.Q8:W1?IR&SHX9HC*Y)^ET(;^3KAK4$^ZJK,#?SH.>W$>XVC+S

M<=FVM%L^UATGJR%ZV0E$SFZP>A$1171O>**"VA MH1QD+6F#SM-'MALB@WYKDY:C$CSX(..R6A_R6-TDR.5QLJY7ZECE)F1 ,I\ MA4QHT@N5/;IR1"4W7O=F*)" _)"M!51,

[KO'NBG_);9[5P]% M#Z?7M|QM1H;E2H7L'6H"]>|3Y$$ <;BA =XD6S+UC'8[<'5MP28<-)E:D]+1Y*=?4?=+=U-RY2S?\]M'>U9 ;OS^HFZ[MF[K]^6$50^5VF.GV!

+HE^FO*+0.R NR"L5O&+B!=S4WQL.K!RHY7-IS[5> MSCQ5B-^UZW1.P&?X#)6Y((#0B8J7:*1Z@:S_2%[I[%SX63=9 T6I! M>#OR;BYU^P)2.:_@,26@92X:.!Y5.,/-HO[^W<2K^8

#7[TC0(;_MV8.SRZ M!70ZA5EFT]GG A-HKQC/5]N>>595Y\>A-"U3C6 1TVQH^1PNM0#=+,#:XH2[9;Z MS3H=R&. ,/[P<$A'@$DTL$/ARW\9/

F99P&\||+0B!A;7N,1=QZ<_HD,*P&7 M8%?=G R8PR#6&>2>"&M(5F#. 9+W?PT(#CE5)Q2@"[.8OP06MR@#(^+KW$!)=$[.YIZ-= M$$5'*2$*@Q=_;

(&H5VARH]SAZQ/HR;4T3J9^O.2+LYG !W8O.|.;==G2SPT[MP0XJ$KAPL5B7*NLBI09*^$C=M2"^(VS]]>8)\?(T:N5@%[\#5XD89[CVE*M/

M/#],]#QK^%Y$CBTC>MWU(U(ZY)]R&%H-6'0[9BV[M'50Y7>]EY]D*Y+<$\%(Z%B;BRX]^'&'0\;.3 MX&GR'>R8-P'S[!?L3JG1K^*!. ^"%N)M#L1:CA/^]*O+ 6@[S91@$O?

HDG9I ME1PSG]293&.4[S.*$-GYNCDR:0+RN#;&N/S(7'2#@&"@F'2$;.0*J+lj;PN M5+DFMVSYK6+5N&?.*1B7WC6CTS2(.\LNK_C;J27:WLXY-/!V7&C@:2Z+>)A;.M;]#*]

[7"M(630&JV,!GW%V99M@-#-#O/F5!4YW8Y2DW89;],H?V]ABV@SU)- M8@H7C:QLW^QS9 H3GQ5;=$SP//AN%2=Y.S.RN[X=[MW6;0+,U!E(,_W26%9@

M5/+O'!:A,\,YBN5KM:'-!I4M-C,>+U/$U:WPC/0=.1Y(F>8/J34"PCY M4/G^>N09.S=F-8.(OLG!"PSQSB1'Y" --UV6S\]- 2/AUDRDM%C?5IAQ"Z*; MR(\OU7)R9*6*Z3J-T]>1P+C_6.

[;H6K$2?=$1\5IV-9VO?$4B:Z&H/!=V7 MDWD@AM?+!' 6&]# V64@TU@!LOY1=H\7^[:KG]B7'T\L OIXK]!#&-4A6I:'W[1BMK!K#TS>MO3/!N#^CRNW6\&>Y]?XI0=,*8O

MS(LN/W&EZ\-[,Q)FE'HJ[U0,!NQT^-@283,2>L-=]5>[XL%WF='M!K<7U9) TZSWV)A/1*EJ9S(V%_M.RCX,)>Z AXYXBZVK)#2GFQK\[,.

(0O4S/X>7D03;8SW)QR7%)^:NNW)0[GFK1Q-7VP]% XE<. .+EIL#E$RP@/WI.WIE)Z*JZ5RX$_0+8_-0K.([:OV1!.MQ&MR%^$XA:I;P#25!!M//N:,.>.SOJ)?JS;=OE2E#M>BZHV

M,ORELQWXA-.^3PB2N40_Y"?HZ0W1?4%]P.1*D-M_3.GV9=<3,I*]0!7,Z'K';A.U$WIH,FA'6CK'&V4W%L$36QIBB +39N*4O

M)8")6HY,I)N]1[H"O/EN]WZ_>:|>*U"W{{AQRG+ID2TS4;7$!/*=L(E:2%C MY%O=ZJ[]YF.Q_F.U_50T?!|.HIQ'AX3TK1?(8*\#.-(&7$TL0QTK7RQZ72@>DM<(M7 6 MZ-

S1VG%]I*?2>78XY$W=T1%40]*0*KW"#AWRW%6R MK#:7X--G-\)31%>5=(1#>*4=-R&[GQO(^42/ASW>"9)A2H*HI'-=&51CW]], ^N1E(;;S4QJM-L0K1U\G0M0MX[;SLM-

($C\&79?V,!HN2-$9E BY M+9N8<*[92E,(;A:N!Q9Z'(8V?'S-."3H[#31KGTGH= 511+F^IUNH\IP\ T%< MN5LVXWM(X[,1%B:

[&PJ9LPK,>O$)HS'QTFCFL((JAL3U7HVI3,'S/!+P_I&H M&D2FH=NR_:-E^\Q7)G73%64%4*%$K AO2UAC,F@=AHW@1^02)+2C&"MA^V'/=0^542Z*;9K\V1.6R7=MIBD",(80

<"J^(2BV MWK QOW\[!)K?4+8A6*1$SKB8M^2[>=_@)$V0"L_?1M2/,61;X 5PV0,>1J<< M'^F)%6BOF'.$+*#"_J*,'U",;Q+X-&IN5TH#1>Q-P6N-[RI\/?TC96AEI2 MEN?

&$Q/9<^E)TQ0J--J)?-(IW)!;WQRH>PD&2ZVH67U0WK$\5I[H3E1V# MU%C;#5O_=W_2W0O[5%?=H_?*,ZFVU:J$>0W8J5HX)GKIUB@F:]&2#65#-]+_

M^%XE$D621$0CHIRMNID- <#/$PD)9!V!">*C%F >=2*_&Y{(;&,W$*5?G^NJ MYR:S3O'36E/O+&L*+D F])? >$PZ.)!LN3W2R0*[3HZ1VD+=

MG/A:6K+U5S[1X2(;%_>2W_D2=@G6U-HK\A\:4=$#:Tj%lQ-P5#/K* MWFO@-;B|)\)"'@D#FL!Z:S* &@F)N3_+X[3CA4X6&0[:--Y=(:]-.4BBGN(TMY3+88P]$C'

!.\3%M/_:\!PVJ Y*H14;V(;#:#V0@*9,U&@OB8I_&IW-&VJRLJ-\E(7HZ M6J/$)GO1K^*!.V,7Q>6]#LN-Y;P_*$I[%V.Y]

M&7+YFTCNH]:'DS&05&ZNUH'IV1'63'1(P2V)FZTLO"1I/=Q8J%3Z5RU+8 MD$GHECX59:5VCF+=[8O='6V>WJ48.|>6J3>&Y2A3KX=&C+$1&%SE:'\R?#:

M9SG6!#+3%*J(906 XU:VOZJ;+84@0Y!W]3Z-=NW>P;JF>-4&>1?3OX.RXOCH M5O>C!YR;.&L.DV8?SG,9&3I%I.<'"*QQS7N-<-5DE;?=/XN-5Y>K^7N]8 M-

^!"#-4P.8&59:GZ8=AE CL1S(LB)(K(G9^;:>[(5Q!TDB MLF.>K;#9-O21?9/E"Q45*,1J3BSO.6@OJS_,^.-(%=M?$N[*'9V:

MRU%KD=#GL$'||CAMAYCXJ'&NNJJ5V2Q6B0P7QBH\F0LU'179]HV; RA+|\"LF MGS,&EJ84W&-?#.2N^$9;R+V[H=ZID;/!'Y4)}3>9:FUXQ^Y2NT]"_"C26]_'M&4HFM#-E\MN]

7%\4.2 [/C1AU-'2LVJ1S|$2 M"C;15A'8!$2>RU+V=;-ZQ7UWQ>,]@JP8U"'<$M4%@3YR^UQ29?4T!#FZ!'+2O"#W/.\1*9YM1989Z^<_43\)]8,SR; MV4U53?

KLCU,VYBFG&_,5'PIU11CM_4?$>G&WYDMW=U5^S,WP/LJ:N_DF1M6[JN'ZKR7^R0YSP%5W4C?P3/>=.K4I"O8@3*'H-7LIVY)5VI'_KOA5\0$[

MX\UYDI2X2G8MRQS3C%Z]0676IE5O4$!GIV%UCMZRP5DQ/5:B'0('I!U$?.& MDDA$H[;-ENFB%,BU[<450#F_CV,D"O:OT0_=MAOW(7'1(0%'-M0(!DX44

XR="@)+.SF.!E,:P_HV E!,FP^1#R;F(&4KQ6MV[_18M<[?OQX M$8GP\(>)>)KHQS/RG;M&;SM-_3*BAP<:V.4NJ?CS&G)+GXMRYH2/+&

(R>1$1"93TX8B=AK\M$G(>JYN%D+L;`M;^B?_#<3BB=H7ROK0SR0V1!-DM-Y]JO<11X)S(!;<*04NH<`MF:UER]>JN6I#'?(6.XK/MZ?:441#F)D#E-=O+E\H@,YTU"_J.C#;<=O$B,;Z`M2^/FR=`-R^::I#1]H"43?(&(;I-_^LPN*$_%FNX{(&]LF<9`1.EC'P2-X:=KN^_5Q+SJ0)ZOJ6QJ@H`M]Q7.0R,S\M9VF,^C^YG?=FO;('=`M"P,"'A>)B<1X&OB0=(U$\0@8(@<`-%ODQHPDA4[;7LZK;$=F06/3@>8F4`M8G)9M^\T12!^?!"@[`!5*Z4S14)WRPSF!8X;&*R/,(;28(Z]J9`M9+V8LS4J"B0RZK2+`TQQ'H];D*!QGF%XHCLR2;(AKA35O-E2WIGS4Z9=,N<`MG4:\389Z'G@H*T^T9B[$X&T"XC.L"M2YN:%`4M@N[IJ87?)B9CL]/`!Q]!XC`M,NQIKH&"L<*[9G2:`I%!%_OGYOT?4[%[7^S@RO+D=NLFS?N|K=-PF?H]D'MD9T0W@LQNG%_G#G\1B-$=CI^1JL,$YAD5/].2U%X/[,4A?=)*0HN&0=?3IK!`MPZ.QNKX-^T;9]MN]`EEU!PS_R@9V6T#0FILUQ_S'K[\(TV9L?ZAEC]/'Y8.V`MJ,I"_#+M?>MFZ=\&%SZ(@BP(+Q!UHN/4P3G)=0O*_(M(8Q[MF#,.?PK7E#R`<@84VTJFAZ@`M/#,>R6RR]P`QVN>'HB"KTLS`K\&BO(6`D==M>T`WP%L0T22G\>61PAD1#@F,M:R4'72V3G5#S\3V-]CJA1CF`:\.^G]H&,$+W*<2]BBJ`1$M9G0=L$6B`GL$`MY4;U#_`$6ZI#2+1J5SS4^J3K!NA,N!AX0^%)V>)W"=&?KIF0!4_:}8%GM(4,QJ]4_1\.?2&]DJN7W&YGB=^XTE#UJ\6B;.J2!H#E^9IPB0F6K8`M$LNMF,`!$9;(6M(I"D";C1|//G^WEG(%<>^_H,1!Y&Y>=%]JU;`F\C1O%LH[4F5\R6>G=2Q5EKYS3@D8=[^2-E'E$;;2^`M%G6F;)W=E9D@F^US2M4'7KY.^5"5VW)=&/SUT0W8:&10^,NVWPS3$A+(GI"X`M^$,7P\27,R1D<>#H=?6\!S1H5]\]TO>[8OT'>X@)U7ZJ-W1W53?LQSHW8:(_`M^LB7(5)`G&C("7YL_0(BWD#@%>0.`B/P$B+?0OAKH&85_YU^D\O5G<_3?9K5`MY"'#GV`:YH;.'X7.YG5;,-<4S:'>MP)8HCDZ>NJ`MA=Q0\.YP;\+=8U%)35WGJBV?,;U)/4C;%(PI,.C;9?K7l[*_]PSS<[VFA`MCE7]29?OM'G'.$X>3<,OV4OYEGJ^W5OMLW]%-%6-)@`[#-.[@`[JF!;W"UA))"H6-)8E!OB>B;R.YE1[_J?D'@!42_@9BOR)N4`M<;1^?-_IB92.ZFM7L'=(@N11,*\YR&8H\58U-CH`M2!C#`N,V38Z1VS?1XK;$Y\AYV5HPK[HT)%R\WCL]#(5$# I5.I@X#`[_/7%GMV!.3J@GK59V72G^^DVK?ZF8Y3$1_MB-=3U"FLT6?2$4O',^\0=ZKF5L(]['G`M%Q=3[2Z8>&!A,_#5>0.0;B'H%^\LAO6O+`M(W3B>),.D;C\N"5&]H)WH*/==LN7XIR!U5,M[FH#X";14CQ-+%)C}:Z#`GT^(;H/L&38"(,9,>"U_]S4]OJL@WRBX;XF3`0KM.9-QS\U^3F*N44'\,5,FIQO6=GT#7R$`NMC,!VRM;M%"H>_/^]6L+3I6K`MLBJJ-3,.ENNN?EFF,)S^ES51_@6_@)NB%E]8;HGDC?5?Z/5%FSUX^2F.8`M114D1&F9"0\'3-R9S)\[F0&%PW^<(]7:*81K*D+BXN&X,;+_=]&O.O5P[,H`MK^`8OGU_],(^;'4ICL)1;D-D]8-R^6)[P;503JS%Q7'65]JKS7F[JJ57C3`M7XA"-%&1)`XPU:WR[OD!<5S3$94><5LZEV=-`MB=F'"S,+HGHF@ZZ'3XK.,Y<:.T8OKMWP%)I&VS!OZ]=BQPY2NF8KF:U2WQXFMGR/ZP6R[R.&(K0_;+1*N^1*Y9=A?9/>^Y&Q]3/*?5!"=A?]_OJ60G33Z0PS$WTA).!QPFA`M`A+2F0%NC78/C)^4TR.4_@*QJBE9540)K6U+4BK&0&!?$+L5/X?P`,@`ML34*(AA$?**"KZX5&C0G,0.>XG,`JH:3CIHZ=Q\7[-X#:S5P18GY2D$GUGW:`MFKYW+&FU:(T1C4F!RY[JACH)[@6>81T@A[U3E`/S_%#'E1>U`#7E)E'TOZ_`M&Y?@$1.9CNRO1UY<_OH=7%QB,OHN+FFZ^^Q[E>=G:QG`EV38=\+HLBK=?>$`MJ[\@\@VY2SL>]2#7_)]&Z=!?.EA/2A8"GQ'(>"9Z8PO:>KIGPHM*W9%$)6J+E0F2]A@5*Y(JL.EV^6V$L/R6.9ABOB847V@;9*ID!Q7$_+<^JK`M/B&4MW&`OS-MYSYIG-]24'+$[5=6U:F$76%_D29/5[LVXX=`TUBW4A5;YP3`MKF@<_Y^L(Z)Z"E:-S)-C-49RUR1.T1UJ%3EQ%_SMR'OR;]_!/3DFH^^>G*:,`M?.6C^E'$"D?-)?1B#=[UY7@DQ#QITK/H+LO=OJ/>>,F4Y$399?[4E7$J<$WE`M1+UB^0IU8M1J.R0QNX8(;$4Y323LVG>/M_B#K<"W^=G9*'MMH?L=A#5ZM]`MX!6P^[^^9';,:LF4E$?WN8D0F9Z#^2&4?M1'1"5_"(.("NN:P)&:PK=7#Z$81/(#T^RTN$R)<,YQ?'8M?9S5TPK7R)`M+@Q6=/R#76TAU_!5__9NJN2@,@MDYG+NRW:>RZT[.HGO(")`M*%Z2\BKL:%-@++YB(ZH).!EX&C)OY621H%+CZ1PXIP$0W@\F/(_?"!;C:`M"@XL(V`4(P.Q8!>B)^X7$@QA@Y"=M#KGPP0R5@^NF9VF2]SP#X\R#/D4C9QJ`M?ZW1`XI*1QYYKA*C3F&<0;B(Z,@IX;'-=ENV?UPUE*K$1X@0C;9KH1,"O1"=_M"LIC<#-Q0Z3+G&+EQC2&;>!Z(KP1>@9_<-O^P.83X0Y18PEJ0#W?E@TM5MN/`MA9\4&YZ8PJ>R<7)_,,_%,LX9,B9H3!P"TOJ51'@T5LS3_EK57;^TLK<`M3I/:]&-+O+!>UJ8N>'LU.&J93J5QH@^XA(5TAWN??K(W#L#M3NL)-(6'6CM`M+Q63#W!1%LTZU[F9YQ'75[,YW[VXGH^)OMF4G%)]]DH`1U2/)==L7/#$4VW`MQ"UE-]ZV(}AYUKP(}*W[\B"QX:`B/7JO-9^O+Q;N]=?K4ZU"6'?KAA?AW=8-`MKXU&C'?D7H5{JG3?LA!G$;$]CBH4I@EZSE.KK6,`K(=EQ31Y]AY>LA6IK\60P[3A^AEMI[AF]]ZGX9.6/@O].*-L4.]\W3V55PMT9_'3R.PNK7C86`M#).#YNH[M4$,&;[>!E=7[.(Y:!2^);M>E<#K&*U-;]F6:.^*?[A6_NC1>R_;`M69U[:@ZNWN,4X)K]D^@4%Q9FI`7(*B=0[%0S6(FD.=]D&QD7]9;H]B;5V(+(`M/,-0OF&&V4^2VS7'(Q3V`]#4#:&,7ZL-;7:O9?5@4D#);.!+C1R*`M.]_F@,!E`M)R&H*PU!]0<`!Q3,4+&#W!0OMIDVA?*V8V0+*"B'R$'M>Z9W%W2@'T#HSA'NLH,_`]>3N':IVZ(MG;$A'M!FC6!*S!\0FM,\>@,;!$V42V92:V/LC,&O`MQ^1.CI7Q??'Q$ABP428S[^UG#L&^SF-74R&]9Z6W]=M).TZT[W]K62O:=;/`MK\:%P0`E_.2_Y5EAOXY[\5I/(Q4]2]&HNH]QU]Z:HPK4I'Z-41)M_`M-%+7",2="1_6*)AL`MKU!S_'?Q>L)2D%$U!,/C$>1PK2CV70#=6.:[2YIAQQ`M1Q$P!GG)BK!2"BR((MMSY-WFRI,>CM\U?UXQ\9H/O4>QO^T<2`]=A^10`-PH`M#O^Z=`U0?QF98M-OYP(O1:/6+5W,OL$QBI@+`[`MH$5,UW`B1-S@HNP3CDX&MS=)//ONY[L`HIH9NQ@258U\?[RES!8IUYT$S?$TM@=LO7\-G?]H(E=Z#9N0GUK!],Q-3(*B8^SR+:,@+QH(UKN],AE8]%9O`&TY55`M\5.+=I8ZN.K&G.4\<^57?=1,"=ED]TC(LOQ(.M';J_E0:Q9_3[NKHIDXI=LCV+(<(7UU*&3:*;XA)-.PR2G]AD6`M`F+X/7`S1REJ[W>8R%@[1M5[`_,92^WV<8LIX;C8]RF)^%$S8OGPT-"'HCM(`MT%>F0QKAX1%%KM-,4CW^0SZ&W@AU0N9>_G]K7)Y1GMP42Z6=6F>GKDK)FBLO`ME%!KF4?0(!Q&-?.M3+V1!%=47]WC6C&YVEISHBO">16ZOZ(M!9SHOX2+E=`M!L$DU6'.K6E%\VJX83S8H>/E?(SC]`%VX<:4C=$M)>[B;.N7UZN1Y^0KLt+W4@VB"<;K>\`Z$A6;XK>_OH4J<34'ICB_'/:.&Q$9N2+R6HJL;JBC1I+2G*<`M!8HLH8QBDE;FEF(0NXM=UMGM03&V\H6=6I]WQ9]+Z5NEGN)9-52XXST0W456+%":E*X5,$8_N&>*#97F=X,^`M-[+'1\=(-CW@.*CLDE$PU!1%W]J,^K`M1Q`O9M0G,R(]W(=OZT?8]Y?LQDWC1#`J<:*?SUTRV2._93L'!<6fM2QW75$V`M8266+9_+#+LRQ6QIT!4&,.GDJALGJ:%A.,-^%<%KQM:R'_DC)75O\).5AFF]I`M%JW;##$QL,"'$/8KLV,>Q.X<]RH.@.!^!8:BSJ/+.TK\P3'B7E>_N%!IT`M7B+.,$>XIN:AN1O>DRW3?RZEX=QBN*U\0;H\2,)=MB)\D1VTC)`M-\4@:]0DJFG>HHH)8EGG9Z(B$/VIN<(Y"=BT.80!#[!H_T8AP!`"+?>"030ZM!1%S8GD/\?#[*GLXA7"=%@%IT=&SC_5N0YLV?$*;3\Z!@-8>N?L+`+@CW?22<`M1WF63A832`T)A&FZO]]`P&FT/LG_?\H)OJ7IO8D9XE8K#HXA,L?TO1:$MUU1D]A,'|PVQ&I;[[K%N`M@+B>YPL8MW]VW>RQO'QCN(5]1GF=C$(^9<2-HC9CAZ$]0-[H29`M<)1*7#6D;T0X#$=4U.7H>>GY=?K>,MOZ0?DB-X`$W>#[CU*B[>+!A,-:1#;[`M.Q8LGT$X'+#WI2A,R3/)*L!NT6K-UD)?,2>Z]OFIB-P2LQ_2=^0K.90M9&=`M=+<78[SRD!T8D@(8QGA=/>]Y=@SP!@$E?;CN8K0DO*FHS<>9E*A9C#E4_HJ+MYYJW5*5@5<.3_"|_'4/&HSAV_CH_1IV0.':8(BH[ZH'C*I>BSL=7515,U'C8`M@%,BBGWGQ>Z?M/!.E+>YC.YV0;J.W%,"U8`71'>M2+'E$.0_Y4UKC@8+PV+,26)E!M=0J=,AGFMV#H=ONZR%N'P#&ID*VOU.*,2@<3+6Y86H*`MAQG'EI?(XVJ=)+3'$WN$`I%G^V)7M.UJ*[%D]^86$`R#H);^92M_V[UF16\`M,S`"90M(^^=-K"AD_TRK'\]fB8IPGG%GJ]Y1,.2W>7_1M:H:\,.AXD.24%L@`MT$R8;TL0U!1XY46,!L8U/OGCQ\O(NXE`M>)3P9XE^.:,%%XABZ96IXQ4,^9M@I5RNS6MC?$2)>LX&^_,@V;W*O>Z\TK@4?`M$1WU.CO<`L?2^EBG0#*S3_Y380R[SQ@MX1[90P\4MQU66W9KY>AT+Z3GT(W`MV_U<;W]F+0EOFGNN@G*YIBA!$;E2(1)3(')[8F9CHX,F(0E=%*GFH;+KUS^`AT12!(@C09"V/NR.VV4B$YF)`M1"+/O_[WPH[_L451C,/@;]^]_M.KIUZ@P`T]'"S_]MVGVY>3VI.KJ^_^^[]>`MO/B/O_[GRY2BF/IBQO'GUEQ_>_>6"U]\NCLC__'FS_DG__%7'P=?[!T8O2!X!_'?O]M->KB/`M_#^%?+DS:M?;T`_*/_PN_\N/-!?U!/^Z[OLKU^_?__^)O7W9_&N.T/R;*O`M3WH]>WKKM#;>?#>LD&24[\7K!_`OZ7R_+/WM)?_7RM[9N7;U`_Z2'VOLO]N+%7Z/01W.T>)%A_I?D<8/^]EV,UQN?(I3]:A6A18Y(`M3.!D,&+D_FD9;D^0ZYU0JM(?7M(?Z-K_9[;=G./8]<,XC<@[%,*G^=5N+P?GABDHA708P]%)$C0<_0)")'8XG6*$AB480Y`M*U#,#>$]^>I$WAU>$Y#R-&[_6!;;-`?,X1>O7_[*D.*_N:WZ+>S,(A#'WM4M39PZ/CUUMRN6D/TZ&FB'U$MDZ/&_%925*61^VW+(1I*Y1@U_%;N"^.:W.I`M$ZA?$:V_1K<)^9G*FBRZS<_!>'^[(GM?A3XY$?'%'RE.'N_((F_"Z*T(BIROMHY\]A!4:!4%S6S'9>>.R$B,;^%NS_6:YQD`MA^*6Z`SD]8Q\@*((>1E8$?PZUP`C8!/2*0"V!VN`8?O9H?9R^R3ZUX$NX-O`M0*\RNK]3HA(\]J)>()LUN46$1//P2C%0W*+D.XWB&HLQ*$D&I^0F\.'ZMWP&>G,,;2H+AS(_A$&RJ5W'L&%_"V@8'&E;2>]SO`26OH7;%`M6GS_$%0#N2ODI3ZYV2\=+'/WB^"GZ&1-YC!P542.7F+P77>SX)0N)OA(3D%*`M+GXGV7V1X25$<#AH4-IKC]+9B5CJRS`MI!RE<)"O4%.(SWXECHEN1AX-K\]3R`MWRIL7Q.6W`G:840,NHV#0B!>@X0->BG!*"H+(VHZVH2QZC0R7(;%5_6C%3/`MHI"H[^1Q1NZ8A$"G3]0-?,(H[86[%N"5L`-97-[QS'FD,!20;EW!$*I1BKS*`MV57#MG412/_.#MA')TFC#$BXR.YV/=R{ES.RB]SFP]_(&])-\)9HC448%8I$`M91L"Z\'K7JH"L\OW*MBD"=&+24C4Q*GON%_('Q$X\9GSE._V*B.KY/=2>85'8_;\CM!N-`MQ06GLK/N!>`%KV)V9+&_^_,5$.3I6'*M2\&C3DA%WI7>,?93J;-1);;@_B"`M)LL;E.@?:D:0EV4&*9Z%"3$FB/WK/V:XX"VZ16YQIRAL3`4`YD1"3N=I\3!`M8M%5F>4@;UHAGXK$/N06!)2\MOB4#-Z\[P$)?A"PDL"1^2V4'JH[@V2DM_5#MR:/&"A=)(-FU!&S,G1D]DL!88!6P*^C0UR9S>MA?0U*U*ZXD@;'H4J;".LT@`MDP;JK*6@4&`Z;21097I*>8.U6IBRLLM<`")GT$,XSVDC/'QSVMQPBZ*.#;Z`M98:0%[HIU0-$)=^O@)($VQ%SL#16D]3#R55`LV5K<<`-,NBOL>^77BRA<=|,V"=MW&4;DUOC;=V]I=O>F`M5&37.568Z&2X).2V0=E?5F^9DZ;.8MB2W8O4QR/TO@DI/'5<*61E\/-$LNCM5!ZETJQ4,C+TCP)Y%,BG]R8/8!`4T56"UK&6;'*6/9$V>>>ICUZ_NO_A=84$`M'T,OB[M?^LY22&((%SGY+UO2V\T#*L/=5"@D^O4/NB(MPYR;,.!A)L2;KC5V`M*V2.9T4*9GRXO|4C40%%TO)R(A%G6+.L[FMUWETG22!C0+8YQQOY.(.I=-.M.!GX<3W%6F*]0]UXR=Q^9N]_$'%"2GM!VL781\$B->2B=1Q%%'66@VE7Q_`MIU5%S.C99?&S/++R)!;O'%8MKF6Y9=,_#QYP,;8=P"GBKM-%M:.5BNS#DD$`MPC<5ME51.0_7#@Z_^=4"8#"'C26J5:.U$;AB@LL?F"+H\:8>.9!YP_6&`5M^210/PL'5H<\7YH1'6F^,!88$5]8)"CX\J9GOI0[Z..+`MJ[B<&[8C./3"-#-`M;Y\,W;=KQ6Q4%UE?Y4U9HI*GGY>YZ&9>"`>TP,+PXN^WV*IL8M(`S:BE9042`\-MHO]',^^WCD]=57-$4,-NT8!A$GCU7U3^$MI@TL+%!@!PQ;YF4^F1&TI6%&^A`M2MW)I"@[]>T<_E+J&A9.0LS7HAZ@/;?O08VJ,6M&X7"2&OGD(HE$"..KZFL`MZQF/<[Q<)=/%)R).%$E@?O%A[3UH86A*(RIR'(9,20"-%U9-(:IPH5(-2`2DF@Z<-S8S\X0!CN4ARW-M52).1+`SI\EKLZ]+#B":!U-6UADL-OCZ5%2DI6)J0[9G.Q`[^.0/B$EW3MPPZ`M@?%/D7F-YG)C`&/L;QBI7G((I=M>Z:L9Z;N!VHNQY5*1V!F0HV#\/P7&SDZF,.'#[`M/(I5>,/CJ,19K-+-`M@%,V8BY'[\<9.`<%W#8`)HI^[DK6U<9HZDH.P6IX0LXYTTH@`MP$M-576&@3&.'2QO]X#)<.N0.E`O=R7_B^=E>=*,/W.P=Q6<.1M.KDUH[PL#`MBFT34HY53%K9?;/;>N&ZZ3K.>,;O>_*#<% XN!I0C[P`M)$!=":\XY3*RH]E&;(OO]\YH2\\11>NO^.5H$%V4*_"'BOK#D:754PP?`AG)")1A[`M2#"K>N"-OS(9B>][+KOV]"CK;)[.9@%H'!sz:22W?!T)9[7TQT]`M`G$4:E:(=!IN?'U=6\'0\+7)@V3;=R_)2^9]]=VC4/^(&M2O+"CCL&69-"IX M!]7'4)]YYFP=+]B1LK'-TGDW_)Z45P'Y-=KMF1DM4Q2]QO^&8F0L*!]GX1@:`M&V9HK$.@#$?#C]&P8RCL&`HS&PIKQ!N*A!3YB!AWG;$<"8&X&@)>-G):B\#0MSXJ<:?YX'E8T=PSES[*_]S&$4Z<4UP\?MEV9VVX-^0`&=`4]PFWAK'&"Z#3KDV@Q+NZ#9O-;D>-I)-MOI/@YV8U]_6G:#`M2W&OA3A0?1^U>)6]*.[#V!BW*A#&HT!;Z0/5ET[M>-V$05C]FS\;L.BHKLY!!.P.YYGW,T0$L..M+BZ:6#HRP!8>+!GN8B-UV43;J`MN32W8:0AHWDD`D-.E0P=%3+E`&[..H9TWL@.R[NP'J`0-M"L;(K#?LHRE%&844.>;MJ*!0)UL'^S3X,O,F66-=+=)/2X/UT<9"U:>(4RL$>13Q3DIP%]H];B7$R`M<"U$TW26LRST,5RUTA0MO4Q0:0K`J=`9QK6>1W>$R&`"Z"TG$UJS?;?AR7&EXC@%N-MAYS[41R[124WH'9*F4)T:.==VDZ3R,B+K,`MY5D&+OTZ3PQ7;1;W&0`TT7Y1V=AW$S*8]E.L""'S6UH^EIQ'3`VL6_QU9^A`M;,]"AB^11@\H0.=BC2&Z4)"=8:JM13=$C[UG`1WMI,*D)EM=J`M|BG;\%EG(^)WF0V?-F%0W5;#"72&]KZ`MY$DI>%9FI_,.V`WZFOU+G\;-'N:(++=PF]4H.6^O6PA7GGMG`R\,?\!VG0=12"/3]JN"FJ$4QX"$PZ'M+A["E*`T$# 5]BT[52"JZ&C3`MKHSRU?W,T1\ICG&"B+K;8A?E^YXC-UP&V8H6`KT06(_C8=0;#TM9U78+PR1G`M_O;JG_3,@;,_G3!E-IER>N9%X&E>,\T\1'A^C72Z7BME2H8I)VE6&69VJA[M`M07;IAU^_JY&TVD1"LX=$"<#4T`TN*+T.5[K>+`JIX\,[??P4TQF$N[[@$S?!MVRRT;JK]MCP"0(&L.%QO),U*DQBL(OV8]LUTPK`M;@L%+O91#<6[T.Z1-X+B,,P>09$@ADDV1L^5.SI'!**+'0-/]K2=@-\)@]7`M53[]U+0]6*S!)6;",CX$\CSXS:*P[5%'QZ$O8H!_!P!.*-PMY5K1.1T3KL.`M3A=DEY,X1LED'48)_I;QO,QL`6GPMDW+OF1&GB|0Y5AJDV/)+S)B]-=YZ.H/!+#K$>N*Z84KT[IO6$-?WP)&1"ALX:A]7VG'$&MGI6)GER$O$NRWWT^O4)IE,@ZX^.B'*%LAJ8+!&,>AL2Z`MR'^!R#^V,%??EE-#PNXL,"VYT"6_79_T3C!2`M4^%U!SL!5D1$&_)))-90'%P3F4%;_094!H\?4&:?GN+8U1+W?=4H8YPRM`M8B3H#MB'T.RKT=IKT,(^T3A-.F!'K6PI??\SQ9+`^W5U;1V2;GV.B-!CMRAB`M(/NM_Z+REWG]4\-E?_`@^BDMV2_.K)Q@B>9$<"\6"P3N@^@^9>X`P-A?%3QR0\;-8V63E`4S3[!=XYB-\)9O[EP<9K&`M.$#[KCB'?:34BJLK(/=MJRA5LQC":A/31>&0<_R=.\941BD.3JJ*L21TA?H$`M[JD3XSA[=^[`WQ'BG_KP470%!"RK5U`AJAY?%5[>8K@#_AMNEX[T6.XN,7+`M_"^(]4"L@;QVD79`;>3HMAQQOH$"@*U^?2]VL[7F`M3Q6DY*#/3V4/RPCE"@3X1CP+?9_HILCQ\3?D[<$8.C*=X.0G@!40B7%26(WNMN2M8C06)3B2\SE'6Q2D_"M:!%,%C+9HHDTZN7ASAEAWQ]G#H^]>O=KA!*`M.+NS,.BX/!0>$'!4H.8]A5<`8L\=D0%N]MGN1XSTI:Z"8OU"DSX,.HM=M@GBT5"M&\K<)!84C:-S39ZP"-4I8^RP`M=-"S?`=U\+!Z(KJH-F#K3CZ,R=*'N\B)XB=+(V!?=6H63OM0(P9;QW@E'W.MK)7WJL.^'WFO4!:E[M,S0&P`M`S5I@-K3S9@W0`,V>MVA$!Q3ITX2N.UL=R59J.4E2Q(:.,\IVO]6&9]SCA;8`MQ0GHE78XGNK?6'SYTHGS$0+FZF(`MC41AJ)N,51YFYCQU05-NHE%=S=3984&Q;?4)LK!>P\X@V}!=<\VC<6KX..@`S`M^ALZ04!(R=]2-`X;?O*]23]=5.ZH:/*-ZR347-'?(V`L`M!ZJZ&%<.[(!QB#?G-=0Q>3O^B/E'QXL3602-<2SE@=QSTQTK-M)E^=*&_4E,?X8^J6RD4YCM-U_KN>K$40Y&P[F*5;`T$$|"X;@C;K@G8IP#W`MH;J9$8L#DP2`CHD>FD39!\'(8KO-U.VFTVZV&:1NZ*_`7UZP.,HM7!],GJ2C!6@OG-Q0U_Y^7?'WMN/=NZ6+NNL)Z@>]WK&V4-[M'D()<6UF$_39#7TXTFAX4E@1<[R0R;28[,P_"V`M3((&>Q1\O"7&GDN#)QC%%P^NGY*K)&_PM-ZDY4#ZOOJ<&D#0CM]=1Z#@>`.?`MWV?\U/L-USL>_(?H3+GH3;H`MM%M.K/'AH!#EYY\+9=&?H\}3!?@S/++#YI+.&FW4R%'/N]_S9+!=R'J-6R=1GFM)%Q"M4F4+=WF1LXRU=76SHP]GCX3:N:8N&R0.V\Q\H+9"-9959VM=-M0`=[0-1(2WZ*765E9X>HGH=K!P>FQ$@(MN6WMMQ!.Y4!,1)7'B`:B'3_W&&`MW^N/:'V/(E-,,(%D-Z<&@&-MU+/<,;D-MS>]GC4V):*4.(%'=@%!KF@`M;"@BY.4TI8EF`MDMV&I-%B3:P/0&XLQ+!,`=)$<-%|>W02;>+^G<4*#G<;D@0_K62B(#G*K`M!SZ.5IMAIUAC=`S1<(RN;<#%%76XDP)L#}\$;J;>0@:R1DBC`,5$-&CFL+,`M+O;+VS3P%9A95ZQ-4MFIWRSP(/_CDE]CU_&+>K]R$T(.U^Y5;!O5BNP2(`]8`MCH;*B,=^=QY$D$HF7U+WNTA7HU5PDZ0'Y3Y(PDQ(M`M'[=-`M"Q\"L<;%5K6,]^56I/25HA7ZTT4;O-4>R/O/QXDN_$`10YQ26>S3%@WIW/9"M"2P=4,#(R;=C=H/@_8D<`M4/;#`:"*{Z.>AJ53\QR:=!PVYM`N@LK1Z4*P6QED-=K;OHQ>5,O:C"!\5`M/:2:IN*Q,D3$-QP!B_7"(L;%O/EK)96DZ`M9X'.>90NSVDI1)B9E5D';9D\'(%E;\Z%F>5*$U`NQJJF17,/9FP+MC+'MB`ME`YA%_VL3L#LBZ|/BZ7=W!QV9DTQ/9#@'2Y[*.!7ONZ^A)5DI`MH=M]._4E)#M:VTX'$$78DE38MOGZD@=`;O!>##X%'KG_J/L,>1(TPMZ?F_"P.V3WQ5X3_L5RE.L/T=1$6X2:=/WO86?I.ZA+`M,"H+V^'FRNPR$]M'.5)P2Y1G.S)&&_Z1$MRN`L*A-6-1YD"[6SE!,1N6$'^+`M8G>)YI'O7X81_0A8L'M&7F/XF7E$;U(#*<7]X6TI0=?*,:A5@O4G(KKME&K-`M<^3J.(UM\C.B;8*0-R':VEFBBP<4N3A&LP@W6S^P2D+MH&;]YK4G^+9D`;1U`MU.!N@TJ7K`81*DIS9=KFAR3Y3+*WH979,\XB+&;=SVUC/2ZE:L9NT,Y%19$R-U5S50XT-S#/B0`M/7&O@EF&Z&CNI0;.O]/1DW@H>.$!TNT,[P]Y`W\(B&#X;-`QE@5#(WBAG!G3`M^TU8ND$+BH@?!YM(/O,7OE7Y4(CU0&3_F"-Y>>]!=C.IR0A$!^[.41/4?^`W`M\%)PF#F#5,V\'WQ0%/V(X'L7?DFP41^(G"T?QA6WH\]PC:`IFL_I86!9I(K#`M\1{@=8V[0UU^`M+@G)6X<3V"01*2_9[ZCON%_!'VV_ACZ"%_$4;DU[L4#[B,B'V/`MI@8FA+KA70LFA-=W%%4P4&]!J`I/66,V)>G<+#E`XP-VZ4034.QW%<;K.CA6A`M]ZX1#Q=G#H^;,8I_NT(H.2>';,H@/$)$V).8QCAPD"+O+CQ%/R/?.WV\(WN+`MR?D*HIPY.PZ6>5/G;.6'P;6A+KFV=F&Y12[.@:7*VNSIL#4>L!C`0B^1#&U#`M;7N98*R(1Q^*KNKY9A-Y*&R?;#.10PV"3"L8Z4$!:)F5+[K^/`XVDX_2UT:`M6$C6GD6]\+@-HF5K7X?+K02TV[NAB6*&VB^A3TB:SYSO@9HWURO'*P"MK%`,+I*/*C@.`AWSXNJ4O(.O29/C>GB`MHQ-](6^3^_[NP_4N;KHX6H:249FS1SJ"\`IE397J?CH7>S2W:\J@4R)PIT_ML+/1N;M'.`M"-4X2GZ;TT"OZ-5`/JA<"_2:VG?!DTJ*;^,O8.[9][`MK;)8V0+7:!$NX\XP.M4XNW:0;WZ>I9\RUSR-79L1[EGB#@/L*2OK3=(TM=WM#*WGGZ!ZM9TMH.%PTPN(EIE1D\";TUS";AUK\\$)_(Z3`FVW+[K=3)BJ@,KQ`M"^P%8S++[8I0EY[`68G@:1*Z7\3Z^RBFL_%!*;`M"2X*-#R]@/$!P`T;&9B8`M?@A+8\"9E[!)093'G4(^D'FX*6<=\&R9GJK"R\J5WB(//.R5;A\YCLQ48[%`M%J91UJD,>`+9<&RG5HL;.%$RO.):7H'9<.1=%,NC@$MP5+$2B-K-Y1R(;,LPUEJKM#YVSC+:<$#'GL5#%G(YU"[0U8549^%#IMXCCV+2Z379"I?[`QU_`]+7+%__S;M-^O=LN__48?#\/OWYX%/U_]X\WOW^2>XS!=UOWVRO_[\E)O:O5UOO-G+^N#KY[/WZZCQZ__[5NS^GMW?X[???`M7@??-LX//R;?WY[\GL3ANW=_7+Q]_^F/?_[T2^S>_O,.?;K[X>_NMW_^A.>_`M_OH!??[W3U_PP\7??W_YMOSY>__=OR`MK+X_F?_Z_?*

4U^O?-W/WGTKV+OR7X?O+^Y]O[X>N|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f@B1* M?JA!VB:?_I<,CC)W1;C(!QEQI^)5_\,UK0.2_'!WIF2 M-_-O @*01M1UM_ DCE%"'6AE-S2,XH_(B5,BJ=._'(TTHD$ \@/HVB@/ES\'F?'L>1$1[?YO'4?+;G#I715_AY(.* M9)#_VDM%?2TKK /4$Y2I#>] <$>-/>+FN0B#:B^L_MG4*G0U>C?,Z/)Q*TV[MC\1"7Z=K,.K5U[/T0N62K[%C]!>G NF=!UC2U!8;).GK.Q[Q$O!:C_9GWH \ M_7HN_JU2)5V?@W+G 8)8CEOEP$PX\6ZC)?G^!QOL8<"_^@R MWHKO4<8-R "8E=AK*Q[>_@;>5EZH;4N'<98Q:69\@1QLC;RR M-CA]!JFV!WNA+A56UR*B?#K"6?\}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|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~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§4Z_^@$E6O"-_UU;;$AAF>W(MP-.I'<806D#*OID8U +H=;L4==OC$4\"IR8.G/UQKWHC9Q.6>AV3RQ7$JLI MEB;JYN.KC$_.TLA=.;%2=_#N56Q;*9WD%R_$_$MK1)I'+<(.T*562IR+B#8O MH"TDT"+K6':@ZJ0\4,8*D4JIG0N4>[4!1X'I%>DE#8<-W>X=HRL2RC2WT\6W M5KYZ6+.;)YG?H*_9/QDI$^X&:OO>@Q()41HK.+W::MR4Q*!2L(-)V-;G//!. MR&\$ 4+::$K8DJ5BE+TL,%9C!F"\91(1OK7A,;U_@ (@G?'?>|$-KVSOF77\ M,JU9C_7H SN]#>XJE/1HMN^:!$'J^':. MK8HBEU)V*=@FK^W#D>O9=F+]7#1/WWG>(L]%'@\A@&?0P,(W-P%]I:)[,4G?$;,U ( ]G$!J3 M4,;,\-V+M& ,?: Q'RGV,A+OZRI;>MP!W\ +HHK>&COWV,?) M8U=G"U7GRSG*:DGQ%I6@:'ZTF:85?%BR.I-!(?',$]P%H)N&'0BLR>Y@U_4&M$O9.M\!TT:/+9R9(YP 55C[=8>,BIZ=KN+B-3@[' >/MA#@,&. ^@VW' N!5Z M'P>,]TOO80T8? [,%[I+7:W>QNX76'\=:=SNU[I.WNA6Z[0N.@K9\$@#66"CP MY< -Z?&E?8$Q\89# TB3' JD?=/G2OL"8^,(@ =SU/_P[M,OO M,U!LPC=!PT MJG@LQ/OKJ],ZH_F4:NCJ7Y/XX0J@GWI^P_T_R/O.HR(MAB%SPF+ AT?,(@ M2DTP4P,^,)"I^%,G1A[MBX."/O>]+/K7EW/?1,!0V$#-1Q46A;QR"H>5Q!8 M1]N&Z6#I2MGRZ>/^3V:.8U;)_-6)/%/A!P"$[+9YU!#OS/H2$!EKT8LY\ND\ MUYD3)8_5S@"GC]5_,>"..D0!L)X%,_*17;PX9>D(P?79?G1GPV+0!LVP#R]MCT!F_C*>]-=TN&_2(5<5\ <([F>TS M?_9>!6Z$R-^?H_Q_3=RCIE&V;;; B'CVPVQ;G<++?=Y1/-+HLS1Z(N.8:F1@9Q;_HWT&/$>\9^2>I2OL6 M%L]M\]ZU[E<2GDQFS]\$F)0CMIP#K>Z[9 S0O8?2> +QAM!6*YS;Y14\ZB MIWHK?FMV^UV;+K4T!0K$AFADILEG?MCDE3?D>*/Z%>E6*ET(OKE-XK&W^M2@P^^_K@N7KO+Y B H@Z.LEA_:@#*$YA.67B-<5>]E9KR; M])P@34Y<4I@'V7X^1&'<:.W=I-A)/\+6IR@ZXIFN*.1HE9E?9.R$?YY'LQ!P\ M:.,#W%.TX[H,+GS6JISL(@2RN{(O?X_,+NPGSB[2U*$C_;?+,U'=:&VEKK MX6(UA|^(\&CR1J/KF|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|C86PN>&UL4$L! A0#% M @ L3AM65'CF'7W2@ >0L% !4 (_'YD! '5N8WDM,C R M-# Y,S!?9&5F+GAM;%!+ 0(4 Q0 (+$X;5DN3FH=*L -/_" 5 M " 2GE 0!U;F-Y+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4 M" "Q.&U91Z&V!;-, "\4@4 %0 @ -%,D0(=6YC>2TR,#(T B,#D5,%|P&UL4$L%!@ + L % , #+> @ $! end XML 79 ea0220114-10q_unicycive_htm.xml IDEA: XBRL DOCUMENT 0001766140 2024-01-012024-09-30 0001766140 2024-11-13 0001766140 2023-12-31 0001766140 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-12-31 0001766140 uncy:SeriesA2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2023-12-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-09-30 0001766140 us-gaap:PreferredStockMember 2023-12-31 0001766140 us-gaap:PreferredStockMember 2024-09-30 0001766140 2023-07-012023-09-30 0001766140 2024-07-012024-09-30 0001766140 2023-01-012023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2023-07-012023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2024-07-012024-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2023-01-012023-09-30 0001766140 uncy:SeriesA1PreferredStockholdersMember 2024-01-012024-09-30 0001766140 uncy:SeriesBHoldersMember 2023-07-012023-09-30 0001766140 uncy:SeriesBHoldersMember 2024-07-012024-09-30 0001766140 uncy:SeriesBHoldersMember 2023-01-012023-09-30 0001766140 uncy:SeriesBHoldersMember 2024-01-012024-09-30 0001766140 uncy:SeriesA1PreferredStockMember 2022-12-31 0001766140 us-gaap:CommonStockMember 2022-12-31 0001766140 uncy:SeriesA2PreferredStockMember 2022-12-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001766140 us-gaap:RetainedEarningsMember 2022-12-31 0001766140 2022-12-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-01-012023-03-31 0001766140 us-gaap:CommonStockMember 2023-01-012023-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2023-01-012023-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001766140 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001766140 2023-01-012023-03-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-03-31 0001766140 us-gaap:CommonStockMember 2023-03-31 0001766140 uncy:SeriesA2PreferredStockMember 2023-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001766140 us-gaap:RetainedEarningsMember 2023-03-31 0001766140 2023-03-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-06-30 0001766140 us-gaap:CommonStockMember 2023-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001766140 us-gaap:RetainedEarningsMember 2023-06-30 0001766140 2023-06-30 0001766140 uncy:SeriesA1PreferredStockMember 2023-07-012023-09-30 0001766140 us-gaap:CommonStockMember 2023-07-012023-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2023-07-012023-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001766140 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001766140 2023-07-012023-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-01-012024-03-31 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-01-012024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-01-012024-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001766140 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001766140 2024-01-012024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-01-012024-03-31 0001766140 uncy:SeriesB1PreferredStockMember 2024-03-31 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-03-31 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001766140 us-gaap:RetainedEarningsMember 2024-03-31 0001766140 2024-03-31 0001766140 uncy:SeriesB2PreferredStockMember 2024-04-012024-06-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-04-012024-06-30 0001766140 us-

gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001766140 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001766140 2024-04-012024-06-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-04-012024-06-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-06-30 0001766140 us-gaap:CommonStockMember 2024-06-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-06-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-06-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-06-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001766140 us-gaap:RetainedEarningsMember 2024-06-30 0001766140 2024-06-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-07-012024-09-30 0001766140 us-gaap:CommonStockMember 2024-07-012024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-07-012024-09-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-07-012024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-07-012024-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001766140 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001766140 uncy:SeriesB1PreferredStockMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PrimePreferredStockMember 2024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-09-30 0001766140 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001766140 us-gaap:RetainedEarningsMember 2024-09-30 0001766140 stpr:DE 2024-01-012024-09-30 0001766140 us-gaap:IPOMember 2021-07-152021-07-15 0001766140 us-gaap:PrivatePlacementMember 2023-03-032023-03-03 0001766140 us-gaap:PrivatePlacementMember 2024-03-132024-03-13 0001766140 us-gaap:SeriesBPreferredStockMember 2024-03-13 0001766140 2024-03-132024-03-13 0001766140 us-gaap:WarrantMember 2023-01-012023-09-30 0001766140 us-gaap:WarrantMember 2024-01-012024-09-30 0001766140 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001766140 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-01-012023-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2023-04-012023-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-07-012023-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-01-012024-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001766140 us-gaap:FairValueInputsLevel3Member 2024-04-012024-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001766140 us-gaap:FairValueInputsLevel3Member 2024-07-012024-09-30 0001766140 uncy:ExclusiveLicenseAgreementMember 2017-10-012017-10-31 0001766140 2017-10-012017-10-31 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2018-09-012018-09-30 0001766140 uncy:InvestmentMemberuncy:SpectrumPharmaceuticalsIncMember 2018-09-30 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2018-09-30 0001766140 2021-07-13 0001766140 us-gaap:CommonStockMember 2021-07-132021-07-13 0001766140 2021-01-012021-09-30 0001766140 uncy:AltairNanomaterialsIncMember 2021-01-012021-09-30 0001766140 uncy:AltairMember 2021-01-012021-09-30 0001766140 uncy:SpectrumPharmaceuticalsIncMember 2021-01-012021-09-30 0001766140 uncy:SublicenseDevelopmentAgreementMember 2022-08-31 0001766140 uncy:SublicenseDevelopmentAgreementMember 2023-02-28 0001766140 uncy:LotusInternationalPteLtdMember 2023-01-012023-09-30 0001766140 uncy:SyneosHealthLLCMember 2021-07-192021-07-19 0001766140 uncy:QuotientSciencesLimitedMember 2022-01-062022-01-06 0001766140 2022-01-06 0001766140 uncy:QuotientSciencesLimitedMember 2024-09-30 0001766140 uncy:QuotientSciencesLimitedMember 2024-01-012024-09-30 0001766140 uncy:QuotientSciencesLimitedMember 2023-12-31 0001766140 uncy:CBCCGlobalResearchIncMember 2022-02-092022-02-09 0001766140 uncy:CBCCGlobalResearchIncMember 2023-03-312023-03-31 0001766140 2023-03-312023-03-31 0001766140 2023-04-102023-04-10 0001766140 uncy:InotivMember 2024-01-012024-09-30 0001766140 uncy:InotivMember 2023-12-31 0001766140 uncy:InotivMember 2024-09-30 0001766140 uncy:LeesPharmaceuticalHKLimitedMember 2022-07-14 0001766140 uncy:LeesPharmaceuticalHKLimitedMember 2022-07-142022-07-14 0001766140 srt:MinimumMember 2022-07-142022-07-14 0001766140 srt:MaximumMember 2022-07-142022-07-14 0001766140 uncy:OxylanthanumCarbonateMember 2023-01-012023-12-31 0001766140 uncy:OxylanthanumCarbonateMember 2023-12-31 0001766140 uncy:LotusInternationalPteLtdMember 2023-02-01 0001766140 2023-02-012023-02-01 0001766140 uncy:ShilpaMedicareLtdMember 2024-01-012024-09-30 0001766140 uncy:UpfrontPaymentMember 2022-07-142022-07-14 0001766140 uncy:MilestonePaymentMember 2022-07-142022-07-14 0001766140 us-gaap:OtherContractMember 2024-01-012024-09-30 0001766140 uncy:UpfrontPaymentMember 2023-02-012023-02-01 0001766140 uncy:MilestonePaymentMember 2023-02-012023-02-01 0001766140 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001766140 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001766140 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001766140 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001766140 us-gaap:EquipmentMember 2023-12-31 0001766140 us-gaap:EquipmentMember 2024-09-30 0001766140 2021-12-31 0001766140 2023-03-15 0001766140 uncy:OperatingLeaseMember 2023-03-15 0001766140 uncy:OperatingLeaseMember 2024-01-012024-09-30 0001766140 uncy:OperatingLeaseMember 2024-09-30 0001766140 srt:ChiefExecutiveOfficerMember 2023-02-28 0001766140 2023-03-012023-03-31 0001766140 uncy:MaximGroupLLCMember 2022-12-012022-12-31 0001766140 uncy:MaximGroupLLCMember 2023-03-012023-03-31 0001766140 2021-12-012021-12-31 0001766140 srt:MaximumMember 2021-12-012021-12-31 0001766140 srt:MinimumMember 2021-12-012021-12-31 0001766140 2023-01-012023-12-31 0001766140 us-gaap:IPOMember 2021-07-31 0001766140 us-gaap:WarrantMember 2021-07-31 0001766140 2021-07-31 0001766140 us-gaap:CommonStockMember 2021-07-31 0001766140 us-gaap:WarrantMember 2021-07-012021-07-31 0001766140 us-gaap:WarrantMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2023-06-26 0001766140 uncy:SeriesA2PreferredStockMember 2023-06-26 0001766140 2023-12-312023-12-31 0001766140 uncy:SeriesA1PreferredStockMember 2023-03-032023-03-03 0001766140 uncy:SeriesA3PreferredStockMemberuncy:TrancheAWarrantMember 2023-03-03 0001766140 uncy:SeriesA4PreferredStockMemberuncy:TrancheBWarrantMember 2023-03-03 0001766140 uncy:SeriesA5PreferredStockMemberuncy:TrancheCWarrantMember 2023-03-03 0001766140 uncy:TrancheAWarrantMember 2023-03-032023-03-03 0001766140 uncy:TrancheBWarrantMember 2023-03-032023-03-03 0001766140 uncy:TrancheCWarrantMember 2023-03-032023-03-03 0001766140 uncy:SeriesA1PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA4PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA5PreferredStockMember 2024-09-30 0001766140 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMember 2023-03-31 0001766140 uncy:SeriesACertificateOfDesignationMember 2023-07-11 0001766140 2023-07-112023-07-11 0001766140 uncy:ShareholderMemberuncy:SeriesA1PreferredStockMember 2023-12-31 0001766140 uncy:ShareholderMemberuncy:SeriesA2PreferredStockMember 2023-12-31 0001766140 us-gaap:PreferredStockMember 2024-03-132024-03-13 0001766140 us-gaap:WarrantMemberuncy:SeriesA3PreferredStockMember 2023-07-11 0001766140 us-gaap:WarrantMemberuncy:SeriesA4PreferredStockMember 2023-07-11 0001766140 uncy:AmendedTrancheBWarrantsMember 2023-07-11 0001766140 uncy:OriginalTrancheCWarrantsMember 2023-07-11 0001766140 uncy:AmendedTrancheCWarrantsMemberuncy:SeriesA5ConvertiblePreferredStockMember 2023-07-11 0001766140 us-gaap:WarrantMemberuncy:SeriesA3PreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMemberuncy:SeriesA4PreferredStockMember 2024-09-30 0001766140 us-gaap:WarrantMemberuncy:SeriesA5PreferredStockMember 2024-09-30 0001766140 uncy:SeriesA2PrimeConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA4ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesA5ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMemberuncy:SeriesA2PrimePreferredStockMember 2024-03-13 0001766140 uncy:ExchangeAgreementMemberuncy:SeriesA3ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMemberuncy:SeriesA4ConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMemberuncy:SeriesA5ConvertiblePreferredStockMember 2024-09-30 0001766140 us-gaap:CommonStockMember 2024-01-012024-09-30 0001766140 us-gaap:CommonStockMember 2024-09-30 0001766140 uncy:ExchangeAgreementMemberuncy:SeriesA2PrimeConvertiblePreferredStockMember 2024-09-30 0001766140 uncy:SeriesB1ConvertiblePreferredStockMember 2024-03-132024-03-13 0001766140 uncy:SeriesB1ConvertiblePreferredStockMemberuncy:SecuritiesPurchaseAgreementMember 2024-03-132024-03-13 0001766140 uncy:SeriesB1PreferredStockMember 2024-03-13 0001766140 uncy:SeriesA1PreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0001766140 uncy:SeriesB2PreferredStockMember 2024-09-30 0001766140 uncy:SeriesBCertificateOfDesignationMember 2024-07-05 0001766140 uncy:SeriesB2PreferredStockMember 2024-07-05 0001766140 uncy:SeriesB1PreferredStockMember 2024-01-012024-09-30 0001766140 uncy:SeriesB1PreferredStockMemberus-gaap:PreferredStockMember 2024-01-012024-09-30 0001766140 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001766140 uncy:SeriesA3PreferredStockMemberuncy:TrancheAWarrantMember 2023-07-11 0001766140 uncy:SeriesA4PreferredStockMemberuncy:TrancheBWarrantMember 2023-07-11 0001766140 uncy:SeriesA5PreferredStockMemberuncy:TrancheCWarrantMember 2023-07-11 0001766140 2023-03-032023-03-03 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheAWarrantMember 2023-12-31 0001766140 srt:MinimumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 srt:MaximumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheAWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-

gaap:MeasurementInputExpectedTermMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheBWarrantMember 2023-12-31 0001766140 uncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheBWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputAppraisedValueMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExercisePriceMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputExpectedDividendRateMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MinimumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MaximumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheCWarrantMember 2023-12-31 0001766140 srt:MinimumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 srt:MaximumMemberuncy:MeasurementInputProbabilityForFDAApprovalMemberuncy:TrancheCWarrantMember 2024-09-30 0001766140 us-gaap:WarrantMember 2023-12-31 0001766140 2023-06-26 0001766140 2023-06-262023-06-26 0001766140 uncy:ShareholdersMember 2024-06-202024-06-20 0001766140 2024-06-202024-06-20 0001766140 us-gaap:StockOptionMember 2024-09-30 0001766140 us-gaap:StockOptionMember 2024-01-012024-09-30 0001766140 2021-01-012021-12-31 0001766140 2022-05-012022-05-31 0001766140 2022-05-31 0001766140 2023-08-012023-08-31 0001766140 2023-08-31 0001766140 2024-08-012024-08-31 0001766140 2024-08-31 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001766140 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001766140 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001766140 srt:MinimumMember 2023-01-012023-09-30 0001766140 srt:MaximumMember 2023-01-012023-09-30 0001766140 srt:MinimumMember 2024-01-012024-09-30 0001766140 srt:MaximumMember 2024-01-012024-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001766140 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001766140 us-gaap:WarrantMember 2023-07-012023-09-30 0001766140 us-gaap:WarrantMember 2024-07-012024-09-30 0001766140 us-gaap:WarrantMember 2023-01-012023-09-30 0001766140 us-gaap:WarrantMember 2024-01-012024-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001766140 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2023-07-012023-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2024-07-012024-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2023-01-012023-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesB2ConvertiblePreferredStockMember 2024-01-012024-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2023-07-012023-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2024-07-012024-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2023-01-012023-09-30 0001766140 uncy:CommonStockIssuableUponConversionOfSeriesA2PrimeConvertiblePreferredStockMember 2024-01-012024-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2023-07-012023-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2024-07-012024-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2023-01-012023-09-30 0001766140 uncy:WarrantsToPurchaseConvertiblePreferredStockMember 2024-01-012024-09-30 0001766140 uncy:ShalabhGuptaMember 2024-07-012024-09-30 0001766140 uncy:ShalabhGuptaMember 2024-09-30 shares iso4217:USD iso4217:USD shares pure utr:sqft10-Qtrue2024-09-302024false001-40582UNICYCIVE THERAPEUTICS, INC.DE81-36386924300 El Camino RealSuite 210Los AltosCA94022(650)351-4495YesYesNon-accelerated FilertruetruefalsefalseCommon Stock, par value $0.001 per shareUNCYNASDAQ10379640697010003234700036980005394000139900037741000766000772000260006100014191000385740008390005480003234000299200013134641541000-79745000-380900027850000141910003857400067500033720003045000866900014726000256600032060006467000813000059380006251000151360002285600062510001513600022856000-5938000-6251000-14461000-22856000227000416000475000947000180001500063000510001396000-17540008697000-67560001605000215500082850007652000-4333000-4096000-22746000-152040007200086700010950004405000-4096000-23613000-16299000-0.13-0.13-0.05-0.05-1.12-1.12-0.3-0.33263307432633074889432128894321221100206211002065407370154073701152316551500033516000-33997000-466000-14575000-14575000301902540700019200-192000-192000218170007000144000144000301902559900015233836150003347500048572000-15082000-3838000-3838000603000-603000-603000218070007000144000144000301902620200015236016150003023000-52410000-19372000-4333000-43330007200072000-72000-72000-30190-26274000195162052000043649440002621100026275000218070007000929000929000347544013500043649440006009800056743000343400034756049350004364960697000-64541000-3809000-20963000-20963000500004618700020800020800043649213880.0128500002000-1396.5-2000581200020005220005220005000046187000376066303700019991.5161011000-85504000-24456000985500098550008870008870005956000600002918.44600010582100010006410006410005000046187000435732124300017073.0760760000-75649000-14846000-4096000-4096000-50000-461870005428500055000-5961.837882461320004618700019460500060500097858406980001111.247882104497000-797450002785000022746000-1520400060001500012170001768000869700067560001960002790001884000167700084900018100017900027100013844000-22027000120005000012000-50000291000368000-381300050000000215300030190000109500027746000447230001389000022646000455000970100014345000323470008670000283100026274000461870003970002930003style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Organization and Description of Business   Overview   Unicycive Therapeutics, Inc. (“the Company”) was incorporated in the State of Delaware on August 18, 2016. The Company was dormant until July 2017 when it began evaluating a number of drug candidates for in-licensing.   In September 2018, the Company purchased a second drug candidate, Renazorb RZB 012 and its trademark, RENALAN, and various patents from Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Note 3). Renazorb (“oxylanthanum carbonate”) is being developed for the treatment of hyperphosphatemia in patients with Chronic Kidney Disease (“CKD”).   In 2017, the Company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte. Ltd, a Singapore-based corporation, (“Sphaera”) (Note 3). UNI 494 is a pro-drug of nicorandil that is being developed as a treatment for acute kidney injury.   The Company continues to evaluate the licensing of additional technologies and drugs, targeting orphan diseases and other renal, liver and other metabolic diseases affecting fibrosis and inflammation.   Liquidity   The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with governmental regulations and the need to obtain additional financing to fund operations. The Company’s product candidates currently under development will require significant additional research and development efforts prior to commercialization. Future revenue streams may consist of collaboration or licensing revenue as well as product sales. The Company has not generated any licensing revenue during the nine months ended September 30, 2024.   The Company has incurred operating losses and negative cash flows from operations since inception and expects to continue to incur negative cash flows from operations in the future. As the Company increases its research and development activities, the operating losses are expected to increase. The Company has historically relied on private equity offerings, debt financing and loans from a stockholder to fund its operations. As of December 31, 2023 and September 30, 2024, the Company had an accumulated deficit of $64.5 million and $79.7 million, respectively.   In connection with its initial public offering (“IPO”), on July 13, 2021, the Company began trading on the Nasdaq Capital Market under the symbol “UNCY”, and on July 15, 2021, received approximately $22.3 million in net proceeds after deducting the underwriting discounts, commissions and other offering expenses. The Company has used the net proceeds from the IPO to complete pre-clinical and clinical studies, prepare regulatory filings for the FDA, and for general and corporate purposes, including hiring additional management and conducting market research and other commercial planning.   On March 3, 2023, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investors that may provide up to $130.0 million in gross proceeds through a private placement and that included initial upfront funding of $28.0 million in net proceeds.   On March 13, 2024, the Company entered into a securities purchase agreement with certain healthcare-focused institutional investors to provide $50.0 million in gross proceeds through a private placement. Pursuant to the securities purchase agreement, the Company issued institutional investors $50.0 million in shares of Series B Convertible Preferred Stock. The Company received $46.2 million in net proceeds (net of issuance costs).   The Company expects to continue incurring losses in the future and will be required to raise additional capital in the future to complete its planned clinical trials, pursue product development initiatives and penetrate markets for the sale of its products. Management believes that the Company will continue to have access to capital resources through possible equity offerings, debt financings, corporate collaborations or other means. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis or at all. If the Company is unable to secure additional capital, it may be required to curtail any clinical trials and

development of new or existing products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. Based on the Company's current level of expenditures, the Company believes that it has sufficient resources such that there is not substantial doubt about the ability to continue operations for at least one year after the date that these financial statements are available to be issued. 2016-08-18-64500000-797000002230000013000000028000005000000050000000046200000 2. Summary of Significant Accounting Policies   Basis of Presentation   The financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").   The accompanying unaudited financial statements of the Company as of September 30, 2024 have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and, accordingly, they do not include all information and footnote disclosures required by accounting principles generally accepted in the U.S. ("GAAP"). The Company believes the footnotes and other disclosures made in the financial statements are adequate for a fair presentation of the results of the interim periods presented. The financial statements include all adjustments (solely of a normal recurring nature) which are, in the opinion of management, necessary to make the information presented not misleading. You should read these financial statements and the accompanying notes in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission ("SEC") on March 28, 2024.   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates.   Revenue Recognition   The Company recognizes revenue in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers ("ASC 606"). The Company applies the five-step model in ASC 606 and recognizes revenue from product sales or services rendered when control of the promised goods or services are transferred to a counterparty in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.   Warrant Liability   In conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), the Company established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued (and have since been issued – see Note 12), subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. The Company accounts for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liability was initially measured at fair value and is remeasured at fair value each reporting period. Changes in the fair value of the warrant liability are recognized in earnings during each period. The warrant liability is measured using Level 3 fair value inputs. See Note 12 for a description of warrant liability and the related valuations. Segment Information   The Company operates and manages its business as one reportable operating segment. The Company's Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.   Risks and Uncertainties   The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Company's ability to attract and retain employees necessary to support its growth.   The Company's general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions.   Any product candidates developed by the Company will require approvals from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company's current product candidates or any future product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company.   The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs, which would materially and adversely affect its business, financial condition and operations.   The Company is dependent upon the services of its employees, consultants and other third parties.   Property, Plant and Equipment   Property, plant, and equipment are recorded at cost less accumulated depreciation. Additions, improvements, and major renewals or replacements that substantially extend the useful life of an asset are capitalized. Repairs and maintenance expenditures are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.   Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value at that time. At September 30, 2024, management determined there were no impairments of the Company's property and equipment. Leases   The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.   Fair Value of Financial Instruments   The Company's financial instruments include the warrant liability, cash and cash equivalents, accounts payable and accrued liabilities.   Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The fair value hierarchy contains the following levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1 — defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets;</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2 — defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3 — defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable.</td></tr> </table>   The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%;

border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> — </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months Ended
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: justify">Issuance of Warrants (March 3, 2023)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,831</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at March 31, 2023</td><td> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">13,206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at June 30, 2023</td><td> </td> <td> </td><td style="text-align: left"> </td><td style="text-align: right">12,924</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Fair value at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,134</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,807</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,941</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,810</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Fair value at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The expense relating to the change in fair value of the warrant liability of $8.7 million and $6.8 million for the nine months ended September 30, 2023 and September 30, 2024, respectively, is included in other income (expense) in the statements of operations.   ASC 820, Fair Value Measurement and Disclosures requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of December 31, 2023 and September 30, 2024, the recorded values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to the short-term nature of the instruments. Cash and cash equivalents, accounts payable, and accrued liabilities are Level 1 financial instruments.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024.   Prepaid Expenses and Other Current Assets   Prepaid expenses and other current assets represent costs incurred that benefit future periods. These costs are amortized over specific time periods based on the agreements.   Research and Development Expenses   Substantially all the Company's research and development expenses consist of expenses incurred in connection with the development of the Company's product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on the Company's behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for the Company's research and product development employees. The Company expenses both internal and external research and development expenses as they are incurred. General and Administrative Expenses   General and administrative expenses represent personnel costs for employees involved in general corporate functions, including finance, accounting, legal and human resources, among others. Additional costs included in general and administrative expenses consist of professional fees for legal (including patent costs), audit and other consulting services, stock-based compensation and other general corporate overhead expenses as well as costs from a service agreement with a related party (See Note 7).   Patent Costs   The Company expenses all costs as incurred in connection with patent licenses and applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are reflected in general and administrative expenses in the statements of operations. <p style="font:

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Stock-Based Compensation   The Company accounts for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. The Company recognizes forfeitures related to stock-based compensation as they occur. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, risk-free interest rate, and the estimated fair value (prior to the Company's initial public offering) or the public market closing price of the Company's underlying common stock on the date of grant.   Income Taxes   The Company accounts for corporate income taxes in accordance with GAAP as stipulated in ASC, Topic 740, Income Taxes, ("ASC 740"). This standard entails the use of the asset and liability method of computing the provision for income tax expense. Current tax expense results from corporate tax payable at the Federal and California jurisdictions for the Company, which relates to the current accounting period. Deferred tax expense results primarily from temporary differences between financial statement and tax return reporting, which result in additional tax payable in future periods. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates and law. Net future tax benefits are subject to a valuation allowance when management expects that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.   Current and non-current tax assets and liabilities are based upon an estimate of taxes refundable or payable for each of the jurisdictions in which the Company is subject to tax. In the ordinary course of business there is inherent uncertainty in quantifying income tax positions. The Company assess income tax positions and record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Company's policy is to recognize interest or penalties related to income tax matters in income tax expense.   The Tax Cuts and Jobs Act of 2017 eliminated the option to immediately deduct research and development expenditures in the year incurred under Section 174, which became effective January 1, 2022. We are monitoring legislation for any further changes to Section 174 and the impact, if any, to the financial statements in 2024.   Comprehensive Loss   Comprehensive loss includes all changes in equity (net assets) during a period from non-owner sources. There were no elements of other comprehensive income (loss) in the periods presented, as a result comprehensive loss is the same as net loss for each period presented. Net Income (Loss) per Share   Basic and diluted net income (loss) per share is presented in conformity with the two-class method required for participating securities. Basic and diluted net income (loss) for common stock and for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. Diluted net income (loss) per share includes potentially dilutive securities outstanding for the period. See Note 14 for reconciliations of basic and diluted net income (loss) per share.   Recent Accounting Pronouncements   From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's financial position or results of operations upon adoption.   In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements.   The Company adopted Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses ("ASC 326"), as of October 1, 2023. This new standard adds to U.S. GAAP an impairment model, known as the current expected credit loss ("CECL") model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the timelier recognition of losses. Under the CECL model, entities estimate credit losses over the entire contractual term from the date of initial recognition of the financial instrument. As the Company does not currently have any trade receivables, there was no cumulative effect adjustment, and the adoption of this standard did not have a material impact on the Company's financial statements.   Income Taxes Disclosures – In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. Basis of Presentation The financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The accompanying unaudited financial statements of the Company as of September 30, 2024 have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and, accordingly, they do not include all information and footnote disclosures required by accounting principles generally accepted in the U.S. ("GAAP"). The Company believes the footnotes and other disclosures made in the financial statements are adequate for a fair presentation of the results of the interim periods presented. The financial statements include all adjustments (solely of a normal recurring nature) which are, in the opinion of management, necessary to make the information presented not misleading. You should read these financial statements and the accompanying notes in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission ("SEC") on March 28, 2024. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include revenues, stock-based compensation, research contract progress estimates, and the fair value of warrant liabilities. Actual results may materially differ from those estimates. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers ("ASC 606"). The Company applies the five-step model in ASC 606 and recognizes revenue from product sales or services rendered when control of the promised goods or services are transferred to a counterparty in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. Warrant Liability In conjunction with the issuance of Series A-1 Preferred Stock (see Note 10), the Company established a warrant liability as of March 3, 2023, representing the fair value of warrants that may be issued (and have since been issued – see Note 12), subject to shareholder approval, upon conversion of the Series A-1 Preferred Stock. The Company accounts for these warrants as liabilities (in accordance with ASC 480, Distinguishing Liabilities from Equity) on the balance sheets as a result of certain redemption clauses that are not within the control of the Company. The warrant liability was initially measured at fair value and is remeasured at fair value each reporting period. Changes in the fair value of the warrant liability are recognized in earnings during each period. The warrant liability is measured using Level 3 fair value inputs. See Note 12 for a description of warrant liability and the related valuations. Segment Information The Company operates and manages its business as one reportable operating segment. The Company's Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. 1 Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Company's ability to attract and retain employees necessary to support its growth. The Company's general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. Any product candidates developed by the Company will require approvals from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company's current product candidates or any future product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs, which would materially and adversely affect its business, financial condition and operations. The Company is dependent upon the services of its employees, consultants and other third parties. Property, Plant and Equipment Property, plant, and equipment are recorded at cost less accumulated depreciation. Additions, improvements, and major renewals or replacements that substantially extend the useful life of an asset are capitalized. Repairs and maintenance expenditures are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value at that time. At September 30, 2024, management determined there were no impairments of the Company's property and equipment. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;

text-align: justify"> Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Fair Value of Financial Instruments The Company's financial instruments include the warrant liability, cash and cash equivalents, accounts payable and accrued liabilities. Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The fair value hierarchy contains the following levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1 — defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2 — defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3 — defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable.</td></tr> </table> The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250"> -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254"> -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months Ended
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: justify">Issuance of Warrants (March 3, 2023)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,831</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at March 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at June 30, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,924</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Fair value at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,134</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,807</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,941</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,810</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Fair value at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The expense relating to the

change in fair value of the warrant liability of $8.7 million and $6.8 million for the nine months ended September 30, 2023 and September 30, 2024, respectively, is included in other income (expense) in the statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurement and Disclosures </i>requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of December 31, 2023 and September 30, 2024, the recorded values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to the short-term nature of the instruments. Cash and cash equivalents, accounts payable, and accrued liabilities are Level 1 financial instruments.</p>The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of September 30, 2024 (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> — </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,377</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>The following table summarizes the fair value hierarchy of financial liabilities measured at fair value as of December 31, 2023 (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted
 Prices in
 Active
 Markets for
 Identical
 Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Other
 Observable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant
 Unobservable
 Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> — </td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,134</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>6377000637700063770006377000131340001313400013134000131340000The following table summarizes the changes in fair value of the warrant liability classified in Level 3. Gains and losses reported in this table include changes in fair value that are attributable to unobservable inputs (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months Ended
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: justify">Issuance of Warrants (March 3, 2023)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,831</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at March 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at June 30, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,924</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Fair value at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify" > </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: justify">Fair value at January 1, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,134</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,807</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,941</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,810</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Fair value at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Fair value at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>28310001037500013206000-28200012924000-13960001152800013134000118070002494100O-16810000813100O-17540006377000-8700000-6800000 Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The cash and cash equivalents the Company uses to satisfy working capital and operating expense needs are held in accounts at various financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through September 30, 2024. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets represent costs incurred that benefit future periods. These costs are amortized over specific time periods based on the agreements. Research and Development Expenses Substantially all the Company's research and development expenses consist of expenses incurred in connection with the development of the Company's product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on the Company's behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for the Company's research and product development employees. The Company expenses both internal and external research and development expenses as they are incurred. <p style="font: 10pt Times New Roman,

Times, Serif; margin: 0pt 0; text-align: justify"> General and Administrative Expenses General and administrative expenses represent personnel costs for employees involved in general corporate functions, including finance, accounting, legal and human resources, among others. Additional costs included in general and administrative expenses consist of professional fees for legal (including patent costs), audit and other consulting services, stock-based compensation and other general corporate overhead expenses as well as costs from a service agreement with a related party (See Note 7). Patent Costs The Company expenses all costs as incurred in connection with patent licenses and applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are reflected in general and administrative expenses in the statements of operations. Stock-Based Compensation The Company accounts for stock-based compensation for all share-based payments made to employees and non-employees by estimating the fair value on the date of grant and recognizing compensation expense over the requisite service period on a straight-line basis. The Company recognizes forfeitures related to stock-based compensation as they occur. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected common stock volatility, expected dividend yield, expected term, risk-free interest rate, and the estimated fair value (prior to the Company's initial public offering) or the public market closing price of the Company's underlying common stock on the date of grant. Income Taxes The Company accounts for corporate income taxes in accordance with GAAP as stipulated in ASC, Topic 740, Income Taxes, ("ASC 740"). This standard entails the use of the asset and liability method of computing the provision for income tax expense. Current tax expense results from corporate tax payable at the Federal and California jurisdictions for the Company, which relates to the current accounting period. Deferred tax expense results primarily from temporary differences between financial statement and tax return reporting, which result in additional tax payable in future periods. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates and law. Net future tax benefits are subject to a valuation allowance when management expects that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. Current and non-current tax assets and liabilities are based upon an estimate of taxes refundable or payable for each of the jurisdictions in which the Company is subject to tax. In the ordinary course of business there is inherent uncertainty in quantifying income tax positions. The Company assess income tax positions and record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Company's policy is to recognize interest or penalties related to income tax matters in income tax expense. The Tax Cuts and Jobs Act of 2017 eliminated the option to immediately deduct research and development expenditures in the year incurred under Section 174, which became effective January 1, 2022. We are monitoring legislation for any further changes to Section 174 and the impact, if any, to the financial statements in 2024. 0.50 Comprehensive Loss Comprehensive loss includes all changes in equity (net assets) during a period from non-owner sources. There were no elements of other comprehensive income (loss) in the periods presented, as a result comprehensive loss is the same as net loss for each period presented. Net Income (Loss) per Share Basic and diluted net income (loss) per share is presented in conformity with the two-class method required for participating securities. Basic and diluted net income (loss) for common stock and for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. Diluted net income (loss) per share includes potentially dilutive securities outstanding for the period. See Note 14 for reconciliations of basic and diluted net income (loss) per share. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's financial position or results of operations upon adoption. In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. We do not expect the adoption of this guidance to have a material impact on our financial statements. The Company adopted Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses ("ASC 326"), as of October 1, 2023. This new standard adds to U.S. GAAP an impairment model, known as the current expected credit loss ("CECL") model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the timelier recognition of losses. Under the CECL model, entities estimate credit losses over the entire contractual term from the date of initial recognition of the financial instrument. As the Company does not currently have any trade receivables, there was no cumulative effect adjustment, and the adoption of this standard did not have a material impact on the Company's financial statements. Income Taxes Disclosures – In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. 3. Significant Agreements   With regards to manufacturing, testing and potential commercial supply of oxylanthanum carbonate, on October 31, 2020, the Company entered into an agreement with Shilpa Medicare Ltd ("Shilpa") based in India. Pursuant to the Agreement, Shilpa provides certain development, manufacturing, supply and other CMC-related services related to the development and commercialization of oxylanthanum carbonate ("OLC").   In June 2024, the Company entered into the First Amendment to Manufacturing and Supply Agreement with Shilpa (the "Amendment"). The Company has entered into the Amendment in anticipation of an increased manufacturing demand for OLC. Pursuant to the Amendment, the Company has agreed to make a binding purchase order for tablets of OLC and Shilpa has agreed to deliver such order by September 30, 2025. In addition, the Company has agreed to order additional tablets for delivery between December 31, 2025, and September 30, 2026. Further, the Company has agreed to make certain milestone payments and to provide certain funding to Shilpa for a new manufacturing line. The initial term of the Agreement shall continue until the eighth (8th) anniversary of the date of receipt by the Company of FDA approval of its NDA of OLC (the "Initial Term"). Following the Initial Term, the Agreement shall continue in effect for consecutive periods of four (4) years each unless earlier terminated pursuant to the terms of the Agreement.   In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No payments were made upon execution of the agreement but payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. If the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter. In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. ("Spectrum Agreement") pursuant to which the Company purchased certain assets from Spectrum, including Spectrum's right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALAN™ ("Renalan") and RZB 014, also known as SPI 014 ("SPI" and together with Renalan, the "Compounds"), to further develop and commercialize oxylanthanum carbonate and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Company's shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the oxylanthanum carbonate Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Company's common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrum's ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Company's stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Company's initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. In the event an NDA filing for oxylanthanum carbonate is accepted by the FDA, the Company will be required to pay $0.2 million to Altair Nanomaterials, Inc., ("Altair") in accordance with the Spectrum Agreement. In addition, in the event FDA approval for oxylanthanum carbonate is received, the Company will be required to pay $4.5 million to Altair. The Company is also required to pay Spectrum 40% of all the Company's sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Spectrum Agreement) and 20% of all other sublicense income. The Company's payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Spectrum Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million resulting from a sublicense development agreement with Lee's Pharmaceutical (HK) Limited. In February 2023, the Company received an upfront payment of approximately $0.7 million resulting from a sublicense development agreement with Lotus International Pte Ltd. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the nine months ended September 30, 2023.   On July 19, 2021, the Company entered into an agreement with Syneos Health LLC ("Syneos") pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The initial budget for the study, which includes clinical pharmacology, translational sciences, and bioanalytical services, was approximately $2.3 million. Approximately $2.0 million has been paid to Syneos and the research was completed during 2023.   On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited ("Quotient"), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494. The initial budget for the study is approximately $3.7 million, and subsequent revisions reduced the overall budget to $2.9 million. Related payments totaling approximately $2.8 million have been paid to Quotient as of September 30, 2024, approximately 2.8 million of related expense has been recorded, and approximately $0.6 million and $0.6 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively.   On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. ("CBCC"), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of oxylanthanum carbonate. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.4 million have been paid to CBCC as of March 31, 2023, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million, and the research was completed as of March 31, 2023.   On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. <p style="font:

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On April 10, 2023, the Company entered into an agreement with Inotiv that provides preclinical trial and related services, for the purpose of performing research in support of UNI-494. The budget for these services is approximately $2.9 million. Approximately $2.9 million has been paid to Inotiv as of September 30, 2024 and approximately $0.3 million and $0.1 million has been recorded as prepaid expenses and other current assets in the accompanying balance sheets as of December 31, 2023 and September 30, 2024, respectively. On July 14, 2022, the Company entered into a license agreement with Lee's Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Lee's Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Lee's Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.   On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of oxylanthanum carbonate. The budget for the services is approximately $2.7 million, and approximately $2.7 million has been paid to Celerion as of December 31, 2023, and the research was completed during 2023.   On February 1, 2023, the Company entered into a license agreement with Lotus International Pte Ltd. ("Lotus") (see Note 4). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements.   On June 29, 2023 and October 26, 2023, the Company entered into services agreements with Shilpa Medicare Ltd related to NDA filing support for oxylanthanum carbonate. The agreements provide for total payments of up to $3.7 million, and the Company has made $3.0 million in payments pursuant to the agreements as of September 30, 2024.
500005000016500000.0231366340000.045000000050000000438374220000020000045000000.400.2010000007000000.2023000002000000370000029000002800000
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Licensing Revenues   On July 14, 2022, the Company entered into a license agreement (the "Lee's Agreement") with Lee's Pharmaceutical (HK) Limited ("Lee's"). Under the terms of the agreement, Lee's Pharmaceutical will be responsible for development, registration filing and approval for oxylanthanum carbonate in China, Hong Kong, and certain other Asian markets. In addition, Lee's will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territories. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Lee's with oxylanthanum carbonate product. The Company has received an upfront payment of approximately $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.   The Company has evaluated the Lee's Agreement in accordance with ASC 808, Collaborative Arrangements ("ASC 808") and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entity's "ordinary activities". The Lee's Agreement is consistent with the Company's current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship.   The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Lee's, and therefore the promise does not represent a current performance obligation. The Company has concluded the agreement contains one performance obligation - the IP license.   ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved. For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date.   The Company has concluded that at contract inception the total transaction price is the $1.0 million upfront fee.   The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP as it contains all the necessary information for Lee's to develop for commercialization in the Territory. Unicycive's ongoing activities do not significantly affect the standalone functionality of the IP. In addition, the functionality of the IP is not expected to substantially change during the license period based on Unicycive's activities. The revenue should therefore be recognized at a point in time. This intellectual property was transferred to Lee's in July 2022.   On February 1, 2023, the Company entered into a license agreement (the "Lotus Agreement") with Lotus International Pte Ltd. ("Lotus"). Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for oxylanthanum carbonate in the licensed territory of South Korea. In addition, Lotus will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of oxylanthanum carbonate in the licensed territory. The Company has agreed to complete development of the drug product, at its own expense, as required for obtaining regulatory approval in the U.S. Both parties agreed to enter into a separate manufacturing and supply agreement whereby Unicycive will supply Lotus with oxylanthanum carbonate product. The Company has received an upfront payment of $0.7 million, may receive up to $3.7 million in future milestone payments and will be eligible for tiered royalties upon achievement of specified commercial achievements.   The Company has evaluated the Lotus Agreement in accordance with ASC 808 and ASC 606. The Company first assessed whether the contractual arrangement is within the scope of ASC 808 which defines a collaborative arrangement as a contractual arrangement that involves a joint operating activity. Under ASC 606, the counterparty is considered a customer only if it is acquiring goods or services that are an output of the entity's "ordinary activities". The Lotus Agreement is consistent with the Company's current ongoing operations, which is an operating model adopted by many early-stage biotech companies. The license portion of the contract as well as the future potential transactions under a manufacturing and supply agreement both represent a vendor-customer relationship.   The Company does not believe that its promise to provide goods under a future manufacturing and supply agreement represents a material right to Lotus, and therefore the promise does not represent a current performance obligation. The Company evaluated the development services and concluded that although not material in cost, they are highly interrelated with the license grant. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. The combination of the license grant and development services is distinct as Lotus plans to use the product of this bundled unit for developing its regulatory applications. The Company concluded that the Lotus agreement contains one performance obligation, the bundle of the license grant and development services.   ASC 606 indicates that constrained variable consideration should be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations consisting of milestone payments and sales-based royalties may be received based on the completion of certain clinical, regulatory, and commercial activities. The Company has concluded that the future milestone payments should be excluded from the transaction price due to the uncertainty of achievement as of September 30, 2024. The Company will reassess this conclusion at each reporting date until the uncertainties are resolved. For the sales-based royalty payments, guidance requires an entity to recognize revenue for a sales-based royalty promised in exchange for a license of intellectual property only when the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all the sales-based or usage-based royalty has been allocated has been satisfied or partially satisfied. The Company has concluded that the future sales-based royalties should be excluded from the transaction price as of December 31, 2023 and September 30, 2024. The Company will reassess this conclusion at each reporting date.   The Company has concluded that at contract inception the total transaction price is $675,000 amount of the upfront payment. ASC 606 generally requires an entity to allocate the transaction price to the performance obligations in proportion to their standalone selling prices (i.e., on a relative standalone selling price basis). The Company identified the bundle of the license grant and development services as the single performance obligation in the agreement. The $675,000 initial transaction price will therefore be entirely allocated to this obligation.   The Company has concluded that the license of the oxylanthanum carbonate IP is functional IP. However, since it is not distinct, revenue must be recognized based on the combination of the functional IP and the related development services. Lotus will not simultaneously receive and consume the benefits of the oxylanthanum carbonate IP or development services. Since the performance of the development services creates an asset that will also be used by the Company and can be licensed to other customers outside of the Territory, the Company is considered to control the asset as it is created, and it does create an asset with an alternative use. Therefore, the Company concluded that control is not deemed to be transferred over time and is instead transferred at a point in time. The intellectual property was transferred to Lotus in February 2023, and the development services were determined to be immaterial to the contract. The Company has recognized a total of $675,000 in the accompanying statements of operations as licensing revenue for the nine months ended September 30, 2023. 100000010000000.070.10100000070000037000006750006750006750

style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid directors' and officers' liability insurance premiums</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">397</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid preclinical services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">325</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">687</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Property, plant and equipment as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Leasehold improvements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lab Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accounts payable as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Trade accounts payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">821</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Credit card liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">548</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Accrued liabilities as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued labor costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,917</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,402</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued drug development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,068</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">522</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>Prepaid expenses and other current assets as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid directors' and officers' liability insurance premiums</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">397</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid preclinical services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">325</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">687</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>270000397000310300043100003250006870003698000539400OProperty, plant and equipment as of December 31, 2023 and September 30, 2024 consisted of the

following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Leasehold improvements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lab Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2100037000210002900026000420009200016000310002600061000Accounts payable as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Trade accounts payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">821</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Credit card liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">548</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>821000519000180002900083900054800OAccrued liabilities as of December 31, 2023 and September 30, 2024 consisted of the following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued labor costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,917</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,402</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued drug development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,034</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,068</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">522</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>191700014020001034000106800028300052200032340002992000 6. Operating Lease   The Company leases office space under an operating lease. In December 2021, the Company entered into a lease agreement for 2,367 square feet of office space commencing December 1, 2021. The initial lease term was for two years, and there was an option to extend the lease for an additional year. On March 3, 2023, the Company expanded its leased space through a lease amendment by an additional 2,456 square feet commencing March 15, 2023. The term of the amended lease is for three years with an option to extend the lease for three additional years.   The lease amendment represents a modification of the original lease, and the Company evaluated the new agreement under ASC 842, Leases. The Company classified the lease as an operating lease and, on March 15, 2023, determined that the present value of the lease was approximately $1.0 million using an estimated incremental borrowing rate of 10%. During the nine months ended September 30, 2024, the Company reflected amortization of right-of-use asset of approximately $ 265,000, resulting in a right of use asset balance of approximately $0.8 million.   During the nine months ended September 30, 2024, the Company made cash payments on the lease of $ 329,000 towards the lease liabilities. As of September 30, 2024, the total lease liability was approximately $ 0.8 million.   As of September 30, 2024, maturities of the Company's lease liabilities are as follows (in thousands, unaudited):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Year ending December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">608</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Year ending December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">871</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest rate / present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Present value of lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">807</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542</td><td style="padding-bottom: 1.5pt; text-align: left">) </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Long term portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>2367P2Y2456three additional years10000000.10265000800000329000800000As of September 30, 2024, maturities of the Company's lease liabilities are as follows (in thousands, unaudited):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Year ending December 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">608</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Year ending December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black

1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">871</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest rate / present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Present value of lease liability</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">807</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Long term portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>1440006080001180008710006400080700054200026500 7. Related Party Transactions   Loan from Chief Executive Officer and Stockholder   The Company received advances from the stockholder of $210,000 during February 2023. The Company repaid amounts owed to the stockholder of $210,000 plus accrued interest during March 2023. 210000210000 8. Commitments and Contingencies   Contingencies   The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company's financial statements. The Company currently has no pending claims or legal proceedings.   In December 2022, the Company signed an advisory services agreement with Maxim Group LLC ("Maxim") pursuant to which the Company will pay Maxim $100,000 upon the closing of a private placement of the Company's equity or equity-linked securities. Maxim provided advisory services with respect to a private placement securities purchase agreement with certain healthcare-focused institutional investors, which closed in March of 2023. The Company paid the $100,000 advisory fee in March 2023.   Indemnification   In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.   The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. However, the Company may record charges in the future as a result of these indemnification obligations.   Additionally, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company's request in such capacity. The indemnification period covers all pertinent events and occurrences during the director's or officer's service.   Employee Benefit Plan   In December 2021, the Company implemented a 401(k) Plan which covers all eligible employees of the Company (the "401(k) Plan"). Employer matching contributions are immediately 100% vested. The Company's 401(k) Plan provides that the Company match each participant's contribution at 100% up to 4% of the employee's eligible compensation. Company contributions to the 401(k) Plan totaled approximately $107,000 and $104,000 for the year ended December 31, 2023 and for the nine months ended September 30, 2024, respectively. 100000100000110.04107000104000 9. Stockholders' Deficit   Authorized Common Stock   The Company is authorized to issue up to 400,000,000 shares of common stock at par value of $0.001 per share.   Issuance of Common Stock and Warrants from Initial Public Offering   During July 2021, as a result of its initial public offering, the Company issued 5,000,000 shares of common stock and 4,000,000 warrants to investors in exchange for cash at $5.00 per unit, consisting of $4.99 per share of common stock and $.0125 per four fifths of a warrant. The warrants have a 5-year term and an exercise price of $6.00 per warrant. The underwriters exercised their option to purchase an additional 600,000 warrants, and the Company received $7,500 in proceeds.   As a result of the initial public offering, the Company's outstanding convertible notes and unpaid accrued interest were converted into 736,773 shares of common stock. Additionally, in accordance with the original terms of the warrant agreements convertible noteholders were granted a total of 184,193 common stock warrants with a 5-year term and with an exercise price of $6.00 per warrant.   The warrants from the initial public offering are equity classified. The following table summarizes activity for the Company's IPO warrants for the nine months ended September 30, 2024:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,784,193</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,784,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">6.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">1.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   See Note 12 for information on preferred stock warrants associated with our sale in March of Series A-1 Preferred Stock.   Issuance of Common Stock Upon Conversion of Series A-1 Preferred Stock   On June 26, 2023, the Company held its annual shareholder meeting and, as a result, shareholder approval

for the issuance of common shares upon the conversion of the Series A-1 Preferred Stock was obtained (see Notes 10 and 11). On July 11, 2023, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (the "Series A Certificate of Designation"), the Company issued a total of 19,516,205 shares of common stock and 43,649 Series A-2 Preferred Stock in settlement of the auto-conversion of the Series A-1 Preferred Stock.   Voting Rights of Common Stock   Each holder of shares of common stock shall be entitled to one vote for each share thereof held. 4000000000.0015000000400000054.990.0125P5Y660000075007367734184193P5Y6The warrants from the initial public offering are equity classified. The following table summarizes activity for the Company's IPO warrants for the nine months ended September 30, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,784,193</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,784,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">6.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">1.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>47841936P2Y6M14D47841936P1Y9M14D1951620543649 Note 10. Issuance of Series A-1 Preferred Stock   On March 3, 2023, the Company issued and sold, in a private placement, 30,190 shares of Series A-1 Preferred Stock for an aggregate net proceeds of $28.0 million (the "Preferred Stock Offering"), net of placement agent fees and offering expenses of $2.2 million. The Company intends to use the net proceeds from the Preferred Stock Offering to support the Company's New Drug Application (NDA) submission for approval of oxylanthanum carbonate for the treatment of hyperphosphatemia and, if approved, for the commercial launch of oxylanthanum carbonate in the U.S.   Pursuant to the Series A Certificate of Designation, as of March 3, 2023, each share of Series A-1 Preferred Stock was, subject to approval of the Company's stockholders, convertible into a unit ("Unit") consisting of: (i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of common stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares (excluding deemed dividends) of Series A-3 Preferred Stock (the "Tranche A Warrant"), (iii) a tranche B warrant to acquire approximately 42,432,672 shares (excluding deemed dividends) of Series A-4 Preferred Stock (the "Tranche B Warrant"), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares (excluding deemed dividends) of Series A-5 Preferred Stock (the "Tranche C Warrant", together with the Tranche A Warrant and the Tranche B Warrant, the "Warrants"). The Tranche A Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company's announcement of receipt of FDA approval for oxylanthanum carbonate, the Tranche B Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment ("TDAPA") approval for oxylanthanum carbonate, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million is exercisable until 21 days following four quarters of commercial sales of oxylanthanum carbonate following receipt of TDAPA approval. The Company has designated 30,190 shares of Series A-1 Preferred Stock, 1,800,000 shares of Series A-2 Preferred Stock, 1,800,000 shares of Series A-3 Preferred Stock, 1,800,000 shares of Series A-4 Preferred Stock, and 3,600,000 shares of Series A-5 Preferred Stock, together the "Series A Preferred Stock". The Series A Preferred Stock has a par value of $0.001 per share. The Series A Certificate of Designation states that, to the extent that the conversion of the Series A-1 preferred stock as well as the exercise of the Warrants into Series A-2, Series A-3, Series A-4, and Series A-5 preferred stock results in a beneficial ownership interest in excess of the maximum percentage of common stock upon conversion, the holders will receive the as converted equivalent for the remaining shares in preferred stock.   The Company determined that the Warrants are freestanding from the Series A-1 Preferred Stock, because the stock will automatically convert into shares of common stock, and the holders will be able to sell those shares while retaining the Warrants. The Company noted that at contract inception, the Warrants were contingently issuable upon the occurrence of a specified event (shareholder approval).   In connection with the Series A-1 Preferred Stock issuance, the Company recognized liabilities for the associated Warrants, which had an aggregate fair value of $2.8 million at the time of issuance. Offering costs of $0.2 million were allocated to the Warrants and expensed during March 2023. The fair value of the Warrants was accounted for as a reduction to the net proceeds of the Preferred Stock Offering, which resulted in an initial carrying value of $25.4 million for the Series A-1 Preferred Stock (net of $2.0 million of placement agent fees and offering costs allocated to the Series A-1 Preferred Stock). Refer to Note 12 for disclosures related to the Warrants.   On June 26, 2023, the Company held its annual shareholder meeting and, as a result, shareholder approval for the conversion of the Series A-1 Preferred Stock was obtained. On July 11, 2023, pursuant to the Series A Certificate of Designation, the Company issued 19,516,205 shares of common stock (see Note 9) and 43,649 shares of Series A-2 Preferred Stock in partial settlement of the auto-conversion of the Series A-1 preferred shares. As of December 31, 2023, there were zero shares of Series A-1 preferred stock issued and outstanding and there were 43,649 shares of Series A-2 Preferred Stock issued and outstanding.   The Series A-2, A-3, A-4, and A-5 Preferred Stock have the following rights: Dividends: While shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends(other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.   Voting: Holders of the Series A-2, A-3, A-4, and A-5 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis as determined by dividing the liquidation preference with respect to such shares of Preferred Stock by the conversion price. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders.   At the option of the holder thereof, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, or Series A-5 Preferred Stock shall be convertible into one share of common stock. Exchange Agreement   On March 13, 2024, the Company entered into an exchange agreement (the "Exchange Agreement") with certain accredited investors (the "Investors"), pursuant to which the Investors surrendered all shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as "Series A-2 Prime Preferred" (the "Exchanged Preferred") having rights set forth the Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (the "Amended Series A Certificate of Designation").   Concurrent with execution of the Exchange Agreement, but prior to filing of the Amended Series

A Certificate of Designation with the Delaware Secretary of State, the Company filed Certificates of Elimination for each of its Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Certificates of Elimination") with the Delaware Secretary of State.   Concurrent with the execution of the Exchange Agreement, the Company and each Investor have amended and restated the following warrants: (i) tranche A warrants to acquire an aggregate of 47,852,430 shares of Series A-3 Convertible Preferred Stock of the Company that were issued on July 11 2023 (the "Original Tranche A Warrants") have been amended and restated to acquire an aggregate of 25,840.3122 shares of Series A-3 Convertible Preferred Stock (as amended, the "Amended Tranche A Warrants"); (ii) tranche B warrants to acquire an aggregate of 43,502,206 shares of Series A-4 Convertible Preferred Stock of the Company that were issued on July 11, 2023 (the "Original Tranche B Warrants") have been amended and restated to acquire an aggregate of 25,666.30154 shares of Series A-4 Convertible Preferred Stock (as amended, the "Amended Tranche B Warrants") and (iii) tranche C warrants to acquire an aggregate of 69,603,531 shares of Series A-5 Convertible Preferred Stock of the Company that were issued on July 11, 2023(the "Original Tranche C Warrants", and together with the Original Tranche A Warrants and Tranche B Warrants, the "Original Warrants") have been amended and restated to acquire 51,506.61294 shares of Series A-5 Convertible Preferred Stock (as amended, the "Amended Tranche C Warrants," together with the Amended Tranche A Warrants and the Amended Tranche B Warrants, the "Amended Warrants"). The Amended Warrants have the same terms and conditions as the original warrants except that such Amended Warrants: (i) reduced the amount of shares of Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock into which such Amended Warrants are convertible as described above; (ii) allow for the issuance of fractional shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, as applicable upon exercise of such Amended Warrants and (ii) revised the exercise price to be $1,000 per share of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, as applicable in such Amended Warrants. The aggregate exercise price, the amount of shares of Common Stock upon conversion of the Series A-3 Preferred Stock, the Series A-4 Preferred Stock and the Series A-5 Preferred Stock and exercise period in the Amended Warrants did not change from the Original Warrants.   Subject to the terms and limitations contained in the Amended Series A Certificate of Designation, each share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock are convertible into a number shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock by the applicable conversion price of $0.49, $0.54, $0.59 and $0.74 of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock, respectively.   Pursuant to the terms of the Exchange Agreement, effective March 13, 2024, the Company filed the Amended Certificate of Designation with the Delaware Secretary of State designating, 21,400 shares as Series A-2 Prime Preferred Stock, 25,900 shares as Series A-3 Convertible Preferred Stock, 25,700 shares as Series A-4 Convertible Preferred Stock, and 51,600 shares as Series A-5 Convertible Preferred Stock (all such series of preferred stock referred to herein collectively as "Series A Preferred Stock"), each with a stated value of $1,000 per share (the "Original Per Share Price"). The Amended Certificate of Designation sets forth the rights, preferences and limitations of the shares of Series A Preferred Stock. Terms not otherwise defined in this item shall have the meanings given in the Amended Certificate of Designation. The Amended Certificate of Designation was filed with an effective date of March 14, 2024. Dividends. At all times following the Issuance Date, while shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Amended Certificate of Designation) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Amended Certificate of Designation) are paid on shares of the Common Stock.   Voting Rights. Subject to certain limitations described in the Amended Certificate of Designation, the Series A Preferred Stock is voting stock. Holders of the Series A Preferred Stock are entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock basis. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders.   Liquidation. Upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series A Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of the Amended Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Amended Certificate of Designation or otherwise.   Conversion. Subject to the limitations set forth in the Amended Certificate of Designation, at the option of the holder, each share of Series A-2 Prime Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock shall be convertible into a number shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) of each such share of Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock by the applicable conversion price of $0.49, $0.54, $0.59 and $0.74 for the Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock or Series A-5 Convertible Preferred Stock, respectively.

* 3019028000000220000046675940424326726789227625000000250000005000000030190180000018000001800000360000000.001280000020000025400000200000015*

style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 11. Issuance of Series B-1 Preferred Stock   On March 13, 2024, we signed a securities purchase agreement with certain healthcare-focused institutional investors that provided $50 million in gross proceeds to us through a private placement. Pursuant to the securities purchase agreement, we issued to institutional investors $50.0 million in shares of our Series B-1 Convertible Preferred Stock. 50,000 Shares of Series B-1 Convertible Preferred Stock were issued at a price of $1,000.00 per share and each share is convertible into shares of common stock at a rate equal to the initial $1,000 purchase price divided by the initial conversion price of $1.00 per share.   Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the "Series B Certificate of Designation"), as of March 14, 2024, each share of Series B-1 Preferred Stock is, subject to approval of the Company's stockholders, convertible into shares of common stock of the Company and, if applicable, shares of Series B-2 Convertible Preferred Stock (the "Series B-2 Preferred Stock"), in lieu of common stock   The Company has designated 50,000 shares of Series A-1 Preferred Stock and 50,000 shares of Series B-2 Preferred Stock. The Series B Certificate of Designation states that, to the extent that the conversion of the Series B-1 preferred stock results in a beneficial ownership interest in excess of the maximum percentage of common stock upon conversion, the holders will receive the as converted equivalent for the remaining shares in preferred stock.   On June 20, 2024, we held our annual stockholder meeting, and as a result, stockholder approval for the conversion of the Series B-1 Convertible Preferred Stock was obtained. On July 5, 2024, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, the Company issued 42,118,000 shares of common stock and 7,882 shares of Series B-2 preferred stock in settlement of the automatic conversion of the Series B-1 Convertible Preferred Stock. The Series B-1 Preferred Stock have the following rights: Dividends: Prior to the receiving Stockholder Approval, dividends will accrue, on all issued and outstanding shares of Series A-1 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts); provided that such annual dividend rate shall increase to fourteen percent (14%) if Stockholder Approval is not obtained at the first meeting of stockholders following the date of the Preferred Stock offering. If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding of the Series B-1 Preferred Stock. At all times following the Issuance Date, while shares of Series B-1 Preferred Stock are issued and outstanding, holders of Series B Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series B-1 Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock, which shall be made in accordance with the terms of the Series B Certificate of Designation) are paid on shares of the Common Stock. Stockholder approval was received on June 20, 2024.   Voting: : Subject to certain limitations described in the Series B Certificate of Designation holders of the Series B-1 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis as determined by dividing the liquidation preference with respect to such shares of Series B-1 Preferred Stock by the conversion price. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Unless and until the Company has obtained the Stockholder Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series B Preferred Stock (for purposes of calculating the number of aggregate votes that the holders of Series B Preferred Stock are entitled to on an as-converted basis) will be equal to that number of shares equal to 19.9% of the Company's outstanding Common Stock as of the Signing Date (excluding for purposes of the calculation, any securities issued on the Signing Date) (the "Cap"), which each such holder being able to vote the number of shares of Series B Preferred Stock held by it relative to the total number of shares of Series B Preferred Stock then outstanding multiplied by the Cap. Notwithstanding the foregoing, the holders of the Series B Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis with regard to the approval of the issuance of Common Stock upon conversion of the Series B Preferred Stock.   On the tenth trading day following the announcement of the Stockholder Approval, each share of Series B-1 Preferred Stock shall automatically convert into a unit consisting of: (1) the number of shares of common stock equal to the quotient of (A) the liquidation preference with respect to such share of Series B-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holder's beneficial ownership to exceed 9.99%, such holder shall receive shares of Series B-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership divided by 1,000.   Liquidation Preference: The Series B-1 Preferred Stock had a liquidation preference of one-times the original per share price of $1,000 per share, plus any accrued but unpaid dividends thereon, whether or not declared, subject to certain customary anti-dilution adjustments.   The Series B-2 Preferred Stock has the following rights: Dividends: Dividends will accrue, on all issued and outstanding shares of Series B-2 Preferred Stock, prior to and in preference to all other shares of capital stock of the Company, at an annual rate of eight percent (8%) compounded annually on the original per share price (plus any such accreted compounded amounts). If such dividends are not declared and paid in cash, the dividend amounts will be added to the aggregate liquidation preference then outstanding.   Voting: Subject to certain limitations described in the Series B Certificate of Designation, the Series B-2 Preferred Stock is voting stock. Holders of the Series B-2 Preferred Stock are entitled to vote together with the common stock on an as-if-converted-to-common-stock basis. Holders of common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of

stockholders. Accordingly, holders of Series B-2 Preferred Stock will be entitled to one vote for each whole share of common stock into which their Series B-2 Preferred Stock is then-convertible on all matters submitted to a vote of stockholders. Liquidation. Upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series B Preferred Stock and common stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series B Preferred Stock as if they had been converted to common stock pursuant to the terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Series B Certificate of Designation or otherwise.   Conversion: Subject to the limitations set forth in the Series B Certificate of Designation, at the option of the holder thereof, each share of Series B-2 Preferred Stock, is convertible into the number of shares of common stock equal to the quotient of (A) the stated value ($1,000), divided by (B) the conversion price on the applicable conversion date, which is $1.00 as of the date of this report.
5000000005000000050000010001000150000500004211800078820.080.14one0.1990.09990.09991000100000.08oneone10000001 12. Warrant Liability   In connection with the Series A Preferred Stock Offering (see Note 10), the Company issued the Warrants.   After the Warrants were legally issued as a result of the automatic conversion of the Series A-1 Preferred Stock upon shareholder approval, they became immediately exercisable at the option of the holder. The Company determined that the Warrants, while initially contingently issuable, qualified as derivative instruments pursuant to ASC 815-40, Contracts in an Entity's Own Equity and that the Warrants were considered issued for accounting purposes concurrently with the Series A-1 Preferred Stock.   On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the conversion of the Series A-1 Preferred Stock was obtained. On July 11, 2023, pursuant to the Series A Certificate of Designation, the Company issued, in addition to common stock and Series A-2 Preferred Stock, (i) a Tranche A Warrant to acquire 47,852,430 shares of Series A-3 Preferred Stock, (ii) a Tranche B Warrant to acquire 43,502,206 shares of Series A-4 Preferred Stock, and (iii) a Tranche C Warrant to acquire 69,603,531 shares of Series A-5 Preferred Stock. See Note 10 for discussion of exchange agreement related to Series A-2 Preferred Stock and warrants.   The Warrants are recognized as liabilities in the balance sheets and were initially recognized at fair value at the time of issuance. The Warrants are also subject to remeasurement at each balance sheet date after issuance. Any change in fair value is recognized as a component of other income (expense) in the statements of operations in the period of change.   The valuation of the Warrants contains unobservable inputs that reflect the Company's own assumptions for which there is little market data. Accordingly, the Warrants are measured at fair value on a recurring basis using unobservable inputs and are classified as Level 3 inputs. The significant unobservable inputs used in the fair value measurement of the Company's Warrants include, but are not limited to, probability of obtaining certain shareholder approvals, probability of reaching certain technical milestones related to the development of oxylanthanum carbonate, and the estimated term of the Warrants. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, a change in the assumption used for the probability of obtaining certain shareholder approvals is not correlated to a change in the probability of reaching certain technical milestones. However, a change to the assumption used for the probability of obtaining certain shareholder approvals or a change in the probability of reaching certain technical milestones would have been accompanied by a directionally opposite change and a directionally similar change, respectively, in the assumption used for the estimated term. The fair value of the Warrants associated with the Company's March 2023 private placement transaction was determined as of March 3, 2023, and March 31, 2023, by using a Monte Carlo simulation technique ("MCS") to value the embedded derivatives associated with the Warrants. The MCS methodology calculates the theoretical value of a warrant based on certain parameters, including: (i) the threshold of exercising the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, (vi) the number of paths, (vii) estimated probability assumptions surrounding shareholder approval as well as the achievement by the Company of technical milestones associated with regulatory and commercial progress, and (viii) an estimated discount for lack of marketability.   The MCS valuation model was used for the valuation performed as of the transaction inception on March 3, 2023, and on March 31, 2023, due to uncertainty in the timing of shareholder approval and the potential variability in the Warrant exercise price. On June 26, 2023, the Company held its annual shareholder meeting, and as a result, shareholder approval for the issuance of common shares upon the conversion of the Series A-1 Preferred Stock was obtained and the exercise price for the Warrants became fixed. Therefore, as of December 31, 2023 and September 30, 2024, the fair value of the Warrants was determined using a Black Scholes model using parameters including (i) the exercise price of the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, and (vi) estimated probability assumptions surrounding the achievement by the Company of technical milestones associated with regulatory and commercial progress.   These valuation techniques involve management's estimates and judgment based on unobservable inputs and are classified in Level 3. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Generally, a significant increase (decrease) in the probabilities of shareholder approval and the achievement of technical milestones would have resulted in a significantly higher (lower) fair value measurement; however, changes in other inputs such as expected term and price of the underlying common stock will have a directionally opposite impact on fair value measurement.   The Company uses a third-party valuation expert to assist in the determination of the fair value of the Warrants. The tables below summarize the valuation inputs into the Black Scholes model for the liability associated with the three tranches of Warrants at December 31, 2023 and September 30, 2024.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Tranche A Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96.5% – 139.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.7% – 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.6% – 5.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8% – 4.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5 – 1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.7 – 1.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36.55 – 38.50</td><td style="text-align: left">%</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Tranche B Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114.6% – 139.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109.8% – 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4% – 4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7% – 3.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.0 – 2.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.3 – 2.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Tranche C Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%;

text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.8% - 114.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116.1% - 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0% - 4.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6% - 3.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.0 - 3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.7 - 2.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.3 % - 12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01%-27.46</td><td style="text-align: left">%</td></tr> </table>   As of the issuance date (March 3, 2023), the Company estimated the fair value of the Warrants to be $2.8 million. As of December 31, 2023 and September 30, 2024, the Company estimated the fair value of the Warrants to be $13.1 million and $6.4 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity for the Company's preferred stock warrants for the nine months ended September 30, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160,958,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants contingently issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">160,958,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>4785243043502206696035311The Company uses a third-party valuation expert to assist in the determination of the fair value of the Warrants. The tables below summarize the valuation inputs into the Black Scholes model for the liability associated with the three tranches of Warrants at December 31, 2023 and September 30, 2024.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Tranche A Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96.5% - 139.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.7% - 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.6% - 5.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8% - 4.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5 - 1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.7 - 1.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36.55 - 38.50</td><td style="text-align: left">%</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Tranche B Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114.6% - 139.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109.8% - 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4% - 4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7% - 3.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td>

<td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.0 – 2.0 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.3 – 2.3</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.0</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Tranche C Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Fair value of underlying stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.8% - 114.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116.1% - 129.2</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk free rate</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0% - 4.4</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6% - 3.8</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.0 - 3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.7 – 2.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount for lack of marketability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Probability for FDA approval</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.3 % - 12.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01%-27.46</td><td style="text-align: left">%</td></tr>
</table>0.870.410.540.5496.5139.2107.7129.24.65.33.84.1000.51.50.71.712.57.529.336.5538.50.870.410.590.59114.6139.2109.8129.24.44.83.73.800121.32.312.57.51211(
following table summarizes activity for the Company's preferred stock warrants for the nine months ended September 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160,958,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants contingently issuable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">160,958,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"> - </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>1609581670.64P2Y4M2D3686400001609581670.64P2Y4M13D 13. Stock-based Compensation   On July 15, 2021, in connection with the completion of the Company's IPO, the Company adopted a new comprehensive equity incentive plan, the 2021 Omnibus Equity Incentive Plan (the "2021 Plan"). Following the effective date of the 2021 Plan, no further awards may be issued under the 2018 Plan or the 2019 Plan (collectively, the "Prior Plans"). However, all awards under the Prior Plans that are outstanding as of the effective date of the 2021 Plan will continue to be governed by the terms, conditions and procedures set forth in the Prior Plans and any applicable award agreements. A total of 1,302,326 shares of common stock were reserved for issuance pursuant to the 2021 Plan prior to our annual meeting on June 26, 2023. Shareholders approved an increase to the number of shares reserved on June 26, 2023, for a total of 12,775,996 shares. On June 20, 2024, shareholders approved a further increase of 8,000,000 shares, to the number of shares reserved, for a total of 20,775,996 shares. The 2021 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. As of December 31, 2023, approximately 2,815,503 shares of common stock were available under the 2021 Plan. As of September 30, 2024, there are approximately 7,433,327 shares of common stock available under the 2021 Plan. The following table summarizes activity for stock options under all plans for the nine months ended September 30, 2024:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td>

<td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td><td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,302,086</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,196</td><td style="width: 1%; text-align: left"> </td></tr><tr style="vertical-align: bottom; "><td style="text-align: left">Options granted</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">3,370,411</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">9.60</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Options forfeited</td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; "><td style="text-align: left; padding-bottom: 1.5pt">Options exercised</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,357</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">3.27</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td><td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">13,671,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">1.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; "><td> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td>Options vested and exercisable as of September 30, 2024</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">4,675,005</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">1.28</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">8.31</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr></table> As of September 30, 2024, the unrecognized compensation cost related to outstanding stock options was $6.0 million, which is expected to be recognized as expense over approximately 4.0 years. During the year ended December 31, 2021, employees and consultants exercised a total of 383,721 stock options and the Company received $119,000 in proceeds. A portion of these options were exercised early (prior to vesting), and as of September 30, 2024, none of the options remained unvested. Proceeds received related to the vested portion of options of $2,500 were reclassified to equity during the nine months ended September 30, 2024. During May 2022, the Company granted a consultant 10,000 restricted stock units with a grant date fair value of $7,200, resulting in a fair value per share of $0.72. The restricted stock units vested in May 2024. During August 2023, the Company granted a consultant 10,000 restricted stock units with a grant date fair value of $7,500, resulting in a fair value per share of $0.75. The restricted stock units will vest in March 2025. During August 2024, the Company granted a consultant 11,765 restricted stock units with a grant date fair value of $4,000, resulting in a fair value per share of $0.34. The restricted stock units will vest in August 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has recorded stock-based compensation expense, which includes expense related to restricted stock units, allocated by functional cost as follows for the three and nine months ended September 30, 2023 and 2024 (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold"> </td><td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td><td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td> </td><td> </td><td> </td><td colspan="2" style="text-align: center"> </td><td> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td> </td><td colspan="2" style="text-align: center"> </td><td> </td><td> </td><td> </td><td colspan="2" style="text-align: center"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">450</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">275</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">614</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785</td><td style="width: 1%; text-align: left"> </td></tr><tr style="vertical-align: bottom; "><td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">330</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">603</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 4pt">Total stock-based compensation</td><td style="padding-bottom: 4pt"> </td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,217</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,768</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table> Fair Value of Stock Options The assumptions are based on the following for each of the periods presented: Expected Term - The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. Common Stock Fair Value - The fair value of the common stock underlying the Company's stock options prior to the initial public offering was estimated at each grant date and was determined on a periodic basis and based either on transactions with third parties in which common stock was sold for cash or with the assistance of an independent third-party valuation expert. Subsequent to our initial public offering, the fair value underlying the Company's common stock is determined based on the public market closing price on each date of grant. The assumptions underlying these valuations represented management's best estimates, which involved inherent uncertainties and the application of significant levels of management judgment. Volatility - The expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options. Risk-free Interest Rate - The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options. Expected Dividend - Through September 30, 2024, the Company has never declared nor paid any cash dividends to common stockholders. SERIES B-1 DIVIDENDS PAID IN CASHThe Company shall modify its dividend policy to state that the Company intends to pay dividends to all stockholders, including holders of Series A Preferred Stock on an as-if-converted-to-common-stock basis, on a quarterly basis in an amount of which the aggregate of all quarterly dividends shall equal at least seventy-five percent (75%) of its annual net

cash flow from operations following the approval of oxylanthanum carbonate by the FDA if obtained, and the commencement of commercial sales.   The following averaged assumptions were used to calculate the fair value of awards granted to employees, directors and non-employees for the nine months ended September 30, 2023 and September 30, 2024:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Nine months Ended</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Expected volatility</td><td style="width: 1%"> </td> <td style="width: 12%; text-align: center">104% - 108%</td><td style="text-align: center; width: 1%"> </td> <td style="width: 12%; text-align: center">104% - 106%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center">4.35% - 4.36%</td><td style="text-align: center"> </td> <td style="text-align: center">3.77% - 4.65%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td> <td> </td> <td style="text-align: center"> - </td><td style="text-align: center"> </td> <td style="text-align: center"> - </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: center">5.92 years</td><td style="text-align: center"> </td> <td style="text-align: center">6.25 years</td></tr>
</table>1302326127759968000000207759962815503743333?The following table summarizes activity for stock options under all plans for the nine months ended September 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Outstanding, December 31, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,302,086</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,196</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,370,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,357</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">3.27</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">13,671,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">1.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.84</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options vested and exercisable as of September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,675,005</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr>
</table>103020861P9Y4M2D119600033704111P9Y7M6D13573.27136711401P8Y10M2D8100046750051.28P8Y3M21D390006000000P4Y383721119000025001000072000Company has recorded stock-based compensation expense, which includes expense related to restricted stock units, allocated by functional cost as follows for the three and nine months ended September 30, 2023 and 2024 (in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">450</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">275</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">614</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">330</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">603</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total stock-based compensation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,217</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align:

right">1,768</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>450000275000614000785000479000330000603000983000929000605000121700017680000.75The following averaged assumptions were used to calculate the fair value of awards granted to employees, directors and non-employees for the nine months ended September 30, 2023 and September 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; "> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Nine months Ended</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Expected volatility</td><td style="width: 1%"> </td> <td style="width: 12%; text-align: center">104% - 108%</td><td style="text-align: center; width: 1%"> </td> <td style="width: 12%; text-align: center">104% - 106%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center">4.35% - 4.36%</td><td style="text-align: center"> </td> <td style="text-align: center">3.77% - 4.65%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: center"> - </td><td style="text-align: center"> </td> <td style="text-align: center"> - </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: center">5.92 years</td><td style="text-align: center"> </td> <td style="text-align: center">6.25 years</td></tr>
</table>1.041.081.041.060.04350.04360.03770.0465P5Y11M1DP6Y3M 14. Net Loss Per Share   The Company computes net loss per share using the two-class method. The two-class method uses an earnings allocation formula that determines net loss per share for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings.   Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units; (ii) common stock to be issued upon the assumed exercise of the Company's common stock warrants; (iii) convertible preferred stock; and (iv) prior to issuance, the issuable warrants related to the Company's March private placement financing. The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended
 September 30,</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended
 September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2023</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2024</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2023</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Basic net loss per share</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF"> <td>Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(4,333</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(4,096</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(22,746</td> <td>)</td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="text-align: right">(15,204</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Deemed dividends on preferred stock</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">(72</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">(867</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: bottom">Cash Dividends to Series B holders</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">(1,095</td> <td style="vertical-align: bottom">)</td> </tr> <tr> <td style="vertical-align: bottom">Net loss attributable to common shares, basic and diluted</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(4,405</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(4,096</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(23,613</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(16,299</td> <td style="vertical-align: bottom">)</td> </tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: bottom">Denominator:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">32,633,074</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">88,943,212</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">21,100,206</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">54,073,701</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: bottom">Net loss per share attributable to common stockholders, basic and diluted</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.13</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.05</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1.12</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.30</td> <td style="vertical-align: bottom">)</td> </tr>
</table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt

0; text-align: justify"> The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options to purchase common stock</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,321,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,671,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,321,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,671,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,765</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issuable upon conversion of Series B-2 convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,882,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,882,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,649,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,676,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,649,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,676,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Warrants to purchase convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">176,063,976</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">209,993,175</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">176,063,976</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">209,993,175</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended
 September 30,</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended
 September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2023</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2024</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2023</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Basic net loss per share</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(4,333</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(4,096</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(22,746</td> <td>)</td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="text-align: right">(15,204</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Deemed dividends on preferred stock</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">(72</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">(867</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> - </td> <td style="width: 1%"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Cash Dividends to Series B holders</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">(1,095</td> <td style="vertical-align: bottom">)</td> <td> </td></tr> <tr> <td style="vertical-align: bottom">Net loss attributable to common shares, basic and diluted</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(4,405</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(4,096</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(23,613</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(16,299</td> <td style="vertical-align: bottom">)</td> </tr> <tr> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">

bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">32,633,074</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">88,943,212</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">21,100,206</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">54,073,701</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: bottom">Net loss per share attributable to common stockholders, basic and diluted</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.13</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.05</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(1.12</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="border-bottom: Black 4pt double; text-align: right">(0.30</td> <td style="vertical-align: bottom">)</td> </tr> </table>-4333000-4096000-22746000-1520400072000867000-1095000-4405000-4405000-4096000-4096000-23613000-23613000-16299000-16299000326330743263307488943212889432122110020621100206540737015407370154073701-0.13-0.13-0.05-0.05-1.12-1.12-0.3-0.3The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options to purchase common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,321,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,671,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,321,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,671,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,784,193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,765</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issuable upon conversion of Series B-2 convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,882,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,882,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,649,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,676,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,649,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,676,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Warrants to purchase convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,958,167</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">176,063,976</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">209,993,175</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">176,063,976</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">209,993,175</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr>
</table>10321616136711401032161613671140478419347841934784193478419321765217657882000788200043649000226760004364900022676000160958167160958167 style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. Subsequent Events   On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. During the three months ended September 30, 2024, no Section 16 officers and directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act), except that on September 20, 2024, Shalabh Gupta, M.D., our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 900,000 shares of our common stock beginning on January 20, 2025 and terminating on January 19, 2026. falsefalsefalsefalseSeptember 20, 2024Shalabh GuptaM.D., our Chief Executive Officertrue900000trueJanuary 19, 2026 false--12-31Q300017661400

"